			concept-negdistance-avg	concept-overlap-pos-ratio	parsehead-negdistances-min	parsehead-proximities-min	parsehead-proximities-avg	stopword-min	stopword-avg	concept-overlap-any-one	parsehead-negdistances-avg	concept-overlap-avg	type-coercion-3-pos-ratio	concept-negdistance-min	type-coercion-1-avg	type-coercion-1-min	token-negdistance-avg	parsehead-proximities-max	token-proximities-min	focus-overlap-pos-ratio	concept-proximity-min	concept-proximity-avg	avg-covered-token-count	token-proximities-avg	token-overlap-avg	cao-count	type-coercion-1-pos-ratio	token-negdistance-min	token-proximities-pos-ratio	type-coercion-3-max	stopword-one-ratio	token-overlap-pos-ratio	stopword-any-one	type-coercion-1-one-ratio	concept-proximity-pos-ratio	type-coercion-3-min	type-coercion-3-avg	name-count	parsehead-proximities-pos-ratio	token-count	concept-proximity-max	type-coercion-3-any-one	token-proximities-max	token-overlap-any-one	type-coercion-1-max	focus-overlap-avg	type-coercion-3-one-ratio	type-coercion-1-any-one
198	D356N	0.6748536755795161	-2.8000000000000007	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04504504504504505	0.04504504504504505	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04504504504504505	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	main;Main	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
291	Potential;potential	0.0925071381544399	-2.428571428571427	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.428571428571427	0.0	0.0	0.0	0.04	0.04	0.0	0.04430379746835443	0.04430379746835443	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04430379746835443	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	The inhibitory activity of hydralazine	0.1338870361537569	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
131	This effect	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
107	practice	0.08037075232258246	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.142857142857142	0.04	0.056	0.0	0.04	0.04	1.0	0.056	0.0	1.0	0.0	-7.142857142857142	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.056	0.0	0.0	0.0	0.0	0.0
115	putative novel regulatory elements in a subset	0.07315313996107475	0.0	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
99	Autosomal dominant;autosomal dominant inheritance;Autosomal Dominant Inheritance;autosomal dominant	0.9961119723564084	-2.328125	0.0	0.0	0.04	0.04	0.3333333333333333	0.4375	0.0	0.0	0.0	1.0	-9.5	1.0	1.0	-1.267857142857143	0.04	0.04	0.0	0.04	0.04530791262630472	2.375	0.0423957316030614	0.125	16.0	1.0	-4.2857142857142865	1.0	0.5	0.0	0.375	0.0	1.0	1.0	0.5	0.5	4.0	1.0	38.0	0.06451612903225806	0.0	0.04827586206896552	0.0	1.0	0.0	0.0	1.0
8	parental and nascent centrioles	0.42836705803159997	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
116	the absorption of levothyroxine	0.12044944574543226	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.6	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
14	Integral Membrane Proteins;transmembrane β-barrels from other kinds of proteins;inner membrane proteins;inner membrane protein;transmembrane β-barrel protein;transmembrane proteins;integral beta-barrel outer membrane proteins;transmembrane beta barrel proteins;TMH proteins;transmembrane β-barrel proteins;integral membrane proteins;integral beta-barrel outer membrane protein;Transmembrane Protein;transmembrane beta-barrel proteins;transmembrane helical proteins;transmembrane α-helical proteins;transmembrane β barrel proteins;transmembrane strands of outer membrane proteins;Integral Membrane Protein;transmembrane regions of beta-barrel membrane proteins;transmembrane residues in transmembrane beta barrel proteins;integral membrane beta-barrel proteins	0.9999999999999989	-0.8254716981132075	1.0	-10.833333333333334	0.04	0.04057713651498335	0.0	0.20351901766996106	1.0	-0.20440251572327045	0.7977987421383648	0.0	-14.0	0.0	0.0	-2.481132075471698	0.07058823529411765	0.04	0.0	0.04	0.041948598282342556	4.754716981132075	0.04497160015661038	0.7463911350703804	53.0	0.0	-11.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	22.0	1.0	252.0	0.09090909090909091	0.0	0.07407407407407407	1.0	0.0	0.0	0.0	0.0
320	features;feature;Feature	0.09545940947392528	-2.6666666666666665	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-3.6666666666666665	0.04	0.04	0.0	0.04	0.04515151515151516	1.0	0.04752386518605104	0.0	3.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	3.0	0.05	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
147	one adult	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	duodenal gastrinomas	0.8375942713045537	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	2.0	0.04	1.0	0.04	0.0	0.0	0.0	1.0	0.0
332	Syk activity by R788	0.18916618552744635	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
90	Respond42	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	conjunction with lymphoid malignancy	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
31	anaerobic;Anaerobic	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
261	release;Release	0.09970568496548785	-4.571428571428571	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.571428571428571	0.0	0.0	0.0	0.04	0.04	0.0	0.048951048951048945	0.048951048951048945	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.048951048951048945	0.0	0.04	0.0	0.0	0.0	0.0	0.0
99	electrical;Electrical	0.10032753139019	-4.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04938271604938271	0.04938271604938271	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04938271604938271	0.0	0.04	0.0	0.0	0.0	0.0	0.0
204	the genetic point mutations	0.08996615178433509	-4.75	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04938271604938271	0.04938271604938271	4.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04938271604938271	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
25	ASD symptomatology	0.8438081425716739	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.5	0.04	0.04	0.0	0.04	0.04	2.0	0.04777777777777778	0.0	4.0	0.0	-7.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
115	tissue-specific expression of reporter genes;Tissue-Specific Gene Expression	0.05079695335392808	0.0	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
158	Ser252Trp	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	Exist;exists	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
126	found;Found	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	candidate regions	0.14684823062145294	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	DDT	0.6936550463420394	-15.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-15.5	0.0	0.0	-9.0	0.04	0.0625	0.0	0.10526315789473684	0.10526315789473684	1.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.10526315789473684	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
156	BRAIN DAMAGE;brain damage	0.11707437433269925	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
152	a rational alternative to insulin therapy	0.16506277051840676	-3.3999999999999986	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	1.0	-3.3999999999999986	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.046296296296296294	0.046296296296296294	6.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.046296296296296294	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
95	endonuclease;endonucleases;Endonucleases	0.798205499433094	-0.6666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04126984126984127	1.0	0.04	0.0	6.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	6.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
49	a greater depth of understanding	0.09245381186559004	-3.125	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.125	0.0	0.0	0.0	0.04	0.04	0.0	0.045714285714285714	0.045714285714285714	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.045714285714285714	0.0	0.04	0.0	0.0	0.0	0.0	0.0
131	the identification and validation	0.06649166306655643	-3.3000000000000007	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-3.3000000000000007	0.0	0.0	-2.8000000000000007	0.04	0.04504504504504505	0.0	0.04608294930875576	0.04608294930875576	4.0	0.04504504504504505	0.25	1.0	0.0	-2.8000000000000007	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04608294930875576	0.0	0.04504504504504505	0.0	0.0	0.0	0.0	0.0
241	Repeated	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
331	strengths	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
298	a rapid decline in T3	0.08551016867550651	-4.111111111111111	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-4.111111111111111	0.0	0.0	-4.375	0.04	0.048484848484848485	0.0	0.047872340425531915	0.047872340425531915	5.0	0.048484848484848485	0.0	1.0	0.0	-4.375	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.047872340425531915	0.0	0.048484848484848485	0.0	0.0	0.0	0.0	0.0
220	probands	0.6243502839300525	-3.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04597701149425287	0.04597701149425287	1.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04597701149425287	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
41	Exhibit;exhibits;exhibit	0.0956065627048219	-4.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-10.0	0.0	0.0	-8.416666666666666	0.04	0.047619047619047616	0.0	0.04	0.05229166666666667	1.0	0.06262903762903763	0.0	4.0	0.0	-12.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.06666666666666667	0.0	0.07692307692307693	0.0	0.0	0.0	0.0	0.0
99	one of the genes	0.03991000951918782	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-4.5	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.04878048780487805	0.04878048780487805	4.0	0.06666666666666667	0.5	1.0	0.0	-10.0	1.0	0.3333333333333333	1.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04878048780487805	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
229	a training set of genes;a method for disease gene;Gene, A;Genes, A;a web resource for the prioritization of candidate genes	0.268296981665891	0.0	0.0	0.0	0.04	0.04	0.8888888888888888	0.9722222222222222	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.5	0.04	0.04	0.25	0.04	0.04	6.0	0.04666666666666667	0.23333333333333334	4.0	0.0	-10.0	1.0	0.0	0.75	0.5	1.0	0.0	1.0	0.0	0.0	5.0	1.0	24.0	0.04	0.0	0.06666666666666667	0.0	0.0	0.05	0.0	0.0
318	constitutively active tyrosine kinase	0.4936006687287706	-1.8148148148148155	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.3333333333333333	1.0	-1.8888888888888893	0.0	0.0	-6.282051282051282	0.04	0.046762589928057555	1.0	0.0430622009569378	0.0431312108943688	4.0	0.054083337103901785	0.5	3.0	0.0	-8.692307692307692	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	12.0	0.04326923076923077	0.0	0.06132075471698114	0.0	0.0	0.25	0.0	0.0
172	26 families	0.2643617943626036	-2.3999999999999986	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04424778761061947	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04424778761061947	0.0	0.04	0.0	0.0	0.0	0.0	0.0
130	a pediatric intensive care unit	0.08318069329912932	-1.2727272727272734	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-1.2727272727272734	0.0	0.0	-7.2857142857142865	0.04	0.056451612903225805	0.0	0.0421455938697318	0.0421455938697318	5.0	0.056451612903225805	0.2	1.0	0.0	-7.2857142857142865	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.0421455938697318	0.0	0.056451612903225805	0.0	0.0	0.0	0.0	0.0
271	severe psychomotor defects	0.6023058948528892	-2.133333333333333	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-2.8333333333333335	0.04	0.04	0.0	0.04	0.04391437308868501	3.0	0.04546184738955824	0.0	3.0	0.0	-4.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04587155963302752	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
304	fostamatinib;FOSTAMATINIB;Fostamatinib	0.7595322266229249	-2.125	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.375	1.0	1.0	-6.666666666666667	0.04	0.04	0.0	0.0427807486631016	0.04372617957278341	1.0	0.05777777777777778	0.0	3.0	1.0	-10.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	3.0	1.0	3.0	0.04419889502762431	0.0	0.06666666666666667	0.0	1.0	0.0	0.0	1.0
44	inhibitors	0.6656063561796837	-6.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.75	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.0547945205479452	0.0547945205479452	1.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.0547945205479452	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
343	the individual SPRY domains	0.02066629928885651	0.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
52	Containing;containing	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
155	an autosomal recessive or dominant form	0.23205795446732097	-8.666666666666666	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-8.666666666666666	0.0	0.0	-2.833333333333332	0.04	0.045112781954887216	0.0	0.06122448979591836	0.06122448979591836	6.0	0.045112781954887216	0.0	1.0	0.0	-2.833333333333332	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.06122448979591836	0.0	0.045112781954887216	0.0	0.0	0.0	0.0	0.0
270	Gfi-1b	0.7089005770367779	-1.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04212389380530973	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04424778761061947	0.0	0.04	0.0	0.0	0.0	0.0	0.0
304	a Bruton	0.11920816277647094	-3.625	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.875	0.0	0.0	-8.142857142857142	0.04	0.059322033898305086	0.0	0.04419889502762431	0.04694416801070656	2.0	0.059322033898305086	0.5	2.0	0.0	-8.142857142857142	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.049689440993788817	0.0	0.059322033898305086	0.0	0.0	0.0	0.0	0.0
85	two;Two	0.083561063311364	-2.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	-2.2857142857142847	0.04	0.0440251572327044	0.0	0.043859649122807015	0.043859649122807015	1.0	0.0440251572327044	0.0	1.0	0.0	-2.2857142857142847	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043859649122807015	0.0	0.0440251572327044	0.0	0.0	0.0	0.0	0.0
97	Autosomal Dominant Inheritance;Autosomal dominant;autosomal dominant pattern of inheritance;autosomal dominant;autosomal dominant inheritance	0.7111200306845702	-1.4285714285714286	0.0	0.0	0.04	0.04	0.3333333333333333	0.4666666666666667	0.0	0.0	0.0	1.0	-10.0	1.0	1.0	-5.285714285714286	0.04	0.04	0.0	0.04	0.043809523809523805	2.7142857142857144	0.05218045112781955	0.0	7.0	1.0	-8.333333333333334	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	5.0	1.0	19.0	0.06666666666666667	0.0	0.06000000000000001	0.0	1.0	0.0	0.0	1.0
14	obtained;Obtained	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
293	limit drug;limits to the use of these drugs	0.011106245759018002	-3.75	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.2	0.0	-3.75	0.0	0.0	-6.5	0.04	0.05405405405405406	1.0	0.047058823529411764	0.047058823529411764	7.0	0.05405405405405406	0.42857142857142855	1.0	0.0	-6.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	7.0	0.047058823529411764	0.0	0.05405405405405406	0.0	0.0	0.14285714285714285	0.0	0.0
293	Amitriptyline and-in case	0.12536669187253235	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	5.0	0.05263157894736842	0.2	1.0	0.0	-6.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
86	TR DNA binding to the transcriptional regulatory region	0.11656603315215432	0.0	0.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.125	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
41	strength;Strength	0.06711321033896941	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04	0.04	1.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
244	to;TO	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	treat;TREAT	0.07330141096011375	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.047619047619047616	0.047619047619047616	1.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
229	a gene/protein relationship networ	0.12960115906551592	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
3	the dcm gene	0.08625370922799482	-4.833333333333334	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-4.833333333333334	0.0	0.0	-2.1428571428571423	0.04	0.04375	0.0	0.04958677685950414	0.04958677685950414	3.0	0.04375	0.3333333333333333	1.0	0.0	-2.1428571428571423	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04958677685950414	0.0	0.04375	0.0	0.0	0.0	0.0	0.0
43	pathogen-host-vector system	0.10787643081113926	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.2	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	1.0	0.04	0.04	6.0	0.05	0.16666666666666666	1.0	0.0	-5.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.05	0.0	0.0	0.16666666666666666	0.0	0.0
58	chitosan microspheres;Chitosan microspheres	0.8314281821237175	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
155	Episode of;episodes of	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
130	Health;health	0.0037784751046727036	-15.181818181818182	1.0	-12.555555555555555	0.08035714285714285	0.08035714285714285	1.0	1.0	1.0	-12.555555555555555	1.0	0.0	-15.181818181818182	0.0	0.0	-9.857142857142858	0.08035714285714285	0.0660377358490566	0.0	0.10185185185185185	0.10185185185185185	1.0	0.0660377358490566	1.0	1.0	0.0	-9.857142857142858	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.10185185185185185	0.0	0.0660377358490566	1.0	0.0	0.0	0.0	0.0
132	found;Found	0.07296156602125722	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.04	0.04	1.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
293	cancer patients;Cancer Patient	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
26	the 21 patients	0.0793662226340656	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	automatic PPI detection	0.2458488016044363	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.4	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
29	Aspergillus terreus	0.9999985617341955	-2.6236559139784945	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-5.833333333333334	1.0	1.0	-3.5698924731182795	0.04	0.04	0.0	0.04	0.04496047750256412	2.0	0.0471648590773662	0.0	31.0	1.0	-5.666666666666666	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	62.0	0.052173913043478265	0.0	0.051724137931034475	0.0	1.0	0.0	0.0	1.0
91	a first-line pharmacologic treatment	0.12780620229685105	-2.571428571428573	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-2.571428571428573	1.0	1.0	0.0	0.04	0.04	1.0	0.0445859872611465	0.0445859872611465	6.0	0.04	0.16666666666666666	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.0445859872611465	0.0	0.04	0.0	1.0	0.16666666666666666	0.0	1.0
14	neural networks;Neural Networks	0.6909234191631183	-1.21875	0.0	0.0	0.04	0.04	0.0	0.375	0.0	0.0	0.0	0.0	-1.625	0.0	0.0	-1.3749999999999991	0.04	0.04	0.0	0.04	0.0420855614973262	2.0	0.042374100719424455	0.0	4.0	0.0	-1.8333333333333321	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.0427807486631016	0.0	0.043165467625899276	0.0	0.0	0.0	0.0	0.0
185	Prominent	0.11848588980406836	-2.833333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.045112781954887216	0.045112781954887216	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.045112781954887216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
215	p38 mitogen-activated protein kinase (MAPK)	0.5123003084139073	-4.0	0.0	0.0	0.04	0.04	0.1	0.1	0.0	0.0	0.0	1.0	-4.0	1.0	1.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	10.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.047619047619047616	0.0	0.04	0.0	1.0	0.0	0.0	1.0
254	A subset of synovial DCs	0.36572603755531863	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	several filters	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	all proteins against each other	0.08848691453375389	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
97	proximal myotonic myopathy (PROMM) and type 2 DM	0.3746382977268361	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.1	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	pulses;Pulses	0.11090581907745846	-10.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-11.333333333333334	0.0	0.0	-7.666666666666667	0.04	0.046875	0.0	0.06382978723404256	0.06850025947067982	1.0	0.0609375	0.0	2.0	0.0	-11.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.07317073170731708	0.0	0.075	0.0	0.0	0.0	0.0	0.0
158	patients with Apert syndrome	0.028576991555969898	-2.6	1.0	-12.333333333333332	0.04	0.052982456140350874	0.75	0.75	1.0	-4.111111111111111	1.0	1.0	-7.800000000000001	1.0	1.0	-4.111111111111111	0.07894736842105263	0.04	1.0	0.04	0.04604651162790698	4.0	0.052982456140350874	1.0	3.0	1.0	-12.333333333333332	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	12.0	0.05813953488372093	0.0	0.07894736842105263	1.0	1.0	0.25	0.0	1.0
67	Assess;assess	0.0889281189202495	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.04878048780487805	0.04878048780487805	1.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04878048780487805	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
343	the early development of germ cells	0.057725667489823246	-3.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
160	CKD patients	0.44067785631379464	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	likely;Likely	0.09493235089127515	-3.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.04580152671755725	0.04580152671755725	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04580152671755725	0.0	0.04	0.0	0.0	0.0	0.0	0.0
140	whole;Whole	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
242	a risk factor for SCD	0.015833810518771817	-2.0	1.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.25	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	1.0	0.043478260869565216	0.043478260869565216	5.0	0.04	0.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.2	0.0	0.0
94	functional impairment	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	Janus Kinases;Janus kinases	0.7917488313648039	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.0	1.0	1.0	-4.5	0.04	0.04878048780487805	0.0	0.045454545454545456	0.045454545454545456	2.0	0.04878048780487805	0.0	2.0	1.0	-4.5	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	4.0	0.045454545454545456	0.0	0.04878048780487805	0.0	1.0	0.0	0.0	1.0
80	Synonym;synonymous	0.5944509710896444	-3.333333333333332	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04615384615384615	0.04615384615384615	0.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04615384615384615	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
223	's Disease InvestigaTIONs (EXPEDITION) studies	0.1360028556071491	-1.3636363636363633	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	-1.3636363636363633	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.04230769230769231	0.04230769230769231	7.0	0.05555555555555555	0.14285714285714285	1.0	0.0	-7.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04230769230769231	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
285	commonly HER2	0.07374483989733635	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.5	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
237	the potent transcriptional activation properties of NF	0.12153866667505499	-2.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-4.428571428571429	0.04	0.04861111111111112	0.0	0.043478260869565216	0.043478260869565216	7.0	0.04861111111111112	0.2857142857142857	1.0	0.0	-4.428571428571429	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.043478260869565216	0.0	0.04861111111111112	0.0	0.0	0.0	0.0	0.0
245	cardiac troponin C (cTnC)	0.44363696222765703	-4.428571428571429	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.428571428571429	1.0	1.0	-4.6	0.04	0.04901960784313726	0.0	0.04861111111111112	0.04861111111111112	6.0	0.04901960784313726	0.3333333333333333	1.0	1.0	-4.6	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04861111111111112	0.0	0.04901960784313726	0.0	1.0	0.0	0.0	1.0
247	INDIA;India	0.5393248407082849	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-6.25	0.04	0.05333333333333334	0.0	0.043478260869565216	0.043478260869565216	1.0	0.05333333333333334	0.0	1.0	0.0	-6.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.05333333333333334	0.0	0.0	0.0	0.0	0.0
134	Essential	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
173	the development	0.13092093959868686	-5.6	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.199999999999999	0.0	0.0	-5.916666666666667	0.04	0.052173913043478265	0.0	0.047619047619047616	0.051899411449973246	2.0	0.05240274599542334	0.0	2.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.056179775280898875	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
204	genetic mutations;mutation;genetic point mutations;Mutation	0.4706171319841473	-2.3333333333333335	0.0	0.0	0.04	0.04	0.0	0.12962962962962962	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-2.2222222222222223	0.04	0.04	0.0	0.04	0.044508023900535425	1.3333333333333333	0.04494663231505337	0.7777777777777778	9.0	0.0	-8.5	1.0	0.0	0.0	0.7777777777777778	0.0	0.0	1.0	0.0	0.0	4.0	1.0	12.0	0.05	0.0	0.06060606060606061	1.0	0.0	0.0	0.0	0.0
160	receptor activator of nuclear factor-kappaB ligand modulators	0.14741957572919828	-3.333333333333332	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-3.333333333333332	1.0	1.0	-8.142857142857142	0.04	0.059322033898305086	0.0	0.04615384615384615	0.04615384615384615	9.0	0.059322033898305086	0.3333333333333333	1.0	1.0	-8.142857142857142	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04615384615384615	0.0	0.059322033898305086	0.0	1.0	0.0	0.0	1.0
44	Method of detection;method for the in vitro detection of	0.04967466516645085	-13.5	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	0.0	-13.5	0.0	0.0	-9.0	0.04	0.0625	0.0	0.08695652173913043	0.08695652173913043	7.0	0.0625	0.2857142857142857	1.0	0.0	-9.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	7.0	0.08695652173913043	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
60	consists;CONSIST	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	Cytotoxic;cytotoxic	0.5377715751454067	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	1.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
13	XFEL data	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	defined populations	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
26	Gastrointestinal symptoms;gastrointestinal symptoms	0.2974032164301945	-2.2857142857142847	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.2857142857142847	0.0	0.0	0.0	0.04	0.04	0.0	0.0440251572327044	0.0440251572327044	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.0440251572327044	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	outcome and response to adjuvant chemotherapy	0.14120207851724045	-4.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
160	bone formation sclerostin and dickkopf-1	0.1960771843176281	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
44	cyanobacteria;Cyanobacteria	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
127	cytoreductive effect;Cytoreductive effect	0.20146510080365157	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
217	the recently described terminal amine isotopic labeling	0.1660217668892227	-2.125	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	-2.125	0.0	0.0	-2.428571428571427	0.04	0.04430379746835443	0.0	0.04371584699453552	0.04371584699453552	7.0	0.04430379746835443	0.14285714285714285	1.0	0.0	-2.428571428571427	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04371584699453552	0.0	0.04430379746835443	0.0	0.0	0.0	0.0	0.0
152	no certain influence	0.13666104237584165	-3.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-3.6000000000000014	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04672897196261683	0.04672897196261683	3.0	0.04716981132075472	0.0	1.0	0.0	-3.8000000000000007	1.0	0.3333333333333333	1.0	0.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04672897196261683	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
336	the SWI/SNF and RSC chromatin remodelling	0.32075704328164617	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.04	0.04	8.0	0.047058823529411764	0.125	1.0	0.0	-3.75	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
78	a neo-marked segment from the distal long arm	0.08342580943199569	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	8.0	0.05263157894736842	0.0	1.0	1.0	-6.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.05263157894736842	0.0	1.0	0.0	0.0	1.0
127	First;first	0.06314044178413722	-5.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-12.0	0.04	0.07692307692307693	0.0	0.051724137931034475	0.051724137931034475	1.0	0.07692307692307693	0.0	1.0	0.0	-12.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.051724137931034475	0.0	0.07692307692307693	0.0	0.0	0.0	0.0	0.0
49	found MECP2 mutations in 83 (40	0.14057971988533155	0.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.2857142857142857	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.375	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	calcitonin synthesis	0.8095998584107535	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
254	UNDERSTOOD;understood	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
238	clinical and angiographic data	0.058863757776091825	-1.3333333333333321	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-1.3333333333333321	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04225352112676056	0.04225352112676056	4.0	0.047619047619047616	0.25	1.0	0.0	-4.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04225352112676056	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
68	c)	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
290	Preliminary	0.10820314746866086	-10.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-10.25	0.0	0.0	-8.666666666666666	0.04	0.06122448979591836	0.0	0.06779661016949153	0.06779661016949153	1.0	0.06122448979591836	0.0	1.0	0.0	-8.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.06779661016949153	0.0	0.06122448979591836	0.0	0.0	0.0	0.0	0.0
251	the kinase inhibitor staurosporine (ST)	0.20494111440760107	-2.0	0.0	0.0	0.04	0.04	0.14285714285714285	0.14285714285714285	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-5.777777777777779	0.04	0.05202312138728324	0.0	0.043478260869565216	0.043478260869565216	7.0	0.05202312138728324	0.42857142857142855	1.0	0.0	-5.777777777777779	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.043478260869565216	0.0	0.05202312138728324	0.0	0.0	0.0	0.0	0.0
288	connected;Connect	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
90	The Cluster Randomized Usual Care vs Caduet Investigation Assessing Long-term	0.07389040794853105	-2.6000000000000014	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.044642857142857144	0.044642857142857144	12.0	0.04	0.08333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	12.0	0.044642857142857144	0.0	0.04	0.0	0.0	0.0	0.0	0.0
206	Plus;plus	0.10342684077091369	-6.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.05263157894736842	0.05263157894736842	1.0	0.054545454545454536	0.0	2.0	0.0	-6.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.05263157894736842	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
221	ventral striatum;Ventral Striatum	0.7680212118392316	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	1.0	0.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
222	this disease	0.11222438816558657	-3.1111111111111107	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.1111111111111107	0.0	0.0	0.0	0.04	0.04	0.0	0.04568527918781726	0.04568527918781726	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04568527918781726	0.0	0.04	0.0	0.0	0.0	0.0	0.0
341	tests;Tests	0.09028917690936211	-3.625	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.625	0.0	0.0	-1.625	0.04	0.0427807486631016	0.0	0.04678362573099415	0.04678362573099415	1.0	0.0427807486631016	0.0	1.0	0.0	-1.625	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04678362573099415	0.0	0.0427807486631016	0.0	0.0	0.0	0.0	0.0
310	The success	0.034516290818914525	-3.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.04597701149425287	0.04597701149425287	2.0	0.05128205128205128	0.5	1.0	0.0	-5.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04597701149425287	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
262	TSC1 mutations	0.7268739028102027	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	miR-132 in the livers	0.01777577588902897	0.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.2	0.0	0.0	0.0	0.0	-3.8571428571428577	0.04	0.0472972972972973	0.0	0.04	0.04	4.0	0.0472972972972973	0.5	1.0	0.0	-3.8571428571428577	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.0472972972972973	0.0	0.0	0.0	0.0	0.0
239	transmission	0.08868222039193942	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04	0.04	1.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
319	external;External	0.07222112379244935	-4.166666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.166666666666666	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.047999999999999994	0.047999999999999994	1.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047999999999999994	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
102	mCry1	0.7658838657016142	-2.6666666666666665	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.045119909181211865	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04938271604938271	0.0	0.04	0.0	0.0	0.0	0.0	0.0
203	Inheritance;inheritance	0.6284149959227107	-4.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
34	GH3-PV and ME gene	0.10078539506118378	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.2	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.16666666666666666	0.0	1.0
181	79)	0.6593307639162203	-2.8571428571428577	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.8571428571428577	0.0	0.0	0.0	0.04	0.04	0.0	0.04516129032258065	0.04516129032258065	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04516129032258065	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	benzodiazepine agonists without tranquillising or anticonvulsant actions	0.261000807037155	0.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-3.5	0.04	0.046511627906976744	0.0	0.04	0.04	7.0	0.046511627906976744	0.14285714285714285	1.0	1.0	-3.5	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	7.0	0.04	0.0	0.046511627906976744	0.0	1.0	0.0	0.0	1.0
225	surveillance	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
130	resistance to cephalosporins	0.0383335979310236	-1.2727272727272734	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.2727272727272734	0.0	0.0	-4.2857142857142865	0.04	0.04827586206896552	0.0	0.0421455938697318	0.0421455938697318	3.0	0.04827586206896552	0.6666666666666666	1.0	0.0	-4.2857142857142865	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.0421455938697318	0.0	0.04827586206896552	0.0	0.0	0.0	0.0	0.0
87	transcription of beta	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
194	functional delineation of viral genes	0.07102433777577496	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.04	0.04	5.0	0.06666666666666667	0.2	1.0	0.0	-10.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
316	Which amino acid residue	0.017828441736075843	-10.818181818181818	1.0	0.0	0.04	0.04	0.5	0.5	1.0	0.0	1.0	1.0	-10.818181818181818	1.0	1.0	-6.0	0.04	0.05263157894736842	1.0	0.07051282051282051	0.07051282051282051	4.0	0.05263157894736842	1.0	1.0	1.0	-6.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.07051282051282051	0.0	0.05263157894736842	1.0	1.0	0.25	0.0	1.0
340	including;Including	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	VDWS;vdW	0.7111192058369022	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
110	IV	0.6052148580033511	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.04	0.04	1.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
236	queries sample sets for the presence and quantity	0.042565234018144896	0.0	0.0	0.0	0.04	0.04	0.875	0.875	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.125	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
213	LQT11	0.7999733836848668	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	1.0	0.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
99	Coupled;coupled	0.58186787222913	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.2857142857142847	0.04	0.0440251572327044	0.0	0.04	0.04	0.0	0.0440251572327044	0.0	1.0	0.0	-2.2857142857142847	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.0440251572327044	0.0	0.0	0.0	0.0	0.0
341	Mutagenesis;mutagenesis	0.04481844398823881	-14.125	1.0	-15.0	0.1	0.1	0.0	0.0	1.0	-15.0	1.0	0.0	-14.125	0.0	0.0	-15.375	0.1	0.1038961038961039	0.0	0.09195402298850575	0.09195402298850575	1.0	0.1038961038961039	1.0	1.0	0.0	-15.375	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.09195402298850575	0.0	0.1038961038961039	1.0	0.0	0.0	0.0	0.0
121	Successful results	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
215	genetic Skp2 inactivation	0.3735129069398205	-5.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-5.0	1.0	1.0	-7.4	0.04	0.056818181818181816	0.0	0.05	0.05	3.0	0.056818181818181816	0.0	1.0	1.0	-7.4	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.05	0.0	0.056818181818181816	0.0	1.0	0.0	0.0	1.0
88	Maintain;maintaining	0.11118027593353519	-3.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-2.0	0.04	0.04	0.0	0.0449438202247191	0.04600132187706543	1.0	0.04380952380952381	0.0	2.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.047058823529411764	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
195	Pluripotent Stem Cells;pluripotent stem cells	0.273186749315542	-4.25	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-6.333333333333333	0.04	0.053571428571428575	0.0	0.04819277108433735	0.04819277108433736	3.0	0.053571428571428575	0.0	3.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.04819277108433735	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
251	Knockdown	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	capability;Capability	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
108	ZAP-70;ZAP70	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	SFX	0.6358706525256298	-10.333333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-10.333333333333334	0.0	0.0	-10.333333333333334	0.04	0.06818181818181819	0.0	0.06818181818181819	0.06818181818181819	1.0	0.06818181818181819	0.0	1.0	0.0	-10.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.06818181818181819	0.0	0.06818181818181819	0.0	0.0	0.0	0.0	0.0
83	extensive metabolization	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	use	0.0068670293986300476	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-7.4	0.04	0.056818181818181816	0.0	0.045454545454545456	0.045454545454545456	1.0	0.056818181818181816	1.0	1.0	0.0	-7.4	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.045454545454545456	0.0	0.056818181818181816	1.0	0.0	0.0	0.0	0.0
199	a centromere-specific histone H3 variant	0.13807809287462666	-3.0	1.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.6	1.0	-3.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.045454545454545456	0.045454545454545456	7.0	0.045454545454545456	0.2857142857142857	1.0	0.0	-3.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.045454545454545456	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
145	/-3.19	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
171	an MYH7-associated spectrum	0.2911515016289677	-3.6000000000000014	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	-3.6000000000000014	1.0	1.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04672897196261683	0.04672897196261683	5.0	0.053571428571428575	0.0	1.0	1.0	-6.333333333333334	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04672897196261683	0.0	0.053571428571428575	0.0	1.0	0.0	0.0	1.0
79	First;first	0.06901263893103253	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
95	Group;group	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
237	the mutual masking of the NLS	0.07482839671622277	-4.2857142857142865	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-4.2857142857142865	0.0	0.0	-7.2857142857142865	0.04	0.056451612903225805	0.0	0.04827586206896552	0.04827586206896552	6.0	0.056451612903225805	0.16666666666666666	1.0	0.0	-7.2857142857142865	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04827586206896552	0.0	0.056451612903225805	0.0	0.0	0.0	0.0	0.0
16	TYPE OF EVENT;type of event	0.01641018735644576	-1.7272727272727266	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.7272727272727266	0.0	0.0	-6.75	0.04	0.0547945205479452	0.0	0.04296875	0.04296875	3.0	0.0547945205479452	0.6666666666666666	1.0	0.0	-6.75	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04296875	0.0	0.0547945205479452	0.0	0.0	0.0	0.0	0.0
60	removing;remove	0.07499322504562757	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.04819277108433735	0.04819277108433735	1.0	0.054545454545454536	0.0	1.0	0.0	-6.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04819277108433735	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
63	twice (25 mg)	0.4175122847513681	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	apoptotic cell death;apoptosis;Apoptosis	0.8730210851874689	0.0	0.0	0.0	0.04	0.04	0.0	0.2857142857142857	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.8571428571428572	0.04	0.0	7.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	13.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
326	Portuguese type	0.18234127873147196	-4.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-12.0	0.04	0.07692307692307693	0.0	0.047619047619047616	0.047619047619047616	2.0	0.07692307692307693	0.0	1.0	0.0	-12.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047619047619047616	0.0	0.07692307692307693	0.0	0.0	0.0	0.0	0.0
334	Relaxation;relaxation	0.5507698756409757	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.04	0.04	1.0	0.046511627906976744	0.0	1.0	0.0	-3.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
95	many;MANY	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
76	patients;Patients	0.05565668960013652	-2.1666666666666674	1.0	-17.0	0.04	0.049444444444444444	1.0	1.0	1.0	-1.8888888888888888	1.0	0.0	-10.333333333333334	0.0	0.0	-2.2222222222222223	0.125	0.04	0.0	0.04	0.044940237959105886	1.0	0.05777777777777778	1.0	9.0	0.0	-20.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.06818181818181819	0.0	0.2	1.0	0.0	0.0	0.0	0.0
142	276 families	0.21653605649741273	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.7777777777777786	0.04	0.04712041884816754	0.0	0.04	0.04	2.0	0.04712041884816754	0.0	1.0	0.0	-3.7777777777777786	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04712041884816754	0.0	0.0	0.0	0.0	0.0
44	Major;major	0.1069223543550944	-7.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-12.0	0.0	0.0	-7.888888888888888	0.04	0.04	0.0	0.04	0.06083228247162673	1.0	0.06403936670945658	0.0	3.0	0.0	-12.333333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.07692307692307693	0.0	0.07894736842105263	0.0	0.0	0.0	0.0	0.0
311	affecting;Affecting	0.0020220470683890266	-16.0	1.0	0.0	0.04	0.04	1.0	1.0	1.0	0.0	1.0	0.0	-16.0	0.0	0.0	-17.0	0.04	0.125	0.0	0.1111111111111111	0.1111111111111111	1.0	0.125	1.0	1.0	0.0	-17.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.1111111111111111	0.0	0.125	1.0	0.0	0.0	0.0	0.0
215	splenic B	0.6088816151902646	-3.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-5.4	0.04	0.0510204081632653	0.0	0.046511627906976744	0.046511627906976744	2.0	0.0510204081632653	0.0	1.0	0.0	-5.4	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.046511627906976744	0.0	0.0510204081632653	0.0	0.0	0.0	0.0	0.0
279	physiological;Physiological	0.037738533022495885	-7.0	1.0	-12.666666666666668	0.08108108108108109	0.08108108108108109	0.0	0.0	1.0	-12.666666666666668	1.0	0.0	-7.0	0.0	0.0	-11.833333333333334	0.08108108108108109	0.0759493670886076	0.0	0.05555555555555555	0.05555555555555555	1.0	0.0759493670886076	1.0	1.0	0.0	-11.833333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05555555555555555	0.0	0.0759493670886076	1.0	0.0	0.0	0.0	0.0
287	spindle organization;spindle organisation	0.19328562913352193	-3.6000000000000014	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04672897196261683	0.04672897196261683	2.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04672897196261683	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
58	standard triple therapies for the first-line empirical treatment	0.05648401595583746	0.0	0.0	0.0	0.04	0.04	0.7	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
58	necessitating culture	0.36693796800475276	-3.666666666666668	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.046875	0.046875	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.046875	0.0	0.04	0.0	0.0	0.0	0.0	0.0
152	the glucose tolerance and insulin secretion	0.13798448006026953	-2.6000000000000014	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.044642857142857144	0.044642857142857144	6.0	0.045454545454545456	0.16666666666666666	1.0	0.0	-3.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.044642857142857144	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
251	led;LED	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
228	8-chloro-4-(3-chloro-4-fluorophenylamino)-6-((1-(1-ethylpiperidin-4-yl)-1H-1,2,3-triazol-4-yl)methylamino)quinoline-3-carbonitrile	0.12781749284540694	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	38.0	0.04	0.02631578947368421	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	38.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
129	states	0.10489297860865987	-1.4444444444444429	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.4444444444444429	0.0	0.0	-1.8571428571428577	0.04	0.043209876543209874	0.0	0.04245283018867924	0.04245283018867924	1.0	0.043209876543209874	0.0	1.0	0.0	-1.8571428571428577	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04245283018867924	0.0	0.043209876543209874	0.0	0.0	0.0	0.0	0.0
264	total and low-density lipoprotein-cholesterol levels	0.08489870484127501	-2.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-6.199999999999999	0.04	0.05319148936170213	0.0	0.043478260869565216	0.043478260869565216	9.0	0.05319148936170213	0.0	1.0	0.0	-6.199999999999999	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.043478260869565216	0.0	0.05319148936170213	0.0	0.0	0.0	0.0	0.0
41	MORTALITY FACTOR 4;(mortality factor on chromosome 4);MORF4 gene;MORF4-Related Gene;mortality factor on chromosome 4;MORF4	0.909587348869429	-3.2857142857142856	0.0	0.0	0.04	0.04	0.0	0.2183673469387755	0.0	0.0	0.0	1.0	-6.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.0468324657798342	2.857142857142857	0.04	0.0	7.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	6.0	1.0	20.0	0.05263157894736842	0.0	0.04	0.0	1.0	0.0	0.0	1.0
125	proximal Xq2	0.6888603927198186	-6.333333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.053571428571428575	0.053571428571428575	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.053571428571428575	0.0	0.04	0.0	0.0	0.0	0.0	0.0
140	Evolution;evolutionary	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
297	P;P NOS	0.8177154085095099	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	5.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
319	using;Using	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
344	the physiological adaptation	0.20746220121390285	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
258	specialized	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
224	a purine analogue	0.158721371904578	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.3333333333333333	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
9	the isochore composition	0.0848516545750064	-3.666666666666668	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.3333333333333333	0.0	-3.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.046875	0.046875	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.046875	0.0	0.04	0.0	0.0	0.0	0.0	0.0
216	Oak Ridge	0.07884817754029713	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	2.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
216	highest;Highest	0.06998091245582899	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	1.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
206	substance P-induced nociceptive behaviors	0.39579883826205237	-6.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-6.0	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.05263157894736842	0.05263157894736842	6.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.05263157894736842	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
287	investigational oral drug MLN8237	0.3198958898100202	-7.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-7.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.05555555555555555	0.05555555555555555	4.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.05555555555555555	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
332	EBV+ B cell lymphoma PTLD lines	0.595434504696659	0.0	0.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	14.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	Gene;gene;genes;Genes	0.26132458634749434	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-9.0	1.0	1.0	-6.0	0.04	0.046875	0.0	0.04	0.04750000000000001	1.0	0.05337628128576404	0.0	6.0	1.0	-10.0	1.0	1.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	4.0	1.0	6.0	0.0625	1.0	0.06666666666666667	0.0	1.0	0.0	1.0	1.0
62	an azathioprine-	0.5545875773905614	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
97	progressive disease	0.19118778544733417	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-7.666666666666666	0.04	0.05769230769230768	0.0	0.04	0.04	2.0	0.05769230769230768	0.0	1.0	0.0	-7.666666666666666	1.0	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	2.0	0.04	1.0	0.05769230769230768	0.0	0.0	0.0	1.0	0.0
331	effective;Efficacy;efficacy	0.41814509681559564	-2.166666666666667	0.0	0.0	0.04	0.04	0.0	0.5	0.0	0.0	0.0	0.0	-4.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04419354838709678	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.5	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.048387096774193554	0.0	0.04	0.0	0.0	0.0	0.0	0.0
68	Syndromic craniosynostosis	0.48938387720182974	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
331	truncation;Truncation	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
142	one;ONE	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	a variety of macromolecular complexes	0.11273377370854186	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	5.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
29	production of itaconic acid	0.005242358843181751	0.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.8	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	1.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	1.0	0.0	0.0	0.0	0.0
3	target site	0.12502993145013133	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.142857142857142	0.04	0.04794520547945205	0.0	0.04	0.04	2.0	0.04794520547945205	0.0	2.0	0.0	-4.142857142857142	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04794520547945205	0.0	0.0	0.0	0.0	0.0
329	CSBB-ConeExclusion	0.7409201488454747	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	Keep;kept	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
198	Family members of patients	0.050131550227233534	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.047619047619047616	0.047619047619047616	4.0	0.04938271604938271	0.25	1.0	0.0	-4.75	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.047619047619047616	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
89	bone pain in 3 (11%) children	0.04281128177060935	-6.800000000000001	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.25	0.0	-6.800000000000001	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.054945054945054944	0.054945054945054944	8.0	0.05405405405405406	0.375	1.0	0.0	-6.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.054945054945054944	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
134	Lacritin;lacritin;LACRITIN	0.9158389857548518	-1.619047619047619	1.0	-9.5	0.04	0.041167434715821814	0.0	0.0	1.0	-0.4523809523809524	1.0	0.0	-13.0	0.0	0.0	-1.880952380952381	0.06451612903225806	0.04	1.0	0.04	0.04410896134013194	1.0	0.04449615743733391	1.0	21.0	0.0	-10.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	21.0	0.08333333333333333	0.0	0.06666666666666667	1.0	0.0	1.0	0.0	0.0
103	Which	0.004962948615109367	-15.666666666666668	1.0	-11.625	0.07476635514018691	0.07476635514018691	1.0	1.0	1.0	-11.625	1.0	0.0	-15.666666666666668	0.0	0.0	-9.428571428571429	0.07476635514018691	0.06422018348623854	0.0	0.10714285714285715	0.10714285714285715	1.0	0.06422018348623854	1.0	1.0	0.0	-9.428571428571429	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.10714285714285715	0.0	0.06422018348623854	1.0	0.0	0.0	0.0	0.0
241	the fifth lumbar vertebra in which	0.04827417868691507	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
104	Set;sets	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
143	abundant;Abundant	0.5452066125383197	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
264	sHT	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
279	LKB1	0.2851361668253713	-5.0	1.0	-13.0	0.04	0.05444444444444444	0.0	0.0	1.0	-4.333333333333333	1.0	1.0	-15.0	0.0	0.0	-6.277777777777778	0.08333333333333333	0.04	0.0	0.04	0.06	1.0	0.05985074626865672	1.0	6.0	0.0	-13.833333333333332	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.1	0.0	0.08955223880597014	1.0	0.0	0.0	0.0	0.0
203	associated with;Associated with	0.12172938320782319	-3.1666666666666665	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-9.5	0.0	0.0	-3.866666666666667	0.04	0.04716981132075472	0.0	0.04	0.048172043010752695	2.0	0.04731955675351902	0.0	3.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.06451612903225806	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
125	the ubiquitously expressed MTM1 gene	0.07594933472817433	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
37	II inhibition	0.3326745161379748	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	2.0	0.05	0.5	1.0	0.0	-5.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
251	cell-cell adhesion	0.9962502698519727	-3.644444444444445	1.0	-13.6	0.04	0.04954385964912281	0.5	0.5	1.0	-2.7199999999999998	1.0	0.0	-13.88888888888889	0.0	0.0	-3.400000000000001	0.08771929824561403	0.04	0.0	0.04	0.05167741935483871	4.0	0.05092401643685019	1.0	15.0	0.0	-13.777777777777779	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	60.0	0.09	0.0	0.08910891089108912	1.0	0.0	0.0	0.0	0.0
88	pluripotency of embryonic stem (ES) and embryonal carcinoma (EC) cells	0.21304979602236793	-3.25	0.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.04597701149425287	0.04597701149425287	14.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	14.0	0.04597701149425287	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
100	insights	0.09785621730280385	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.04	0.044117647058823525	0.0	0.04	0.04	1.0	0.044117647058823525	0.0	1.0	0.0	-2.333333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.044117647058823525	0.0	0.0	0.0	0.0	0.0
61	Possible;possibility	0.068089662058489	-3.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-8.25	0.04	0.05970149253731343	0.0	0.046296296296296294	0.046296296296296294	1.0	0.05970149253731343	0.0	1.0	0.0	-8.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046296296296296294	0.0	0.05970149253731343	0.0	0.0	0.0	0.0	0.0
203	Example;example	0.07089744013313976	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-7.800000000000001	0.04	0.05813953488372093	0.0	0.047619047619047616	0.047619047619047616	1.0	0.05813953488372093	0.0	1.0	0.0	-7.800000000000001	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.05813953488372093	0.0	0.0	0.0	0.0	0.0
20	mother centrioles	0.3503133802618813	-4.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-4.5	1.0	1.0	-8.0	0.04	0.058823529411764705	0.0	0.04878048780487805	0.04878048780487805	2.0	0.058823529411764705	0.0	2.0	1.0	-8.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04878048780487805	0.0	0.058823529411764705	0.0	1.0	0.0	0.0	1.0
90	CHOLESTEROL;cholesterol	0.08437381651973458	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.04	0.04	1.0	0.05405405405405406	0.0	2.0	0.0	-6.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
319	series of novel diastereoisomeric σ	0.10699058841176723	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
17	the most common secreting pituitary adenoma	0.06318411562006669	-7.166666666666666	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.4	1.0	-7.166666666666666	1.0	1.0	0.0	0.04	0.04	0.0	0.05607476635514018	0.05607476635514018	6.0	0.04	0.5	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.05607476635514018	0.0	0.04	0.0	1.0	0.0	0.0	1.0
144	motifs;Motif	0.5284544855105483	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.04	0.04	1.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
222	the immune system such as CD52 (alemtuzumab)	0.12546998365403636	0.0	1.0	0.0	0.04	0.04	0.5555555555555556	0.5555555555555556	0.0	0.0	0.25	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.1111111111111111	1.0	1.0	0.0	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	9.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
160	Pharmacologic;pharmacologic	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
149	male mice	0.14684823062145294	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
158	noted;Note	0.07586760580212178	-3.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04716981132075472	0.04716981132075472	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04716981132075472	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
318	a selective Bcr-Abl tyrosine kinase inhibitor;a selective BCR-ABL tyrosine kinase inhibitor	0.7090636233097198	-0.518518518518519	0.0	0.0	0.04	0.04	0.125	0.125	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	-3.5384615384615388	0.04	0.04529616724738676	1.0	0.04	0.04088467614533966	8.0	0.04661429066573388	0.5	3.0	0.0	-3.9230769230769234	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	24.0	0.04265402843601896	0.0	0.04744525547445255	0.0	0.0	0.125	0.0	0.0
75	PROTEIN;protein	0.15392674727082623	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.5	1.0	0.0	1.0	0.0	1.0	0.5	0.5	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
315	mutations of the Notch3 gene;mutations of the NOTCH3 gene	0.24862582335131503	-6.75	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	-7.5	1.0	1.0	-3.25	0.04	0.04	1.0	0.05263157894736842	0.054887218045112776	5.0	0.04702702702702703	0.2	2.0	1.0	-6.5	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	10.0	0.05714285714285714	0.0	0.05405405405405406	0.0	1.0	0.2	0.0	1.0
21	type;TYPE	0.08255200685360059	-4.428571428571429	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.428571428571429	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04861111111111112	0.04861111111111112	1.0	0.04878048780487805	0.0	1.0	0.0	-4.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04861111111111112	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
143	investigated	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	the prediction of functional associations	0.01192475605658471	0.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.6	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
140	Technology;technology	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
268	SBH with epilepsy	0.18447131462377844	-4.5	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-4.5	1.0	1.0	-12.8	0.04	0.0819672131147541	0.0	0.04878048780487805	0.04878048780487805	3.0	0.0819672131147541	0.3333333333333333	1.0	1.0	-12.8	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04878048780487805	0.0	0.0819672131147541	0.0	1.0	0.0	0.0	1.0
291	Field's;fields	0.0034860098735072223	-13.714285714285715	1.0	-19.0	0.16666666666666666	0.16666666666666666	1.0	1.0	1.0	-19.0	1.0	0.0	-13.714285714285715	0.0	0.0	-16.0	0.16666666666666666	0.1111111111111111	1.0	0.08860759493670887	0.08860759493670887	1.0	0.1111111111111111	1.0	1.0	0.0	-16.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.08860759493670887	0.0	0.1111111111111111	1.0	0.0	1.0	0.0	0.0
331	a single disease subgroup	0.13156433783172206	-5.333333333333334	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.05084745762711865	0.05084745762711865	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.05084745762711865	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	the gene cluster method	0.04714489269000447	-1.4545454545454533	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-1.4545454545454533	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.04247104247104247	0.04247104247104247	4.0	0.046511627906976744	0.5	1.0	0.0	-3.5	1.0	0.3333333333333333	1.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04247104247104247	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
118	Five;five	0.0029712787336165845	-13.571428571428571	1.0	-17.0	0.125	0.125	1.0	1.0	1.0	-17.0	1.0	0.0	-13.571428571428571	0.0	0.0	-16.5	0.125	0.11764705882352941	0.0	0.0875	0.0875	1.0	0.11764705882352941	1.0	1.0	0.0	-16.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0875	0.0	0.11764705882352941	1.0	0.0	0.0	0.0	0.0
328	observation;Observation	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
22	5	0.7123617662367117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
144	MEF-2) in the regulation	0.03039815438477624	0.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.5	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.6	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
146	In Vivo;in vivo	0.17915280039691042	-2.833333333333332	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.045112781954887216	0.045112781954887216	2.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.045112781954887216	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
285	positive;% Positive	0.228830197272528	-4.72	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.199999999999999	0.0	0.0	-0.8	0.04	0.04	0.0	0.04	0.05011746770487335	1.0	0.041523809523809525	0.0	5.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.056179775280898875	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
329	each docking program	0.026700136328971828	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.6666666666666666	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
207	strategies	0.11916100613273456	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	The anti-angiogenic effect	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
189	31	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	the interactions	0.008393483074012111	-1.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	0.0	0.04	0.04	0.0	0.0425531914893617	0.0425531914893617	2.0	0.04	1.0	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.0425531914893617	0.0	0.04	1.0	0.0	0.0	0.0	0.0
276	the review of the pertinent literature	0.02759745460703475	-2.375	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-2.375	0.0	0.0	-9.6	0.04	0.06493506493506493	0.0	0.04419889502762431	0.04419889502762431	6.0	0.06493506493506493	0.3333333333333333	1.0	0.0	-9.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04419889502762431	0.0	0.06493506493506493	0.0	0.0	0.0	0.0	0.0
25	Eighty Nine;Eighty-nine	0.20699498922391737	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.04	0.04	3.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
224	an aggressive course	0.11532309302555079	-2.8571428571428577	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.8571428571428577	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04516129032258065	0.04516129032258065	3.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04516129032258065	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
222	treat;TREAT	0.08371445526796811	-3.7777777777777786	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.7777777777777786	0.0	0.0	-3.6000000000000014	0.04	0.04672897196261683	0.0	0.04712041884816754	0.04712041884816754	1.0	0.04672897196261683	0.0	1.0	0.0	-3.6000000000000014	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04712041884816754	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
41	only the HP1a fragments	0.07271193806005032	-9.5	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-9.5	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.06451612903225806	0.06451612903225806	4.0	0.05263157894736842	0.25	1.0	0.0	-6.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.06451612903225806	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
154	autosomal dominant diseases of skeletal and cardiac muscle	0.18162647824710096	-5.090909090909092	0.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.0	1.0	-5.090909090909092	1.0	1.0	-2.8000000000000007	0.04	0.04504504504504505	0.0	0.05022831050228311	0.05022831050228311	8.0	0.04504504504504505	0.125	1.0	1.0	-2.8000000000000007	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.05022831050228311	0.0	0.04504504504504505	0.0	1.0	0.0	0.0	1.0
160	inhibitor for RANKL;RANKL Inhibitor	0.4543160064788393	-3.333333333333332	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-3.333333333333332	1.0	1.0	-2.7142857142857153	0.04	0.04487179487179487	0.0	0.04615384615384615	0.04615384615384615	3.0	0.04487179487179487	0.0	1.0	1.0	-2.7142857142857153	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	3.0	0.04615384615384615	0.0	0.04487179487179487	0.0	1.0	0.0	0.0	1.0
179	a key signalling pathway for synaptic plasticity	0.06598717818057913	0.0	1.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.14285714285714285	0.0	0.0	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	1.0	0.04	0.04	7.0	0.04716981132075472	0.2857142857142857	1.0	0.0	-3.8000000000000007	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04716981132075472	0.0	0.0	0.14285714285714285	0.0	0.0
47	a training set of abundant validated genes	0.10057254967379158	0.0	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	insight into the biological relevance	0.08848691453375389	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
130	allow	0.10361573801894432	-1.09090909090909	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.09090909090909	0.0	0.0	-1.8571428571428577	0.04	0.043209876543209874	0.0	0.04182509505703422	0.04182509505703422	1.0	0.043209876543209874	0.0	1.0	0.0	-1.8571428571428577	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04182509505703422	0.0	0.043209876543209874	0.0	0.0	0.0	0.0	0.0
184	8)	0.6087867693893387	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
307	Distributed;distributed;distribution	0.0868068106467973	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
330	improving;Improving	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
140	modifications on the same histone	0.054558358707091664	0.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.4	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
127	activating	0.7075479496093484	-1.666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.043076923076923075	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04615384615384615	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	0.05)	0.6049773248431876	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.04	0.04	2.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
225	the calcitonin/CGRP gene in Williams syndrome	0.09673579917478398	-5.333333333333334	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.375	1.0	-5.333333333333334	1.0	1.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.05084745762711865	0.05084745762711865	8.0	0.04918032786885245	0.375	1.0	1.0	-4.666666666666666	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	8.0	0.05084745762711865	1.0	0.04918032786885245	0.0	1.0	0.0	1.0	1.0
68	2 domain	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	cpSRP43 with those	0.09640179081965947	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-11.0	0.04	0.07142857142857142	0.0	0.04	0.04	3.0	0.07142857142857142	0.0	1.0	0.0	-11.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0
15	A large number of systems	0.049229933674124475	-1.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6000000000000014	0.0	0.0	-3.6000000000000014	0.04	0.04672897196261683	0.0	0.042735042735042736	0.042735042735042736	5.0	0.04672897196261683	0.2	1.0	0.0	-3.6000000000000014	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.042735042735042736	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
241	mechanical low back pain;Low Back Pain, Mechanical	0.17787402945782355	-4.166666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-6.333333333333334	0.0	0.0	-3.5	0.04	0.04	0.0	0.043478260869565216	0.048524844720496896	4.0	0.04777777777777778	0.0	2.0	0.0	-7.0	1.0	0.3333333333333333	1.0	0.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	8.0	0.053571428571428575	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
199	cancer;CANCER	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
220	novel point mutation	0.0414775029729854	-2.25	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.3333333333333333	0.0	-2.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04395604395604396	0.04395604395604396	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04395604395604396	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	bioinformatics;Bio-Informatics	0.5961070020639527	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.166666666666667	0.04	0.045454545454545456	0.0	0.04	0.04	0.0	0.04815100154083205	0.0	2.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
331	involved;Involved	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
276	either;Either	0.0907248911674243	-1.875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.875	0.0	0.0	0.0	0.04	0.04	0.0	0.043243243243243246	0.043243243243243246	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043243243243243246	0.0	0.04	0.0	0.0	0.0	0.0	0.0
135	List	0.003914569547393997	-7.235294117647058	1.0	-10.0	0.06666666666666667	0.06666666666666667	1.0	1.0	1.0	-10.0	1.0	0.0	-7.235294117647058	0.0	0.0	-6.5	0.06666666666666667	0.05405405405405406	0.0	0.05629139072847682	0.05629139072847682	1.0	0.05405405405405406	1.0	1.0	0.0	-6.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.05629139072847682	0.0	0.05405405405405406	1.0	0.0	0.0	0.0	0.0
73	the membrane residues	0.20039700037850638	-1.7777777777777786	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-2.5	0.04	0.044444444444444446	0.0	0.0430622009569378	0.0430622009569378	3.0	0.044444444444444446	0.3333333333333333	1.0	0.0	-2.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.0430622009569378	0.0	0.044444444444444446	0.0	0.0	0.0	0.0	0.0
276	abnormal serum TH levels	0.8112915885175437	-3.5625	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-7.699999999999999	0.04	0.050505050505050504	0.0	0.04419889502762431	0.04679080553850351	4.0	0.05903630903630903	0.0	4.0	0.0	-10.2	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	16.0	0.04938271604938271	0.0	0.06756756756756756	0.0	0.0	0.0	0.0	0.0
277	Risk;risk	0.09791626349566201	-1.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-2.5	0.04	0.04	0.0	0.04	0.042727272727272725	1.0	0.045	0.0	2.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.045454545454545456	0.0	0.05	0.0	0.0	0.0	0.0	0.0
249	histone modifications	0.3250093325916772	-7.583333333333334	1.0	-12.75	0.04	0.060816326530612246	0.0	0.0	1.0	-6.375	1.0	1.0	-12.166666666666668	1.0	1.0	-5.125	0.08163265306122448	0.04	1.0	0.045454545454545456	0.061688311688311695	2.0	0.053898305084745766	1.0	4.0	1.0	-10.25	1.0	0.5	0.0	1.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	8.0	0.07792207792207793	0.0	0.06779661016949153	1.0	1.0	0.5	0.0	1.0
122	430C	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
246	clopidogrel treatment	0.07928746847952328	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
194	Overcome;overcome	0.05710314513152379	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.04	0.04	1.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
224	Aggressive course;aggressive course	0.06080557737520937	-2.428571428571427	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.428571428571427	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.04430379746835443	0.04430379746835443	2.0	0.06060606060606061	0.0	1.0	0.0	-8.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04430379746835443	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
294	oral;Oral	0.07096173573097679	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.04	0.04	1.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
302	Stimulated;stimulated	0.09241438672407117	-2.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04424778761061947	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04424778761061947	0.0	0.04	0.0	0.0	0.0	0.0	0.0
317	so;SO	0.093065404135075	-2.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.044642857142857144	0.044642857142857144	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.044642857142857144	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	available interaction and disease association data	0.07748277985570153	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	Increase;increase	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
20	the ortholog	0.08975770543432947	-3.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.046511627906976744	0.046511627906976744	2.0	0.05555555555555555	0.5	1.0	0.0	-7.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.046511627906976744	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
44	its role in the general system	0.05188490880056764	-12.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-12.25	0.0	0.0	-11.333333333333334	0.04	0.07317073170731708	0.0	0.0784313725490196	0.0784313725490196	6.0	0.07317073170731708	0.16666666666666666	1.0	0.0	-11.333333333333334	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.0784313725490196	0.0	0.07317073170731708	0.0	0.0	0.0	0.0	0.0
124	the clinical validity	0.07311816216437765	-6.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-11.666666666666666	0.04	0.075	0.0	0.053571428571428575	0.053571428571428575	3.0	0.075	0.0	1.0	0.0	-11.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.053571428571428575	0.0	0.075	0.0	0.0	0.0	0.0	0.0
320	ring;Ring	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
21	found;Found	0.07689054439380835	-2.1428571428571423	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1428571428571423	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04375	0.04375	1.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04375	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
44	ODC and AdoMetDC	0.4805519658837638	-2.75	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0449438202247191	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
287	Support, NOS;supporting	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
183	significant	0.11705101972382376	-6.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.25	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.05333333333333334	0.05333333333333334	1.0	0.04597701149425287	0.0	1.0	0.0	-3.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.05333333333333334	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
222	lymphocytes and monocytes	0.4513932814444703	-2.2222222222222214	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-4.2	0.04	0.04	0.0	0.04245283018867924	0.04395368782161235	3.0	0.05012048192771084	0.0	2.0	0.0	-8.4	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.045454545454545456	0.0	0.06024096385542168	0.0	0.0	0.0	0.0	0.0
303	ADP	0.6723018388194858	-2.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	0.0	0.04	0.04	0.0	0.044444444444444446	0.044444444444444446	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.044444444444444446	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	Rare;rare;Infrequently;infrequently	0.3179952054180665	-1.8000000000000007	0.0	0.0	0.04	0.04	0.0	0.5	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-4.125	0.04	0.04	0.0	0.04	0.04336448598130842	1.0	0.049850746268656716	0.0	2.0	0.0	-8.25	1.0	0.0	0.5	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.04672897196261683	0.0	0.05970149253731343	0.0	0.0	0.0	0.0	0.0
62	treated with;Treated with	0.14129667528025572	-1.962962962962963	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.7777777777777786	0.0	0.0	-4.5	0.04	0.04	0.0	0.04	0.04360324641217236	2.0	0.050307059195948085	0.0	3.0	0.0	-8.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04712041884816754	0.0	0.06153846153846154	0.0	0.0	0.0	0.0	0.0
88	a cascade	0.22676431879742096	-4.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04878048780487805	0.04878048780487805	2.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04878048780487805	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
124	High;high	0.10367987604807946	-5.333333333333333	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-5.5	0.04	0.04	0.0	0.04918032786885245	0.05090595340811044	1.0	0.055714285714285716	0.0	2.0	0.0	-11.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.05263157894736842	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0
153	paranoid schizophrenia;PARANOID SCHIZOPHRENIA	0.7256698908806898	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
221	outcomes;Outcome	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
206	(4 mg/kg	0.5734705360634784	-6.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.05263157894736842	0.05263157894736842	5.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.05263157894736842	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
82	many Asian populations other than Han Chinese	0.03839430964860704	-4.857142857142858	1.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.125	0.0	-4.857142857142858	0.0	0.0	-2.8000000000000007	0.04	0.04504504504504505	1.0	0.04964539007092199	0.04964539007092199	7.0	0.04504504504504505	0.0	1.0	0.0	-2.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04964539007092199	0.0	0.04504504504504505	0.0	0.0	0.14285714285714285	0.0	0.0
140	posttranslational modifications;Post-Translational Modifications	0.6721500832556117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
235	hypothalamic hypocretin/orexin	0.5694888191786677	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.04	0.04504504504504505	0.0	0.04	0.04	4.0	0.04504504504504505	0.0	1.0	0.0	-2.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04504504504504505	0.0	0.0	0.0	0.0	0.0
14	a consensus prediction method	0.029668956213677863	-1.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.25	0.0	-2.0	0.0	0.0	-4.0	0.04	0.04	1.0	0.04	0.04173913043478261	4.0	0.04941176470588235	0.5	2.0	0.0	-8.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.043478260869565216	0.0	0.058823529411764705	0.0	0.0	0.25	0.0	0.0
199	Interaction;interaction	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	preferential;Preference;preference	0.45450485395060874	-1.1944444444444438	0.0	0.0	0.04	0.04	0.0	0.75	0.0	0.0	0.0	0.0	-2.2222222222222214	0.0	0.0	-2.357142857142857	0.04	0.04	0.0	0.04	0.042053008729376486	1.0	0.044365577406062645	0.0	4.0	0.0	-4.2857142857142865	1.0	0.0	0.75	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.04390243902439024	0.0	0.04827586206896552	0.0	0.0	0.0	0.0	0.0
301	work;Work	0.05832455349431528	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04	0.04	1.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
46	the sonic hedgehog signaling pathway	0.23760369998293066	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	treated;Treated	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	CTCF and DNA methyltransferases DNMT1 and DNMT3B to Epstein-Barr virus restricted latency	0.23230275323426616	0.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	14.0	0.04	0.14285714285714285	1.0	1.0	0.0	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	14.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
321	MMP-13 inhibitors;MMP Inhibitors	0.6286822022715947	-2.3999999999999986	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.3999999999999986	1.0	1.0	-12.0	0.04	0.07692307692307693	0.0	0.04424778761061947	0.04424778761061947	2.0	0.07692307692307693	0.0	2.0	1.0	-12.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	4.0	0.04424778761061947	0.0	0.07692307692307693	0.0	1.0	0.0	0.0	1.0
58	those of strategies	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	a novel factor	0.09192472200753661	-1.5555555555555571	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04265402843601896	0.04265402843601896	3.0	0.043478260869565216	0.0	1.0	0.0	-2.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04265402843601896	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
137	Progressive;progressive	0.0986904768548595	-1.7777777777777768	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1111111111111107	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04245283018867924	0.04307107528851438	1.0	0.04716981132075472	0.0	2.0	0.0	-3.8000000000000007	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.043689320388349516	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
186	this condition	0.1801467773787151	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.5	1.0	0.0	1.0	0.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
330	function	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	four;Four	0.0985949953261355	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	at;At	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
286	0;0%	0.6066186994119565	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
235	AUTOIMMUNE DISEASE;autoimmune basis for the disease	0.027391247475725095	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.04	0.04	5.0	0.04587155963302752	0.4	1.0	0.0	-3.1999999999999993	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
124	The oncotype DX® genomic assay;the Oncotype DX genomic assay	0.2446731727764982	0.0	1.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.26666666666666666	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.30000000000000004	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	disease in patients	0.028463520491508895	-1.6999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04291845493562232	0.04291845493562232	3.0	0.04	0.6666666666666666	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04291845493562232	0.0	0.04	0.0	0.0	0.0	0.0	0.0
291	Physical Activity;physical activity	0.08446653651773954	-1.7142857142857153	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.7142857142857153	0.0	0.0	0.0	0.04	0.04	0.0	0.04294478527607362	0.04294478527607362	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04294478527607362	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	BCR;Bcr	0.8834660355010626	-0.24074074074074048	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-1.4444444444444429	0.0	0.0	-3.5	0.04	0.04406779661016949	0.0	0.04	0.04040880503144654	1.0	0.04658760726817176	0.0	6.0	0.0	-4.615384615384615	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.04245283018867924	0.0	0.0490566037735849	0.0	0.0	0.0	0.0	0.0
50	three-quarters of the UCs	0.06492807365026797	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
180	germline retrotransposition event	0.3101551084390735	-2.666666666666668	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04477611940298508	0.04477611940298508	3.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04477611940298508	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
307	similar intensity	0.11103082798026633	-2.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04504504504504505	0.04504504504504505	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04504504504504505	0.0	0.04	0.0	0.0	0.0	0.0	0.0
234	28	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
86	Ca2;Ca(2;Ca2+;CA+2;Ca;CA	0.6300501810524535	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	6.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	Associated with;with associated	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
30	the pathogenesis of Alzheimer disease	0.08764873397589622	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-2.1999999999999993	0.04	0.043859649122807015	0.0	0.04	0.04	5.0	0.043859649122807015	0.4	1.0	1.0	-2.1999999999999993	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.043859649122807015	0.0	1.0	0.0	0.0	1.0
84	Design;designed	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	myeloma therapy	0.0871924695075329	-5.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-9.0	0.04	0.0625	0.0	0.05	0.05	2.0	0.0625	0.5	1.0	0.0	-9.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
149	bout	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
297	a significant inverse relationship between fT3 levels	0.10057254967379158	0.0	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
90	Identified;identified	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
71	mitochondrial respiration	0.9262345119848289	-2.4666666666666672	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-4.25	0.04	0.046511627906976744	0.0	0.04	0.04463292776112385	2.0	0.04822494392041251	0.0	6.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	12.0	0.04716981132075472	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
102	promoter-binding protein	0.337091341148186	-3.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-3.5	0.0	0.0	0.0	0.04	0.04	0.0	0.046511627906976744	0.046511627906976744	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.046511627906976744	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	processes;process;Process	0.09714018666575822	-1.6666666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-1.2222222222222225	0.04	0.04	0.0	0.04	0.043333333333333335	1.0	0.04229166666666667	0.0	3.0	0.0	-3.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	3.0	0.05	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
144	SERCA1, 2, and 3 genes	0.18412236603119664	0.0	1.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.16666666666666666	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	1.0	0.14285714285714285	0.0	1.0
146	the first time	0.04354719151390066	-2.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-5.0	0.04	0.05	0.0	0.04477611940298508	0.04477611940298508	3.0	0.05	0.3333333333333333	1.0	0.0	-5.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04477611940298508	0.0	0.05	0.0	0.0	0.0	0.0	0.0
237	Human T-cell leukemia virus type	0.1441829124213599	-2.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-4.2857142857142865	0.04	0.04827586206896552	0.0	0.043478260869565216	0.043478260869565216	5.0	0.04827586206896552	0.0	1.0	0.0	-4.2857142857142865	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.043478260869565216	0.0	0.04827586206896552	0.0	0.0	0.0	0.0	0.0
44	The merozoite surface protein	0.07131403734352044	-6.25	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-6.25	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.05333333333333334	0.05333333333333334	4.0	0.046875	0.25	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.05333333333333334	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
100	Binding site;binding site	0.20146510080365157	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
152	ENZYMES;enzymes	0.5116380224701204	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.04	0.04	1.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
130	most;Most	0.006385123783370011	-4.318181818181818	1.0	-9.11111111111111	0.04	0.045734265734265735	1.0	1.0	1.0	-2.2777777777777777	1.0	0.0	-12.272727272727273	0.0	0.0	-5.642857142857144	0.06293706293706293	0.0445859872611465	0.0	0.042801556420233464	0.051785822852973874	1.0	0.05314401542570846	1.0	4.0	0.0	-10.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.07857142857142857	0.0	0.06666666666666667	1.0	0.0	0.0	0.0	0.0
318	the synthesis	0.11471589821973863	-0.7777777777777786	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	-7.230769230769231	0.04	0.05508474576271186	0.0	0.04	0.04132701421800948	2.0	0.056303434828258586	0.5	2.0	0.0	-7.615384615384615	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04265402843601896	0.0	0.0575221238938053	0.0	0.0	0.0	0.0	0.0
96	Phial;vial	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
125	proximal Xq28	0.725193331728137	-3.166666666666667	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04678571428571429	2.5	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.053571428571428575	0.0	0.04	0.0	0.0	0.0	0.0	0.0
186	A novel gain-of-function KCNJ2 mutation	0.17567475839044147	-6.333333333333334	0.0	0.0	0.04	0.04	0.5555555555555556	0.5555555555555556	0.0	0.0	0.0	1.0	-6.333333333333334	1.0	1.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.053571428571428575	0.053571428571428575	9.0	0.05084745762711865	0.0	1.0	1.0	-5.333333333333334	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.053571428571428575	0.0	0.05084745762711865	0.0	1.0	0.0	0.0	1.0
254	FLS	0.7937116027904941	-1.0833333333333335	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04209677419354839	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.048387096774193554	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	Novartis	0.655601183833683	-3.0555555555555554	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-7.461538461538461	0.04	0.05179282868525897	0.0	0.043689320388349516	0.04565418400369857	1.0	0.05760373141580022	0.0	2.0	0.0	-9.23076923076923	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047619047619047616	0.0	0.06341463414634146	0.0	0.0	0.0	0.0	0.0
276	an X-linked mental retardation in which	0.1173691574700253	-7.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-7.0	1.0	1.0	-9.6	0.04	0.06493506493506493	0.0	0.05555555555555555	0.05555555555555555	6.0	0.06493506493506493	0.3333333333333333	1.0	1.0	-9.6	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.05555555555555555	0.0	0.06493506493506493	0.0	1.0	0.0	0.0	1.0
215	depend;depends	0.07563896052907934	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.04	0.04504504504504505	0.0	0.04	0.04	1.0	0.04504504504504505	0.0	1.0	0.0	-2.8000000000000007	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04504504504504505	0.0	0.0	0.0	0.0	0.0
246	post;Post	0.6517082239846936	-5.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05	0.05	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.05	0.0	0.04	0.0	0.0	0.0	0.0	0.0
321	a three dimensional quantitative structure-activity relationship	0.12287429190678524	0.0	0.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
139	the effect	0.003430209842711467	0.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	1.0	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	1.0	0.0	0.0	0.0	0.0
237	nuclear translocation of the NF	0.07871147090028174	-6.142857142857142	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-6.142857142857142	0.0	0.0	-4.428571428571429	0.04	0.04861111111111112	0.0	0.05303030303030303	0.05303030303030303	5.0	0.04861111111111112	0.4	1.0	0.0	-4.428571428571429	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.05303030303030303	0.0	0.04861111111111112	0.0	0.0	0.0	0.0	0.0
322	lack of structural data	0.052997877725278884	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	Ability;ability	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	10%);10%;10	0.7221328429096205	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	black;Black	0.12630014064898384	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.048387096774193554	0.05005561735261402	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.051724137931034475	0.0	0.04	0.0	0.0	0.0	0.0	0.0
274	several monoclonal and polyclonal antibodies	0.10014495686525313	-1.7272727272727266	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.3333333333333333	1.0	-1.7272727272727266	0.0	0.0	-2.2857142857142847	0.04	0.0440251572327044	0.0	0.04296875	0.04296875	5.0	0.0440251572327044	0.4	1.0	0.0	-2.2857142857142847	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04296875	0.0	0.0440251572327044	0.0	0.0	0.0	0.0	0.0
158	syndactyly of the Apert hand	0.09588013765816412	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
254	a possible link between the behavior	0.08929268021643819	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
344	data;Data	0.10504459973324444	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.166666666666666	0.04	0.04	0.0	0.04	0.04	1.0	0.04205882352941176	0.0	2.0	0.0	-2.333333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.044117647058823525	0.0	0.0	0.0	0.0	0.0
293	use	0.007574212670265181	-3.875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.75	0.0	0.0	-9.5	0.04	0.06451612903225806	1.0	0.04	0.04898550724637681	1.0	0.06451612903225806	1.0	2.0	0.0	-9.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.057971014492753624	0.0	0.06451612903225806	1.0	0.0	1.0	0.0	0.0
318	a potent and selective inhibitor	0.1512334620476482	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	5.0	0.05263157894736842	0.2	1.0	0.0	-6.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
344	the substantial and relatively uniform macroH2A1 enrichment along the inactive X chromosome	0.1412816360538147	0.0	0.0	0.0	0.04	0.04	0.5833333333333334	0.5833333333333334	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	12.0	0.04	0.16666666666666666	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	12.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
138	coupling with a phosphoprotein or phosphopeptide enrichment method	0.16674879238771032	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.125	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
104	algorithms;Algorithms	0.7549583354935522	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	1.0	0.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
122	the discovery	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
141	Verified;verified	0.53963204112352	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04	0.04	1.0	0.04878048780487805	0.0	1.0	0.0	-4.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
332	Pharmacokinetics of fostamatinib	0.11067740640158652	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
31	Reverse;reverse	0.1373781489479031	-0.7142857142857143	1.0	-17.5	0.04	0.04666666666666667	1.0	1.0	1.0	-1.25	1.0	0.0	-10.0	0.0	0.0	-10.607142857142858	0.13333333333333333	0.06666666666666667	0.0	0.04	0.0419047619047619	1.0	0.07289377289377288	1.0	14.0	0.0	-18.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	14.0	0.06666666666666667	0.0	0.15384615384615385	1.0	0.0	0.0	0.0	0.0
5	temporary, symptomatic treatment for all forms	0.045266548316961606	-9.75	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	0.0	-9.75	0.0	0.0	-13.75	0.04	0.08888888888888889	0.0	0.06557377049180328	0.06557377049180328	7.0	0.08888888888888889	0.2857142857142857	1.0	0.0	-13.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.06557377049180328	0.0	0.08888888888888889	0.0	0.0	0.0	0.0	0.0
91	the preference of the parents	0.03776773949451835	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	catalyse;catalyze	0.6472846101807735	-3.7222222222222214	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-2.571428571428573	0.04	0.0445859872611465	0.0	0.04433497536945812	0.04716748768472906	1.0	0.0445859872611465	0.0	2.0	0.0	-2.571428571428573	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.05	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
115	Gene Regulation;Regulation of Gene Expression;gene regulation;of a more precise regulation of gene expression	0.24157446072741462	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.5	0.04	0.0	4.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	14.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
243	Genetic Test;genetic test	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	INFORMATION;information	0.08264397268880755	-1.8888888888888893	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-2.2857142857142847	0.04	0.0440251572327044	0.0	0.04326923076923077	0.04326923076923077	1.0	0.0440251572327044	0.0	1.0	0.0	-2.2857142857142847	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04326923076923077	0.0	0.0440251572327044	0.0	0.0	0.0	0.0	0.0
49	45 sporadic cases	0.38037400910155467	-3.75	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	0.0	0.04	0.04	0.0	0.047058823529411764	0.047058823529411764	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.047058823529411764	0.0	0.04	0.0	0.0	0.0	0.0	0.0
206	s.c.)	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
339	Colorectal;colorectal	0.5585368507767386	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.04	0.04504504504504505	0.0	0.04	0.04	1.0	0.04504504504504505	0.0	1.0	0.0	-2.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04504504504504505	0.0	0.0	0.0	0.0	0.0
30	interactive ligand	0.5731567106891328	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-7.4	0.04	0.056818181818181816	0.0	0.043478260869565216	0.043478260869565216	2.0	0.056818181818181816	0.0	1.0	0.0	-7.4	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043478260869565216	0.0	0.056818181818181816	0.0	0.0	0.0	0.0	0.0
204	a mutation	0.10549951416075809	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
184	0.4	0.8625334661978433	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-3.625	0.04	0.0449438202247191	0.0	0.04	0.04	1.0	0.046862154014798575	0.0	2.0	0.0	-4.5	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	2.0	0.04	1.0	0.04878048780487805	0.0	0.0	0.0	1.0	0.0
291	self-assessment;Self-Assessment	0.6157476116558734	-2.8571428571428577	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.8571428571428577	0.0	0.0	0.0	0.04	0.04	0.0	0.04516129032258065	0.04516129032258065	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04516129032258065	0.0	0.04	0.0	0.0	0.0	0.0	0.0
139	A novel system	0.08553621821222154	-2.125	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.125	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04371584699453552	0.04371584699453552	3.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04371584699453552	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
188	impaired;Impaired	0.5576779774663313	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-4.6	0.04	0.04901960784313726	0.0	0.043478260869565216	0.043478260869565216	1.0	0.04901960784313726	0.0	1.0	0.0	-4.6	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.04901960784313726	0.0	0.0	0.0	0.0	0.0
319	an inhibitor	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
40	known;Known	0.06601588882641835	-2.833333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.045112781954887216	0.045112781954887216	1.0	0.06060606060606061	0.0	1.0	0.0	-8.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045112781954887216	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
149	miR-133a	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	Approach;approach	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
57	Two patients	0.06454209877709652	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-10.8	0.04	0.07042253521126761	0.0	0.04	0.04	2.0	0.07042253521126761	0.0	1.0	0.0	-10.8	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.07042253521126761	0.0	0.0	0.0	0.0	0.0
62	frequent;Frequent	0.0918391414846449	-2.2222222222222214	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.2222222222222214	0.0	0.0	0.0	0.04	0.04	0.0	0.04390243902439024	0.04390243902439024	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04390243902439024	0.0	0.04	0.0	0.0	0.0	0.0	0.0
111	synthase	0.6123470632438762	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.04	0.04	1.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
129	Mammals;Mammalian;mammalian;mammals	0.9673375021251305	-0.8650793650793648	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.444444444444443	0.0	0.0	-1.2448979591836742	0.04	0.04	0.0	0.04	0.041509667591244755	1.0	0.04216586568783876	0.0	14.0	0.0	-2.571428571428573	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	14.0	0.04639175257731958	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
25	clinical;Clinical	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	large;LARGE	0.21445745448356465	-2.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-1.8	0.04	0.04	0.0	0.04	0.04513331804164437	1.0	0.0435134849286092	0.0	5.0	0.0	-4.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04878048780487805	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
138	robust;Robust	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	Cell Cycle Progression;cell cycle progression	0.3207963476190355	-2.8000000000000007	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04504504504504505	0.04504504504504505	3.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.04504504504504505	0.0	0.04	0.0	0.0	0.0	0.0	0.0
163	Potential;potential	0.14270794741604015	-3.733333333333333	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.199999999999999	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.047730496453900706	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.05319148936170213	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	Europe (http://xfel.desy.de/)	0.6209288267526557	-4.666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.04918032786885245	0.04918032786885245	3.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04918032786885245	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
15	Our methods for gene	0.056191904608501216	-1.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.042735042735042736	0.042735042735042736	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.042735042735042736	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	safety;Safety	0.09993126082156532	-1.416666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-2.0	0.04	0.04	0.0	0.04	0.04255639097744361	1.0	0.04380952380952381	0.0	2.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.045112781954887216	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
24	the Phase II study of the Polycap	0.044041499774054436	0.0	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.42857142857142855	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
175	10%;10	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	human cancers	0.035767652370540116	-1.6999999999999993	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.25	1.0	-1.6999999999999993	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04291845493562232	0.04291845493562232	2.0	0.053571428571428575	0.5	2.0	0.0	-6.333333333333334	1.0	0.3333333333333333	1.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04291845493562232	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
14	diverse important functions	0.08885022849456611	-1.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.75	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.043010752688172046	0.043010752688172046	3.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043010752688172046	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
208	a late stage	0.11135912480252187	-4.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04938271604938271	0.04938271604938271	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04938271604938271	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	Deletion Xq28;Xq28 deletions	0.7635148111334668	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04	0.04	3.0	0.04819277108433736	0.0	3.0	0.0	-4.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.04	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
330	renal transplantation;Renal Transplantation	0.7733024347045858	-3.666666666666668	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.0	0.0	-1.375	0.04	0.042328042328042326	0.0	0.046875	0.046875	2.0	0.042328042328042326	0.0	3.0	0.0	-1.375	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.046875	0.0	0.042328042328042326	0.0	0.0	0.0	0.0	0.0
102	an essential component of the interlocking loop	0.056871526020296055	0.0	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.2857142857142857	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
338	associated with regional myocardial function;associated with function	0.04525336347841148	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
314	Protein Methylation;protein methylation	0.2763232303254625	-1.75	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.75	0.0	0.0	-1.8333333333333321	0.04	0.043165467625899276	0.0	0.043010752688172046	0.043010752688172046	2.0	0.043165467625899276	0.0	2.0	0.0	-1.8333333333333321	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.043010752688172046	0.0	0.043165467625899276	0.0	0.0	0.0	0.0	0.0
77	adjunctive agents	0.35661697118172314	-2.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
223	treatment;treatment nos	0.004937072634532772	-1.3636363636363633	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.3636363636363633	0.0	0.0	-7.571428571428571	0.04	0.05737704918032786	0.0	0.04230769230769231	0.04230769230769231	1.0	0.05737704918032786	1.0	1.0	0.0	-7.571428571428571	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04230769230769231	0.0	0.05737704918032786	1.0	0.0	0.0	0.0	0.0
303	and;And	0.07208202620761509	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-7.833333333333334	0.04	0.05825242718446603	0.0	0.04878048780487805	0.04878048780487805	1.0	0.05825242718446603	0.0	1.0	0.0	-7.833333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04878048780487805	0.0	0.05825242718446603	0.0	0.0	0.0	0.0	0.0
258	unexpressed euchromatin	0.8498767559317133	-7.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.6	0.0	0.0	-8.7	0.04	0.056818181818181816	0.0	0.056818181818181816	0.05714472309299896	2.0	0.061742424242424244	0.0	4.0	0.0	-10.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.0574712643678161	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
229	Given;GIVEN	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
345	depend;depends	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	viruses;VIRUS;virus;VIRUSES	0.09662868018875136	-1.1666666666666665	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	-1.3333333333333335	0.04	0.04	0.0	0.04	0.04229508196721311	1.0	0.04271186440677966	0.0	4.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	4.0	0.04918032786885245	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
49	one;ONE	0.14095469534932045	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
90	further insight into the potential adherence benefits	0.04674180248996833	0.0	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	nuclear receptor subfamily 1, group D	0.422133438958043	0.0	0.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	6-diamines	0.6171953679194666	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
1	the intact AAUAAA	0.06465614833967585	-3.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.045454545454545456	0.045454545454545456	3.0	0.05714285714285714	0.3333333333333333	1.0	0.0	-7.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.045454545454545456	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
137	safety and efficacy	0.13888370569667688	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.8000000000000007	0.04	0.04310344827586207	0.0	0.04	0.04	3.0	0.04310344827586207	0.0	1.0	0.0	-1.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04310344827586207	0.0	0.0	0.0	0.0	0.0
252	in-hospital and long term mortality	0.0961834170647091	-2.375	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-2.375	0.0	0.0	0.0	0.04	0.04	0.0	0.04419889502762431	0.04419889502762431	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04419889502762431	0.0	0.04	0.0	0.0	0.0	0.0	0.0
39	epsilon;Epsilon	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	poly(A) mRNA	0.7409201488454747	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
326	entire coding sequence	0.18852434007754904	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.04	0.04	3.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
176	bovine histones by short-chain poly	0.1336581618357883	0.0	1.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.1111111111111111	1.0	0.0	1.0	1.0	-6.6	0.04	0.05434782608695653	0.0	0.04	0.04	7.0	0.05434782608695653	0.14285714285714285	1.0	1.0	-6.6	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	7.0	0.04	0.0	0.05434782608695653	0.0	1.0	0.0	0.0	1.0
78	the diagnosis	0.09537604656195404	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.05	0.05	2.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
315	a small vessel disease of the brain	0.10738218466298043	-10.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-10.0	0.0	0.0	-9.0	0.04	0.0625	0.0	0.06666666666666667	0.06666666666666667	7.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.3333333333333333	1.0	0.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.06666666666666667	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
223	bapineuzumab;BAPINEUZUMAB;Bapineuzumab	0.9533524095552723	-2.3818181818181814	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-6.181818181818182	1.0	1.0	-5.642857142857143	0.04	0.04294478527607362	0.0	0.04	0.044521697857576537	1.0	0.052690228368526194	0.0	10.0	1.0	-10.714285714285714	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	3.0	1.0	10.0	0.05314009661835748	0.0	0.06999999999999999	0.0	1.0	0.0	0.0	1.0
31	Bacillus anthracis [7] and group B streptococci	0.33280790095779406	0.0	0.0	0.0	0.04	0.04	0.2222222222222222	0.2222222222222222	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
37	spermine moiety	0.7681653543609436	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-6.0	0.0	0.0	-4.375	0.04	0.04	0.0	0.04	0.04631578947368421	2.0	0.050769230769230775	0.0	2.0	0.0	-8.75	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.05263157894736842	0.0	0.06153846153846154	0.0	0.0	0.0	0.0	0.0
83	mg;MG	0.605512584520538	-4.125	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-8.0	0.04	0.05555555555555555	0.0	0.047058823529411764	0.04791965566714491	1.0	0.059027777777777776	0.0	2.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04878048780487805	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
269	>90;90	0.6267343958350274	-2.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.043859649122807015	0.043859649122807015	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.043859649122807015	0.0	0.04	0.0	0.0	0.0	0.0	0.0
293	Reuptake Inhibitors;reuptake inhibitors	0.8007758977422971	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	an unusual, essential organelle	0.2871601333601656	-7.75	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-7.75	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.057971014492753624	0.057971014492753624	5.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.057971014492753624	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
225	Typical;Usually;typical;usually	0.0613131281061132	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.666666666666667	0.04	0.04	0.0	0.04	0.04	1.0	0.04542372881355933	0.0	2.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.04	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
14	transmembrane beta-barrels in proteomes	0.07033975646893406	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.16666666666666666	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
142	small;SMALL	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	fatal human malaria	0.0946082416022893	-9.25	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.2	1.0	-9.25	1.0	1.0	-6.0	0.04	0.05263157894736842	0.0	0.06349206349206349	0.06349206349206349	3.0	0.05263157894736842	0.3333333333333333	2.0	1.0	-6.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.06349206349206349	0.0	0.05263157894736842	0.0	1.0	0.0	0.0	1.0
198	G400A	0.7025538668937902	-4.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04878048780487805	0.0	2.0	0.0	-4.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047619047619047616	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
255	disorder;Disorder	0.06541008828048778	-2.1428571428571423	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1428571428571423	0.0	0.0	-8.125	0.04	0.05925925925925926	0.0	0.04375	0.04375	1.0	0.05925925925925926	0.0	1.0	0.0	-8.125	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04375	0.0	0.05925925925925926	0.0	0.0	0.0	0.0	0.0
331	polo-like kinase signaling pathways	0.5386165578382909	0.0	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
81	1,282	0.6812344866687358	-3.555555555555557	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.555555555555557	0.0	0.0	0.0	0.04	0.04	0.0	0.04663212435233161	0.04663212435233161	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04663212435233161	0.0	0.04	0.0	0.0	0.0	0.0	0.0
103	traditional model	0.14684823062145294	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	new opportunities for imaging	0.13720615534077008	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
121	pharmacogenetic testing for this	0.04209665520988177	-4.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.047619047619047616	0.047619047619047616	4.0	0.046875	0.5	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.047619047619047616	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
48	PIK3CA (8%)	0.6172946614798615	-1.875	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.875	0.0	0.0	0.0	0.04	0.04	0.0	0.043243243243243246	0.043243243243243246	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.043243243243243246	0.0	0.04	0.0	0.0	0.0	0.0	0.0
330	a mouse collagen	0.09938382669364451	-1.8888888888888893	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-11.875	0.04	0.0761904761904762	0.0	0.04326923076923077	0.04326923076923077	3.0	0.0761904761904762	0.0	1.0	0.0	-11.875	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04326923076923077	0.0	0.0761904761904762	0.0	0.0	0.0	0.0	0.0
73	profile;Profile	0.18930551832926565	-1.3555555555555556	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-4.133333333333333	0.04	0.04580152671755725	0.0	0.04	0.04240020174000757	1.0	0.04800358239166654	0.0	5.0	0.0	-5.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.045454545454545456	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
261	Catecholaminergic polymorphic ventricular tachycardia (CPVT	0.5140198040470424	-2.1428571428571423	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.1428571428571423	1.0	1.0	-3.333333333333332	0.04	0.04615384615384615	0.0	0.04375	0.04375	6.0	0.04615384615384615	0.16666666666666666	1.0	1.0	-3.333333333333332	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04375	0.0	0.04615384615384615	0.0	1.0	0.0	0.0	1.0
342	HSC;HSCs	0.6037996097766218	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.04	0.04	0.0	0.046296296296296294	0.0	2.0	0.0	-3.3999999999999986	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
96	the biological relevance of multi-targeted CDK inhibition	0.2246359044634622	0.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	resolution;Resolved;Resolution;resolved	0.2204577447013769	-5.259259259259259	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-18.333333333333332	0.0	0.0	-3.814814814814815	0.04	0.04	0.0	0.04	0.06329454182561528	1.0	0.04911521475853062	0.0	9.0	0.0	-10.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	9.0	0.15	0.0	0.06818181818181819	0.0	0.0	0.0	0.0	0.0
242	Support, NOS;support	0.09849952886901459	-4.222222222222221	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.222222222222221	0.0	0.0	0.0	0.04	0.04	0.0	0.0481283422459893	0.0481283422459893	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0481283422459893	0.0	0.04	0.0	0.0	0.0	0.0	0.0
25	the efficacy	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	a depth-dependent insertion potential	0.10757332122311179	-1.875	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-1.875	1.0	1.0	-2.0	0.04	0.043478260869565216	0.0	0.043243243243243246	0.043243243243243246	6.0	0.043478260869565216	0.16666666666666666	1.0	1.0	-2.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.043243243243243246	0.0	0.043478260869565216	0.0	1.0	0.0	0.0	1.0
186	a central role	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	allows;allow	0.10213986585771082	-0.5999999999999996	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.1999999999999993	0.0	0.0	-1.6999999999999993	0.04	0.04	0.0	0.04	0.041008403361344536	1.0	0.043148148148148144	0.0	2.0	0.0	-3.3999999999999986	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04201680672268907	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
71	Target;target	0.0938569137288475	-1.4000000000000004	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	-3.625	0.04	0.04	0.0	0.04	0.042522522522522525	1.0	0.04816901408450704	0.0	2.0	0.0	-7.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04504504504504505	0.0	0.056338028169014086	0.0	0.0	0.0	0.0	0.0
278	the HNPCC (hereditary nonpolyposis colorectal cancer)	0.15031869774840592	0.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.14285714285714285	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.125	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
242	Family History of Sudden Cardiac Death;family history of sudden cardiac death	0.007847525201032315	0.0	1.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.6666666666666666	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	6.0	0.045454545454545456	0.5	1.0	0.0	-3.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
140	FTICR-MS	0.45407459901601915	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
28	stiff-person	0.10037402207263992	-6.666666666666666	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.054545454545454536	0.054545454545454536	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.054545454545454536	0.0	0.04	0.0	0.0	0.0	0.0	0.0
150	as;AS	0.08590753406008302	-6.7142857142857135	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.7142857142857135	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.0546875	0.0546875	1.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0546875	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
15	Protein Phosphorylation for extraction	0.07660335945094762	-1.6000000000000014	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.6000000000000014	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.042735042735042736	0.042735042735042736	4.0	0.05263157894736842	0.5	1.0	0.0	-6.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.042735042735042736	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
16	major genomic context based methods	0.1319948718854169	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
231	I (TnI	0.31150437670764053	-4.7142857142857135	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-4.7142857142857135	0.0	0.0	-6.857142857142858	0.04	0.05511811023622047	0.0	0.04929577464788733	0.04929577464788733	2.0	0.05511811023622047	0.0	1.0	0.0	-6.857142857142858	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04929577464788733	0.0	0.05511811023622047	0.0	0.0	0.0	0.0	0.0
41	the process of non-specific integration	0.057961055114664525	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
146	spontaneous cardiomyopathy and heart failure by 6 wk	0.16686476906158354	-4.666666666666666	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04918032786885245	0.04918032786885245	8.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04918032786885245	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
89	72 Hours;72 hours	0.26295890366673136	-6.1000000000000005	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-6.4	0.0	0.0	-6.75	0.04	0.05405405405405406	0.0	0.052083333333333336	0.05292338709677419	2.0	0.054804804804804805	0.0	2.0	0.0	-7.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.05376344086021505	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
96	MM cells	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
68	a single amino acid substitution	0.228462092954257	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
304	high-risk CLL	0.1466683010909701	-1.5	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	1.0	-1.5	0.0	0.0	-5.142857142857142	0.04	0.050359712230215826	0.0	0.0425531914893617	0.0425531914893617	4.0	0.050359712230215826	0.0	1.0	0.0	-5.142857142857142	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.0425531914893617	0.0	0.050359712230215826	0.0	0.0	0.0	0.0	0.0
139	non;Non	0.6066186994119565	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
86	kinase (TAK1) and p3	0.5710363745156423	0.0	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-2.75	0.04	0.0449438202247191	0.0	0.04	0.04	6.0	0.0449438202247191	0.0	1.0	1.0	-2.75	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.04	0.0	0.0449438202247191	0.0	1.0	0.0	0.0	1.0
253	the treatment	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
199	and;And	0.07208202620761509	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-7.833333333333334	0.04	0.05825242718446603	0.0	0.04878048780487805	0.04878048780487805	1.0	0.05825242718446603	0.0	1.0	0.0	-7.833333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04878048780487805	0.0	0.05825242718446603	0.0	0.0	0.0	0.0	0.0
254	the blood stream	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
7	significant, unreasonable harm to a fetus	0.15253371083258746	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
10	one with the CD3- pattern	0.06492807365026797	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
154	central core disease;Central Core Disease	0.14270804807435206	-3.1818181818181834	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-3.1818181818181834	0.0	0.0	-10.8	0.04	0.07042253521126761	0.0	0.04583333333333334	0.04583333333333334	3.0	0.07042253521126761	0.0	1.0	0.0	-10.8	1.0	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	2.0	1.0	3.0	0.04583333333333334	1.0	0.07042253521126761	0.0	0.0	0.0	1.0	0.0
49	228 unrelated female patients with a diagnosis	0.12872337633420927	-1.375	0.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.0	0.0	-1.375	0.0	0.0	0.0	0.04	0.04	0.0	0.042328042328042326	0.042328042328042326	8.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.042328042328042326	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	both terms of per-residue and per-segment measures	0.06589451142654722	0.0	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.5	0.04	0.044444444444444446	0.0	0.04	0.04	7.0	0.044444444444444446	0.14285714285714285	1.0	0.0	-2.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.044444444444444446	0.0	0.0	0.0	0.0	0.0
61	6 members (microtubule-	0.35880820880251285	-2.6000000000000014	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	-7.75	0.04	0.057971014492753624	0.0	0.044642857142857144	0.044642857142857144	5.0	0.057971014492753624	0.0	1.0	0.0	-7.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.044642857142857144	0.0	0.057971014492753624	0.0	0.0	0.0	0.0	0.0
160	AML cells	0.3376233537207202	-2.666666666666668	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04477611940298508	0.04477611940298508	2.0	0.043478260869565216	0.0	2.0	0.0	-2.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04477611940298508	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
327	the disruption	0.22880103732992577	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.04	0.043859649122807015	0.0	0.04	0.04	2.0	0.043859649122807015	0.0	1.0	0.0	-2.1999999999999993	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.043859649122807015	0.0	0.0	0.0	0.0	0.0
344	studies	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	to;TO	0.3870467951744636	-1.3194444444444446	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-2.142857142857143	0.04	0.04	0.0	0.04	0.04227322982487915	1.0	0.04383837946586147	0.0	8.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.043478260869565216	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
215	robust;Robust	0.5486147974231931	-5.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.05	0.05	1.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
300	a transcriptional repressor of the HO-1 gene (Hmox-1	0.11574160085404607	-2.8571428571428577	1.0	0.0	0.04	0.04	0.4444444444444444	0.4444444444444444	0.0	0.0	0.1111111111111111	1.0	-2.8571428571428577	0.0	0.0	0.0	0.04	0.04	0.0	0.04516129032258065	0.04516129032258065	9.0	0.04	0.4444444444444444	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	9.0	0.04516129032258065	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	approximately 50–60%	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
235	the result of an autoimmune reaction	0.0642231839827859	-3.8888888888888893	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.8888888888888893	0.0	0.0	-10.6	0.04	0.06944444444444445	0.0	0.04736842105263158	0.04736842105263158	6.0	0.06944444444444445	0.16666666666666666	1.0	0.0	-10.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04736842105263158	0.0	0.06944444444444445	0.0	0.0	0.0	0.0	0.0
66	F508 and 2183AA	0.36562966416991133	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.04	0.04	4.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
127	EGFR tyrosine kinase inhibitor (EGFR-TKI), gefitinib, or erlotinib	0.3139712225679586	0.0	1.0	0.0	0.04	0.04	0.07142857142857142	0.07142857142857142	0.0	0.0	0.3333333333333333	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	14.0	0.04	0.14285714285714285	1.0	1.0	0.0	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	14.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
60	Residue;residues	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
75	an incidence	0.6625317607701119	-7.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.0	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.05555555555555555	0.05555555555555555	2.0	0.04597701149425287	0.0	1.0	0.0	-3.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05555555555555555	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
200	a baseball	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	(WAXS) from molecules	0.25641571135275343	-5.666666666666666	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.051724137931034475	0.051724137931034475	5.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.051724137931034475	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
79	5 mg flumazenil	0.7165749481424364	-3.6000000000000014	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.6000000000000014	1.0	1.0	-8.75	0.04	0.06153846153846154	0.0	0.04672897196261683	0.04672897196261683	3.0	0.06153846153846154	0.0	1.0	1.0	-8.75	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.04672897196261683	0.0	0.06153846153846154	0.0	1.0	0.0	0.0	1.0
78	the pericentromeric region of human chromosome 17	0.10266351886946141	-4.25	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	7.0	0.04	0.2857142857142857	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
151	a random distribution	0.08056777232950978	-2.8571428571428577	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.8571428571428577	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04516129032258065	0.04516129032258065	3.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04516129032258065	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
254	synovial monocyte/macrophage population	0.4175122847513681	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
286	fluorogenic peptide	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
249	Embryonic;embryonic	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	moderately;Moderately;Moderate;moderate	0.3460932445916757	-3.0555555555555554	0.0	0.0	0.04	0.04	0.0	0.6666666666666666	0.0	0.0	0.0	0.0	-6.166666666666666	0.0	0.0	-2.111111111111111	0.04	0.04	0.0	0.04	0.04618396352909627	1.0	0.04452380952380952	0.0	3.0	0.0	-6.333333333333334	1.0	0.0	0.6666666666666666	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.053097345132743355	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
342	SACCHAROMYCES CEREVISIAE;Saccharomyces cerevisiae;yeast	0.803346794196659	-0.6399999999999999	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-0.6799999999999997	0.04	0.04	0.0	0.04	0.041174311926605506	1.6	0.04125925925925926	0.0	5.0	0.0	-3.3999999999999986	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	8.0	0.04587155963302752	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
184	235	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
185	Reported;reported	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
322	SUV39H1 impaired enzyme activity despite the presence	0.16597821491480907	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
307	nigro-amygdaloid pathways	0.620260588662733	-2.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.043859649122807015	0.043859649122807015	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.043859649122807015	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	SEIZURES;seizures	0.6485259049595223	-3.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.04587155963302752	0.04587155963302752	1.0	0.046511627906976744	0.0	2.0	0.0	-3.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04587155963302752	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
101	The method	0.045414372337844816	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	the maintenance methyltransferase activity of DNMT1	0.047506957014491515	-1.5555555555555571	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	-1.7142857142857153	0.04	0.04294478527607362	0.0	0.04265402843601896	0.04265402843601896	6.0	0.04294478527607362	0.5	1.0	0.0	-1.7142857142857153	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04265402843601896	0.0	0.04294478527607362	0.0	0.0	0.0	0.0	0.0
261	the CASQ2 gene	0.034454554648281295	-5.2857142857142865	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.6666666666666666	1.0	-5.2857142857142865	0.0	0.0	0.0	0.04	0.04	0.0	0.05072463768115942	0.05072463768115942	3.0	0.04	0.6666666666666666	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.05072463768115942	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	Association;association	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
204	reliable;Reliability	0.07527453356339515	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.045454545454545456	0.045454545454545456	1.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
278	an autosomic dominant condition	0.3075309072386389	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
30	Setting;setting	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
181	arising	0.094472773144196	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.04	0.04	1.0	0.04587155963302752	0.0	1.0	0.0	-3.1999999999999993	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
334	Residue;residues;residue	0.7113552677409815	-0.44444444444444464	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04076555023923445	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.0430622009569378	0.0	0.04	0.0	0.0	0.0	0.0	0.0
208	models;Model;model;Models	0.1354166208133195	-0.55	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04098876404494382	1.0	0.04	0.0	5.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	5.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	multivariate and univariate analysis	0.1926784229531745	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.833333333333332	0.04	0.047244094488188976	0.0	0.04	0.04	4.0	0.047244094488188976	0.0	1.0	0.0	-3.833333333333332	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.047244094488188976	0.0	0.0	0.0	0.0	0.0
245	a pediatric HCM	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
91	the individual versus 41%	0.11461112152694763	-2.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
128	Machinery;machinery	0.5694344815451721	-1.1666666666666679	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.1666666666666679	0.0	0.0	-2.8181818181818166	0.04	0.04508196721311475	0.0	0.04195804195804196	0.04195804195804196	1.0	0.04508196721311475	0.0	1.0	0.0	-2.8181818181818166	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04195804195804196	0.0	0.04508196721311475	0.0	0.0	0.0	0.0	0.0
257	Prx-2;PRX2;Prx2	0.8941180489021396	-5.261904761904762	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-6.333333333333334	0.0	0.0	-11.16326530612245	0.04	0.058333333333333334	0.0	0.04580152671755725	0.05088209489469664	1.0	0.0740244280604327	0.0	7.0	0.0	-13.428571428571429	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	3.0	1.0	7.0	0.053571428571428575	0.0	0.08641975308641975	0.0	0.0	0.0	0.0	0.0
222	known;Known	0.09782697295100191	-2.2222222222222214	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.2222222222222214	0.0	0.0	-4.8	0.04	0.04901960784313726	0.0	0.04390243902439024	0.04390243902439024	1.0	0.04950980392156863	0.0	2.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04390243902439024	0.0	0.05	0.0	0.0	0.0	0.0	0.0
229	known disease genes	0.04578228101611979	0.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
17	treated;Treated	0.0956710754513943	-2.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	-5.25	0.04	0.0449438202247191	0.0	0.043795620437956206	0.044798573577756726	1.0	0.051457417358736365	0.0	2.0	0.0	-7.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04580152671755725	0.0	0.057971014492753624	0.0	0.0	0.0	0.0	0.0
276	obligate carriers	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	shows;shown;show;Show	0.07420224363615915	-7.5555555555555545	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-12.0	0.0	0.0	-5.888888888888888	0.04	0.04	0.0	0.05	0.05954907161803713	1.0	0.055877192982456136	0.0	3.0	0.0	-11.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.07692307692307693	0.0	0.075	0.0	0.0	0.0	0.0	0.0
41	possesses;possess	0.08867690148147342	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.04	0.048387096774193554	0.0	0.04	0.04	1.0	0.05097926267281107	0.0	2.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
255	the autosomal dominant (AD) inheritance	0.09859913260953256	0.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-1.625	0.04	0.0427807486631016	0.0	0.04	0.04	7.0	0.0427807486631016	0.5714285714285714	1.0	1.0	-1.625	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.0427807486631016	0.0	1.0	0.0	0.0	1.0
286	Cell-based assays	0.3947729784748357	-3.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	4.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
130	47 MBL producers	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
330	methotrexate (MTX)	0.6627362794520611	-0.6111111111111107	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-1.2222222222222214	1.0	1.0	-2.75	0.04	0.0425531914893617	0.0	0.04	0.04102803738317757	4.0	0.04508611955420466	0.5	2.0	1.0	-4.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.04205607476635514	0.0	0.047619047619047616	0.0	1.0	0.0	0.0	1.0
60	antibody block;blocked by antibodies	0.17424828127776124	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	Administration;administration	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	the genome from P. falciparum	0.3204328858336823	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
188	preclinical development targeting specific cortical processing abnormalities	0.2172884268453377	-5.166666666666666	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	-5.166666666666666	0.0	0.0	-5.4	0.04	0.0510204081632653	0.0	0.050420168067226885	0.050420168067226885	7.0	0.0510204081632653	0.0	1.0	0.0	-5.4	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.050420168067226885	0.0	0.0510204081632653	0.0	0.0	0.0	0.0	0.0
79	needed;Needed	0.07046974704668095	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04	0.04	1.0	0.04878048780487805	0.0	1.0	0.0	-4.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
47	the software	0.04283159789439488	-2.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.04477611940298508	0.04477611940298508	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04477611940298508	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	impaired;Impaired	0.6284149959227107	-4.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
5	the symptomatic therapy for myasthenia gravis	0.042998382695038855	-3.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.375	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	6.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
99	the cardiac features of patients	0.04610136987392486	-3.5	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	0.0	0.04	0.04	0.0	0.046511627906976744	0.046511627906976744	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.046511627906976744	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	a novel scoring program	0.06637442787073183	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	The absence of an action	0.04049964488517651	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
195	β-globin	0.7032572802948344	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.045454545454545456	0.045454545454545456	3.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.045454545454545456	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
207	Late;late	0.06312775193674071	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-11.0	0.04	0.07142857142857142	0.0	0.04878048780487805	0.04878048780487805	1.0	0.07142857142857142	0.0	1.0	0.0	-11.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04878048780487805	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0
189	mutations in the calcitonin/CGRP gene;gene mutations	0.43783159714418957	0.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	14.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
340	post;Post	0.5886645242542263	-2.7142857142857153	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.7142857142857153	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04487179487179487	0.04487179487179487	0.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04487179487179487	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
111	mRNA;mRNAs	0.708788486493509	-4.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.0	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.047619047619047616	0.047619047619047616	1.0	0.054545454545454536	0.0	1.0	0.0	-6.666666666666666	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	1.0	0.047619047619047616	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
102	the mPer2 gene	0.08827123503711563	-3.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
132	Cardiac;cardiac	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
249	binds;Bind;bind	0.1388950400301753	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.0625	0.04	0.04	0.0	0.04	0.04	1.0	0.04204819277108434	0.0	4.0	0.0	-4.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.04	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
14	identity;Identity	0.0980003534450082	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.04	0.045112781954887216	0.0	0.04	0.04	1.0	0.045112781954887216	0.0	2.0	0.0	-2.833333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.045112781954887216	0.0	0.0	0.0	0.0	0.0
137	et al	0.6208974590837759	-1.4444444444444429	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.4444444444444429	0.0	0.0	-2.5	0.04	0.044444444444444446	0.0	0.04245283018867924	0.04245283018867924	2.0	0.044444444444444446	0.0	1.0	0.0	-2.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04245283018867924	0.0	0.044444444444444446	0.0	0.0	0.0	0.0	0.0
20	a wide range of organisms	0.06894611333843674	-4.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.04938271604938271	0.04938271604938271	5.0	0.06060606060606061	0.0	1.0	0.0	-8.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04938271604938271	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
181	germline mutations in the TP53 gene	0.13066233708714262	-7.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.2857142857142857	1.0	-7.0	1.0	1.0	0.0	0.04	0.04	0.0	0.05555555555555555	0.05555555555555555	6.0	0.04	0.3333333333333333	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.05555555555555555	0.0	0.04	0.0	1.0	0.0	0.0	1.0
84	AD	0.11637698631236322	-8.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-8.5	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.06060606060606061	0.06060606060606061	1.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.06060606060606061	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
177	high total and active life expectancy	0.021803876976550823	-1.6666666666666679	1.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.2	0.0	-1.6666666666666679	0.0	0.0	0.0	0.04	0.04	1.0	0.04285714285714286	0.04285714285714286	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04285714285714286	0.0	0.04	0.0	0.0	0.16666666666666666	0.0	0.0
44	glycolysis;Glycolysis	0.691358807693786	-12.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-18.0	0.0	0.0	-6.222222222222221	0.04	0.04	0.0	0.045454545454545456	0.0961038961038961	1.0	0.05590579710144927	0.0	3.0	0.0	-9.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.14285714285714285	0.0	0.06521739130434782	0.0	0.0	0.0	0.0	0.0
261	Genetic Testing;genetic testing	0.11707437433269925	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
153	in;In	0.006569821387325964	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	1.0	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	1.0	0.0	0.0	0.0	0.0
303	a third constitutive centromere protein Cenpc	0.2934783834301444	-2.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	The chromodomain protein Corto [35,36]	0.3222975903142692	-8.5	1.0	0.0	0.04	0.04	0.2222222222222222	0.2222222222222222	0.0	0.0	0.3333333333333333	1.0	-8.5	0.0	0.0	0.0	0.04	0.04	0.0	0.06060606060606061	0.06060606060606061	9.0	0.04	0.2222222222222222	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	9.0	0.06060606060606061	0.0	0.04	0.0	0.0	0.0	0.0	0.0
83	a gene-dose effect on clopidogrel metabolism	0.06661964765933762	-3.0	1.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.1111111111111111	1.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	8.0	0.04	0.25	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
222	benefit in terms	0.09350478878197788	-3.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.0	0.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.046875	0.046875	3.0	0.046296296296296294	0.0	1.0	0.0	-3.3999999999999986	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.046875	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
318	TYROSINE;tyrosine	0.10832785617996563	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-6.153846153846153	0.04	0.053061224489795916	0.0	0.04	0.04	1.0	0.053061224489795916	1.0	1.0	0.0	-6.153846153846153	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	1.0	0.04	0.0	0.053061224489795916	1.0	0.0	0.0	0.0	0.0
75	marked;Marked	0.6329205642252845	-4.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04938271604938271	0.04938271604938271	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04938271604938271	0.0	0.04	0.0	0.0	0.0	0.0	0.0
111	a second one	0.07764680407200207	-4.142857142857142	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.142857142857142	0.0	0.0	-8.333333333333334	0.04	0.06000000000000001	0.0	0.04794520547945205	0.04794520547945205	3.0	0.06000000000000001	0.0	1.0	0.0	-8.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04794520547945205	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
145	the beneficial effects	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
74	epidermoid lung carcinoma	0.5151797490624684	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	3.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
124	particularly those	0.14321842650457825	-10.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-10.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.06818181818181819	0.06818181818181819	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.06818181818181819	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	membrane antigen 1	0.6171953679194666	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
176	the genomic activity	0.19175225441074387	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.04	0.04	3.0	0.04587155963302752	0.0	1.0	0.0	-3.1999999999999993	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
207	Administered;administered	0.053581639307085954	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-11.0	0.04	0.07142857142857142	0.0	0.04	0.04	1.0	0.07142857142857142	0.0	1.0	0.0	-11.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0
250	survival;Survival	0.09112461233357536	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
287	t-cell non-hodgkin's lymphomas;T-cell non-Hodgkin lymphomas	0.7073838554154201	-2.3999999999999986	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04424778761061947	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04424778761061947	0.0	0.04	0.0	0.0	0.0	0.0	0.0
345	proximal stem-loop	0.04214455517147647	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
87	a hypothyroid phenotype	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
90	The trial;the trial	0.0077427621634145296	-2.0999999999999996	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.5	0.0	-3.0	0.0	0.0	-7.25	0.04	0.04	1.0	0.04	0.043789219629927593	2.0	0.058958333333333335	1.0	4.0	0.0	-10.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.045454545454545456	0.0	0.06666666666666667	1.0	0.0	0.5	0.0	0.0
253	usual therapies	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
5	Young;younger	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
111	selenoprotein synthesis in eukaryotes	0.03065606935007183	-5.2857142857142865	1.0	0.0	0.04	0.04	0.25	0.25	1.0	0.0	1.0	1.0	-5.2857142857142865	0.0	0.0	0.0	0.04	0.04	0.0	0.05072463768115942	0.05072463768115942	4.0	0.04	1.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.05072463768115942	0.0	0.04	1.0	0.0	0.0	0.0	0.0
139	the therapeutic relevance of ADSC-derived exosomes	0.23284161524614452	0.0	0.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.125	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
321	(1) antagonists	0.6535975106844943	-2.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.043859649122807015	0.043859649122807015	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043859649122807015	0.0	0.04	0.0	0.0	0.0	0.0	0.0
5	the use of pyridostigmine	0.08232527797268219	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
35	mutant thyroid hormone receptor TRalpha1R384C	0.2508865102689538	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.6	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
8	a universal component	0.10666279720273474	-3.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	0.0	0.04	0.04	0.0	0.046511627906976744	0.046511627906976744	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.046511627906976744	0.0	0.04	0.0	0.0	0.0	0.0	0.0
103	Residue;residues	0.6221201843595147	-3.555555555555557	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.555555555555557	0.0	0.0	0.0	0.04	0.04	0.0	0.04663212435233161	0.04663212435233161	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04663212435233161	0.0	0.04	0.0	0.0	0.0	0.0	0.0
94	severe SSc	0.33464996046184486	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
28	patients with the stiff-man syndrome	0.013495219073443214	0.0	1.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.2	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.5714285714285714	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
80	95% CI	0.6171953679194666	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
284	minimal toxicity	0.5173737216649944	-1.875	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-1.75	0.04	0.04	0.0	0.04	0.043529411764705886	2.0	0.043255813953488376	0.0	4.0	0.0	-3.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.047058823529411764	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
297	fT3 syndrome	0.33464996046184486	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
101	The results	0.045414372337844816	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	alone;Alone	0.06345914824668802	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.04	0.04	1.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
176	dna proteins;protein dna;DNA-packaging proteins;DNA-bending protein	0.22074994148680757	-3.5	0.0	0.0	0.04	0.04	0.25	0.5	0.0	0.0	0.0	1.0	-4.625	1.0	1.0	-7.1	0.04	0.045454545454545456	0.5	0.04419889502762431	0.04663932481442565	4.0	0.058959156785243744	0.375	2.0	1.0	-11.2	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	4.0	1.0	8.0	0.049079754601226995	0.0	0.07246376811594203	0.0	1.0	0.125	0.0	1.0
53	Deiodinase;deiodinases;deiodinase	0.26705658582687997	-3.166666666666667	1.0	-12.0	0.04	0.05846153846153847	0.0	0.0	1.0	-6.0	1.0	1.0	-6.333333333333334	1.0	1.0	-5.333333333333333	0.07692307692307693	0.04	0.0	0.04	0.04678571428571429	1.0	0.05488372093023255	0.5	2.0	1.0	-10.666666666666666	1.0	1.0	0.0	0.5	0.0	1.0	1.0	1.0	1.0	3.0	1.0	2.0	0.053571428571428575	1.0	0.06976744186046512	1.0	1.0	0.0	1.0	1.0
96	Response;response	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
6	multiple;MULTIPLE	0.07325399564638459	-3.1111111111111107	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.1111111111111107	0.0	0.0	-6.25	0.04	0.05333333333333334	0.0	0.04568527918781726	0.04568527918781726	1.0	0.05333333333333334	0.0	1.0	0.0	-6.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04568527918781726	0.0	0.05333333333333334	0.0	0.0	0.0	0.0	0.0
88	cell fate determination	0.22999223610949313	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	1.0	0.0	1.0	0.5	1.0	0.0	1.0	1.0	1.0	0.5	0.5	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
138	Ratios;ratios	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
87	Suppressed;suppressed	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
222	Mechanisms;mechanisms	0.10452324936119646	-2.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.7777777777777786	0.0	0.0	-2.5	0.04	0.04	0.0	0.04265402843601896	0.04382701421800948	1.0	0.045	0.0	2.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.045	0.0	0.05	0.0	0.0	0.0	0.0	0.0
332	a drug fostamatinib	0.004309593867767407	-9.5	1.0	-9.0	0.0625	0.0625	0.6666666666666666	0.6666666666666666	1.0	-9.0	1.0	0.0	-9.5	0.0	0.0	-14.0	0.0625	0.09090909090909091	0.0	0.06451612903225806	0.06451612903225806	3.0	0.09090909090909091	1.0	1.0	0.0	-14.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.06451612903225806	0.0	0.09090909090909091	1.0	0.0	0.0	0.0	0.0
155	brought	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	stored;Stored	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
178	RNGTT and RNMT	0.457566030093766	-6.75	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-6.75	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.0547945205479452	0.0547945205479452	3.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.0547945205479452	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
57	Addition;addition	0.09504320880292803	-3.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04587155963302752	0.04587155963302752	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04587155963302752	0.0	0.04	0.0	0.0	0.0	0.0	0.0
247	Potential;potential	0.06941748366343745	-8.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-8.0	0.0	0.0	-11.75	0.04	0.07547169811320754	0.0	0.058823529411764705	0.058823529411764705	1.0	0.07547169811320754	0.0	1.0	0.0	-11.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.058823529411764705	0.0	0.07547169811320754	0.0	0.0	0.0	0.0	0.0
84	the lack	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
198	A H558R polymorphism	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
304	an important target of ibrutinib and	0.1586316999351512	-2.5	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-2.5	1.0	1.0	-2.571428571428573	0.04	0.0445859872611465	0.0	0.044444444444444446	0.044444444444444446	6.0	0.0445859872611465	0.16666666666666666	1.0	1.0	-2.571428571428573	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.044444444444444446	0.0	0.0445859872611465	0.0	1.0	0.0	0.0	1.0
339	the growth	0.08775916648830363	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.04	0.04	2.0	0.046296296296296294	0.0	1.0	0.0	-3.3999999999999986	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
84	A case	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
233	these tragic fatalities	0.15605818329001778	-1.4444444444444429	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.4444444444444429	0.0	0.0	0.0	0.04	0.04	0.0	0.04245283018867924	0.04245283018867924	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04245283018867924	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	Adopted;adopted	0.07553433605392222	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.04	0.045112781954887216	0.0	0.04	0.04	1.0	0.045112781954887216	0.0	1.0	0.0	-2.833333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.045112781954887216	0.0	0.0	0.0	0.0	0.0
51	PD-1	0.6157039936450832	-1.4166666666666679	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.4166666666666679	0.0	0.0	-4.571428571428571	0.04	0.048951048951048945	0.0	0.04240282685512368	0.04240282685512368	1.0	0.048951048951048945	0.0	1.0	0.0	-4.571428571428571	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04240282685512368	0.0	0.048951048951048945	0.0	0.0	0.0	0.0	0.0
99	OTHER;other	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
89	children (;children;Children	0.9715043700378633	-3.213333333333333	1.0	-16.5	0.04	0.04517647058823529	0.5	0.9833333333333333	1.0	-1.1	1.0	0.0	-14.4	0.0	0.0	-4.6	0.11764705882352941	0.04	0.0	0.04	0.047914617514768484	1.0333333333333334	0.05651816669179098	0.9833333333333333	30.0	0.0	-19.0	1.0	0.0	0.9666666666666667	1.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	31.0	0.09433962264150944	0.0	0.16666666666666666	1.0	0.0	0.0	0.0	0.0
337	aborted	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	the development of hyperplastic or neoplastic changes	0.05475816910330379	-1.75	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	0.0	-1.75	0.0	0.0	-2.3999999999999986	0.04	0.04424778761061947	0.0	0.043010752688172046	0.043010752688172046	7.0	0.04424778761061947	0.2857142857142857	1.0	0.0	-2.3999999999999986	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.043010752688172046	0.0	0.04424778761061947	0.0	0.0	0.0	0.0	0.0
87	Contractile;contractile	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
82	marker;Marker	0.10109579283618836	-1.7142857142857142	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.7142857142857153	0.0	0.0	-8.933333333333335	0.04	0.04672897196261683	0.0	0.04	0.043058530780049765	1.0	0.06670575011696507	0.0	3.0	0.0	-13.8	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04487179487179487	0.0	0.08928571428571429	0.0	0.0	0.0	0.0	0.0
120	phosphatases	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
183	genetic;GENETIC	0.002989143734007746	-14.25	1.0	-17.5	0.13333333333333333	0.13333333333333333	1.0	1.0	1.0	-17.5	1.0	0.0	-14.25	0.0	0.0	-17.25	0.13333333333333333	0.12903225806451613	0.0	0.09302325581395349	0.09302325581395349	1.0	0.12903225806451613	1.0	1.0	0.0	-17.25	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.09302325581395349	0.0	0.12903225806451613	1.0	0.0	0.0	0.0	0.0
44	Synergistic;synergistic	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	Oxidative Stress;oxidative stress	0.42662577637536797	-17.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-17.0	0.0	0.0	-9.666666666666666	0.04	0.06521739130434782	0.0	0.125	0.125	2.0	0.06521739130434782	0.0	3.0	0.0	-9.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.125	0.0	0.06521739130434782	0.0	0.0	0.0	0.0	0.0
225	Adulthood - period;Periodic evaluations during adulthood;adulthood	0.5005044463695905	0.0	0.0	0.0	0.04	0.04	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.5	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
104	SNAP), MG: MGENE	0.4270145456548483	0.0	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
40	FreeTree	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
185	27 ± 10%>	0.6000186669162998	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
72	IR module	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	Apurinic Endonuclease;apurinic/apyrimidinic endonuclease	0.536099372950064	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
145	M1	0.7123617662367117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
215	expression;Expression	0.630510990443643	-4.678571428571429	0.0	0.0	0.04	0.04	0.0	0.8571428571428571	0.0	0.0	0.0	0.0	-8.25	0.0	0.0	-5.571428571428571	0.04	0.04	0.0	0.04	0.04998940933032093	0.8571428571428571	0.05277572802111395	0.0	7.0	0.0	-9.8	1.0	0.0	0.8571428571428571	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.05970149253731343	0.0	0.06578947368421052	0.0	0.0	0.0	0.0	0.0
128	prokaryotes against mobile genetic elements	0.11646264472117837	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-3.1818181818181834	0.04	0.04583333333333334	0.0	0.04	0.04	5.0	0.04583333333333334	0.0	1.0	0.0	-3.1818181818181834	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04583333333333334	0.0	0.0	0.0	0.0	0.0
285	patients with LFS	0.08696436763593744	-2.3999999999999986	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.4	1.0	-2.3999999999999986	1.0	1.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.04424778761061947	0.04424778761061947	3.0	0.046296296296296294	0.0	1.0	1.0	-3.3999999999999986	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04424778761061947	0.0	0.046296296296296294	0.0	1.0	0.0	0.0	1.0
72	a novel algorithm by a frame-based approach	0.051068170721251444	-1.6999999999999993	0.0	0.0	0.04	0.04	0.7777777777777778	0.7777777777777778	0.0	0.0	0.0	0.0	-1.6999999999999993	0.0	0.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.04291845493562232	0.04291845493562232	9.0	0.046296296296296294	0.1111111111111111	1.0	0.0	-3.3999999999999986	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04291845493562232	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
337	P;P NOS	0.7458848899052737	-1.1000000000000014	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-1.1000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.041841004184100423	0.041841004184100423	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	1.0	0.041841004184100423	0.0	0.04	0.0	0.0	0.0	0.0	0.0
57	iodine-induced thyrotoxicosis	0.3458799837153245	-3.8000000000000007	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.2	0.0	-3.8000000000000007	0.0	0.0	-3.6000000000000014	0.04	0.04672897196261683	0.0	0.04716981132075472	0.04716981132075472	4.0	0.04672897196261683	0.5	2.0	0.0	-3.6000000000000014	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04716981132075472	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
104	Recently;recently	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
84	a 6-week open study	0.13496962551888703	-10.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-10.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.06666666666666667	0.06666666666666667	6.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.06666666666666667	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
225	calcium loading	0.7307823555398101	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	play;Play;plays;playing	0.08033772381205563	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.523809523809524	0.04	0.04	0.0	0.04	0.04	1.0	0.04483906164757229	0.0	3.0	0.0	-4.857142857142858	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.04	0.0	0.04964539007092199	0.0	0.0	0.0	0.0	0.0
80	beta-myosin;beta-Myosin	0.7088885673264128	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
246	cytochrome P450 2C19 (CYP2C19) loss-of-function alleles	0.20053485623214098	0.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.1111111111111111	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	12.0	0.04	0.16666666666666666	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	12.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
151	PAUSE software	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
77	the reduction	0.09351779462417427	-3.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	-4.571428571428571	0.04	0.048951048951048945	0.0	0.04580152671755725	0.04580152671755725	2.0	0.048951048951048945	0.0	1.0	0.0	-4.571428571428571	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04580152671755725	0.0	0.048951048951048945	0.0	0.0	0.0	0.0	0.0
333	More;more	0.07120891807649092	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04	0.04	1.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
124	patients with Stage-II colon cancer	0.16250458460889108	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	7.0	0.047619047619047616	0.0	1.0	1.0	-4.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.047619047619047616	0.0	1.0	0.0	0.0	1.0
270	Our work	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
86	phospholamban (PLB;phospholamban (PLB)	0.7815373875206534	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.5	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	the known structures	0.048894972933717654	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
75	and;And	0.12818450744558102	-2.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-2.8333333333333335	0.04	0.04	0.0	0.04	0.04527977044476327	1.0	0.04546651180797522	0.0	3.0	0.0	-4.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04878048780487805	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
103	Daughter;daughter	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
334	ataxia telangiectasia;ATAXIA-TELANGIECTASIA;(ataxia telangiectasia	0.7179071917012705	-3.444444444444443	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.444444444444443	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.04639175257731958	0.04639175257731958	2.3333333333333335	0.046511627906976744	0.0	3.0	0.0	-3.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	7.0	0.04639175257731958	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
100	the different scaffolds of other non-nucleoside DNMT inhibitors	0.2113068443688701	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	8.0	0.04	0.25	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.125	0.0	1.0
71	antioxidant;Antioxidant	0.5828698811102787	-2.8000000000000007	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04504504504504505	0.04504504504504505	1.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04504504504504505	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
137	to;TO	0.3013835145736781	-1.7460317460317465	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8888888888888893	0.0	0.0	-3.2714285714285714	0.04	0.04	0.0	0.04	0.043142295968673264	1.0	0.0485134896546693	0.0	7.0	0.0	-12.6	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	7.0	0.04736842105263158	0.0	0.08064516129032258	0.0	0.0	0.0	0.0	0.0
209	this short-lived fish as an animal model	0.045452387177963474	0.0	0.0	0.0	0.04	0.04	0.7777777777777778	0.7777777777777778	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.2222222222222222	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
343	inflammasome components	0.3535647946510758	-2.166666666666668	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.043795620437956206	0.043795620437956206	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.043795620437956206	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	albumin;ALBUMIN	0.7648227568532582	-3.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.75	0.0	0.0	0.0	0.04	0.04	0.0	0.047058823529411764	0.047058823529411764	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	1.0	0.047058823529411764	0.0	0.04	0.0	0.0	0.0	0.0	0.0
155	a rare cause	0.025435421748564634	-5.833333333333334	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.3333333333333333	0.0	-5.833333333333334	0.0	0.0	-2.833333333333332	0.04	0.045112781954887216	0.0	0.052173913043478265	0.052173913043478265	3.0	0.045112781954887216	0.3333333333333333	1.0	0.0	-2.833333333333332	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.052173913043478265	0.0	0.045112781954887216	0.0	0.0	0.0	0.0	0.0
16	sequence comparison	0.09061157656887911	-3.6363636363636367	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.6363636363636367	0.0	0.0	-5.75	0.04	0.05194805194805195	0.0	0.04680851063829787	0.04680851063829787	2.0	0.05194805194805195	0.0	1.0	0.0	-5.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04680851063829787	0.0	0.05194805194805195	0.0	0.0	0.0	0.0	0.0
28	Possible;possible	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
151	Frequency;frequency	0.09386865310857494	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.428571428571427	0.0	0.0	-5.166666666666667	0.04	0.047619047619047616	0.0	0.042682926829268296	0.04349336214881136	1.0	0.050595238095238096	0.0	2.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04430379746835443	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
213	two mutations	0.25745086463349837	-4.666666666666666	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.04918032786885245	0.04918032786885245	2.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04918032786885245	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
66	sonographic finding;ultrasonography finding	0.18065388922953812	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	2.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
199	genome;Genome	0.8102538359307317	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04	1.0	0.04	0.0	0.0	0.0	1.0	0.0
313	RNA processing factors	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
146	effects;Effects	0.002557622572817574	-9.166666666666666	1.0	-17.333333333333332	0.13043478260869565	0.13043478260869565	1.0	1.0	1.0	-17.333333333333332	1.0	0.0	-9.166666666666666	0.0	0.0	-18.0	0.13043478260869565	0.14285714285714285	1.0	0.06315789473684211	0.06315789473684211	1.0	0.14285714285714285	1.0	1.0	0.0	-18.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.06315789473684211	0.0	0.14285714285714285	1.0	0.0	1.0	0.0	0.0
16	PFAM (v15) database	0.4175122847513681	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	II studies of CML	0.13561424080190387	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.9230769230769234	0.04	0.04153354632587859	0.0	0.04	0.04	4.0	0.04153354632587859	0.25	1.0	0.0	-0.9230769230769234	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04153354632587859	0.0	0.0	0.0	0.0	0.0
199	CBX1	0.8414062292814679	-5.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-5.0	0.0	0.0	-2.333333333333332	0.04	0.044117647058823525	0.0	0.05	0.05	1.0	0.044117647058823525	0.0	2.0	0.0	-2.333333333333332	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	2.0	0.05	0.0	0.044117647058823525	0.0	0.0	0.0	0.0	0.0
179	the Ras/Rap subfamily	0.44919250808934624	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-2.8000000000000007	0.04	0.04504504504504505	0.0	0.04	0.04	5.0	0.04504504504504505	0.0	1.0	1.0	-2.8000000000000007	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04504504504504505	0.0	1.0	0.0	0.0	1.0
102	physiology;Physiology	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
84	other antidepressants	0.3390675980923809	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
165	Represent;represented	0.6770993937463372	-1.9285714285714286	1.0	-13.25	0.04	0.04563829787234043	0.0	0.0	1.0	-1.65625	1.0	0.0	-15.428571428571429	0.0	0.0	-1.625	0.0851063829787234	0.04	0.0	0.04	0.04805970149253731	0.0	0.04541666666666667	0.0	8.0	0.0	-13.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.1044776119402985	0.0	0.08333333333333333	0.0	0.0	0.0	0.0	0.0
229	the similarity	0.058369021933077955	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
61	PE	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	enhances;Enhance	0.12513967977201348	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.04880952380952381	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.05	0.0	0.04	0.0	0.0	0.0	0.0	0.0
118	Recent evidence	0.092313190140296	-2.7142857142857153	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.7142857142857153	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04487179487179487	0.04487179487179487	2.0	0.04878048780487805	0.0	1.0	0.0	-4.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04487179487179487	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
145	USA and Japan	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
198	G1408R	0.6714489485407028	-2.3999999999999986	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04424778761061947	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04424778761061947	0.0	0.04	0.0	0.0	0.0	0.0	0.0
255	FSHD A1 gene;FSHD gene	0.34374419387460664	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-1.5	0.04	0.0425531914893617	0.0	0.04	0.04	3.0	0.0425531914893617	0.3333333333333333	2.0	0.0	-1.5	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.04	0.0	0.0425531914893617	0.0	0.0	0.0	0.0	0.0
242	The ICD	0.10549951416075809	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	exons and introns of a given DNA sequence	0.0845555934170069	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
125	which haplotype data	0.0793662226340656	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
188	tf/J (BTBR) strain	0.2630588373489208	0.0	0.0	0.0	0.04	0.04	0.14285714285714285	0.14285714285714285	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.04	0.04504504504504505	0.0	0.04	0.04	7.0	0.04504504504504505	0.2857142857142857	1.0	0.0	-2.8000000000000007	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04504504504504505	0.0	0.0	0.0	0.0	0.0
37	a potential predictor	0.11665569089612685	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.25	0.04	0.05333333333333334	0.0	0.04	0.04	3.0	0.05333333333333334	0.0	1.0	0.0	-6.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.05333333333333334	0.0	0.0	0.0	0.0	0.0
72	the literature [4]	0.17363098722383116	-3.1000000000000014	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-3.1000000000000014	0.0	0.0	-5.0	0.04	0.05	0.0	0.04566210045662101	0.04566210045662101	5.0	0.05	0.2	1.0	0.0	-5.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04566210045662101	0.0	0.05	0.0	0.0	0.0	0.0	0.0
11	Increase;increase	0.07127877842178537	-2.833333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.045112781954887216	0.045112781954887216	1.0	0.054545454545454536	0.0	1.0	0.0	-6.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045112781954887216	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
113	transcription of all 15 genes;genes transcription	0.19107309203202613	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	5.0	0.04	0.2	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.2	0.0	0.0
223	the EXPanding alzhEimer	0.20746220121390285	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	inhibitors of DNA methylation	0.09107072326177978	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.04	0.043795620437956206	1.0	0.04	0.04	4.0	0.043795620437956206	0.5	1.0	0.0	-2.166666666666668	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.043795620437956206	0.0	0.0	0.25	0.0	0.0
102	shRNA	0.7392910546844472	-3.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	0.0	0.04	0.04	0.0	0.046511627906976744	0.046511627906976744	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.046511627906976744	0.0	0.04	0.0	0.0	0.0	0.0	0.0
232	a genetic disorder of the connective tissue	0.04385695697911764	-3.0	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	1.0	-3.0	1.0	1.0	-3.75	0.04	0.047058823529411764	0.0	0.045454545454545456	0.045454545454545456	7.0	0.047058823529411764	0.2857142857142857	1.0	1.0	-3.75	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.045454545454545456	0.0	0.047058823529411764	0.0	1.0	0.0	0.0	1.0
304	question;Question	0.08139218367223842	-1.625	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.625	0.0	0.0	-2.428571428571427	0.04	0.04430379746835443	0.0	0.0427807486631016	0.0427807486631016	1.0	0.04430379746835443	0.0	1.0	0.0	-2.428571428571427	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0427807486631016	0.0	0.04430379746835443	0.0	0.0	0.0	0.0	0.0
72	finds;find;Find	0.11778981438707256	-2.175	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.300000000000001	0.0	0.0	-3.5	0.04	0.04	0.0	0.04	0.04415116402480049	1.0	0.04778120755648846	0.0	4.0	0.0	-7.199999999999999	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.050761421319796954	0.0	0.056179775280898875	0.0	0.0	0.0	0.0	0.0
96	many solid tumors	0.11858912668535745	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	1.0	0.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
156	the impairment	0.10181047214897065	-2.166666666666668	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.043795620437956206	0.043795620437956206	2.0	0.0449438202247191	0.5	1.0	0.0	-2.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043795620437956206	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
157	Which virus	0.006103990342021993	-14.6	1.0	0.0	0.04	0.04	1.0	1.0	1.0	0.0	1.0	1.0	-14.6	0.0	0.0	-16.6	0.04	0.11904761904761904	1.0	0.09615384615384615	0.09615384615384615	2.0	0.11904761904761904	1.0	2.0	0.0	-16.6	1.0	0.3333333333333333	1.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.09615384615384615	0.0	0.11904761904761904	1.0	0.0	0.5	0.0	0.0
47	molecular sequences	0.33464996046184486	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	the method	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
330	week;weeks;WEEKS;/week	0.11076333011291174	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.0	0.04	0.04	0.0	0.04	0.04	1.0	0.0419047619047619	0.0	4.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	4.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
88	one;ONE	0.07925523080182051	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04819277108433735	0.04819277108433735	1.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04819277108433735	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
180	an in-frame deletion of exon 8	0.44096877893716097	-6.5	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	0.0	-6.5	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.05405405405405406	0.05405405405405406	6.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.05405405405405406	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
111	selenoprotein mRNAs	0.4313342601746212	-1.571428571428573	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.25	1.0	-1.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.042682926829268296	0.042682926829268296	2.0	0.04	0.5	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.042682926829268296	0.0	0.04	0.0	0.0	0.0	0.0	0.0
120	's neuroprotective effect	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
86	HCN2	0.8203285026441218	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
46	Essential;essential	0.05434604831994678	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-10.666666666666666	0.04	0.06976744186046512	0.0	0.04	0.04	1.0	0.06976744186046512	0.0	1.0	0.0	-10.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.06976744186046512	0.0	0.0	0.0	0.0	0.0
76	Cardiology clinic;cardiology community clinic	0.1187176919696614	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	the first step	0.03862858390022017	-3.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.046511627906976744	0.046511627906976744	3.0	0.06060606060606061	0.3333333333333333	1.0	0.0	-8.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.046511627906976744	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
51	anti-PD-1 antibodies MK-3475	0.22300543579063453	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.2	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	3.0	0.04	0.6666666666666666	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	1.0	0.3333333333333333	0.0	1.0
93	common;commonest;Common	0.4255891210783576	-3.458333333333333	0.0	0.0	0.04	0.04	0.0	0.75	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-5.5	0.04	0.047619047619047616	0.0	0.04	0.046921094378260086	1.0	0.05147257114470229	0.0	4.0	0.0	-6.666666666666666	1.0	0.0	0.75	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.051724137931034475	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
209	longevity and age-related pathologies	0.22270145532256086	-4.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
209	expression of age markers	0.0930088940883712	-10.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-10.333333333333334	0.0	0.0	-7.666666666666666	0.04	0.05769230769230768	0.0	0.06818181818181819	0.06818181818181819	4.0	0.05769230769230768	0.0	1.0	0.0	-7.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.06818181818181819	0.0	0.05769230769230768	0.0	0.0	0.0	0.0	0.0
215	the c-myc;the c-Myc	0.5572299632446925	-10.875	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.5	-12.0	0.0	0.0	-13.600000000000001	0.04	0.07936507936507936	0.0	0.06557377049180328	0.07124842370744011	4.0	0.08870214752567694	0.0	2.0	0.0	-14.8	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.0	0.16666666666666666	2.0	1.0	8.0	0.07692307692307693	0.0	0.09803921568627452	0.0	0.0	0.0	0.0	0.0
152	Glutathione, Reduced;Reduced Glutathione	0.3726598362328088	-3.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-3.0	0.0	0.0	-7.800000000000001	0.04	0.05813953488372093	0.0	0.045454545454545456	0.045454545454545456	2.0	0.05813953488372093	0.0	1.0	0.0	-7.800000000000001	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	2.0	1.0	2.0	0.045454545454545456	1.0	0.05813953488372093	0.0	0.0	0.0	1.0	0.0
222	improved contrast sensitivity	0.10727874554288186	-3.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.046875	0.046875	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.046875	0.0	0.04	0.0	0.0	0.0	0.0	0.0
82	Stevens-Johnson syndrome (SJS;Stevens-Johnson syndrome (SJS)	0.5248409068308368	-2.2857142857142847	0.0	0.0	0.04	0.04	0.14285714285714285	0.15476190476190477	0.0	0.0	0.0	1.0	-2.428571428571427	1.0	1.0	-9.1	0.04	0.06097560975609757	0.0	0.04375	0.044026898734177214	6.5	0.06295533734558124	0.15476190476190477	2.0	1.0	-9.6	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	13.0	0.04430379746835443	0.0	0.06493506493506493	0.0	1.0	0.0	0.0	1.0
71	networks	0.10427187935184253	-2.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.044642857142857144	0.044642857142857144	1.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.044642857142857144	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
330	Moderate;moderate	0.07727144272937582	-1.5555555555555571	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	-3.625	0.04	0.04678362573099415	0.0	0.04265402843601896	0.04265402843601896	1.0	0.04678362573099415	0.0	1.0	0.0	-3.625	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04265402843601896	0.0	0.04678362573099415	0.0	0.0	0.0	0.0	0.0
2	orbital fibroblasts	0.8724432576559539	-2.8999999999999986	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04527204195345788	2.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.046296296296296294	0.0	0.04	0.0	0.0	0.0	0.0	0.0
345	specific UGA codons	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
298	0.0001)	0.7268739028102027	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
227	low iron;Low iron	0.0896483519378213	-3.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.046296296296296294	0.046296296296296294	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.046296296296296294	0.0	0.04	0.0	0.0	0.0	0.0	0.0
276	elevated serum T3 levels	0.7213571928442707	-0.8333333333333334	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04148148148148148	4.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	12.0	0.044444444444444446	0.0	0.04	0.0	0.0	0.0	0.0	0.0
26	Five;five	0.14168821943523796	-2.2857142857142847	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.428571428571427	0.0	0.0	-1.8333333333333333	0.04	0.04	0.0	0.043478260869565216	0.04402861860209136	1.0	0.04376068376068376	0.0	3.0	0.0	-5.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04430379746835443	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
115	a role in the regulation	0.05411772315431602	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
298	Reaching;reaching	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	Resistance;resistance	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	(1) subcellular localization	0.5939535099351959	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.04	0.043795620437956206	0.0	0.04	0.04	3.0	0.043795620437956206	0.0	1.0	0.0	-2.166666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.043795620437956206	0.0	0.0	0.0	0.0	0.0
267	Dream	0.6668594340272865	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
307	Attempt;attempt	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	alone;only;Only;Alone	0.05410911162152848	-2.833333333333333	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-4.833333333333333	0.04	0.04	0.0	0.04	0.04586206896551724	1.0	0.05260869565217391	0.0	2.0	0.0	-9.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.051724137931034475	0.0	0.06521739130434782	0.0	0.0	0.0	0.0	0.0
293	with;With	0.11362346904787234	-1.0833333333333333	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-4.0	0.04	0.04	0.0	0.04	0.04199233716475096	1.0	0.048445368445368446	0.0	3.0	0.0	-6.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04597701149425287	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
44	Schistosoma mansoni	0.7268739028102027	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
5	Other acetylcholinesterase inhibitors	0.08774958840829021	-3.5	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.5	1.0	-3.5	1.0	1.0	0.0	0.04	0.04	1.0	0.046511627906976744	0.046511627906976744	3.0	0.04	0.6666666666666666	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.046511627906976744	0.0	0.04	0.0	1.0	0.3333333333333333	0.0	1.0
40	Separate;separate	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
192	Homozygosity for the T-allele	0.31293343547565033	-5.666666666666666	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-5.666666666666666	1.0	1.0	0.0	0.04	0.04	0.0	0.051724137931034475	0.051724137931034475	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.051724137931034475	0.0	0.04	0.0	1.0	0.0	0.0	1.0
199	CENPA in humans	0.054200737996269045	-5.166666666666666	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.4	1.0	-5.166666666666666	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.050420168067226885	0.050420168067226885	3.0	0.051724137931034475	0.3333333333333333	1.0	0.0	-5.666666666666666	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.050420168067226885	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
293	compounds;Compound	0.10500750719274476	-12.125	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-12.5	0.0	0.0	-11.25	0.04	0.06060606060606061	0.0	0.07547169811320754	0.07773584905660377	1.0	0.07575757575757576	0.0	2.0	0.0	-14.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.08	0.0	0.09090909090909091	0.0	0.0	0.0	0.0	0.0
157	Drugs;drugs	0.1833023325138208	-3.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-3.6000000000000014	1.0	1.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.04672897196261683	0.04672897196261683	1.0	0.046296296296296294	0.0	1.0	1.0	-3.3999999999999986	1.0	1.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04672897196261683	1.0	0.046296296296296294	0.0	1.0	0.0	1.0	1.0
20	two core centriolar proteins	0.24733013785030114	-4.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.16666666666666666	1.0	-4.0	1.0	1.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.047619047619047616	0.0	0.04	0.0	1.0	0.0	0.0	1.0
4	deletions of the MEN1 gene	0.07594933472817433	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	TKIs (tyrosine kinase inhibitors;TKIs (tyrosine kinase inhibitors)	0.38680025900674964	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.269230769230769	0.04	0.050387596899224806	1.0	0.04	0.04	5.5	0.05068399452804378	0.6333333333333333	2.0	0.0	-5.384615384615385	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	11.0	0.04	0.0	0.05098039215686275	0.0	0.0	0.18333333333333335	0.0	0.0
222	III trials	0.26219402599679126	-2.1111111111111107	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.1111111111111107	0.0	0.0	0.0	0.04	0.04	0.0	0.043689320388349516	0.043689320388349516	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043689320388349516	0.0	0.04	0.0	0.0	0.0	0.0	0.0
8	an important role	0.12300721905568236	-4.75	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04938271604938271	0.04938271604938271	3.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04938271604938271	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
152	opinion	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
26	Last;last	0.09021328365335247	-1.7142857142857153	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.7142857142857153	0.0	0.0	0.0	0.04	0.04	0.0	0.04294478527607362	0.04294478527607362	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04294478527607362	0.0	0.04	0.0	0.0	0.0	0.0	0.0
89	majority	0.11835126447297398	-2.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04504504504504505	0.04504504504504505	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04504504504504505	0.0	0.04	0.0	0.0	0.0	0.0	0.0
274	Abeta;A-BETA	0.6202717995804564	-0.5909090909090917	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.1818181818181834	0.0	0.0	-3.428571428571429	0.04	0.04	0.0	0.04	0.04099236641221374	1.0	0.04755905511811023	0.0	2.0	0.0	-6.857142857142858	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04198473282442748	0.0	0.05511811023622047	0.0	0.0	0.0	0.0	0.0
287	the safety, pharmacokinetics, pharmacodynamics, and efficacy	0.13458684528148115	-2.8000000000000007	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.2857142857142857	0.0	-2.8000000000000007	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.04504504504504505	0.04504504504504505	9.0	0.04597701149425287	0.0	1.0	0.0	-3.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04504504504504505	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
8	the centrosome	0.16212333384713432	-2.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-4.0	1.0	1.0	-3.75	0.04	0.04	0.0	0.04	0.04380952380952381	2.0	0.04857142857142857	0.5	2.0	1.0	-7.5	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.047619047619047616	0.0	0.05714285714285714	0.0	1.0	0.0	0.0	1.0
137	clinical trial;Trial;Clinical Trial;trial	0.08838718173168532	-1.037037037037038	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	-3.599999999999999	0.04	0.045454545454545456	0.0	0.04	0.0417693522906793	1.6666666666666667	0.04674709177078845	0.0	3.0	0.0	-3.8999999999999986	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	5.0	0.04265402843601896	0.0	0.04739336492890995	0.0	0.0	0.0	0.0	0.0
307	the relationship between the loss	0.036056483102006556	-3.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.046296296296296294	0.046296296296296294	5.0	0.047619047619047616	0.4	1.0	0.0	-4.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.046296296296296294	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
30	chemosensitivity in acute myeloid leukemia	0.4175122847513681	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
283	tumor;TUMOR	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
200	the use of safety baseballs	0.08279735195665178	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	detection;Detection	0.8351950065404442	-0.7222222222222214	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-1.4444444444444429	0.0	0.0	-2.416666666666667	0.04	0.04	0.0	0.04	0.04122641509433962	1.0	0.04479338842975207	0.0	2.0	0.0	-4.833333333333334	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	2.0	1.0	2.0	0.04245283018867924	1.0	0.04958677685950414	0.0	0.0	0.0	1.0	0.0
329	the program	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	SAME;same	0.1791087318291414	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
29	itaconic acid producing strain	0.030999308543395578	0.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.3333333333333333	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
291	Obesity, Pediatric;pediatric obesity	0.5985482029484777	-2.8571428571428577	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.8571428571428577	0.0	0.0	0.0	0.04	0.04	0.0	0.04516129032258065	0.04516129032258065	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04516129032258065	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	CCR4;Ccr4	0.8382656644072564	-0.625	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.041176470588235294	1.0	0.04	0.0	6.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.047058823529411764	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	T';T	0.7355613391945985	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.04	0.04	0.0	0.04	0.04	1.0	0.051250000000000004	0.0	4.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
115	animal development	0.163309797611514	-3.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
199	the incorporation	0.10309337361928098	-5.333333333333334	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	-5.166666666666666	0.04	0.050420168067226885	0.0	0.05084745762711865	0.05084745762711865	2.0	0.050420168067226885	0.5	1.0	0.0	-5.166666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05084745762711865	0.0	0.050420168067226885	0.0	0.0	0.0	0.0	0.0
213	expression level;expression levels	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
176	Yeast Protein;protein from yeast	0.20372095740119225	-1.875	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-1.875	1.0	1.0	-3.0	0.04	0.045454545454545456	0.0	0.043243243243243246	0.043243243243243246	3.0	0.045454545454545456	0.0	1.0	1.0	-3.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	3.0	0.043243243243243246	0.0	0.045454545454545456	0.0	1.0	0.0	0.0	1.0
325	ubiquitination sites	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
335	LOCALIZED;localized	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
137	bilateral;BILATERAL	0.5541018374593665	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.04	0.04	1.0	0.04587155963302752	0.0	1.0	0.0	-3.1999999999999993	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
102	only;Only	0.129137643735555	-4.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04938271604938271	0.04938271604938271	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04938271604938271	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	PROTEIN;protein	0.3188263695536692	-5.777777777777778	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-17.0	0.0	0.0	-2.8333333333333335	0.04	0.04	0.0	0.04	0.06049048904312062	1.0	0.04712121212121212	0.0	6.0	0.0	-10.333333333333334	1.0	0.5	1.0	0.0	1.0	0.0	1.0	0.5	0.5	2.0	1.0	6.0	0.125	0.0	0.06818181818181819	0.0	0.0	0.0	0.0	0.0
269	the CD133	0.10549951416075809	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	a single nucleotide polymorphism (SNP) in CYP4F2	0.24984375837649686	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.1111111111111111	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
57	consists;CONSIST	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
205	dizziness;DIZZINESS	0.7786266455789895	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
73	several approaches	0.09355910388963645	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.04	0.043165467625899276	0.0	0.04	0.04	2.0	0.043165467625899276	0.0	1.0	0.0	-1.8333333333333321	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.043165467625899276	0.0	0.0	0.0	0.0	0.0
200	baseballs, softballs, hockey pucks	0.29956052836315394	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	mammalian neuronal network	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	characterized;Characterized	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	a potential anticancer agent	0.12158908048401756	-3.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
335	a chromatin	0.3573719689041136	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.04	0.04	2.0	0.04587155963302752	0.0	1.0	0.0	-3.1999999999999993	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
107	such searches	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
221	small;SMALL	0.09916451854301489	-1.375	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	-3.75	0.04	0.04	0.0	0.042105263157894736	0.04232922732362822	1.0	0.04857142857142857	0.0	2.0	0.0	-7.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.0425531914893617	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
231	Unaffected;unaffected	0.6039131868305536	-1.571428571428573	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.042682926829268296	0.042682926829268296	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.042682926829268296	0.0	0.04	0.0	0.0	0.0	0.0	0.0
265	features of non-compaction cardiomyopathy	0.04486934437691037	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
161	Apert acrocephalosyndactyly syndrome	0.12151811279760774	-5.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.3333333333333333	0.0	-5.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05	0.05	3.0	0.04	0.6666666666666666	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.05	0.0	0.04	0.0	0.0	0.0	0.0	0.0
66	infection;infections;Infections;) infection;Infection, NOS	0.22693301207270333	-1.25	0.0	0.0	0.04	0.04	0.5	0.875	0.0	0.0	0.0	1.0	-2.5	1.0	1.0	-0.75	0.04	0.04	0.0	0.04	0.042222222222222223	1.25	0.041363636363636366	0.0	4.0	1.0	-3.0	1.0	0.3333333333333333	0.75	0.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	5.0	1.0	5.0	0.044444444444444446	0.0	0.045454545454545456	0.0	1.0	0.0	0.0	1.0
44	the fauna of the USSR]	0.06625953742103856	-4.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-8.333333333333334	0.04	0.06000000000000001	0.0	0.047619047619047616	0.047619047619047616	6.0	0.06000000000000001	0.5	1.0	0.0	-8.333333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.047619047619047616	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
180	retrotransposition;Retrotransposition	0.5490230382345567	-2.333333333333332	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.044117647058823525	0.044117647058823525	1.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.044117647058823525	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
213	the occurrence of clinical signs	0.08848691453375389	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
6	implementing training	0.10514754826413983	-1.2222222222222214	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.2222222222222214	0.0	0.0	0.0	0.04	0.04	0.0	0.04205607476635514	0.04205607476635514	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04205607476635514	0.0	0.04	0.0	0.0	0.0	0.0	0.0
6	0;0%	0.6908731423145925	-0.9722222222222223	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.041708048542335056	0.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04477611940298508	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	mean CGIS score;Mean score;mean +/- SD CGIS score	0.6073790555987946	0.0	0.0	0.0	0.04	0.04	0.2857142857142857	0.5714285714285714	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04380952380952381	0.0	4.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	16.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
287	I and II studies	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
344	Associated;associated	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
11	based;Based	0.09906967474117563	-1.083333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	-2.333333333333333	0.04	0.04	0.0	0.04	0.04189781021897811	1.0	0.044590163934426226	0.0	2.0	0.0	-4.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.043795620437956206	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
133	phosphorylated Smad2 after TGFbeta treatment	0.3220043454201129	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
14	areas	0.12434880739804091	-0.6875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.375	0.0	0.0	-2.583333333333333	0.04	0.04	0.0	0.04	0.04116402116402117	1.0	0.04521008403361344	0.0	2.0	0.0	-5.166666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.042328042328042326	0.0	0.050420168067226885	0.0	0.0	0.0	0.0	0.0
126	/day;day	0.077367885887223	-2.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04504504504504505	0.04504504504504505	1.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04504504504504505	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
129	hypermethylation;Hypermethylation	0.64281052323766	-0.8888888888888893	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-1.0714285714285712	0.04	0.04	0.0	0.04	0.041531100478468905	1.0	0.041874999999999996	0.0	2.0	0.0	-2.1428571428571423	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.0430622009569378	0.0	0.04375	0.0	0.0	0.0	0.0	0.0
276	generations;Generations	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
84	VENLAFAXINE HYDROCHLORIDE;venlafaxine hydrochloride	0.8110573818772244	-7.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-7.5	0.0	0.0	0.0	0.04	0.04	0.0	0.05714285714285714	0.05714285714285714	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	4.0	0.05714285714285714	0.0	0.04	0.0	0.0	0.0	0.0	0.0
224	-deoxycoformicin	0.6022904207206905	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	2.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
4	autosomal dominant disorder	0.18034060330160567	-3.625	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-3.625	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.04678362573099415	0.04678362573099415	3.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04678362573099415	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
344	Observed;observed	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
178	the enzyme SAHH (S-adenosylhomocysteine hydrolase)	0.2729972746338125	-1.625	1.0	0.0	0.04	0.04	0.1111111111111111	0.1111111111111111	0.0	0.0	0.3333333333333333	1.0	-1.625	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	1.0	0.0427807486631016	0.0427807486631016	9.0	0.04918032786885245	0.3333333333333333	1.0	0.0	-4.666666666666666	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	9.0	0.0427807486631016	0.0	0.04918032786885245	0.0	0.0	0.1111111111111111	0.0	0.0
189	the basis	0.0854653861045168	-6.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.053571428571428575	0.053571428571428575	2.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.053571428571428575	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
80	Therapies;therapies	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
163	lipid metabolism;Lipid Metabolism	0.7589563682959148	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	comprising;Comprise	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
301	data;Data	0.0661817914888578	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
30	associated with;Associated with	0.003153872916808045	-16.4	1.0	-16.0	0.1111111111111111	0.1111111111111111	1.0	1.0	1.0	-16.0	1.0	0.0	-16.4	0.0	0.0	-15.4	0.1111111111111111	0.10416666666666667	0.0	0.11627906976744186	0.11627906976744186	2.0	0.10416666666666667	1.0	1.0	0.0	-15.4	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.11627906976744186	0.0	0.10416666666666667	1.0	0.0	0.0	0.0	0.0
68	non;Non	0.5224434325106047	-3.333333333333333	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	-9.75	0.04	0.06451612903225806	0.0	0.04	0.04727272727272727	0.0	0.06559139784946236	0.0	2.0	0.0	-10.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.054545454545454536	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
334	a C-terminal serine residue	0.552400512235521	0.0	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
38	Chromosome microdeletion;Chromosomal 16p microdeletion	0.6085810506438792	-6.666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	-13.5	0.04	0.08695652173913043	0.0	0.054545454545454536	0.054545454545454536	3.0	0.08695652173913043	0.0	2.0	0.0	-13.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.054545454545454536	0.0	0.08695652173913043	0.0	0.0	0.0	0.0	0.0
270	the repression	0.08701306836083043	-3.1999999999999993	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.04587155963302752	0.04587155963302752	2.0	0.05714285714285714	0.5	1.0	0.0	-7.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04587155963302752	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
118	growth of human prostate cancer cells;Cells--Growth	0.06616287673433494	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-10.75	0.04	0.07017543859649122	0.0	0.04	0.04	6.0	0.07017543859649122	0.16666666666666666	2.0	0.0	-10.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	12.0	0.04	0.0	0.07017543859649122	0.0	0.0	0.0	0.0	0.0
71	HIF;HIF)	0.6375917977458113	-2.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.043859649122807015	0.043859649122807015	1.5	0.04878048780487805	0.0	2.0	0.0	-4.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.043859649122807015	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
29	Aspergillus terreus SKR10	0.7768787665556641	-2.833333333333332	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.833333333333332	1.0	1.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.045112781954887216	0.045112781954887216	4.0	0.05084745762711865	0.0	2.0	1.0	-5.333333333333334	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.045112781954887216	0.0	0.05084745762711865	0.0	1.0	0.0	0.0	1.0
345	the 3' end	0.008619027888897327	-10.3	1.0	-8.8	0.0617283950617284	0.0617283950617284	0.5	0.5	1.0	-8.8	1.0	0.0	-10.3	0.0	0.0	-9.8	0.0617283950617284	0.06578947368421052	0.0	0.06802721088435375	0.06802721088435375	4.0	0.06578947368421052	1.0	1.0	0.0	-9.8	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.06802721088435375	0.0	0.06578947368421052	1.0	0.0	0.0	0.0	0.0
302	7-naphtyridine-3-carbonitrile	0.6105170479866645	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
28	patients with this syndrome	0.043137485753716585	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	1.0	1.0	0.0	1.0	0.3333333333333333	1.0	1.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
307	the nigro-striatal and nigro-amygdaloid pathways	0.2892686366302624	-2.1999999999999993	0.0	0.0	0.04	0.04	0.2222222222222222	0.2222222222222222	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.043859649122807015	0.043859649122807015	9.0	0.04	0.1111111111111111	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.043859649122807015	0.0	0.04	0.0	0.0	0.0	0.0	0.0
91	15.6 years	0.2866357307544823	-5.2857142857142865	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-5.2857142857142865	0.0	0.0	0.0	0.04	0.04	0.0	0.05072463768115942	0.05072463768115942	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05072463768115942	0.0	0.04	0.0	0.0	0.0	0.0	0.0
245	the effect	0.08709274224709737	-4.428571428571429	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.428571428571429	0.0	0.0	-7.4	0.04	0.056818181818181816	0.0	0.04861111111111112	0.04861111111111112	2.0	0.056818181818181816	0.0	1.0	0.0	-7.4	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04861111111111112	0.0	0.056818181818181816	0.0	0.0	0.0	0.0	0.0
304	impressive responses	0.11725837476176021	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-9.428571428571429	0.04	0.06422018348623854	0.0	0.04819277108433735	0.04819277108433735	2.0	0.06422018348623854	0.0	2.0	0.0	-9.428571428571429	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04819277108433735	0.0	0.06422018348623854	0.0	0.0	0.0	0.0	0.0
67	using;Using	0.08192259218749924	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.25	0.04	0.05405405405405406	0.0	0.04	0.04	1.0	0.05643879173290938	0.0	2.0	0.0	-8.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
239	cardiologic and ophthalmologic evaluation	0.2344897740359552	-2.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
321	a well prediction capacity for CysLT	0.030283520000625293	-3.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-15.0	0.04	0.1	0.0	0.045454545454545456	0.045454545454545456	6.0	0.1	0.16666666666666666	1.0	0.0	-15.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.045454545454545456	0.0	0.1	0.0	0.0	0.0	0.0	0.0
192	ORs 1.52	0.2765738641103709	-4.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	database;Database	0.23644059069736595	-1.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-1.375	0.04	0.04	0.0	0.04	0.041944444444444444	1.0	0.04328358208955224	0.0	6.0	0.0	-8.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.05	0.0	0.05970149253731343	0.0	0.0	0.0	0.0	0.0
129	redundant activities in the establishment and maintenance	0.024865229614463736	0.0	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.571428571428573	0.04	0.0445859872611465	0.0	0.04	0.04	7.0	0.0445859872611465	0.42857142857142855	1.0	0.0	-2.571428571428573	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
238	FIAT	0.7712103795275982	-1.8888888888888882	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.043408521303258146	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.045112781954887216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
144	post coitum	0.33464996046184486	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	Fusion Gene;fusion gene	0.9497440448719725	-0.7676767676767675	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-1.5555555555555571	1.0	1.0	-4.909090909090909	0.04	0.04436860068259385	0.0	0.04	0.04130235152564606	2.0	0.04996930228042215	0.0	11.0	1.0	-6.538461538461538	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	22.0	0.04265402843601896	0.0	0.05416666666666667	0.0	1.0	0.0	0.0	1.0
213	Shaker-like voltage-gated	0.2016352348792595	-4.666666666666666	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.04918032786885245	0.04918032786885245	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04918032786885245	0.0	0.04	0.0	0.0	0.0	0.0	0.0
256	the P250R mutation in the FGFR3 gene	0.15060155264433275	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	1.0	0.14285714285714285	0.0	1.0
319	Series;series	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
37	the topoisomerase II targeting drugs	0.0518119378912566	0.0	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	5.0	0.04	0.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.2	0.0	0.0
334	parallel with increasing levels	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
344	previous;Previous	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
5	individualized;Individualized	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
298	total proteins	0.2303901483676993	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04	0.04	2.0	0.043478260869565216	0.0	1.0	0.0	-2.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
332	syk gene;SYK Gene	0.20146510080365157	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
226	Front;front	0.07296156602125722	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.04	0.04	1.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
311	untranslated repeats	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
181	Recent data	0.12811056045970384	-7.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05555555555555555	0.05555555555555555	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05555555555555555	0.0	0.04	0.0	0.0	0.0	0.0	0.0
276	Research;research	0.08670129078645707	-3.375	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.375	0.0	0.0	-2.3999999999999986	0.04	0.04424778761061947	0.0	0.046242774566473986	0.046242774566473986	1.0	0.04424778761061947	0.0	1.0	0.0	-2.3999999999999986	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046242774566473986	0.0	0.04424778761061947	0.0	0.0	0.0	0.0	0.0
241	a case report and review of the literature	0.04718169599721014	-6.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.053571428571428575	0.053571428571428575	8.0	0.05555555555555555	0.125	1.0	0.0	-7.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.053571428571428575	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
84	Major Depression;major depression	0.20807738681077179	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	1.0	0.0	1.0	0.3333333333333333	1.0	0.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
139	domain;Domain	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
345	The Sec insertion sequence (SECIS) element	0.1904371556388782	0.0	0.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.125	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	dose;doses;Doses;DOSE	0.11464127260930641	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
139	such strategies	0.08217313876208321	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	2.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
13	X-Ray Diffraction;X-ray diffraction	0.5292199564179181	-8.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-12.0	0.0	0.0	-2.444444444444445	0.04	0.04	0.0	0.04	0.06461538461538462	2.0	0.044583333333333336	0.5	3.0	0.0	-3.666666666666668	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.07692307692307693	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
35	TRalpha1	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
91	the use of an internet-based CBT program	0.1070039336330764	-2.2857142857142847	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-2.2857142857142847	1.0	1.0	0.0	0.04	0.04	0.0	0.0440251572327044	0.0440251572327044	9.0	0.04	0.1111111111111111	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.0440251572327044	0.0	0.04	0.0	1.0	0.0	0.0	1.0
99	3;<3	0.6352706962536481	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.2857142857142865	0.04	0.04	0.0	0.04	0.04	0.5	0.04229299363057325	0.0	2.0	0.0	-2.571428571428573	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
209	yeast	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
55	Completely;completely	0.06998091245582899	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	1.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
246	the CYP2C19, CYP2C9, CYP3A4, CYP3A5, ABCB1, P2Y12, and CES genes	0.23354411276625198	0.0	1.0	0.0	0.04	0.04	0.1875	0.1875	0.0	0.0	0.1111111111111111	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	16.0	0.04	0.0625	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	16.0	0.04	0.0	0.04	0.0	1.0	0.0625	0.0	1.0
276	a severe X-linked psychomotor retardation	0.20850986755089124	-2.5	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	-9.6	0.04	0.06493506493506493	0.0	0.044444444444444446	0.044444444444444446	5.0	0.06493506493506493	0.0	1.0	0.0	-9.6	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.044444444444444446	0.0	0.06493506493506493	0.0	0.0	0.0	0.0	0.0
200	occurring;occurred;Occur;Occurred	0.07091882587214722	-1.1333333333333329	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-4.111111111111111	0.04	0.04	0.0	0.04	0.04209876543209876	1.0	0.052982456140350874	0.0	3.0	0.0	-12.333333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.046296296296296294	0.0	0.07894736842105263	0.0	0.0	0.0	0.0	0.0
306	rigorous;Rigor	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	ubiquitin ligases	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
211	a cluster	0.09958173095489553	-1.3333333333333321	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.3333333333333321	0.0	0.0	-1.4444444444444429	0.04	0.04245283018867924	0.0	0.04225352112676056	0.04225352112676056	2.0	0.04245283018867924	0.0	1.0	0.0	-1.4444444444444429	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04225352112676056	0.0	0.04245283018867924	0.0	0.0	0.0	0.0	0.0
78	MDM2	0.8277681527889401	-4.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.75	1.0	1.0	0.0	0.04	0.04	0.0	0.04938271604938271	0.04938271604938271	1.0	0.04	0.0	2.0	1.0	0.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04938271604938271	0.0	0.04	0.0	1.0	0.0	0.0	1.0
25	interventions	0.08424784999938828	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
94	drug plasma monitoring;Drug Monitoring	0.1187176919696614	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	adverse reactions including bleeding	0.19113389002460238	-4.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.047619047619047616	0.047619047619047616	4.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.047619047619047616	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
341	considerations	0.11320335559537567	-1.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	0.0	0.04	0.04	0.0	0.0425531914893617	0.0425531914893617	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.0425531914893617	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	provides	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
61	ATG8/LC3 lipidation	0.47921971247245476	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.25	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
93	33 children with newly diagnosed absence epilepsy	0.03127300211958615	-2.666666666666668	1.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.2857142857142857	0.0	-2.666666666666668	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04477611940298508	0.04477611940298508	7.0	0.05084745762711865	0.14285714285714285	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04477611940298508	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
172	known;Known	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	hGH;HGH	0.8408781356914586	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
276	its presence	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
106	myeloid differentiation	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	the main challenges of the Human Genome Project	0.037954043148339126	-3.0	0.0	0.0	0.04	0.04	0.875	0.875	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	8.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	predicting and discriminating beta barrel membrane proteins	0.04848831280583354	0.0	1.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.2	0.0	0.0	0.0	0.0	-2.833333333333332	0.04	0.045112781954887216	0.0	0.04	0.04	7.0	0.045112781954887216	0.42857142857142855	1.0	0.0	-2.833333333333332	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.045112781954887216	0.0	0.0	0.0	0.0	0.0
90	medications;Medications	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
160	clinically relevant increase	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
245	domain;Domain	0.1062384770697074	-0.8571428571428577	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.571428571428573	0.0	0.0	-5.933333333333333	0.04	0.05	0.0	0.04	0.04152866242038217	1.0	0.05251310514955288	0.0	3.0	0.0	-6.6	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.0445859872611465	0.0	0.05434782608695653	0.0	0.0	0.0	0.0	0.0
77	the cerebral tissue with tolcapone	0.2600705872420841	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-1.8571428571428577	0.04	0.043209876543209874	0.0	0.04	0.04	5.0	0.043209876543209874	0.0	1.0	1.0	-1.8571428571428577	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.04	0.0	0.043209876543209874	0.0	1.0	0.0	0.0	1.0
122	VKORC1 and CYP2C9 polymorphisms	0.5896098312873089	-4.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	-4.0	1.0	1.0	-7.5	0.04	0.05714285714285714	0.0	0.047619047619047616	0.047619047619047616	4.0	0.05714285714285714	0.0	2.0	1.0	-7.5	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.047619047619047616	0.0	0.05714285714285714	0.0	1.0	0.0	0.0	1.0
95	oligo-adenosine RNA like canonical cytoplasmic deadenylases	0.3511134856883897	0.0	0.0	0.0	0.04	0.04	0.125	0.125	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.125	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	the available biomedical text mining tools	0.004427095174947095	-7.4	1.0	-9.8	0.06578947368421052	0.06578947368421052	0.6666666666666666	0.6666666666666666	1.0	-9.8	1.0	0.0	-7.4	0.0	0.0	-9.0	0.06578947368421052	0.0625	1.0	0.056818181818181816	0.056818181818181816	6.0	0.0625	1.0	1.0	0.0	-9.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.056818181818181816	0.0	0.0625	1.0	0.0	0.16666666666666666	0.0	0.0
183	mRNA	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
258	Early;early	0.09860428594217144	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.800000000000001	0.0	0.0	-5.1000000000000005	0.04	0.04672897196261683	0.0	0.04587155963302752	0.04897744648318043	1.0	0.05053839902478668	0.0	2.0	0.0	-6.6	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.052083333333333336	0.0	0.05434782608695653	0.0	0.0	0.0	0.0	0.0
276	neuronal hypothyroidism despite elevated serum T3 levels	0.375662280340917	0.0	0.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
88	Gene;gene	0.07703098046394664	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.05	0.05	1.0	0.054545454545454536	0.0	1.0	0.0	-6.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
152	K+;K	0.6852370244726799	-2.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.1999999999999993	0.0	0.0	-7.6	0.04	0.0574712643678161	0.0	0.043859649122807015	0.043859649122807015	1.0	0.0574712643678161	0.0	1.0	0.0	-7.6	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	1.0	0.043859649122807015	0.0	0.0574712643678161	0.0	0.0	0.0	0.0	0.0
242	a significant associate	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
10	PROSTATE;prostate	0.6105038608051248	-2.2857142857142847	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.2857142857142847	0.0	0.0	0.0	0.04	0.04	0.0	0.0440251572327044	0.0440251572327044	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0440251572327044	0.0	0.04	0.0	0.0	0.0	0.0	0.0
295	pelvic floor muscle exercises;Pelvic floor exercises	0.23353541247758958	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
38	Region;region	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
290	PROBE;probe	0.6170544090123072	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
91	longer;Long;long	0.08445355569689215	-2.1428571428571432	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.2857142857142865	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.044137931034482755	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.04827586206896552	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	DNMT1	0.7479998167357287	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.4444444444444446	0.04	0.04	0.0	0.04	0.04	1.0	0.04477523949889462	0.0	3.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
144	cTnT promoter	0.6351393800659858	-3.3999999999999986	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.3999999999999986	1.0	1.0	-8.5	0.04	0.06060606060606061	0.0	0.046296296296296294	0.046296296296296294	2.0	0.06060606060606061	0.0	1.0	1.0	-8.5	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.046296296296296294	0.0	0.06060606060606061	0.0	1.0	0.0	0.0	1.0
201	cases of blunt thoracic impact causing fatality	0.4131788134731405	-16.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	-16.0	0.0	0.0	-9.0	0.04	0.0625	0.0	0.1111111111111111	0.1111111111111111	7.0	0.0625	0.0	2.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	14.0	0.1111111111111111	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
46	div class="row"	0.29956052836315394	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
251	Dependent;dependent	0.07668540143973003	-1.7777777777777786	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.0430622009569378	0.0430622009569378	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0430622009569378	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
255	evidence of myopathic disease	0.06134183469676007	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.875	0.04	0.043243243243243246	0.0	0.04	0.04	4.0	0.043243243243243246	0.25	1.0	0.0	-1.875	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.043243243243243246	0.0	0.0	0.0	0.0	0.0
332	healthy human subjects;healthy human Subject	0.21667842899134648	-2.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.044117647058823525	0.04411764705882352	3.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.044117647058823525	0.0	0.04	0.0	0.0	0.0	0.0	0.0
339	significant up-regulation	0.13095204795968823	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	Philadelphia chromosome (Ph	0.19981938647217673	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.692307692307692	0.04	0.0546218487394958	0.0	0.04	0.04	4.0	0.0546218487394958	0.75	1.0	0.0	-6.692307692307692	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.0546218487394958	0.0	0.0	0.0	0.0	0.0
14	present BOCTOPUS	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
293	PE	0.6847694837524357	-4.916666666666667	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.0	0.0	0.0	-11.333333333333334	0.04	0.058823529411764705	0.0	0.04597701149425287	0.05010435161822883	1.0	0.08425430778371955	0.0	3.0	0.0	-17.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05555555555555555	0.0	0.13333333333333333	0.0	0.0	0.0	0.0	0.0
334	Gamma;gamma	0.5507698756409757	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.04	0.04	1.0	0.046511627906976744	0.0	1.0	0.0	-3.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
144	endogenous;Endogenous	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
54	5)	0.575106525152481	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.04	0.04	2.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
344	HEK 293 cell lines;HEK 293 Cell Line	0.3091176327648701	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
87	HEART;Cardiac;heart;cardiac	0.05084205948487527	-8.5625	1.0	-17.75	0.04	0.08896551724137931	0.0	0.75	1.0	-8.875	1.0	0.0	-13.75	0.0	0.0	-10.6875	0.13793103448275862	0.04	0.0	0.04	0.06814307458143075	1.0	0.08647907647907649	0.75	4.0	0.0	-16.75	1.0	0.0	0.75	0.75	1.0	0.0	1.0	0.0	0.0	4.0	1.0	4.0	0.08888888888888889	0.0	0.12121212121212122	1.0	0.0	0.0	0.0	0.0
320	the basis of Cat Scramble validation	0.05172733387632983	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
107	Maximum;maximum	0.20575841123895008	-1.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-1.0	0.0	0.0	-2.2857142857142847	0.04	0.0440251572327044	0.0	0.041666666666666664	0.041666666666666664	1.0	0.0440251572327044	0.0	1.0	0.0	-2.2857142857142847	1.0	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	2.0	1.0	1.0	0.041666666666666664	1.0	0.0440251572327044	0.0	0.0	0.0	1.0	0.0
204	in;In	0.10518147901232815	-3.625	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-4.25	0.04	0.04	0.0	0.046511627906976744	0.046785225718194254	1.0	0.05030303030303031	0.0	2.0	0.0	-8.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.047058823529411764	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
119	a right-handed antiparallel	0.15297128841463728	-3.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-3.6000000000000014	0.04	0.04672897196261683	0.0	0.045454545454545456	0.045454545454545456	5.0	0.04672897196261683	0.0	1.0	0.0	-3.6000000000000014	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.045454545454545456	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
127	examinations during epidermal growth factor receptor-tyrosine kinase inhibitors treatment	0.1508433315730507	-7.5	0.0	0.0	0.04	0.04	0.45454545454545453	0.45454545454545453	0.0	0.0	0.0	0.0	-7.5	0.0	0.0	-9.0	0.04	0.0625	0.0	0.05714285714285714	0.05714285714285714	11.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	11.0	0.05714285714285714	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
205	Decrease;decreases	0.06758346897318977	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.04	0.04	1.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
329	AutodockVina;AutoDock Vina	0.640483874983376	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-11.333333333333334	0.04	0.04	0.0	0.04	0.04	1.6666666666666667	0.09666666666666666	0.0	3.0	0.0	-17.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04	0.0	0.125	0.0	0.0	0.0	0.0	0.0
198	Chinese patients with ARVD	0.15393218620903898	-3.3999999999999986	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	-3.3999999999999986	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.046296296296296294	0.046296296296296294	4.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.046296296296296294	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
188	TS2-neo mouse	0.320978819729692	0.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.25	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
231	Generated;generated	0.09990092870061311	-0.7857142857142865	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.571428571428573	0.0	0.0	-2.2142857142857144	0.04	0.04	0.0	0.04	0.04134146341463415	1.0	0.044305555555555556	0.0	2.0	0.0	-4.428571428571429	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.042682926829268296	0.0	0.04861111111111112	0.0	0.0	0.0	0.0	0.0
97	COSTA RICA;Costa Rica	0.6721500832556117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
222	its use for patients	0.009272607126541203	-1.8888888888888893	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.4	0.0	-1.8888888888888893	0.0	0.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.04326923076923077	0.04326923076923077	4.0	0.044642857142857144	0.75	1.0	0.0	-2.6000000000000014	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04326923076923077	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
276	q13;Q13	0.6066186994119565	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
313	finishing steps of sperm maturation and fitness	0.11272340449087064	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
17	bilateral tubal occlusion	0.6171953679194666	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	a format applicable to high-throughput screening	0.09492702730576637	-3.75	0.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-2.666666666666668	0.04	0.04477611940298508	0.0	0.047058823529411764	0.047058823529411764	8.0	0.04477611940298508	0.125	1.0	0.0	-2.666666666666668	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.047058823529411764	0.0	0.04477611940298508	0.0	0.0	0.0	0.0	0.0
279	a consequence	0.09332837339153198	-3.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-5.166666666666666	0.04	0.050420168067226885	0.0	0.04716981132075472	0.04716981132075472	2.0	0.050420168067226885	0.0	1.0	0.0	-5.166666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04716981132075472	0.0	0.050420168067226885	0.0	0.0	0.0	0.0	0.0
91	the parents	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
275	Availability of;of available	0.030155674082559904	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
343	a conserved, positive regulatory role	0.04660310040607219	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.16666666666666666	0.0	0.0
60	Nup107/160	0.6636582128548709	-5.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.75	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.05194805194805195	0.05194805194805195	1.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.05194805194805195	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
72	PPIs);PPIs	0.6559480918715097	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.045454545454545456	0.045454545454545456	1.5	0.046296296296296294	0.0	2.0	0.0	-3.3999999999999986	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.045454545454545456	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
216	Geobacter species during in situ	0.10254923760737483	-14.25	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	-14.25	1.0	1.0	-19.0	0.04	0.16666666666666666	0.0	0.09302325581395349	0.09302325581395349	5.0	0.16666666666666666	0.2	1.0	1.0	-19.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.09302325581395349	0.0	0.16666666666666666	0.0	1.0	0.0	0.0	1.0
189	median levels of OT	0.26339784460399335	-6.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05263157894736842	0.05263157894736842	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.05263157894736842	0.0	0.04	0.0	0.0	0.0	0.0	0.0
142	at;At	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
5	an adjunctive therapy	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	functional annotations of known disease genes	0.038535324914210474	0.0	1.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.14285714285714285	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	the development	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	a hereditary moyamoya multisystem disorder	0.12736062714893276	0.0	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.2	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
217	Generated;generated	0.06592883564082425	-3.875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.875	0.0	0.0	-9.428571428571429	0.04	0.06422018348623854	0.0	0.047337278106508875	0.047337278106508875	1.0	0.06422018348623854	0.0	1.0	0.0	-9.428571428571429	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047337278106508875	0.0	0.06422018348623854	0.0	0.0	0.0	0.0	0.0
49	Communication skills;communication skills	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	Programs;programs	0.09773875734391521	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
339	ERK1/2-dependent down-regulation and subsequent dissociation	0.09097870808901161	-2.833333333333332	0.0	0.0	0.04	0.04	0.5555555555555556	0.5555555555555556	0.0	0.0	0.0	1.0	-2.833333333333332	1.0	1.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.045112781954887216	0.045112781954887216	9.0	0.046296296296296294	0.3333333333333333	1.0	1.0	-3.3999999999999986	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.045112781954887216	0.0	0.046296296296296294	0.0	1.0	0.0	0.0	1.0
115	limb development in human	0.0884415052403157	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
140	H2B gene family	0.31675424358311866	-2.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
211	recognition;Recognition	0.07638159603950415	-1.6666666666666679	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6666666666666679	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04285714285714286	0.04285714285714286	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04285714285714286	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
79	recurrence of benzodiazepine-induced coma	0.5040986920080754	0.0	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
337	cardiomyopathy	0.05399125128862858	-10.8	1.0	-14.4	0.09433962264150944	0.09433962264150944	0.0	0.0	1.0	-14.4	1.0	0.0	-10.8	0.0	0.0	-13.6	0.09433962264150944	0.08771929824561403	0.0	0.07042253521126761	0.07042253521126761	1.0	0.08771929824561403	1.0	1.0	0.0	-13.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.07042253521126761	0.0	0.08771929824561403	1.0	0.0	0.0	0.0	0.0
202	200,000	0.6593268499609605	-5.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.25	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.05063291139240506	0.05063291139240506	1.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.05063291139240506	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
222	a humanized monoclonal antibody against CD52	0.36053559982625444	-2.2222222222222214	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-2.2222222222222214	0.0	0.0	0.0	0.04	0.04	0.0	0.04390243902439024	0.04390243902439024	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.04390243902439024	0.0	0.04	0.0	0.0	0.0	0.0	0.0
84	the most common AD in 2001	0.08218190525806326	-10.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-10.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.06666666666666667	0.06666666666666667	6.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.06666666666666667	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
99	SEVERE;severe	0.1174224367827678	-1.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-2.4761904761904767	0.04	0.042682926829268296	0.0	0.04	0.042926829268292686	1.0	0.04444051522312072	0.0	3.0	0.0	-3.2857142857142847	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04878048780487805	0.0	0.046052631578947366	0.0	0.0	0.0	0.0	0.0
127	patients with EGFR	0.3179440921532574	-2.166666666666668	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-2.166666666666668	1.0	1.0	0.0	0.04	0.04	0.0	0.043795620437956206	0.043795620437956206	3.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	3.0	0.043795620437956206	1.0	0.04	0.0	1.0	0.0	1.0	1.0
129	induce;Induce;induced;Induced	0.4943708666298458	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.2857142857142865	0.04	0.04516129032258065	0.0	0.04	0.04	1.0	0.046070578047196366	0.0	2.0	0.0	-3.7142857142857153	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.04	0.0	0.04697986577181208	0.0	0.0	0.0	0.0	0.0
79	. In 13 patients	0.1405487375957212	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	homology to an Mg2+-dependent DNase/phosphatase family of proteins;homology protein	0.09591552897152979	0.0	1.0	0.0	0.04	0.04	0.3076923076923077	0.3076923076923077	0.0	0.0	0.08333333333333333	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	13.0	0.04	0.15384615384615385	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	13.0	0.04	0.0	0.04	0.0	1.0	0.07692307692307693	0.0	1.0
85	MIR-21;miR-21	0.7869991447765158	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.0	0.0	0.0	-2.8571428571428577	0.04	0.04516129032258065	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04516129032258065	0.0	2.0	0.0	-2.8571428571428577	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	2.0	0.045454545454545456	0.0	0.04516129032258065	0.0	0.0	0.0	0.0	0.0
256	a Pro250Arg substitution in fibroblast growth factor	0.20194852323334084	-5.333333333333334	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	1.0	-5.333333333333334	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.05084745762711865	0.05084745762711865	7.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.05084745762711865	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
41	other types	0.12176731746802462	-5.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.5	0.0	0.0	0.0	0.04	0.04	0.0	0.05128205128205128	0.05128205128205128	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05128205128205128	0.0	0.04	0.0	0.0	0.0	0.0	0.0
127	60-70%)	0.6591238372358369	-2.833333333333332	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.045112781954887216	0.045112781954887216	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.045112781954887216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
29	level;Level	0.07328683872821115	-2.833333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.045112781954887216	0.045112781954887216	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045112781954887216	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
130	beta-lactamases;Beta lactamases	0.6905212053626832	-0.9090909090909088	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-1.3636363636363633	1.0	1.0	-2.7619047619047628	0.04	0.042682926829268296	0.0	0.04	0.041538461538461545	3.0	0.045241855296250806	0.3333333333333333	3.0	1.0	-5.142857142857142	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	9.0	0.04230769230769231	0.0	0.050359712230215826	0.0	1.0	0.0	0.0	1.0
256	Carrying;carrying	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
171	dilated and non-compaction cardiomyopathy	0.09524008193280124	0.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
155	new insight	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
168	Good;good	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	Overall;overall	0.0661817914888578	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
310	MULTIPLE MYELOMA;myeloma;multiple myeloma;MYELOMA	0.9999994004356512	-2.4473684210526314	0.0	0.0	0.04	0.04	0.0	0.4868421052631579	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-4.25	0.04	0.04	0.0	0.04	0.04462800456677814	1.9736842105263157	0.04980028965760015	0.0	38.0	0.0	-9.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	75.0	0.05	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
160	Acquired;acquired	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	assessed;Assessed	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
49	Recently;recently	0.1126544052544907	-2.125	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.25	0.0	0.0	-1.0999999999999996	0.04	0.04	0.0	0.043478260869565216	0.04371715241280459	1.0	0.04192982456140351	0.0	2.0	0.0	-2.1999999999999993	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04395604395604396	0.0	0.043859649122807015	0.0	0.0	0.0	0.0	0.0
199	mapping;Mapping	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	PFAM domain database	0.15380699959401356	-1.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.0	0.0	0.0	0.0	0.04	0.04	0.0	0.041666666666666664	0.041666666666666664	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.041666666666666664	0.0	0.04	0.0	0.0	0.0	0.0	0.0
37	N NOS;n	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
71	IKK	0.7831569625208262	-3.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.1999999999999993	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04587155963302752	0.04587155963302752	1.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	1.0	0.04587155963302752	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
264	l's;l;L	0.609118067356068	-2.875	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.875	0.0	0.0	0.0	0.04	0.04	0.0	0.043243243243243246	0.04529026067487606	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.047337278106508875	0.0	0.04	0.0	0.0	0.0	0.0	0.0
336	readers;reader;READER	0.08204495988298091	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-4.75	0.04	0.04878048780487805	0.0	0.047619047619047616	0.04819976771196283	1.0	0.04939024390243903	0.0	2.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.04878048780487805	0.0	0.05	0.0	0.0	0.0	0.0	0.0
78	Addition;addition	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
159	consists;CONSIST	0.097133028520796	-1.625	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-2.666666666666667	0.04	0.04	0.0	0.04	0.04298850574712644	1.0	0.04542372881355933	0.0	2.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04597701149425287	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
168	multiple congenital anomalies;MULTIPLE CONGENITAL ANOMALIES	0.420472123462711	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	a minimum of 27% identity	0.08680331008994818	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
197	0.4	0.8255533631578269	-6.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-6.75	0.0	0.0	-9.333333333333334	0.04	0.06382978723404256	0.0	0.0547945205479452	0.0547945205479452	1.0	0.06382978723404256	0.0	1.0	0.0	-9.333333333333334	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	0.0547945205479452	1.0	0.06382978723404256	0.0	0.0	0.0	1.0	0.0
102	Identified;identified	0.0968891560091204	-3.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	0.0	0.04	0.04	0.0	0.047058823529411764	0.047058823529411764	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047058823529411764	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	a BCR-ABL tyrosine kinase	0.2690865648931067	0.0	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-3.3846153846153832	0.04	0.046263345195729534	1.0	0.04	0.04	6.0	0.046263345195729534	0.6666666666666666	1.0	1.0	-3.3846153846153832	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.04	0.0	0.046263345195729534	0.0	1.0	0.16666666666666666	0.0	1.0
187	Outward;outward	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
156	Risk;risk	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
113	24	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
152	the opinion	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	beta-contacts	0.11504033080050197	-1.625	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-1.625	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.0427807486631016	0.0427807486631016	3.0	0.045454545454545456	0.6666666666666666	1.0	0.0	-3.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.0427807486631016	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
215	mitogen-activated protein (MAP) kinase cascade	0.3035872080423539	0.0	0.0	0.0	0.04	0.04	0.2222222222222222	0.2222222222222222	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	9.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
343	monomers	0.6087867693893387	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
176	bending;bend;BENDS;bends	0.34685440829650366	-1.25	0.0	0.0	0.04	0.04	0.0	0.6666666666666666	0.0	0.0	0.0	0.0	-2.25	0.0	0.0	-2.933333333333333	0.04	0.04	0.0	0.04	0.04216974514846855	1.0	0.04606915840325451	0.0	3.0	0.0	-6.6	1.0	0.0	0.6666666666666666	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.04395604395604396	0.0	0.05434782608695653	0.0	0.0	0.0	0.0	0.0
5	an adjunctive therapy in patients	0.15898064341854684	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	algorithm with a cut-off E-value	0.11272340449087064	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
293	delivery;Delivery	0.06922615940956685	-3.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-14.5	0.04	0.09523809523809523	0.0	0.047058823529411764	0.047058823529411764	1.0	0.09523809523809523	0.0	2.0	0.0	-14.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.047058823529411764	0.0	0.09523809523809523	0.0	0.0	0.0	0.0	0.0
235	majority	0.08610674252977572	-1.7777777777777786	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.0430622009569378	0.0430622009569378	1.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.0430622009569378	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
331	the proliferation and/or progression	0.19706491701828815	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	text for summarizing or finding relevant information	0.03846976846308708	-1.6999999999999993	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	-1.6999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04291845493562232	0.04291845493562232	7.0	0.04	0.2857142857142857	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04291845493562232	0.0	0.04	0.0	0.0	0.0	0.0	0.0
161	Hypoplastic midface;hypoplastic midface	0.6721500832556117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	the deletion	0.08699181193519391	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04	0.04	2.0	0.04938271604938271	0.5	1.0	0.0	-4.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
215	Further;further	0.07563896052907934	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.04	0.04504504504504505	0.0	0.04	0.04	1.0	0.04504504504504505	0.0	1.0	0.0	-2.8000000000000007	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04504504504504505	0.0	0.0	0.0	0.0	0.0
267	the difference	0.14684823062145294	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
61	the membrane	0.10549951416075809	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
151	Modification;modification	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
331	a new important element	0.0884415052403157	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
150	a lysosomal receptor for this pathway	0.09227826552670058	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.14285714285714285	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.16666666666666666	0.0	0.0
126	associated with symptoms;associated with gastrointestinal (GI) symptoms	0.1337592381623808	-11.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	-11.0	0.0	0.0	-11.666666666666666	0.04	0.075	1.0	0.07142857142857142	0.07142857142857142	7.0	0.075	0.14285714285714285	1.0	0.0	-11.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	7.0	0.07142857142857142	0.0	0.075	0.0	0.0	0.14285714285714285	0.0	0.0
26	grade I or II reflux esophagitis	0.25808436253731254	-2.428571428571427	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-2.428571428571427	1.0	1.0	0.0	0.04	0.04	0.0	0.04430379746835443	0.04430379746835443	6.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04430379746835443	0.0	0.04	0.0	1.0	0.0	0.0	1.0
124	Decade;decades	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
205	the side effects of Nalmefene	0.0021783404046034354	0.0	1.0	-9.5	0.06451612903225806	0.06451612903225806	0.8	0.8	1.0	-9.5	1.0	0.0	0.0	0.0	0.0	-10.0	0.06451612903225806	0.06666666666666667	1.0	0.04	0.04	5.0	0.06666666666666667	1.0	1.0	0.0	-10.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.06666666666666667	1.0	0.0	0.2	0.0	0.0
102	rhythmic clock gene expression in mCry1	0.10924569603414379	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
6	heroin users for peer administration	0.13377633557080035	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04	0.04	5.0	0.04878048780487805	0.0	1.0	0.0	-4.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
90	the Clinical Utility of Caduet	0.028141532767139266	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
307	patients;Patients	0.16386783184461995	-2.5999999999999996	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-3.0625	0.04	0.04	0.0	0.04	0.04484054172127566	1.0	0.045927313080871134	0.0	4.0	0.0	-4.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.047619047619047616	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
41	methylation;Methylation	0.7990473906750896	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.8000000000000003	0.04	0.04	0.0	0.04	0.04	1.0	0.04552433023510115	0.0	5.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
208	least;Less	0.0985949953261355	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
66	structural malformations	0.26261001335157835	-2.166666666666668	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.043795620437956206	0.043795620437956206	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043795620437956206	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	protein structure) of TMB residues	0.14209989988493577	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	Cancer related;cancer-related	0.09283277756792016	-5.666666666666666	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-11.0	0.04	0.07142857142857142	0.0	0.051724137931034475	0.051724137931034475	3.0	0.07142857142857142	0.0	1.0	0.0	-11.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.051724137931034475	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0
189	serum concentration	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
321	input;Input	0.11741804851085968	-1.9333333333333336	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-5.333333333333333	0.04	0.04	0.0	0.04	0.04350480559196155	1.0	0.0637037037037037	0.0	3.0	0.0	-16.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04587155963302752	0.0	0.1111111111111111	0.0	0.0	0.0	0.0	0.0
26	Chronic colitis	0.5198771727482978	-2.1428571428571423	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-2.1428571428571423	1.0	1.0	0.0	0.04	0.04	0.0	0.04375	0.04374999999999999	2.0	0.04	0.0	3.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04375	0.0	0.04	0.0	1.0	0.0	0.0	1.0
14	for;For	0.008580681448501295	-2.1666666666666665	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.375	0.0	0.0	-8.444444444444445	0.04	0.05	0.0	0.043478260869565216	0.043797667630575014	1.0	0.06181568378778271	1.0	3.0	0.0	-11.166666666666666	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04419889502762431	0.0	0.07228915662650602	1.0	0.0	0.0	0.0	0.0
246	an association	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
76	Prevention	0.12433103832656751	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	small samples	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	means;Means	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
65	active chromatin	0.3093568332809327	-3.75	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-3.75	0.0	0.0	-6.25	0.04	0.05333333333333334	0.0	0.047058823529411764	0.047058823529411764	2.0	0.05333333333333334	0.0	1.0	0.0	-6.25	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.047058823529411764	0.0	0.05333333333333334	0.0	0.0	0.0	0.0	0.0
101	Studies of H3K4me3 demethylation	0.20392792817938546	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	Likelihood	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
203	chromosome 15q11-q13 in Prader	0.18564600969202827	-9.25	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	0.0	-9.25	0.0	0.0	-11.6	0.04	0.07462686567164178	0.0	0.06349206349206349	0.06349206349206349	6.0	0.07462686567164178	0.5	1.0	0.0	-11.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.06349206349206349	0.0	0.07462686567164178	0.0	0.0	0.0	0.0	0.0
80	used	0.138062657829642	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	both mutant MRG15 proteins	0.4831018118224998	-9.5	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	-9.5	1.0	1.0	-5.333333333333334	0.04	0.05084745762711865	1.0	0.06451612903225806	0.06451612903225806	4.0	0.05084745762711865	0.25	1.0	1.0	-5.333333333333334	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.06451612903225806	0.0	0.05084745762711865	0.0	1.0	0.25	0.0	1.0
250	Thyroid Hormone;thyroid hormone	0.03265583745027514	-14.0	1.0	-11.666666666666666	0.075	0.075	0.5	0.5	1.0	-11.666666666666666	1.0	1.0	-14.0	0.0	0.0	-11.0	0.075	0.07142857142857142	0.0	0.09090909090909091	0.0909090909090909	2.0	0.07142857142857142	1.0	3.0	0.0	-11.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.09090909090909091	0.0	0.07142857142857142	1.0	0.0	0.0	0.0	0.0
131	Together;together	0.0627880053816465	-1.1000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.1000000000000014	0.0	0.0	-8.2	0.04	0.05952380952380952	0.0	0.041841004184100423	0.041841004184100423	1.0	0.05952380952380952	0.0	1.0	0.0	-8.2	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.041841004184100423	0.0	0.05952380952380952	0.0	0.0	0.0	0.0	0.0
194	Adjacent;adjacent	0.4580866491569171	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-13.5	0.04	0.08695652173913043	0.0	0.043478260869565216	0.043478260869565216	1.0	0.08695652173913043	0.0	1.0	0.0	-13.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.08695652173913043	0.0	0.0	0.0	0.0	0.0
250	short-term outcome	0.12343749679052406	-3.444444444444443	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-3.444444444444443	0.0	0.0	0.0	0.04	0.04	0.0	0.04639175257731958	0.04639175257731958	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04639175257731958	0.0	0.04	0.0	0.0	0.0	0.0	0.0
342	Specific;specific	0.10499552994549001	-2.1333333333333333	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.4	0.0	0.0	-4.3999999999999995	0.04	0.04	0.0	0.04	0.044587813620071685	1.0	0.04956521739130435	0.0	3.0	0.0	-6.6	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.05376344086021505	0.0	0.05434782608695653	0.0	0.0	0.0	0.0	0.0
142	The germline mutation	0.20746220121390285	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
176	Eucaryotes;eukaryotes;Eukaryotes;eucaryotes	0.47810823567618105	-2.875	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.75	0.0	0.0	-4.0	0.04	0.04	0.0	0.04	0.04597402597402597	1.0	0.04941176470588235	0.0	2.0	0.0	-8.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.05194805194805195	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
26	patients;Patients	0.3591493028993981	-1.660714285714286	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.8571428571428577	0.0	0.0	-4.625	0.04	0.04	0.0	0.04	0.04297479407947609	1.0	0.05175403225806452	0.0	8.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.04516129032258065	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
58	strategies;strategy	0.15015579633667298	-1.3333333333333335	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	-1.3333333333333335	0.04	0.04	0.0	0.04	0.04271186440677966	1.0	0.04271186440677966	0.0	4.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.05084745762711865	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
47	information from database searches;information search	0.16450389990834433	-6.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.5	0.0	0.0	0.0	0.04	0.04	0.0	0.05405405405405406	0.05405405405405406	4.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.05405405405405406	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	constant darkness (DD)	0.3220043454201129	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
208	treatment for patients;patient treatment	0.07435842344587819	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
40	no;NO	0.09992486473856607	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.3333333333333333	1.0	0.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	1.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
126	Complete;completing	0.08322767935477703	-6.4	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.4	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.05376344086021505	0.05376344086021505	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05376344086021505	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
6	High;high	0.0686853008759912	-4.222222222222221	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.222222222222221	0.0	0.0	-8.75	0.04	0.06153846153846154	0.0	0.0481283422459893	0.0481283422459893	1.0	0.06153846153846154	0.0	1.0	0.0	-8.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0481283422459893	0.0	0.06153846153846154	0.0	0.0	0.0	0.0	0.0
229	the several rankings into a global ranking	0.07315313996107475	0.0	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
281	autosomal recessive parkinsonism of juvenile onset	0.29597979970871185	0.0	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.5	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
304	studies	0.11271879652072071	-1.375	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.375	0.0	0.0	0.0	0.04	0.04	0.0	0.042328042328042326	0.042328042328042326	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.042328042328042326	0.0	0.04	0.0	0.0	0.0	0.0	0.0
114	The Dnmt3 family	0.022381827982806697	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	3.0	0.04	0.6666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.3333333333333333	0.0	0.0
150	the lysosomal membrane	0.5020297682278894	-2.9285714285714284	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-9.428571428571429	0.0	0.0	-3.4999999999999996	0.04	0.04	0.0	0.04	0.047061335179735736	3.0	0.04935048464534831	0.3333333333333333	4.0	0.0	-11.166666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	12.0	0.06422018348623854	0.0	0.07228915662650602	0.0	0.0	0.0	0.0	0.0
73	scale;Scale, NOS	0.06853316678232349	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.166666666666666	0.04	0.050420168067226885	0.0	0.04	0.04	1.0	0.050420168067226885	0.0	1.0	0.0	-5.166666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.050420168067226885	0.0	0.0	0.0	0.0	0.0
340	relatively low-risk individuals	0.09929016665334428	-3.2857142857142847	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-3.2857142857142847	0.0	0.0	0.0	0.04	0.04	0.0	0.046052631578947366	0.046052631578947366	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.046052631578947366	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	tissue inhibitor of metalloproteinase (TIMP) 4;tissue inhibitor of metalloproteinase 4	0.6397846774553042	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04	0.04	8.0	0.04819277108433735	0.0	2.0	0.0	-4.25	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	16.0	0.04	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
62	resulted;Result	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
35	results;Result	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
287	Decreased;decreased	0.08047004051092009	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
208	atypical;Atypical	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
170	duodenal/jejunal atresia;Duodenal Atresia	0.7030365753523068	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
193	X-LINKED;X-linked	0.5575576376141831	-4.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.047619047619047616	0.047619047619047616	1.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
115	identification of a large number;Identification number	0.06502025263039986	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	Length;length	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
337	up period	0.10579644136923662	-1.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.0423728813559322	0.0423728813559322	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.0423728813559322	0.0	0.04	0.0	0.0	0.0	0.0	0.0
145	Full reversal of Alzheimer	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
158	these 10 patients	0.038631336126419676	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.3333333333333333	0.0	0.0
16	gene-fusion events in complete genomes	0.0376194086438117	0.0	1.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.4444444444444444	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.5714285714285714	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
250	(1.31	0.6518436242247154	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
69	include;including;Including	0.10750552049264789	-0.7222222222222227	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04126520681265207	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	3.0	0.043795620437956206	0.0	0.04	0.0	0.0	0.0	0.0	0.0
27	the management of patients	0.027121219827278935	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-6.75	0.04	0.0547945205479452	0.0	0.043478260869565216	0.043478260869565216	4.0	0.0547945205479452	0.5	1.0	0.0	-6.75	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.043478260869565216	0.0	0.0547945205479452	0.0	0.0	0.0	0.0	0.0
140	provides	0.12328186590527837	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	proportion;Proportion	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	differentiated tissues;Tissue Differentiation	0.38419098369705906	-1.2222222222222214	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.2222222222222214	0.0	0.0	0.0	0.04	0.04	0.0	0.04205607476635514	0.04205607476635514	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04205607476635514	0.0	0.04	0.0	0.0	0.0	0.0	0.0
91	session;Session	0.0925071381544399	-2.428571428571427	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.428571428571427	0.0	0.0	0.0	0.04	0.04	0.0	0.04430379746835443	0.04430379746835443	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04430379746835443	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	cyclic clock gene expression	0.24572565887241135	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
267	made;Make	0.09066791716240748	-1.8571428571428577	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8571428571428577	0.0	0.0	0.0	0.04	0.04	0.0	0.043209876543209874	0.043209876543209874	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043209876543209874	0.0	0.04	0.0	0.0	0.0	0.0	0.0
133	Approach;approach	0.07658658416984693	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.5	0.04	0.044444444444444446	0.0	0.04	0.04	1.0	0.044444444444444446	0.0	1.0	0.0	-2.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.044444444444444446	0.0	0.0	0.0	0.0	0.0
155	164A	0.6254355969870318	-2.666666666666668	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04477611940298508	0.04477611940298508	0.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.04477611940298508	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
101	investigated	0.08050086836638404	-3.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-10.333333333333334	0.04	0.06818181818181819	0.0	0.047058823529411764	0.047058823529411764	1.0	0.06818181818181819	0.0	1.0	0.0	-10.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.047058823529411764	0.0	0.06818181818181819	0.0	0.0	0.0	0.0	0.0
293	changes in central neurotransmission	0.12158908048401756	-3.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
180	causing;Causing	0.07720939985480645	-7.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.0	0.0	0.0	-8.333333333333334	0.04	0.06000000000000001	0.0	0.05555555555555555	0.05555555555555555	1.0	0.06000000000000001	0.0	1.0	0.0	-8.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05555555555555555	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
325	the proteomic analysis of endogenously ubiquitinated protein complexes	0.09387836918694582	-9.0	1.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.125	1.0	-9.0	1.0	1.0	-7.666666666666666	0.04	0.05769230769230768	0.0	0.0625	0.0625	8.0	0.05769230769230768	0.125	1.0	1.0	-7.666666666666666	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.0625	0.0	0.05769230769230768	0.0	1.0	0.0	0.0	1.0
212	QT interval;Q-T interval	0.11599698895618442	-3.4375	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-5.5	0.0	0.0	-2.0	0.04	0.04	0.0	0.042328042328042326	0.0468050468050468	2.0	0.04380952380952381	0.5	2.0	0.0	-4.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.05128205128205128	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
80	4 with sporadic HCM)	0.4175122847513681	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
40	Support, NOS;support	0.16769759256161115	-0.666666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04119402985074627	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04477611940298508	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	Notch Protein;Notch protein	0.10711941421841682	-1.8999999999999986	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.8999999999999986	0.0	0.0	-5.0	0.04	0.05	0.0	0.04329004329004329	0.04329004329004329	2.0	0.05	0.5	2.0	0.0	-5.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04329004329004329	0.0	0.05	0.0	0.0	0.0	0.0	0.0
343	pole cells;cell pole	0.11707437433269925	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	the active sites	0.10483360673160709	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
205	minor;Minor	0.11130010282840286	-7.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.75	0.0	0.0	0.0	0.04	0.04	0.0	0.057971014492753624	0.057971014492753624	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.057971014492753624	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	the University	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
199	Many;MANY	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	the same genomic locus	0.20392792817938546	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	the intense X-ray-matter interactions	0.03602560522236462	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.2	0.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	6.0	0.04918032786885245	0.16666666666666666	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
82	conducted;Conduct	0.08935877145015479	-1.3571428571428577	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.7142857142857153	0.0	0.0	-4.9	0.04	0.04	0.0	0.04	0.042435897435897436	1.0	0.05289473684210525	0.0	2.0	0.0	-9.8	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04487179487179487	0.0	0.06578947368421052	0.0	0.0	0.0	0.0	0.0
75	deleted;Deleted	0.6261537547779711	-4.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	Autosomal dominant;autosomal dominant	0.4048980310737076	-1.666666666666666	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-6.1875	0.04	0.045454545454545456	0.0	0.04	0.043076923076923075	2.0	0.05448955921339642	0.0	4.0	0.0	-9.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.04615384615384615	0.0	0.06349206349206349	0.0	0.0	0.0	0.0	0.0
153	antipsychotics for adults	0.0793662226340656	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
176	dual;Dual	0.5422789662681092	-3.875	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.875	0.0	0.0	-7.6	0.04	0.0574712643678161	0.0	0.047337278106508875	0.047337278106508875	1.0	0.0574712643678161	0.0	1.0	0.0	-7.6	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047337278106508875	0.0	0.0574712643678161	0.0	0.0	0.0	0.0	0.0
302	GROWTH;growth	0.09372053408889891	-2.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04504504504504505	0.04504504504504505	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04504504504504505	0.0	0.04	0.0	0.0	0.0	0.0	0.0
317	reverse transcriptase activity	0.13829001417641099	-3.1999999999999993	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04587155963302752	0.04587155963302752	3.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04587155963302752	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
73	More;more	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	intoxication;intoxications;INTOXICATION	0.6119869976855364	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.25	0.04	0.04	0.0	0.04	0.04	0.6666666666666666	0.04646090534979424	0.0	3.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
100	The inhibitory effect	0.0793662226340656	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
215	phenotype;Phenotypes;Phenotype;phenotypes	0.4931965737380889	-1.625	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-3.0	0.04	0.04	0.0	0.04	0.04298850574712644	1.0	0.04631578947368421	0.0	2.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.04597701149425287	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
315	(Fas-L	0.6000186669162998	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
103	development	0.15606793528555324	-0.6296296296296298	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-2.2380952380952386	0.04	0.042682926829268296	0.0	0.04	0.04108974358974359	1.0	0.043956458128184446	0.0	3.0	0.0	-2.8571428571428577	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04326923076923077	0.0	0.04516129032258065	0.0	0.0	0.0	0.0	0.0
4	skin collagenomas	0.44067785631379464	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	placental;Placental	0.6503470434639805	-1.3333333333333321	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.3333333333333321	0.0	0.0	-1.7142857142857153	0.04	0.04294478527607362	0.0	0.04225352112676056	0.04225352112676056	1.0	0.04294478527607362	0.0	2.0	0.0	-1.7142857142857153	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04225352112676056	0.0	0.04294478527607362	0.0	0.0	0.0	0.0	0.0
53	multiplied;Multiply	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	secondary	0.22991707846339096	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-4.0	1.0	1.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04587155963302752	0.0	1.0	1.0	-3.1999999999999993	1.0	1.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	0.047619047619047616	1.0	0.04587155963302752	0.0	1.0	0.0	1.0	1.0
156	Reducing;reducing	0.09493235089127515	-3.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.04580152671755725	0.04580152671755725	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04580152671755725	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	Inhibiting;inhibitory;inhibition;INHIBITION;inhibiting;Inhibitory;Inhibition	0.951389470309631	-2.359375	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.75	0.0	0.0	-4.072916666666667	0.04	0.04	0.0	0.04	0.04475041401551509	1.0	0.05108497854692055	0.0	16.0	0.0	-13.166666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	7.0	1.0	16.0	0.057971014492753624	0.0	0.08450704225352114	0.0	0.0	0.0	0.0	0.0
44	the parasite	0.09652660676568509	-3.25	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-5.0	0.04	0.05	0.0	0.04597701149425287	0.04597701149425287	2.0	0.05	0.5	1.0	0.0	-5.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04597701149425287	0.0	0.05	0.0	0.0	0.0	0.0	0.0
97	3' untranslated region	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
292	NERVE DAMAGE;nerve damage	0.06152581003196704	-3.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04615384615384615	0.04615384615384615	2.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04615384615384615	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
164	a range of components	0.052997877725278884	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
83	used	0.09983111582723572	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.04819277108433735	0.04819277108433735	1.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04819277108433735	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
134	lipophilin;Lipophilin	0.6614323002826458	-5.666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-5.666666666666666	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.051724137931034475	0.051724137931034475	1.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	1.0	0.051724137931034475	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
56	symptomatic response	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
57	an isolated form	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
86	SERCA2	0.7850128565492788	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
303	centromeric chromatin	0.7725917477983353	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	the Connolly surface	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	This study	0.12245853354622971	-5.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.051724137931034475	0.051724137931034475	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.051724137931034475	0.0	0.04	0.0	0.0	0.0	0.0	0.0
254	an increased proportion	0.17691283686292264	-5.333333333333334	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.05084745762711865	0.05084745762711865	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05084745762711865	0.0	0.04	0.0	0.0	0.0	0.0	0.0
163	significant	0.138062657829642	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
264	baPWV	0.6903940463760263	-3.0625	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-3.3000000000000007	0.04	0.045454545454545456	0.0	0.0427807486631016	0.04578061823398982	1.0	0.04609175870858114	0.0	2.0	0.0	-3.6000000000000014	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04878048780487805	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
14	the identification of TMBs	0.04409653314825431	-3.125	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-3.125	0.0	0.0	-1.8333333333333321	0.04	0.043165467625899276	0.0	0.045714285714285714	0.045714285714285714	4.0	0.043165467625899276	0.5	1.0	0.0	-1.8333333333333321	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.045714285714285714	0.0	0.043165467625899276	0.0	0.0	0.0	0.0	0.0
58	the least expensive strategy	0.052997877725278884	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
342	decreased H3K4 methylation	0.4065610553183088	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
121	apparently	0.12752460253404646	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05	0.05	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.05	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	A girl with Williams syndrome (WS	0.05545448122048213	0.0	1.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.2857142857142857	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.2857142857142857	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
336	acetylated lysines within H3 and H4 amino-terminal peptides	0.42472880071923225	-4.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	-4.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.047619047619047616	0.047619047619047616	10.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.047619047619047616	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
195	Mutations;mutation;mutations;Mutation	0.5537837314344468	-1.0833333333333333	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-2.777777777777778	0.04	0.04	0.0	0.04	0.04199233716475096	1.0	0.045351775956284146	0.0	3.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.04597701149425287	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
147	D3 activities in fetal human liver	0.033511876709338105	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.125	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
300	a hypoxia-inducible repressor for the HO-1 gene	0.13749600074386706	-2.428571428571427	1.0	0.0	0.04	0.04	0.4444444444444444	0.4444444444444444	0.0	0.0	0.1	1.0	-2.428571428571427	0.0	0.0	0.0	0.04	0.04	0.0	0.04430379746835443	0.04430379746835443	9.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	9.0	0.04430379746835443	0.0	0.04	0.0	0.0	0.0	0.0	0.0
84	any of the outcomes	0.0884415052403157	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	many methods	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
292	this use	0.08592014252659605	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.045454545454545456	0.045454545454545456	2.0	0.05405405405405406	0.0	1.0	0.0	-6.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.045454545454545456	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
15	sentence filter	0.09241283227731266	-1.6999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6999999999999993	0.0	0.0	-3.6000000000000014	0.04	0.04672897196261683	0.0	0.04291845493562232	0.04291845493562232	2.0	0.04672897196261683	0.0	1.0	0.0	-3.6000000000000014	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04291845493562232	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
34	SK-Hep-1;SK 1	0.7527708188256417	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	2.0	1.0	3.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
39	the substrate lysine epsilon-amino group	0.44657606488433216	0.0	0.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	1.0	0.0	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	7.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
41	deletion analysis;Analysis of deletion	0.1187176919696614	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	developmental enhancers	0.435809293607436	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	one;ONE	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
104	a second informant genome [3,4,14-16	0.21613679155544355	-3.0	1.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.16666666666666666	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	10.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
291	news;News	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
243	with;With	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	Up to;up to	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
158	bilateral;BILATERAL	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
190	clinical trials on sarcopenia	0.011061424302621454	0.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	reports;Reported;reported;Reports	0.05741098037561241	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-3.6428571428571432	0.04	0.04	0.0	0.04	0.04380952380952381	1.0	0.0482258064516129	0.0	2.0	0.0	-7.2857142857142865	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.047619047619047616	0.0	0.056451612903225805	0.0	0.0	0.0	0.0	0.0
142	MEN2 patients	0.22102523448930045	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	a custom-designed set of 34 novel numerical descriptors	0.07709797336147999	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
68	ASPARAGINE;asparagine	0.7377347907742027	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	BLASTp search algorithm	0.298594281526906	-1.5454545454545467	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-1.5454545454545467	0.0	0.0	-6.25	0.04	0.05333333333333334	0.0	0.04263565891472868	0.04263565891472868	3.0	0.05333333333333334	0.0	1.0	0.0	-6.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04263565891472868	0.0	0.05333333333333334	0.0	0.0	0.0	0.0	0.0
46	Individual;individuals	0.49248689108067345	-1.299999999999999	0.0	0.0	0.04	0.04	0.0	0.5	0.0	0.0	0.0	0.0	-1.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04201680672268907	0.04219484403931063	0.5	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.5	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0423728813559322	0.0	0.04	0.0	0.0	0.0	0.0	0.0
138	strong cation exchange (	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	the causative agent for the most severe form	0.00986674371060517	-5.0	1.0	0.0	0.04	0.04	0.875	0.875	0.0	0.0	0.3333333333333333	0.0	-5.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	1.0	0.05	0.05	8.0	0.053571428571428575	0.5	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.05	0.0	0.053571428571428575	0.0	0.0	0.125	0.0	0.0
96	1;1+	0.636187340945155	-3.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
137	Involving;involving	0.08568055659544704	-2.1111111111111107	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1111111111111107	0.0	0.0	-1.6000000000000014	0.04	0.042735042735042736	0.0	0.043689320388349516	0.043689320388349516	1.0	0.042735042735042736	0.0	1.0	0.0	-1.6000000000000014	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043689320388349516	0.0	0.042735042735042736	0.0	0.0	0.0	0.0	0.0
26	biliary;Biliary	0.6696898375195467	-1.571428571428573	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.042682926829268296	0.042682926829268296	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.042682926829268296	0.0	0.04	0.0	0.0	0.0	0.0	0.0
213	the Romano-Ward long-QT syndrome	0.05829025132530059	0.0	1.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.5	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.625	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
24	raised cardiovascular risk	0.19428068380337132	-2.1999999999999993	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.043859649122807015	0.043859649122807015	3.0	0.05714285714285714	0.0	2.0	0.0	-7.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.043859649122807015	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
327	reveal;reveals	0.10243761896455562	-3.375	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-4.3	0.04	0.043859649122807015	0.0	0.045454545454545456	0.04625668449197861	1.0	0.04881154499151103	0.0	2.0	0.0	-6.4	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.047058823529411764	0.0	0.05376344086021505	0.0	0.0	0.0	0.0	0.0
102	mCry2 gene	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	abacavir hypersensitivity syndrome;Abacavir hypersensitivity syndrome	0.22933027090729105	-2.222222222222222	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.5555555555555555	1.0	-6.666666666666666	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04484848484848484	3.0	0.04	0.3333333333333333	3.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	9.0	0.054545454545454536	0.0	0.04	0.0	1.0	0.0	0.0	1.0
4	changes	0.09759216302354513	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.04	0.04424778761061947	0.0	0.04	0.04	1.0	0.04424778761061947	0.0	1.0	0.0	-2.3999999999999986	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04424778761061947	0.0	0.0	0.0	0.0	0.0
73	Predicted;predicted;Prediction;predictions;prediction	0.6292559370706158	-1.5925925925925923	1.0	-16.333333333333332	0.04	0.04314102564102564	1.0	1.0	1.0	-0.6805555555555555	1.0	0.0	-14.333333333333332	0.0	0.0	-4.798611111111111	0.11538461538461539	0.04	0.0	0.04	0.04402213337206556	1.0	0.05278668148012194	0.875	24.0	0.0	-16.5	1.0	0.0	1.0	0.875	1.0	0.0	1.0	0.0	0.0	5.0	1.0	24.0	0.09374999999999999	0.0	0.11764705882352941	1.0	0.0	0.0	0.0	0.0
49	seven families with two or more affected females	0.07218608482495625	-1.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.75	0.0	0.0	0.0	0.04	0.04	0.0	0.043010752688172046	0.043010752688172046	8.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.043010752688172046	0.0	0.04	0.0	0.0	0.0	0.0	0.0
323	Two cases	0.14684823062145294	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
213	molecular genetic testing	0.1534854104372759	-5.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.05	0.05	3.0	0.046511627906976744	0.0	1.0	0.0	-3.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
289	clinical trials as new anticancer drugs	0.061800349313191484	-4.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.047619047619047616	0.047619047619047616	6.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.047619047619047616	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
60	First;first	0.06998091245582899	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	1.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
216	Sediment;sediments;sediment	0.6313697659474833	-9.9375	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-13.75	0.0	0.0	-13.583333333333332	0.04	0.04	0.0	0.04	0.07405228758169935	1.0	0.11892857142857143	0.0	4.0	0.0	-18.333333333333332	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.08888888888888889	0.0	0.15	0.0	0.0	0.0	0.0	0.0
286	SNAP-25	0.7108574184889408	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.583333333333333	0.04	0.05194805194805195	0.0	0.04	0.04	1.0	0.05453253214447245	0.0	3.0	0.0	-8.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.05970149253731343	0.0	0.0	0.0	0.0	0.0
173	the development of hypertension	0.05646751935971613	-1.5999999999999996	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.25	0.0	-3.1999999999999993	0.0	0.0	-2.75	0.04	0.04477611940298508	0.0	0.04	0.04293577981651376	4.0	0.04494445067893615	0.25	2.0	0.0	-2.833333333333332	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04587155963302752	0.0	0.045112781954887216	0.0	0.0	0.0	0.0	0.0
253	.ALPHA.-LIPOIC ACID;alpha-lipoic acid	0.3932819752712341	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
189	Young Child;young children	0.2085847828816521	-6.666666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.054545454545454536	0.054545454545454536	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.054545454545454536	0.0	0.04	0.0	0.0	0.0	0.0	0.0
223	Cohort;cohort	0.5242390396779455	-1.6363636363636367	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.6363636363636367	0.0	0.0	-7.2857142857142865	0.04	0.056451612903225805	0.0	0.042801556420233464	0.042801556420233464	1.0	0.056451612903225805	0.0	1.0	0.0	-7.2857142857142865	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.042801556420233464	0.0	0.056451612903225805	0.0	0.0	0.0	0.0	0.0
61	found;in;In;Found	0.013530208034361776	-1.0999999999999996	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04192982456140351	1.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	1.0	0.5	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.043859649122807015	0.0	0.04	1.0	0.0	0.0	0.0	0.0
198	a family	0.13990388469880813	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-3.625	0.04	0.04597701149425287	0.0	0.04504504504504505	0.045458302339036284	2.0	0.046798029556650245	0.0	2.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04587155963302752	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
140	, highly complementary to that	0.15898064341854684	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
252	an increased risk of 1-year mortality	0.13807404764628659	0.0	0.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.125	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	the pharmacophore generation process	0.0227240643751227	-2.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.2	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
62	mo;MO	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	The emergence of femtosecond diffractive imaging	0.24344445862974867	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04	0.04	6.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
199	CENPA chromatin from the neocentromere	0.16299761518395914	0.0	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.14285714285714285	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
208	Overall	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
269	liver-specific	0.07382727549706677	-3.1999999999999993	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04587155963302752	0.04587155963302752	3.0	0.04878048780487805	0.3333333333333333	1.0	0.0	-4.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04587155963302752	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
221	Record;recorded	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
259	mixed-sports (aerobic and anaerobic) athletes	0.09829685251263177	-6.0	1.0	0.0	0.04	0.04	0.4444444444444444	0.4444444444444444	0.0	0.0	0.2	0.0	-6.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05263157894736842	0.05263157894736842	9.0	0.04	0.1111111111111111	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.05263157894736842	0.0	0.04	0.0	0.0	0.0	0.0	0.0
8	two core centriolar proteins	0.24733013785030114	-4.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.16666666666666666	1.0	-4.0	1.0	1.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.047619047619047616	0.0	0.04	0.0	1.0	0.0	0.0	1.0
25	the present study	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	Thirty-two children	0.028314097541395106	-2.333333333333332	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.4	0.0	-2.333333333333332	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.044117647058823525	0.044117647058823525	4.0	0.047619047619047616	0.25	1.0	0.0	-4.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.044117647058823525	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
241	the sacral ala	0.2748309978672997	-3.166666666666667	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-3.7	0.04	0.04	0.0	0.04	0.04678571428571429	3.0	0.04840909090909091	0.3333333333333333	2.0	0.0	-7.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.053571428571428575	0.0	0.056818181818181816	0.0	0.0	0.0	0.0	0.0
208	antinociceptive potential in experimental animal models	0.0747829060298053	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
217	Required;required	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	differential expression using machine learning approaches	0.05341333849499294	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.04	0.04	6.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
44	a causative agent of tropical malaria	0.02323953860728246	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.3333333333333333	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	6.0	0.04	0.6666666666666666	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.16666666666666666	0.0	1.0
26	Revealed;revealed	0.09297215030954452	-2.571428571428573	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.0445859872611465	0.0445859872611465	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0445859872611465	0.0	0.04	0.0	0.0	0.0	0.0	0.0
208	antiepileptic effectiveness in different rodent seizure models	0.17925102680052402	-5.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05	0.05	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.05	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	a functional EGFR-dependent autocrine growth pathway	0.1752341279380678	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	these	0.07611188378663937	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-12.333333333333332	0.04	0.07894736842105263	0.0	0.04878048780487805	0.04878048780487805	1.0	0.07894736842105263	0.0	1.0	0.0	-12.333333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04878048780487805	0.0	0.07894736842105263	0.0	0.0	0.0	0.0	0.0
100	high-throughput screening;High Throughput Screening	0.20944694815758738	-3.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.045454545454545456	0.045454545454545456	4.0	0.043478260869565216	0.25	2.0	0.0	-2.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.045454545454545456	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
213	ion channel;Ion Channel	0.283260439120505	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
161	known;Known	0.06901263893103253	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
130	using;Using	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
11	lovastatin production;lovastatin production)	0.20798129465882906	-2.5	1.0	0.0	0.04	0.04	0.3333333333333333	0.41666666666666663	0.0	0.0	0.29166666666666663	1.0	-2.5	0.0	0.0	-4.166666666666667	0.04	0.047619047619047616	0.0	0.044444444444444446	0.044444444444444446	2.5	0.04800307219662059	0.41666666666666663	2.0	0.0	-4.333333333333334	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	5.0	0.044444444444444446	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
146	no effect;No effect	0.042423982724825914	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-6.0	0.04	0.05263157894736842	1.0	0.045454545454545456	0.045454545454545456	2.0	0.05263157894736842	0.5	2.0	0.0	-6.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.045454545454545456	0.0	0.05263157894736842	0.0	0.0	0.5	0.0	0.0
163	30 mg epigallocatechin gallate	0.6593457951374962	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
148	showed;Show	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
158	FGFR2 gene;FGFR2 Gene	0.27926268070552995	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
261	the cardiac ryanodine receptor gene (RYR2) or mutations in the cardiac calsequestrin gene CASQ2	0.056792122419054396	-5.571428571428571	1.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.25	1.0	-5.571428571428571	0.0	0.0	0.0	0.04	0.04	0.0	0.051470588235294115	0.051470588235294115	16.0	0.04	0.5	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	16.0	0.051470588235294115	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	SNF2-like chromodomain	0.4673109045655551	-9.5	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	-9.5	1.0	1.0	0.0	0.04	0.04	0.0	0.06451612903225806	0.06451612903225806	4.0	0.04	0.25	1.0	1.0	0.0	1.0	0.5	0.0	1.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	4.0	0.06451612903225806	0.0	0.04	0.0	1.0	0.0	0.0	1.0
13	less than 1 micrometer	0.2812817665111152	-8.333333333333334	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-8.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.06000000000000001	0.06000000000000001	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.06000000000000001	0.0	0.04	0.0	0.0	0.0	0.0	0.0
84	these outcomes	0.12385109639947729	-6.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05263157894736842	0.05263157894736842	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05263157894736842	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	the (9	0.10038387791856343	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	3.0	0.05	0.6666666666666666	1.0	0.0	-5.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
144	Activate;activates	0.5363485111040948	-3.6000000000000014	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.04672897196261683	0.04672897196261683	0.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04672897196261683	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
76	acute coronary syndrome;Acute Coronary Syndrome	0.8815981206563718	-2.7500000000000013	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-4.083333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.04240282685512368	0.04510579589768136	3.0	0.04	0.0	6.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	18.0	0.04780876494023905	0.0	0.04	0.0	0.0	0.0	0.0	0.0
165	Oligonucleotides;oligonucleotides	0.07003717318952633	-16.0	1.0	-13.25	0.0851063829787234	0.0851063829787234	0.0	0.0	1.0	-13.25	1.0	0.0	-16.0	0.0	0.0	-13.5	0.0851063829787234	0.08695652173913043	1.0	0.1111111111111111	0.1111111111111111	1.0	0.08695652173913043	1.0	2.0	0.0	-13.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.1111111111111111	0.0	0.08695652173913043	1.0	0.0	1.0	0.0	0.0
166	treatment;treatment nos	0.07637649673633763	-3.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04672897196261683	0.04672897196261683	1.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04672897196261683	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
317	Drug;drug	0.006569821387325964	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	1.0	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	1.0	0.0	0.0	0.0	0.0
100	Stability;stable;STABLE;stability	0.08149775240453785	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.277777777777778	0.04	0.04	0.0	0.04	0.04	1.0	0.04501529051987768	0.0	3.0	0.0	-6.833333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.04	0.0	0.05504587155963304	0.0	0.0	0.0	0.0	0.0
16	combinations in many eukaryotic proteins [10]	0.19508655080811416	-1.6363636363636367	0.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.0	0.0	-1.6363636363636367	0.0	0.0	-7.75	0.04	0.057971014492753624	0.0	0.042801556420233464	0.042801556420233464	8.0	0.057971014492753624	0.0	1.0	0.0	-7.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.042801556420233464	0.0	0.057971014492753624	0.0	0.0	0.0	0.0	0.0
73	[15,19]	0.5825924784454449	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
322	a 1263 amino acid H3-K9 methyltransferase	0.496925353822205	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.0	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
203	UPD	0.7846761373749651	-4.125	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-8.25	0.0	0.0	-2.95	0.04	0.04	0.0	0.04	0.049850746268656716	1.0	0.04582039486294806	0.0	4.0	0.0	-6.199999999999999	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.05970149253731343	0.0	0.05319148936170213	0.0	0.0	0.0	0.0	0.0
6	the primary cause of altered mental status	0.05777043447891018	-3.8888888888888893	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8888888888888893	0.0	0.0	-8.75	0.04	0.06153846153846154	0.0	0.04736842105263158	0.04736842105263158	7.0	0.06153846153846154	0.0	1.0	0.0	-8.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04736842105263158	0.0	0.06153846153846154	0.0	0.0	0.0	0.0	0.0
13	Biological Processes;biological processes	0.169188290062278	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
24	placebo-controlled	0.3826561668419928	-4.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
35	-) mice;Mice;mice	0.3165477831575951	0.0	0.0	0.0	0.04	0.04	0.5	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.2	0.04	0.04	0.0	0.04	0.04	1.2	0.04752941176470588	0.0	5.0	0.0	-8.0	1.0	0.0	0.8	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	6.0	0.04	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
138	TITANIUM DIOXIDE;titanium dioxide	0.9619017050731953	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-1.875	0.04	0.0427807486631016	0.0	0.04	0.04	2.0	0.04324834563847172	0.0	7.0	0.0	-2.375	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	14.0	0.04	0.0	0.04419889502762431	0.0	0.0	0.0	0.0	0.0
65	mono;Mono	0.6033439587898671	-4.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.047619047619047616	0.047619047619047616	0.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.047619047619047616	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
60	a luminal submembranous protein skeleton	0.4745770079714268	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
63	DURING;During	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
67	Process, The;the best available model for the inflammatory processes	0.03236425167728734	0.0	1.0	0.0	0.04	0.04	0.875	0.875	0.0	0.0	0.1111111111111111	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	8.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	16.0	0.04	0.0	0.04	0.0	0.0	0.125	0.0	0.0
78	several markers	0.11668968578773643	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
133	0.05) decrease in folate uptake	0.14322806830504042	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.166666666666666	0.04	0.050420168067226885	0.0	0.04	0.04	6.0	0.050420168067226885	0.3333333333333333	1.0	0.0	-5.166666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.050420168067226885	0.0	0.0	0.0	0.0	0.0
236	Interest;interest	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	a Syk inhibitor prodrug for the treatment	0.10455247186881324	-3.333333333333332	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04615384615384615	0.04615384615384615	7.0	0.04938271604938271	0.14285714285714285	1.0	0.0	-4.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04615384615384615	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
53	thyroid hormone levels in response	0.045206299999455225	0.0	1.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.16666666666666666	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
156	the assumption of autosomal recessive inheritance	0.10236730042406146	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.5	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
206	Group 2;group 2	0.169835875204511	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	2.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
340	T1 values	0.07834558736064173	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
293	organic disorders	0.21750049677404396	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	1.0	0.0	1.0	0.5	1.0	0.0	1.0	1.0	1.0	0.5	0.5	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
194	Site of insertion;of insertion sites	0.044030951708472994	-1.571428571428573	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.571428571428573	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.042682926829268296	0.042682926829268296	3.0	0.06451612903225806	0.3333333333333333	1.0	0.0	-9.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.042682926829268296	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
317	telomerase as an immunotherapy	0.5686077676215348	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
99	a variably associated trait	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
5	therapy	0.08798111076154215	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-9.25	0.04	0.06349206349206349	0.0	0.05	0.05	1.0	0.06349206349206349	0.0	1.0	0.0	-9.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.05	0.0	0.06349206349206349	0.0	0.0	0.0	0.0	0.0
179	TSC1/2	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
48	approximately 90% of pancreatic carcinomas	0.2833678207917082	-4.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-4.0	0.0	0.0	-6.428571428571429	0.04	0.05384615384615385	0.0	0.047619047619047616	0.047619047619047616	6.0	0.05384615384615385	0.16666666666666666	1.0	0.0	-6.428571428571429	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.047619047619047616	0.0	0.05384615384615385	0.0	0.0	0.0	0.0	0.0
95	C-terminal domain	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
189	a hormone	0.07332891475176541	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.5	1.0	1.0	1.0	0.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
139	Support, NOS;Supporting	0.07501320457875972	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	1.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
345	these elements	0.10653066399039185	-1.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.042735042735042736	0.042735042735042736	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.042735042735042736	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	databases;database;Databases;Database	0.08167091892325752	-0.6111111111111107	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	-1.2222222222222225	0.04	0.04	0.0	0.04	0.04105515587529976	1.0	0.04229166666666667	0.0	3.0	0.0	-3.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.043165467625899276	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
75	enzymatic and clinical signs	0.24331620473011134	-6.25	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-6.25	0.0	0.0	0.0	0.04	0.04	0.0	0.05333333333333334	0.05333333333333334	4.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.05333333333333334	0.0	0.04	0.0	0.0	0.0	0.0	0.0
120	M3/6 phosphatase	0.6909610553634022	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
11	carried	0.0943710018713268	-2.833333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.045112781954887216	0.045112781954887216	1.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.045112781954887216	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
71	target genes	0.08187367858114117	-2.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.04504504504504505	0.04504504504504505	2.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04504504504504505	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
225	GHD;Growth hormone deficiency;growth hormone (GH) deficiency;growth hormone deficiency	0.9421865782083017	-2.2380952380952386	0.0	0.0	0.04	0.04	0.0	0.42857142857142855	0.0	0.0	0.0	1.0	-4.666666666666666	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04425790398126463	2.857142857142857	0.04	0.21428571428571427	7.0	1.0	0.0	1.0	1.0	0.0	0.7142857142857143	0.0	1.0	1.0	0.3333333333333333	0.42857142857142855	4.0	1.0	20.0	0.04918032786885245	1.0	0.04	0.0	1.0	0.0	0.14285714285714285	1.0
44	pyrimidine biosynthetic pathway	0.722211751218205	-6.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-9.25	0.0	0.0	-4.5	0.04	0.048387096774193554	0.0	0.047058823529411764	0.055275443510737626	3.0	0.048783712321523	0.0	2.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.06349206349206349	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
102	night cycles	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	dose variability	0.21443049433649095	-4.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.047619047619047616	0.047619047619047616	2.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047619047619047616	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
97	the most common form of muscular dystrophy	0.09917633325051568	-9.0	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	1.0	-9.0	0.0	0.0	-10.333333333333334	0.04	0.06818181818181819	0.0	0.0625	0.0625	7.0	0.06818181818181819	0.14285714285714285	1.0	0.0	-10.333333333333334	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.0625	0.0	0.06818181818181819	0.0	0.0	0.0	0.0	0.0
114	the four plant C5-MTase families	0.0374356736925193	0.0	1.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	7.0	0.04	0.42857142857142855	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.14285714285714285	0.0	0.0
6	peer	0.09051424824235178	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04	0.04	1.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
16	Identification of fused gene families	0.06201819376871694	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
233	sudden cardiac death in athletes	0.003054502010930468	-4.333333333333334	1.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.8571428571428571	0.0	-4.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.048387096774193554	0.048387096774193554	5.0	0.04	1.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.048387096774193554	0.0	0.04	1.0	0.0	0.0	0.0	0.0
73	search;searching	0.08139069839681567	-0.8333333333333339	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6666666666666679	0.0	0.0	-7.166666666666667	0.04	0.05263157894736842	0.0	0.04	0.041428571428571426	1.0	0.056315789473684215	0.0	2.0	0.0	-8.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04285714285714286	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
345	Sec;SEC	0.6948478553644184	-0.6000000000000002	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.8000000000000007	0.0	0.0	-1.6666666666666667	0.04	0.04	0.0	0.04	0.04103448275862069	1.0	0.043333333333333335	0.0	3.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04310344827586207	0.0	0.05	0.0	0.0	0.0	0.0	0.0
54	the adenovirus genome	0.45074511727053684	-4.666666666666666	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-4.666666666666666	1.0	1.0	0.0	0.04	0.04	0.0	0.04918032786885245	0.04918032786885245	3.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04918032786885245	0.0	0.04	0.0	1.0	0.0	0.0	1.0
16	Confidence;confidence	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
99	the 14 emerin mutations	0.2522197690342439	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.428571428571427	0.04	0.04430379746835443	0.0	0.04	0.04	4.0	0.04430379746835443	0.25	1.0	0.0	-2.428571428571427	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04430379746835443	0.0	0.0	0.0	0.0	0.0
37	II catalytic inhibitor ICRF-187	0.6290957210300513	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	4.0	0.05	0.25	1.0	0.0	-5.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
257	known;Known	0.07472369767654521	-12.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-12.166666666666668	0.0	0.0	-13.571428571428571	0.04	0.0875	0.0	0.07792207792207793	0.07792207792207793	1.0	0.0875	0.0	1.0	0.0	-13.571428571428571	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.07792207792207793	0.0	0.0875	0.0	0.0	0.0	0.0	0.0
102	1179-1198 in PER2	0.3639041798063458	-4.25	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	-4.25	1.0	1.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	4.0	0.04	0.25	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04819277108433735	0.0	0.04	0.0	1.0	0.0	0.0	1.0
180	linkage disequilibrium;Linkage Disequilibrium	0.5272738105881803	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	2.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
222	alemtuzumab (anti-CD52 monoclonal antibody) in patients	0.1975409432678538	-2.1111111111111107	1.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.6666666666666666	1.0	-2.1111111111111107	1.0	1.0	-3.0	0.04	0.045454545454545456	0.0	0.043689320388349516	0.043689320388349516	10.0	0.045454545454545456	0.3	1.0	1.0	-3.0	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	10.0	0.043689320388349516	1.0	0.045454545454545456	0.0	1.0	0.0	1.0	1.0
13	1 micrometer	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	Enabled;enabled	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
295	TRANS;trans	0.6066186994119565	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
49	our previous report	0.10258610916431014	-2.375	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.375	0.0	0.0	0.0	0.04	0.04	0.0	0.04419889502762431	0.04419889502762431	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04419889502762431	0.0	0.04	0.0	0.0	0.0	0.0	0.0
142	the patient and family	0.03443263715295205	-2.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-1.5555555555555571	0.04	0.04265402843601896	0.0	0.044117647058823525	0.044117647058823525	4.0	0.04265402843601896	0.5	1.0	0.0	-1.5555555555555571	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.044117647058823525	0.0	0.04265402843601896	0.0	0.0	0.0	0.0	0.0
24	an Untreated Subject Population trial),60 compared SPAA plus therapeutic lifestyle changes (TLC)	0.11757942920860587	0.0	0.0	0.0	0.04	0.04	0.4117647058823529	0.4117647058823529	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	17.0	0.04	0.058823529411764705	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	17.0	0.04	0.0	0.04	0.0	0.0	0.058823529411764705	0.0	0.0
213	LQT2	0.9108132030584362	-5.166666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-5.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.04918032786885245	0.05045223289994347	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	4.0	0.051724137931034475	0.0	0.04	0.0	0.0	0.0	0.0	0.0
317	Phase I/II clinical trials for several hematological and solid tumor malignancies	0.0724027079070132	0.0	0.0	0.0	0.04	0.04	0.6923076923076923	0.6923076923076923	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	13.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	13.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	identification;Identification	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
201	gross structural damage of the heart	0.07748277985570153	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	Required;required	0.09945790750549682	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	0.0	0.04	0.04	0.0	0.04878048780487805	0.04878048780487805	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04878048780487805	0.0	0.04	0.0	0.0	0.0	0.0	0.0
149	HEART;heart	0.12275070562653406	-3.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	in-house program	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
241	an anomalous enlargement	0.6171953679194666	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
99	this clinical picture	0.09587937605811031	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-3.2857142857142847	0.04	0.046052631578947366	0.0	0.04819277108433735	0.04819277108433735	3.0	0.046052631578947366	0.0	1.0	0.0	-3.2857142857142847	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04819277108433735	0.0	0.046052631578947366	0.0	0.0	0.0	0.0	0.0
62	17	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
342	H3K4) in Saccharomyces cerevisiae	0.4804707422996111	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
215	senescence in pancreatic beta-cells	0.22469265617921486	-4.75	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04938271604938271	0.04938271604938271	6.0	0.047619047619047616	0.16666666666666666	1.0	0.0	-4.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04938271604938271	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
59	propranolol (160 mg/day)	0.4394642533361071	-4.6	0.0	0.0	0.04	0.04	0.14285714285714285	0.14285714285714285	0.0	0.0	0.0	1.0	-4.6	1.0	1.0	-8.666666666666666	0.04	0.06122448979591836	0.0	0.04901960784313726	0.04901960784313726	7.0	0.06122448979591836	0.0	1.0	1.0	-8.666666666666666	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04901960784313726	0.0	0.06122448979591836	0.0	1.0	0.0	0.0	1.0
110	osteoblast-like cells	0.2015261957399042	-2.8000000000000007	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	-5.0	0.04	0.05	0.0	0.04504504504504505	0.04504504504504505	4.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04504504504504505	0.0	0.05	0.0	0.0	0.0	0.0	0.0
318	Ph+) acute lymphatic leukemia	0.31333427596370234	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.538461538461538	0.04	0.05726872246696036	0.0	0.04	0.04	6.0	0.05726872246696036	0.3333333333333333	1.0	0.0	-7.538461538461538	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.05726872246696036	0.0	0.0	0.0	0.0	0.0
101	H3K4me3	0.8471672674973125	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	0.04	1.0	0.04	0.0	0.0	0.0	1.0	0.0
132	3,5-Dimethyl-3'-isopropyl-L-thyronine	0.49645722449656676	-2.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.043859649122807015	0.043859649122807015	11.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	11.0	0.043859649122807015	0.0	0.04	0.0	0.0	0.0	0.0	0.0
185	The form	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
220	Combination;combination	0.09152591734464818	-2.125	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.125	0.0	0.0	0.0	0.04	0.04	0.0	0.04371584699453552	0.04371584699453552	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04371584699453552	0.0	0.04	0.0	0.0	0.0	0.0	0.0
323	3 patients (11%), pectus and scoliosis	0.2988596846421086	0.0	0.0	0.0	0.04	0.04	0.2222222222222222	0.2222222222222222	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.04	0.04	9.0	0.046511627906976744	0.0	1.0	0.0	-3.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
4	evidence;Evidence	0.07626950608522387	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.04	0.04	1.0	0.044642857142857144	0.0	1.0	0.0	-2.6000000000000014	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
122	owever	0.6005147459597806	-3.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.047058823529411764	0.047058823529411764	1.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.047058823529411764	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
204	the fibroblast growth factor	0.3080199512390903	-2.25	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-6.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04493150684931507	4.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	12.0	0.0547945205479452	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	Leiomyomas;leiomyomas	0.8102538359307317	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04	1.0	0.04	0.0	0.0	0.0	1.0	0.0
178	-methyltransferase;methyltransferase;Methyltransferase	0.8827671948617789	-0.22916666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-1.375	1.0	1.0	-2.2777777777777777	0.04	0.04	0.0	0.04	0.04038800705467372	1.1666666666666667	0.04432804968740356	0.08333333333333333	6.0	1.0	-5.333333333333334	1.0	0.6666666666666666	0.0	0.16666666666666666	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	3.0	1.0	7.0	0.042328042328042326	0.0	0.05084745762711865	0.0	1.0	0.0	0.0	1.0
13	viruses particles;particles such as viruses	0.06954445570481105	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
189	blunted calcitonin responses after calcium infusion	0.40117425969833087	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
155	defects in CASQ2	0.06853517028754211	-6.166666666666666	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.5	1.0	-6.166666666666666	0.0	0.0	-10.833333333333334	0.04	0.07058823529411765	0.0	0.053097345132743355	0.053097345132743355	3.0	0.07058823529411765	0.6666666666666666	1.0	0.0	-10.833333333333334	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.053097345132743355	0.0	0.07058823529411765	0.0	0.0	0.0	0.0	0.0
317	Dose-dependent;dose-dependent	0.17405290187015546	-3.1999999999999993	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-5.333333333333333	0.04	0.05	0.0	0.045454545454545456	0.045875420875420875	3.0	0.05086206896551724	0.0	2.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.046296296296296294	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
337	risk assessment in borderline or controversial cases	0.04674180248996833	0.0	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	ophthalmologic;Ophthalmologic	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
291	tracking drinking consumption	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
25	Take;take	0.0648071641734773	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.04	0.04	1.0	0.05405405405405406	0.0	1.0	0.0	-6.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
131	Gene;gene	0.07738529911481844	-1.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8000000000000007	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04310344827586207	0.04310344827586207	1.0	0.04716981132075472	0.0	1.0	0.0	-3.8000000000000007	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04310344827586207	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
129	an important role	0.3125325399744923	-0.7037037037037036	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.1111111111111107	0.0	0.0	-3.285714285714286	0.04	0.04375	0.0	0.04	0.04122977346278317	3.0	0.04623189983045411	0.0	3.0	0.0	-5.142857142857142	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.043689320388349516	0.0	0.050359712230215826	0.0	0.0	0.0	0.0	0.0
321	weighted	0.05609723474768649	-3.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-19.0	0.04	0.16666666666666666	0.0	0.04716981132075472	0.04716981132075472	1.0	0.16666666666666666	0.0	1.0	0.0	-19.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04716981132075472	0.0	0.16666666666666666	0.0	0.0	0.0	0.0	0.0
346	Active;active	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	Derived;derived	0.15939738587816463	-0.90625	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.25	0.0	0.0	-2.4583333333333335	0.04	0.04	0.0	0.04	0.04157102157102157	1.0	0.04469018128097459	0.0	4.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04395604395604396	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
59	pre-treatment values	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
224	activity in treatment	0.04770751668068608	-2.428571428571427	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.428571428571427	0.0	0.0	-2.666666666666668	0.04	0.04477611940298508	0.0	0.04430379746835443	0.04430379746835443	3.0	0.04477611940298508	0.3333333333333333	1.0	0.0	-2.666666666666668	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04430379746835443	0.0	0.04477611940298508	0.0	0.0	0.0	0.0	0.0
185	2) in the apical and mid left ventricular segments	0.0960279056466503	-5.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-5.5	0.0	0.0	-11.0	0.04	0.07142857142857142	0.0	0.05128205128205128	0.05128205128205128	10.0	0.07142857142857142	0.1	1.0	0.0	-11.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.05128205128205128	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0
34	Which genes	0.00681630840263499	-13.75	1.0	-18.75	0.16	0.16	1.0	1.0	1.0	-18.75	1.0	1.0	-13.75	1.0	1.0	-15.75	0.16	0.10810810810810811	1.0	0.08888888888888889	0.08888888888888889	2.0	0.10810810810810811	1.0	1.0	1.0	-15.75	1.0	0.5	1.0	1.0	1.0	1.0	1.0	0.5	0.5	1.0	1.0	2.0	0.08888888888888889	0.0	0.10810810810810811	1.0	1.0	0.5	0.0	1.0
313	environmental differences in adults	0.0884415052403157	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
290	transabdominal US measurements of BWT	0.15898064341854684	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	Interaction;interaction;interactions	0.1086535422955834	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.8888888888888893	0.04	0.04	0.0	0.04	0.04	1.0	0.041592039800995025	0.0	3.0	0.0	-2.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	3.0	0.04	0.0	0.04477611940298508	0.0	0.0	0.0	0.0	0.0
290	bladder volume	0.09900366822125146	-4.75	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04938271604938271	0.04938271604938271	2.0	0.051724137931034475	0.5	1.0	0.0	-5.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04938271604938271	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
50	32,361 UCs	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
31	a vaccine	0.14076245325553055	-7.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-7.5	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.05714285714285714	0.05714285714285714	2.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.3333333333333333	1.0	0.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.05714285714285714	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
82	caused;cause	0.08200700836759107	-1.571428571428573	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.571428571428573	0.0	0.0	-2.1999999999999993	0.04	0.043859649122807015	0.0	0.042682926829268296	0.042682926829268296	1.0	0.043859649122807015	0.0	1.0	0.0	-2.1999999999999993	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.042682926829268296	0.0	0.043859649122807015	0.0	0.0	0.0	0.0	0.0
41	involved;Involved	0.11952707541888186	-4.666666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.5	0.0	0.0	-5.222222222222222	0.04	0.04	0.0	0.04	0.0503989703989704	1.0	0.054599358974358976	0.0	3.0	0.0	-12.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.05714285714285714	0.0	0.07692307692307693	0.0	0.0	0.0	0.0	0.0
68	the homeodomain of the human MSX2 gene	0.19125422145998264	-5.0	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	1.0	-5.333333333333334	1.0	1.0	-6.5	0.04	0.05405405405405406	1.0	0.04918032786885245	0.05001389274798555	7.0	0.05405405405405406	0.2857142857142857	2.0	1.0	-6.5	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	14.0	0.05084745762711865	0.0	0.05405405405405406	0.0	1.0	0.14285714285714285	0.0	1.0
86	increased myocyte size;Increased size	0.1928597827393889	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	2005)	0.3842585586614058	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	HER-2/neu;HER-2/NEU	0.7962401126268869	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	attempting;Attempt	0.08403764594924196	-2.2222222222222214	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.2222222222222214	0.0	0.0	-2.166666666666668	0.04	0.043795620437956206	0.0	0.04390243902439024	0.04390243902439024	1.0	0.043795620437956206	0.0	1.0	0.0	-2.166666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04390243902439024	0.0	0.043795620437956206	0.0	0.0	0.0	0.0	0.0
151	a new web tool	0.055666661300124605	-3.571428571428573	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.571428571428573	0.0	0.0	-3.666666666666668	0.04	0.046875	1.0	0.04666666666666667	0.04666666666666667	4.0	0.046875	0.25	1.0	0.0	-3.666666666666668	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04666666666666667	0.0	0.046875	0.0	0.0	0.25	0.0	0.0
329	measure;Measure	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
10	one in association	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
203	chromosome 15 and SNRPN gene as a candidate gene	0.10188588043889102	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
220	MTND6 at np 14459	0.22367955800957937	-2.25	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.4	1.0	-2.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04395604395604396	0.04395604395604396	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04395604395604396	0.0	0.04	0.0	0.0	0.0	0.0	0.0
125	generalized hypotonia and muscle weakness	0.17036647602105637	-5.333333333333334	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.05084745762711865	0.05084745762711865	5.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.05084745762711865	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
339	level;Level	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
130	OXA-;OXA	0.8824259685268523	-1.0303030303030298	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.909090909090908	1.0	1.0	-2.492063492063492	0.04	0.04	0.0	0.04	0.04191190534290512	0.3333333333333333	0.04480310202342861	0.05555555555555555	9.0	1.0	-5.2857142857142865	1.0	0.5	0.0	0.1111111111111111	0.0	1.0	1.0	0.5	0.5	2.0	1.0	3.0	0.049773755656108594	0.0	0.05072463768115942	0.0	1.0	0.0	0.0	1.0
291	alcohol treatment	0.21236619798695786	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	1.0	0.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
215	beta-galactosidase activity	0.5364165660035951	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.04	0.04	4.0	0.04587155963302752	0.0	2.0	0.0	-3.1999999999999993	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
124	distant relapse	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
189	3 months	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
313	Exome;exome	0.7786266455789895	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
298	Day 5;day 5	0.20146510080365157	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
28	VIRUS;virus	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	Typical of a multimembrane-spanning protein	0.21993439663386755	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
25	limited;Limited	0.03720843761442639	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-19.5	0.04	0.18181818181818182	0.0	0.04	0.04	1.0	0.18181818181818182	0.0	1.0	0.0	-19.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.18181818181818182	0.0	0.0	0.0	0.0	0.0
26	significantly higher fluid output	0.0884415052403157	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	the prescribing information	0.12060473783871761	-4.75	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.04938271604938271	0.04938271604938271	3.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04938271604938271	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
129	9-11]	0.6246950713232555	-2.1111111111111107	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.1111111111111107	0.0	0.0	-2.7142857142857153	0.04	0.04487179487179487	0.0	0.043689320388349516	0.043689320388349516	2.0	0.04487179487179487	0.0	1.0	0.0	-2.7142857142857153	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043689320388349516	0.0	0.04487179487179487	0.0	0.0	0.0	0.0	0.0
261	These proteins	0.16142912244681984	-2.7142857142857153	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.7142857142857153	0.0	0.0	-14.166666666666668	0.04	0.09230769230769231	0.0	0.04487179487179487	0.04487179487179487	2.0	0.09230769230769231	0.0	1.0	0.0	-14.166666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04487179487179487	0.0	0.09230769230769231	0.0	0.0	0.0	0.0	0.0
264	lipid;Lipid	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	The problem of drug resistance	0.03874550463237943	-10.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-10.75	0.0	0.0	-8.666666666666666	0.04	0.06122448979591836	0.0	0.07017543859649122	0.07017543859649122	5.0	0.06122448979591836	0.4	1.0	0.0	-8.666666666666666	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.07017543859649122	0.0	0.06122448979591836	0.0	0.0	0.0	0.0	0.0
53	enable	0.0889852165802779	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	1.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
265	A (p.D117N)	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
112	human LINE	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
160	antiosteoclast activity	0.24438889480224602	-1.8333333333333321	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	-1.8571428571428577	0.04	0.043209876543209874	0.0	0.043165467625899276	0.043165467625899276	2.0	0.043209876543209874	0.0	1.0	0.0	-1.8571428571428577	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043165467625899276	0.0	0.043209876543209874	0.0	0.0	0.0	0.0	0.0
129	a maintenance DNA methyltransferase enzyme	0.054828887790286836	-1.2222222222222214	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.4	1.0	-1.2222222222222214	0.0	0.0	-4.2857142857142865	0.04	0.04827586206896552	1.0	0.04205607476635514	0.04205607476635514	5.0	0.04827586206896552	0.6	1.0	0.0	-4.2857142857142865	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.04205607476635514	0.0	0.04827586206896552	0.0	0.0	0.2	0.0	0.0
147	D3 activities	0.435809293607436	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
277	Increase;increase	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	benzodiazepine toxicity	0.6595261230399247	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	2.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
115	GRB target gene	0.3269915475311465	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	renal angiomyolipoma;Renal Angiomyolipoma	0.842638596810195	-2.125	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.125	0.0	0.0	0.0	0.04	0.04	0.0	0.04371584699453552	0.04371584699453552	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.04371584699453552	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	regulation of embryonic development	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
164	growth retardation without an accumulation	0.26905681404095005	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
11	glycolytic flux	0.6023931981924998	-2.333333333333332	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-5.0	0.04	0.05	0.0	0.044117647058823525	0.044117647058823525	2.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.044117647058823525	0.0	0.05	0.0	0.0	0.0	0.0	0.0
139	models of Alzheimer's disease;disease model	0.02437902387964185	-1.5	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.5	0.0	-1.5	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.0425531914893617	0.0425531914893617	5.0	0.04597701149425287	0.4	1.0	0.0	-3.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.0425531914893617	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
318	the discovery;The discovery	0.0547533203386259	-0.5925925925925929	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-4.435897435897437	0.04	0.04693140794223827	0.0	0.04	0.0410207336523126	2.0	0.04874723085298868	0.5	3.0	0.0	-5.846153846153847	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.0430622009569378	0.0	0.052208835341365466	0.0	0.0	0.0	0.0	0.0
139	basic research;Basic Research	0.11707437433269925	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
307	Parkinson's disease and dementia	0.2576848311095208	-4.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.047619047619047616	0.047619047619047616	5.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.047619047619047616	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
40	SuperTRI	0.7097200136964369	-0.9166666666666661	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.041582733812949635	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043165467625899276	0.0	0.04	0.0	0.0	0.0	0.0	0.0
301	brain tumor progression and radiation therapy induced necrosis	0.09279875453807646	0.0	0.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.04	0.04	8.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
322	Su(var)3-9, E(z)	0.6783997457276245	-4.666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.04918032786885245	0.04918032786885245	8.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04918032786885245	0.0	0.04	0.0	0.0	0.0	0.0	0.0
264	Events;events	0.00712873568729587	-2.125	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.125	0.0	0.0	0.0	0.04	0.04	0.0	0.04371584699453552	0.04371584699453552	1.0	0.04	1.0	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04371584699453552	0.0	0.04	1.0	0.0	0.0	0.0	0.0
62	initiation;Initiation	0.5549538324718414	-1.8888888888888893	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04326923076923077	0.04326923076923077	1.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04326923076923077	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
122	10%;10	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
34	HR	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
87	the presence	0.03793554588998235	-12.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-12.75	0.0	0.0	-11.5	0.04	0.07407407407407407	0.0	0.08163265306122448	0.08163265306122448	2.0	0.07407407407407407	0.5	1.0	0.0	-11.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.08163265306122448	0.0	0.07407407407407407	0.0	0.0	0.0	0.0	0.0
14	the exposure status of transmembrane residues	0.0391117900426688	-4.375	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-4.375	0.0	0.0	-8.666666666666666	0.04	0.06122448979591836	0.0	0.048484848484848485	0.048484848484848485	6.0	0.06122448979591836	0.5	1.0	0.0	-8.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.048484848484848485	0.0	0.06122448979591836	0.0	0.0	0.0	0.0	0.0
332	*Number;number	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
94	January 31, 2001	0.6329321060285652	-3.6000000000000014	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.04672897196261683	0.04672897196261683	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04672897196261683	0.0	0.04	0.0	0.0	0.0	0.0	0.0
288	the large core subunit of MINOS	0.10631760218989013	-6.666666666666666	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.054545454545454536	0.054545454545454536	6.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.054545454545454536	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
73	k-nearest neighbor algorithm	0.23136852087586654	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
16	an analysis similar in spirit but different	0.06495544270537182	0.0	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
250	T3	0.7123617662367117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	mother to daughter cells;Mother Cells;maternal to daughter cells	0.36220316881987585	-1.5555555555555571	0.0	0.0	0.04	0.04	0.75	0.875	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	-4.857142857142858	0.04	0.0445859872611465	0.0	0.04265402843601896	0.04265402843601896	4.0	0.050292993630573254	0.0	4.0	0.0	-7.142857142857142	1.0	0.0	0.5	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	16.0	0.04265402843601896	0.0	0.056	0.0	0.0	0.0	0.0	0.0
101	low;Low	0.1078003961190134	-1.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.042727272727272725	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	mouse;Mouse, NOS	0.09547314421894679	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.5	0.04	0.045454545454545456	0.0	0.04	0.04	1.0	0.046536796536796536	0.0	2.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
199	histone H3-like proteins	0.40976907254209727	-5.166666666666666	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	-5.166666666666666	0.0	0.0	-5.0	0.04	0.05	0.0	0.050420168067226885	0.050420168067226885	5.0	0.05	0.2	1.0	0.0	-5.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.050420168067226885	0.0	0.05	0.0	0.0	0.0	0.0	0.0
5	intranasal neostigmine	0.8591449681689061	-3.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.25	1.0	1.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	2.0	0.04	0.0	2.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04597701149425287	0.0	0.04	0.0	1.0	0.0	0.0	1.0
256	Coronal;coronal	0.6324704996253049	-11.666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-11.666666666666666	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.075	0.075	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.075	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
225	release;Release	0.12285803530981637	-1.5555555555555554	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	-1.3333333333333333	0.04	0.04	0.0	0.04	0.04306010928961748	1.0	0.042539682539682544	0.0	3.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04918032786885245	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
239	A genome-wide association study of 785,720 single-nucleotide polymorphisms	0.13735333677615716	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	12.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	12.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
131	a selected group of high abundance	0.06597667240099289	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	6.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
267	an algorithm	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	TransMembrane;transmembrane;TMH;TM	0.9999278702591925	-1.2471590909090908	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.625	0.0	0.0	-4.390151515151515	0.04	0.04	0.0	0.04	0.04225566899748553	1.0	0.049466943351664704	0.7954545454545454	44.0	0.0	-9.333333333333334	1.0	0.0	0.0	0.7954545454545454	0.0	0.0	1.0	0.0	0.0	4.0	1.0	44.0	0.049079754601226995	0.0	0.06382978723404256	1.0	0.0	0.0	0.0	0.0
245	Assess;assess	0.07218477163881303	-1.7142857142857153	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.7142857142857153	0.0	0.0	-5.4	0.04	0.0510204081632653	0.0	0.04294478527607362	0.04294478527607362	1.0	0.0510204081632653	0.0	1.0	0.0	-5.4	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04294478527607362	0.0	0.0510204081632653	0.0	0.0	0.0	0.0	0.0
129	embryonic development;Embryonic Development	0.45507996125633315	-1.333333333333334	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-2.642857142857144	0.04	0.0445859872611465	0.0	0.04	0.04229665071770335	2.0	0.04472981302650504	0.0	4.0	0.0	-2.8571428571428577	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.0430622009569378	0.0	0.04516129032258065	0.0	0.0	0.0	0.0	0.0
20	find;Find	0.0022200129519666005	-19.0	1.0	0.0	0.04	0.04	1.0	1.0	1.0	0.0	1.0	0.0	-19.0	0.0	0.0	-17.5	0.04	0.13333333333333333	0.0	0.16666666666666666	0.16666666666666666	1.0	0.13333333333333333	1.0	1.0	0.0	-17.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.16666666666666666	0.0	0.13333333333333333	1.0	0.0	0.0	0.0	0.0
26	regression and bowel symptoms	0.23647973556497437	-2.2857142857142847	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.2857142857142847	0.0	0.0	0.0	0.04	0.04	0.0	0.0440251572327044	0.0440251572327044	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.0440251572327044	0.0	0.04	0.0	0.0	0.0	0.0	0.0
180	Exon;exon	0.7113970241420249	-0.708333333333333	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-5.416666666666666	0.04	0.04	0.0	0.04	0.0412781954887218	1.0	0.05432700603968938	0.0	4.0	0.0	-12.333333333333332	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.045112781954887216	0.0	0.07894736842105263	0.0	0.0	0.0	0.0	0.0
344	regions;Region	0.14095469534932045	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
232	children;Children	0.0840711566556274	-4.833333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.833333333333334	0.0	0.0	-10.75	0.04	0.07017543859649122	0.0	0.04958677685950414	0.04958677685950414	1.0	0.07017543859649122	0.0	2.0	0.0	-10.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04958677685950414	0.0	0.07017543859649122	0.0	0.0	0.0	0.0	0.0
262	renal angiomyolipomas;Renal Angiomyolipoma	0.9216103490361107	-2.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.5	1.0	1.0	-4.5	0.04	0.04	0.0	0.04	0.04439024390243903	2.0	0.05125	0.0	6.0	1.0	-9.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	12.0	0.04878048780487805	0.0	0.0625	0.0	1.0	0.0	0.0	1.0
49	two families	0.10894795440739571	-2.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04395604395604396	0.04395604395604396	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04395604395604396	0.0	0.04	0.0	0.0	0.0	0.0	0.0
209	Research;research	0.10238296519538877	-5.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.05084745762711865	0.05084745762711865	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05084745762711865	0.0	0.04	0.0	0.0	0.0	0.0	0.0
152	glibenclamide (improvement	0.06774331260269002	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.5	1.0	0.0	0.0	0.0	-5.800000000000001	0.04	0.052083333333333336	0.0	0.04	0.04	3.0	0.052083333333333336	0.6666666666666666	1.0	0.0	-5.800000000000001	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.052083333333333336	0.0	0.0	0.0	0.0	0.0
10	to;TO	0.0729029923940863	-4.428571428571429	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.428571428571429	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.04861111111111112	0.04861111111111112	1.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04861111111111112	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
199	the role and dynamics	0.05138367338610427	-2.833333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-3.166666666666668	0.04	0.04580152671755725	0.0	0.045112781954887216	0.045112781954887216	4.0	0.04580152671755725	0.25	1.0	0.0	-3.166666666666668	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.045112781954887216	0.0	0.04580152671755725	0.0	0.0	0.0	0.0	0.0
128	functional similarities and differences	0.08207454129279072	-1.5833333333333321	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5833333333333321	0.0	0.0	-3.1818181818181834	0.04	0.04583333333333334	0.0	0.042704626334519574	0.042704626334519574	4.0	0.04583333333333334	0.0	1.0	0.0	-3.1818181818181834	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.042704626334519574	0.0	0.04583333333333334	0.0	0.0	0.0	0.0	0.0
25	moderate autistic symptomology (per SRS	0.29956052836315394	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
31	this new approach	0.09593917205062095	-8.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-8.0	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.058823529411764705	0.058823529411764705	3.0	0.05405405405405406	0.0	1.0	0.0	-6.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.058823529411764705	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
74	presynaptic voltage-gated calcium channels (VGCC)	0.3309957341735216	0.0	0.0	0.0	0.04	0.04	0.2222222222222222	0.2222222222222222	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.04	0.04	9.0	0.047058823529411764	0.1111111111111111	1.0	0.0	-3.75	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
342	regulated;Regulated	0.5769712368525785	-2.3999999999999986	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	-4.800000000000001	0.04	0.04950495049504951	0.0	0.04424778761061947	0.04424778761061947	0.0	0.04950495049504951	0.0	1.0	0.0	-4.800000000000001	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04424778761061947	0.0	0.04950495049504951	0.0	0.0	0.0	0.0	0.0
178	the cap structure	0.04456246934269313	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.04	0.043795620437956206	0.0	0.04	0.04	3.0	0.043795620437956206	0.3333333333333333	1.0	0.0	-2.166666666666668	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.043795620437956206	0.0	0.0	0.0	0.0	0.0
324	ADAMTS10 and FBN1 genes	0.3075309072386389	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	a previously described method of candidate gene prioritization	0.029148122512979723	0.0	0.0	0.0	0.04	0.04	0.875	0.875	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	8.0	0.04	0.375	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.125	0.0	0.0
202	90	0.6637224919960596	-1.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	0.0	0.04	0.04	0.0	0.0425531914893617	0.0425531914893617	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.0425531914893617	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	Endocrine;endocrine	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	FORMERLY;formerly	0.1467196247533815	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-6.23076923076923	0.04	0.05327868852459016	0.0	0.04	0.04	1.0	0.05327868852459016	0.0	1.0	1.0	-6.23076923076923	1.0	1.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04	1.0	0.05327868852459016	0.0	1.0	0.0	1.0	1.0
322	shares;Share	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
293	duloxetine and pregabalin	0.5166279445859454	-4.75	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-4.75	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.04938271604938271	0.04938271604938271	3.0	0.06060606060606061	0.0	1.0	0.0	-8.5	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.04938271604938271	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
100	inactivation;Inactivation	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	an important determinant	0.2973158582863151	-4.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.047619047619047616	0.047619047619047616	3.0	0.06060606060606061	0.0	1.0	0.0	-8.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.047619047619047616	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
310	now;Now	0.06784116058861199	-4.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.04938271604938271	0.04938271604938271	1.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04938271604938271	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
332	induces;Induce;induced;Induced	0.5003336186873707	-1.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-2.375	0.04	0.04	0.0	0.04	0.042727272727272725	1.0	0.04469135802469136	0.0	2.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.045454545454545456	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
132	T4(3,3',5,5'-tetraiodo-L-thyronine	0.37701342238284336	-10.2	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-10.2	0.0	0.0	-11.333333333333334	0.04	0.07317073170731708	0.0	0.06756756756756756	0.06756756756756756	15.0	0.07317073170731708	0.0	1.0	0.0	-11.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	15.0	0.06756756756756756	0.0	0.07317073170731708	0.0	0.0	0.0	0.0	0.0
139	Convection-enhanced delivery of neprilysin	0.178839295874081	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.14285714285714285	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	1.0	0.0	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	6.0	0.04	1.0	0.04	0.0	1.0	0.16666666666666666	1.0	1.0
321	1â15;1â15)	0.6641753767711227	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.5	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
158	border;Border	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
128	this gene neighborhood	0.07452770991750864	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.3333333333333333	1.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
223	CSF	0.6797780558186116	-0.5909090909090917	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.1818181818181834	0.0	0.0	-3.2857142857142847	0.04	0.04430379746835443	0.0	0.04	0.04099236641221374	1.0	0.04612450147390324	0.0	2.0	0.0	-4.142857142857142	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04198473282442748	0.0	0.04794520547945205	0.0	0.0	0.0	0.0	0.0
225	gender;Gender	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
338	a causative role for myocardial fibrosis	0.19706491701828815	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	the interplay between import receptors	0.16741634592668644	-8.75	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	-8.75	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.06153846153846154	0.06153846153846154	5.0	0.05263157894736842	0.2	1.0	0.0	-6.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.06153846153846154	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
130	type;TYPE	0.07151135548791998	-1.8181818181818166	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8181818181818166	0.0	0.0	-5.7142857142857135	0.04	0.05185185185185186	0.0	0.043137254901960784	0.043137254901960784	1.0	0.05185185185185186	0.0	1.0	0.0	-5.7142857142857135	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043137254901960784	0.0	0.05185185185185186	0.0	0.0	0.0	0.0	0.0
215	a driving force of the senescence	0.05172733387632983	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
311	the landscape	0.04336341107169938	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
201	nonpenetrating injury;Nonpenetrating cardiac injuries;Blunt trauma;Nonpenetrating Injuries;Nonpenetrating Injury;blunt trauma	0.4228822002352852	-14.8	0.0	0.0	0.04	0.04	0.3333333333333333	0.4666666666666666	0.0	0.0	0.0	0.0	-19.0	0.0	0.0	-8.0	0.04	0.04	0.0	0.04	0.1318095238095238	2.2	0.062	0.0	5.0	0.0	-11.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	6.0	1.0	11.0	0.16666666666666666	0.0	0.075	0.0	0.0	0.0	0.0	0.0
4	the parathyroids	0.1320765589555566	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
85	a priority	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	Alignment;alignment	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	prognosis estimation and treatment decisions	0.1593735888093135	-4.333333333333334	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-4.333333333333334	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.048387096774193554	0.048387096774193554	5.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.048387096774193554	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
181	positive;% Positive	0.16267800765737137	-3.0714285714285707	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.142857142857142	0.0	0.0	-2.8499999999999996	0.04	0.04	0.0	0.04	0.045989821086614396	1.0	0.04538359788359788	0.0	4.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.050359712230215826	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
121	the risk	0.101275167708798	-6.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.053571428571428575	0.053571428571428575	2.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.053571428571428575	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
318	a balanced genetic translocation	0.05607031828386142	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	4.0	0.047619047619047616	0.25	1.0	0.0	-4.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
100	DNA (cytosine-C5) methyltranferases	0.09621857848024162	0.0	1.0	0.0	0.04	0.04	0.14285714285714285	0.14285714285714285	0.0	0.0	0.5	1.0	0.0	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04	0.04	7.0	0.0625	0.5714285714285714	1.0	0.0	-9.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
41	trimethylated	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	the individual predictions	0.023106849155345194	0.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
187	K+;K	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
80	5'UTR region	0.21667286533370525	-2.833333333333332	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-6.199999999999999	0.04	0.05319148936170213	0.0	0.045112781954887216	0.045112781954887216	2.0	0.05319148936170213	0.0	1.0	0.0	-6.199999999999999	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.045112781954887216	0.0	0.05319148936170213	0.0	0.0	0.0	0.0	0.0
269	bronchial epithelial cell;Bronchial Epithelial Cell	0.1541077396274211	-2.6000000000000014	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.044642857142857144	0.044642857142857144	3.0	0.04878048780487805	0.3333333333333333	1.0	0.0	-4.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.044642857142857144	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
144	Position;position	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
176	Imaging;imaging	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
120	kinases;Kinases	0.6850968178223322	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-2.75	0.04	0.0449438202247191	0.0	0.04	0.04	1.0	0.0449438202247191	0.0	2.0	1.0	-2.75	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	2.0	0.04	0.0	0.0449438202247191	0.0	1.0	0.0	0.0	1.0
206	striatal basal extracellular glutamate concentration and potassium-evoked glutamate release in urethane-anesthetized rats	0.38942584153683807	-4.0	0.0	0.0	0.04	0.04	0.3125	0.3125	0.0	0.0	0.0	1.0	-4.0	1.0	1.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	16.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	16.0	0.047619047619047616	1.0	0.04	0.0	1.0	0.0	1.0	1.0
304	ibrutinib -inhibitor of Btk	0.4072941988615474	-2.25	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	-2.25	1.0	1.0	0.0	0.04	0.04	0.0	0.04395604395604396	0.04395604395604396	5.0	0.04	0.4	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.04395604395604396	0.0	0.04	0.0	1.0	0.0	0.0	1.0
100	a covalent complex with DNA methyltransferases	0.14557840684705667	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
180	abnormal expansions of the CTG repeats	0.13810335847274388	-3.333333333333332	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.04615384615384615	0.04615384615384615	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04615384615384615	0.0	0.04	0.0	0.0	0.0	0.0	0.0
245	position 29	0.3495750831508339	-1.7142857142857153	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.7142857142857153	0.0	0.0	0.0	0.04	0.04	0.0	0.04294478527607362	0.04294478527607362	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04294478527607362	0.0	0.04	0.0	0.0	0.0	0.0	0.0
304	Targeting BTK with ibrutinib	0.5160958561513499	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-4.7142857142857135	0.04	0.04929577464788733	0.0	0.04	0.04	4.0	0.04929577464788733	0.0	1.0	1.0	-4.7142857142857135	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04	0.0	0.04929577464788733	0.0	1.0	0.0	0.0	1.0
79	other sedatives	0.2199916939626395	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-9.0	0.04	0.0625	0.0	0.04	0.04	2.0	0.0625	0.0	1.0	1.0	-9.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.0625	0.0	1.0	0.0	0.0	1.0
222	previously untreated patients with relapsing	0.09959027239040807	-3.722222222222223	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.25	0.0	-3.8888888888888893	0.0	0.0	-7.6	0.04	0.046296296296296294	0.0	0.04663212435233161	0.047000272702481596	5.0	0.06102693602693603	0.2	2.0	0.0	-11.8	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04736842105263158	0.0	0.07575757575757576	0.0	0.0	0.0	0.0	0.0
73	Diverse;diverse	0.07929713080039498	-1.5555555555555571	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04265402843601896	0.04265402843601896	1.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04265402843601896	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
222	EUROPEAN;European	0.09698322959012073	-3.7777777777777786	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.7777777777777786	0.0	0.0	0.0	0.04	0.04	0.0	0.04712041884816754	0.04712041884816754	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04712041884816754	0.0	0.04	0.0	0.0	0.0	0.0	0.0
262	of brain findings;Finding of brain	0.03809459826425287	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
292	Ligand;ligand	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	Inhibited;inhibited	0.6037829363001277	-7.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.75	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.057971014492753624	0.057971014492753624	1.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.057971014492753624	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
32	performs;Perform	0.09705854714792957	-3.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04716981132075472	0.04716981132075472	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04716981132075472	0.0	0.04	0.0	0.0	0.0	0.0	0.0
140	Phosphorylation;phosphorylation	0.771351746239246	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	responsible;Responsible	0.07255748982549837	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04	0.04	1.0	0.04716981132075472	0.0	1.0	0.0	-3.8000000000000007	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
203	The genetic defects	0.015467649896952776	-4.5	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.5	0.0	-4.5	0.0	0.0	-10.8	0.04	0.07042253521126761	1.0	0.04878048780487805	0.04878048780487805	3.0	0.07042253521126761	0.6666666666666666	1.0	0.0	-10.8	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04878048780487805	0.0	0.07042253521126761	0.0	0.0	0.3333333333333333	0.0	0.0
231	sympathetic drive	0.2489991902711937	-2.1428571428571423	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.1428571428571423	0.0	0.0	-1.571428571428573	0.04	0.042682926829268296	0.0	0.04375	0.04375	2.0	0.042682926829268296	0.0	1.0	0.0	-1.571428571428573	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04375	0.0	0.042682926829268296	0.0	0.0	0.0	0.0	0.0
85	Herpes Simplex Virus;Herpes simplex virus	0.36246320818203	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.428571428571429	0.04	0.05109489051094891	0.0	0.04	0.04	3.0	0.05109489051094891	0.0	2.0	0.0	-5.428571428571429	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.05109489051094891	0.0	0.0	0.0	0.0	0.0
243	involved;Involved	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
339	bmi-1 oncoprotein;Bmi-1 oncoprotein	0.778745502569687	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	4.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
277	Status;status	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
177	Thirty-four deaths	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	multi-drug resistance;Multi-Drug Resistance	0.3730670842758065	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
139	Reducing	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
143	miRNAs and tRNAs	0.6555921211985825	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
231	and;And	0.09093400350936061	-4.428571428571429	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.428571428571429	0.0	0.0	-2.1428571428571423	0.04	0.04375	0.0	0.04861111111111112	0.04861111111111112	1.0	0.04375	0.0	1.0	0.0	-2.1428571428571423	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04861111111111112	0.0	0.04375	0.0	0.0	0.0	0.0	0.0
231	Cardiac Troponin I;cardiac troponin I	0.4209438591954511	-4.428571428571429	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-4.428571428571429	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04861111111111112	0.04861111111111112	3.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	3.0	0.04861111111111112	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
11	itaconic acid production;Itaconic acid production	0.05453714906604404	-1.3333333333333328	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.6333333333333333	1.0	-3.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04246153846153846	3.0	0.04	1.0	5.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	15.0	0.04615384615384615	0.0	0.04	1.0	0.0	0.0	0.0	0.0
216	Desulfovibrio;DESULFOVIBRIO	0.7786266455789895	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
293	the class of serotonin receptor antagonists	0.1593359254589332	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
256	date;DATE	0.07487150684841119	-6.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.053571428571428575	0.053571428571428575	1.0	0.06060606060606061	0.0	1.0	0.0	-8.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.053571428571428575	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
131	a tissue microarray	0.1406096370617351	-1.3000000000000007	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.3000000000000007	0.0	0.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.04219409282700422	0.04219409282700422	3.0	0.044642857142857144	0.0	1.0	0.0	-2.6000000000000014	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04219409282700422	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
219	significantly inhibited biofilm formation	0.2263061588938384	-4.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.047619047619047616	0.047619047619047616	4.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.047619047619047616	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
183	Characterization of the somatic mutational spectrum	0.11759958551453945	-4.25	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.04819277108433735	0.04819277108433735	6.0	0.06060606060606061	0.16666666666666666	1.0	0.0	-8.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04819277108433735	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
176	topoisomerase I	0.539562068555742	-0.875	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04150537634408602	2.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.043010752688172046	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	Rare;rare	0.0661817914888578	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
233	sudden cardiac death (SCD)	0.06822864846146098	-3.555555555555557	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.6	0.0	-3.555555555555557	0.0	0.0	0.0	0.04	0.04	0.0	0.04663212435233161	0.04663212435233161	6.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04663212435233161	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	the cytoplasmic/NPC side	0.20602609405179692	-2.75	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0449438202247191	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
147	Fetal Activities;activities in fetal	0.06227578876492644	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
237	complex;Complex	0.09055120456255263	-3.071428571428572	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.2857142857142865	0.0	0.0	-6.071428571428571	0.04	0.04861111111111112	0.0	0.043209876543209874	0.045742869306087695	1.0	0.053231175390266304	0.0	2.0	0.0	-7.7142857142857135	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04827586206896552	0.0	0.05785123966942149	0.0	0.0	0.0	0.0	0.0
178	GTP	0.6973995532021896	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
261	calcium;CALCIUM	0.6275743957528072	-6.2857142857142865	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.2857142857142865	0.0	0.0	-1.8333333333333321	0.04	0.043165467625899276	0.0	0.05343511450381679	0.05343511450381679	1.0	0.043165467625899276	0.0	1.0	0.0	-1.8333333333333321	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05343511450381679	0.0	0.043165467625899276	0.0	0.0	0.0	0.0	0.0
91	Regression Analyses;Regression analyses	0.2997180448251998	-2.571428571428573	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.0445859872611465	0.0445859872611465	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.0445859872611465	0.0	0.04	0.0	0.0	0.0	0.0	0.0
49	suggestive but non-diagnostic features	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
34	exhibited;Exhibit	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
82	carbamazepine-induced SJS/TEN	0.3061712609742807	-2.571428571428573	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	1.0	-2.571428571428573	1.0	1.0	-10.8	0.04	0.07042253521126761	0.0	0.0445859872611465	0.0445859872611465	6.0	0.07042253521126761	0.16666666666666666	1.0	1.0	-10.8	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.0445859872611465	0.0	0.07042253521126761	0.0	1.0	0.0	0.0	1.0
211	These data	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	the DNMT1 binding site	0.1405487375957212	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
291	sunscreen/UV recommendation	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
163	direct;Direct	0.06435489027425928	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.04	0.04	1.0	0.054545454545454536	0.0	1.0	0.0	-6.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
213	a recessive form of the Romano-Ward long-QT syndrome	0.04758637540657741	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.25	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	12.0	0.04	0.4166666666666667	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	12.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	not;Not	0.21400371063111104	-1.8	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-0.9199999999999996	0.04	0.04	0.0	0.04	0.0432081836928289	1.0	0.0416214873466853	0.0	5.0	0.0	-2.3999999999999986	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04672897196261683	0.0	0.04424778761061947	0.0	0.0	0.0	0.0	0.0
277	cystatin C;Cystatin C	0.7625556914551705	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
108	Lymphocytic Leukemia	0.05484818297441266	-12.857142857142858	1.0	-10.4	0.0684931506849315	0.0684931506849315	0.0	0.0	1.0	-10.4	1.0	0.0	-12.857142857142858	0.0	0.0	-11.0	0.0684931506849315	0.07142857142857142	0.0	0.08235294117647059	0.08235294117647059	2.0	0.07142857142857142	1.0	1.0	0.0	-11.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.08235294117647059	0.0	0.07142857142857142	1.0	0.0	0.0	0.0	0.0
40	Sequences;sequences	0.07074466065402268	-5.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	-9.0	0.04	0.0625	0.0	0.05084745762711865	0.05084745762711865	1.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05084745762711865	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
200	injuries	0.14700204181668	-1.0666666666666664	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-3.4444444444444446	0.04	0.04	0.0	0.04	0.0419571865443425	1.0	0.0493939393939394	0.0	3.0	0.0	-10.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04587155963302752	0.0	0.06818181818181819	0.0	0.0	0.0	0.0	0.0
61	/GABARAP family members	0.29119110248524577	-3.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-3.0	1.0	1.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.045454545454545456	0.0	0.04	0.0	1.0	0.0	0.0	1.0
204	the transmembrane domain	0.3116957008293064	-2.9166666666666665	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-8.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04717948717948719	3.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.06153846153846154	0.0	0.04	0.0	0.0	0.0	0.0	0.0
322	Protein Methyltransferases;protein methyltransferases	0.21991438229100652	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.4999999999999996	0.04	0.04	0.0	0.04	0.04	2.0	0.04688524590163934	0.5	4.0	0.0	-4.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
16	protein pairs	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
285	the cohort	0.11776571325534792	-3.1999999999999993	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04587155963302752	0.04587155963302752	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04587155963302752	0.0	0.04	0.0	0.0	0.0	0.0	0.0
342	purified;Purified	0.6100559097304536	-1.5999999999999996	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-4.0	0.04	0.043859649122807015	0.0	0.04	0.04293577981651376	1.0	0.04797149122807018	0.0	2.0	0.0	-5.800000000000001	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04587155963302752	0.0	0.052083333333333336	0.0	0.0	0.0	0.0	0.0
82	with;With	0.054461167075688405	-4.857142857142858	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.857142857142858	0.0	0.0	-14.8	0.04	0.09803921568627452	0.0	0.04964539007092199	0.04964539007092199	1.0	0.09803921568627452	0.0	1.0	0.0	-14.8	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04964539007092199	0.0	0.09803921568627452	0.0	0.0	0.0	0.0	0.0
46	row;Row	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
319	improved;Improved	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	-class proteasome inhibitor	0.3492303890296884	-4.25	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.04819277108433735	0.04819277108433735	4.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04819277108433735	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
317	CSC subpopulations	0.7449140685389586	-2.3999999999999986	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04424778761061947	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04424778761061947	0.0	0.04	0.0	0.0	0.0	0.0	0.0
20	the connection	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
45	8	0.7123617662367117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
206	2 5;2.5	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
291	patients with enlarged prostates	0.06997729912768738	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
71	diminished mitochondrial respiration;diminished respiration	0.27527342400666754	-3.6000000000000014	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04672897196261683	0.04672897196261683	3.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04672897196261683	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
267	using;Using	0.10818645089529971	-1.2142857142857135	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.428571428571427	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04215189873417721	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04430379746835443	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	possible causal links	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
205	prolonged infusions	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
253	72% as large	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	patients;Patients	0.09318406539324527	-7.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-9.25	0.0	0.0	-7.5	0.04	0.054545454545454536	0.0	0.04938271604938271	0.0564373897707231	1.0	0.057272727272727274	0.0	2.0	0.0	-8.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.06349206349206349	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
130	List	0.004521537328463142	-15.272727272727273	1.0	-9.666666666666666	0.06521739130434782	0.06521739130434782	1.0	1.0	1.0	-9.666666666666666	1.0	0.0	-15.272727272727273	0.0	0.0	-10.0	0.06521739130434782	0.06666666666666667	0.0	0.10280373831775702	0.10280373831775702	1.0	0.06666666666666667	1.0	1.0	0.0	-10.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.10280373831775702	0.0	0.06666666666666667	1.0	0.0	0.0	0.0	0.0
185	reminiscence;reminiscent	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
84	other agents in the management	0.08279735195665178	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
114	the full-length coding sequences	0.06008415884008202	-4.142857142857142	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-4.142857142857142	0.0	0.0	-12.4	0.04	0.07936507936507936	0.0	0.04794520547945205	0.04794520547945205	6.0	0.07936507936507936	0.16666666666666666	1.0	0.0	-12.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04794520547945205	0.0	0.07936507936507936	0.0	0.0	0.0	0.0	0.0
223	the degenerative process	0.12465303028307266	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.571428571428571	0.04	0.048951048951048945	0.0	0.04	0.04	3.0	0.048951048951048945	0.0	1.0	0.0	-4.571428571428571	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.048951048951048945	0.0	0.0	0.0	0.0	0.0
125	Presence;presence	0.09078242774839765	-5.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.051724137931034475	0.051724137931034475	1.0	0.04597701149425287	0.0	1.0	0.0	-3.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.051724137931034475	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
229	gene prioritization	0.28895548421531403	0.0	0.6666666666666666	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.2962962962962963	0.0	0.0	0.0	0.0	-1.0	0.04	0.04	0.0	0.04	0.04	2.0	0.0425	1.0	9.0	0.0	-9.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	18.0	0.04	0.0	0.0625	1.0	0.0	0.0	0.0	0.0
319	described inhibitors	0.20376909896291234	-2.333333333333332	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.044117647058823525	0.044117647058823525	2.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.044117647058823525	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
217	the blocked mature original N	0.06515020837261519	-1.375	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-1.375	0.0	0.0	-4.857142857142858	0.04	0.04964539007092199	0.0	0.042328042328042326	0.042328042328042326	5.0	0.04964539007092199	0.4	1.0	0.0	-4.857142857142858	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.042328042328042326	0.0	0.04964539007092199	0.0	0.0	0.0	0.0	0.0
47	exon-intron	0.6171953679194666	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
150	Recently;recently	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
127	Cross;cross	0.551746232121474	-7.333333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.333333333333334	0.0	0.0	-11.333333333333334	0.04	0.07317073170731708	0.0	0.05660377358490567	0.05660377358490567	0.0	0.07317073170731708	0.0	1.0	0.0	-11.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.05660377358490567	0.0	0.07317073170731708	0.0	0.0	0.0	0.0	0.0
229	process;Process	0.05590579645193492	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.04	0.04	1.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
100	target site	0.25224964345586603	-2.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-3.583333333333333	0.04	0.04	0.0	0.04	0.04439024390243902	2.0	0.04803738317757009	0.0	4.0	0.0	-7.166666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04878048780487805	0.0	0.05607476635514018	0.0	0.0	0.0	0.0	0.0
213	the genes KCNQ1 and KCNH2 (HERG)	0.24715508729140884	0.0	0.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	8.0	0.04	0.125	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.125	0.0	1.0
2	TSH	0.11717834148852534	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	1.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	1.0	0.0	0.0	0.0	0.0
142	gene scanning of all relevant RET exons	0.16856871164621162	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-1.3333333333333321	0.04	0.04225352112676056	1.0	0.04	0.04	7.0	0.04225352112676056	0.14285714285714285	1.0	0.0	-1.3333333333333321	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04225352112676056	0.0	0.0	0.14285714285714285	0.0	0.0
44	the vector for the transmission	0.039424864733942994	-10.5	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-10.5	0.0	0.0	-9.666666666666666	0.04	0.06521739130434782	0.0	0.06896551724137931	0.06896551724137931	5.0	0.06521739130434782	0.4	1.0	0.0	-9.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.06896551724137931	0.0	0.06521739130434782	0.0	0.0	0.0	0.0	0.0
306	RECURRENT;recurrent	0.6519800255497299	-1.3000000000000007	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04232142857142857	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.044642857142857144	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	DNMT3A and DNMT3B enzymes	0.3675138666332524	0.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.25	1.0	0.0	1.0	1.0	-3.428571428571427	0.04	0.04635761589403973	1.0	0.04	0.04	4.0	0.04635761589403973	0.0	1.0	1.0	-3.428571428571427	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04	0.0	0.04635761589403973	0.0	1.0	0.25	0.0	1.0
267	genesis and symptoms of heart failure exacerbation	0.13757496648804304	0.0	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	7.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
61	functions;Functions	0.0943797958812142	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
192	The genotypes	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
276	psychomotor retardation;Psychomotor Retardation	0.8658068189648607	-2.525	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-4.959999999999999	0.04	0.04	0.0	0.043010752688172046	0.04451263661386634	2.0	0.05109002328804309	0.0	5.0	0.0	-9.6	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	10.0	0.045454545454545456	0.0	0.06493506493506493	0.0	0.0	0.0	0.0	0.0
14	Topology prediction	0.051472778215414114	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
89	Analgesic;analgesic;analgesics;ANALGESICS	0.7251879571696008	-4.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-7.0	1.0	1.0	-6.125	0.04	0.04	0.0	0.04	0.0502046783625731	1.0	0.054700460829493085	0.0	4.0	1.0	-9.5	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	4.0	1.0	4.0	0.05555555555555555	0.0	0.06451612903225806	0.0	1.0	0.0	0.0	1.0
131	EF-1-beta;EF-1-Beta	0.5711198898128478	-1.6999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-1.6999999999999993	1.0	1.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.04291845493562232	0.04291845493562232	3.0	0.044642857142857144	0.3333333333333333	2.0	1.0	-2.6000000000000014	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.04291845493562232	0.0	0.044642857142857144	0.0	1.0	0.0	0.0	1.0
39	the binding site for the adenosylmethionine methyl donor	0.062207525588905285	0.0	1.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.14285714285714285	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	8.0	0.04	0.5	1.0	1.0	0.0	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	8.0	0.04	1.0	0.04	0.0	1.0	0.125	1.0	1.0
318	Ph+) acute lymphoblastic leukemia;Ph+ acute lymphoblastic leukaemia	0.26878439981844804	-1.3333333333333321	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.3333333333333321	0.0	0.0	-7.692307692307692	0.04	0.05777777777777778	0.0	0.04225352112676056	0.04225352112676056	6.0	0.05777777777777778	0.3333333333333333	1.0	0.0	-7.692307692307692	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04225352112676056	0.0	0.05777777777777778	0.0	0.0	0.0	0.0	0.0
256	described	0.13340097378685323	-2.833333333333333	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04586206896551724	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.051724137931034475	0.0	0.04	0.0	0.0	0.0	0.0	0.0
189	immunoreactivity;I-;I;i	0.470150107910833	0.0	0.0	0.0	0.04	0.04	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.6666666666666666	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.3333333333333333	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	substantial delay	0.11769028749903916	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	0.0	0.04	0.04	0.0	0.04878048780487805	0.04878048780487805	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04878048780487805	0.0	0.04	0.0	0.0	0.0	0.0	0.0
50	RNA-seq experiments	0.02600604411299479	-9.555555555555555	1.0	-6.800000000000001	0.054945054945054944	0.054945054945054944	0.25	0.25	1.0	-6.800000000000001	1.0	1.0	-9.555555555555555	1.0	1.0	-7.199999999999999	0.054945054945054944	0.056179775280898875	0.0	0.06474820143884892	0.06474820143884892	4.0	0.056179775280898875	1.0	1.0	1.0	-7.199999999999999	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.06474820143884892	0.0	0.056179775280898875	1.0	1.0	0.0	0.0	1.0
301	radiation therapy	0.07884817754029713	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	2.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
13	X-ray free electron laser (X-FEL;x-ray free-electron laser (XFEL	0.16258050090392784	0.0	1.0	0.0	0.04	0.04	0.25	0.26785714285714285	0.0	0.0	0.5833333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	7.5	0.04	0.5357142857142857	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	15.0	0.04	0.0	0.04	0.0	0.0	0.13392857142857142	0.0	0.0
215	DNA repair protein	0.161435969786893	-4.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.04938271604938271	0.04938271604938271	3.0	0.04587155963302752	0.0	2.0	0.0	-3.1999999999999993	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04938271604938271	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
216	carbon;Carbon	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
103	[6];6)	0.5303043739280011	-0.6111111111111107	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.2222222222222214	0.0	0.0	-2.6428571428571432	0.04	0.04	0.0	0.04	0.04102803738317757	2.5	0.04536231884057971	0.25	2.0	0.0	-5.2857142857142865	1.0	0.0	0.0	0.5	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04205607476635514	0.0	0.05072463768115942	0.0	0.0	0.0	0.0	0.0
290	detrusor wall thickness	0.06614965347428858	-11.25	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.25	0.0	-11.25	0.0	0.0	-10.0	0.04	0.06666666666666667	1.0	0.07272727272727272	0.07272727272727272	3.0	0.06666666666666667	0.6666666666666666	1.0	0.0	-10.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.07272727272727272	0.0	0.06666666666666667	0.0	0.0	0.3333333333333333	0.0	0.0
72	Extracting interactions	0.10549951416075809	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
304	Bruton Tyrosine Kinase;Bruton's tyrosine kinase	0.9989334670982248	-1.4296875	1.0	-1.8571428571428577	0.04	0.04020061728395062	0.0	0.0	1.0	-0.1160714285714286	0.9583333333333334	0.0	-11.875	0.0	0.0	-1.330357142857143	0.043209876543209874	0.04	0.0	0.04	0.04345282095282096	4.0	0.04244539839533421	1.0	16.0	0.0	-3.8571428571428577	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	64.0	0.0761904761904762	0.0	0.0472972972972973	1.0	0.0	0.0	0.0	0.0
14	as;AS	0.06853316678232349	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.166666666666666	0.04	0.050420168067226885	0.0	0.04	0.04	1.0	0.050420168067226885	0.0	1.0	0.0	-5.166666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.050420168067226885	0.0	0.0	0.0	0.0	0.0
129	hemi-methylated DNA;hemimethylated DNA	0.22043257061868335	-0.75	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-2.9642857142857144	0.04	0.04	0.0	0.04	0.041279568930823234	2.0	0.04587210741792008	0.5	4.0	0.0	-6.142857142857142	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.0430622009569378	0.0	0.05303030303030303	0.0	0.0	0.0	0.0	0.0
229	public microarray cancer datasets	0.26782860435995465	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
90	the Phase II study	0.06637442787073183	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
187	cause	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	the components	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	Mice;mice	0.12945990575996694	-14.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-14.5	0.0	0.0	-8.333333333333334	0.04	0.06000000000000001	0.0	0.09523809523809523	0.09523809523809523	1.0	0.06000000000000001	0.0	2.0	0.0	-8.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.09523809523809523	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
102	the arrhythmic wheel	0.0793662226340656	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
258	Combination;combined;Combined;combination	0.05248630635192708	-3.7	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.4	0.0	0.0	-5.3	0.04	0.04	0.0	0.04	0.04840909090909091	1.0	0.05472222222222223	0.0	2.0	0.0	-10.6	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.056818181818181816	0.0	0.06944444444444445	0.0	0.0	0.0	0.0	0.0
117	various tissues of globotriaosylceramide (Gb	0.20027494225234993	-3.7142857142857153	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.7142857142857153	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.04697986577181208	0.04697986577181208	6.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04697986577181208	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
144	myocyte;Myocyte	0.6129014127844747	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.04504504504504505	0.045458302339036284	1.0	0.05405405405405406	0.0	2.0	0.0	-6.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04587155963302752	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
96	pro;Pro	0.6389088701129451	-3.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-2.5999999999999996	0.04	0.043859649122807015	0.0	0.045454545454545456	0.0459830866807611	0.0	0.044657097288676235	0.0	2.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.046511627906976744	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
102	essential components	0.11869831628550497	-4.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04938271604938271	0.04938271604938271	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04938271604938271	0.0	0.04	0.0	0.0	0.0	0.0	0.0
150	a CMA receptor	0.16046409045960752	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.5	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.3333333333333333	0.0	0.0
122	two genes in particular	0.022657969142938918	0.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.25	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	4.0	0.04	0.5	1.0	1.0	0.0	1.0	0.3333333333333333	1.0	1.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.25	0.0	1.0
215	3;3);<3	0.5634222051283244	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.700000000000001	0.04	0.04672897196261683	0.0	0.04	0.04	1.5	0.046949391641685774	0.0	2.0	0.0	-3.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	3.0	0.04	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
285	onset;Onset	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
38	Thr910Ala variant	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
83	intervention	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
217	Amine;amine	0.836763021475424	-2.875	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.375	0.0	0.0	-4.285714285714286	0.04	0.04375	0.0	0.04371584699453552	0.045281754846105894	1.0	0.04908916212515151	0.0	6.0	0.0	-8.571428571428571	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.048484848484848485	0.0	0.0608695652173913	0.0	0.0	0.0	0.0	0.0
78	Cell Lines;cell lines	0.09236852687006426	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
52	regulation;Regulation	0.10297704762030026	-5.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.5	0.0	0.0	0.0	0.04	0.04	0.0	0.05128205128205128	0.05128205128205128	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05128205128205128	0.0	0.04	0.0	0.0	0.0	0.0	0.0
75	complementation between Krabbe disease patient	0.07594933472817433	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
30	secondary structure;Secondary Structure	0.06180441802652712	-1.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6000000000000014	0.0	0.0	-7.4	0.04	0.056818181818181816	0.0	0.042735042735042736	0.042735042735042736	2.0	0.056818181818181816	0.0	1.0	0.0	-7.4	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.042735042735042736	0.0	0.056818181818181816	0.0	0.0	0.0	0.0	0.0
80	Caucasians of up to 1%	0.07299915512537664	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
247	covering	0.08781317743323842	-2.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.044117647058823525	0.044117647058823525	1.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.044117647058823525	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
47	an online tool for the determination	0.017291777477893237	-3.333333333333332	1.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.16666666666666666	0.0	-3.333333333333332	0.0	0.0	0.0	0.04	0.04	1.0	0.04615384615384615	0.04615384615384615	6.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04615384615384615	0.0	0.04	0.0	0.0	0.16666666666666666	0.0	0.0
97	myotonic dystrophy;Myotonic dystrophy;DYSTROPHY, MYOTONIC	0.14642743575056086	-5.0	1.0	-6.333333333333334	0.04	0.04678571428571429	0.0	0.0	1.0	-3.166666666666667	1.0	1.0	-10.0	0.0	0.0	-3.166666666666667	0.053571428571428575	0.04	0.0	0.04	0.05333333333333334	2.0	0.04678571428571429	1.0	4.0	0.0	-6.333333333333334	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	3.0	1.0	8.0	0.06666666666666667	0.0	0.053571428571428575	1.0	0.0	0.0	0.0	0.0
312	an HSP70 and HSP90 interacting co-chaperone	0.1408104136093504	-9.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.16666666666666666	1.0	-9.0	1.0	1.0	-10.2	0.04	0.06756756756756756	0.0	0.0625	0.0625	6.0	0.06756756756756756	0.16666666666666666	1.0	1.0	-10.2	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.0625	0.0	0.06756756756756756	0.0	1.0	0.0	0.0	1.0
79	OD;(OD	0.6857437786396716	-2.6666666666666665	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-5.833333333333333	0.04	0.04	0.0	0.04	0.04507936507936508	1.3333333333333333	0.05436868686868687	0.0	3.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.047619047619047616	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
282	using;Using	0.10505060751407336	-4.1000000000000005	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.6	0.0	0.0	-4.25	0.04	0.04	0.0	0.04672897196261683	0.047874289902877044	1.0	0.05030303030303031	0.0	2.0	0.0	-8.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04901960784313726	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
11	over;Over	0.5667032648028064	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.04	0.04	0.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
101	small-molecule inhibitors	0.09788398745736286	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.25	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	4.0	0.04	0.25	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.25	0.0	1.0
24	indigenous and non indigenous people at high cardiovascular risk	0.036610184049302115	-2.1999999999999993	0.0	0.0	0.04	0.04	0.7777777777777778	0.7777777777777778	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	-18.0	0.04	0.14285714285714285	0.0	0.043859649122807015	0.043859649122807015	9.0	0.14285714285714285	0.0	1.0	0.0	-18.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.043859649122807015	0.0	0.14285714285714285	0.0	0.0	0.0	0.0	0.0
216	Energy Integrated Field	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
290	bladder and detrusor wall thickness	0.05344463241248642	0.0	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	5.0	0.04	0.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.2	0.0	0.0
138	Signal Transduction;signal transduction	0.2648097831816699	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.625	0.04	0.0427807486631016	0.0	0.04	0.04	2.0	0.0427807486631016	0.0	2.0	0.0	-1.625	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.0427807486631016	0.0	0.0	0.0	0.0	0.0
119	nuclear bodies;Nuclear body	0.16006265132970474	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.043478260869565216	0.043478260869565216	2.0	0.04587155963302752	0.0	3.0	0.0	-3.1999999999999993	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.043478260869565216	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
168	disorder;Disorder	0.20638113314928527	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-4.25	0.0	0.0	-5.0	0.04	0.05	0.0	0.04819277108433735	0.04819277108433735	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04819277108433735	1.0	0.05	0.0	0.0	0.0	1.0	0.0
38	Novel cAMP binding protein	0.10308732026805119	-4.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.047619047619047616	0.047619047619047616	4.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.047619047619047616	0.0	0.05	0.0	0.0	0.0	0.0	0.0
155	G;g%	0.6322851238020618	-4.666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04918032786885245	0.04918032786885245	1.0	0.053571428571428575	0.0	2.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04918032786885245	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
245	open;Open	0.08714017103211491	-3.2857142857142847	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.2857142857142847	0.0	0.0	-2.1999999999999993	0.04	0.043859649122807015	0.0	0.046052631578947366	0.046052631578947366	1.0	0.043859649122807015	0.0	1.0	0.0	-2.1999999999999993	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046052631578947366	0.0	0.043859649122807015	0.0	0.0	0.0	0.0	0.0
17	ml) than those	0.1880629005599729	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04	0.04	4.0	0.04878048780487805	0.0	1.0	0.0	-4.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
29	potent;Potential	0.545881316828822	-3.166666666666668	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.04580152671755725	0.04580152671755725	1.0	0.054545454545454536	0.0	1.0	0.0	-6.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04580152671755725	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
144	directed;Direct	0.09571079213856525	-3.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.046296296296296294	0.046296296296296294	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046296296296296294	0.0	0.04	0.0	0.0	0.0	0.0	0.0
333	T';T	0.6039131868305536	-1.571428571428573	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.042682926829268296	0.042682926829268296	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.042682926829268296	0.0	0.04	0.0	0.0	0.0	0.0	0.0
223	/40;40	0.6183047952717975	-1.2727272727272734	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.2727272727272734	0.0	0.0	0.0	0.04	0.04	0.0	0.0421455938697318	0.0421455938697318	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.0421455938697318	0.0	0.04	0.0	0.0	0.0	0.0	0.0
178	enzyme-GMP intermediate	0.30322480076007946	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.25	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.25	0.0	0.0
17	significant	0.1145044042437165	-1.8333333333333321	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.043165467625899276	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.043165467625899276	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	Cryptochrome 1;CRYPTOCHROME 2;CRYPTOCHROME 1;cryptochrome 1;Cry1 and Cry2;Cryptochrome-2;Cryptochrome 1 and 2;Cry2);cryptochrome 1/2;Cry1;Cry1);Cry2;cry1;Cryptochrome-1;CRY2;CRY1;(cry1;cryptochrome-1;/Cry2	0.9999999999999818	-2.3975	1.0	-8.5	0.04	0.04041212121212121	0.0	0.0325	1.0	-0.17	0.9858333333333333	1.0	-9.75	1.0	1.0	-0.18	0.06060606060606061	0.04	0.0	0.04	0.04486197079613749	1.58	0.04045	0.05	100.0	1.0	-9.0	1.0	0.6666666666666666	0.0	0.05	0.0	1.0	1.0	0.6666666666666666	0.6666666666666665	19.0	1.0	158.0	0.06557377049180328	0.0	0.0625	1.0	1.0	0.0	0.0	1.0
125	known;Known	0.10557247514320854	-3.166666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04678571428571429	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.053571428571428575	0.0	0.04	0.0	0.0	0.0	0.0	0.0
11	Which species	0.00736127179792771	-14.833333333333332	1.0	-10.666666666666666	0.06976744186046512	0.06976744186046512	1.0	1.0	1.0	-10.666666666666666	1.0	0.0	-14.833333333333332	0.0	0.0	-9.0	0.06976744186046512	0.0625	1.0	0.0983606557377049	0.0983606557377049	2.0	0.0625	1.0	2.0	0.0	-9.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.0983606557377049	0.0	0.0625	1.0	0.0	0.5	0.0	0.0
79	an excellent antidote for benzodiazepine overdose	0.0975618330238469	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.25	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.6666666666666666	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
343	relatively low affinity of the individual SPRY domains	0.02591538832996011	0.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.125	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
321	Fitting;fitting	0.05081746099294185	-3.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-15.0	0.04	0.1	0.0	0.04587155963302752	0.04587155963302752	1.0	0.1	0.0	1.0	0.0	-15.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04587155963302752	0.0	0.1	0.0	0.0	0.0	0.0	0.0
25	71.4% of the treated participants	0.0991100821260222	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.04	0.04	6.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
259	their better survival rates	0.0884415052403157	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	Revealed;revealed	0.09945790750549682	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	0.0	0.04	0.04	0.0	0.04878048780487805	0.04878048780487805	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04878048780487805	0.0	0.04	0.0	0.0	0.0	0.0	0.0
215	telomerase;Telomerase	0.7056756442708898	-6.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-6.75	1.0	1.0	-6.4	0.04	0.05376344086021505	0.0	0.0547945205479452	0.0547945205479452	1.0	0.05376344086021505	0.0	2.0	1.0	-6.4	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	2.0	0.0547945205479452	0.0	0.05376344086021505	0.0	1.0	0.0	0.0	1.0
96	the disease period	0.05267714337970258	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.3333333333333333	0.0	0.0
6	the medical records	0.1583361509225394	-1.8888888888888893	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	0.0	0.04	0.04	0.0	0.04326923076923077	0.04326923076923077	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04326923076923077	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	Protein Phosphorylation;phosphorylation of a given protein	0.28259219469041685	-2.0999999999999996	0.0	0.0	0.04	0.04	0.5	0.65	0.0	0.0	0.0	0.0	-2.8999999999999986	0.0	0.0	-4.5	0.04	0.045454545454545456	0.0	0.04219409282700422	0.043721480802642376	3.5	0.04904306220095694	0.45	4.0	0.0	-6.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	14.0	0.04524886877828054	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
14	scale;Scale, NOS	0.06345914824668802	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.04	0.04	1.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
102	regulator;Regulator;regulators	0.10313879436720975	-1.4166666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04273092369477912	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	3.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
218	systematic	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
125	proximal;PROXIMAL	0.6460156637878214	-3.166666666666667	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04678571428571429	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.053571428571428575	0.0	0.04	0.0	0.0	0.0	0.0	0.0
208	PHENYTOIN;phenytoin	0.5643947700361456	-3.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.047058823529411764	0.047058823529411764	1.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047058823529411764	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
329	data base;database;base of available experimental data;Database	0.07796796944351285	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
137	Real;real	0.08502450761592693	-1.7777777777777786	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-1.5	0.04	0.0425531914893617	0.0	0.0430622009569378	0.0430622009569378	1.0	0.0425531914893617	0.0	1.0	0.0	-1.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0430622009569378	0.0	0.0425531914893617	0.0	0.0	0.0	0.0	0.0
25	the effects of a modified;the modified	0.06502025263039986	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
128	at least several genes	0.13193036697555843	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	1.0	0.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
20	Active;active	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
286	purpose;purposes;Purpose	0.0868068106467973	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
258	regulation;Regulation	0.08309336917915155	-3.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04716981132075472	0.04716981132075472	1.0	0.04716981132075472	0.0	1.0	0.0	-3.8000000000000007	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04716981132075472	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
83	Group 3;group 3	0.20146510080365157	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
155	one family	0.10102773884428821	-3.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	-2.666666666666668	0.04	0.04477611940298508	0.0	0.04580152671755725	0.04580152671755725	2.0	0.04477611940298508	0.0	1.0	0.0	-2.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04580152671755725	0.0	0.04477611940298508	0.0	0.0	0.0	0.0	0.0
186	I(ks) (SQT2) and KCNJ2 for I(k1) (SQT3)	0.39667584420242397	0.0	0.0	0.0	0.04	0.04	0.23529411764705882	0.23529411764705882	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	17.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	17.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
298	Typical NTIS	0.05309538362722049	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
331	negative regulator	0.12667702936462114	-6.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.054545454545454536	0.054545454545454536	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.054545454545454536	0.0	0.04	0.0	0.0	0.0	0.0	0.0
75	Fold;fold	0.6316985367701653	-2.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0449438202247191	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	the success of protein	0.04580344068684378	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.045454545454545456	0.045454545454545456	4.0	0.05263157894736842	0.25	1.0	0.0	-6.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.045454545454545456	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
331	the key recombinase in HR	0.228462092954257	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
143	development	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
300	function gene;functions as a repressor of gene	0.02950497974746102	0.0	1.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.6666666666666666	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
257	Revealed;revealed	0.06951326081481611	-7.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.333333333333334	0.0	0.0	-11.142857142857142	0.04	0.07216494845360824	0.0	0.05660377358490567	0.05660377358490567	1.0	0.07216494845360824	0.0	1.0	0.0	-11.142857142857142	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05660377358490567	0.0	0.07216494845360824	0.0	0.0	0.0	0.0	0.0
242	risk stratification and management of patients	0.020814721304228255	-1.8888888888888893	1.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.14285714285714285	0.0	-1.8888888888888893	0.0	0.0	0.0	0.04	0.04	0.0	0.04326923076923077	0.04326923076923077	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04326923076923077	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	the major histocompatibility complex HLA-B*5701 allele	0.2478763548966058	-6.0	0.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.05263157894736842	0.05263157894736842	8.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.05263157894736842	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
91	anxiety management;management of child anxiety	0.04497994608751568	-2.2857142857142847	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.2857142857142847	0.0	0.0	0.0	0.04	0.04	0.0	0.0440251572327044	0.0440251572327044	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.0440251572327044	0.0	0.04	0.0	0.0	0.0	0.0	0.0
163	monitor	0.12328186590527837	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
293	the prevalence and medication use	0.04366222398827446	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.2	0.0	0.0
238	acutely	0.581590164926276	-2.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	-8.666666666666666	0.04	0.06122448979591836	0.0	0.044444444444444446	0.044444444444444446	1.0	0.06122448979591836	0.0	1.0	0.0	-8.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.044444444444444446	0.0	0.06122448979591836	0.0	0.0	0.0	0.0	0.0
15	a system for automatic PPI detection	0.0491688633403706	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.25	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
330	Pre-clinical;preclinical;Preclinical	0.5462749138150246	-2.1111111111111107	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.222222222222221	0.0	0.0	-3.8125	0.04	0.045714285714285714	0.0	0.04	0.044064171122994655	1.0	0.047247386759581886	0.0	2.0	0.0	-4.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.0481283422459893	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
13	the door	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
89	2 to 16 years	0.24578296406867936	-3.6000000000000014	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.04672897196261683	0.04672897196261683	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04672897196261683	0.0	0.04	0.0	0.0	0.0	0.0	0.0
249	dpi	0.6167805750699545	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.04	0.04	1.0	0.04597701149425287	0.0	1.0	0.0	-3.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
52	the presence of D3 mRNA	0.15898064341854684	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	the native enzyme acetylcholinesterase (AChE	0.29956052836315394	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	array comparative genomic hybridization;Array Comparative Genomic Hybridization	0.3343947422312221	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	ADME	0.5871932892548255	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
47	non;Non	0.6531703502019017	-5.166666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.166666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.050420168067226885	0.050420168067226885	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.050420168067226885	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	the CYP2C9 (Cytochrome P450 2C9) and VKORC1 (Vitamin K	0.4287912326370408	-3.5	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	-3.5	1.0	1.0	-7.0	0.04	0.05555555555555555	0.0	0.046511627906976744	0.046511627906976744	12.0	0.05555555555555555	0.0	1.0	1.0	-7.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	12.0	0.046511627906976744	1.0	0.05555555555555555	0.0	1.0	0.0	1.0	1.0
129	three major DNA methyltransferases	0.1110733089153429	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-7.428571428571429	0.04	0.05691056910569106	0.0	0.04	0.04	4.0	0.05691056910569106	0.25	1.0	0.0	-7.428571428571429	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04	0.0	0.05691056910569106	0.0	0.0	0.0	0.0	0.0
38	% total;total	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
40	results;Result	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	metazoan nucleoporins	0.4164939722787993	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.5	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.5	0.0	0.0
241	Surgically;surgically	0.6214117162482886	-1.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	-3.0999999999999996	0.04	0.04	0.0	0.04	0.042222222222222223	1.0	0.046595744680851064	0.0	2.0	0.0	-6.199999999999999	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.044444444444444446	0.0	0.05319148936170213	0.0	0.0	0.0	0.0	0.0
128	thought;Thought	0.07529704722780727	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.90909090909091	0.04	0.04526748971193416	0.0	0.04	0.04	1.0	0.04526748971193416	0.0	1.0	0.0	-2.90909090909091	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04526748971193416	0.0	0.0	0.0	0.0	0.0
66	Bowel;bowel	0.15311848114435575	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	1.0	3.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	1.0	0.0	0.0	0.0	0.0
137	multiple sclerosis patients	0.015042617322721453	-2.1111111111111107	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.4	0.0	-2.1111111111111107	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.043689320388349516	0.043689320388349516	3.0	0.06060606060606061	0.6666666666666666	1.0	0.0	-8.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043689320388349516	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
165	the history of H1N1 influenza replication	0.1760821772384391	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
41	The histone tail inserts as a beta strand	0.2214704904418728	-7.5	0.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.0	1.0	-7.5	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.05714285714285714	0.05714285714285714	8.0	0.046875	0.125	1.0	0.0	-3.666666666666668	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.05714285714285714	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
170	cause	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
322	three;Three	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
235	a preexisting genetic susceptibility	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	deoxycytidine analogues	0.575106525152481	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.04	0.04	2.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
154	a rare arrythmogenic disease	0.12484253559924796	-5.181818181818182	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	-5.181818181818182	0.0	0.0	-11.2	0.04	0.07246376811594203	0.0	0.05045871559633027	0.05045871559633027	4.0	0.07246376811594203	0.0	1.0	0.0	-11.2	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.05045871559633027	0.0	0.07246376811594203	0.0	0.0	0.0	0.0	0.0
258	acetylated histone H4	0.6844702530881854	-7.199999999999999	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-7.199999999999999	0.0	0.0	-6.6	0.04	0.05434782608695653	0.0	0.056179775280898875	0.056179775280898875	3.0	0.05434782608695653	0.3333333333333333	2.0	0.0	-6.6	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.056179775280898875	0.0	0.05434782608695653	0.0	0.0	0.0	0.0	0.0
66	elevated maternal serum alpha-fetoprotein;Elevated maternal serum alpha-fetoprotein	0.5242636545968602	-2.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	0.0	0.04	0.04	0.0	0.044444444444444446	0.044444444444444446	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.044444444444444446	0.0	0.04	0.0	0.0	0.0	0.0	0.0
256	allowed	0.0915143095098061	-4.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.04918032786885245	0.04918032786885245	1.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04918032786885245	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
14	Sopma);Sopma	0.6641753767711227	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.5	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
305	mutations in the gene	0.055910701416715856	-1.8571428571428577	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-1.8571428571428577	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.043209876543209874	0.043209876543209874	4.0	0.051724137931034475	0.25	1.0	0.0	-5.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.043209876543209874	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
317	exposure to imetelstat	0.03581950993142455	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
66	1.5%), bowel abnormality	0.48708466922839816	-1.8333333333333321	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.043165467625899276	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.043165467625899276	0.0	0.04	0.0	0.0	0.0	0.0	0.0
251	morphology;Morphology	0.5491591038681916	-1.4444444444444429	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.4444444444444429	0.0	0.0	-4.888888888888889	0.04	0.049723756906077346	0.0	0.04245283018867924	0.04245283018867924	1.0	0.049723756906077346	0.0	1.0	0.0	-4.888888888888889	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04245283018867924	0.0	0.049723756906077346	0.0	0.0	0.0	0.0	0.0
267	monitor;monitored	0.022532079946894785	-1.2857142857142865	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04229299363057325	1.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	1.0	0.5	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.0445859872611465	0.0	0.04	1.0	0.0	0.0	0.0	0.0
203	paternal chromosome 15	0.6508408618193768	-3.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	0.0	0.04	0.04	0.0	0.047058823529411764	0.047058823529411764	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.047058823529411764	0.0	0.04	0.0	0.0	0.0	0.0	0.0
233	Programs;programs	0.09006219608192875	-1.6666666666666679	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6666666666666679	0.0	0.0	0.0	0.04	0.04	0.0	0.04285714285714286	0.04285714285714286	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04285714285714286	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	pancreatic, pituitary, and parathyroid tumors	0.27226165774146305	0.0	1.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.125	1.0	0.0	1.0	1.0	-3.3999999999999986	0.04	0.046296296296296294	1.0	0.04	0.04	7.0	0.046296296296296294	0.14285714285714285	1.0	1.0	-3.3999999999999986	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	7.0	0.04	1.0	0.046296296296296294	0.0	1.0	0.14285714285714285	1.0	1.0
239	MMD risk	0.3150445295387198	-2.333333333333332	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.044117647058823525	0.044117647058823525	2.0	0.047619047619047616	0.0	2.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.044117647058823525	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
293	psychotherapy\behavior therapy for rapid ejaculation	0.16982768102642146	-10.75	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-10.75	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.07017543859649122	0.07017543859649122	5.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.07017543859649122	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
100	A-DNA;a covalent complex with DNA	0.06008174537184056	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-3.333333333333332	0.04	0.04615384615384615	0.0	0.04	0.04	5.0	0.04615384615384615	0.2	1.0	0.0	-3.333333333333332	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	5.0	0.04	0.0	0.04615384615384615	0.0	0.0	0.0	0.0	0.0
104	GRAIL2	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
127	60-70%) to EGFR tyrosine kinase inhibitors	0.5917277435522652	-2.833333333333332	0.0	0.0	0.04	0.04	0.14285714285714285	0.14285714285714285	0.0	0.0	0.0	1.0	-2.833333333333332	1.0	1.0	0.0	0.04	0.04	0.0	0.045112781954887216	0.045112781954887216	7.0	0.04	0.14285714285714285	1.0	1.0	0.0	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	7.0	0.045112781954887216	1.0	0.04	0.0	1.0	0.0	1.0	1.0
41	multiple ARK(S/T) motifs	0.4331021793222318	0.0	0.0	0.0	0.04	0.04	0.125	0.125	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-5.0	0.04	0.05	0.0	0.04	0.04	8.0	0.05	0.0	1.0	1.0	-5.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.05	0.0	1.0	0.0	0.0	1.0
56	EoE. OVB	0.6171953679194666	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
175	16 female members [81%]) and periodic paralysis (10	0.3201246986674788	0.0	0.0	0.0	0.04	0.04	0.2727272727272727	0.2727272727272727	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	11.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	11.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
132	receptor;Receptor	0.5836889916485597	-8.7	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-11.0	0.0	0.0	-11.666666666666668	0.04	0.07317073170731708	0.0	0.05376344086021505	0.06259600614439323	1.0	0.075046904315197	0.0	2.0	0.0	-12.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.07142857142857142	0.0	0.07692307692307693	0.0	0.0	0.0	0.0	0.0
13	opens;open;Open	0.0868068106467973	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
77	tolcapone in Parkinson	0.34600714816249717	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
41	Plant;plants;plant;Plants	0.12869360370039004	-4.9	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-9.5	0.0	0.0	-2.4	0.04	0.04	0.0	0.04	0.052062861869313484	1.0	0.045052631578947365	0.0	5.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	5.0	0.06451612903225806	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
108	Alternative;alternative	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
302	halo;Halo	0.5652319844921083	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04	0.04	0.0	0.04716981132075472	0.0	1.0	0.0	-3.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
28	GAD	0.8883542610132342	-4.555555555555556	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.04895076674737692	0.8333333333333334	0.04	0.0	6.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.05084745762711865	0.0	0.04	0.0	0.0	0.0	0.0	0.0
62	a mean	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
324	generations;Generations	0.09056621469221923	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.04	0.0	0.04	0.04	1.0	0.05333333333333332	0.0	2.0	0.0	-10.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
100	the 5-azacytidine effects on DNA and RNA synthesis	0.09913159506219821	-3.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.1111111111111111	1.0	-3.0	1.0	1.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	10.0	0.04	0.3	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	10.0	0.045454545454545456	0.0	0.04	0.0	1.0	0.0	0.0	1.0
189	fluorescence in situ hybridization;Fluorescence in Situ Hybridization	0.34836375177625295	-6.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.05263157894736842	0.05263157894736842	4.0	0.05714285714285714	0.25	2.0	0.0	-7.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.05263157894736842	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
294	medications;Medications	0.17474090157335903	-5.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-5.5	1.0	1.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.05128205128205128	0.05128205128205128	1.0	0.053571428571428575	0.0	1.0	1.0	-6.333333333333334	1.0	1.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	2.0	1.0	1.0	0.05128205128205128	1.0	0.053571428571428575	0.0	1.0	0.0	1.0	1.0
156	hemochromatosis;HEMOCHROMATOSIS	0.8044449496756574	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-4.25	0.04	0.04597701149425287	0.0	0.04	0.04	1.0	0.04824748119767277	0.0	3.0	0.0	-4.75	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	3.0	0.04	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
66	Echogenic bowel coexistent	0.13609126872713453	-2.833333333333332	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.5	0.0	-2.833333333333332	0.0	0.0	-5.75	0.04	0.05194805194805195	0.0	0.045112781954887216	0.045112781954887216	3.0	0.05194805194805195	0.6666666666666666	1.0	0.0	-5.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.045112781954887216	0.0	0.05194805194805195	0.0	0.0	0.0	0.0	0.0
113	The 15 human and 24 mouse kallikreins	0.13197850650818488	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.2857142857142857	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
40	rearrangement-based phylogenetic analysis	0.18916618552744635	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
307	's disease and dementia	0.21096337301140927	-4.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.047619047619047616	0.047619047619047616	4.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.047619047619047616	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
48	Observed;observed	0.07885540855954787	-6.375	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.375	0.0	0.0	-7.2857142857142865	0.04	0.056451612903225805	0.0	0.053691275167785234	0.053691275167785234	1.0	0.056451612903225805	0.0	1.0	0.0	-7.2857142857142865	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.053691275167785234	0.0	0.056451612903225805	0.0	0.0	0.0	0.0	0.0
149	the expression of these myomiRs	0.08848691453375389	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
204	chromosome region 4p16.3;4p16.3 chromosome	0.6110057405264401	-4.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-4.0	0.0	0.0	-9.0	0.04	0.0625	0.0	0.047619047619047616	0.047619047619047616	3.0	0.0625	0.0	3.0	0.0	-9.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	9.0	0.047619047619047616	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
40	Uncertainty;uncertainty	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
216	IFC) site	0.2978327784755477	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	3.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
194	RECOVERY;recovery	0.05957043663626119	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.04	0.04	1.0	0.06060606060606061	0.0	1.0	0.0	-8.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
319	models;Model;model;Models	0.044554213001043196	-7.888888888888888	1.0	-17.5	0.04	0.0711111111111111	0.0	0.6666666666666666	1.0	-5.833333333333333	1.0	0.0	-14.5	0.0	0.0	-13.333333333333334	0.13333333333333333	0.06666666666666667	0.0	0.045454545454545456	0.06459666194179468	0.6666666666666666	0.11111111111111112	0.6666666666666666	3.0	0.0	-20.0	1.0	0.0	0.6666666666666666	0.6666666666666666	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.09523809523809523	0.0	0.2	1.0	0.0	0.0	0.0	0.0
15	a web-based application providing access to a comprehensively annotated version	0.05455178721514525	-1.3999999999999986	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-1.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.0423728813559322	0.0423728813559322	12.0	0.04	0.08333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	12.0	0.0423728813559322	0.0	0.04	0.0	0.0	0.0	0.0	0.0
203	screening test	0.11471062143466125	-3.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	0.0	0.04	0.04	0.0	0.047058823529411764	0.047058823529411764	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047058823529411764	0.0	0.04	0.0	0.0	0.0	0.0	0.0
203	chromosome 15 uniparental disomy;Chromosome 15 uniparental disomy	0.6912699495653913	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.3000000000000007	0.04	0.04	0.0	0.04	0.04	4.0	0.04232142857142857	0.0	2.0	0.0	-2.6000000000000014	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.04	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
20	the protein Cep135	0.007348264868794557	-4.75	1.0	-9.5	0.06451612903225806	0.06451612903225806	0.6666666666666666	0.6666666666666666	1.0	-9.5	1.0	1.0	-4.75	0.0	0.0	-10.0	0.06451612903225806	0.06666666666666667	1.0	0.04938271604938271	0.04938271604938271	3.0	0.06666666666666667	1.0	1.0	0.0	-10.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04938271604938271	0.0	0.06666666666666667	1.0	0.0	0.3333333333333333	0.0	0.0
47	edu;EDU	0.8704218395556754	-1.3095238095238098	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04238723108952117	0.0	0.04	0.0	7.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	0.0	0.04580152671755725	0.0	0.04	0.0	0.0	0.0	0.0	0.0
104	YACOP parses	0.7268739028102027	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
63	infliximab (INF) and adalimumab (ADA)	0.5798784858364182	-9.0	0.0	0.0	0.04	0.04	0.1111111111111111	0.1111111111111111	0.0	0.0	0.0	1.0	-9.0	1.0	1.0	-9.0	0.04	0.0625	0.0	0.0625	0.0625	9.0	0.0625	0.0	1.0	1.0	-9.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	9.0	0.0625	0.0	0.0625	0.0	1.0	0.0	0.0	1.0
345	contain	0.11359231025382059	-1.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.042735042735042736	0.042735042735042736	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.042735042735042736	0.0	0.04	0.0	0.0	0.0	0.0	0.0
25	account	0.08084633458897826	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.04	0.04	1.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
101	specific inhibitor	0.10732914473190366	-3.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	1.0	0.046511627906976744	0.046511627906976744	2.0	0.048387096774193554	0.5	1.0	0.0	-4.333333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.046511627906976744	0.0	0.048387096774193554	0.0	0.0	0.5	0.0	0.0
125	deletion;Deletion	0.6321712230487025	-4.666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.04918032786885245	0.04918032786885245	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04918032786885245	0.0	0.04	0.0	0.0	0.0	0.0	0.0
319	further refinement	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
120	polyglutamine	0.8325329594369599	-2.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.1999999999999993	1.0	1.0	0.0	0.04	0.04	0.0	0.043859649122807015	0.043859649122807015	1.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	0.043859649122807015	1.0	0.04	0.0	1.0	0.0	1.0	1.0
26	secretion	0.7100982839409137	-0.7857142857142865	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04134146341463415	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.042682926829268296	0.0	0.04	0.0	0.0	0.0	0.0	0.0
238	randomized trial	0.11050950804903742	-3.666666666666668	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.666666666666668	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.046875	0.046875	2.0	0.043478260869565216	0.5	1.0	0.0	-2.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.046875	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
79	consideration;Consideration	0.07046974704668095	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04	0.04	1.0	0.04878048780487805	0.0	1.0	0.0	-4.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
140	PTMs previously undetectable with bottom	0.228462092954257	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
101	DOT1L inhibitors	0.23697824731472905	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.5	0.0	0.0
294	use of;Use of	0.08943808721679036	-3.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.04615384615384615	0.04615384615384615	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04615384615384615	0.0	0.04	0.0	0.0	0.0	0.0	0.0
76	screening for depression;Screening for depression;for depression screening	0.010645334725791652	-5.805555555555556	1.0	-17.0	0.04	0.06833333333333334	1.0	1.0	1.0	-5.666666666666667	0.8333333333333334	0.0	-13.25	0.0	0.0	-6.0	0.125	0.04	0.0	0.04285714285714286	0.05746932342677024	3.0	0.07428571428571429	1.0	3.0	0.0	-18.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	9.0	0.0851063829787234	0.0	0.14285714285714285	1.0	0.0	0.0	0.0	0.0
4	MEN I patients	0.11522276798105215	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.25	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
84	1.83) and epilepsy/seizures (2.24, 95% CI 1.60 to 3.15)	0.29392753187058357	0.0	0.0	0.0	0.04	0.04	0.125	0.125	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	16.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	16.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
293	Prescription;prescription;prescriptions;Prescriptions	0.10349109462660781	-2.1875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-2.0	0.04	0.04	0.0	0.04	0.04424331472230385	1.0	0.04470588235294118	0.0	4.0	0.0	-8.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	4.0	0.04878048780487805	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
318	considered	0.09329467842518455	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-5.23076923076923	0.04	0.05058365758754864	0.0	0.043478260869565216	0.043478260869565216	1.0	0.05058365758754864	0.0	1.0	0.0	-5.23076923076923	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.043478260869565216	0.0	0.05058365758754864	0.0	0.0	0.0	0.0	0.0
88	stem cell transcription factor;Stem Cell Factor	0.22019306378420925	-5.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	-5.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.05	0.05	4.0	0.05263157894736842	0.0	2.0	0.0	-6.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	8.0	0.05	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
93	a consequence	0.09593381635036272	-5.166666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.166666666666666	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.050420168067226885	0.050420168067226885	2.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.050420168067226885	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
256	identification;Identification	0.06758346897318977	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.04	0.04	1.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
129	DNA demethylation	0.21763911248024423	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	3.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
195	Which	0.005473816448112247	-16.75	1.0	-6.333333333333334	0.053571428571428575	0.053571428571428575	1.0	1.0	1.0	-6.333333333333334	1.0	0.0	-16.75	0.0	0.0	-5.0	0.053571428571428575	0.05	0.0	0.12121212121212122	0.12121212121212122	1.0	0.05	1.0	1.0	0.0	-5.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.12121212121212122	0.0	0.05	1.0	0.0	0.0	0.0	0.0
16	profiling;profile;profiles;Profile	0.35183142804319884	-0.7575757575757578	0.0	0.0	0.04	0.04	0.0	0.6666666666666666	0.0	0.0	0.0	0.0	-1.2727272727272734	0.0	0.0	-2.6666666666666665	0.04	0.04	0.0	0.04	0.04127075351213282	1.0	0.04627450980392157	0.0	3.0	0.0	-8.0	1.0	0.0	0.6666666666666666	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.0421455938697318	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
216	the organisms in the family Geobacteraceae	0.06575405386500124	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
49	neurodevelopmental disorder;Neurodevelopmental Disorder	0.015025269354585168	-8.3125	1.0	-7.6	0.04	0.04873563218390805	0.5	0.5	1.0	-3.8	1.0	0.0	-12.375	0.0	0.0	-4.0	0.0574712643678161	0.04	1.0	0.04819277108433735	0.06370034593820828	2.0	0.04941176470588235	1.0	2.0	0.0	-8.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.07920792079207921	0.0	0.058823529411764705	1.0	0.0	0.5	0.0	0.0
131	cumulative database	0.2277256618499362	-1.6999999999999993	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.6999999999999993	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04291845493562232	0.04291845493562232	2.0	0.04716981132075472	0.0	1.0	0.0	-3.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04291845493562232	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
103	domain;Domain	0.09877230872885301	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.642857142857144	0.04	0.0445859872611465	0.0	0.04	0.04	1.0	0.04472889106647068	0.0	2.0	0.0	-2.7142857142857153	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04487179487179487	0.0	0.0	0.0	0.0	0.0
127	3;<3;3]	0.6037376978604453	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.5	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	man;Man	0.09681358565278671	-16.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-16.5	0.0	0.0	-11.0	0.04	0.07142857142857142	0.0	0.11764705882352941	0.11764705882352941	1.0	0.07142857142857142	0.0	1.0	0.0	-11.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.11764705882352941	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0
127	exon 21	0.8590810765825182	-2.083333333333333	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.166666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.044	2.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.047999999999999994	0.0	0.04	0.0	0.0	0.0	0.0	0.0
83	a significant determinant of the pharmacodynamic effects	0.08134679860473049	-5.0	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.05	0.05	7.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.05	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
26	(age;age;AGE	0.22249432516004392	-4.857142857142858	0.0	0.0	0.04	0.04	0.5	0.75	0.0	0.0	0.0	0.0	-4.857142857142858	0.0	0.0	0.0	0.04	0.04	0.0	0.04964539007092199	0.04964539007092199	1.5	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.5	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	3.0	0.04964539007092199	0.0	0.04	0.0	0.0	0.0	0.0	0.0
331	larger tumor size	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	template-based methods	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
339	Rapidly;rapidly	0.08425352195552505	-2.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-2.1999999999999993	0.04	0.043859649122807015	0.0	0.044117647058823525	0.044117647058823525	1.0	0.043859649122807015	0.0	1.0	0.0	-2.1999999999999993	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.044117647058823525	0.0	0.043859649122807015	0.0	0.0	0.0	0.0	0.0
15	PPI-related sentences from documents	0.07179027159718268	-1.1999999999999993	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.14285714285714285	1.0	-1.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04201680672268907	0.04201680672268907	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04201680672268907	0.0	0.04	0.0	0.0	0.0	0.0	0.0
241	the sacrum or ilium	0.25094304051692007	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
246	target proteins for the drug;drug target	0.07389244724341681	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
287	Aurora A inhibition	0.3535222827468276	-2.1999999999999993	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	1.0	0.043859649122807015	0.043859649122807015	3.0	0.04	0.3333333333333333	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.043859649122807015	0.0	0.04	0.0	0.0	0.3333333333333333	0.0	0.0
256	To;TO	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
89	oral route	0.1133427152386913	-3.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.046296296296296294	0.046296296296296294	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.046296296296296294	0.0	0.04	0.0	0.0	0.0	0.0	0.0
179	1)-Tsc2 in the TOR (target	0.20652695159416534	-5.333333333333334	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-5.333333333333334	0.0	0.0	-14.4	0.04	0.09433962264150944	0.0	0.05084745762711865	0.05084745762711865	9.0	0.09433962264150944	0.1111111111111111	1.0	0.0	-14.4	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.05084745762711865	0.0	0.09433962264150944	0.0	0.0	0.0	0.0	0.0
24	comparison with amlodipine (5–10 mg) plus TLC	0.2562130401173304	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
185	53%	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
125	the phosphoinositide phosphatase myotubularin	0.4263455919807033	-6.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	-6.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05263157894736842	0.05263157894736842	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.05263157894736842	0.0	0.04	0.0	0.0	0.0	0.0	0.0
178	K+;K	0.6215159245475167	-1.625	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.625	0.0	0.0	0.0	0.04	0.04	0.0	0.0427807486631016	0.0427807486631016	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.0427807486631016	0.0	0.04	0.0	0.0	0.0	0.0	0.0
163	antioxidant vitamin E to athletes	0.04809279589730593	0.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.4444444444444444	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	5.0	0.04	0.4	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	1.0	0.2	0.0	1.0
100	led;LED	0.07553433605392222	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.04	0.045112781954887216	0.0	0.04	0.04	1.0	0.045112781954887216	0.0	1.0	0.0	-2.833333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.045112781954887216	0.0	0.0	0.0	0.0	0.0
278	the main defects of the HNPCC (hereditary	0.08093408989808458	-3.5	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.14285714285714285	0.0	-3.5	0.0	0.0	0.0	0.04	0.04	0.0	0.046511627906976744	0.046511627906976744	8.0	0.04	0.125	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.046511627906976744	0.0	0.04	0.0	0.0	0.0	0.0	0.0
116	these drugs	0.041831373405131954	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.5	0.0	0.0
156	synthesis;Synthesis	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	an;AN	0.801461992758371	-1.5666666666666664	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-2.3	0.04	0.04	0.0	0.04	0.04280423686954613	1.0	0.04436801752464403	0.0	5.0	0.0	-4.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.045112781954887216	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
160	this molecule	0.10140298260574158	-2.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-1.8571428571428577	0.04	0.043209876543209874	0.0	0.044117647058823525	0.044117647058823525	2.0	0.043209876543209874	0.0	1.0	0.0	-1.8571428571428577	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.044117647058823525	0.0	0.043209876543209874	0.0	0.0	0.0	0.0	0.0
13	Inject;injected	0.6702214230437574	-9.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-9.0	0.0	0.0	0.0	0.04	0.04	0.0	0.0625	0.0625	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0625	0.0	0.04	0.0	0.0	0.0	0.0	0.0
317	the bulk tumor cells	0.04885177327936736	-3.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04587155963302752	0.04587155963302752	4.0	0.04918032786885245	0.25	1.0	0.0	-4.666666666666666	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04587155963302752	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
344	Regulation of Gene Expression;regulation of gene expression	0.06954445570481105	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	Movement;movement	0.10568831434589065	-6.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.25	0.0	0.0	0.0	0.04	0.04	0.0	0.05333333333333334	0.05333333333333334	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05333333333333334	0.0	0.04	0.0	0.0	0.0	0.0	0.0
159	poorly;Poorly	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
213	the KCNQ1 gene	0.17051679440876724	-2.666666666666667	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-5.333333333333334	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04542372881355933	3.0	0.04	0.3333333333333333	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.05084745762711865	0.0	0.04	0.0	1.0	0.3333333333333333	0.0	1.0
10	epithelial;Epithelial	0.543572945125966	-1.571428571428573	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.571428571428573	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.042682926829268296	0.042682926829268296	1.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.042682926829268296	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
96	treatment of primary;First-Line Treatment;first-line medical treatment;primary treatment	0.07885070621648115	-1.625	0.0	0.0	0.04	0.04	0.8	0.9	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-4.9	0.04	0.04	0.0	0.04	0.04298850574712644	4.0	0.05289473684210526	0.0	2.0	0.0	-9.8	1.0	0.0	0.5	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	8.0	0.04597701149425287	0.0	0.06578947368421052	0.0	0.0	0.0	0.0	0.0
107	software;Software	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
203	a human genetic disorder	0.07615384836191483	-3.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-3.75	0.0	0.0	-4.6	0.04	0.04901960784313726	0.0	0.047058823529411764	0.047058823529411764	4.0	0.04901960784313726	0.25	1.0	0.0	-4.6	1.0	0.3333333333333333	1.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.047058823529411764	0.0	0.04901960784313726	0.0	0.0	0.0	0.0	0.0
160	osteoclast formation	0.3178073435621982	-2.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-3.428571428571427	0.04	0.04635761589403973	0.0	0.043478260869565216	0.043478260869565216	2.0	0.04635761589403973	0.0	2.0	0.0	-3.428571428571427	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.043478260869565216	0.0	0.04635761589403973	0.0	0.0	0.0	0.0	0.0
75	less than;Less Than	0.09156086948925596	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
137	Venous stent;venous stent	0.44056086277309287	-1.6666666666666679	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.6666666666666679	0.0	0.0	0.0	0.04	0.04	0.0	0.04285714285714286	0.04285714285714286	2.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04285714285714286	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	Smith-Magenis syndrome and Moyamoya disease in a patient	0.0411439610769651	0.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.2222222222222222	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.3	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
61	protein-1 light chain 3A (MAP1LC3A), MAP1LC3B, MAP1LC3C, GABA	0.4029982717599662	-2.8000000000000007	0.0	0.0	0.04	0.04	0.15384615384615385	0.15384615384615385	0.0	0.0	0.0	1.0	-2.8000000000000007	1.0	1.0	0.0	0.04	0.04	0.0	0.04504504504504505	0.04504504504504505	13.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	13.0	0.04504504504504505	0.0	0.04	0.0	1.0	0.0	0.0	1.0
73	entire genomes	0.20248779099856298	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04	0.04	2.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
84	those whose sedative property	0.16182494360968655	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	multiple endocrine tumors	0.024828887966978522	-1.625	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.625	0.0	0.0	0.0	0.04	0.04	1.0	0.0427807486631016	0.0427807486631016	3.0	0.04	1.0	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.0427807486631016	0.0	0.04	1.0	0.0	0.3333333333333333	0.0	0.0
178	methylation;Methylation	0.7971718700342308	-1.125	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.125	0.0	0.0	-2.8666666666666663	0.04	0.04	0.0	0.04	0.041951947263422676	1.0	0.04578056426332288	0.0	5.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04371584699453552	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
175	abnormal QT-U complex	0.4175122847513681	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
319	a hit list	0.11858912668535745	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	1.0	0.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
207	the use	0.004568827951072829	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-12.333333333333332	0.04	0.07894736842105263	0.0	0.04	0.04	2.0	0.07894736842105263	1.0	1.0	0.0	-12.333333333333332	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.07894736842105263	1.0	0.0	0.0	0.0	0.0
256	Pro 250	0.3699386730264902	-4.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
322	Set1A complex	0.34576694794742524	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.04	0.04	2.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
230	form;Form	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	anticancer drug target	0.0852940573019331	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.3333333333333333	0.0	0.0
339	renewal of stem cells;stem cell renewal;stem cell self-renewal;stem cell (NSC) self-renewal	0.5097343167594018	-2.791666666666667	0.0	0.0	0.04	0.04	0.3333333333333333	0.6666666666666666	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	-2.6500000000000004	0.04	0.04	0.0	0.043478260869565216	0.04504852406489174	3.75	0.04494854202401372	0.0	4.0	0.0	-3.8000000000000007	1.0	0.0	0.25	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	15.0	0.04580152671755725	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
224	short median survival	0.1290980728264842	-3.8571428571428577	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.8571428571428577	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.0472972972972973	0.0472972972972973	3.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.0472972972972973	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
24	Caduet	0.80008753946491	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.75	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
343	for;For	0.007372373203196505	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04	1.0	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.04	1.0	0.0	0.0	0.0	0.0
82	an increased frequency of HLA-B*1502 allele	0.051195904986385515	0.0	1.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.25	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.75	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
319	inhibiting parasitic growth;Retarded growth	0.3078672080398682	-2.166666666666668	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.043795620437956206	0.043795620437956206	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.043795620437956206	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	List;list	0.1313539408801738	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04421052631578948	0.0	3.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
259	Functional;functional	0.08936013162597148	-1.4444444444444429	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.4444444444444429	0.0	0.0	0.0	0.04	0.04	0.0	0.04245283018867924	0.04245283018867924	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04245283018867924	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	cooperation between p53 and maintenance DNA	0.03466146215627461	-2.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	1.0	-2.0	1.0	1.0	-9.714285714285714	0.04	0.06542056074766354	0.0	0.043478260869565216	0.043478260869565216	6.0	0.06542056074766354	0.3333333333333333	1.0	1.0	-9.714285714285714	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.043478260869565216	0.0	0.06542056074766354	0.0	1.0	0.0	0.0	1.0
23	53	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	Biochemical;biochemical	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
62	a side effect of therapy	0.013924912148958076	0.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	5.0	0.04	0.6	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.2	0.0	0.0
129	the maintenance of methylation patterns	0.09260180653832321	-0.9444444444444446	1.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.2857142857142857	0.0	-1.8888888888888893	0.0	0.0	-3.9642857142857144	0.04	0.04430379746835443	0.0	0.04	0.04163461538461538	5.0	0.04764361084550262	0.8	4.0	0.0	-4.857142857142858	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	20.0	0.04326923076923077	0.0	0.04964539007092199	0.0	0.0	0.0	0.0	0.0
312	Ca(2	0.6171953679194666	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
99	The patient	0.03305463273564032	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-7.142857142857142	0.04	0.056	0.0	0.047619047619047616	0.047619047619047616	2.0	0.056	0.5	1.0	0.0	-7.142857142857142	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047619047619047616	0.0	0.056	0.0	0.0	0.0	0.0	0.0
89	unable;Unable	0.0963825651646273	-3.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.04672897196261683	0.04672897196261683	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04672897196261683	0.0	0.04	0.0	0.0	0.0	0.0	0.0
158	Possible;possible	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
222	sustained disability accumulation	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
337	enhancement;Enhancement	0.0657219686705178	-8.7	1.0	-13.6	0.04	0.06385964912280702	0.0	0.0	1.0	-6.8	1.0	0.0	-15.7	0.0	0.0	-8.2	0.08771929824561403	0.046296296296296294	0.0	0.04291845493562232	0.07522266832802621	1.0	0.06481481481481481	1.0	2.0	0.0	-13.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.1075268817204301	0.0	0.08333333333333333	1.0	0.0	0.0	0.0	0.0
317	similar average length to the telomeres	0.05172733387632983	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
307	the LBs	0.045440184226485075	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
218	Benzyldimethylphenylammonium	0.6987017868929465	-5.666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.051724137931034475	0.051724137931034475	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.051724137931034475	0.0	0.04	0.0	0.0	0.0	0.0	0.0
26	pancreas and liver	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
29	enhanced glycolytic flux	0.31659866924493996	-2.666666666666668	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04477611940298508	0.04477611940298508	3.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04477611940298508	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
146	deficiency;Deficiency	0.5442824615479207	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.045454545454545456	0.045454545454545456	1.0	0.054545454545454536	0.0	1.0	0.0	-6.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
231	M-alphaMHC	0.6532989499564287	-3.2142857142857144	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.7142857142857135	0.0	0.0	-4.642857142857142	0.04	0.04430379746835443	0.0	0.04294478527607362	0.046120279961980475	3.0	0.04971095385228745	0.3333333333333333	2.0	0.0	-6.857142857142858	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04929577464788733	0.0	0.05511811023622047	0.0	0.0	0.0	0.0	0.0
318	significant activity	0.08113670188508262	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.307692307692308	0.04	0.05078125	0.0	0.04	0.04	2.0	0.05078125	0.0	1.0	0.0	-5.307692307692308	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05078125	0.0	0.0	0.0	0.0	0.0
245	Analysis;analysis	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
35	a 10;A-10	0.06213730858761587	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.04	0.04	1.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
129	a member of the maintenance-type methyltransferase family	0.07183287789491438	-2.0	0.0	0.0	0.04	0.04	0.7777777777777778	0.7777777777777778	0.0	0.0	0.0	1.0	-2.0	0.0	0.0	-1.571428571428573	0.04	0.042682926829268296	0.0	0.043478260869565216	0.043478260869565216	9.0	0.042682926829268296	0.4444444444444444	1.0	0.0	-1.571428571428573	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	9.0	0.043478260869565216	0.0	0.042682926829268296	0.0	0.0	0.0	0.0	0.0
83	Extensive;extensive	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	Transcription Regulation;regulation of transcription;transcriptional regulation;Transcriptional Regulation	0.5677664193209743	0.0	0.0	0.0	0.04	0.04	0.5	0.5277777777777778	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.7777777777777777	0.04	0.04	0.0	0.04	0.04	2.1666666666666665	0.041530054644808745	0.0	6.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	13.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
205	First;first	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
246	platelet inhibition after a clopidogrel 600-mg loading dose	0.12038163216570258	0.0	1.0	0.0	0.04	0.04	0.3	0.3	0.0	0.0	0.125	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.1	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
247	the second peak	0.04797613874614413	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.05	0.05	3.0	0.04938271604938271	0.3333333333333333	1.0	0.0	-4.75	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
139	adipose tissue;ADIPOSE TISSUE	0.24571691536575627	-0.8125	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.625	0.0	0.0	-3.625	0.04	0.04597701149425287	0.0	0.04	0.0413903743315508	2.0	0.046798029556650245	0.0	2.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.0427807486631016	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
41	surface charge potentials	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
173	Ala92 allele	0.767779374193696	-2.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.1999999999999993	0.0	0.0	-2.5	0.04	0.044444444444444446	0.0	0.043859649122807015	0.043859649122807015	2.0	0.044444444444444446	0.0	1.0	0.0	-2.5	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	2.0	0.043859649122807015	0.0	0.044444444444444446	0.0	0.0	0.0	0.0	0.0
298	Platelets;platelets	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
5	so;SO	0.08328507985162469	-7.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.0	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.05555555555555555	0.05555555555555555	1.0	0.05405405405405406	0.0	1.0	0.0	-6.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05555555555555555	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
58	best;Best	0.005586315510141083	-6.333333333333334	1.0	-17.666666666666668	0.04	0.08818181818181818	1.0	1.0	1.0	-8.833333333333334	1.0	0.0	-12.666666666666668	0.0	0.0	-7.5	0.13636363636363635	0.04	0.0	0.04	0.06054054054054055	1.0	0.07	1.0	2.0	0.0	-15.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.08108108108108109	0.0	0.1	1.0	0.0	0.0	0.0	0.0
139	Previous studies	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	the transmembrane strands of outer membrane proteins	0.038848086081155836	0.0	1.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.14285714285714285	0.0	0.0	0.0	0.0	-2.5	0.04	0.044444444444444446	0.0	0.04	0.04	7.0	0.044444444444444446	0.5714285714285714	1.0	0.0	-2.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.044444444444444446	0.0	0.0	0.0	0.0	0.0
252	FT4	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
97	heterogeneous neuromuscular disorder;Heterogeneous disorder	0.2547166480650842	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	3.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
305	impairment;Impairment	0.5099038596765331	-2.1428571428571423	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.1428571428571423	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04375	0.04375	1.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04375	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
221	several small samples	0.07183719006483419	-1.5833333333333321	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5833333333333321	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.042704626334519574	0.042704626334519574	3.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.042704626334519574	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
15	Protein level;Protein term co-occurrences at sentence level	0.04032784878955516	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
82	CBZ	0.7345981216126474	-1.3809523809523807	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.2857142857142847	0.0	0.0	-4.266666666666667	0.04	0.04	0.0	0.04	0.04241167792530476	1.0	0.050736808236808234	0.0	3.0	0.0	-10.2	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.0440251572327044	0.0	0.06756756756756756	0.0	0.0	0.0	0.0	0.0
228	Further	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
245	p;P NOS	0.6815137310566854	-5.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-5.0	0.0	0.0	-12.0	0.04	0.07692307692307693	0.0	0.05	0.05	0.0	0.07692307692307693	0.0	1.0	0.0	-12.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	0.0	0.05	0.0	0.07692307692307693	0.0	0.0	0.0	0.0	0.0
102	core components	0.11668968578773643	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
215	c-Myc;myc oncogene;c myc;Oncogene, myc	0.7043195485027126	-8.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-12.0	0.0	0.0	-8.666666666666666	0.04	0.04901960784313726	0.3333333333333333	0.045454545454545456	0.06265046428980856	2.6666666666666665	0.06362822906940553	0.16666666666666666	3.0	0.0	-12.4	1.0	0.5	0.0	0.3333333333333333	0.0	0.0	1.0	0.5	0.5	4.0	1.0	8.0	0.07692307692307693	0.0	0.07936507936507936	0.0	0.0	0.16666666666666666	0.0	0.0
89	adjunctive and monotherapy	0.5409049090678651	-3.1999999999999993	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-3.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04587155963302752	0.04587155963302752	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	3.0	0.04587155963302752	0.0	0.04	0.0	0.0	0.0	0.0	0.0
282	parkin protein;parkin-binding protein	0.10404939271503945	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
30	the APP to the amyloid β	0.09181473272261886	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	6.0	0.047619047619047616	0.3333333333333333	1.0	0.0	-4.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
158	Computed tomography angiography;computed tomography angiography	0.7259721588864877	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.0	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.045454545454545456	0.045454545454545456	3.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	2.0	1.0	3.0	0.045454545454545456	1.0	0.06666666666666667	0.0	0.0	0.0	1.0	0.0
299	the resistance	0.04230601849037912	-2.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.044117647058823525	0.044117647058823525	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.044117647058823525	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	Major;major	0.07018513125503545	-2.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	-6.75	0.04	0.0547945205479452	0.0	0.044444444444444446	0.044444444444444446	1.0	0.0547945205479452	0.0	1.0	0.0	-6.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.044444444444444446	0.0	0.0547945205479452	0.0	0.0	0.0	0.0	0.0
66	Swallowing of amniotic fluid	0.15264275393655777	-2.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	0.0	0.04	0.04	0.0	0.044444444444444446	0.044444444444444446	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.044444444444444446	0.0	0.04	0.0	0.0	0.0	0.0	0.0
24	these two studies	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
276	the profile	0.04217558991703029	-2.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04395604395604396	0.04395604395604396	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04395604395604396	0.0	0.04	0.0	0.0	0.0	0.0	0.0
50	2008)	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
74	Dependent;dependent	0.07549176562671912	-2.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	-5.0	0.04	0.05	0.0	0.044444444444444446	0.044444444444444446	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.044444444444444446	0.0	0.05	0.0	0.0	0.0	0.0	0.0
3	using;Using	0.07117376818911687	-5.833333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.833333333333334	0.0	0.0	-9.285714285714286	0.04	0.06363636363636364	0.0	0.052173913043478265	0.052173913043478265	1.0	0.06363636363636364	0.0	1.0	0.0	-9.285714285714286	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.052173913043478265	0.0	0.06363636363636364	0.0	0.0	0.0	0.0	0.0
90	comparison with amlodipine (5–10 mg) plus TLC	0.2562130401173304	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
10	HGF production and suppression	0.17697664244516847	-2.1428571428571423	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.1428571428571423	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.04375	0.04375	4.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04375	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
68	FGFR3;FGFR3)	0.6654801706095689	-3.3333333333333335	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-6.833333333333333	0.04	0.05263157894736842	0.0	0.04	0.046750208855472014	1.3333333333333333	0.05528973950026581	0.0	3.0	0.0	-8.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.05263157894736842	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
332	external signals from the tissue microenvironment	0.08079329090901974	-2.166666666666668	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.043795620437956206	0.043795620437956206	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.043795620437956206	0.0	0.04	0.0	0.0	0.0	0.0	0.0
80	subjects;Subject	0.0805615830914637	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.043478260869565216	0.043478260869565216	1.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
189	High;Elevated;elevated;higher	0.49133563728964147	-3.916666666666667	0.0	0.0	0.04	0.04	0.0	0.5	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-1.75	0.04	0.04	0.0	0.04	0.048042641625615765	1.0	0.04388888888888889	0.0	4.0	0.0	-7.0	1.0	0.0	0.5	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	4.0	0.053571428571428575	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
342	the carboxyl-terminal SET domain	0.12650688307762037	-2.8000000000000007	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	-5.4	0.04	0.0510204081632653	0.0	0.04504504504504505	0.04504504504504505	6.0	0.0510204081632653	0.16666666666666666	1.0	0.0	-5.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04504504504504505	0.0	0.0510204081632653	0.0	0.0	0.0	0.0	0.0
160	the armamentarium against osteoporotic fractures	0.23392097961690056	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	5.0	0.047619047619047616	0.2	1.0	0.0	-4.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
304	alone;Alone	0.09152591734464818	-2.125	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.125	0.0	0.0	0.0	0.04	0.04	0.0	0.04371584699453552	0.04371584699453552	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04371584699453552	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	multiple roles in development and disease	0.023599348580508557	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-10.666666666666666	0.04	0.06976744186046512	0.0	0.04	0.04	6.0	0.06976744186046512	0.5	1.0	1.0	-10.666666666666666	1.0	0.3333333333333333	1.0	1.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.06976744186046512	0.0	1.0	0.0	0.0	1.0
213	homozygous mutations	0.684162633597787	-6.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-9.75	0.04	0.06557377049180328	0.0	0.05263157894736842	0.05263157894736842	2.0	0.06557377049180328	0.0	2.0	0.0	-9.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.05263157894736842	0.0	0.06557377049180328	0.0	0.0	0.0	0.0	0.0
253	analyses;Analysis	0.09520971290739387	-3.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
331	Create;create	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
50	profilingThe RNA levels	0.1745748517026411	-1.2222222222222214	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-1.2222222222222214	0.0	0.0	-5.800000000000001	0.04	0.052083333333333336	0.0	0.04205607476635514	0.04205607476635514	3.0	0.052083333333333336	0.3333333333333333	1.0	0.0	-5.800000000000001	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04205607476635514	0.0	0.052083333333333336	0.0	0.0	0.0	0.0	0.0
142	high-risk areas in HSCR	0.08680331008994818	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
249	the genome	0.23540581826944307	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.375	0.04	0.042328042328042326	0.0	0.04	0.04	2.0	0.042328042328042326	0.0	1.0	0.0	-1.375	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.042328042328042326	0.0	0.0	0.0	0.0	0.0
335	Set1;SET1	0.6208739529754159	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.04	0.04	1.0	0.046296296296296294	0.0	2.0	0.0	-3.3999999999999986	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
137	likely;Likely	0.0794951111665361	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.6000000000000014	0.04	0.042735042735042736	0.0	0.04	0.04	1.0	0.042735042735042736	0.0	1.0	0.0	-1.6000000000000014	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.042735042735042736	0.0	0.0	0.0	0.0	0.0
91	associated Anxiety disorder;associated with several forms of anxiety disorder	0.01632045051919722	-2.7142857142857153	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.3333333333333333	0.0	-2.7142857142857153	0.0	0.0	0.0	0.04	0.04	0.0	0.04487179487179487	0.04487179487179487	7.0	0.04	0.2857142857142857	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	7.0	0.04487179487179487	0.0	0.04	0.0	0.0	0.0	0.0	0.0
130	Carbapenemase-producing;carbapenemase-producing	0.02728653126117635	-3.454545454545454	1.0	-6.0	0.04	0.04631578947368421	0.3333333333333333	0.3333333333333333	1.0	-3.0	1.0	1.0	-6.909090909090908	1.0	1.0	-2.7857142857142856	0.05263157894736842	0.04	0.0	0.04	0.04763819095477387	3.0	0.045735294117647055	1.0	2.0	1.0	-5.571428571428571	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.05527638190954773	0.0	0.051470588235294115	1.0	1.0	0.0	0.0	1.0
337	SCD	0.7670749621955456	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
345	selenoprotein;Selenoprotein;Selenoproteins;selenoproteins	0.7937185690725347	-1.8833333333333335	1.0	-11.0	0.04	0.04523809523809524	0.0	0.0	1.0	-1.8333333333333333	1.0	1.0	-10.3	0.0	0.0	-4.316666666666666	0.07142857142857142	0.04	0.0	0.04	0.04496105688652272	1.0	0.0522875109863414	0.3333333333333333	12.0	0.0	-13.6	1.0	0.3333333333333333	0.0	0.3333333333333333	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	4.0	1.0	12.0	0.06802721088435375	0.0	0.08771929824561403	1.0	0.0	0.0	0.0	0.0
316	molecular;Molecular	0.5737004712248787	-1.3636363636363633	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.3636363636363633	0.0	0.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.04230769230769231	0.04230769230769231	1.0	0.044642857142857144	0.0	1.0	0.0	-2.6000000000000014	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04230769230769231	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
215	Immune System;immune system	0.08761716678548931	-2.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0449438202247191	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
287	used	0.10304370892281756	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04878048780487805	0.0	1.0	0.0	-4.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.047619047619047616	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
144	MLC-2v promoter region	0.26602968377748804	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.04	0.04	3.0	0.06060606060606061	0.0	1.0	0.0	-8.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
72	computational and literature mining techniques	0.09782130026245342	-1.6000000000000014	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-1.6000000000000014	0.0	0.0	-3.6000000000000014	0.04	0.04672897196261683	0.0	0.042735042735042736	0.042735042735042736	5.0	0.04672897196261683	0.2	1.0	0.0	-3.6000000000000014	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.042735042735042736	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
322	marks	0.06565052670972442	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-12.0	0.04	0.07692307692307693	0.0	0.04	0.04	1.0	0.07692307692307693	0.0	1.0	0.0	-12.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.07692307692307693	0.0	0.0	0.0	0.0	0.0
137	Risks;risks	0.08700643238236141	-2.7777777777777786	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.7777777777777786	0.0	0.0	-1.8000000000000007	0.04	0.04310344827586207	0.0	0.045	0.045	1.0	0.04310344827586207	0.0	1.0	0.0	-1.8000000000000007	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045	0.0	0.04310344827586207	0.0	0.0	0.0	0.0	0.0
157	the treatment	0.1010771816533661	-3.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.04716981132075472	0.04716981132075472	2.0	0.04587155963302752	0.0	1.0	0.0	-3.1999999999999993	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04716981132075472	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
13	Angle;angle	0.08174206851709978	-6.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.054545454545454536	0.054545454545454536	1.0	0.054545454545454536	0.0	1.0	0.0	-6.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.054545454545454536	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
280	at least one family member	0.09450270299689957	-3.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	0.0	0.04	0.04	0.0	0.047058823529411764	0.047058823529411764	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.047058823529411764	0.0	0.04	0.0	0.0	0.0	0.0	0.0
140	instruments	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
107	its complexity	0.012996404919004119	-4.416666666666666	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.5	0.0	-4.416666666666666	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.048582995951417	0.048582995951417	2.0	0.06666666666666667	0.5	1.0	0.0	-10.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.048582995951417	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
131	the Hsp90 inhibitor PU-H71 for clinical trials	0.11129124768649672	0.0	0.0	0.0	0.04	0.04	0.4444444444444444	0.4444444444444444	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.04	0.04	9.0	0.04587155963302752	0.2222222222222222	1.0	0.0	-3.1999999999999993	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
96	this study with promising antitumor activity	0.07750095570901203	-4.25	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-2.8000000000000007	0.04	0.04504504504504505	0.0	0.04819277108433735	0.04819277108433735	6.0	0.04504504504504505	0.0	1.0	0.0	-2.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04819277108433735	0.0	0.04504504504504505	0.0	0.0	0.0	0.0	0.0
7	's ability	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
34	mRNA	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
130	recognition;Recognition	0.08159600765398338	-1.3636363636363633	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.3636363636363633	0.0	0.0	-2.1428571428571423	0.04	0.04375	0.0	0.04230769230769231	0.04230769230769231	1.0	0.04375	0.0	1.0	0.0	-2.1428571428571423	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04230769230769231	0.0	0.04375	0.0	0.0	0.0	0.0	0.0
86	KCNE1 expression	0.39355556332182906	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
90	benefits;Benefit;Benefits	0.4394531601678155	0.0	0.0	0.0	0.04	0.04	0.0	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.6666666666666666	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
204	growth-plate;Growth Plate	0.1187176919696614	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
40	cz;CZ	0.6066186994119565	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	the conditions of larvae	0.04250011404863432	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
302	Tpl2 kinase inhibition	0.5121902064515971	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.25	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
142	clinical management;Clinical Management	0.08482337904592585	-1.8333333333333321	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.043165467625899276	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.043165467625899276	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	lymphocytes;Lymphocytes	0.6349380365288271	-2.833333333333332	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.045112781954887216	0.045112781954887216	1.0	0.04878048780487805	0.0	2.0	0.0	-4.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.045112781954887216	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
101	Family;family	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	see	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	the Tas3 protein	0.09526385182855508	-9.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.3333333333333333	1.0	-9.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.0625	0.0625	3.0	0.05263157894736842	0.3333333333333333	1.0	0.0	-6.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.0625	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
214	identifiable characteristics	0.055442725841852704	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.5	0.0	0.0
41	TgMYST-A and -B	0.263263874546574	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	6.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
3	the complex	0.03905213992060833	-2.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-1.8571428571428577	0.04	0.043209876543209874	0.0	0.044117647058823525	0.044117647058823525	2.0	0.043209876543209874	0.5	1.0	0.0	-1.8571428571428577	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.044117647058823525	0.0	0.043209876543209874	0.0	0.0	0.0	0.0	0.0
47	all;ALL	0.09059200192985256	-1.8333333333333321	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.043165467625899276	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043165467625899276	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	the establishment and inheritance of tissue	0.03444661906426624	-3.444444444444443	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-3.444444444444443	0.0	0.0	-5.428571428571429	0.04	0.05109489051094891	0.0	0.04639175257731958	0.04639175257731958	6.0	0.05109489051094891	0.3333333333333333	1.0	0.0	-5.428571428571429	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04639175257731958	0.0	0.05109489051094891	0.0	0.0	0.0	0.0	0.0
93	charts;Charts	0.10786690271059986	-5.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.051724137931034475	0.051724137931034475	1.0	0.05084745762711865	0.0	2.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.051724137931034475	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
128	a family of genes	0.07646298406317496	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-1.2727272727272734	0.04	0.0421455938697318	0.0	0.04	0.04	4.0	0.0421455938697318	0.25	1.0	0.0	-1.2727272727272734	1.0	0.3333333333333333	1.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.0421455938697318	0.0	0.0	0.0	0.0	0.0
15	Specified;Specific;specific;specified	0.1410993914534359	-0.5600000000000002	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	-0.5200000000000002	0.04	0.04	0.0	0.04	0.040949456863273184	1.0	0.04092857142857143	0.0	5.0	0.0	-2.6000000000000014	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	5.0	0.0425531914893617	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
332	clinical experiences with the Syk inhibitor fostamatinib disodium (R788)	0.09569266884877668	0.0	1.0	0.0	0.04	0.04	0.36363636363636365	0.36363636363636365	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	11.0	0.04	0.09090909090909091	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	11.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
297	Mortality (PRISM	0.48501901710734213	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
39	methionine;Met;METHIONINE	0.9457049812040397	-0.40625	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.25	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04074712643678161	1.0	0.04	0.0	8.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	3.0	1.0	8.0	0.04597701149425287	1.0	0.04	0.0	1.0	0.0	1.0	1.0
270	Eto-2	0.5989411634628165	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.045454545454545456	0.045454545454545456	1.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.045454545454545456	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
251	de;DE	0.5695976092134639	-2.1111111111111107	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.1111111111111107	0.0	0.0	-5.222222222222221	0.04	0.05056179775280899	0.0	0.043689320388349516	0.043689320388349516	0.0	0.05056179775280899	0.0	1.0	0.0	-5.222222222222221	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.043689320388349516	0.0	0.05056179775280899	0.0	0.0	0.0	0.0	0.0
332	a phase 1/2 clinical trial of fostamatinib disodium	0.038524785371219554	0.0	1.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.14285714285714285	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
296	2;+2	0.6045139404606406	-1.6363636363636367	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.6363636363636367	0.0	0.0	0.0	0.04	0.04	0.0	0.042801556420233464	0.042801556420233464	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.042801556420233464	0.0	0.04	0.0	0.0	0.0	0.0	0.0
125	an X-linked MTM1 missense mutation.Muscle	0.3049062225174881	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.14285714285714285	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
86	Consistently	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
69	organelle;Organelle	0.5575047118876476	-2.833333333333332	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.045112781954887216	0.045112781954887216	1.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045112781954887216	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
304	B-cell receptor induced activation	0.39135079511216714	0.0	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.2857142857142847	0.04	0.046052631578947366	0.0	0.04	0.04	6.0	0.046052631578947366	0.0	1.0	0.0	-3.2857142857142847	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.046052631578947366	0.0	0.0	0.0	0.0	0.0
131	the Ras/Raf/MAPK pathway and G(2)-M phase	0.20076437223335894	0.0	0.0	0.0	0.04	0.04	0.23076923076923078	0.23076923076923078	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	13.0	0.04	0.15384615384615385	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	13.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
158	years of age;Age-Years	0.07435842344587819	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
154	Identified;identified	0.11259169819821752	-2.7272727272727266	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.8181818181818166	0.0	0.0	-1.6999999999999993	0.04	0.04	0.0	0.044715447154471545	0.04489870718379314	1.0	0.043148148148148144	0.0	2.0	0.0	-3.3999999999999986	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04508196721311475	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
140	Retention;retention	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
281	autosomal recessive parkinsonism with early-onset	0.2826103210330343	0.0	0.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.2857142857142857	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
86	debutyl-dronedarone;DBD;(DBD)	0.9425248045643643	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.75	0.04	0.0	8.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	14.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	the cytochrome P450 2C9 enzyme (CYP2C9)	0.6452426804512784	0.0	0.0	0.0	0.04	0.04	0.125	0.125	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
287	the selectivity	0.23457970068046666	-3.8000000000000007	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04716981132075472	0.04716981132075472	2.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04716981132075472	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
318	a constitutively active tyrosine kinase (TK)	0.13410262894771818	-1.8888888888888893	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.2	1.0	-1.8888888888888893	0.0	0.0	-4.846153846153847	0.04	0.04961832061068702	1.0	0.04326923076923077	0.04326923076923077	8.0	0.04961832061068702	0.625	1.0	0.0	-4.846153846153847	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.04326923076923077	0.0	0.04961832061068702	0.0	0.0	0.125	0.0	0.0
130	cloacae (11 isolates	0.34396695497091734	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.857142857142858	0.04	0.04964539007092199	0.0	0.04	0.04	4.0	0.04964539007092199	0.0	1.0	0.0	-4.857142857142858	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04964539007092199	0.0	0.0	0.0	0.0	0.0
102	abnormally high synthesis of the mineralocorticoid	0.10793650749311251	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	most regions	0.04903808582705814	0.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
217	neo;NEO	0.7648110616469854	-1.5833333333333333	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.375	0.0	0.0	-5.095238095238096	0.04	0.05	0.0	0.04	0.04279926335174954	0.0	0.05024154589371981	0.0	3.0	0.0	-5.2857142857142865	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	0.0	0.04419889502762431	0.0	0.05072463768115942	0.0	0.0	0.0	0.0	0.0
15	∼21 million PubMed abstracts	0.2337960379185331	-1.8999999999999986	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.8999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04329004329004329	0.04329004329004329	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04329004329004329	0.0	0.04	0.0	0.0	0.0	0.0	0.0
317	telomerase activity in a dose-dependent manner	0.07450343271563736	-3.8000000000000007	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04716981132075472	0.04716981132075472	8.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04716981132075472	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
25	predictive	0.5926267089015415	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.04	0.04	1.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
13	This technique	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
80	the well-	0.07124089286741464	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.04	0.04	3.0	0.044642857142857144	0.3333333333333333	1.0	0.0	-2.6000000000000014	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
168	2 consists	0.2295652628219922	-3.75	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.047058823529411764	0.047058823529411764	2.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047058823529411764	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
193	Encoding;encoding	0.6097150563298547	-2.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.043859649122807015	0.043859649122807015	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043859649122807015	0.0	0.04	0.0	0.0	0.0	0.0	0.0
159	Identified;identified	0.07810231649216244	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.05	0.05	1.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
41	each CD	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
49	familial;Familial;Families;families	0.37681982799685343	-1.1666666666666667	0.0	0.0	0.04	0.04	0.0	0.6666666666666666	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04201048411964231	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.6666666666666666	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	malaria worldwide	0.0970904419271694	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
125	common;Common	0.09660742387934279	-3.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.046875	0.046875	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046875	0.0	0.04	0.0	0.0	0.0	0.0	0.0
30	APP;amyloid precursor protein	0.875463954180682	0.0	0.0	0.0	0.04	0.04	0.0	0.16666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.5	0.04	0.04587155963302752	0.0	0.04	0.04	2.0	0.046518001694412926	0.0	6.0	0.0	-3.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	12.0	0.04	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
212	autosomal-recessive form	0.26057100584304677	-4.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	-4.0	1.0	1.0	-10.571428571428571	0.04	0.0693069306930693	0.0	0.047619047619047616	0.047619047619047616	4.0	0.0693069306930693	0.25	1.0	1.0	-10.571428571428571	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.047619047619047616	0.0	0.0693069306930693	0.0	1.0	0.0	0.0	1.0
281	putative kinase 1	0.6745765631078627	-2.1500000000000004	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.300000000000001	0.0	0.0	-6.5	0.04	0.053571428571428575	0.0	0.04	0.044154589371980676	3.0	0.054058441558441556	0.0	2.0	0.0	-6.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04830917874396135	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
130	Carbapenemases including Klebsiella pneumoniae carbapenemases (KPC)	0.27132141165696677	-1.2727272727272734	1.0	0.0	0.04	0.04	0.125	0.125	0.0	0.0	0.25	1.0	-1.2727272727272734	1.0	1.0	-3.2857142857142847	0.04	0.046052631578947366	0.0	0.0421455938697318	0.0421455938697318	8.0	0.046052631578947366	0.25	1.0	1.0	-3.2857142857142847	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.0421455938697318	0.0	0.046052631578947366	0.0	1.0	0.0	0.0	1.0
28	likely;Likely	0.10238296519538877	-5.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.05084745762711865	0.05084745762711865	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05084745762711865	0.0	0.04	0.0	0.0	0.0	0.0	0.0
224	T';T	0.5508177664663845	-2.7142857142857153	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.7142857142857153	0.0	0.0	-5.833333333333334	0.04	0.052173913043478265	0.0	0.04487179487179487	0.04487179487179487	1.0	0.052173913043478265	0.0	1.0	0.0	-5.833333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04487179487179487	0.0	0.052173913043478265	0.0	0.0	0.0	0.0	0.0
157	the treatment of CMV infection and disease	0.09842838499938796	-3.8000000000000007	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	1.0	-3.8000000000000007	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.04716981132075472	0.04716981132075472	7.0	0.04587155963302752	0.0	1.0	0.0	-3.1999999999999993	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04716981132075472	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
16	modular rearrangements—fusion, fission, terminal deletion	0.4394031538227669	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.1111111111111111	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
49	R106W	0.6828657932045992	-3.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	0.0	0.04	0.04	0.0	0.047058823529411764	0.047058823529411764	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.047058823529411764	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	logarithm;Logarithm	0.547989743176474	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.04	0.04	1.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
49	X-linked dominant	0.26028566670088676	-6.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-6.5	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.05405405405405406	0.05405405405405406	2.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05405405405405406	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
307	demented patients with PD	0.21246102744165618	-2.1999999999999993	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.043859649122807015	0.043859649122807015	4.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.043859649122807015	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
242	Discharges;discharges;discharge;Discharge	0.5288751826354895	-0.6111111111111107	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.2222222222222214	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04102803738317757	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.04205607476635514	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	the flumazenil (3.25	0.5686077676215348	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
200	death	0.11595057611586562	-2.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.043859649122807015	0.043859649122807015	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.043859649122807015	0.0	0.04	0.0	0.0	0.0	0.0	0.0
282	a new interacting partner	0.019239874270645923	-4.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.3333333333333333	0.0	-4.0	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.047619047619047616	0.047619047619047616	4.0	0.06451612903225806	0.25	1.0	0.0	-9.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.047619047619047616	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
194	system;systems;System	0.11449237557451308	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.04	0.0	0.04	0.04	1.0	0.05430363543266769	0.0	4.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.04	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
242	predictive	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
267	user-friendly graphical user interface;USER INTERFACE	0.3620634951849434	-2.428571428571427	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.428571428571427	0.0	0.0	0.0	0.04	0.04	0.0	0.04430379746835443	0.04430379746835443	6.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	12.0	0.04430379746835443	0.0	0.04	0.0	0.0	0.0	0.0	0.0
191	problems with attention, memory	0.029571943746062652	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9.0	0.04	0.0625	1.0	0.04	0.04	5.0	0.0625	0.4	1.0	0.0	-9.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.0625	0.0	0.0	0.2	0.0	0.0
242	the ST segment during exercise testing	0.057725667489823246	-3.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
175	mutations in the gene KCNJ2	0.15801935105881773	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	Represent;represent	0.09548779979060394	-3.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.04615384615384615	0.04615384615384615	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04615384615384615	0.0	0.04	0.0	0.0	0.0	0.0	0.0
139	NEP by gene transfer	0.09528480584220633	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.04	0.04	4.0	0.046511627906976744	0.0	1.0	0.0	-3.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
96	Bortezomib-treated MM patients	0.1505210329752598	0.0	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.2	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	[14,24]	0.6120491579615571	-3.166666666666668	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.04580152671755725	0.04580152671755725	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04580152671755725	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	parent;PARENT	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
334	H2A variant	0.4324935375823289	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.3333333333333333	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.5	0.0	0.0
93	SKIN REACTION;skin reactions;reactions skin;skin reaction	0.21093432640378623	-5.966666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.166666666666666	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.052173913043478265	0.0525432858791843	2.0	0.05357142857142858	0.0	5.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	10.0	0.053097345132743355	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
95	Superfamily;superfamily	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	BCR-ABL with greater potency	0.3601379592233414	-2.1111111111111107	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-2.1111111111111107	1.0	1.0	-2.6153846153846168	0.04	0.044673539518900345	0.0	0.043689320388349516	0.043689320388349516	6.0	0.044673539518900345	0.16666666666666666	1.0	1.0	-2.6153846153846168	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.043689320388349516	0.0	0.044673539518900345	0.0	1.0	0.0	0.0	1.0
329	the optimal binding pose	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
251	focal contact size reduction	0.10252349596779275	-1.7777777777777786	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-3.2222222222222214	0.04	0.04591836734693877	0.0	0.0430622009569378	0.0430622009569378	4.0	0.04591836734693877	0.0	1.0	0.0	-3.2222222222222214	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.0430622009569378	0.0	0.04591836734693877	0.0	0.0	0.0	0.0	0.0
330	Twice Daily;twice daily	0.11707437433269925	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	the next generation	0.04695896373046952	-1.8888888888888893	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-2.571428571428573	0.04	0.0445859872611465	0.0	0.04326923076923077	0.04326923076923077	3.0	0.0445859872611465	0.3333333333333333	1.0	0.0	-2.571428571428573	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04326923076923077	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
322	Polycomb	0.6503725508875263	-5.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.05	0.05	1.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.05	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
135	traditional IP	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
213	no symptoms	0.11569647565355703	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
103	an;AN	0.5961686058735757	-3.8888888888888893	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.8888888888888893	0.0	0.0	-2.7142857142857153	0.04	0.04487179487179487	0.0	0.04736842105263158	0.04736842105263158	1.0	0.04487179487179487	0.0	1.0	0.0	-2.7142857142857153	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04736842105263158	0.0	0.04487179487179487	0.0	0.0	0.0	0.0	0.0
243	found;in;In;Found	0.0034570271273280276	-3.6428571428571423	1.0	0.0	0.04	0.04	1.0	1.0	1.0	0.0	1.0	0.0	-17.142857142857142	0.0	0.0	-6.416666666666667	0.04	0.04	0.0	0.04	0.05593361366229768	1.0	0.062298733604703754	0.8333333333333334	6.0	0.0	-17.0	1.0	0.0	1.0	0.8333333333333334	1.0	0.0	1.0	0.0	0.0	4.0	1.0	6.0	0.12727272727272726	0.0	0.125	1.0	0.0	0.0	0.0	0.0
67	the animal model	0.03865372457551209	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.125	0.04	0.04597701149425287	1.0	0.04	0.04	3.0	0.054238505747126436	0.6666666666666666	2.0	0.0	-9.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.0625	0.0	0.0	0.3333333333333333	0.0	0.0
176	a very stable and compact aggregate at higher protein concentrations	0.06339710992521655	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
252	low;Low	0.08757206893200613	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-1.8333333333333321	0.04	0.043165467625899276	0.0	0.045454545454545456	0.045454545454545456	1.0	0.043165467625899276	0.0	1.0	0.0	-1.8333333333333321	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.043165467625899276	0.0	0.0	0.0	0.0	0.0
122	its effect on phenprocoumon metabolism	0.14147821017287887	-4.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.047619047619047616	0.047619047619047616	5.0	0.05405405405405406	0.0	1.0	0.0	-6.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.047619047619047616	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
95	29+;29	0.6066186994119565	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
185	ejection fraction	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
231	approximately 30 wk of age	0.10699058841176723	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	special;specialized;Special	0.07861550683882343	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.416666666666668	0.04	0.043795620437956206	0.0	0.04	0.04	1.0	0.04428586992047064	0.0	2.0	0.0	-2.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.04	0.0	0.04477611940298508	0.0	0.0	0.0	0.0	0.0
262	LAM	0.6586561094009697	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-5.166666666666667	0.04	0.04	0.0	0.04	0.04380952380952381	1.0	0.054090909090909085	0.0	2.0	0.0	-10.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047619047619047616	0.0	0.06818181818181819	0.0	0.0	0.0	0.0	0.0
214	Sod1 activity to Gpx1 activity	0.228462092954257	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
297	prognostic;Prognostic	0.0434058148773582	-10.5	1.0	-14.0	0.09090909090909091	0.09090909090909091	0.0	0.0	1.0	-14.0	1.0	0.0	-10.5	0.0	0.0	-12.4	0.09090909090909091	0.07936507936507936	0.0	0.06896551724137931	0.06896551724137931	1.0	0.07936507936507936	1.0	1.0	0.0	-12.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.06896551724137931	0.0	0.07936507936507936	1.0	0.0	0.0	0.0	0.0
127	survival;Survival	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
200	due to;Due To	0.05321716822965557	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-13.0	0.04	0.08333333333333333	0.0	0.047619047619047616	0.047619047619047616	2.0	0.08333333333333333	0.0	1.0	0.0	-13.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.047619047619047616	0.0	0.08333333333333333	0.0	0.0	0.0	0.0	0.0
189	involvement;Involvement	0.09409935286849357	-5.666666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-8.0	0.04	0.05405405405405406	0.0	0.05	0.05178571428571429	1.0	0.05928509154315606	0.0	2.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.053571428571428575	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
111	SECIS;Insertion Sequence	0.7544809966416454	-2.2857142857142847	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.2857142857142847	0.0	0.0	0.0	0.04	0.04	0.0	0.0440251572327044	0.0440251572327044	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	1.0	0.0440251572327044	0.0	0.04	0.0	0.0	0.0	0.0	0.0
218	-charge measurements	0.0793662226340656	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
27	recurrent urinary tract infections;Recurrent urinary tract infections	0.7054451380664583	-2.2222222222222214	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	-2.2222222222222214	1.0	1.0	-4.75	0.04	0.04938271604938271	0.0	0.04390243902439024	0.04390243902439025	4.0	0.04938271604938271	0.0	3.0	1.0	-4.75	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	12.0	0.04390243902439024	0.0	0.04938271604938271	0.0	1.0	0.0	0.0	1.0
209	genes;Genes	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	rbbp4	0.6123470632438762	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.04	0.04	1.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
142	deleterious mutations within the RET protooncogene. MEN2 RET mutations	0.437337552396741	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.2	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
319	the most active antileishmanial benzothiophenes	0.08192114030521683	-2.833333333333332	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-9.0	0.04	0.0625	0.0	0.045112781954887216	0.045112781954887216	5.0	0.0625	0.2	1.0	0.0	-9.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.045112781954887216	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
124	additional biomarkers	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
91	Internet;internet	0.09066791716240748	-1.8571428571428577	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8571428571428577	0.0	0.0	0.0	0.04	0.04	0.0	0.043209876543209874	0.043209876543209874	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043209876543209874	0.0	0.04	0.0	0.0	0.0	0.0	0.0
30	the ADAM10 5'-UTR	0.20896310213888816	-1.3000000000000007	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	-1.3000000000000007	0.0	0.0	-4.800000000000001	0.04	0.04950495049504951	0.0	0.04219409282700422	0.04219409282700422	5.0	0.04950495049504951	0.4	1.0	0.0	-4.800000000000001	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04219409282700422	0.0	0.04950495049504951	0.0	0.0	0.0	0.0	0.0
86	the absence	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
297	the duration	0.10549951416075809	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
39	2 µCi	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	one of the first reports	0.07713408336477952	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.7142857142857153	0.04	0.04294478527607362	0.0	0.04	0.04	5.0	0.04294478527607362	0.0	1.0	0.0	-1.7142857142857153	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04294478527607362	0.0	0.0	0.0	0.0	0.0
200	Several	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
143	Target;targets	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
316	NOTCH3 Gene;Notch3 gene;NOTCH3 gene	0.7698595949780475	-2.6590909090909083	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.8181818181818166	0.0	0.0	-4.5	0.04	0.04587155963302752	0.0	0.04230769230769231	0.044828851776115786	2.0	0.048926068273060744	0.0	8.0	0.0	-5.800000000000001	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	16.0	0.047210300429184546	0.0	0.052083333333333336	0.0	0.0	0.0	0.0	0.0
16	Order;order	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	a major component	0.10852003510562176	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
66	vaginal bleeding;VAGINAL BLEEDING	0.7659465760509158	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	2.0	1.0	2.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
222	rapid and prolonged T lymphocyte depletion	0.29956052836315394	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
242	Implantable Cardioverter Defibrillator;implantable cardioverter-defibrillator	0.5690324420476768	-3.444444444444443	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.444444444444443	0.0	0.0	0.0	0.04	0.04	0.0	0.04639175257731958	0.04639175257731958	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04639175257731958	0.0	0.04	0.0	0.0	0.0	0.0	0.0
319	more potent and selective tankyrase inhibitors	0.29956052836315394	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
86	mRNA	0.8577888870421878	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-1.6666666666666667	0.04	0.04	0.0	0.04	0.04	1.0	0.043333333333333335	0.0	3.0	0.0	-5.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	3.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
114	DNA Methylation;DNA methylation	0.06438471843343678	-4.428571428571429	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.428571428571429	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.04861111111111112	0.04861111111111112	2.0	0.06666666666666667	0.5	1.0	0.0	-10.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04861111111111112	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
326	an abnormal pattern of exon 10	0.25181289414670893	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04	0.04	6.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
40	Fast and accurate phylogenetic reconstruction	0.054901103960623907	0.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
250	Progression;progression	0.6078722860890746	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	ligand-contacting areas	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
257	correlated;Correlated	0.5629031577367272	-5.666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-7.2857142857142865	0.04	0.056451612903225805	0.0	0.051724137931034475	0.051724137931034475	1.0	0.056451612903225805	0.0	1.0	0.0	-7.2857142857142865	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.051724137931034475	0.0	0.056451612903225805	0.0	0.0	0.0	0.0	0.0
329	areas	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
150	the levels of the lysosome-associated membrane protein type 2a	0.0503383109558241	-4.7142857142857135	0.0	0.0	0.04	0.04	0.6363636363636364	0.6363636363636364	0.0	0.0	0.0	0.0	-4.7142857142857135	0.0	0.0	-6.833333333333334	0.04	0.05504587155963304	0.0	0.04929577464788733	0.04929577464788733	11.0	0.05504587155963304	0.2727272727272727	1.0	0.0	-6.833333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	11.0	0.04929577464788733	0.0	0.05504587155963304	0.0	0.0	0.0	0.0	0.0
14	atomic resolution with a jackknife procedure	0.11039095838711509	-1.75	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-1.75	1.0	1.0	-10.0	0.04	0.06666666666666667	0.0	0.043010752688172046	0.043010752688172046	6.0	0.06666666666666667	0.0	1.0	1.0	-10.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.043010752688172046	0.0	0.06666666666666667	0.0	1.0	0.0	0.0	1.0
121	Pharmacogenetic studies	0.1504667639648523	-6.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.05263157894736842	0.05263157894736842	2.0	0.051724137931034475	0.5	2.0	0.0	-5.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.05263157894736842	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
329	SAXS experiments	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
132	Cell Lines;cell lines	0.11707437433269925	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
344	macroH2A1 nucleosomes	0.9400229386823862	-2.375	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.5	0.0	0.0	-1.583333333333334	0.04	0.04	0.0	0.04395604395604396	0.0442002442002442	2.0	0.042900763358778626	0.0	4.0	0.0	-3.166666666666668	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.044444444444444446	0.0	0.04580152671755725	0.0	0.0	0.0	0.0	0.0
323	arachnodactyly;ARACHNODACTYLY;dolichostenomelia;DOLICHOSTENOMELIA	0.6747675154862415	-1.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.0	1.0	1.0	-2.25	0.04	0.04	0.0	0.04	0.04181818181818182	1.0	0.04493150684931507	0.0	3.0	1.0	-6.75	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	4.0	1.0	3.0	0.045454545454545456	0.0	0.0547945205479452	0.0	1.0	0.0	0.0	1.0
318	the presence	0.618513484509749	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.853846153846154	0.04	0.041401273885350316	0.0	0.04	0.04	2.0	0.047600460794388594	0.5	10.0	0.0	-6.23076923076923	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	20.0	0.04	0.0	0.05327868852459016	0.0	0.0	0.0	0.0	0.0
50	kilobase of exon model	0.4608339796537201	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-0.8666666666666671	0.04	0.04	0.0	0.04	0.04	4.0	0.04154761904761905	0.25	3.0	1.0	-2.6000000000000014	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	12.0	0.04	0.0	0.044642857142857144	0.0	1.0	0.0	0.0	1.0
214	aberrant gene expression	0.2602042347140343	-3.25	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	Notch2 receptor;Receptor, Notch2	0.6839723138007986	-1.3999999999999986	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.0423728813559322	0.0423728813559322	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.0423728813559322	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	specific prognostic subtypes in other breast cancer datasets	0.15307927516564176	0.0	0.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
17	ng/ml;ng/mL	0.6518729610532259	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.625	0.04	0.046511627906976744	0.0	0.04	0.04	3.0	0.046785225718194254	0.0	2.0	0.0	-3.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
122	Hepatocytes;hepatocytes	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
227	Link;linked	0.07529198519860014	-3.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04587155963302752	0.04587155963302752	1.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04587155963302752	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
30	frontotemporal dementia (FTD	0.832289260160181	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	2.0	1.0	0.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
86	Fetal;fetal	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	green tea;Green tea	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
176	proteins (NAPs) in bacteria	0.16126433452380806	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	1.0	0.04	0.04	6.0	0.04716981132075472	0.3333333333333333	1.0	0.0	-3.8000000000000007	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04716981132075472	0.0	0.0	0.16666666666666666	0.0	0.0
78	the NF1 region	0.11522276798105215	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.25	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
164	Isolated;isolated	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
91	AS-Control	0.3589487071582361	-1.4285714285714282	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.1428571428571423	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.0425	3.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04375	0.0	0.04	0.0	0.0	0.0	0.0	0.0
176	key architectural proteins present	0.14123803578052474	-2.125	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.2	1.0	-2.125	1.0	1.0	-3.0	0.04	0.045454545454545456	1.0	0.04371584699453552	0.04371584699453552	4.0	0.045454545454545456	0.25	1.0	1.0	-3.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04371584699453552	0.0	0.045454545454545456	0.0	1.0	0.25	0.0	1.0
96	Pharmaceuticals	0.5728694516531513	-4.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-11.4	0.04	0.07352941176470588	0.0	0.04938271604938271	0.04938271604938271	1.0	0.07352941176470588	0.0	1.0	0.0	-11.4	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04938271604938271	0.0	0.07352941176470588	0.0	0.0	0.0	0.0	0.0
14	the propensities	0.10549951416075809	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
277	long term;Long Term	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
114	a higher eukaryote	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
243	a heterozygous single nucleotide transition from A	0.10057254967379158	0.0	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	the gene fusion method	0.013003815564633862	0.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	Group;group	0.09086961217953075	-8.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-8.5	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.06060606060606061	0.06060606060606061	1.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.06060606060606061	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
21	the UCR	0.07877430444369662	-2.428571428571427	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.428571428571427	0.0	0.0	-9.25	0.04	0.06349206349206349	0.0	0.04430379746835443	0.04430379746835443	2.0	0.06349206349206349	0.5	1.0	0.0	-9.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04430379746835443	0.0	0.06349206349206349	0.0	0.0	0.0	0.0	0.0
293	Other off-label	0.026965164001440185	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	an integral beta-barrel outer membrane protein	0.04602682720301151	0.0	1.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.6	0.0	0.0	0.0	0.0	-5.166666666666666	0.04	0.050420168067226885	0.0	0.04	0.04	8.0	0.050420168067226885	0.375	1.0	0.0	-5.166666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.050420168067226885	0.0	0.0	0.0	0.0	0.0
179	Subfamily;subfamily	0.5585368507767386	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.04	0.04504504504504505	0.0	0.04	0.04	1.0	0.04504504504504505	0.0	1.0	0.0	-2.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04504504504504505	0.0	0.0	0.0	0.0	0.0
205	its effect	0.034253636722407645	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-8.5	0.04	0.06060606060606061	1.0	0.04878048780487805	0.04878048780487805	2.0	0.06060606060606061	0.5	1.0	0.0	-8.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04878048780487805	0.0	0.06060606060606061	0.0	0.0	0.5	0.0	0.0
49	pathogenic;Pathogenic	0.6215159245475167	-1.625	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.625	0.0	0.0	0.0	0.04	0.04	0.0	0.0427807486631016	0.0427807486631016	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.0427807486631016	0.0	0.04	0.0	0.0	0.0	0.0	0.0
262	tubers on MRI	0.384943510570668	-4.25	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	function mutations of the chromodomain helicase DNA-binding protein 7 (CHD7) gene	0.11729442313723966	0.0	0.0	0.0	0.04	0.04	0.4666666666666667	0.4666666666666667	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	15.0	0.04	0.13333333333333333	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	15.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
93	A postmarketing surveillance study reported gabapentin treatment failure	0.02110239838774672	-2.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.4	0.0	-2.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.043478260869565216	0.043478260869565216	8.0	0.047619047619047616	0.25	1.0	0.0	-4.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.043478260869565216	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
156	iron overload;Iron Overload	0.4317053300729861	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
330	active RA over 24 weeks	0.15898064341854684	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
189	Population;population	0.10599342158052662	-6.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.053571428571428575	0.053571428571428575	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.053571428571428575	0.0	0.04	0.0	0.0	0.0	0.0	0.0
276	confirmatory deranged thyroid levels	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
187	new;NEW	0.10772550641833523	-2.916666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	-2.833333333333333	0.04	0.04	0.0	0.04477611940298508	0.04528882306027117	1.0	0.04586206896551724	0.0	2.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04580152671755725	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
251	DELTAEF1;deltaEF1	0.8175434618781715	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-1.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04173913043478261	0.0	2.0	1.0	-2.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	2.0	1.0	2.0	0.04	1.0	0.043478260869565216	0.0	1.0	0.0	1.0	1.0
341	the per-base mutation frequency	0.030749273134679074	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	4.0	0.04	0.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.25	0.0	0.0
66	Maternal serology for cytomegalovirus (CMV)	0.4287814295309841	0.0	0.0	0.0	0.04	0.04	0.14285714285714285	0.14285714285714285	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
258	early preimplantation embryos	0.4755553574103497	-3.1999999999999993	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-3.6000000000000014	0.04	0.04672897196261683	0.0	0.04587155963302752	0.04587155963302752	3.0	0.04672897196261683	0.0	2.0	0.0	-3.6000000000000014	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04587155963302752	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
7	at least 25 years	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
209	a promising model system	0.008073302223818371	0.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	4.0	0.04918032786885245	0.75	1.0	0.0	-4.666666666666666	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
297	the FT3	0.10549951416075809	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
264	cross-sectional survey;Survey, Cross-Sectional	0.20146510080365157	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	art;Art	0.03641213519420361	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-20.0	0.04	0.2	0.0	0.04	0.04	1.0	0.2	0.0	1.0	0.0	-20.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.2	0.0	0.0	0.0	0.0	0.0
53	mRNA Expression;expression of D2 mRNA;mRNA expression	0.4341312481910032	-6.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.3333333333333333	-6.666666666666666	0.0	0.0	-6.111111111111112	0.04	0.05263157894736842	0.0	0.051724137931034475	0.05266457680250783	2.6666666666666665	0.05294486215538847	0.0	3.0	0.0	-6.333333333333334	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.0	0.1111111111111111	3.0	1.0	8.0	0.054545454545454536	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
163	activating	0.6187891566464014	-3.8000000000000007	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04716981132075472	0.04716981132075472	1.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04716981132075472	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
78	detect	0.12328186590527837	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
322	Polycomb repressive complex 2 (PRC2)	0.3783745862078184	0.0	0.0	0.0	0.04	0.04	0.14285714285714285	0.14285714285714285	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	7.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
44	possesses;possess	0.09774472470178364	-16.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-16.0	0.0	0.0	-10.333333333333334	0.04	0.06818181818181819	0.0	0.1111111111111111	0.1111111111111111	1.0	0.06818181818181819	0.0	1.0	0.0	-10.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.1111111111111111	0.0	0.06818181818181819	0.0	0.0	0.0	0.0	0.0
46	Mutations in NOTCH2	0.08931354696161327	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.4	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.6666666666666666	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
137	11% (26 of 239)	0.2068160979800119	0.0	0.0	0.0	0.04	0.04	0.14285714285714285	0.14285714285714285	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04	0.04	7.0	0.04716981132075472	0.42857142857142855	1.0	0.0	-3.8000000000000007	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
317	hematological;Haematology NOS	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	abacavir-related hypersensitivity among HIV-infected patients	0.1398904222743754	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.18181818181818182	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.1111111111111111	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
30	poorly;Poorly	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	Binding site;binding site	0.27926268070552995	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
287	Inhibition of AURKA	0.2298490630899124	-2.6000000000000014	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-2.6000000000000014	1.0	1.0	-2.75	0.04	0.0449438202247191	1.0	0.044642857142857144	0.044642857142857144	3.0	0.0449438202247191	0.6666666666666666	1.0	1.0	-2.75	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.044642857142857144	0.0	0.0449438202247191	0.0	1.0	0.3333333333333333	0.0	1.0
304	mediated	0.6648009807513278	-1.625	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.625	0.0	0.0	0.0	0.04	0.04	0.0	0.0427807486631016	0.0427807486631016	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.0427807486631016	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	discovered;Discover	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
131	differential expression patterns	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
101	reduced;Reduced	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
322	SET (suppressor	0.48501901710734213	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
206	Conversion;conversion	0.0825252537144009	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.05	0.05	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05	0.0	0.05	0.0	0.0	0.0	0.0	0.0
251	Focal Contact;focal contact	0.19105855228361238	-1.7777777777777786	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.0430622009569378	0.0430622009569378	2.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.0430622009569378	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
147	4.3-60 pmol/min/mg protein	0.49200386044090294	0.0	0.0	0.0	0.04	0.04	0.14285714285714285	0.14285714285714285	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
189	immunoreactive calcitonin	0.7102744372039573	-4.333333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.333333333333334	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.048387096774193554	0.048387096774193554	2.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.048387096774193554	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
291	mobile apps;Mobile apps;mobile smartphone applications;Mobile applications;Mobile Applications;mobile applications;Mobile Apps	0.7898657812223663	-0.8035714285714286	1.0	-18.0	0.04	0.04642857142857143	0.5	0.7604166666666666	1.0	-1.125	0.96875	0.0	-12.857142857142858	0.0	0.0	-0.9375	0.14285714285714285	0.04	0.0	0.04	0.04264705882352941	2.0625	0.043750000000000004	0.7604166666666666	16.0	0.0	-15.0	1.0	0.0	0.5	1.0	1.0	0.0	1.0	0.0	0.0	7.0	1.0	33.0	0.08235294117647059	0.0	0.1	1.0	0.0	0.0	0.0	0.0
307	alpha-Synuclein immunostaining	0.8613260586732145	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	2.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
306	structures	0.06545297567602774	-3.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-15.0	0.04	0.1	0.0	0.046296296296296294	0.046296296296296294	1.0	0.1	0.0	1.0	0.0	-15.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.046296296296296294	0.0	0.1	0.0	0.0	0.0	0.0	0.0
317	Promoter;promoter	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
163	Intake;intake	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
304	conducted;Behavior;Conduct;behavior	0.06762235149832889	-0.6875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.375	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04116402116402117	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.042328042328042326	0.0	0.04	0.0	0.0	0.0	0.0	0.0
6	To;TO;to	0.15883198234642523	-2.3999999999999995	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.111111111111111	0.0	0.0	-4.05	0.04	0.04	0.0	0.04245283018867924	0.04434650215198769	1.0	0.049488017895813995	0.0	5.0	0.0	-9.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	5.0	0.047872340425531915	0.0	0.06349206349206349	0.0	0.0	0.0	0.0	0.0
20	Required;required	0.07417486094086273	-3.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.047058823529411764	0.047058823529411764	1.0	0.05405405405405406	0.0	1.0	0.0	-6.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047058823529411764	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
68	Associated;associated	0.07167819017446007	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.04	0.04631578947368421	1.0	0.06451612903225806	0.0	2.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.05263157894736842	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
180	resulting	0.07416042970090647	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-11.666666666666666	0.04	0.075	0.0	0.045454545454545456	0.045454545454545456	1.0	0.075	0.0	1.0	0.0	-11.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.045454545454545456	0.0	0.075	0.0	0.0	0.0	0.0	0.0
307	and;And	0.16241047454878718	-4.200000000000001	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.800000000000001	0.0	0.0	-3.25	0.04	0.04	0.0	0.044642857142857144	0.04837167384282091	1.0	0.04629150749338819	0.0	4.0	0.0	-4.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.054945054945054944	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
139	Implanted;implanted	0.5368409442571505	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04	0.04	1.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
103	This de novo methylation function	0.2687005778678541	-1.7777777777777786	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-1.571428571428573	0.04	0.042682926829268296	0.0	0.0430622009569378	0.0430622009569378	5.0	0.042682926829268296	0.0	1.0	0.0	-1.571428571428573	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.0430622009569378	0.0	0.042682926829268296	0.0	0.0	0.0	0.0	0.0
15	human proteins from literature	0.15184596242539156	-1.3000000000000007	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	-1.3000000000000007	0.0	0.0	-2.8000000000000007	0.04	0.04504504504504505	0.0	0.04219409282700422	0.04219409282700422	4.0	0.04504504504504505	0.0	1.0	0.0	-2.8000000000000007	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04219409282700422	0.0	0.04504504504504505	0.0	0.0	0.0	0.0	0.0
52	a protein fragment	0.11858912668535745	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	1.0	0.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
146	Required;required	0.09548779979060394	-3.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.04615384615384615	0.04615384615384615	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04615384615384615	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	chromosome 22q11.2;Chromosome 2	0.4804616184411076	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.538461538461538	0.04	0.048872180451127824	0.0	0.04	0.04	2.0	0.048872180451127824	0.5	3.0	0.0	-4.538461538461538	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.048872180451127824	0.0	0.0	0.0	0.0	0.0
95	displays	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	and;And	0.14095469534932045	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	several proteins	0.21866617296931679	-6.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-8.666666666666666	0.04	0.06122448979591836	0.0	0.05263157894736842	0.05263157894736842	2.0	0.06122448979591836	0.0	1.0	0.0	-8.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05263157894736842	0.0	0.06122448979591836	0.0	0.0	0.0	0.0	0.0
180	Myotonic dystrophy (DM)	0.6719943606362041	-3.333333333333332	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.333333333333332	1.0	1.0	0.0	0.04	0.04	0.0	0.04615384615384615	0.04615384615384615	5.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04615384615384615	0.0	0.04	0.0	1.0	0.0	0.0	1.0
317	a small oligonucleotide targeted therapy (Imetelstat)	0.05728878727173258	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.14285714285714285	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
339	immortalization;Immortalization	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	many HCNE sequences	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	AMA1	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
5	used drug	0.03741357016431266	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04819277108433735	0.04819277108433735	2.0	0.04878048780487805	0.5	1.0	0.0	-4.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04819277108433735	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
286	detection;Detection	0.8984354554861325	-0.7200000000000003	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.6000000000000014	0.0	0.0	-6.55	0.04	0.04	0.0	0.04	0.041345794392523366	1.0	0.05612085910446566	0.0	5.0	0.0	-9.75	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	2.0	1.0	5.0	0.04672897196261683	1.0	0.06557377049180328	0.0	0.0	0.0	1.0	0.0
121	the risk of hypersensitivity reaction	0.05183350624936706	-6.666666666666666	1.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.4	1.0	-6.666666666666666	1.0	1.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.054545454545454536	0.054545454545454536	5.0	0.053571428571428575	0.0	1.0	1.0	-6.333333333333334	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.054545454545454536	0.0	0.053571428571428575	0.0	1.0	0.0	0.0	1.0
327	histone H3K36	0.6223598228099416	0.0	0.3333333333333333	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.16666666666666666	0.3333333333333333	0.0	0.0	0.0	-1.3333333333333333	0.04	0.04	0.0	0.04	0.04	2.0	0.042539682539682544	0.5	3.0	0.0	-4.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.0	0.1111111111111111	1.0	1.0	6.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
47	Identification of human gene structure	0.05792237881194445	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.3333333333333333	1.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	nearby master developmental genes	0.13193036697555843	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	1.0	0.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	TMHPs	0.6092727683517799	-2.375	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.375	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04419889502762431	0.04419889502762431	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04419889502762431	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
198	MLPA;MLPA)	0.672124294994799	-6.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-4.375	0.04	0.04819277108433735	0.0	0.05263157894736842	0.05263157894736842	1.5	0.0484866294446077	0.0	2.0	0.0	-4.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.05263157894736842	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
229	the Gene Ontology	0.04397919086969007	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.6666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	efficient;Efficient	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	score;SCORE	0.09979047448650916	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.5	0.04	0.04	0.0	0.04	0.04	1.0	0.045	0.0	2.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
247	immunity;Immunity	0.6449044100446489	-2.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.044444444444444446	0.044444444444444446	1.0	0.04597701149425287	0.0	2.0	0.0	-3.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.044444444444444446	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
255	Consensual diagnostic criteria for facioscapulohumeral dystrophy (FSHD)	0.08632802918258423	0.0	1.0	0.0	0.04	0.04	0.2222222222222222	0.2222222222222222	0.0	0.0	0.375	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.5555555555555556	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
74	right eye palsy	0.16238745582996147	-2.666666666666668	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.04477611940298508	0.04477611940298508	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04477611940298508	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	total gene deletions	0.15583186196235907	-1.3999999999999986	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.0423728813559322	0.0423728813559322	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.0423728813559322	0.0	0.04	0.0	0.0	0.0	0.0	0.0
213	sodium	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	resource;Resource	0.05832455349431528	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04	0.04	1.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
239	both classifications	0.2244708340038517	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.04	0.04	2.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
317	the activity	0.0352239206432226	-3.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04672897196261683	0.04672897196261683	2.0	0.05084745762711865	0.5	1.0	0.0	-5.333333333333334	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04672897196261683	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
14	the identification of these proteins	0.023795899413353017	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.833333333333332	0.04	0.047244094488188976	0.0	0.04	0.04	5.0	0.047244094488188976	0.6	1.0	0.0	-3.833333333333332	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.047244094488188976	0.0	0.0	0.0	0.0	0.0
125	the MTM1 gene;The MTM1 gene	0.9603854005518145	-2.307692307692308	0.15384615384615385	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0641025641025641	0.0	-6.333333333333334	0.0	0.0	-2.730769230769231	0.04	0.04	0.0	0.04	0.04466920451494637	3.0	0.0484016867305992	0.6666666666666666	13.0	0.0	-13.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	39.0	0.053571428571428575	0.0	0.08333333333333333	0.0	0.0	0.0	0.0	0.0
205	mg kg;mg/kg	0.5344168470738581	-7.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.25	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.056338028169014086	0.056338028169014086	3.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.056338028169014086	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
270	the overlapping functions of these two factors	0.034409116765500763	-2.1999999999999993	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	-9.0	0.04	0.0625	0.0	0.043859649122807015	0.043859649122807015	7.0	0.0625	0.14285714285714285	1.0	0.0	-9.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.043859649122807015	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
246	4 alleles	0.6492869849885022	-3.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.25	1.0	1.0	-7.0	0.04	0.05555555555555555	0.0	0.04597701149425287	0.04597701149425287	2.0	0.05555555555555555	0.0	1.0	1.0	-7.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04597701149425287	0.0	0.05555555555555555	0.0	1.0	0.0	0.0	1.0
318	22q11	0.6152447918183105	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	0.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
318	the BCR-ABL kinase	0.5548404767811072	-0.9444444444444446	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	-1.8888888888888893	1.0	1.0	-4.269230769230769	0.04	0.04377104377104377	1.0	0.04	0.04163461538461538	5.0	0.048745026017753296	0.6	2.0	1.0	-6.384615384615385	1.0	1.0	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.8333333333333333	1.0	1.0	10.0	0.04326923076923077	1.0	0.05371900826446282	0.0	1.0	0.2	0.5	1.0
258	response to a decrease	0.07140064350880865	-5.6	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.6	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.051546391752577324	0.051546391752577324	4.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.051546391752577324	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
343	important biological pathways	0.031702599963303234	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.25	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	3.0	0.05	0.3333333333333333	1.0	0.0	-5.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
59	TSH suppression	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
231	the structures	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
238	endovascular coil embolization for the treatment	0.028222221428722737	-1.1666666666666679	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	0.0	-1.1666666666666679	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.04195804195804196	0.04195804195804196	6.0	0.06060606060606061	0.5	1.0	0.0	-8.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04195804195804196	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
206	Group 3;group 3	0.1656552584159238	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04	0.04	2.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
242	nonsustained ventricular tachycardia on Holter electrocardiographic recording	0.44005325271810397	-1.8888888888888893	0.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.0	1.0	-1.8888888888888893	0.0	0.0	0.0	0.04	0.04	0.0	0.04326923076923077	0.04326923076923077	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04326923076923077	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	the formation of a hybrid BCR-ABL gene	0.09861834939246114	0.0	0.0	0.0	0.04	0.04	0.5555555555555556	0.5555555555555556	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-4.307692307692308	0.04	0.0483271375464684	0.0	0.04	0.04	9.0	0.0483271375464684	0.4444444444444444	1.0	1.0	-4.307692307692308	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	9.0	0.04	0.0	0.0483271375464684	0.0	1.0	0.0	0.0	1.0
2	Thyroid-Associated Ophthalmopathy;thyroid-associated ophthalmopathy	0.48395024419094423	-3.3999999999999986	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-8.714285714285714	0.04	0.06140350877192983	0.0	0.046296296296296294	0.0462962962962963	4.0	0.06140350877192983	0.25	3.0	0.0	-8.714285714285714	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	12.0	0.046296296296296294	0.0	0.06140350877192983	0.0	0.0	0.0	0.0	0.0
133	our findings	0.08217313876208321	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	2.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
149	Sustained;sustained	0.15270141463164083	-3.3333333333333335	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.046176046176046176	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	interpretable diffraction data from micrometer-	0.29956052836315394	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
57	response to anti-thyroid drugs;response to drugs	0.0455474356186744	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	4.0	0.04	0.5	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.25	0.0	1.0
94	established indications	0.029926285430394172	0.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	2.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.5	0.0	0.0
99	apparent	0.09691608242490507	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.571428571428573	0.04	0.0445859872611465	0.0	0.04	0.04	1.0	0.0445859872611465	0.0	1.0	0.0	-2.571428571428573	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
11	its high citric acid producing capability and broad applicability in industry	0.10962669905913784	-2.166666666666668	0.0	0.0	0.04	0.04	0.8181818181818182	0.8181818181818182	0.0	0.0	0.0	1.0	-2.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.043795620437956206	0.043795620437956206	11.0	0.04	0.09090909090909091	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	11.0	0.043795620437956206	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	Transition;transition	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
275	Five;five	0.07126214710155644	-4.375	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.375	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.048484848484848485	0.048484848484848485	1.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.048484848484848485	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
44	considered	0.10476109708497189	-11.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-11.25	0.0	0.0	-10.333333333333334	0.04	0.06818181818181819	0.0	0.07272727272727272	0.07272727272727272	1.0	0.06818181818181819	0.0	1.0	0.0	-10.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.07272727272727272	0.0	0.06818181818181819	0.0	0.0	0.0	0.0	0.0
323	features;Feature	0.14316330249380058	-2.5500000000000003	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.4	0.0	0.0	-2.6875	0.04	0.04	0.0	0.04	0.04546580671580672	1.0	0.04594183740912095	0.0	4.0	0.0	-8.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.056818181818181816	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
114	adenine;ADENINE	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	tumor gene expression	0.17550619424813224	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-2.666666666666667	0.04	0.04	0.0	0.04	0.04	3.0	0.04542372881355933	0.0	2.0	1.0	-5.333333333333334	1.0	0.3333333333333333	1.0	0.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.05084745762711865	0.0	1.0	0.0	0.0	1.0
318	1973	0.625116700202313	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.46153846153846	0.04	0.04436860068259385	0.0	0.04	0.04	1.0	0.04436860068259385	0.0	1.0	0.0	-2.46153846153846	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04436860068259385	0.0	0.0	0.0	0.0	0.0
144	SERCA	0.6043241503152926	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.045454545454545456	0.045454545454545456	1.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.045454545454545456	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
186	the SQTS phenotype in this family	0.08680331008994818	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
72	the biomedical literature	0.01908280113278511	-2.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.3333333333333333	0.0	-2.0	0.0	0.0	-3.6000000000000014	0.04	0.04672897196261683	0.0	0.043478260869565216	0.043478260869565216	3.0	0.04672897196261683	0.6666666666666666	1.0	0.0	-3.6000000000000014	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043478260869565216	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
88	connected;Connect	0.0815380320002953	-3.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.046511627906976744	0.046511627906976744	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046511627906976744	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
226	the Gulf War Syndrome (GWS)	0.0677596013804125	-2.6000000000000014	1.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.3333333333333333	1.0	-2.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.044642857142857144	0.044642857142857144	7.0	0.04	0.5714285714285714	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.044642857142857144	0.0	0.04	0.0	0.0	0.0	0.0	0.0
159	a higher risk for neurodevelopmental problems	0.0747829060298053	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
78	female;FEMALE	0.12805384199965505	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	0.0	0.04	0.04	0.0	0.04878048780487805	0.04878048780487805	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04878048780487805	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	ne;NE	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
72	frame-based approach	0.06118451344089897	-1.6999999999999993	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-1.6999999999999993	0.0	0.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.04291845493562232	0.04291845493562232	4.0	0.046296296296296294	0.25	1.0	0.0	-3.3999999999999986	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04291845493562232	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
334	Post-Translational Modifications;post-translational modifications	0.5257597432097272	-4.777777777777779	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.777777777777779	0.0	0.0	-8.25	0.04	0.05970149253731343	0.0	0.049450549450549455	0.049450549450549455	2.0	0.05970149253731343	0.0	1.0	0.0	-8.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.049450549450549455	0.0	0.05970149253731343	0.0	0.0	0.0	0.0	0.0
73	TIME;time	0.08844032088011314	-3.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.0	0.0	-2.166666666666668	0.04	0.043795620437956206	0.0	0.046875	0.046875	1.0	0.043795620437956206	0.0	1.0	0.0	-2.166666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046875	0.0	0.043795620437956206	0.0	0.0	0.0	0.0	0.0
14	Combined prediction	0.014026008589989328	-1.625	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.3333333333333333	0.0	-1.625	0.0	0.0	-7.333333333333334	0.04	0.05660377358490567	0.0	0.0427807486631016	0.0427807486631016	2.0	0.05660377358490567	0.5	1.0	0.0	-7.333333333333334	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.0427807486631016	0.0	0.05660377358490567	0.0	0.0	0.0	0.0	0.0
102	arrhythmic wheel-running behavior	0.15898064341854684	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
343	Role;role;roles;Roles	0.008179617587097766	-3.0	1.0	-16.0	0.04	0.05422222222222223	1.0	1.0	1.0	-3.2	1.0	0.0	-15.0	0.0	0.0	-3.0666666666666664	0.1111111111111111	0.04	1.0	0.04	0.052000000000000005	1.0	0.052689655172413793	1.0	5.0	0.0	-15.333333333333332	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	5.0	0.1	0.0	0.10344827586206895	1.0	0.0	1.0	0.0	0.0
65	methylation;Methylation	0.8316679213021553	-1.625	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.25	0.0	0.0	-1.875	0.04	0.04	0.0	0.04	0.04298850574712644	0.5	0.043529411764705886	0.0	2.0	0.0	-3.75	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04597701149425287	1.0	0.047058823529411764	0.0	0.0	0.0	1.0	0.0
38	ten;TEN	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
251	unchanged;Unchanged	0.5526215475635718	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.04	0.04615384615384615	0.0	0.04	0.04	1.0	0.04615384615384615	0.0	1.0	0.0	-3.333333333333332	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04615384615384615	0.0	0.0	0.0	0.0	0.0
147	infants;Infants;INFANT;infant	0.11464127260930641	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
24	middle-aged individuals	0.3025179068747552	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.04	0.04	4.0	0.05405405405405406	0.0	2.0	0.0	-6.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
285	High;higher	0.09176746255704875	-2.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.043859649122807015	0.043859649122807015	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043859649122807015	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	the known families	0.00243546208538469	-5.0	1.0	-18.0	0.14285714285714285	0.14285714285714285	1.0	1.0	1.0	-18.0	1.0	0.0	-5.0	0.0	0.0	-18.5	0.14285714285714285	0.15384615384615385	1.0	0.05	0.05	3.0	0.15384615384615385	1.0	1.0	0.0	-18.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05	0.0	0.15384615384615385	1.0	0.0	0.3333333333333333	0.0	0.0
242	Risk;risk	0.029991396553258116	-1.9841269841269844	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.555555555555555	0.0	0.0	-2.7857142857142856	0.04	0.04	0.0	0.04	0.043657386867790596	1.0	0.047387700019278965	1.0	7.0	0.0	-10.75	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	7.0	0.04891304347826087	0.0	0.07017543859649122	1.0	0.0	0.0	0.0	0.0
102	Detected;detected	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
203	to;TO	0.08076557193035509	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04716981132075472	0.0	1.0	0.0	-3.8000000000000007	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
301	provides	0.07698808476967817	-2.1111111111111107	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1111111111111107	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.043689320388349516	0.043689320388349516	1.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.043689320388349516	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
247	45 years	0.31718573992953314	-1.083333333333334	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	-1.5	0.04	0.04	0.0	0.04	0.04189781021897811	2.0	0.042727272727272725	0.0	2.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.043795620437956206	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
149	Young;young	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
291	weight-loss mobile apps	0.11876268564574168	0.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
272	a transcriptional repressor of heme oxygenase-1	0.10161115884227312	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.2857142857142857	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.5	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	the chromodomain helicase DNA-binding protein 1 (Chd1) DNA-binding domain in complex	0.07922723268243224	0.0	0.0	0.0	0.04	0.04	0.5294117647058824	0.5294117647058824	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	17.0	0.04	0.17647058823529413	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	17.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
155	induced polymorphic ventricular tachycardia;Induced ventricular tachycardia	0.6104044357723993	-2.833333333333332	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.833333333333332	1.0	1.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.045112781954887216	0.045112781954887216	4.0	0.053571428571428575	0.0	1.0	1.0	-6.333333333333334	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	4.0	0.045112781954887216	0.0	0.053571428571428575	0.0	1.0	0.0	0.0	1.0
147	mostly;Mostly	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
327	modified nucleosomes with trimethylation	0.2238347898074956	-8.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-8.0	0.0	0.0	-6.0	0.04	0.05263157894736842	1.0	0.058823529411764705	0.058823529411764705	4.0	0.05263157894736842	0.25	1.0	0.0	-6.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.058823529411764705	0.0	0.05263157894736842	0.0	0.0	0.25	0.0	0.0
74	The cancer	0.009809378545259151	-3.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-3.333333333333332	1.0	1.0	-3.75	0.04	0.047058823529411764	0.0	0.04615384615384615	0.04615384615384615	2.0	0.047058823529411764	1.0	1.0	1.0	-3.75	1.0	0.3333333333333333	1.0	1.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04615384615384615	0.0	0.047058823529411764	1.0	1.0	0.0	0.0	1.0
325	Thousand;thousands	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
120	a dual-specificity phosphatase	0.6595599117682039	-1.8000000000000007	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	-3.6000000000000014	1.0	1.0	-2.25	0.04	0.04	0.0	0.04	0.04336448598130842	5.0	0.04439024390243902	0.0	2.0	1.0	-4.5	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.04672897196261683	0.0	0.04878048780487805	0.0	1.0	0.0	0.0	1.0
130	not;Not	0.10907193324507547	-1.045454545454545	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.09090909090909	0.0	0.0	-1.0714285714285712	0.04	0.04	0.0	0.041666666666666664	0.04174588086185044	1.0	0.041874999999999996	0.0	2.0	0.0	-2.1428571428571423	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04182509505703422	0.0	0.04375	0.0	0.0	0.0	0.0	0.0
183	normal control;normal controls	0.18908199122859048	-3.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	0.0	0.04	0.04	0.0	0.046511627906976744	0.046511627906976744	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.046511627906976744	0.0	0.04	0.0	0.0	0.0	0.0	0.0
222	patients with early	0.022101528479679992	-4.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.5	0.0	-4.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.047619047619047616	0.047619047619047616	3.0	0.045454545454545456	0.3333333333333333	1.0	0.0	-3.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.047619047619047616	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
137	2009b)	0.35028838531314704	-1.4444444444444429	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.4444444444444429	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04245283018867924	0.04245283018867924	2.0	0.04878048780487805	0.5	1.0	0.0	-4.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04245283018867924	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
276	Contribute;contributes	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
24	blood pressure lowering agents	0.0884415052403157	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
31	vaccine targets for human herpes	0.09793899937175997	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.04	0.04	5.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
215	Recent	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	the best	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
10	TPL2 overexpression in human ADI prostate cancer samples	0.11236100583576558	-2.7142857142857153	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	1.0	-2.7142857142857153	1.0	1.0	0.0	0.04	0.04	0.0	0.04487179487179487	0.04487179487179487	8.0	0.04	0.25	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.04487179487179487	0.0	0.04	0.0	1.0	0.0	0.0	1.0
344	Structure;structure	0.07605879023739286	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.04	0.04477611940298508	0.0	0.04	0.04	1.0	0.04477611940298508	0.0	1.0	0.0	-2.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04477611940298508	0.0	0.0	0.0	0.0	0.0
126	a discontinuation in abacavir prior	0.09157204353345731	-4.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.3333333333333333	1.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	top;Top	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	ANN- and SVM-based methods	0.24174543433208628	-0.9375	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	-1.875	0.0	0.0	-5.416666666666667	0.04	0.04	1.0	0.04	0.04162162162162163	7.0	0.05529411764705883	0.42857142857142855	2.0	0.0	-10.833333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	14.0	0.043243243243243246	0.0	0.07058823529411765	0.0	0.0	0.14285714285714285	0.0	0.0
121	Real;real	0.09660742387934279	-3.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.046875	0.046875	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046875	0.0	0.04	0.0	0.0	0.0	0.0	0.0
39	S-adenosylhomocysteine or methyl donor deficiency	0.11451551809232358	0.0	1.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	7.0	0.04	0.2857142857142857	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.14285714285714285	0.0	0.0
332	BAY-61-3606;BAY 61-3606	0.632331070958031	-2.833333333333332	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.045112781954887216	0.045112781954887216	1.0	0.04938271604938271	0.0	2.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.045112781954887216	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
293	hypnotic;Hypnotic	0.8102538359307317	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04	1.0	0.04	0.0	0.0	0.0	1.0	0.0
14	performance;Performance	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
11	gene (cadA) from Aspergillus terreus	0.3461773173698943	-2.5	0.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.0	1.0	-2.5	1.0	1.0	-5.0	0.04	0.05	0.0	0.044444444444444446	0.044444444444444446	7.0	0.05	0.0	1.0	1.0	-5.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.044444444444444446	0.0	0.05	0.0	1.0	0.0	0.0	1.0
254	systemic lupus erythematosus;Lupus Erythematosus, Systemic	0.7602568357195746	-6.333333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-6.333333333333334	0.0	0.0	-12.333333333333332	0.04	0.07894736842105263	0.0	0.053571428571428575	0.053571428571428575	3.0	0.07894736842105263	0.0	2.0	0.0	-12.333333333333332	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	6.0	0.053571428571428575	0.0	0.07894736842105263	0.0	0.0	0.0	0.0	0.0
71	Shift;shift	0.09213346986549198	-1.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	-4.0	0.04	0.046511627906976744	0.0	0.04	0.04212389380530973	1.0	0.0476460578559274	0.0	2.0	0.0	-4.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04424778761061947	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
307	ubiquitin immunostaining	0.843231783377379	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
122	EPHX1	0.9133466855863861	-1.375	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.042471910112359554	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
267	The design of this system	0.058826846821675965	-2.2857142857142847	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.2857142857142847	0.0	0.0	0.0	0.04	0.04	0.0	0.0440251572327044	0.0440251572327044	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.0440251572327044	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	normal;NORMAL	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
312	in vitro;In Vitro	0.38189205531728154	-2.333333333333332	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.04416159380188157	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04615384615384615	0.0	0.04	0.0	0.0	0.0	0.0	0.0
216	acetate;ACETATE	0.8167064950478904	-6.333333333333333	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-10.0	0.0	0.0	-3.777777777777778	0.04	0.04	0.0	0.04	0.056388888888888884	1.0	0.04818910256410256	0.0	3.0	0.0	-7.666666666666666	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	3.0	0.06666666666666667	0.0	0.05769230769230768	0.0	0.0	0.0	0.0	0.0
96	NaCl 0.9% for injection	0.4465874596892555	-3.25	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
140	the most comprehensive analysis of histone H4	0.026612966047158588	0.0	1.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.14285714285714285	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.5714285714285714	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
345	Analysis;Analyses	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
257	endotoxic shock;Endotoxic Shock	0.3716819202636673	-2.666666666666668	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-2.428571428571427	0.04	0.04430379746835443	0.0	0.04477611940298508	0.04477611940298507	2.0	0.044303797468354424	0.0	3.0	0.0	-2.428571428571427	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04477611940298508	0.0	0.04430379746835443	0.0	0.0	0.0	0.0	0.0
17	severe hyperprolactinemia	0.4614294101819725	-2.166666666666668	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-2.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.043795620437956206	0.043795620437956206	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.043795620437956206	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	the drug	0.05451766449153056	-6.916666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-8.833333333333334	0.0	0.0	-5.333333333333333	0.04	0.05	0.0	0.05	0.0559278350515464	2.0	0.05086206896551724	0.5	2.0	0.0	-5.666666666666666	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.06185567010309279	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
178	associated with;Associated with	0.07422351430941987	-1.375	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.375	0.0	0.0	-2.833333333333332	0.04	0.045112781954887216	0.0	0.042328042328042326	0.042328042328042326	2.0	0.045112781954887216	0.0	1.0	0.0	-2.833333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.042328042328042326	0.0	0.045112781954887216	0.0	0.0	0.0	0.0	0.0
14	integral membrane proteins including both alpha-helical and beta-barrel membrane proteins	0.053238420804887214	0.0	1.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	14.0	0.04	0.42857142857142855	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	14.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
206	CHRONIC;Chronic	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
288	the MINOS complex	0.12311779065144425	-5.833333333333333	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	-7.75	0.04	0.05405405405405406	1.0	0.05	0.05227272727272727	3.0	0.05827702702702703	0.3333333333333333	2.0	0.0	-9.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.054545454545454536	0.0	0.0625	0.0	0.0	0.3333333333333333	0.0	0.0
293	non-hormonal treatments	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
177	indicated;Indicated	0.10518152324987534	-6.111111111111111	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.111111111111111	0.0	0.0	0.0	0.04	0.04	0.0	0.052941176470588235	0.052941176470588235	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.052941176470588235	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	established;Established	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	sequence homology and clustering to attempt	0.12345732182283334	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
269	the cell;cell;the cells;Cells;cells;THE CELL;Cell	0.07433616598892216	-1.3800000000000001	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-5.6	0.04	0.04	0.0	0.04	0.04256257998545575	1.3	0.056399572310782076	0.4	10.0	0.0	-12.5	1.0	0.0	1.0	0.5	1.0	0.0	1.0	0.0	0.0	7.0	1.0	13.0	0.04672897196261683	0.0	0.08	1.0	0.0	0.0	0.0	0.0
86	K+;K	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
281	named	0.13092751886131468	-0.5500000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.1000000000000014	0.0	0.0	-1.25	0.04	0.04	0.0	0.04	0.04092050209205021	1.0	0.042222222222222223	0.0	2.0	0.0	-2.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.041841004184100423	0.0	0.044444444444444446	0.0	0.0	0.0	0.0	0.0
141	The results	0.033100061865277156	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-6.25	0.04	0.05333333333333334	0.0	0.045454545454545456	0.045454545454545456	2.0	0.05333333333333334	0.5	1.0	0.0	-6.25	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.045454545454545456	0.0	0.05333333333333334	0.0	0.0	0.0	0.0	0.0
178	the mammalian cap methyltransferase	0.2333591492273323	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-1.8333333333333321	0.04	0.043165467625899276	0.0	0.04	0.04	4.0	0.043165467625899276	0.25	1.0	1.0	-1.8333333333333321	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04	0.0	0.043165467625899276	0.0	1.0	0.0	0.0	1.0
177	with;With	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	MMR-P)	0.6454225055224085	-5.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05	0.05	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.05	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	Glucose tolerance;glucose tolerance	0.3730670842758065	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
125	encoded	0.6663674738622192	-5.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.05	0.05	1.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.05	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
131	prognostic markers;Prognostic Marker	0.25296082304678	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	2.0	0.045454545454545456	0.0	2.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
164	ENZYMES;enzymes	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	GH) deficiency;GH deficiency	0.841279671778446	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.3333333333333335	0.04	0.0	3.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	the transmembrane strands	0.16921116259197755	-2.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.1111111111111107	0.0	0.0	-6.0	0.04	0.05	0.0	0.04326923076923077	0.04347927557879014	3.0	0.05277777777777778	0.6666666666666666	2.0	0.0	-7.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.043689320388349516	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
15	PubMed articles	0.29036655989416565	-1.3999999999999986	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.3999999999999986	0.0	0.0	-5.800000000000001	0.04	0.052083333333333336	0.0	0.0423728813559322	0.0423728813559322	2.0	0.052083333333333336	0.0	2.0	0.0	-5.800000000000001	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.0423728813559322	0.0	0.052083333333333336	0.0	0.0	0.0	0.0	0.0
24	the Phase II study	0.06637442787073183	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	SAH;(SAH)	0.44324499949616375	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.2857142857142865	0.04	0.04827586206896552	0.0	0.04	0.04	2.0	0.05405246094901267	0.3333333333333333	2.0	0.0	-8.285714285714286	1.0	0.0	0.0	0.5	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.059829059829059825	0.0	0.0	0.0	0.0	0.0
193	G-to-A mutation	0.29956052836315394	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	Philadelphia chromosome and Bcr-Abl oncogene	0.28522481325436105	0.0	0.0	0.0	0.04	0.04	0.14285714285714285	0.14285714285714285	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.42857142857142855	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
8	inner and outer centriole components	0.11131152685406459	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
66	intrauterine fetal demise	0.9322552192911382	-1.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04173913043478261	3.0	0.04	0.3333333333333333	6.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	18.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	DNA replication foci	0.06719038748769064	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	3.0	0.047619047619047616	0.3333333333333333	1.0	0.0	-4.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
16	an analysis similar	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	bortezomib;Bortezomib;BORTEZOMIB	0.999977556744347	-0.7205882352941176	1.0	-8.5	0.04	0.0404040404040404	0.0	0.0	1.0	-0.16666666666666666	1.0	0.0	-14.5	0.0	0.0	-0.1568627450980392	0.06060606060606061	0.04	0.0	0.04	0.041907443634149825	1.0	0.04036908881199539	1.0	51.0	0.0	-8.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	51.0	0.09523809523809523	0.0	0.058823529411764705	1.0	0.0	0.0	0.0	0.0
164	Pathway;pathway	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
298	leukocytes	0.6622818498392087	-1.3333333333333321	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.3333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.04225352112676056	0.04225352112676056	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04225352112676056	0.0	0.04	0.0	0.0	0.0	0.0	0.0
231	cardiac electrophysiology method	0.31051003823661766	-1.7142857142857153	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-1.7142857142857153	0.0	0.0	-5.142857142857142	0.04	0.050359712230215826	0.0	0.04294478527607362	0.04294478527607362	3.0	0.050359712230215826	0.0	1.0	0.0	-5.142857142857142	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04294478527607362	0.0	0.050359712230215826	0.0	0.0	0.0	0.0	0.0
76	2- and 9-item instruments	0.2478904757530383	-3.333333333333332	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.04615384615384615	0.04615384615384615	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04615384615384615	0.0	0.04	0.0	0.0	0.0	0.0	0.0
125	loss-of-function mutations;loss of function mutations	0.5441717534568059	-4.222222222222222	0.0	0.0	0.04	0.04	0.5	0.5833333333333334	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.04813947436898256	5.333333333333333	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	16.0	0.04918032786885245	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	expression;Expression;expressions	0.36692412803441105	-0.7777777777777773	0.0	0.0	0.04	0.04	0.0	0.6666666666666666	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-4.0	0.04	0.046511627906976744	0.0	0.04	0.041372549019607845	0.6666666666666666	0.04765105582859041	0.0	3.0	0.0	-4.75	1.0	0.0	0.6666666666666666	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.044117647058823525	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
265	caused;cause;causal;causality	0.34027397165534135	-1.0999999999999996	0.0	0.0	0.04	0.04	0.0	0.5	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	-2.0	0.04	0.04	0.0	0.04	0.04192982456140351	1.0	0.04380952380952381	0.0	2.0	0.0	-4.0	1.0	0.0	0.5	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.043859649122807015	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
102	Peripheral alteration;alterations in peripheral	0.16781609487119212	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
59	6 months	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
25	peer	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	comparison with thalidomide (THAL)	0.20852332232902263	-2.75	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-2.75	0.0	0.0	-7.4	0.04	0.056818181818181816	0.0	0.0449438202247191	0.0449438202247191	6.0	0.056818181818181816	0.3333333333333333	1.0	0.0	-7.4	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.0449438202247191	0.0	0.056818181818181816	0.0	0.0	0.0	0.0	0.0
283	human tumor xenografts	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
215	Activated RAS/BRAF oncogenes	0.6259735210376014	-9.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-9.5	1.0	1.0	-11.4	0.04	0.07352941176470588	1.0	0.06451612903225806	0.06451612903225806	5.0	0.07352941176470588	0.2	1.0	1.0	-11.4	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.06451612903225806	0.0	0.07352941176470588	0.0	1.0	0.2	0.0	1.0
185	treated with;Treated with	0.11707437433269925	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
287	pharmacokinetics;mechanism of action;Pharmacokinetics	0.48093418220828693	-5.666666666666667	1.0	-18.0	0.04	0.07428571428571427	0.0	0.3333333333333333	1.0	-6.0	1.0	0.0	-11.8	0.0	0.0	-7.166666666666667	0.14285714285714285	0.04	0.0	0.043859649122807015	0.05502392344497608	1.6666666666666667	0.0764562569213732	0.3333333333333333	6.0	0.0	-18.0	1.0	0.0	0.3333333333333333	0.3333333333333333	1.0	0.0	1.0	0.0	0.0	3.0	1.0	10.0	0.07575757575757576	0.0	0.14285714285714285	1.0	0.0	0.0	0.0	0.0
344	GFP-H2A	0.7163601152334724	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	the protein	0.09011469336263386	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.6666666666666666	1.0	1.0	1.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
219	its MIC	0.2129590542449012	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04	0.04	2.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
279	Consequence of;consequence of	0.027764490495879767	-3.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-5.166666666666666	0.04	0.050420168067226885	0.0	0.04716981132075472	0.04716981132075472	2.0	0.050420168067226885	0.5	1.0	0.0	-5.166666666666666	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04716981132075472	0.0	0.050420168067226885	0.0	0.0	0.0	0.0	0.0
89	Trial;trials	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
146	abnormal histology	0.7171103039010437	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.045454545454545456	0.045454545454545456	2.0	0.046875	0.0	2.0	0.0	-3.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.045454545454545456	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
251	TGF beta;TGFbeta	0.8239906476238521	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
242	variables	0.11341929787188944	-1.5555555555555571	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	0.0	0.04	0.04	0.0	0.04265402843601896	0.04265402843601896	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04265402843601896	0.0	0.04	0.0	0.0	0.0	0.0	0.0
20	term UNIMOD	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
87	Behavior;behavior	0.09879086499366053	-7.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.5	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.05714285714285714	0.05714285714285714	1.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05714285714285714	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
4	least;Less	0.11777856355602326	-3.3125	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04419889502762431	0.04619583305598083	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	transmembrane beta-barrel proteins in prokaryotes	0.04372200468599169	-2.0	1.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.5714285714285714	0.0	-2.0	0.0	0.0	-2.333333333333332	0.04	0.044117647058823525	0.0	0.043478260869565216	0.043478260869565216	7.0	0.044117647058823525	0.7142857142857143	1.0	0.0	-2.333333333333332	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.043478260869565216	0.0	0.044117647058823525	0.0	0.0	0.0	0.0	0.0
121	EXCLUSION;exclusion	0.5952169860575758	-5.666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.051724137931034475	0.051724137931034475	1.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.051724137931034475	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
334	Consensus Sequence;consensus sequence	0.08499037322511777	-1.8888888888888893	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	0.0	0.04	0.04	0.0	0.04326923076923077	0.04326923076923077	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04326923076923077	0.0	0.04	0.0	0.0	0.0	0.0	0.0
198	Analyzed;analyzed	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
6	naloxone 0.8 mg s.q. (n	0.7476026326176954	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	7.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
152	no;NO	0.12347122094348187	-3.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-3.6000000000000014	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04672897196261683	0.04672897196261683	1.0	0.04716981132075472	0.0	1.0	0.0	-3.8000000000000007	1.0	0.3333333333333333	1.0	0.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	1.0	0.04672897196261683	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
213	confirmed disease occurrence	0.21502134065069065	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
80	Possible;possible	0.09919730632964434	-1.083333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	-2.3	0.04	0.04	0.0	0.04	0.04189781021897811	1.0	0.04450980392156863	0.0	2.0	0.0	-4.6	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.043795620437956206	0.0	0.04901960784313726	0.0	0.0	0.0	0.0	0.0
163	production;Production	0.09960421053733139	-3.0999999999999996	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-5.0	0.04	0.04918032786885245	0.0	0.045454545454545456	0.045663052543786484	1.0	0.05001389274798555	0.0	2.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04587155963302752	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
261	CASQ2-encoded calsequestrin 2	0.20206469163050303	-2.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.6	1.0	-2.0	0.0	0.0	-3.166666666666668	0.04	0.04580152671755725	0.0	0.043478260869565216	0.043478260869565216	5.0	0.04580152671755725	0.6	1.0	0.0	-3.166666666666668	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.043478260869565216	0.0	0.04580152671755725	0.0	0.0	0.0	0.0	0.0
279	Activation;activation	0.5366581521882713	-2.3999999999999986	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	-6.833333333333334	0.04	0.05504587155963304	0.0	0.04424778761061947	0.04424778761061947	1.0	0.05504587155963304	0.0	1.0	0.0	-6.833333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04424778761061947	0.0	0.05504587155963304	0.0	0.0	0.0	0.0	0.0
215	Safe-Guard;safeguard	0.5761661541369315	-3.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04597701149425287	0.04597701149425287	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04597701149425287	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
276	ARMS;arms	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
322	zest and trithorax) domain	0.09808003582556085	0.0	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.2	0.0	0.0
88	a novel role in tumor development	0.07748277985570153	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
189	our sample	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
28	Associated;associated	0.10722162528744765	-6.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.054545454545454536	0.054545454545454536	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.054545454545454536	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	the spatial gene-expression patterns	0.06492807365026797	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
198	cardiac death	0.2400451321575014	-4.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.047619047619047616	0.047619047619047616	2.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047619047619047616	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
288	keeping;Keep	0.09888188928863312	-4.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.048387096774193554	0.048387096774193554	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.048387096774193554	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	the maintenance methyltransferase DNA methyltransferase (cytosine 5)-1 (Dnmt1)	0.11402045020879366	0.0	1.0	0.0	0.04	0.04	0.23076923076923078	0.23076923076923078	0.0	0.0	0.2222222222222222	1.0	0.0	0.0	0.0	-2.428571428571427	0.04	0.04430379746835443	0.0	0.04	0.04	13.0	0.04430379746835443	0.5384615384615384	1.0	0.0	-2.428571428571427	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	13.0	0.04	0.0	0.04430379746835443	0.0	0.0	0.0	0.0	0.0
276	clinical;Clinical	0.09032674913440437	-1.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.75	0.0	0.0	0.0	0.04	0.04	0.0	0.043010752688172046	0.043010752688172046	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043010752688172046	0.0	0.04	0.0	0.0	0.0	0.0	0.0
127	Involving;involving	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	coma;COMATOSE;comatose;COMA	0.9512656862359555	-2.242857142857143	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-10.6	0.0	0.0	-5.160714285714286	0.04	0.04	0.0	0.04	0.04480332971650141	1.0	0.05201714555901613	0.0	14.0	0.0	-11.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	14.0	0.06944444444444445	0.0	0.07407407407407407	0.0	0.0	0.0	0.0	0.0
103	the Dnmt1, Dnmt2 and Dnmt3 enzyme families in eukaryotes	0.10272571187299556	0.0	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.1	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	10.0	0.04	0.2	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.04	0.0	0.04	0.0	1.0	0.1	0.0	1.0
25	comorbid anxiety disorders	0.08440126094814814	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.04	0.04	3.0	0.06060606060606061	0.3333333333333333	1.0	0.0	-8.5	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
305	a rare autosomal recessive condition	0.1814069333671327	-2.571428571428573	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	-2.571428571428573	0.0	0.0	-8.666666666666666	0.04	0.06122448979591836	0.0	0.0445859872611465	0.0445859872611465	5.0	0.06122448979591836	0.0	1.0	0.0	-8.666666666666666	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.0445859872611465	0.0	0.06122448979591836	0.0	0.0	0.0	0.0	0.0
206	previous levels	0.09895169750624769	-5.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.051724137931034475	0.051724137931034475	2.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.051724137931034475	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
270	's ability	0.17938023233523773	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04	0.04	2.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
24	guideline-indicated therapies	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
194	the combined use of Red/ET recombination	0.04307640132093339	-1.7142857142857153	0.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.0	0.0	-1.7142857142857153	0.0	0.0	-14.5	0.04	0.09523809523809523	0.0	0.04294478527607362	0.04294478527607362	8.0	0.09523809523809523	0.25	1.0	0.0	-14.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04294478527607362	0.0	0.09523809523809523	0.0	0.0	0.0	0.0	0.0
226	1990;1990s	0.5303196997977364	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04	0.04	1.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
3	K-12	0.6537765618210096	-5.166666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.166666666666666	0.0	0.0	-4.142857142857142	0.04	0.04794520547945205	0.0	0.050420168067226885	0.050420168067226885	1.0	0.04794520547945205	0.0	1.0	0.0	-4.142857142857142	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.050420168067226885	0.0	0.04794520547945205	0.0	0.0	0.0	0.0	0.0
208	(R)-2-	0.5967405344368791	-4.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04938271604938271	0.04938271604938271	3.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04938271604938271	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
215	the senescence in activated hepatic stellate cells	0.1697773434878509	0.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	a comprehensively annotated version	0.20732857444704947	-1.3999999999999986	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.3999999999999986	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.0423728813559322	0.0423728813559322	4.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.0423728813559322	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
225	Williams syndrome children	0.02654134909204532	-5.666666666666666	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.4	1.0	-5.666666666666666	1.0	1.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.051724137931034475	0.051724137931034475	3.0	0.048387096774193554	0.6666666666666666	1.0	1.0	-4.333333333333334	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.051724137931034475	0.0	0.048387096774193554	0.0	1.0	0.0	0.0	1.0
196	the effects of hyperthyroidism and ADHD symptoms	0.07315313996107475	0.0	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
275	List	0.004675973324467088	-12.5	1.0	-17.0	0.125	0.125	1.0	1.0	1.0	-17.0	1.0	0.0	-12.5	0.0	0.0	-13.0	0.125	0.08333333333333333	1.0	0.08	0.08	1.0	0.08333333333333333	1.0	1.0	0.0	-13.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.08	0.0	0.08333333333333333	1.0	0.0	1.0	0.0	0.0
96	refractory myeloma;refractory multiple myeloma	0.9536938863582908	-0.5	0.0	0.0	0.04	0.04	0.0	0.14285714285714285	0.0	0.0	0.0	1.0	-3.5	1.0	1.0	-0.4000000000000001	0.04	0.04	0.0	0.04	0.04093023255813954	2.4285714285714284	0.04072072072072073	0.0	7.0	1.0	-2.8000000000000007	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	17.0	0.046511627906976744	0.0	0.04504504504504505	0.0	1.0	0.0	0.0	1.0
78	5% of the patients	0.11859582082123679	-3.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
183	Five;five	0.10712771428609377	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04380952380952381	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
199	the centromere identity	0.09835155307757487	-4.333333333333334	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-4.333333333333334	1.0	1.0	-4.166666666666666	0.04	0.047999999999999994	0.0	0.048387096774193554	0.048387096774193554	3.0	0.047999999999999994	0.3333333333333333	1.0	1.0	-4.166666666666666	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.048387096774193554	0.0	0.047999999999999994	0.0	1.0	0.0	0.0	1.0
339	Encoding;encoding	0.6078722860890746	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
186	the short QT syndrome	0.0172193578300717	0.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.6666666666666666	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.75	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
236	Presence;presence	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	radial;Radial	0.5433496108361215	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.166666666666666	0.04	0.047999999999999994	0.0	0.04	0.04	1.0	0.047999999999999994	0.0	1.0	0.0	-4.166666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.047999999999999994	0.0	0.0	0.0	0.0	0.0
239	12 Japanese families	0.16326638755106748	-2.833333333333332	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.045112781954887216	0.045112781954887216	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.045112781954887216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
245	reconstituted thin filaments to calcium	0.12817804812278952	-1.571428571428573	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.16666666666666666	1.0	-1.571428571428573	0.0	0.0	-5.800000000000001	0.04	0.052083333333333336	0.0	0.042682926829268296	0.042682926829268296	5.0	0.052083333333333336	0.2	1.0	0.0	-5.800000000000001	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.042682926829268296	0.0	0.052083333333333336	0.0	0.0	0.0	0.0	0.0
14	the program BETAWRAP	0.06719038748769064	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	3.0	0.047619047619047616	0.3333333333333333	1.0	0.0	-4.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
126	a wide range of signs and symptoms	0.04013528348149354	-2.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	1.0	0.04504504504504505	0.04504504504504505	7.0	0.048387096774193554	0.2857142857142857	1.0	0.0	-4.333333333333334	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04504504504504505	0.0	0.048387096774193554	0.0	0.0	0.14285714285714285	0.0	0.0
203	imprinting;imprinted	0.7910443680429464	-3.05	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.25	0.0	0.0	-1.5599999999999994	0.04	0.04	0.0	0.04	0.04633955114252993	1.0	0.042803118908382065	0.0	5.0	0.0	-3.3999999999999986	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.056338028169014086	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
116	proton-pump inhibitors;Inhibitors, Proton Pump	0.638232014659699	-5.800000000000001	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	-5.800000000000001	1.0	1.0	-3.666666666666668	0.04	0.046875	0.0	0.052083333333333336	0.052083333333333336	4.0	0.046875	0.0	2.0	1.0	-3.666666666666668	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	8.0	0.052083333333333336	0.0	0.046875	0.0	1.0	0.0	0.0	1.0
14	a computational method	0.054557771475720475	-0.6666666666666666	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.5	0.0	-2.0	0.0	0.0	-2.611111111111111	0.04	0.04	1.0	0.04	0.04115942028985507	3.0	0.045097300690521036	0.6666666666666666	3.0	0.0	-5.333333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.043478260869565216	0.0	0.05084745762711865	0.0	0.0	0.3333333333333333	0.0	0.0
100	the inhibition of c5 DNA methyltransferases	0.1216161135605925	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.5	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	functional element;Functional assay of such elements	0.12640500091474718	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	10.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
208	-induced seizures in rats and mice	0.15253371083258746	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	physical interactions	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
76	coronary artery disease	0.4781381551209605	-2.5	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-2.5	0.0	0.0	0.0	0.04	0.04	0.0	0.044444444444444446	0.044444444444444446	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.044444444444444446	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	clinical features;clinical feature	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	inactivation of mCry1	0.23060711103797382	-3.5	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	0.0	0.04	0.04	0.0	0.046511627906976744	0.046511627906976744	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.046511627906976744	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	macrophages;Macrophages	0.7493740636533489	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-1.833333333333334	0.04	0.04	0.0	0.04	0.04631578947368421	1.0	0.043437500000000004	0.0	4.0	0.0	-3.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.05263157894736842	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
282	mediated	0.6061727918900499	-3.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.04587155963302752	0.04587155963302752	1.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04587155963302752	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
74	Association;association	0.10222361792257627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.875	0.04	0.04	0.0	0.04	0.04	1.0	0.043529411764705886	0.0	2.0	0.0	-3.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
30	Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD);amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD	0.7975500414001471	0.0	0.0	0.0	0.04	0.04	0.08333333333333333	0.08712121212121213	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	11.5	0.04	0.0	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	23.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
102	2 genes	0.33894568817070503	-5.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-5.0	1.0	1.0	0.0	0.04	0.04	0.0	0.05	0.05	2.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.05	0.0	0.04	0.0	1.0	0.0	0.0	1.0
61	Several;several	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
34	these results	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
99	clinical;Clinical	0.07889401043874317	-2.375	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-7.5	0.04	0.05	0.0	0.04	0.04469135802469136	1.0	0.058333333333333334	0.0	2.0	0.0	-10.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04938271604938271	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
193	a nonsense mutation	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
107	log(N +	0.22882855041971736	-1.1666666666666679	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-1.1666666666666679	0.0	0.0	-6.2857142857142865	0.04	0.05343511450381679	0.0	0.04195804195804196	0.04195804195804196	4.0	0.05343511450381679	0.25	1.0	0.0	-6.2857142857142865	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04195804195804196	0.0	0.05343511450381679	0.0	0.0	0.0	0.0	0.0
216	previous;Previous	0.09657747641108697	-4.625	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-9.25	0.0	0.0	-1.833333333333334	0.04	0.04	0.0	0.04	0.05174603174603175	1.0	0.043437500000000004	0.0	2.0	0.0	-3.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.06349206349206349	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
102	Mutations;mutations	0.6802751404187134	-3.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.046536796536796536	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	the establishment and maintenance	0.059947674062335914	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.571428571428573	0.04	0.0445859872611465	0.0	0.04	0.04	4.0	0.0445859872611465	0.5	2.0	0.0	-2.571428571428573	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
234	60	0.8471672674973125	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	0.04	1.0	0.04	0.0	0.0	0.0	1.0	0.0
34	TR beta	0.9820469621963847	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	8.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	16.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	inter-individual variation in the amount	0.057961055114664525	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
245	binding properties of the FHC-associated cardiac troponin C;troponin C binding	0.10336938994049073	-2.7142857142857153	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-2.7142857142857153	0.0	0.0	0.0	0.04	0.04	0.0	0.04487179487179487	0.04487179487179487	10.0	0.04	0.3	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	10.0	0.04487179487179487	0.0	0.04	0.0	0.0	0.0	0.0	0.0
94	patients;Patients	0.39185169320113883	-0.875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.0415452694235589	1.0	0.04	0.0	8.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.044642857142857144	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	20%;20	0.6066186994119565	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	the use	0.044333383448042274	-2.833333333333333	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-5.833333333333333	0.04	0.04	0.0	0.04	0.04586206896551724	2.0	0.057499999999999996	0.5	2.0	0.0	-11.666666666666666	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.051724137931034475	0.0	0.075	0.0	0.0	0.0	0.0	0.0
44	Toxoplasma gondii;TOXOPLASMA GONDII	0.6721500832556117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
220	caused;cause	0.004915385825868393	-7.9375	1.0	-15.666666666666668	0.04	0.07357142857142858	1.0	1.0	1.0	-7.833333333333334	1.0	0.0	-15.875	0.0	0.0	-7.333333333333334	0.10714285714285715	0.04	0.0	0.04	0.0747945205479452	1.0	0.06838709677419355	1.0	2.0	0.0	-14.666666666666668	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.1095890410958904	0.0	0.09677419354838711	1.0	0.0	0.0	0.0	0.0
303	DNA	0.1330392608937733	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04173913043478261	0.0	2.0	0.0	-2.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
255	autosomal-dominant disorder	0.20499056134690424	-2.571428571428573	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-2.571428571428573	1.0	1.0	-10.0	0.04	0.06666666666666667	0.0	0.0445859872611465	0.0445859872611465	4.0	0.06666666666666667	0.0	1.0	1.0	-10.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.0445859872611465	0.0	0.06666666666666667	0.0	1.0	0.0	0.0	1.0
7	Six	0.08901268029888651	-4.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-8.75	0.04	0.06153846153846154	0.0	0.04938271604938271	0.04938271604938271	1.0	0.06153846153846154	0.0	1.0	0.0	-8.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04938271604938271	0.0	0.06153846153846154	0.0	0.0	0.0	0.0	0.0
212	two different entities	0.08651458826887391	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.1428571428571423	0.04	0.04375	0.0	0.04	0.04	3.0	0.04375	0.0	1.0	0.0	-2.1428571428571423	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04375	0.0	0.0	0.0	0.0	0.0
125	origin	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
152	kg extract	0.5740084868557815	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.6	0.04	0.051546391752577324	0.0	0.04	0.04	2.0	0.051546391752577324	0.0	1.0	0.0	-5.6	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.051546391752577324	0.0	0.0	0.0	0.0	0.0
5	one small and inconclusive trial	0.08848691453375389	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
142	The susceptibility gene	0.07408740368206129	-3.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-3.0	0.0	0.0	-2.0	0.04	0.043478260869565216	1.0	0.045454545454545456	0.045454545454545456	3.0	0.043478260869565216	0.6666666666666666	1.0	0.0	-2.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.045454545454545456	0.0	0.043478260869565216	0.0	0.0	0.3333333333333333	0.0	0.0
73	identification;Identification	0.10186030917515071	-2.0370370370370368	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.111111111111111	0.0	0.0	-7.722222222222221	0.04	0.045112781954887216	0.0	0.04	0.04378353376503238	1.0	0.06044575725026852	0.0	3.0	0.0	-11.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.047872340425531915	0.0	0.075	0.0	0.0	0.0	0.0	0.0
165	tetramers with the repeat structure (PuPyPuPy)2 or (PyPuPyPu)	0.15744451377743687	-1.8571428571428577	0.0	0.0	0.04	0.04	0.38461538461538464	0.38461538461538464	0.0	0.0	0.0	0.0	-1.8571428571428577	0.0	0.0	0.0	0.04	0.04	0.0	0.043209876543209874	0.043209876543209874	13.0	0.04	0.07692307692307693	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	13.0	0.043209876543209874	0.0	0.04	0.0	0.0	0.0	0.0	0.0
269	A-549;A549	0.7447506179556209	-4.040000000000001	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.199999999999999	0.0	0.0	-10.65	0.04	0.05405405405405406	0.0	0.045454545454545456	0.04785475801244719	1.0	0.07208493565315155	0.0	5.0	0.0	-13.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.05319148936170213	0.0	0.08695652173913043	0.0	0.0	0.0	0.0	0.0
321	one of the gliptin input ligands	0.15378049819718018	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
25	account of the neuropsychological features	0.06085164612027579	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04	0.04	5.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
318	The cytogenetic characteristic	0.06828137293581767	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.6153846153846168	0.04	0.046762589928057555	0.0	0.04	0.04	3.0	0.046762589928057555	0.3333333333333333	1.0	0.0	-3.6153846153846168	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.046762589928057555	0.0	0.0	0.0	0.0	0.0
222	an effective treatment	0.07403184058486137	-2.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.043478260869565216	0.043478260869565216	3.0	0.046296296296296294	0.3333333333333333	1.0	0.0	-3.3999999999999986	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043478260869565216	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
72	data analysis algorithms	0.15685241812070536	-1.6000000000000014	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.042735042735042736	0.042735042735042736	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.042735042735042736	0.0	0.04	0.0	0.0	0.0	0.0	0.0
74	myasthenia-like syndrome	0.10527877685808237	-6.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-6.0	0.0	0.0	-12.0	0.04	0.07692307692307693	0.0	0.05263157894736842	0.05263157894736842	4.0	0.07692307692307693	0.5	1.0	0.0	-12.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.05263157894736842	0.0	0.07692307692307693	0.0	0.0	0.0	0.0	0.0
13	femtosecond pulses from a hard-X-	0.19722029354744475	-10.333333333333334	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-10.333333333333334	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.06818181818181819	0.06818181818181819	8.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.06818181818181819	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
122	Greatly;greatly	0.06723208080351806	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.04878048780487805	0.04878048780487805	1.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04878048780487805	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
253	novel treatment;novel therapeutic strategy for the treatment	0.029782876514914843	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	dynamic programming.The space	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
24	CARDIOVASCULAR;cardiovascular	0.6150326596888851	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-10.5	0.04	0.05555555555555555	0.0	0.04	0.04	1.0	0.07335722819593787	0.0	3.0	0.0	-15.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.1	0.0	0.0	0.0	0.0	0.0
239	MTCP1/MTCP1NB	0.5821655744883394	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.04	0.04	3.0	0.04597701149425287	0.0	1.0	0.0	-3.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
66	structural;Structural	0.09166003846162973	-2.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.043795620437956206	0.043795620437956206	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043795620437956206	0.0	0.04	0.0	0.0	0.0	0.0	0.0
72	confirm	0.10106438918132002	-1.6999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6999999999999993	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04291845493562232	0.04291845493562232	1.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04291845493562232	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
182	BRCA1-like status	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	Per2);Per2 gene;Per2;PER2;PER2 gene	0.9834848453519115	-3.65	0.0	0.0	0.04	0.04	0.0	0.03333333333333333	0.0	0.0	0.0	1.0	-5.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04706327574859026	1.1333333333333333	0.04	0.0	15.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	5.0	1.0	17.0	0.05	0.0	0.04	0.0	1.0	0.0	0.0	1.0
242	this finding in larger populations	0.05728222954842886	-1.5555555555555571	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	0.0	0.04	0.04	0.0	0.04265402843601896	0.04265402843601896	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04265402843601896	0.0	0.04	0.0	0.0	0.0	0.0	0.0
297	early spontaneous cardioversion of AF	0.18916618552744635	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	Analysis;analysis	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
140	antibody-based, assays	0.5289233211830923	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
33	cDNA Expression;Expression of SMIM1 cDNA	0.3336903408140467	-1.8000000000000007	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-1.8000000000000007	1.0	1.0	-4.7142857142857135	0.04	0.04929577464788733	0.0	0.04310344827586207	0.04310344827586207	4.0	0.04929577464788733	0.0	2.0	1.0	-4.7142857142857135	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	8.0	0.04310344827586207	0.0	0.04929577464788733	0.0	1.0	0.0	0.0	1.0
103	replication;DNA replication;Replication	0.3725182203178566	0.0	0.0	0.0	0.04	0.04	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.6666666666666667	0.04	0.3333333333333333	3.0	0.0	0.0	1.0	0.0	0.0	0.6666666666666666	0.0	0.0	1.0	0.0	0.0	3.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
233	Cardiac;cardiac	0.4259333838850865	-9.876543209876543	1.0	-8.0	0.04	0.04209150326797386	0.0	0.0	1.0	-0.8888888888888888	1.0	0.0	-14.11111111111111	0.0	0.0	-1.5555555555555556	0.058823529411764705	0.04	0.0	0.049723756906077346	0.06840791583498286	1.0	0.04349501203990368	1.0	9.0	0.0	-8.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.09183673469387754	0.0	0.058823529411764705	1.0	0.0	0.0	0.0	0.0
49	15 different MECP2 mutations	0.14155284349154496	0.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.4	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
322	Factor;factor	0.09773875734391521	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	2 doses of the orally available SYK inhibitor	0.1618371876243834	-3.333333333333332	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-5.0	0.04	0.05	0.0	0.04615384615384615	0.04615384615384615	8.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04615384615384615	0.0	0.05	0.0	0.0	0.0	0.0	0.0
251	This	0.10140117636038026	-1.6666666666666679	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6666666666666679	0.0	0.0	-2.8888888888888893	0.04	0.04522613065326633	0.0	0.04285714285714286	0.04285714285714286	1.0	0.04522613065326633	0.0	1.0	0.0	-2.8888888888888893	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04285714285714286	0.0	0.04522613065326633	0.0	0.0	0.0	0.0	0.0
160	crosstalk;Crosstalk	0.5925339255793207	-3.333333333333332	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-2.571428571428573	0.04	0.0445859872611465	0.0	0.04615384615384615	0.04615384615384615	1.0	0.0445859872611465	0.0	1.0	0.0	-2.571428571428573	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04615384615384615	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
79	charcoal	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	blinded randomized controlled trials	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
208	recent findings	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
75	GALC gene	0.6458974614826881	-9.833333333333334	0.3333333333333333	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.1111111111111111	0.3333333333333333	-12.25	0.3333333333333333	0.0	-7.5	0.04	0.04	0.0	0.05	0.06895424836601306	2.0	0.06181818181818182	0.0	3.0	0.3333333333333333	-11.25	1.0	1.0	0.0	0.0	0.0	0.3333333333333333	1.0	0.0	0.3333333333333333	1.0	1.0	6.0	0.0784313725490196	1.0	0.07272727272727272	0.0	1.0	0.0	0.3333333333333333	1.0
318	tyrosine kinase activity	0.7787164584849127	-0.8148148148148154	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.16666666666666666	-1.7777777777777786	0.0	0.0	-3.384615384615385	0.04	0.043478260869565216	1.0	0.04	0.04139504297149595	3.0	0.04653300234903048	0.6666666666666666	6.0	0.0	-6.307692307692308	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.0	0.05555555555555555	1.0	1.0	18.0	0.0430622009569378	0.0	0.053497942386831275	0.0	0.0	0.3333333333333333	0.0	0.0
86	H+;h	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
331	targeted therapy;Targeted Therapy	0.13404199281913834	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
144	the myocyte enhancer-specific factor-2 (MEF-2)	0.1525332334269564	0.0	1.0	0.0	0.04	0.04	0.2222222222222222	0.2222222222222222	0.0	0.0	0.3333333333333333	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.2222222222222222	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
138	Preferred;preferred	0.04768390210553414	-13.307692307692307	1.0	-14.625	0.0963855421686747	0.0963855421686747	0.0	0.0	1.0	-14.625	1.0	0.0	-13.307692307692307	0.0	0.0	-13.0	0.0963855421686747	0.08333333333333333	0.0	0.08552631578947367	0.08552631578947367	1.0	0.08333333333333333	1.0	1.0	0.0	-13.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.08552631578947367	0.0	0.08333333333333333	1.0	0.0	0.0	0.0	0.0
11	systematic	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	widespread adaptation	0.1845843424121211	-4.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-11.666666666666666	0.04	0.075	0.0	0.047619047619047616	0.047619047619047616	2.0	0.075	0.0	1.0	0.0	-11.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047619047619047616	0.0	0.075	0.0	0.0	0.0	0.0	0.0
317	Imetelstat;IMETELSTAT;imetelstat	0.9989397942965054	-0.31666666666666665	1.0	-12.0	0.04	0.041025641025641026	0.0	0.0	1.0	-0.3333333333333333	1.0	0.0	-11.4	0.0	0.0	-0.32407407407407407	0.07692307692307693	0.04	0.0	0.04	0.04093137254901961	1.0	0.04097222222222222	1.0	36.0	0.0	-11.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	36.0	0.07352941176470588	0.0	0.075	1.0	0.0	0.0	0.0	0.0
258	heterochromatin;Heterochromatin	0.9651143875286543	-2.5545454545454542	1.0	-14.2	0.04	0.042390572390572395	0.0	0.0	1.0	-0.6454545454545454	1.0	0.0	-11.4	0.0	0.0	-4.163636363636363	0.09259259259259259	0.04	0.0	0.04	0.045598976207224154	1.0	0.04965502540428199	1.0	22.0	0.0	-14.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	22.0	0.07352941176470588	0.0	0.09259259259259259	1.0	0.0	0.0	0.0	0.0
26	three children with autistic spectrum disorders	0.018337901140077738	0.0	1.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.2857142857142857	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
131	results;Result	0.12291303496386365	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.733333333333334	0.04	0.04	0.0	0.04	0.04	1.0	0.04853948896631824	0.0	3.0	0.0	-8.6	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.06097560975609757	0.0	0.0	0.0	0.0	0.0
275	a search of available case studies	0.053643096511266454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	serial	0.7626866064381601	-3.5833333333333335	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-9.0	0.0	0.0	-3.75	0.04	0.04	0.0	0.04	0.04833686440677966	1.0	0.04763789973467393	0.0	4.0	0.0	-6.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.0625	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
262	most;Most	0.06312775193674071	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-11.0	0.04	0.07142857142857142	0.0	0.04878048780487805	0.04878048780487805	1.0	0.07142857142857142	0.0	1.0	0.0	-11.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04878048780487805	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0
144	T3R alpha 1-vs. T3R beta 1-specific interactions	0.30088132920195854	-3.3999999999999986	0.0	0.0	0.04	0.04	0.18181818181818182	0.18181818181818182	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.046296296296296294	0.046296296296296294	11.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	11.0	0.046296296296296294	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
95	nucleotide substrate with a sequence;Nucleotide Sequence	0.12711341317138453	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	automatically;Automatically	0.13494617005089593	-2.4333333333333336	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.300000000000001	0.0	0.0	-1.1333333333333329	0.04	0.04	0.0	0.04201680672268907	0.04447647791417083	1.0	0.04209876543209876	0.0	3.0	0.0	-3.3999999999999986	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04830917874396135	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
83	Maintenance;maintenance	0.10573857383457658	-1.4166666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-5.333333333333333	0.04	0.04	0.0	0.04	0.04273092369477912	1.0	0.052582972582972586	0.0	3.0	0.0	-8.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04819277108433735	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
227	characterized;Characterized	0.10418417110693494	-2.299999999999999	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	-3.333333333333333	0.04	0.04	0.0	0.043859649122807015	0.04405371836671324	1.0	0.04727272727272727	0.0	2.0	0.0	-6.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04424778761061947	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
7	occur;Occur	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
277	Reduction;reduction	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	the available biomedical text mining tools for the detection	0.00294559226409174	-2.0	1.0	-6.4	0.05376344086021505	0.05376344086021505	0.6666666666666666	0.6666666666666666	1.0	-6.4	1.0	0.0	-2.0	0.0	0.0	-6.6	0.05376344086021505	0.05434782608695653	1.0	0.043478260869565216	0.043478260869565216	9.0	0.05434782608695653	1.0	1.0	0.0	-6.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.043478260869565216	0.0	0.05434782608695653	1.0	0.0	0.1111111111111111	0.0	0.0
47	cgi;CGI	0.8222087737705759	-1.314814814814815	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04232871145592777	0.0	0.04	0.0	9.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.045112781954887216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
103	prokaryotic DNA MTases	0.3350784820733574	-2.8888888888888893	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-2.8888888888888893	1.0	1.0	-3.571428571428573	0.04	0.04666666666666667	0.0	0.04522613065326633	0.04522613065326633	3.0	0.04666666666666667	0.3333333333333333	1.0	1.0	-3.571428571428573	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.04522613065326633	0.0	0.04666666666666667	0.0	1.0	0.0	0.0	1.0
96	a poor outcome because of multi-drug resistance	0.06495544270537182	0.0	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
293	contraindicated;Contraindicated	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
281	Homozygous or compound heterozygous mutations in the phosphatase and tensin homolog	0.21269757873584078	-1.3000000000000007	0.0	0.0	0.04	0.04	0.45454545454545453	0.45454545454545453	0.0	0.0	0.0	1.0	-1.3000000000000007	1.0	1.0	0.0	0.04	0.04	0.0	0.04219409282700422	0.04219409282700422	11.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	11.0	0.04219409282700422	0.0	0.04	0.0	1.0	0.0	0.0	1.0
205	50, 100, 200	0.6434604460564624	-3.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.75	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.047058823529411764	0.047058823529411764	5.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.047058823529411764	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
79	Incremental intravenous bolus injections of flumazenil 0.1	0.602724312364287	0.0	0.0	0.0	0.04	0.04	0.14285714285714285	0.14285714285714285	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	7.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
79	effects;effect;Effect;Effects	0.16131893325306468	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.9166666666666665	0.04	0.04	0.0	0.04	0.04	1.0	0.04771855866706815	0.0	6.0	0.0	-4.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	6.0	0.04	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
94	U S;U.S	0.6066186994119565	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
7	the FDA	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
200	contact with;Contact with	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
127	a subset of non-small cell lung cancer (NSCLC	0.12581656468356353	-2.0	0.0	0.0	0.04	0.04	0.5555555555555556	0.5555555555555556	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.043478260869565216	0.043478260869565216	9.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.043478260869565216	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
219	cells;Cells	0.06901263893103253	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
276	tri-iodothyronine;triiodothyronine;T(3);Triiodothyronine;T-3;T(3;T3	0.9776617034703303	-0.4270833333333333	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04073435008516905	1.5	0.04	0.0	12.0	0.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	7.0	1.0	18.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
215	due to;Due To	0.03228304556134835	-9.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-9.25	0.0	0.0	-6.4	0.04	0.05376344086021505	0.0	0.06349206349206349	0.06349206349206349	2.0	0.05376344086021505	0.5	1.0	0.0	-6.4	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.06349206349206349	0.0	0.05376344086021505	0.0	0.0	0.0	0.0	0.0
53	fasting and insulin	0.45057787421661794	-4.666666666666666	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-4.666666666666666	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.04918032786885245	0.04918032786885245	3.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04918032786885245	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
254	the perpetuation	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
168	skull at birth	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
84	>90;90	0.5935840892414983	-4.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-9.5	0.0	0.0	-3.0	0.04	0.04	0.0	0.04	0.052258064516129035	0.0	0.04631578947368421	0.0	2.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.06451612903225806	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
124	a validated genomic predictor of outcome and response	0.10308189426194062	-5.333333333333334	0.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	-9.0	0.04	0.0625	0.0	0.05084745762711865	0.05084745762711865	8.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.05084745762711865	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
225	State;state	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
282	four;Four	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
343	the non-SPRY domain	0.021402506562452035	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.6666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
227	the interplay	0.09771392938906225	-3.6000000000000014	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-5.0	0.04	0.05	0.0	0.04672897196261683	0.04672897196261683	2.0	0.05	0.5	1.0	0.0	-5.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04672897196261683	0.0	0.05	0.0	0.0	0.0	0.0	0.0
4	Defined;defined	0.06856647583576071	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-8.6	0.04	0.06097560975609757	0.0	0.047619047619047616	0.047619047619047616	1.0	0.06097560975609757	0.0	1.0	0.0	-8.6	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.06097560975609757	0.0	0.0	0.0	0.0	0.0
79	an;AN	0.06151353459721207	-3.6000000000000014	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-13.0	0.04	0.08333333333333333	0.0	0.04672897196261683	0.04672897196261683	1.0	0.08333333333333333	1.0	1.0	0.0	-13.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04672897196261683	0.0	0.08333333333333333	1.0	0.0	0.0	0.0	0.0
44	the invasive merozoite form of Plasmodia species	0.11396010004646988	-18.5	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	-18.5	0.0	0.0	-9.666666666666666	0.04	0.06521739130434782	0.0	0.15384615384615385	0.15384615384615385	7.0	0.06521739130434782	0.2857142857142857	1.0	0.0	-9.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.15384615384615385	0.0	0.06521739130434782	0.0	0.0	0.0	0.0	0.0
73	the computational tools for the prediction	0.002103042686670756	-6.111111111111111	1.0	-12.333333333333332	0.07894736842105263	0.07894736842105263	0.8333333333333334	0.8333333333333334	1.0	-12.333333333333332	1.0	0.0	-6.111111111111111	0.0	0.0	-13.666666666666668	0.07894736842105263	0.08823529411764706	1.0	0.052941176470588235	0.052941176470588235	6.0	0.08823529411764706	1.0	1.0	0.0	-13.666666666666668	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.052941176470588235	0.0	0.08823529411764706	1.0	0.0	0.16666666666666666	0.0	0.0
129	Take;takes	0.08328873685347998	-1.4444444444444429	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.4444444444444429	0.0	0.0	-1.7142857142857153	0.04	0.04294478527607362	0.0	0.04245283018867924	0.04245283018867924	1.0	0.04294478527607362	0.0	1.0	0.0	-1.7142857142857153	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04245283018867924	0.0	0.04294478527607362	0.0	0.0	0.0	0.0	0.0
96	resistant;Resistant	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	Distributed;distributed	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
125	one;ONE	0.07565309101895304	-6.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-8.25	0.04	0.05970149253731343	0.0	0.053571428571428575	0.053571428571428575	1.0	0.05970149253731343	0.0	1.0	0.0	-8.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.053571428571428575	0.0	0.05970149253731343	0.0	0.0	0.0	0.0	0.0
318	BCR-ABL kinase activity by its kinase inhibitor	0.20832700306817833	-2.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-2.0	1.0	1.0	-9.384615384615385	0.04	0.06403940886699508	1.0	0.043478260869565216	0.043478260869565216	9.0	0.06403940886699508	0.3333333333333333	1.0	1.0	-9.384615384615385	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	9.0	0.043478260869565216	0.0	0.06403940886699508	0.0	1.0	0.2222222222222222	0.0	1.0
124	The 21-gene recurrence score (Oncotype DX	0.09326196445708311	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.16666666666666666	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.2222222222222222	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
189	growth hormone releasing hormone;Growth Hormone-Releasing Hormone	0.07950944431639867	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	2.0	0.0	0.0	1.0	0.3333333333333333	1.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
175	specific variable expressivity	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
183	LOH-positive tumors	0.30127214136079755	-4.25	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-4.25	1.0	1.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04819277108433735	0.0	0.04	0.0	1.0	0.0	0.0	1.0
133	dynein;Dynein	0.4985383547967809	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.166666666666666	0.04	0.059405940594059396	0.0	0.04	0.04	1.0	0.059405940594059396	0.0	1.0	0.0	-8.166666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.059405940594059396	0.0	0.0	0.0	0.0	0.0
179	Ras homologue	0.7367267345127414	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	1.0	0.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
250	T(3) levels	0.3576098223542579	-1.2222222222222214	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-1.2222222222222214	0.0	0.0	0.0	0.04	0.04	0.0	0.04205607476635514	0.04205607476635514	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04205607476635514	0.0	0.04	0.0	0.0	0.0	0.0	0.0
221	several small samples of patients	0.01268275647519386	0.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.2857142857142857	0.0	0.0	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.04	0.04	5.0	0.058823529411764705	0.4	1.0	0.0	-8.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
342	di-, and trimethylation	0.4157568543918074	-2.6000000000000014	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	-2.3999999999999986	0.04	0.04424778761061947	0.0	0.044642857142857144	0.044642857142857144	5.0	0.04424778761061947	0.0	1.0	0.0	-2.3999999999999986	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.044642857142857144	0.0	0.04424778761061947	0.0	0.0	0.0	0.0	0.0
71	the glucose metabolic pathway	0.33740264771975137	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.04	0.04	4.0	0.04597701149425287	0.25	1.0	0.0	-3.25	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
246	cytochrome P-450 (CYP) enzymes for its antiplatelet effect	0.2548987755535382	-4.0	0.0	0.0	0.04	0.04	0.3	0.3	0.0	0.0	0.0	1.0	-4.0	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.047619047619047616	0.047619047619047616	10.0	0.06060606060606061	0.1	1.0	0.0	-8.5	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.047619047619047616	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
129	Copying;copying	0.0702598612648431	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.571428571428571	0.04	0.048951048951048945	0.0	0.04	0.04	1.0	0.048951048951048945	0.0	1.0	0.0	-4.571428571428571	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.048951048951048945	0.0	0.0	0.0	0.0	0.0
178	1981)	0.6229441665957601	-2.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.25	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04395604395604396	0.04395604395604396	2.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04395604395604396	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
125	intracellular vesicle trafficking and autophagy	0.4619600301147112	-4.666666666666666	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.04918032786885245	0.04918032786885245	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04918032786885245	0.0	0.04	0.0	0.0	0.0	0.0	0.0
78	Variant;variant	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
334	the expression	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
200	part of daily routine and recreational activities	0.06495544270537182	0.0	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
307	ALZHEIMER DISEASE;Alzheimer's disease	0.5443286430405467	-2.2666666666666657	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-2.3333333333333335	0.04	0.04	0.0	0.04	0.04419753086419753	3.0	0.04434108527131783	0.0	3.0	0.0	-3.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.046296296296296294	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
249	PcG) proteins;PcG proteins	0.1738275296523439	-9.666666666666666	1.0	-10.875	0.04	0.060530973451327436	0.0	0.0	1.0	-7.25	0.8333333333333334	0.3333333333333333	-14.5	0.0	0.0	-7.083333333333333	0.07079646017699115	0.04	0.0	0.04	0.07682539682539682	2.6666666666666665	0.059710144927536235	1.0	3.0	0.0	-10.625	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.0	0.1111111111111111	2.0	1.0	8.0	0.09523809523809523	0.0	0.06956521739130435	1.0	0.0	0.0	0.0	0.0
128	the CRISPR associated system (CASS	0.09527712544872205	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.09090909090909	0.04	0.04564315352697095	0.0	0.04	0.04	6.0	0.04564315352697095	0.3333333333333333	1.0	0.0	-3.09090909090909	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04564315352697095	0.0	0.0	0.0	0.0	0.0
288	maintenance of cristae morphology	0.18129967949078968	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.04	0.04	4.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
320	Well;well	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
82	the treatment	0.041127749290535025	-1.571428571428573	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.042682926829268296	0.042682926829268296	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.042682926829268296	0.0	0.04	0.0	0.0	0.0	0.0	0.0
267	technologies	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	open data access	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
195	integration of therapeutic, full-length beta-globin cDNA	0.39811620799586034	0.0	0.0	0.0	0.04	0.04	0.36363636363636365	0.36363636363636365	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	11.0	0.04	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	11.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
212	Includes;includes	0.09112461233357536	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
251	SIRT1-mediated EMT	0.25259685787558406	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.2	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
303	the proposal of a critical epigenetic function	0.05283547285065848	-3.333333333333332	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.04615384615384615	0.04615384615384615	7.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04615384615384615	0.0	0.04	0.0	0.0	0.0	0.0	0.0
205	greater duration and intensity	0.10527348842875911	-9.25	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-9.25	0.0	0.0	-9.0	0.04	0.0625	0.0	0.06349206349206349	0.06349206349206349	4.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.06349206349206349	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
139	exploration of a new possibility	0.08688815312496023	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-4.5	0.04	0.04878048780487805	0.0	0.04	0.04	5.0	0.04878048780487805	0.0	1.0	1.0	-4.5	1.0	0.3333333333333333	1.0	0.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04878048780487805	0.0	1.0	0.0	0.0	1.0
271	transporter MCT8	0.46550922673215583	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	2.0	0.04	0.5	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.5	0.0	1.0
179	tuberous sclerosis 1)-Tsc2	0.43637422742410015	-3.666666666666668	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.666666666666668	1.0	1.0	-4.6	0.04	0.04901960784313726	0.0	0.046875	0.046875	6.0	0.04901960784313726	0.3333333333333333	1.0	1.0	-4.6	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.046875	0.0	0.04901960784313726	0.0	1.0	0.0	0.0	1.0
154	RyR1 and RyR2	0.11006929630256981	-1.3636363636363633	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.4	0.0	-1.3636363636363633	0.0	0.0	0.0	0.04	0.04	0.0	0.04230769230769231	0.04230769230769231	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04230769230769231	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	the effect of biologically active substances	0.044397287274752686	-9.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-9.0	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.0625	0.0625	6.0	0.048387096774193554	0.3333333333333333	1.0	0.0	-4.333333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.0625	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
247	all vaccination doses	0.050957470784973355	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.3333333333333333	1.0	0.0	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.04	0.04	3.0	0.04597701149425287	0.3333333333333333	1.0	0.0	-3.25	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
98	many genera	0.010593696200901915	-9.25	1.0	-12.333333333333332	0.07894736842105263	0.07894736842105263	0.5	0.5	1.0	-12.333333333333332	1.0	0.0	-9.25	0.0	0.0	-11.333333333333334	0.07894736842105263	0.07317073170731708	1.0	0.06349206349206349	0.06349206349206349	2.0	0.07317073170731708	1.0	1.0	0.0	-11.333333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.06349206349206349	0.0	0.07317073170731708	1.0	0.0	0.5	0.0	0.0
175	facial and skeletal dysmorphisms	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	aberrant tyrosine kinase activity	0.31485382214711366	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.76923076923077	0.04	0.04498269896193772	1.0	0.04	0.04	4.0	0.04498269896193772	0.5	2.0	0.0	-2.76923076923077	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04498269896193772	0.0	0.0	0.25	0.0	0.0
231	of skinned left ventricular papillary muscle;Papillary muscle of left ventricle	0.06715077639101796	-1.7142857142857153	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.7142857142857153	0.0	0.0	-1.8571428571428577	0.04	0.043209876543209874	0.0	0.04294478527607362	0.04294478527607362	6.0	0.043209876543209874	0.16666666666666666	1.0	0.0	-1.8571428571428577	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04294478527607362	0.0	0.043209876543209874	0.0	0.0	0.0	0.0	0.0
72	two components of a literature-mining system	0.03734094096623492	-1.6000000000000014	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-1.6000000000000014	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.042735042735042736	0.042735042735042736	8.0	0.04587155963302752	0.375	1.0	0.0	-3.1999999999999993	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.042735042735042736	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
242	SUDDEN CARDIAC DEATH;sudden cardiac death	0.04303363400037677	-4.888888888888888	1.0	-11.0	0.04	0.05257142857142857	0.6666666666666666	0.6666666666666666	1.0	-4.4	1.0	0.0	-12.222222222222221	0.0	0.0	-4.8	0.07142857142857142	0.04	0.0	0.04	0.05530434782608695	3.0	0.05476923076923077	1.0	5.0	0.0	-12.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	15.0	0.07826086956521738	0.0	0.07692307692307693	1.0	0.0	0.0	0.0	0.0
73	two separate components	0.07313525775184386	-1.8888888888888893	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-7.833333333333334	0.04	0.05825242718446603	0.0	0.04326923076923077	0.04326923076923077	3.0	0.05825242718446603	0.0	1.0	0.0	-7.833333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04326923076923077	0.0	0.05825242718446603	0.0	0.0	0.0	0.0	0.0
107	this result	0.09486958366324963	-2.083333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.083333333333332	0.0	0.0	-3.2857142857142847	0.04	0.046052631578947366	0.0	0.04363636363636363	0.04363636363636363	2.0	0.046052631578947366	0.0	1.0	0.0	-3.2857142857142847	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04363636363636363	0.0	0.046052631578947366	0.0	0.0	0.0	0.0	0.0
60	Presence;presence	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
241	a form	0.08842207777913372	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-5.800000000000001	0.04	0.052083333333333336	0.0	0.045454545454545456	0.045454545454545456	2.0	0.052083333333333336	0.0	1.0	0.0	-5.800000000000001	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.045454545454545456	0.0	0.052083333333333336	0.0	0.0	0.0	0.0	0.0
329	DockTrina	0.4758116184090327	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-16.0	0.04	0.1111111111111111	0.0	0.04	0.04	1.0	0.1111111111111111	0.0	1.0	0.0	-16.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.1111111111111111	0.0	0.0	0.0	0.0	0.0
192	Greek sample	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
251	a loosening	0.23966322080969865	-1.3333333333333321	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.3333333333333321	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04225352112676056	0.04225352112676056	2.0	0.043478260869565216	0.0	1.0	0.0	-2.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04225352112676056	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
47	internal exons	0.33464996046184486	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	an essential role in the faithful propagation	0.0852775520079777	-1.7777777777777786	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-2.428571428571427	0.04	0.04430379746835443	0.0	0.0430622009569378	0.0430622009569378	7.0	0.04430379746835443	0.2857142857142857	1.0	0.0	-2.428571428571427	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.0430622009569378	0.0	0.04430379746835443	0.0	0.0	0.0	0.0	0.0
121	HLA-B*5701 positivity	0.6483681487328262	-5.333333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.05084745762711865	0.05084745762711865	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.05084745762711865	0.0	0.04	0.0	0.0	0.0	0.0	0.0
189	thyroid function in WS	0.09116837715691324	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.25	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
310	an anticancer target	0.1152605736278717	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.3333333333333333	0.0	0.0
77	down;Lanugo	0.0686014733773157	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.142857142857142	0.04	0.050359712230215826	0.0	0.04	0.04	1.0	0.050359712230215826	0.0	1.0	0.0	-5.142857142857142	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.050359712230215826	0.0	0.0	0.0	0.0	0.0
78	recombinant events in families	0.12367023879385085	-3.5	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	0.0	0.04	0.04	0.0	0.046511627906976744	0.046511627906976744	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.046511627906976744	0.0	0.04	0.0	0.0	0.0	0.0	0.0
222	Potential;potential	0.09736033964489457	-3.8888888888888893	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8888888888888893	0.0	0.0	0.0	0.04	0.04	0.0	0.04736842105263158	0.04736842105263158	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04736842105263158	0.0	0.04	0.0	0.0	0.0	0.0	0.0
137	MS. Data from a few small case series	0.028138854549800932	0.0	1.0	0.0	0.04	0.04	0.875	0.875	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
132	TR	0.6932992203809668	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-2.666666666666667	0.04	0.04	0.0	0.044642857142857144	0.045469576719576715	0.0	0.04542372881355933	0.0	2.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.046296296296296294	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
270	FOG-1	0.951246258961892	-2.7	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.0	1.0	1.0	-3.75	0.04	0.04	0.0	0.04	0.04505489480367299	1.0	0.04857142857142857	0.0	8.0	1.0	-7.5	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.4583333333333333	1.0	1.0	8.0	0.047619047619047616	0.0	0.05714285714285714	0.0	1.0	0.0	0.0	1.0
323	clinicians	0.6284576761118874	-6.800000000000001	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.800000000000001	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.054945054945054944	0.054945054945054944	1.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.054945054945054944	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
206	1.0 mg/kg	0.7544880182025683	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
207	reviewed;Reviewed	0.0626675064812143	-2.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.75	0.0	0.0	-9.666666666666666	0.04	0.06521739130434782	0.0	0.0449438202247191	0.0449438202247191	1.0	0.06521739130434782	0.0	1.0	0.0	-9.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0449438202247191	0.0	0.06521739130434782	0.0	0.0	0.0	0.0	0.0
127	100-fold more resistance to gefitinib and erlotinib	0.024765160258627492	0.0	1.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.5714285714285714	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	femtosecond serial X-ray crystallography results from an irreversible photo-chemical reaction	0.21510976869181234	0.0	0.0	0.0	0.04	0.04	0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.1	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
65	Using H3K4me2	0.3338491380011756	-3.75	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-3.75	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.047058823529411764	0.047058823529411764	2.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.047058823529411764	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
112	few;Few	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
101	GLP	0.7123617662367117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	A mutation in the mPer2 gene	0.0743118587892265	-3.75	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	0.0	0.04	0.04	0.0	0.047058823529411764	0.047058823529411764	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.047058823529411764	0.0	0.04	0.0	0.0	0.0	0.0	0.0
37	the cytotoxic activity	0.13395780048212444	-4.666666666666666	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	-6.75	0.04	0.0547945205479452	0.0	0.04918032786885245	0.04918032786885245	3.0	0.0547945205479452	0.0	1.0	0.0	-6.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04918032786885245	0.0	0.0547945205479452	0.0	0.0	0.0	0.0	0.0
44	a yearly death toll of 1	0.14208246158641555	-2.75	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0449438202247191	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	marked fluctuation with a 17-fold peak	0.22270145532256086	-4.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
249	K27me3 to histone H3 (Suz12)	0.2951082100880776	0.0	0.0	0.0	0.04	0.04	0.14285714285714285	0.14285714285714285	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.04	0.04	7.0	0.04597701149425287	0.42857142857142855	1.0	0.0	-3.25	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
184	1:5000	0.6082487461780236	-5.166666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.166666666666666	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.050420168067226885	0.050420168067226885	1.0	0.06060606060606061	0.0	1.0	0.0	-8.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.050420168067226885	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
100	competitive inhibitors	0.08757876755022728	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	1.0	0.04	0.04	2.0	0.053571428571428575	0.5	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.053571428571428575	0.0	0.0	0.5	0.0	0.0
244	malaria-related transfusions	0.43522476564368545	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	The template-based methods	0.15898064341854684	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
264	atrial fibrillation;ATRIAL FIBRILLATION	0.7589563682959148	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
182	six tumors	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	Standard of Care;standard of care	0.03809459826425287	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	following;subsequent;Subsequent;follow	0.06603694320895509	-2.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.045	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.05	0.0	0.04	0.0	0.0	0.0	0.0	0.0
209	Takifugu and Tetraodon	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
220	whose clinical presentations	0.08509869002293811	-3.625	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.625	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04678362573099415	0.04678362573099415	3.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04678362573099415	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
83	Modulating;modulating	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
153	recommendations	0.19835470683095144	-2.5833333333333335	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-1.4166666666666665	0.04	0.04	0.0	0.04	0.04525466893039049	1.0	0.04293103448275862	0.0	4.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.05263157894736842	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
145	Cevimeline;CEVIMELINE	0.7377347907742027	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
254	HOXD9 protein	0.2970403598762433	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
274	The most advanced	0.15609162684833364	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
257	its absence in knock-out mice	0.06495544270537182	0.0	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
88	transfection of OCT4	0.4342141531406293	-4.5	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-4.5	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04878048780487805	0.04878048780487805	3.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04878048780487805	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
41	a leucine zipper	0.39203418905402276	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04	0.04	3.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
208	various animal models	0.11231982977445785	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05	0.05	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	with;With	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
91	PERCENT;percent	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
147	amounted;Amount	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
25	effective;Efficacy;efficacy	0.46494547529749425	0.0	0.0	0.0	0.04	0.04	0.0	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.75	0.04	0.04	0.0	0.04	0.04	1.0	0.04388888888888889	0.0	4.0	0.0	-7.0	1.0	0.0	0.75	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.04	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
73	PATH;paths	0.08320867127850672	-1.5555555555555571	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	-1.8333333333333321	0.04	0.043165467625899276	0.0	0.04265402843601896	0.04265402843601896	1.0	0.043165467625899276	0.0	1.0	0.0	-1.8333333333333321	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04265402843601896	0.0	0.043165467625899276	0.0	0.0	0.0	0.0	0.0
129	genome stability;stability preservation in the transcriptionally repressed genome;Stability, Genome	0.228336197318578	-0.7777777777777786	0.0	0.0	0.04	0.04	0.42857142857142855	0.4642857142857143	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	-0.8571428571428577	0.04	0.04	0.0	0.04	0.04132701421800948	4.5	0.041472392638036815	0.14285714285714285	2.0	0.0	-1.7142857142857153	1.0	0.0	0.0	0.5	0.0	0.0	1.0	0.0	0.0	3.0	1.0	9.0	0.04265402843601896	0.0	0.04294478527607362	0.0	0.0	0.0	0.0	0.0
198	4810+6dupGGGT	0.6406061742371958	-3.8000000000000007	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04716981132075472	0.04716981132075472	1.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04716981132075472	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
200	28%	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	a fusion event	0.03618461597715179	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.6666666666666666	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
67	the CNS	0.10549951416075809	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
321	Study;study	0.08225122141989441	-3.2000000000000006	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-15.666666666666666	0.04	0.07692307692307693	0.0	0.04504504504504505	0.045889800606781744	1.0	0.11823361823361822	0.0	3.0	0.0	-19.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04716981132075472	0.0	0.16666666666666666	0.0	0.0	0.0	0.0	0.0
16	top scoring hits	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
117	Mutant;mutant	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
344	mH2A1 enrichment	0.7307823555398101	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	Increase;increase	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	hypothalamic;Hypothalamic	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
238	registry portion	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	a promising approach	0.08113288696702693	-2.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04477611940298508	0.04477611940298508	3.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04477611940298508	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
10	the CD3- pattern of chronic NK-lymphocytosis	0.12632243189274936	0.0	0.0	0.0	0.04	0.04	0.4444444444444444	0.4444444444444444	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.2222222222222222	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
75	Which enzyme	0.013543779004151966	-9.75	1.0	-13.75	0.08888888888888889	0.08888888888888889	0.5	0.5	1.0	-13.75	1.0	1.0	-9.75	1.0	1.0	-12.75	0.08888888888888889	0.08163265306122448	1.0	0.06557377049180328	0.06557377049180328	2.0	0.08163265306122448	1.0	1.0	1.0	-12.75	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.06557377049180328	0.0	0.08163265306122448	1.0	1.0	0.5	0.0	1.0
250	patients with heart failure	0.0024713664829488697	-9.0	1.0	-17.0	0.125	0.125	1.0	1.0	1.0	-17.0	1.0	0.0	-9.0	0.0	0.0	-17.666666666666668	0.125	0.13636363636363635	0.0	0.0625	0.0625	4.0	0.13636363636363635	1.0	1.0	0.0	-17.666666666666668	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.0625	0.0	0.13636363636363635	1.0	0.0	0.0	0.0	0.0
227	a case	0.1029765857531556	-7.199999999999999	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.199999999999999	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.056179775280898875	0.056179775280898875	2.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.056179775280898875	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
94	Imatinib;imatinib;IMATINIB	0.9949567141121263	-1.98	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.800000000000001	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04394616704505859	1.0	0.04	0.0	20.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	20.0	0.05813953488372093	0.0	0.04	0.0	0.0	0.0	0.0	0.0
221	Activities;activities	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
281	responsible;Responsible	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
324	affected individuals in 3 generations	0.05833458103272553	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.04	0.04	5.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
267	Transabdominal;trans-abdominal	0.6131290147623241	-2.571428571428573	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.0445859872611465	0.0445859872611465	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0445859872611465	0.0	0.04	0.0	0.0	0.0	0.0	0.0
63	non;Non	0.6066186994119565	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
265	MYH7	0.7965895500474719	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.0	1.0	1.0	-6.0	0.04	0.05263157894736842	0.0	0.045454545454545456	0.045454545454545456	1.0	0.05263157894736842	0.0	1.0	1.0	-6.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	0.045454545454545456	1.0	0.05263157894736842	0.0	1.0	0.0	1.0	1.0
7	neurotubular defects	0.7268739028102027	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	proliferation of MCF7 cells	0.1405487375957212	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
188	Intact	0.14672163679950384	-1.8333333333333321	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.043165467625899276	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043165467625899276	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	Approach;Approaches;approaches;approach	0.1268668715282373	-0.35555555555555574	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-2.666666666666667	0.04	0.04	0.0	0.04	0.04061244019138756	1.0	0.045737145636236376	0.0	5.0	0.0	-8.166666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	5.0	0.0430622009569378	0.0	0.059405940594059396	0.0	0.0	0.0	0.0	0.0
308	sorafenib;SORAFENIB	0.7786266455789895	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
85	Signal;signals	0.06778594253829696	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.428571428571429	0.04	0.05109489051094891	0.0	0.04	0.04	1.0	0.05109489051094891	0.0	1.0	0.0	-5.428571428571429	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05109489051094891	0.0	0.0	0.0	0.0	0.0
85	Herpes simplex virus (HSV)	0.2686867400794902	0.0	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
58	Bismuth compound;bismuth compounds	0.27926268070552995	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
125	female;FEMALE	0.1422472386923776	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04587301587301587	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.05	0.0	0.04	0.0	0.0	0.0	0.0	0.0
344	H3K4me3	0.827827262387126	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-3.166666666666668	0.04	0.04580152671755725	0.0	0.04	0.04	1.0	0.04580152671755725	0.0	1.0	0.0	-3.166666666666668	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	0.04	1.0	0.04580152671755725	0.0	0.0	0.0	1.0	0.0
125	a muscular disorder	0.11877604834947796	-6.333333333333334	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-11.25	0.04	0.07272727272727272	0.0	0.053571428571428575	0.053571428571428575	3.0	0.07272727272727272	0.0	1.0	0.0	-11.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.053571428571428575	0.0	0.07272727272727272	0.0	0.0	0.0	0.0	0.0
129	Li;LI	0.6147170205764493	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.000000000000001	0.04	0.04666666666666667	0.0	0.04	0.04	1.0	0.0476388888888889	0.0	2.0	0.0	-4.428571428571429	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04861111111111112	0.0	0.0	0.0	0.0	0.0
231	Biochemical analysis of one FHC mutant (Arg-249	0.1904371556388782	0.0	0.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.125	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	Transcriptional Repressor;transcriptional co-repressor	0.8615636194843206	-5.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-5.5	0.0	0.0	0.0	0.04	0.04	0.0	0.05128205128205128	0.05128205128205128	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	4.0	0.05128205128205128	0.0	0.04	0.0	0.0	0.0	0.0	0.0
200	commercially available chest barriers	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
50	popularity;popular	0.0029046988824738933	-10.777777777777779	1.0	-17.0	0.125	0.125	1.0	1.0	1.0	-17.0	1.0	0.0	-10.777777777777779	0.0	0.0	-14.6	0.125	0.09615384615384615	0.0	0.0703125	0.0703125	1.0	0.09615384615384615	1.0	1.0	0.0	-14.6	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0703125	0.0	0.09615384615384615	1.0	0.0	0.0	0.0	0.0
153	histamine;HISTAMINE	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	HLA-B*5701 positivity and risk of ABC HSRs	0.18244407713278427	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.1111111111111111	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
16	a broad phylogenetic spectrum	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
176	histone-like molecules	0.015148022415618526	-7.0	1.0	-10.6	0.06944444444444445	0.06944444444444445	0.5	0.5	1.0	-10.6	1.0	1.0	-7.0	1.0	1.0	-11.0	0.06944444444444445	0.07142857142857142	0.0	0.05555555555555555	0.05555555555555555	4.0	0.07142857142857142	1.0	1.0	1.0	-11.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.05555555555555555	0.0	0.07142857142857142	1.0	1.0	0.0	0.0	1.0
102	the core negative feedback loop	0.05411772315431602	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
10	Tpl2/Cot	0.648157441448931	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.27777777777777773	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	3.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
101	Screening;screening	0.0943797958812142	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
84	/40;40	0.6902280558668709	-7.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-8.0	0.0	0.0	-2.0	0.04	0.04	0.0	0.05405405405405406	0.05643879173290938	1.0	0.04380952380952381	0.0	2.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.058823529411764705	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
101	inhibit malaria parasite	0.5217690789566897	-5.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-13.0	0.04	0.08333333333333333	0.0	0.05	0.05	3.0	0.08333333333333333	0.0	1.0	0.0	-13.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05	0.0	0.08333333333333333	0.0	0.0	0.0	0.0	0.0
100	Fig. 1	0.534447536048864	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9.166666666666666	0.04	0.06315789473684211	0.0	0.04	0.04	2.0	0.06315789473684211	0.0	1.0	0.0	-9.166666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.06315789473684211	0.0	0.0	0.0	0.0	0.0
125	due to;Due To	0.24704562035539837	-4.916666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	-2.8125	0.04	0.04	0.0	0.048387096774193554	0.04980863860032805	2.0	0.045458923099372536	0.0	4.0	0.0	-5.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.05084745762711865	0.0	0.05194805194805195	0.0	0.0	0.0	0.0	0.0
60	a single hydrophobic transmembrane segment	0.055584779442315144	0.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.16666666666666666	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
62	the lymphocyte stimulation test	0.1405487375957212	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
160	for;For	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
114	The topologies of the trees	0.04049964488517651	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
137	its relationship	0.10807257653448761	-4.222222222222221	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.222222222222221	0.0	0.0	-1.8999999999999986	0.04	0.04329004329004329	0.0	0.0481283422459893	0.0481283422459893	2.0	0.04329004329004329	0.0	1.0	0.0	-1.8999999999999986	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.0481283422459893	0.0	0.04329004329004329	0.0	0.0	0.0	0.0	0.0
8	Role;role	0.07094275253162535	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.04819277108433735	0.04819277108433735	1.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04819277108433735	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
25	al;Al	0.5408087306035974	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	0.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
115	a part of which	0.052997877725278884	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	an excellent prognosis with hormonal therapy	0.17123474164884292	-6.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-9.0	0.04	0.0625	0.0	0.05263157894736842	0.05263157894736842	6.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.05263157894736842	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
100	the intertwined roles	0.0790943678901998	-3.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-2.666666666666668	0.04	0.04477611940298508	0.0	0.045454545454545456	0.045454545454545456	3.0	0.04477611940298508	0.3333333333333333	1.0	0.0	-2.666666666666668	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.045454545454545456	0.0	0.04477611940298508	0.0	0.0	0.0	0.0	0.0
154	mapped to chromosome;chromosome map	0.32232942907590056	-3.136363636363636	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-4.909090909090908	1.0	1.0	-5.449999999999999	0.04	0.04201680672268907	0.0	0.04230769230769231	0.046040723981900455	3.0	0.053688141923436045	0.0	2.0	1.0	-9.7	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	2.0	1.0	6.0	0.049773755656108594	1.0	0.06535947712418301	0.0	1.0	0.0	1.0	1.0
68	activity;Activity	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
222	the CD52 antigen	0.46743094347522784	-1.6111111111111107	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-1.7777777777777786	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.04245283018867924	0.04275751557280852	3.0	0.05555555555555555	0.3333333333333333	2.0	0.0	-7.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.0430622009569378	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
293	this off-label use	0.009174481298676401	0.0	1.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	5.0	0.04	0.8	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.2	0.0	0.0
344	the X inactivation center	0.20392792817938546	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
6	Injectable;injectable	0.545792675049377	-1.2222222222222214	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.2222222222222214	0.0	0.0	-5.0	0.04	0.05	0.0	0.04205607476635514	0.04205607476635514	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04205607476635514	0.0	0.05	0.0	0.0	0.0	0.0	0.0
124	Excellent;excellent	0.07187384308196876	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-8.333333333333334	0.04	0.06000000000000001	0.0	0.05	0.05	1.0	0.06000000000000001	0.0	1.0	0.0	-8.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
306	her symptomatology	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
68	the gene	0.06585775897075465	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	2.0	0.04	0.5	1.0	1.0	0.0	1.0	0.5	1.0	1.0	1.0	1.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.5	0.0	1.0
187	dysfunctional;dysfunction	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	clinical trial;Clinical Trial;CLINICAL TRIALS;clinical trials	0.22293356675319623	-2.5333333333333328	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-1.6	0.04	0.04	0.0	0.044117647058823525	0.044516721206800225	2.0	0.04304761904761904	0.0	5.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	10.0	0.045454545454545456	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
303	inner kinetochore plate	0.34967495155189593	-1.8333333333333321	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-1.8333333333333321	1.0	1.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.043165467625899276	3.0	0.04	0.0	2.0	1.0	0.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	6.0	0.043165467625899276	0.0	0.04	0.0	1.0	0.0	0.0	1.0
125	the patients	0.038952555705675095	-5.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.05084745762711865	0.05084745762711865	2.0	0.04878048780487805	0.5	1.0	0.0	-4.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05084745762711865	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
74	patients with LEMS	0.11897498756001104	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
326	rich;Rich	0.07898372362362704	-7.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.25	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.056338028169014086	0.056338028169014086	1.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.056338028169014086	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
148	type III iodothyronine deiodinase activity	0.4604438542904824	-5.666666666666666	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.051724137931034475	0.051724137931034475	5.0	0.05084745762711865	0.0	2.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.051724137931034475	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
204	Later;later	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
90	established cardiovascular disease	0.14879000158161207	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.04	0.04	3.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
160	used	0.1379986312468486	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-2.2142857142857135	0.04	0.043478260869565216	0.0	0.04477611940298508	0.04546498277841561	1.0	0.04389102916895982	0.0	2.0	0.0	-2.428571428571427	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04615384615384615	0.0	0.04430379746835443	0.0	0.0	0.0	0.0	0.0
341	Mean;mean	0.07128176914946818	-1.625	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.625	0.0	0.0	-5.625	0.04	0.05161290322580645	0.0	0.0427807486631016	0.0427807486631016	1.0	0.05161290322580645	0.0	1.0	0.0	-5.625	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0427807486631016	0.0	0.05161290322580645	0.0	0.0	0.0	0.0	0.0
7	Hydantoin syndrome;fetal hydantoin syndrome;hydantoin syndrome	0.5046654985359014	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.41666666666666663	0.0	0.0	0.0	1.0	0.0	0.5	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.5	0.04	0.0	2.0	0.5	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	0.5	1.0	0.3333333333333333	0.5	3.0	1.0	5.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
201	commotio cordis' or 'concussion of the heart'	0.07489405532775086	0.0	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	10.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.1	0.0	0.0
100	complex formation	0.10652034422460001	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-2.5	0.04	0.044444444444444446	0.0	0.04878048780487805	0.04878048780487805	2.0	0.044444444444444446	0.0	1.0	0.0	-2.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04878048780487805	0.0	0.044444444444444446	0.0	0.0	0.0	0.0	0.0
247	developing countries;Developing Countries	0.10830453777046287	-2.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04477611940298508	0.04477611940298508	2.0	0.04819277108433735	0.0	2.0	0.0	-4.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04477611940298508	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
74	mouth	0.1145044042437165	-1.8333333333333321	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.043165467625899276	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.043165467625899276	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	B	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	the fidelity	0.07818215494507082	-1.6363636363636367	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.6363636363636367	0.0	0.0	-8.75	0.04	0.06153846153846154	0.0	0.042801556420233464	0.042801556420233464	2.0	0.06153846153846154	0.5	1.0	0.0	-8.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.042801556420233464	0.0	0.06153846153846154	0.0	0.0	0.0	0.0	0.0
184	Edwards syndrom	0.06609206177726432	-16.0	1.0	-9.5	0.06451612903225806	0.06451612903225806	0.0	0.0	1.0	-9.5	1.0	0.0	-16.0	0.0	0.0	-8.75	0.06451612903225806	0.06153846153846154	0.0	0.1111111111111111	0.1111111111111111	2.0	0.06153846153846154	1.0	1.0	0.0	-8.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.1111111111111111	0.0	0.06153846153846154	1.0	0.0	0.0	0.0	0.0
121	efficacy of drug;drug efficacy	0.1187176919696614	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
163	antioxidant effect;antioxidant effects;Anti-Oxidant Effects;Anti-Oxidant Effect	0.17441901736554816	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	2.0	0.04	0.5	4.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.5	0.0	0.0
171	associates;Associate	0.06810664428752435	-6.6	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.6	0.0	0.0	-11.0	0.04	0.07142857142857142	0.0	0.05434782608695653	0.05434782608695653	1.0	0.07142857142857142	0.0	1.0	0.0	-11.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05434782608695653	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0
15	correct;Correct	0.08112697097579084	-1.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	-2.3999999999999986	0.04	0.04424778761061947	0.0	0.0425531914893617	0.0425531914893617	1.0	0.04424778761061947	0.0	1.0	0.0	-2.3999999999999986	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0425531914893617	0.0	0.04424778761061947	0.0	0.0	0.0	0.0	0.0
154	arrythmogenic disease	0.20488807148904947	-5.181818181818182	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-5.181818181818182	0.0	0.0	-9.8	0.04	0.06578947368421052	0.0	0.05045871559633027	0.05045871559633027	2.0	0.06578947368421052	0.0	1.0	0.0	-9.8	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05045871559633027	0.0	0.06578947368421052	0.0	0.0	0.0	0.0	0.0
73	the discrimination problem.Because TMB	0.12341571945004828	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.04	0.04615384615384615	0.0	0.04	0.04	4.0	0.04615384615384615	0.25	1.0	0.0	-3.333333333333332	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04615384615384615	0.0	0.0	0.0	0.0	0.0
49	% total;total	0.09152591734464818	-2.125	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.125	0.0	0.0	0.0	0.04	0.04	0.0	0.04371584699453552	0.04371584699453552	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04371584699453552	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	all of the predicted protein pairs	0.019935739393098374	0.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.16666666666666666	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
188	ASD core symptoms	0.03498895046659576	-3.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.4	0.0	-3.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.045454545454545456	0.045454545454545456	3.0	0.047619047619047616	0.3333333333333333	1.0	0.0	-4.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.045454545454545456	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
47	Institute;institute	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
172	transport;Transport, NOS	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	Give;gives	0.07935458306167596	-5.833333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.833333333333334	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.052173913043478265	0.052173913043478265	1.0	0.054545454545454536	0.0	1.0	0.0	-6.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.052173913043478265	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
242	upright exercise	0.34623155829418123	-1.3333333333333321	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.3333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.04225352112676056	0.04225352112676056	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04225352112676056	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	22)	0.6483235114517603	-1.6000000000000014	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.042735042735042736	0.042735042735042736	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.042735042735042736	0.0	0.04	0.0	0.0	0.0	0.0	0.0
20	the flagellum central microtubule pair	0.1479264435304858	-3.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	-3.0	1.0	1.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	5.0	0.04	0.2	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.045454545454545456	0.0	0.04	0.0	1.0	0.0	0.0	1.0
127	immediate;Immediate	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
198	4;4+	0.6585772962056206	-5.499999999999999	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.6	0.0	0.0	-2.125	0.04	0.04	0.0	0.046296296296296294	0.05188378033205619	1.0	0.04409638554216867	0.0	2.0	0.0	-4.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.0574712643678161	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
231	Finding;finding	0.0715278920969546	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.142857142857142	0.04	0.04794520547945205	0.0	0.04	0.04	1.0	0.04794520547945205	0.0	1.0	0.0	-4.142857142857142	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04794520547945205	0.0	0.0	0.0	0.0	0.0
338	the severity of heart failure symptoms	0.051070176805214175	-1.1818181818181834	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	1.0	-1.1818181818181834	1.0	1.0	0.0	0.04	0.04	0.0	0.04198473282442748	0.04198473282442748	6.0	0.04	0.3333333333333333	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04198473282442748	0.0	0.04	0.0	1.0	0.0	0.0	1.0
13	Employment;employment	0.133178591342231	-5.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.051724137931034475	0.051724137931034475	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.051724137931034475	0.0	0.04	0.0	0.0	0.0	0.0	0.0
254	Evidence of;evidence of	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
258	pericentromeric heterochromatin	0.7581771581523532	-1.485714285714286	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.35714285714285715	0.0	-3.6000000000000014	0.0	0.0	-2.885714285714286	0.04	0.04	0.0	0.04	0.042761357651180165	2.0	0.04637953882851842	0.5	7.0	0.0	-7.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	14.0	0.04672897196261683	0.0	0.056818181818181816	0.0	0.0	0.0	0.0	0.0
330	Regimen;regimen	0.6365035156830914	-2.1111111111111107	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-2.8125	0.04	0.04	0.0	0.04205607476635514	0.04375531011045029	1.0	0.045806451612903226	0.0	2.0	0.0	-5.625	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.045454545454545456	0.0	0.05161290322580645	0.0	0.0	0.0	0.0	0.0
301	found;in;In;Found	0.010305301061237207	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.5	0.04	0.05263157894736842	0.0	0.04	0.04	1.0	0.054093567251461985	0.5	2.0	0.0	-7.0	1.0	0.0	1.0	0.5	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.04	0.0	0.05555555555555555	1.0	0.0	0.0	0.0	0.0
69	one;ONE	0.0921982914832669	-2.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.044117647058823525	0.044117647058823525	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.044117647058823525	0.0	0.04	0.0	0.0	0.0	0.0	0.0
138	phosphorylated peptides;Phosphorylated Peptide	0.17361773729430982	-5.884615384615385	1.0	-8.375	0.04	0.050075187969924814	0.0	0.0	1.0	-4.1875	1.0	1.0	-10.846153846153847	1.0	1.0	-4.53125	0.06015037593984962	0.04	0.0	0.04153354632587859	0.05609286011946104	1.5	0.050545933434432117	1.0	4.0	1.0	-8.25	1.0	0.5	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.41666666666666663	2.0	1.0	6.0	0.07065217391304349	0.0	0.05970149253731343	1.0	1.0	0.0	0.0	1.0
28	an autoimmune paraneoplastic origin	0.44175424078184927	-5.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05	0.05	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.05	0.0	0.04	0.0	0.0	0.0	0.0	0.0
199	chromosome segregation during cell division	0.15526599128044707	-4.5	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04878048780487805	0.04878048780487805	5.0	0.04878048780487805	0.0	1.0	0.0	-4.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04878048780487805	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
24	Asia Pacific	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
269	-PC-1) or lung (A-549 and NCI-H520) cancer cell lines	0.05428927474458002	0.0	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.1	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	15.0	0.04	0.3333333333333333	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	15.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
14	each algorithm	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
185	Radiofrequency Ablation;radiofrequency ablation	0.5717231683879584	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
321	HCV NS3 protease hypothesis	0.5912226607682981	-2.3999999999999986	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	-2.3999999999999986	1.0	1.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04424778761061947	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04424778761061947	0.0	0.04	0.0	1.0	0.0	0.0	1.0
78	the centromere	0.2412987905475347	-3.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.046511627906976744	0.046511627906976744	2.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.046511627906976744	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
96	nine cancer cell line	0.06784023195684744	-3.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-9.2	0.04	0.06329113924050632	0.0	0.04597701149425287	0.04597701149425287	4.0	0.06329113924050632	0.0	1.0	0.0	-9.2	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04597701149425287	0.0	0.06329113924050632	0.0	0.0	0.0	0.0	0.0
11	A potent itaconic acid producing strain	0.05009567906681801	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.2	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
231	month;/month	0.07545968566628361	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.8571428571428577	0.04	0.04516129032258065	0.0	0.04	0.04	1.0	0.04516129032258065	0.0	1.0	0.0	-2.8571428571428577	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04516129032258065	0.0	0.0	0.0	0.0	0.0
91	Clinician ratings of impairment and self-report levels	0.1613057280317767	-1.7142857142857153	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	-1.7142857142857153	0.0	0.0	0.0	0.04	0.04	0.0	0.04294478527607362	0.04294478527607362	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04294478527607362	0.0	0.04	0.0	0.0	0.0	0.0	0.0
30	induces;Induce	0.5743492966658548	-1.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.1999999999999993	0.0	0.0	-2.3999999999999986	0.04	0.04424778761061947	0.0	0.04201680672268907	0.04201680672268907	1.0	0.04424778761061947	0.0	1.0	0.0	-2.3999999999999986	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04201680672268907	0.0	0.04424778761061947	0.0	0.0	0.0	0.0	0.0
177	that of the general population	0.00778917573983902	-1.3333333333333321	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.6666666666666666	0.0	-1.3333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.04225352112676056	0.04225352112676056	5.0	0.04	0.8	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04225352112676056	0.0	0.04	0.0	0.0	0.0	0.0	0.0
228	4;4+	0.6865728997757393	-2.1999999999999997	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.6	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.044782608695652176	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.05434782608695653	0.0	0.04	0.0	0.0	0.0	0.0	0.0
74	small cell lung cancer (SCLC	0.1966689384896521	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	12.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
10	prostate cancer cell growth	0.09108166790100636	-2.2857142857142847	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	-2.2857142857142847	1.0	1.0	0.0	0.04	0.04	0.0	0.0440251572327044	0.0440251572327044	4.0	0.04	0.25	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.0440251572327044	0.0	0.04	0.0	1.0	0.0	0.0	1.0
114	shows;show;Show;showing	0.09744682018057459	-0.4642857142857144	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8571428571428577	0.0	0.0	-2.95	0.04	0.04	0.0	0.04	0.04080246913580247	1.0	0.04578649893081327	0.0	4.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	4.0	0.043209876543209874	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
320	critical;Critical	0.07534688037406433	-2.833333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.045112781954887216	0.045112781954887216	1.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045112781954887216	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
246	outcomes in these patients;Patient Outcome	0.055193940796780985	-3.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.046511627906976744	0.046511627906976744	4.0	0.06060606060606061	0.0	1.0	0.0	-8.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.046511627906976744	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
47	Exons;exons;'exon;exon';Exon;exon	0.8516489046135803	-0.5555555555555556	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04098819627353429	1.2222222222222223	0.04	0.0	9.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	6.0	1.0	11.0	0.04477611940298508	0.0	0.04	0.0	0.0	0.0	0.0	0.0
312	the ubiquitin proteasomal degradation pathway	0.2278487289615858	-3.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.045454545454545456	0.045454545454545456	5.0	0.04716981132075472	0.4	1.0	0.0	-3.8000000000000007	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.045454545454545456	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
103	Developmental;developmental	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
103	mediated;mediate;Mediate	0.5785387835867111	-0.7222222222222214	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.4444444444444429	0.0	0.0	-1.3571428571428577	0.04	0.04	0.0	0.04	0.04122641509433962	1.0	0.042435897435897436	0.0	2.0	0.0	-2.7142857142857153	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.04245283018867924	0.0	0.04487179487179487	0.0	0.0	0.0	0.0	0.0
158	release;Release	0.10989457657074642	-6.6000000000000005	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-9.4	0.0	0.0	-2.5	0.04	0.04	0.0	0.04716981132075472	0.055636187711659416	1.0	0.045	0.0	2.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.06410256410256411	0.0	0.05	0.0	0.0	0.0	0.0	0.0
161	First;first	0.07685293903594642	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.045454545454545456	0.045454545454545456	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.05	0.0	0.0	0.0	0.0	0.0
6	Comprehensive;comprehensive	0.06901263893103253	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
175	81%]) and periodic paralysis (10 of 25 male members	0.21305815400128145	0.0	0.0	0.0	0.04	0.04	0.36363636363636365	0.36363636363636365	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	11.0	0.04	0.09090909090909091	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	11.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
239	8.07 (under the broad classification)	0.1904371556388782	0.0	0.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.125	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
204	of;Of	0.006569821387325964	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	1.0	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	1.0	0.0	0.0	0.0	0.0
158	syndactyly;symphalangism;Symphalangism;SYNDACTYLY	0.9425590977594388	-2.5333333333333337	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-10.6	1.0	1.0	-2.472222222222222	0.04	0.04	0.0	0.04	0.04553689816080664	1.0	0.04496846646770577	0.0	12.0	1.0	-6.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	4.0	1.0	12.0	0.06944444444444445	0.0	0.05263157894736842	0.0	1.0	0.0	0.0	1.0
199	Mitotic;mitotic	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
274	The most advanced of these immunological approaches	0.12138339614232922	0.0	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.571428571428573	0.04	0.042682926829268296	0.0	0.04	0.04	7.0	0.04467479674796748	0.14285714285714285	2.0	0.0	-3.571428571428573	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	14.0	0.04	0.0	0.04666666666666667	0.0	0.0	0.0	0.0	0.0
7	Analysis;analysis	0.0943797958812142	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
272	an activator	0.09303369959826575	-16.0	1.0	-14.2	0.09259259259259259	0.09259259259259259	0.0	0.0	1.0	-14.2	1.0	0.0	-16.0	0.0	0.0	-14.6	0.09259259259259259	0.09615384615384615	1.0	0.1111111111111111	0.1111111111111111	2.0	0.09615384615384615	1.0	2.0	0.0	-14.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.1111111111111111	0.0	0.09615384615384615	1.0	0.0	0.5	0.0	0.0
227	Interfere;interfere	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
84	fatigue;FATIGUE	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
159	cases;Cases	0.1345326763983756	-2.1666666666666665	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-1.3333333333333333	0.04	0.04	0.0	0.04	0.04400088125137696	1.0	0.042539682539682544	0.0	3.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.047058823529411764	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
208	a series	0.11373208731249453	-3.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	0.0	0.04	0.04	0.0	0.046511627906976744	0.046511627906976744	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.046511627906976744	0.0	0.04	0.0	0.0	0.0	0.0	0.0
12	Histone H4;histone H4	0.5886172517696204	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	2.0	1.0	2.0	0.04	1.0	0.04	0.0	0.0	0.0	1.0	0.0
329	the binding energy function in YASARA	0.12345732182283334	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
132	Novel;novel	0.09773875734391521	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	Directly;directly	0.10746359223427752	-1.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.043255813953488376	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.046511627906976744	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	its large regulatory N	0.09780345880660814	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.8571428571428577	0.04	0.04516129032258065	0.0	0.04	0.04	4.0	0.04516129032258065	0.0	1.0	0.0	-2.8571428571428577	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04516129032258065	0.0	0.0	0.0	0.0	0.0
4	major manifestations	0.335209962941697	-1.8125	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.875	0.0	0.0	-1.5	0.04	0.04	0.0	0.043010752688172046	0.043126997965707646	2.0	0.042727272727272725	0.0	2.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.043243243243243246	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
177	found;Found	0.09006219608192875	-1.6666666666666679	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6666666666666679	0.0	0.0	0.0	0.04	0.04	0.0	0.04285714285714286	0.04285714285714286	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04285714285714286	0.0	0.04	0.0	0.0	0.0	0.0	0.0
209	the effects of natural selection	0.08279735195665178	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
168	Toe abnormalities;toe abnormalities	0.4775050255551367	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
99	lamin A/C gene (LMNA)	0.44641782095052324	-3.5	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	-3.5	0.0	0.0	-1.8571428571428577	0.04	0.043209876543209874	0.0	0.046511627906976744	0.046511627906976744	8.0	0.043209876543209874	0.0	1.0	0.0	-1.8571428571428577	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.046511627906976744	0.0	0.043209876543209874	0.0	0.0	0.0	0.0	0.0
130	New York	0.3815936603529221	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	2.0	0.05000000000000001	0.0	3.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
165	DNA sequences	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
257	hydrogen peroxide and lipid peroxides	0.4211298668258482	-11.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	-11.0	0.0	0.0	-9.142857142857142	0.04	0.06306306306306306	0.0	0.07142857142857142	0.07142857142857142	5.0	0.06306306306306306	0.0	1.0	0.0	-9.142857142857142	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.07142857142857142	0.0	0.06306306306306306	0.0	0.0	0.0	0.0	0.0
265	mut cTNT mice	0.5142234813045365	-3.3999999999999986	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-3.3999999999999986	1.0	1.0	-6.0	0.04	0.05263157894736842	0.0	0.046296296296296294	0.046296296296296294	3.0	0.05263157894736842	0.0	2.0	1.0	-6.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.046296296296296294	0.0	0.05263157894736842	0.0	1.0	0.0	0.0	1.0
71	protein);PROTEIN;protein	0.34548678841220043	-1.5999999999999996	0.0	0.0	0.04	0.04	0.5	0.75	0.0	0.0	0.0	1.0	-3.1999999999999993	0.0	0.0	-1.75	0.04	0.04	0.0	0.04	0.04293577981651376	1.5	0.043255813953488376	0.0	2.0	0.0	-3.5	1.0	0.6666666666666666	0.5	0.0	1.0	0.0	1.0	0.6666666666666666	0.6666666666666666	3.0	1.0	3.0	0.04587155963302752	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
28	ductal carcinoma	0.6805085449979903	-5.333333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.05084745762711865	0.05084745762711865	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05084745762711865	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	data;Data	0.1689291556695771	-0.3611111111111107	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.4444444444444429	0.0	0.0	-0.7142857142857144	0.04	0.04	0.0	0.04	0.04061320754716981	1.0	0.04129032258064516	0.0	4.0	0.0	-2.8571428571428577	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04245283018867924	0.0	0.04516129032258065	0.0	0.0	0.0	0.0	0.0
41	Contact with;contacts with	0.08474539115956715	-8.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-8.0	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.058823529411764705	0.058823529411764705	2.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.058823529411764705	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
241	vertebral region	0.017345707910532894	-15.833333333333332	1.0	-10.2	0.06756756756756756	0.06756756756756756	0.5	0.5	1.0	-10.2	1.0	0.0	-15.833333333333332	0.0	0.0	-12.4	0.06756756756756756	0.07936507936507936	0.0	0.10909090909090907	0.10909090909090907	2.0	0.07936507936507936	1.0	2.0	0.0	-12.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.10909090909090907	0.0	0.07936507936507936	1.0	0.0	0.0	0.0	0.0
319	the identification	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	females;FEMALE;female;Females	0.31766419116371947	-2.4166666666666665	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-2.740740740740741	0.04	0.04	0.0	0.04	0.044689977532983545	1.0	0.04582289055973267	0.0	9.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	9.0	0.04938271604938271	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
78	Five;five	0.0655689145988925	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-9.666666666666666	0.04	0.06521739130434782	0.0	0.047619047619047616	0.047619047619047616	1.0	0.06521739130434782	0.0	1.0	0.0	-9.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.06521739130434782	0.0	0.0	0.0	0.0	0.0
195	generation;Generation	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
34	regulated;Regulated	0.08511224846896509	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.05	0.05	1.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
93	7 children	0.04411636247707847	-6.166666666666666	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.6666666666666666	0.0	-6.166666666666666	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.053097345132743355	0.053097345132743355	2.0	0.05263157894736842	0.5	1.0	0.0	-6.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.053097345132743355	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
28	three women with the stiff-man syndrome and breast cancer	0.013035705341129116	0.0	1.0	0.0	0.04	0.04	0.9090909090909091	0.9090909090909091	0.0	0.0	0.1111111111111111	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	11.0	0.04	0.36363636363636365	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	11.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
122	A strong association	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
6	overdose;OVERDOSE	0.5959447173838062	-3.424242424242424	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-4.0	0.04	0.04	0.0	0.04	0.04663972017688664	1.0	0.04796536796536797	1.0	11.0	0.0	-5.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	11.0	0.05263157894736842	0.0	0.05	1.0	0.0	0.0	0.0	0.0
258	associated with;Associated with	0.007210279704537147	-8.120000000000001	1.0	0.0	0.04	0.04	1.0	1.0	1.0	0.0	1.0	0.0	-15.4	0.0	0.0	-10.24	0.04	0.05434782608695653	0.0	0.04716981132075472	0.06387587890273087	2.0	0.08051234646606316	1.0	5.0	0.0	-18.8	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	10.0	0.10416666666666667	0.0	0.16129032258064516	1.0	0.0	0.0	0.0	0.0
60	a large soluble C-terminal half of approximately 300 amino acids	0.2712159971893605	-3.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-3.0	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.045454545454545456	0.045454545454545456	12.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	12.0	0.045454545454545456	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
68	proline 250	0.7307823555398101	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
189	l);/l	0.6721500832556117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	include;including;Including	0.12330598481930177	-2.3000000000000003	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.1	0.0	0.0	-3.083333333333333	0.04	0.04	0.0	0.04219409282700422	0.044298158356194293	1.0	0.049736842105263156	0.0	4.0	0.0	-12.333333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.05025125628140704	0.0	0.07894736842105263	0.0	0.0	0.0	0.0	0.0
327	histone;Histone	0.2677491941694335	-1.5	1.0	-13.8	0.04	0.049857142857142864	0.0	0.0	1.0	-2.7600000000000002	1.0	1.0	-4.75	0.0	0.0	-4.6	0.08928571428571429	0.04	0.0	0.04	0.042865307254820365	1.0	0.05182708445629568	1.0	5.0	0.0	-12.4	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	5.0	0.04938271604938271	0.0	0.07936507936507936	1.0	0.0	0.0	0.0	0.0
16	at;At	0.07790574563957564	-3.09090909090909	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.09090909090909	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04564315352697095	0.04564315352697095	1.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04564315352697095	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
252	Phenomenon;phenomenon	0.07158286883886696	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.04878048780487805	0.04878048780487805	1.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04878048780487805	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
269	human non-small cell lung cancer (NSCLC) cell lines	0.074942957894629	-2.3999999999999986	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.04424778761061947	0.04424778761061947	10.0	0.0449438202247191	0.2	1.0	0.0	-2.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04424778761061947	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
332	the orally available SYK inhibitor	0.25066699742190757	-3.333333333333332	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-5.0	0.04	0.05	0.0	0.04615384615384615	0.04615384615384615	5.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04615384615384615	0.0	0.05	0.0	0.0	0.0	0.0	0.0
86	NUCLEUS;nucleus	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
295	different;Different	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
237	cytoplasmic sequestration	0.9243227272703585	-2.362637362637363	1.0	-12.428571428571429	0.04	0.046083916083916085	0.0	0.0	1.0	-1.9120879120879122	1.0	0.0	-8.142857142857142	0.0	0.0	-6.142857142857143	0.07954545454545454	0.04666666666666667	0.0	0.04	0.044943476366120075	2.0	0.05480503618124317	1.0	13.0	0.0	-12.714285714285715	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	26.0	0.059322033898305086	0.0	0.08139534883720931	1.0	0.0	0.0	0.0	0.0
218	Shift;shift	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	the exon recognition functions	0.07306065820221469	-2.666666666666668	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.04477611940298508	0.04477611940298508	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04477611940298508	0.0	0.04	0.0	0.0	0.0	0.0	0.0
307	Detected;detected	0.08067306512344256	-3.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04587155963302752	0.04587155963302752	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04587155963302752	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
335	the processing	0.08920834675818906	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	2.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
128	the mechanism	0.024439800112387756	-1.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	-11.909090909090908	0.04	0.07638888888888888	0.0	0.0425531914893617	0.0425531914893617	2.0	0.07638888888888888	0.5	1.0	0.0	-11.909090909090908	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.0425531914893617	0.0	0.07638888888888888	0.0	0.0	0.0	0.0	0.0
163	Heretofore, Cr's positive therapeutic benefits	0.3180303740973211	0.0	0.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
189	parathyroid hormone;PARATHYROID HORMONE	0.14090622204851042	-3.666666666666668	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-3.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.046875	0.046875	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	2.0	0.046875	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	biomedical evidence collection	0.10243294226477243	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.04	0.04	3.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
234	156	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
72	articles about biomolecular interactions	0.06305263443515201	-1.6000000000000014	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-1.6000000000000014	0.0	0.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.042735042735042736	0.042735042735042736	4.0	0.044642857142857144	0.25	1.0	0.0	-2.6000000000000014	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.042735042735042736	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
16	Calculate;calculates	0.07270877609889996	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.04	0.04	1.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
222	treatment with alemtuzumab (anti-CD52 monoclonal antibody)	0.20713197064123717	-3.666666666666668	1.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.7142857142857143	1.0	-3.666666666666668	1.0	1.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.046875	0.046875	10.0	0.044642857142857144	0.3	1.0	1.0	-2.6000000000000014	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	10.0	0.046875	1.0	0.044642857142857144	0.0	1.0	0.0	1.0	1.0
319	traditional Chinese herbs	0.11853455819374517	-2.5	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.044444444444444446	0.044444444444444446	3.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.044444444444444446	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
100	Oligonucleotide;oligonucleotide	0.618497949537651	-4.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.04878048780487805	0.04878048780487805	1.0	0.05714285714285714	0.0	2.0	0.0	-7.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04878048780487805	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
222	provides	0.14321488304341004	-2.3888888888888875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.04245283018867924	0.044303338171262696	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04615384615384615	0.0	0.04	0.0	0.0	0.0	0.0	0.0
277	age;AGE	0.07096173573097679	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.04	0.04	1.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
287	the investigational oral drug MLN8237 (alisertib)	0.1599510226967321	-3.0	1.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.3333333333333333	1.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	8.0	0.04	0.125	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
315	most which	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
69	hypothyroidism;HYPOTHYROIDISM	0.7786266455789895	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
250	survived;SURVIVE	0.19797427499629672	-2.1111111111111107	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-2.1111111111111107	1.0	1.0	0.0	0.04	0.04	0.0	0.043689320388349516	0.043689320388349516	1.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	2.0	1.0	1.0	0.043689320388349516	1.0	0.04	0.0	1.0	0.0	1.0	1.0
57	treatment;treatment nos;Treatment	0.10269752175079477	-2.4666666666666663	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-2.6	0.04	0.04	0.0	0.04	0.0446384479717813	1.0	0.04492961964660078	0.0	3.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	3.0	0.047619047619047616	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
15	PPI-related sentences	0.5132474849121641	-0.5500000000000007	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.21250000000000002	1.0	-1.1000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04092050209205021	4.0	0.04	0.25	4.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	16.0	0.041841004184100423	0.0	0.04	0.0	0.0	0.0	0.0	0.0
68	MSX2) causing craniosynostosis	0.2693423423698366	0.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.2	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
334	the coding regions of genes	0.07354704761949611	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
68	a deletion of the asparagine residue	0.27769503014796065	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
137	Safety of endovascular treatment	0.04003722741634715	-2.2222222222222214	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-2.2222222222222214	0.0	0.0	-3.3000000000000007	0.04	0.04608294930875576	0.0	0.04390243902439024	0.04390243902439024	4.0	0.04608294930875576	0.5	1.0	0.0	-3.3000000000000007	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04390243902439024	0.0	0.04608294930875576	0.0	0.0	0.0	0.0	0.0
121	provides	0.102584349537154	-6.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.05263157894736842	0.05263157894736842	1.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.05263157894736842	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
344	autosomes	0.7999733836848668	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	1.0	0.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
93	scores;Scores	0.09112461233357536	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
20	135 kDa centrosomal protein	0.24754249841453624	-5.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.3333333333333333	1.0	-5.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05	0.05	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.05	0.0	0.04	0.0	0.0	0.0	0.0	0.0
86	A group;a group	0.11707437433269925	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	virtual screening studies	0.08773717292688622	-2.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.043795620437956206	0.043795620437956206	3.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043795620437956206	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
87	an improvement in contractile function	0.10699058841176723	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
243	Identified;identified	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
159	the disorder	0.06934300600910344	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-4.25	0.0	0.0	-5.0	0.04	0.05	0.0	0.04819277108433735	0.04819277108433735	2.0	0.05	0.5	1.0	0.0	-5.0	1.0	0.5	1.0	1.0	1.0	0.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04819277108433735	0.0	0.05	0.0	0.0	0.0	0.0	0.0
115	DNA	0.07536960944159946	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-13.0	0.04	0.08333333333333333	0.0	0.05	0.05	1.0	0.08333333333333333	0.0	1.0	0.0	-13.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.05	0.0	0.08333333333333333	0.0	0.0	0.0	0.0	0.0
122	non-coding sequences	0.33464996046184486	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
177	Observed;observed	0.13565270997327908	-0.6666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04115942028985507	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
185	serious sick sinus syndrome (SSS)	0.272095946759199	0.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
226	Reasoning;reasoning	0.07296156602125722	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.04	0.04	1.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
50	RNA levels	0.08771744457305088	-1.2222222222222214	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.2222222222222214	0.0	0.0	-5.6	0.04	0.051546391752577324	0.0	0.04205607476635514	0.04205607476635514	2.0	0.051546391752577324	0.5	1.0	0.0	-5.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04205607476635514	0.0	0.051546391752577324	0.0	0.0	0.0	0.0	0.0
72	advantage of ontologies	0.08430660018543829	-1.6999999999999993	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.6999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04291845493562232	0.04291845493562232	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04291845493562232	0.0	0.04	0.0	0.0	0.0	0.0	0.0
53	The iodothyronine	0.19533061305813837	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.04	0.04	2.0	0.054545454545454536	0.0	1.0	0.0	-6.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
225	noted;Note	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
276	serum 3,3',5-tri-iodothyronine	0.44384581441272253	-4.625	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.625	0.0	0.0	-8.4	0.04	0.06024096385542168	0.0	0.049079754601226995	0.049079754601226995	10.0	0.06024096385542168	0.0	1.0	0.0	-8.4	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.049079754601226995	0.0	0.06024096385542168	0.0	0.0	0.0	0.0	0.0
158	urgical correction of syndactyly	0.3912250240384771	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	4.0	0.05263157894736842	0.0	1.0	1.0	-6.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.05263157894736842	0.0	1.0	0.0	0.0	1.0
150	autophagy by which	0.03259195139587723	-4.428571428571429	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.5	1.0	-4.428571428571429	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04861111111111112	0.04861111111111112	3.0	0.043478260869565216	0.6666666666666666	1.0	0.0	-2.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04861111111111112	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
274	terminated	0.666464354555892	-1.8181818181818166	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.8181818181818166	0.0	0.0	0.0	0.04	0.04	0.0	0.043137254901960784	0.043137254901960784	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.043137254901960784	0.0	0.04	0.0	0.0	0.0	0.0	0.0
99	surface;SURFACE	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	an important endocrine marker for Williams syndrome	0.05258618495785951	0.0	1.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.42857142857142855	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.2857142857142857	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
249	Increase;increase	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
258	the existence of an alternative pathway	0.12471108447656026	-3.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-3.0	1.0	1.0	-8.0	0.04	0.058823529411764705	0.0	0.045454545454545456	0.045454545454545456	6.0	0.058823529411764705	0.0	1.0	1.0	-8.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.045454545454545456	0.0	0.058823529411764705	0.0	1.0	0.0	0.0	1.0
194	functional delineation	0.18271027833687656	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.04	0.04	2.0	0.06060606060606061	0.0	1.0	0.0	-8.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
37	Closed;closed	0.09773875734391521	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
261	inward rectifier potassium channel 2	0.2070430029713261	-2.7142857142857153	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	-2.7142857142857153	0.0	0.0	-14.666666666666668	0.04	0.09677419354838711	0.0	0.04487179487179487	0.04487179487179487	5.0	0.09677419354838711	0.2	1.0	0.0	-14.666666666666668	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04487179487179487	0.0	0.09677419354838711	0.0	0.0	0.0	0.0	0.0
122	data;Data	0.09788117189105187	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04631578947368421	0.0	2.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
15	indications;Indications	0.07858762858463225	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-3.6000000000000014	0.04	0.04672897196261683	0.0	0.043478260869565216	0.043478260869565216	1.0	0.04672897196261683	0.0	1.0	0.0	-3.6000000000000014	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
121	abacavir with respect	0.04574063402018125	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.5	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
281	Homozygous or compound heterozygous mutations	0.26905681404095005	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
282	g-protein-coupled receptor protein;G protein-coupled receptor protein	0.4722858412951278	-2.6000000000000014	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-2.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.044642857142857144	0.044642857142857144	6.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	12.0	0.044642857142857144	0.0	0.04	0.0	0.0	0.0	0.0	0.0
344	a stronger mH2A1 enrichment along the pseudoautosomal X chromosome region	0.22146309749681187	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.1	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	10.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
125	disorder;condition;disease;Disease;conditions;Disorder	0.08488931933193733	-4.733333333333333	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	-4.3	0.04	0.04	0.0	0.04	0.049962359674224084	1.0	0.052209093721002166	0.0	5.0	0.0	-11.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	6.0	1.0	5.0	0.054545454545454536	0.0	0.07547169811320754	0.0	0.0	0.0	0.0	0.0
276	Characteristic;characteristic	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	elevation;Elevation, NOS	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	detailed;Detailed	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
186	central;CENTRAL	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
12	the encoding gene	0.15465774275711847	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	3.0	0.04918032786885245	0.0	1.0	1.0	-4.666666666666666	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04918032786885245	0.0	1.0	0.0	0.0	1.0
239	de novo	0.6138403096724941	-1.8333333333333321	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.043165467625899276	0.043165467625899276	2.0	0.046511627906976744	0.0	1.0	0.0	-3.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043165467625899276	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
327	histone H3;Histone H3	0.2148251117959804	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.5	1.0	0.0	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04	0.04	2.0	0.04716981132075472	0.5	1.0	0.0	-3.8000000000000007	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	2.0	0.04	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
180	retinal coloboma;RETINAL COLOBOMA	0.6721500832556117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
106	Further analysis of these mutations	0.06347336305695774	-2.5	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	0.0	0.04	0.04	0.0	0.044444444444444446	0.044444444444444446	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.044444444444444446	0.0	0.04	0.0	0.0	0.0	0.0	0.0
215	cell-autonomous	0.3735595348537071	-3.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	potent;Potential	0.5340475369537825	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
227	a homozygous loss of function mutation	0.08680331008994818	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	Additional;additional	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
204	the age	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
29	A. itaconicus	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
68	unrelated;Unrelated	0.4891816291325318	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04	0.04	1.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
153	First	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
89	their symptoms	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	a characterization	0.23531644379182606	-2.4545454545454533	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.4545454545454533	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.044354838709677415	0.044354838709677415	2.0	0.046511627906976744	0.0	1.0	0.0	-3.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.044354838709677415	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
16	molecular evolution;Evolution, Molecular	0.31173963441202446	-1.3636363636363633	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.3636363636363633	0.0	0.0	-7.25	0.04	0.056338028169014086	0.0	0.04230769230769231	0.0423076923076923	2.0	0.056338028169014086	0.0	3.0	0.0	-7.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04230769230769231	0.0	0.056338028169014086	0.0	0.0	0.0	0.0	0.0
37	an epipodophyllotoxin derivative	0.7163601152334724	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
78	clinical use	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
275	features;Feature	0.06958782507992307	-4.875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.875	0.0	0.0	-9.0	0.04	0.0625	0.0	0.049689440993788817	0.049689440993788817	1.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.049689440993788817	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
55	Astragalus Membranaceus;Astragalus membranaceus	0.5717231683879584	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
334	best;Best	0.07009049572442126	-3.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.04615384615384615	0.04615384615384615	1.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04615384615384615	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
287	cyclin;Cyclin	0.7514644148533246	-3.0999999999999996	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.8000000000000007	1.0	1.0	-2.375	0.04	0.04	0.0	0.04424778761061947	0.045708799465687094	1.0	0.04469135802469136	0.0	2.0	1.0	-4.75	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	2.0	0.04716981132075472	0.0	0.04938271604938271	0.0	1.0	0.0	0.0	1.0
222	aggressive	0.10440442140742133	-3.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-3.6000000000000014	0.04	0.04672897196261683	0.0	0.04615384615384615	0.04615384615384615	1.0	0.04672897196261683	0.0	1.0	0.0	-3.6000000000000014	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04615384615384615	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
6	Medication;medication	0.011993472405236778	-13.777777777777779	1.0	-7.5	0.05714285714285714	0.05714285714285714	1.0	1.0	1.0	-7.5	1.0	1.0	-13.777777777777779	0.0	0.0	-5.75	0.05714285714285714	0.05194805194805195	1.0	0.08910891089108912	0.08910891089108912	1.0	0.05194805194805195	1.0	1.0	0.0	-5.75	1.0	1.0	1.0	1.0	1.0	0.0	1.0	1.0	1.0	2.0	1.0	1.0	0.08910891089108912	1.0	0.05194805194805195	1.0	0.0	1.0	1.0	0.0
41	Identified;identified	0.11610425248722474	-3.3333333333333335	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-10.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04888888888888889	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.06666666666666667	0.0	0.04	0.0	0.0	0.0	0.0	0.0
307	the pathogenesis	0.15028548759933413	-1.6999999999999993	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.043148148148148144	2.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.046296296296296294	0.0	0.04	0.0	0.0	0.0	0.0	0.0
250	the severity	0.10549951416075809	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
78	Increased;increased	0.09520971290739387	-3.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
206	. R;R;R-	0.6002399066898167	-6.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-5.5	0.04	0.05084745762711865	0.0	0.05263157894736842	0.05263157894736842	1.5	0.05128579777907656	0.0	2.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	3.0	0.05263157894736842	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
24	week;/week	0.09705854714792957	-3.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04716981132075472	0.04716981132075472	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04716981132075472	0.0	0.04	0.0	0.0	0.0	0.0	0.0
37	various;Various	0.09660742387934279	-3.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.046875	0.046875	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046875	0.0	0.04	0.0	0.0	0.0	0.0	0.0
80	rare causes	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
91	a group format	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	targeted therapy;Targeted Therapy	0.169188290062278	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
304	-class specific inhibitor of the phosphoinositol-3 kinase (PI3K) delta isoform	0.13357777889149158	-1.5	0.0	0.0	0.04	0.04	0.3076923076923077	0.3076923076923077	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	0.0	0.04	0.04	0.0	0.0425531914893617	0.0425531914893617	13.0	0.04	0.3076923076923077	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	13.0	0.0425531914893617	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	the basis	0.03328226895392487	-1.8888888888888893	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-5.166666666666666	0.04	0.050420168067226885	0.0	0.04326923076923077	0.04326923076923077	2.0	0.050420168067226885	0.5	1.0	0.0	-5.166666666666666	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04326923076923077	0.0	0.050420168067226885	0.0	0.0	0.0	0.0	0.0
25	children with autism spectrum disorder (ASD)	0.08825530035248558	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.04	0.04	8.0	0.06666666666666667	0.375	1.0	0.0	-10.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
152	LM	0.6723276628083408	-2.8000000000000007	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	-6.6	0.04	0.05434782608695653	0.0	0.04504504504504505	0.04504504504504505	1.0	0.05434782608695653	0.0	2.0	0.0	-6.6	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04504504504504505	0.0	0.05434782608695653	0.0	0.0	0.0	0.0	0.0
96	a type of plasma cell dyscrasia	0.09249734700942609	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.199999999999999	0.04	0.056179775280898875	0.0	0.04	0.04	6.0	0.056179775280898875	0.0	1.0	0.0	-7.199999999999999	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.056179775280898875	0.0	0.0	0.0	0.0	0.0
221	lateral habenula or cortical areas	0.3220043454201129	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
241	Transverse process of lumbar vertebra;lumbar vertebra with a pseudoarticulation of the transverse process	0.08661832784635835	0.0	0.0	0.0	0.04	0.04	0.5555555555555556	0.5555555555555556	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.1111111111111111	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
242	left ventricular	0.25723541494515645	-1.4444444444444429	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.4444444444444429	0.0	0.0	0.0	0.04	0.04	0.0	0.04245283018867924	0.04245283018867924	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04245283018867924	0.0	0.04	0.0	0.0	0.0	0.0	0.0
330	SEVERE;severe	0.07857635917199778	-1.4444444444444429	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.4444444444444429	0.0	0.0	-3.125	0.04	0.045714285714285714	0.0	0.04245283018867924	0.04245283018867924	1.0	0.045714285714285714	0.0	1.0	0.0	-3.125	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04245283018867924	0.0	0.045714285714285714	0.0	0.0	0.0	0.0	0.0
149	Increase;increase	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
150	this;This	0.07398084174238093	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.04	0.04615384615384615	0.0	0.04	0.04	1.0	0.04615384615384615	0.0	1.0	0.0	-3.333333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04615384615384615	0.0	0.0	0.0	0.0	0.0
277	Failed;failed	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	ScoHET1	0.6692795245658281	-9.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-9.5	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.06451612903225806	0.06451612903225806	1.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.06451612903225806	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
277	beginning;Beginning	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
126	this reaction	0.10876031267125157	-2.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.043859649122807015	0.043859649122807015	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043859649122807015	0.0	0.04	0.0	0.0	0.0	0.0	0.0
91	12)	0.669190721745788	-4.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
278	colorectal cancer;Colo-rectal cancer;colo-rectal cancers;colorectal cancer)	0.39460552050374287	-2.5	0.0	0.0	0.04	0.04	0.25	0.3611111111111111	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-5.666666666666667	0.04	0.04	0.0	0.04	0.04470588235294118	3.0	0.05373737373737374	0.0	3.0	0.0	-8.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	9.0	0.047058823529411764	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
267	automatic;Automatic	0.09297215030954452	-2.571428571428573	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.0445859872611465	0.0445859872611465	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0445859872611465	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	(EEP) family;EEP family	0.2817568646909978	0.0	0.3333333333333333	0.0	0.04	0.04	0.25	0.4166666666666667	0.0	0.0	0.16666666666666666	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	2.6666666666666665	0.04	0.4166666666666667	3.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.4166666666666667	0.0	0.0
265	a causal relationship of the pE96K mutation and disease	0.07613672974341872	-2.1999999999999993	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	1.0	0.043859649122807015	0.043859649122807015	9.0	0.048387096774193554	0.1111111111111111	1.0	0.0	-4.333333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.043859649122807015	0.0	0.048387096774193554	0.0	0.0	0.1111111111111111	0.0	0.0
44	Mitochondrion;Mitochondrial;mitochondrial;mitochondrion	0.4990931298945229	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-2.0	0.04	0.04	0.0	0.04	0.04631578947368421	1.0	0.04380952380952381	0.0	2.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.05263157894736842	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
78	-lait spots	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
150	Isoforms;isoforms;Isoform;isoform	0.7902633844621231	-1.0714285714285712	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.1428571428571423	0.0	0.0	-0.666666666666667	0.04	0.04	0.0	0.04	0.041874999999999996	1.0	0.04119402985074627	0.0	4.0	0.0	-2.666666666666668	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	4.0	1.0	4.0	0.04375	0.0	0.04477611940298508	0.0	0.0	0.0	0.0	0.0
276	underlying cause	0.08486422442063896	-6.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.25	0.0	0.0	-9.6	0.04	0.06493506493506493	0.0	0.05333333333333334	0.05333333333333334	2.0	0.06493506493506493	0.0	1.0	0.0	-9.6	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05333333333333334	0.0	0.06493506493506493	0.0	0.0	0.0	0.0	0.0
287	PTCL patients	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
302	inhibitors	0.11301019408679244	-9.600000000000001	1.0	-16.2	0.04	0.07681818181818181	0.0	0.0	1.0	-8.1	1.0	0.0	-15.6	0.0	0.0	-7.9	0.11363636363636363	0.04	1.0	0.04672897196261683	0.07655597534301053	1.0	0.07434782608695653	1.0	2.0	0.0	-15.8	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.10638297872340426	0.0	0.10869565217391305	1.0	0.0	1.0	0.0	0.0
155	Approach;approach	0.08984219005344109	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-2.5	0.04	0.044444444444444446	0.0	0.04878048780487805	0.04878048780487805	1.0	0.044444444444444446	0.0	1.0	0.0	-2.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04878048780487805	0.0	0.044444444444444446	0.0	0.0	0.0	0.0	0.0
73	These methods	0.08860191636780715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.04	0.04580152671755725	0.0	0.04	0.04	2.0	0.04580152671755725	0.0	1.0	0.0	-3.166666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04580152671755725	0.0	0.0	0.0	0.0	0.0
342	end of actively transcribed genes;END Gene	0.06572619910564874	-2.6000000000000014	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	-3.6000000000000014	0.04	0.04672897196261683	0.0	0.044642857142857144	0.044642857142857144	5.0	0.04672897196261683	0.0	1.0	0.0	-3.6000000000000014	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.044642857142857144	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
332	blocking;Blocking	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
19	The authors	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
206	10%;10	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
80	mutations in the Irx4 gene	0.07963497807283	-3.333333333333332	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	-3.333333333333332	1.0	1.0	-7.4	0.04	0.056818181818181816	0.0	0.04615384615384615	0.04615384615384615	5.0	0.056818181818181816	0.4	1.0	1.0	-7.4	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04615384615384615	0.0	0.056818181818181816	0.0	1.0	0.0	0.0	1.0
298	significantly (p	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	Complete;complete	0.07663211478162027	-3.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.046511627906976744	0.046511627906976744	1.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046511627906976744	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
103	the maintenance-type methyltransferase family	0.040003152711571406	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.2	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	6.0	0.04	0.5	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.16666666666666666	0.0	0.0
293	safety and efficacy	0.13152690095571606	-3.25	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04597701149425287	0.04597701149425287	3.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04597701149425287	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
321	data;Data	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
244	uptake;Uptake	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	concept	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	Interaction;interaction	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	sedation	0.88456787236375	-0.9428571428571425	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-4.678571428571429	0.04	0.0449438202247191	0.0	0.04	0.04173826513276054	1.0	0.049835952132957724	0.0	7.0	0.0	-8.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.046296296296296294	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
269	MES	0.770896785551766	-3.6000000000000014	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.6000000000000014	1.0	1.0	-11.5	0.04	0.07407407407407407	0.0	0.04672897196261683	0.04672897196261683	0.0	0.07407407407407407	0.0	1.0	1.0	-11.5	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	0.0	0.04672897196261683	1.0	0.07407407407407407	0.0	1.0	0.0	1.0	1.0
237	autonomic;Autonomic	0.6039131868305536	-1.571428571428573	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.042682926829268296	0.042682926829268296	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.042682926829268296	0.0	0.04	0.0	0.0	0.0	0.0	0.0
51	shown;Show	0.002629411038518084	-16.833333333333332	1.0	0.0	0.04	0.04	1.0	1.0	1.0	0.0	1.0	0.0	-16.833333333333332	0.0	0.0	-11.857142857142858	0.04	0.07608695652173914	0.0	0.12244897959183675	0.12244897959183675	1.0	0.07608695652173914	1.0	1.0	0.0	-11.857142857142858	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.12244897959183675	0.0	0.07608695652173914	1.0	0.0	0.0	0.0	0.0
163	proteins;PROTEINS	0.6888295149660772	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04	0.04	1.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	1.0	0.04	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
310	Excess;excess	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
140	high-field Fourier transform ion cyclotron resonance (FTICR	0.2637062250856764	0.0	0.0	0.0	0.04	0.04	0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
67	an animal model of multiple sclerosis	0.027071358970331756	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.42857142857142855	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	6.0	0.04	0.6666666666666666	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.16666666666666666	0.0	0.0
11	its high citric acid producing capability and broad applicability	0.13467895745845126	-2.0	0.0	0.0	0.04	0.04	0.7777777777777778	0.7777777777777778	0.0	0.0	0.0	1.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	9.0	0.04	0.1111111111111111	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	9.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	Observed;observed	0.08953518362259696	-1.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	0.0	0.04	0.04	0.0	0.0425531914893617	0.0425531914893617	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0425531914893617	0.0	0.04	0.0	0.0	0.0	0.0	0.0
67	the most widely used model	0.0033955194713573083	-12.0	1.0	-16.5	0.11764705882352941	0.11764705882352941	1.0	1.0	1.0	-16.5	1.0	0.0	-12.0	0.0	0.0	-13.0	0.11764705882352941	0.08333333333333333	1.0	0.07692307692307693	0.07692307692307693	5.0	0.08333333333333333	1.0	1.0	0.0	-13.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.07692307692307693	0.0	0.08333333333333333	1.0	0.0	0.2	0.0	0.0
85	cells;Cells	0.10376947035215306	-1.6999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-0.9285714285714288	0.04	0.04	0.0	0.04	0.043148148148148144	1.0	0.04160493827160494	0.0	2.0	0.0	-1.8571428571428577	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.046296296296296294	0.0	0.043209876543209874	0.0	0.0	0.0	0.0	0.0
287	an;AN	0.7034378800326829	-3.5333333333333337	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-4.25	0.04	0.047619047619047616	0.0	0.04587155963302752	0.046590114305466356	1.0	0.048206937095825984	0.0	3.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04716981132075472	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
258	Restricted;restricted	0.10834121266201877	-1.0999999999999996	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04192982456140351	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.043859649122807015	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	range;Range	0.0694260851305318	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.857142857142858	0.04	0.04964539007092199	0.0	0.04	0.04	1.0	0.04964539007092199	0.0	1.0	0.0	-4.857142857142858	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04964539007092199	0.0	0.0	0.0	0.0	0.0
137	Clinical improvement after extracranial venoplasty	0.1596656880857768	-2.2222222222222214	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-2.2222222222222214	0.0	0.0	-1.8000000000000007	0.04	0.04310344827586207	0.0	0.04390243902439024	0.04390243902439024	5.0	0.04310344827586207	0.0	1.0	0.0	-1.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04390243902439024	0.0	0.04310344827586207	0.0	0.0	0.0	0.0	0.0
69	syndrome;Syndrome	0.18532529237663062	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
150	lysosomal receptor	0.6120868525539568	-2.678571428571429	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.3333333333333333	1.0	-5.0	0.0	0.0	-2.2083333333333335	0.04	0.04	1.0	0.04	0.045080645161290324	2.0	0.04440711462450593	0.5	4.0	0.0	-5.833333333333334	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.05	0.0	0.052173913043478265	0.0	0.0	0.5	0.0	0.0
26	characterized;Characterized	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	Human;human	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
75	twitcher	0.6519308230113386	-4.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.04878048780487805	0.04878048780487805	1.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04878048780487805	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
225	DIAGNOSIS;diagnosis;Diagnosed;diagnosed	0.08873571092778124	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
153	blocking;Blocking	0.18532529237663062	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
95	Tob/BTG family	0.19455416253858673	0.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.3333333333333333	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	4.0	0.04	0.25	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.25	0.0	1.0
44	Vulnerable Population;vulnerable populations	0.07805271034929093	-3.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.047058823529411764	0.047058823529411764	2.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.047058823529411764	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
317	a novel human telomerase antagonist	0.25125585504820697	-4.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	-4.0	1.0	1.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.047619047619047616	0.047619047619047616	5.0	0.053571428571428575	0.0	1.0	1.0	-6.333333333333334	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.047619047619047616	0.0	0.053571428571428575	0.0	1.0	0.0	0.0	1.0
44	our understanding	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	due to;Due To	0.030155674082559904	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
49	the spectrum of phenotypes	0.07697472774060232	-4.125	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-4.125	0.0	0.0	0.0	0.04	0.04	0.0	0.04790419161676647	0.04790419161676647	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04790419161676647	0.0	0.04	0.0	0.0	0.0	0.0	0.0
241	often;Often	0.08214200575786534	-5.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	-5.4	0.04	0.0510204081632653	0.0	0.05084745762711865	0.05084745762711865	1.0	0.0510204081632653	0.0	1.0	0.0	-5.4	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05084745762711865	0.0	0.0510204081632653	0.0	0.0	0.0	0.0	0.0
0	women with RA	0.038151651419105405	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	Analysis of uncharacterized human sequences	0.08848691453375389	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	effective anti-cancer drugs (27	0.23136852087586654	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
331	carcinogenesis;Carcinogenesis	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
101	adenosine-containing inhibitors	0.18566125381894819	0.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.25	1.0	0.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	1.0	0.04	0.04	4.0	0.053571428571428575	0.25	1.0	0.0	-6.333333333333334	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.053571428571428575	0.0	0.0	0.25	0.0	0.0
165	the co-evolution of viruses	0.06637442787073183	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
84	doxepin 25 mg	0.6552013350240504	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04	0.04	3.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
327	histone H3 lysine	0.3642247003726121	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.3333333333333333	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
49	50%;50	0.6044088312951653	-1.625	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.625	0.0	0.0	0.0	0.04	0.04	0.0	0.0427807486631016	0.0427807486631016	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0427807486631016	0.0	0.04	0.0	0.0	0.0	0.0	0.0
30	amyloid-β peptide	0.5422399368689563	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	4.0	0.045454545454545456	0.25	1.0	0.0	-3.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
34	the liver	0.0035232316856173783	-13.75	1.0	-17.75	0.13793103448275862	0.13793103448275862	1.0	1.0	1.0	-17.75	1.0	0.0	-13.75	0.0	0.0	-17.5	0.13793103448275862	0.13333333333333333	0.0	0.08888888888888889	0.08888888888888889	2.0	0.13333333333333333	1.0	1.0	0.0	-17.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.08888888888888889	0.0	0.13333333333333333	1.0	0.0	0.0	0.0	0.0
11	improved;Improved	0.09112461233357536	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
66	evidence of bowel obstruction or perforation	0.14917382504017793	-3.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-3.0	1.0	1.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	6.0	0.04	0.3333333333333333	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.045454545454545456	0.0	0.04	0.0	1.0	0.0	0.0	1.0
27	short	0.08777881280371597	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
345	common;Common	0.08953518362259696	-1.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	0.0	0.04	0.04	0.0	0.0425531914893617	0.0425531914893617	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0425531914893617	0.0	0.04	0.0	0.0	0.0	0.0	0.0
344	Nuclear Structure;nuclear structure	0.13798446068209183	-1.875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-1.875	1.0	1.0	-7.833333333333334	0.04	0.05825242718446603	0.0	0.043243243243243246	0.043243243243243246	2.0	0.05825242718446603	0.0	1.0	1.0	-7.833333333333334	1.0	1.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	2.0	1.0	2.0	0.043243243243243246	1.0	0.05825242718446603	0.0	1.0	0.0	1.0	1.0
85	a key regulator of neurite outgrowth	0.1276196294931761	-3.8000000000000007	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-2.428571428571427	0.04	0.04430379746835443	0.0	0.04716981132075472	0.04716981132075472	6.0	0.04430379746835443	0.0	1.0	0.0	-2.428571428571427	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04716981132075472	0.0	0.04430379746835443	0.0	0.0	0.0	0.0	0.0
16	component' proteins).Although gene fusion events	0.060120135293791774	-1.0	1.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.5714285714285714	0.0	-1.0	0.0	0.0	0.0	0.04	0.04	0.0	0.041666666666666664	0.041666666666666664	8.0	0.04	0.375	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.041666666666666664	0.0	0.04	0.0	0.0	0.0	0.0	0.0
188	Shank mutant mouse models	0.08778840244942379	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	different;Different	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
144	Factor;factor;factors	0.12374309264327836	-3.8500000000000005	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-7.125	0.04	0.04	0.0	0.04672897196261683	0.04728421963036669	1.0	0.05838709677419355	0.0	4.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.047619047619047616	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
25	clinically significant levels	0.12017246397945679	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.04	0.04	3.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
118	an antagonist against CXC chemokine receptors	0.35234043969639234	0.0	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.16666666666666666	0.0	0.0
150	CMA effects direct transmembrane import	0.11818945804115175	0.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.375	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
264	Treatment of SCH	0.04397919086969007	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.6666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
150	Lysosomal;lysosomal	0.9389623758944292	-3.814285714285714	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.7142857142857135	0.0	0.0	-3.25	0.04	0.04	0.0	0.04	0.047740189469852395	1.0	0.04671482500031902	0.0	10.0	0.0	-8.833333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	10.0	0.05785123966942149	0.0	0.06185567010309279	0.0	0.0	0.0	0.0	0.0
199	Co-immunoprecipitation;Co-Immunoprecipitation	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	particle capped	0.08847752402144088	-3.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04597701149425287	0.04597701149425287	2.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04597701149425287	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
248	Rheumatoid Arthritis through GWAS	0.015815355148234803	-10.5	1.0	0.0	0.04	0.04	0.25	0.25	1.0	0.0	1.0	0.0	-10.5	0.0	0.0	-9.571428571428571	0.04	0.06481481481481481	0.0	0.06896551724137931	0.06896551724137931	4.0	0.06481481481481481	1.0	1.0	0.0	-9.571428571428571	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.06896551724137931	0.0	0.06481481481481481	1.0	0.0	0.0	0.0	0.0
176	Modification;modification	0.5161265663074225	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.6	0.04	0.05434782608695653	0.0	0.04	0.04	1.0	0.05434782608695653	0.0	1.0	0.0	-6.6	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05434782608695653	0.0	0.0	0.0	0.0	0.0
204	chinese;Chinese	0.18969246335589843	-6.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-8.25	0.0	0.0	-7.4	0.04	0.04	0.0	0.04878048780487805	0.05314888969785221	1.0	0.058806451612903224	0.0	5.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.05970149253731343	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
83	The patient	0.08049499465169332	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.04	0.04	2.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
95	show;Show	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
131	chloride intracellular channel protein 1;CHLORIDE INTRACELLULAR CHANNEL 1	0.25307567068442405	0.0	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.3333333333333333	1.0	0.0	1.0	1.0	-3.6000000000000014	0.04	0.04672897196261683	0.0	0.04	0.04	5.0	0.04672897196261683	0.0	2.0	1.0	-3.6000000000000014	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	10.0	0.04	0.0	0.04672897196261683	0.0	1.0	0.0	0.0	1.0
160	60;60%	0.5658023944960809	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.1428571428571423	0.04	0.04375	0.0	0.04	0.04	1.0	0.04375	0.0	1.0	0.0	-2.1428571428571423	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04375	0.0	0.0	0.0	0.0	0.0
238	SEVERE;severe	0.0974548213491138	-3.916666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.916666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.047430830039525695	0.047430830039525695	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047430830039525695	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	about 50% of malaria cases	0.07185083584207295	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.14285714285714285	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
129	a processive manner	0.15492925226296245	-1.2222222222222214	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.2222222222222214	0.0	0.0	0.0	0.04	0.04	0.0	0.04205607476635514	0.04205607476635514	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04205607476635514	0.0	0.04	0.0	0.0	0.0	0.0	0.0
346	the negative elongation factor NELF	0.1366884286450233	-9.5	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	-9.5	0.0	0.0	-13.714285714285715	0.04	0.08860759493670887	1.0	0.06451612903225806	0.06451612903225806	5.0	0.08860759493670887	0.2	1.0	0.0	-13.714285714285715	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.06451612903225806	0.0	0.08860759493670887	0.0	0.0	0.2	0.0	0.0
274	active vaccine	0.12633707273757303	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	1.0	0.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
72	ontology terms to the interactions	0.042499810905632575	-1.3000000000000007	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-1.3000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04219409282700422	0.04219409282700422	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04219409282700422	0.0	0.04	0.0	0.0	0.0	0.0	0.0
254	macrophages;macrophage;Macrophages;Macrophage	0.6668944226842918	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
264	levothyroxine (LT4) treatment	0.5810353414958467	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
61	Subfamily;subfamily;subfamilies	0.7875745882654053	-1.0333333333333332	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-3.125	0.04	0.04	0.0	0.04	0.041890223556890226	1.0	0.047102721209131025	0.0	6.0	0.0	-8.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	6.0	0.046296296296296294	0.0	0.05970149253731343	0.0	0.0	0.0	0.0	0.0
149	endurance training	0.435809293607436	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	CLL, autoimmune disease	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
208	patients with highly refractory, partial seizures	0.15253371083258746	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
66	placental	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
3	the structure	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
264	powered	0.13671203241059182	-0.8125	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.625	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.0413903743315508	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.0427807486631016	0.0	0.04	0.0	0.0	0.0	0.0	0.0
83	examining	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
50	O NOS;o	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
324	rare condition	0.0833095359500099	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	2.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
261	Autosomal recessive;autosomal recessive	0.6158129811352135	-6.857142857142858	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.857142857142858	0.0	0.0	-1.8333333333333321	0.04	0.043165467625899276	0.0	0.05511811023622047	0.05511811023622047	2.0	0.043165467625899276	0.0	1.0	0.0	-1.8333333333333321	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.05511811023622047	0.0	0.043165467625899276	0.0	0.0	0.0	0.0	0.0
4	conformational;Conformation	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	The role	0.04626036409214738	-4.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04938271604938271	0.04938271604938271	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04938271604938271	0.0	0.04	0.0	0.0	0.0	0.0	0.0
326	caused;cause	0.15469216393526142	-2.4375	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-3.1666666666666665	0.04	0.04	0.0	0.04	0.04484567901234568	1.0	0.046794258373205735	0.0	4.0	0.0	-6.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.05	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
342	effectors of H3K4 methylation	0.4644536462009593	-3.8000000000000007	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	-3.8000000000000007	1.0	1.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.04716981132075472	0.04716981132075472	4.0	0.044642857142857144	0.0	1.0	1.0	-2.6000000000000014	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04716981132075472	0.0	0.044642857142857144	0.0	1.0	0.0	0.0	1.0
256	craniosynostosis in humans	0.14060690506485468	-4.666666666666666	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.04918032786885245	0.04918032786885245	3.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04918032786885245	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
30	formation and stabilization of G-quadruplexes	0.023041398900722834	0.0	1.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.42857142857142855	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	7.0	0.05263157894736842	0.7142857142857143	1.0	0.0	-6.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
101	Molecule;molecule	0.10120390444143419	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05	0.05	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	proximal breakpoint	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
78	the mother	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	the clinical utility of the pharmacogenetic test	0.021969830563351847	-4.333333333333334	1.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.2857142857142857	0.0	-4.333333333333334	0.0	0.0	0.0	0.04	0.04	1.0	0.048387096774193554	0.048387096774193554	7.0	0.04	0.2857142857142857	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.048387096774193554	0.0	0.04	0.0	0.0	0.14285714285714285	0.0	0.0
239	non-expression in the lymphocytes	0.08515174297744192	-2.833333333333332	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.045112781954887216	0.045112781954887216	4.0	0.04878048780487805	0.5	1.0	0.0	-4.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.045112781954887216	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
134	Cloning;cloning	0.5478960285263482	-6.666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.054545454545454536	0.054545454545454536	1.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.054545454545454536	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
266	two large populations of elderly subjects	0.07969782410770486	-3.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-2.333333333333332	0.04	0.044117647058823525	0.0	0.046511627906976744	0.046511627906976744	6.0	0.044117647058823525	0.0	1.0	0.0	-2.333333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.046511627906976744	0.0	0.044117647058823525	0.0	0.0	0.0	0.0	0.0
332	responders	0.7123617662367117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
307	Parkinson disease-specific Lewy bodies;Parkinson's disease;Parkinson disease;PARKINSON'S DISEASE;parkinson disease lewy body	0.9980987254156996	-2.32	0.06666666666666667	0.0	0.04	0.04	0.3333333333333333	0.3555555555555555	0.0	0.0	0.02222222222222222	0.0	-5.199999999999999	0.0	0.0	-3.2666666666666666	0.04	0.04	0.0	0.04	0.044295301297138	3.1333333333333333	0.04645537729245876	0.02222222222222222	15.0	0.0	-7.5	1.0	0.0	0.0	0.06666666666666667	0.0	0.0	1.0	0.0	0.0	5.0	1.0	47.0	0.050505050505050504	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
72	genes or proteins	0.21502134065069065	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
222	Reflecting;reflecting	0.0890109533865753	-1.3333333333333321	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.3333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.04225352112676056	0.04225352112676056	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04225352112676056	0.0	0.04	0.0	0.0	0.0	0.0	0.0
72	a multitude of text	0.030318848685494487	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.800000000000001	0.04	0.05813953488372093	0.0	0.04	0.04	4.0	0.05813953488372093	0.5	1.0	0.0	-7.800000000000001	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.05813953488372093	0.0	0.0	0.0	0.0	0.0
30	the proliferation	0.10549951416075809	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	an HSC (haemopoietic stem cell) as a result	0.0773199454331704	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.1538461538461533	0.04	0.045774647887323945	0.0	0.04	0.04	10.0	0.045774647887323945	0.3	1.0	0.0	-3.1538461538461533	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.045774647887323945	0.0	0.0	0.0	0.0	0.0
267	continuous;CONTINUOUS	0.09390847214108768	-2.8571428571428577	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.8571428571428577	0.0	0.0	0.0	0.04	0.04	0.0	0.04516129032258065	0.04516129032258065	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04516129032258065	0.0	0.04	0.0	0.0	0.0	0.0	0.0
90	United Kingdom (n 	0.23727897674316129	-2.3999999999999986	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04424778761061947	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04424778761061947	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	robust and precise complex expression patterns	0.0747829060298053	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
299	T(0)AM	0.4717066201810369	-1.8333333333333321	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-1.8333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.043165467625899276	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.043165467625899276	0.0	0.04	0.0	0.0	0.0	0.0	0.0
227	0.05)	0.662303744367841	-3.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04587155963302752	0.04587155963302752	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04587155963302752	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	Native;native	0.14095469534932045	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
89	causes;cause	0.10554410433926976	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-3.75	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04857142857142857	0.0	2.0	0.0	-7.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.045454545454545456	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
102	abnormally high synthesis	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	demethylation at these loci	0.26782860435995465	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
144	RXR	0.7468756275773678	-3.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.1999999999999993	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.04587155963302752	0.04587155963302752	1.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	1.0	0.04587155963302752	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
286	in vitro;In Vitro	0.22615488515053817	-3.8000000000000007	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04716981132075472	0.04716981132075472	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04716981132075472	0.0	0.04	0.0	0.0	0.0	0.0	0.0
83	acute coronary syndrome patients on dual antiplatelet treatment	0.1752341279380678	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
243	No Change;No nucleotide change	0.17738079114821875	-2.571428571428573	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.571428571428573	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.0445859872611465	0.0445859872611465	3.0	0.04878048780487805	0.0	2.0	0.0	-4.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.0445859872611465	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
317	proliferation;Proliferation	0.7857791981850705	-2.299999999999999	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.043859649122807015	0.04405371836671324	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04424778761061947	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	a web server (PRED-TMBB	0.32033852697290743	0.0	0.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04	0.04	7.0	0.043478260869565216	0.14285714285714285	1.0	0.0	-2.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
69	pathogenesis	0.66945447551574	-2.166666666666668	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.043795620437956206	0.043795620437956206	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.043795620437956206	0.0	0.04	0.0	0.0	0.0	0.0	0.0
160	cancers	0.10091947888187172	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.571428571428573	0.04	0.042682926829268296	0.0	0.04	0.04	1.0	0.042682926829268296	0.0	1.0	0.0	-1.571428571428573	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.042682926829268296	0.0	0.0	0.0	0.0	0.0
138	the use	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
294	topical minoxidil;Topical minoxidil	0.5717231683879584	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	intracellular proteins	0.7744579530037519	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
160	condition management;management of these conditions	0.03791398157361175	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04	0.04	4.0	0.043478260869565216	0.25	1.0	0.0	-2.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
47	abundant validated genes	0.48501901710734213	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
67	the animal model of MS	0.005941832232185676	0.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	-9.0	0.04	0.0625	1.0	0.04	0.04	5.0	0.0625	0.8	1.0	0.0	-9.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.0625	0.0	0.0	0.2	0.0	0.0
166	affect;Affect	0.0021697281221201457	-18.6	1.0	0.0	0.04	0.04	1.0	1.0	1.0	0.0	1.0	0.0	-18.6	0.0	0.0	-17.666666666666668	0.04	0.13636363636363635	0.0	0.15625	0.15625	1.0	0.13636363636363635	1.0	1.0	0.0	-17.666666666666668	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.15625	0.0	0.13636363636363635	1.0	0.0	0.0	0.0	0.0
30	pathogenesis	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
163	the end of the study	0.03776773949451835	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
275	common;Common	0.003667042364843927	-16.125	1.0	-17.0	0.125	0.125	1.0	1.0	1.0	-17.0	1.0	0.0	-16.125	0.0	0.0	-14.0	0.125	0.09090909090909091	0.0	0.11267605633802817	0.11267605633802817	1.0	0.09090909090909091	1.0	1.0	0.0	-14.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.11267605633802817	0.0	0.09090909090909091	1.0	0.0	0.0	0.0	0.0
320	pharmacophore mapping methods	0.0611302785654711	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	3.0	0.04	0.6666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.3333333333333333	0.0	0.0
137	Shift;shift	0.09041508891473371	-1.7777777777777786	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	0.0	0.04	0.04	0.0	0.0430622009569378	0.0430622009569378	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0430622009569378	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	treated;Treated	0.11862678236368827	-6.166666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-3.333333333333333	0.04	0.04	0.0	0.05263157894736842	0.0531015037593985	1.0	0.04727272727272727	0.0	2.0	0.0	-6.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.053571428571428575	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
189	ACTH	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
10	phenotype;Phenotype	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
262	Diffuse;diffuse	0.5153067090576633	-4.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-10.333333333333334	0.04	0.06818181818181819	0.0	0.04819277108433735	0.04819277108433735	1.0	0.06818181818181819	0.0	1.0	0.0	-10.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04819277108433735	0.0	0.06818181818181819	0.0	0.0	0.0	0.0	0.0
267	control	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
164	oxidative;Oxidative	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
222	the names of anti-CD52 monoclonal antibody	0.022016166551633395	-9.555555555555555	1.0	-6.0	0.05263157894736842	0.05263157894736842	0.5	0.5	1.0	-6.0	1.0	1.0	-9.555555555555555	1.0	1.0	-4.800000000000001	0.05263157894736842	0.04950495049504951	1.0	0.06474820143884892	0.06474820143884892	6.0	0.04950495049504951	1.0	1.0	1.0	-4.800000000000001	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	6.0	0.06474820143884892	1.0	0.04950495049504951	1.0	1.0	0.16666666666666666	1.0	1.0
267	Telemetries;telemetric	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	SHOCK;shock	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
276	severe form of psychomotor retardation;severe X-linked psychomotor retardation;Psychomotor retardation, severe;severe psychomotor retardation	0.9998075868192969	-2.264705882352941	0.0	0.0	0.04	0.04	0.25	0.32941176470588235	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-3.7294117647058824	0.04	0.04	0.0	0.0425531914893617	0.04400485596928538	3.3529411764705883	0.04826277307688992	0.0	17.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	57.0	0.045454545454545456	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
276	Parameters;parameters	0.6044088312951653	-1.625	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.625	0.0	0.0	0.0	0.04	0.04	0.0	0.0427807486631016	0.0427807486631016	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0427807486631016	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	the comprehensive analysis of candidate regions	0.020119380195957874	0.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.14285714285714285	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
237	cytoplasmic sequestration of NF-kB	0.031535945424149725	-5.2857142857142865	1.0	-5.428571428571429	0.05109489051094891	0.05109489051094891	0.16666666666666666	0.16666666666666666	1.0	-5.428571428571429	1.0	1.0	-5.2857142857142865	0.0	0.0	-5.571428571428571	0.05109489051094891	0.051470588235294115	0.0	0.05072463768115942	0.05072463768115942	6.0	0.051470588235294115	1.0	1.0	0.0	-5.571428571428571	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.05072463768115942	0.0	0.051470588235294115	1.0	0.0	0.0	0.0	0.0
4	classical MEN1-associated tumors	0.06006846871692629	-1.625	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.5	1.0	-1.625	0.0	0.0	0.0	0.04	0.04	1.0	0.0427807486631016	0.0427807486631016	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.0427807486631016	0.0	0.04	0.0	0.0	0.2	0.0	0.0
205	selected times	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
231	Characteristic;characteristic	0.08275009250887809	-0.8571428571428577	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.7142857142857153	0.0	0.0	-6.785714285714286	0.04	0.05	0.0	0.04	0.041472392638036815	1.0	0.05543478260869565	0.0	2.0	0.0	-8.571428571428571	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04294478527607362	0.0	0.0608695652173913	0.0	0.0	0.0	0.0	0.0
121	randomized controlled trials;RANDOMIZED CONTROLLED TRIALS	0.1187176919696614	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
159	similar;Similar	0.14095469534932045	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
37	clonogenic assay	0.7268739028102027	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
90	Reducing	0.6832845487132178	-3.8000000000000007	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04716981132075472	0.04716981132075472	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04716981132075472	0.0	0.04	0.0	0.0	0.0	0.0	0.0
266	metabolic syndrome (p	0.4569459889005569	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
318	LABORATORY;laboratory	0.07742260880198093	-1.7777777777777786	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-3.76923076923077	0.04	0.04710144927536232	0.0	0.0430622009569378	0.0430622009569378	1.0	0.04710144927536232	0.0	1.0	0.0	-3.76923076923077	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0430622009569378	0.0	0.04710144927536232	0.0	0.0	0.0	0.0	0.0
30	splice site selection	0.35490565103101407	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
176	Major;major	0.08818882697406123	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.5	0.04	0.04716981132075472	0.0	0.04	0.04	1.0	0.0516747933008268	0.0	2.0	0.0	-7.199999999999999	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.056179775280898875	0.0	0.0	0.0	0.0	0.0
284	other forms	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
178	Interaction;interaction	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
221	five patients	0.01315868787520465	-3.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.5	0.0	-3.0	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.045454545454545456	0.045454545454545456	2.0	0.06060606060606061	0.5	1.0	0.0	-8.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.045454545454545456	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
28	literature;Literature	0.10357417947446557	-5.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.051724137931034475	0.051724137931034475	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.051724137931034475	0.0	0.04	0.0	0.0	0.0	0.0	0.0
302	8-bromo-	0.3842585586614058	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
274	Aggregated;aggregated	0.6011457048714541	-1.2727272727272734	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.2727272727272734	0.0	0.0	0.0	0.04	0.04	0.0	0.0421455938697318	0.0421455938697318	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0421455938697318	0.0	0.04	0.0	0.0	0.0	0.0	0.0
137	Restenosis;restenosis	0.6913470979890001	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.7999999999999994	0.04	0.042735042735042736	0.0	0.04	0.04	1.0	0.045109211775878434	0.0	3.0	0.0	-3.3999999999999986	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
298	effects;Effects	0.09006219608192875	-1.6666666666666679	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6666666666666679	0.0	0.0	0.0	0.04	0.04	0.0	0.04285714285714286	0.04285714285714286	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04285714285714286	0.0	0.04	0.0	0.0	0.0	0.0	0.0
221	patients;Patients	0.0519518442649963	-3.0000000000000004	1.0	-15.5	0.04	0.05305263157894737	1.0	1.0	1.0	-3.1	1.0	0.0	-10.833333333333334	0.0	0.0	-6.5	0.10526315789473684	0.04	0.0	0.04	0.047600164541341014	1.0	0.0655986895986896	1.0	10.0	0.0	-17.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	10.0	0.07058823529411765	0.0	0.13333333333333333	1.0	0.0	0.0	0.0	0.0
20	Defined;defined	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
58	rifabutin;RIFABUTIN	0.7111192058369022	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
38	molecular abnormalities	0.8375942713045537	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	2.0	0.04	1.0	0.04	0.0	0.0	0.0	1.0	0.0
60	virtual	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
322	histone tail	0.08610399755460352	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	2.0	0.05	0.5	1.0	0.0	-5.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
46	Notch pathway	0.10486529524638369	-3.233333333333333	1.0	-5.333333333333334	0.04	0.04361581920903954	0.0	0.0	1.0	-1.777777777777778	1.0	0.0	-8.2	0.0	0.0	-2.222222222222222	0.05084745762711865	0.04	0.0	0.04	0.04735900033772374	2.0	0.04484848484848484	1.0	3.0	0.0	-6.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.05952380952380952	0.0	0.054545454545454536	1.0	0.0	0.0	0.0	0.0
61	the remaining ATG	0.035445674176268094	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	3.0	0.05	0.6666666666666666	1.0	0.0	-5.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
94	Food	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
49	protein 2 (MeCP2)	0.2887043616958875	-1.5	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.0425531914893617	0.0425531914893617	5.0	0.04716981132075472	0.2	1.0	0.0	-3.8000000000000007	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.0425531914893617	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
102	RORα	0.6891157495153456	-4.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	0.0	0.04	0.04	0.0	0.04878048780487805	0.04878048780487805	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04878048780487805	0.0	0.04	0.0	0.0	0.0	0.0	0.0
147	170-313 pmol/min/mg protein in adult livers	0.11287196510450506	0.0	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.1111111111111111	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.1	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
4	a variety of neuroendocrine neoplasias and hormone excess syndromes	0.1824783730422738	-1.75	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-1.75	0.0	0.0	0.0	0.04	0.04	0.0	0.043010752688172046	0.043010752688172046	9.0	0.04	0.1111111111111111	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	9.0	0.043010752688172046	0.0	0.04	0.0	0.0	0.0	0.0	0.0
77	midbrain dopamine neurons	0.5988449027329927	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.7142857142857153	0.04	0.04294478527607362	0.0	0.04	0.04	3.0	0.04294478527607362	0.0	1.0	0.0	-1.7142857142857153	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04294478527607362	0.0	0.0	0.0	0.0	0.0
332	PKC-β inhibitor enzastaurin	0.6012794617063826	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	Genetic variability	0.27080625539909625	-3.25	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
114	Sequences;sequences	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
50	RNA abundance	0.27032536371493515	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.3333333333333333	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
80	thought;Thought	0.06562871919457036	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.199999999999999	0.04	0.05319148936170213	0.0	0.04	0.04	1.0	0.05319148936170213	0.0	1.0	0.0	-6.199999999999999	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05319148936170213	0.0	0.0	0.0	0.0	0.0
150	the degradation of cytosolic proteins	0.14934593264465726	-4.7142857142857135	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-4.7142857142857135	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04929577464788733	0.04929577464788733	5.0	0.043478260869565216	0.4	1.0	0.0	-2.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04929577464788733	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
14	feed;Feed	0.07398084174238093	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.04	0.04615384615384615	0.0	0.04	0.04	1.0	0.04615384615384615	0.0	1.0	0.0	-3.333333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04615384615384615	0.0	0.0	0.0	0.0	0.0
16	Predicted;Prediction;predictions;prediction;predicted	0.2589347283708812	-1.9504132231404958	1.0	-17.0	0.04	0.04772727272727273	0.0	0.9090909090909091	1.0	-1.5454545454545454	1.0	0.0	-14.363636363636363	0.0	0.0	-3.272727272727273	0.125	0.04	0.0	0.04	0.046064238534826774	0.9090909090909091	0.05043930567876556	0.5454545454545454	11.0	0.0	-16.5	1.0	0.0	0.9090909090909091	0.5454545454545454	1.0	0.0	1.0	0.0	0.0	5.0	1.0	10.0	0.09401709401709402	0.0	0.11764705882352941	1.0	0.0	0.0	0.0	0.0
151	the most common or most rare codons	0.02206295785855657	0.0	1.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
270	Cross;cross	0.5072089328528423	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04	0.04	0.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
323	patients;Patients	0.10872156505575219	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-3.6666666666666665	0.04	0.04597701149425287	0.0	0.04	0.04421052631578948	1.0	0.04691150359779459	0.0	3.0	0.0	-4.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.05263157894736842	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
341	Study;study	0.08993018152309656	-1.625	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.625	0.0	0.0	0.0	0.04	0.04	0.0	0.0427807486631016	0.0427807486631016	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0427807486631016	0.0	0.04	0.0	0.0	0.0	0.0	0.0
322	Domains, Catalytic;Catalytic Domain;Core, Catalytic;catalytic domains;Subunit, Catalytic;catalytic SET domain;catalytic subunit;catalytic core;catalytic histone methyltransferase SET-domain	0.9568444853858353	0.0	0.08333333333333333	0.0	0.04	0.04	0.0	0.375	0.0	0.0	0.016666666666666666	0.0	0.0	0.0	0.0	-1.1944444444444444	0.04	0.04	0.5833333333333334	0.04	0.04	2.6666666666666665	0.04236338797814208	0.13888888888888887	12.0	0.0	-5.0	1.0	0.0	0.0	0.4166666666666667	0.0	0.0	1.0	0.0	0.0	9.0	1.0	32.0	0.04	0.0	0.05	0.0	0.0	0.20833333333333334	0.0	0.0
90	New Zealand (n 	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	contribute;Contribute	0.0769443154650848	-10.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-10.0	0.0	0.0	-11.0	0.04	0.07142857142857142	0.0	0.06666666666666667	0.06666666666666667	1.0	0.07142857142857142	0.0	1.0	0.0	-11.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.06666666666666667	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0
269	two kinds	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
90	New Zealand Clinical Trial Registry	0.03162159544757761	-3.1999999999999993	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.25	0.0	-3.1999999999999993	0.0	0.0	-8.5	0.04	0.06060606060606061	1.0	0.04587155963302752	0.04587155963302752	5.0	0.06060606060606061	0.4	1.0	0.0	-8.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04587155963302752	0.0	0.06060606060606061	0.0	0.0	0.2	0.0	0.0
34	ME gene	0.02948549757564901	0.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.5	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	2.0	0.04	0.5	1.0	1.0	0.0	1.0	0.5	1.0	1.0	1.0	1.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.5	0.0	1.0
96	anthracycline-refractory disease	0.39970954470695225	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	1.0	0.04	0.04	4.0	0.05	0.25	2.0	0.0	-5.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.05	0.0	0.0	0.25	0.0	0.0
171	troponin T (TNNT2	0.5162853273309749	-3.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-10.333333333333334	0.04	0.06818181818181819	0.0	0.04587155963302752	0.04587155963302752	4.0	0.06818181818181819	0.0	1.0	0.0	-10.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04587155963302752	0.0	0.06818181818181819	0.0	0.0	0.0	0.0	0.0
41	T';T	0.7342340478353627	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.583333333333333	0.04	0.04	0.0	0.04	0.04	0.75	0.04522611644997173	0.0	4.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
10	GROWTH;growth	0.09112461233357536	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
150	cytosolic substrate proteins for CMA	0.19368041363338975	-4.2857142857142865	1.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.375	1.0	-4.2857142857142865	0.0	0.0	-1.8333333333333321	0.04	0.043165467625899276	0.0	0.04827586206896552	0.04827586206896552	5.0	0.043165467625899276	0.4	1.0	0.0	-1.8333333333333321	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04827586206896552	0.0	0.043165467625899276	0.0	0.0	0.0	0.0	0.0
326	coding sequence;Coding Sequence	0.38907234898998466	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.04	0.04	2.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	2.0	1.0	2.0	0.04	1.0	0.046875	0.0	0.0	0.0	1.0	0.0
41	The histone tail inserts	0.1803456008989565	-6.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	-6.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05263157894736842	0.05263157894736842	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.05263157894736842	0.0	0.04	0.0	0.0	0.0	0.0	0.0
140	connectivity of modifications	0.18756919885203704	-3.333333333333332	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04615384615384615	0.04615384615384615	3.0	0.051724137931034475	0.3333333333333333	1.0	0.0	-5.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04615384615384615	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
40	Content;content	0.6066186994119565	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
205	the course of prolonged infusions	0.07594933472817433	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
50	edgeR	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
344	Highly;highly	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
256	Gene Targeting;gene targeting	0.11369748766110692	-5.666666666666666	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-8.5	0.04	0.06060606060606061	1.0	0.051724137931034475	0.051724137931034475	2.0	0.06060606060606061	0.5	2.0	0.0	-8.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.051724137931034475	0.0	0.06060606060606061	0.0	0.0	0.5	0.0	0.0
216	amendment;Amendment	0.06526239486352117	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04	0.04	1.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
121	Discontinuation;discontinuation	0.5868705614791213	-4.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.047619047619047616	0.047619047619047616	1.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
229	the PageRank and HITS algorithms	0.18916618552744635	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
270	TIME;time	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
31	for;For	0.07738819785095771	-9.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-9.0	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.0625	0.0625	1.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0625	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
177	Group E;/E ratio for the group;E ratio for the group	0.11223282386261772	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.7333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.5	0.04	0.18333333333333335	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	11.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
49	the specific phenotypic characteristics	0.07197647791206133	-2.25	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-2.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04395604395604396	0.04395604395604396	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04395604395604396	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	Networks;Network;networks;network	0.3868587230585672	-0.34375	0.0	0.0	0.04	0.04	0.0	0.75	0.0	0.0	0.0	0.0	-1.375	0.0	0.0	-2.0416666666666665	0.04	0.04	0.0	0.04	0.04058201058201058	1.0	0.043935155753337576	0.0	4.0	0.0	-4.833333333333334	1.0	0.0	0.75	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	4.0	0.042328042328042326	0.0	0.04958677685950414	0.0	0.0	0.0	0.0	0.0
225	the first years	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
117	an X-linked disorder	0.2951219942703977	-2.8571428571428577	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.8571428571428577	0.0	0.0	-7.75	0.04	0.057971014492753624	0.0	0.04516129032258065	0.04516129032258065	3.0	0.057971014492753624	0.0	1.0	0.0	-7.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04516129032258065	0.0	0.057971014492753624	0.0	0.0	0.0	0.0	0.0
246	functional polymorphism	0.20644967047540377	-4.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04878048780487805	0.04878048780487805	2.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04878048780487805	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
122	the genetic information	0.07649944334497959	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04878048780487805	0.04878048780487805	3.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04878048780487805	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
86	absence	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
74	an IgG-mediated reduction in number	0.15521175150126698	-2.166666666666668	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.043795620437956206	0.043795620437956206	7.0	0.04819277108433735	0.14285714285714285	1.0	0.0	-4.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.043795620437956206	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
93	Trial;trials	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
341	mutants;Mutant;mutant	0.7025265773115722	-0.875	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.125	0.0	0.0	-1.5625	0.04	0.04	0.0	0.04	0.04151097233064446	1.0	0.0429839768846861	0.0	4.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.04371584699453552	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
52	mRNA	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
180	Inactivation of CD40LG gene	0.1801910739774446	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04	0.04	4.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
241	the biomechanical properties	0.07584948024908061	-5.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-5.4	0.04	0.0510204081632653	0.0	0.05	0.05	3.0	0.0510204081632653	0.3333333333333333	1.0	0.0	-5.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05	0.0	0.0510204081632653	0.0	0.0	0.0	0.0	0.0
343	Specific Activity;specific antiretroviral restriction activity	0.08671490994812284	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	histone H3 tail	0.7790857095090437	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.6666666666666666	0.0	0.0	0.0	-3.4444444444444446	0.04	0.04	0.0	0.04	0.04	3.0	0.04700622524052065	0.0	3.0	0.0	-6.0	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.0	0.4444444444444444	1.0	1.0	9.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
224	Regimen;regimen	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
345	stem-loops	0.0677710675205816	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
330	Th17 Cells;Th17 cells	0.3730670842758065	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
306	Present;present	0.07886951915057139	-1.5999999999999996	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-8.0	0.04	0.04	0.0	0.04	0.04293577981651376	1.0	0.07555555555555556	0.0	2.0	0.0	-16.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04587155963302752	0.0	0.1111111111111111	0.0	0.0	0.0	0.0	0.0
319	the molecular mechanism	0.0793662226340656	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
24	JEWEL study program	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
139	Aβ-associated neuropathology	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
150	proportional;Proportional	0.6034905724985387	-4.428571428571429	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.428571428571429	0.0	0.0	-2.5	0.04	0.044444444444444446	0.0	0.04861111111111112	0.04861111111111112	1.0	0.044444444444444446	0.0	1.0	0.0	-2.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04861111111111112	0.0	0.044444444444444446	0.0	0.0	0.0	0.0	0.0
155	Thirteen	0.6755054890943064	-6.166666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.166666666666666	0.0	0.0	-2.833333333333332	0.04	0.045112781954887216	0.0	0.053097345132743355	0.053097345132743355	1.0	0.045112781954887216	0.0	1.0	0.0	-2.833333333333332	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.053097345132743355	0.0	0.045112781954887216	0.0	0.0	0.0	0.0	0.0
176	prokaryotic proteins	0.38273219553679333	-1.375	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.5	1.0	-1.375	1.0	1.0	0.0	0.04	0.04	1.0	0.042328042328042326	0.042328042328042326	2.0	0.04	0.5	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	2.0	0.042328042328042326	0.0	0.04	0.0	1.0	0.5	0.0	1.0
239	three;Three	0.07985596352625927	-2.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.044117647058823525	0.044117647058823525	1.0	0.046511627906976744	0.0	1.0	0.0	-3.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.044117647058823525	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
100	cytosine-[C5]-specific DNA methyltransferases	0.1412143948988744	0.0	1.0	0.0	0.04	0.04	0.2222222222222222	0.2222222222222222	0.0	0.0	0.2	1.0	0.0	0.0	0.0	-8.166666666666666	0.04	0.059405940594059396	0.0	0.04	0.04	9.0	0.059405940594059396	0.4444444444444444	1.0	0.0	-8.166666666666666	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	9.0	0.04	0.0	0.059405940594059396	0.0	0.0	0.0	0.0	0.0
229	the effect	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	reports;Report;Reports;Reported;report;reported	0.1326660749322056	-1.3333333333333335	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-0.761904761904762	0.04	0.04	0.0	0.04	0.04262672811059908	1.0	0.04154963680387409	0.0	7.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	6.0	1.0	7.0	0.05	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
140	present cells;present in human cells	0.05400144105253504	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	4.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
84	amitriptyline hydrochloride;AMITRIPTYLINE HYDROCHLORIDE	0.7625556914551705	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	on;On	0.07296156602125722	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.04	0.04	1.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
13	the fundamental processes	0.11231982977445785	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05	0.05	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05	0.0	0.04	0.0	0.0	0.0	0.0	0.0
10	Oncogene;oncogene	0.8668228423515346	-1.1428571428571423	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.2857142857142847	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.0420125786163522	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	4.0	0.0440251572327044	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	[27]	0.6171953679194666	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
40	Confidence Intervals;confidence intervals	0.11707437433269925	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
307	The precursor	0.10549951416075809	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
174	Includes;include;includes	0.07910207571986454	-2.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	-3.8	0.04	0.04	0.0	0.043165467625899276	0.04448349717172827	1.0	0.04873563218390805	0.0	2.0	0.0	-7.6	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.04580152671755725	0.0	0.0574712643678161	0.0	0.0	0.0	0.0	0.0
20	a novel interaction	0.11135912480252187	-4.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04938271604938271	0.04938271604938271	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04938271604938271	0.0	0.04	0.0	0.0	0.0	0.0	0.0
68	evidence;Evidence	0.0773269471278308	-4.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.048387096774193554	0.048387096774193554	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.048387096774193554	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
215	hyperproliferative signaling through AKT	0.5397609114828908	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.04	0.04	4.0	0.044642857142857144	0.0	1.0	1.0	-2.6000000000000014	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04	0.0	0.044642857142857144	0.0	1.0	0.0	0.0	1.0
69	GLIS3;Glis3	0.5489167955477648	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.04	0.04	1.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
102	circadian rhythmicity;Circadian Rhythms;circadian rhythms;circadian rhythm;rhythmic control of E-box-mediated circadian;Circadian rhythm	0.9999939725989351	-2.120967741935484	0.0	0.0	0.04	0.04	0.0	0.36405529953917054	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04403962960094618	2.161290322580645	0.04	0.004608294930875576	31.0	0.0	0.0	1.0	0.0	0.0	0.03225806451612903	0.0	0.0	1.0	0.0	0.0	6.0	1.0	67.0	0.04938271604938271	0.0	0.04	0.0	0.0	0.0	0.0	0.0
244	glucose-6-phosphate dehydrogenase deficiency	0.6362038274936618	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	5.0	0.047619047619047616	0.2	2.0	0.0	-4.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
120	expanded;Expanded	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
55	Support, NOS;support	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	Potential;potential	0.07501320457875972	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	1.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
28	case;Case	0.09888188928863312	-4.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.048387096774193554	0.048387096774193554	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.048387096774193554	0.0	0.04	0.0	0.0	0.0	0.0	0.0
254	Types;types	0.009173034587502982	-6.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	0.0	0.04	0.04	1.0	0.054545454545454536	0.054545454545454536	1.0	0.04	1.0	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.054545454545454536	0.0	0.04	1.0	0.0	1.0	0.0	0.0
90	Randomized;randomized	0.698883568811117	-1.3333333333333333	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.042539682539682544	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	[25]	0.6171953679194666	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
261	the regulation of calcium release	0.08007673288039767	-6.857142857142858	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-6.857142857142858	0.0	0.0	-8.333333333333334	0.04	0.06000000000000001	0.0	0.05511811023622047	0.05511811023622047	5.0	0.06000000000000001	0.0	1.0	0.0	-8.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.05511811023622047	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
307	direct;Direct	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
83	Play;plays	0.06905400356094286	-3.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.046511627906976744	0.046511627906976744	1.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046511627906976744	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
58	a satisfactory vehicle for stomach-specific delivery	0.0845555934170069	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
323	dural ectasia;Dural ectasia	0.8576397788341247	-1.8	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-4.95	0.04	0.04	0.0	0.04	0.043272727272727275	2.0	0.051820895522388055	0.0	5.0	0.0	-8.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	10.0	0.045454545454545456	0.0	0.05970149253731343	0.0	0.0	0.0	0.0	0.0
47	Generated;generated	0.11770021015641213	-2.583333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043795620437956206	0.04462508294625083	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
222	H+;H	0.5509239061828721	-2.2222222222222214	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.2222222222222214	0.0	0.0	-5.4	0.04	0.0510204081632653	0.0	0.04390243902439024	0.04390243902439024	1.0	0.0510204081632653	0.0	1.0	0.0	-5.4	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04390243902439024	0.0	0.0510204081632653	0.0	0.0	0.0	0.0	0.0
94	May	0.1888036027089725	-4.2	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.6	0.0	0.0	0.0	0.04	0.04	0.0	0.04587155963302752	0.048195920902119854	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.051546391752577324	0.0	0.04	0.0	0.0	0.0	0.0	0.0
204	the presence of fibroblast growth factor	0.05172733387632983	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
199	ropagation	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
99	The inheritance pattern of Emery-Dreifuss muscular dystrophy (EDMD)	0.034082752151132864	0.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.7142857142857143	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	12.0	0.04	0.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	12.0	0.04	0.0	0.04	0.0	0.0	0.08333333333333333	0.0	0.0
231	mutation;Mutations;mutations;Mutation	0.11783916694225931	-3.2448979591836737	1.0	-6.571428571428571	0.04	0.042037652270210404	0.0	0.0	1.0	-0.9387755102040816	1.0	0.0	-10.142857142857142	0.0	0.0	-5.408163265306123	0.05426356589147286	0.04	1.0	0.04	0.04710179605340896	1.0	0.05204937593070177	1.0	7.0	0.0	-9.428571428571429	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	7.0	0.0673076923076923	0.0	0.06422018348623854	1.0	0.0	1.0	0.0	0.0
319	modeling;Modeling	0.5262844302736505	-5.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.05	0.05	1.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
40	very large;Very large	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	Cdc2;CDC2	0.7227987842043504	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-3.7142857142857153	0.04	0.04697986577181208	0.0	0.04	0.04	1.0	0.04697986577181208	0.0	2.0	1.0	-3.7142857142857153	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	2.0	0.04	0.0	0.04697986577181208	0.0	1.0	0.0	0.0	1.0
44	the material	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
154	Seen;seen	0.07822027932043239	-1.6363636363636367	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6363636363636367	0.0	0.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.042801556420233464	0.042801556420233464	1.0	0.046296296296296294	0.0	1.0	0.0	-3.3999999999999986	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.042801556420233464	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
163	therapeutic;Therapeutic	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	Association;association	0.18868193103467495	-3.4375	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04673955079577569	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04938271604938271	0.0	0.04	0.0	0.0	0.0	0.0	0.0
208	in;In;Present;presents	0.11464127260930641	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
192	restless leg syndrome in end stage	0.011916719803407975	0.0	1.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
183	Frame;frame	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
77	's original proprietary catechol-O-methyl transferase (COMT) inhibitor	0.20985254956499094	0.0	0.0	0.0	0.04	0.04	0.1111111111111111	0.1111111111111111	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-4.2857142857142865	0.04	0.04827586206896552	1.0	0.04	0.04	9.0	0.04827586206896552	0.6666666666666666	1.0	0.0	-4.2857142857142865	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04	0.0	0.04827586206896552	0.0	0.0	0.1111111111111111	0.0	0.0
127	including deletion mutations in exon 19	0.17412860300851346	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	practically no effect on female sensitivity	0.06995022480023828	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04878048780487805	0.04878048780487805	6.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04878048780487805	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
329	a novel protein docking method	0.04049964488517651	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	the propagation of methylation patterns	0.026479958756095278	-1.4444444444444429	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.14285714285714285	0.0	-1.4444444444444429	0.0	0.0	-1.8571428571428577	0.04	0.043209876543209874	0.0	0.04245283018867924	0.04245283018867924	5.0	0.043209876543209874	0.6	1.0	0.0	-1.8571428571428577	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04245283018867924	0.0	0.043209876543209874	0.0	0.0	0.0	0.0	0.0
213	Na;Na+	0.6641753767711227	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.5	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
316	the Notch3 gene;the NOTCH3 gene	0.23922350444609689	-2.6590909090909083	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.8181818181818166	0.0	0.0	-4.65	0.04	0.04587155963302752	0.0	0.04230769230769231	0.044828851776115786	3.0	0.049304835413431995	0.3333333333333333	4.0	0.0	-6.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	12.0	0.047210300429184546	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
69	PKHD1 GENE;PKHD1 gene	0.20146510080365157	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	Nucleoside Analog;nucleoside analog	0.686352549966944	-4.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.0	1.0	1.0	-7.666666666666666	0.04	0.05769230769230768	0.0	0.047619047619047616	0.047619047619047616	2.0	0.05769230769230768	0.0	2.0	1.0	-7.666666666666666	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	4.0	0.047619047619047616	0.0	0.05769230769230768	0.0	1.0	0.0	0.0	1.0
100	5-azacytosine in the presence	0.10793650749311251	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	Cellular;cellular	0.5581676128239649	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.04	0.045112781954887216	0.0	0.04	0.04	1.0	0.045112781954887216	0.0	1.0	0.0	-2.833333333333332	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.045112781954887216	0.0	0.0	0.0	0.0	0.0
94	limited;Limited	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
169	a known partner of GATA-1	0.0398772590368705	0.0	1.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.5	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	a role of DNMT1	0.06637442787073183	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
208	partial seizures;partial-onset seizures;Partial seizures	0.5729447668945514	0.0	0.0	0.0	0.04	0.04	0.25	0.4375	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.5	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
203	rare disorder;Rare Disorder	0.18181963531464768	-9.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-9.25	0.0	0.0	-11.2	0.04	0.07246376811594203	0.0	0.06349206349206349	0.06349206349206349	2.0	0.07246376811594203	0.0	1.0	0.0	-11.2	1.0	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	2.0	1.0	2.0	0.06349206349206349	1.0	0.07246376811594203	0.0	0.0	0.0	1.0	0.0
125	a recent founder in the local population	0.052276168001750584	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
127	amino acid	0.33464996046184486	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
246	CYP2C19*2 and *4 alleles	0.5453625000725163	-3.25	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	-3.25	1.0	1.0	-7.0	0.04	0.05555555555555555	0.0	0.04597701149425287	0.04597701149425287	5.0	0.05555555555555555	0.0	1.0	1.0	-7.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.04597701149425287	0.0	0.05555555555555555	0.0	1.0	0.0	0.0	1.0
334	histone variant H2Av in Drosophila melanogaster	0.1258364585120706	0.0	1.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.14285714285714285	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	6.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.16666666666666666	0.0	0.0
85	Functional studies	0.10365465571641648	-2.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	-1.7142857142857153	0.04	0.04294478527607362	0.0	0.04504504504504505	0.04504504504504505	2.0	0.04294478527607362	0.0	1.0	0.0	-1.7142857142857153	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04504504504504505	0.0	0.04294478527607362	0.0	0.0	0.0	0.0	0.0
331	negative;Negative	0.10599342158052662	-6.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.053571428571428575	0.053571428571428575	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.053571428571428575	0.0	0.04	0.0	0.0	0.0	0.0	0.0
343	a gene	0.15325027982670122	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	1.0	0.0	1.0	0.5	1.0	0.0	1.0	1.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
24	additional reduction	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
335	locus;Locus	0.5629625446638944	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.04	0.04424778761061947	0.0	0.04	0.04	1.0	0.04424778761061947	0.0	1.0	0.0	-2.3999999999999986	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04424778761061947	0.0	0.0	0.0	0.0	0.0
60	eukaryoteshNDC1	0.6123470632438762	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.04	0.04	1.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
91	Seen;seen	0.09112461233357536	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
200	the children	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
78	recent genetic studies	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	prokaryotic genomes	0.6647440932729793	-1.875	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.875	0.0	0.0	-8.166666666666666	0.04	0.059405940594059396	0.0	0.043243243243243246	0.043243243243243246	2.0	0.059405940594059396	0.0	2.0	0.0	-8.166666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.043243243243243246	0.0	0.059405940594059396	0.0	0.0	0.0	0.0	0.0
79	BZD OD in the UK	0.18916618552744635	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
71	Observed;observed	0.09166524161837002	-1.5999999999999996	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-4.0	0.04	0.046511627906976744	0.0	0.04	0.04293577981651376	1.0	0.0476460578559274	0.0	2.0	0.0	-4.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04587155963302752	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
30	the C9orf72 gene;the C9ORF72 gene	0.09985724787866009	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.4000000000000004	0.04	0.04	0.0	0.04	0.04	3.0	0.042522522522522525	0.3333333333333333	2.0	0.0	-2.8000000000000007	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04504504504504505	0.0	0.0	0.0	0.0	0.0
118	colorectal cancer proliferation	0.26154494832477987	-2.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-7.75	0.04	0.057971014492753624	0.0	0.043478260869565216	0.043478260869565216	3.0	0.057971014492753624	0.3333333333333333	2.0	0.0	-7.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.043478260869565216	0.0	0.057971014492753624	0.0	0.0	0.0	0.0	0.0
343	100 human proteins	0.30839099265035763	-2.166666666666668	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-2.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.043795620437956206	0.043795620437956206	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.043795620437956206	0.0	0.04	0.0	0.0	0.0	0.0	0.0
282	7)	0.6166128545324334	-6.199999999999999	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.199999999999999	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.05319148936170213	0.05319148936170213	2.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05319148936170213	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
330	Stimulus;stimulus	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
86	Agonist;agonist	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	Program;program	0.39961311507971786	-0.5263157894736842	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-7.315789473684211	0.04	0.04	0.0	0.04	0.04105263157894737	1.0	0.08894736842105264	1.0	19.0	0.0	-20.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	19.0	0.05	0.0	0.2	1.0	0.0	0.0	0.0	0.0
310	the target of bortezomib	0.003630729971769322	-4.75	1.0	-9.5	0.06451612903225806	0.06451612903225806	0.75	0.75	1.0	-9.5	1.0	0.0	-4.75	0.0	0.0	-8.0	0.06451612903225806	0.058823529411764705	1.0	0.04938271604938271	0.04938271604938271	4.0	0.058823529411764705	1.0	1.0	0.0	-8.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04938271604938271	0.0	0.058823529411764705	1.0	0.0	0.25	0.0	0.0
264	the risk of cardiovascular events	0.014094949472540662	-2.5	1.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.4	0.0	-2.5	0.0	0.0	0.0	0.04	0.04	0.0	0.044444444444444446	0.044444444444444446	5.0	0.04	0.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.044444444444444446	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	introduced;introduce	0.09224825987546924	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.461538461538461	0.04	0.04234527687296417	0.0	0.04	0.04	1.0	0.049806999669962264	0.0	2.0	0.0	-7.538461538461538	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.05726872246696036	0.0	0.0	0.0	0.0	0.0
172	males;Males	0.14095469534932045	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	/hsa-miR-212 miRNA cluster induction	0.4631789849380446	-3.6000000000000014	0.0	0.0	0.04	0.04	0.14285714285714285	0.14285714285714285	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.04672897196261683	0.04672897196261683	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04672897196261683	0.0	0.04	0.0	0.0	0.0	0.0	0.0
163	no benefits	0.12218164286884722	-5.6	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.6	0.0	0.0	0.0	0.04	0.04	0.0	0.051546391752577324	0.051546391752577324	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.051546391752577324	0.0	0.04	0.0	0.0	0.0	0.0	0.0
75	species;Species	0.12372782746440301	-6.166666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-8.0	0.0	0.0	-6.666666666666667	0.04	0.045454545454545456	0.0	0.04819277108433735	0.05344987794314513	1.0	0.05601522539066073	0.0	3.0	0.0	-10.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.058823529411764705	0.0	0.06779661016949153	0.0	0.0	0.0	0.0	0.0
131	one specific protein	0.05099698556091588	-1.1999999999999993	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.4	1.0	-1.1999999999999993	1.0	1.0	-3.6000000000000014	0.04	0.04672897196261683	0.0	0.04201680672268907	0.04201680672268907	3.0	0.04672897196261683	0.0	1.0	1.0	-3.6000000000000014	1.0	0.3333333333333333	1.0	0.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04201680672268907	0.0	0.04672897196261683	0.0	1.0	0.0	0.0	1.0
9	the GC	0.3979379877516507	-5.833333333333333	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-6.0	0.0	0.0	-8.75	0.04	0.06060606060606061	0.0	0.051724137931034475	0.05217785843920145	2.0	0.061553030303030304	0.0	2.0	0.0	-9.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.05263157894736842	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
230	an MYH7-associated spectrum	0.2629218408210859	-3.6000000000000014	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04672897196261683	0.04672897196261683	5.0	0.04716981132075472	0.0	1.0	0.0	-3.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04672897196261683	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
334	Up-Regulation;upregulation	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
84	LOWER;lower	0.09556194584807255	-8.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-8.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.058823529411764705	0.058823529411764705	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.058823529411764705	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
307	fibrils	0.6220752059249444	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.04	0.04	1.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
295	muscle;MUSCLE	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
237	IkappaB alpha protein;I Kappa B-Alpha;IkappaBalpha;I Kappa B-Alpha Protein;IkappaB alpha;I kappa B-alpha	0.9959985495840732	-1.78021978021978	0.0	0.0	0.04	0.04	0.0	0.05641025641025642	0.0	0.0	0.0	1.0	-2.428571428571427	0.0	0.0	-6.032967032967033	0.04	0.04697986577181208	0.0	0.04	0.043114302488755155	2.3846153846153846	0.053364792196755446	0.03076923076923077	13.0	0.0	-8.857142857142858	1.0	0.6666666666666666	0.0	0.15384615384615385	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	6.0	1.0	31.0	0.04430379746835443	0.0	0.061946902654867256	0.0	0.0	0.0	0.0	0.0
331	deletion mutation;Deletion Mutation	0.5717231683879584	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
76	9-item	0.36455145303528796	-2.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
205	period;/period	0.0968891560091204	-3.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	0.0	0.04	0.04	0.0	0.047058823529411764	0.047058823529411764	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047058823529411764	0.0	0.04	0.0	0.0	0.0	0.0	0.0
302	Inhibiting;INHIBITION;inhibiting;inhibition	0.6069071457302061	-2.4666666666666672	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04463292776112385	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.04716981132075472	0.0	0.04	0.0	0.0	0.0	0.0	0.0
74	High;high	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	5-methylcytosine residues	0.7678365906596795	-2.925925925925926	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.0	0.0	-3.7619047619047614	0.04	0.04430379746835443	0.0	0.04245283018867924	0.04540094339622641	4.0	0.04717533989685888	0.25	3.0	0.0	-4.428571428571429	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	12.0	0.046875	0.0	0.04861111111111112	0.0	0.0	0.0	0.0	0.0
14	common;Common	0.07605879023739286	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.04	0.04477611940298508	0.0	0.04	0.04	1.0	0.04477611940298508	0.0	1.0	0.0	-2.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04477611940298508	0.0	0.0	0.0	0.0	0.0
310	manageable toxicities	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
28	the associated insulin-dependent diabetes mellitus	0.23109930500699358	-6.666666666666666	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	1.0	-6.666666666666666	1.0	1.0	0.0	0.04	0.04	0.0	0.054545454545454536	0.054545454545454536	7.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.054545454545454536	0.0	0.04	0.0	1.0	0.0	0.0	1.0
189	Role;role	0.07268327190128901	-6.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.054545454545454536	0.054545454545454536	1.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.054545454545454536	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
5	pharmacodynamic	0.6786620167432701	-3.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
66	not;Not	0.08990245200359774	-2.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-6.75	0.04	0.04819277108433735	0.0	0.043795620437956206	0.04497473329590118	1.0	0.05584241728820042	0.0	2.0	0.0	-9.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04615384615384615	0.0	0.06349206349206349	0.0	0.0	0.0	0.0	0.0
11	Aspergillus terreus controlled batch fermentations	0.4550060119099613	-2.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	-2.0	1.0	1.0	-4.0	0.04	0.047619047619047616	0.0	0.043478260869565216	0.043478260869565216	5.0	0.047619047619047616	0.0	1.0	1.0	-4.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.043478260869565216	0.0	0.047619047619047616	0.0	1.0	0.0	0.0	1.0
60	a major transmembrane glycoprotein	0.17423540272965482	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
124	poor-prognosis ER-positive breast cancers	0.43644426881144266	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	16.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
292	FIBROMYALGIA;fibromyalgia	0.7796962371019726	-2.3333333333333335	1.0	-8.0	0.04	0.04221453287197232	0.0	0.0	1.0	-0.9411764705882353	1.0	0.0	-15.0	0.0	0.0	-1.1764705882352942	0.058823529411764705	0.04	0.0	0.04	0.0481866796305299	1.0	0.04313725490196079	1.0	17.0	0.0	-10.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	17.0	0.1	0.0	0.06666666666666667	1.0	0.0	0.0	0.0	0.0
13	systems;System	0.14678893288712352	-1.5833333333333335	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-1.25	0.04	0.04	0.0	0.04	0.04339285714285714	1.0	0.0425	0.0	4.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.053571428571428575	0.0	0.05	0.0	0.0	0.0	0.0	0.0
150	UCH-L1;Uch-L1	0.9660942044553477	-3.8571428571428577	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.8571428571428577	1.0	1.0	-3.083333333333334	0.04	0.043795620437956206	0.0	0.0472972972972973	0.04729729729729729	3.0	0.04570733402850191	0.0	6.0	1.0	-4.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	18.0	0.0472972972972973	0.0	0.047619047619047616	0.0	1.0	0.0	0.0	1.0
73	whole sequence amino acid composition	0.3773891021663985	0.0	0.0	0.0	0.04	0.04	0.8	0.8000000000000002	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-3.3333333333333335	0.04	0.04	0.0	0.04	0.04	5.0	0.04667592849865704	0.0	3.0	1.0	-5.333333333333334	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	15.0	0.04	0.0	0.05084745762711865	0.0	1.0	0.0	0.0	1.0
318	a genetic aberration	0.0599957662966252	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.692307692307692	0.04	0.0546218487394958	0.0	0.04	0.04	3.0	0.0546218487394958	0.3333333333333333	1.0	0.0	-6.692307692307692	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.0546218487394958	0.0	0.0	0.0	0.0	0.0
337	Detected;detected	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	a gradual loss	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
160	the pathophysiology of osteoporosis	0.12970523993473232	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-1.571428571428573	0.04	0.042682926829268296	0.0	0.04	0.04	4.0	0.042682926829268296	0.5	1.0	0.0	-1.571428571428573	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.042682926829268296	0.0	0.0	0.0	0.0	0.0
276	HYPOTONIA;hypotonia	0.6055644994452098	-1.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.75	0.0	0.0	0.0	0.04	0.04	0.0	0.043010752688172046	0.043010752688172046	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043010752688172046	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	cell nuclear antigen in replication foci	0.08448551464116509	-1.8888888888888893	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-2.2857142857142847	0.04	0.0440251572327044	0.0	0.04326923076923077	0.04326923076923077	6.0	0.0440251572327044	0.16666666666666666	1.0	0.0	-2.2857142857142847	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04326923076923077	0.0	0.0440251572327044	0.0	0.0	0.0	0.0	0.0
99	autosomal dominant variant	0.5558630145945828	-5.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.5	-5.0	0.5	0.0	-6.071428571428571	0.04	0.04	0.0	0.05	0.05	3.0	0.05888888888888889	0.0	2.0	0.5	-12.142857142857142	1.0	0.3333333333333333	0.0	0.0	0.0	0.5	1.0	0.0	0.16666666666666666	1.0	1.0	6.0	0.05	0.0	0.07777777777777778	0.0	1.0	0.0	0.0	1.0
346	Activation, Transcriptional;transcriptional activation	0.7661605119014627	-7.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.0	0.0	0.0	-5.142857142857142	0.04	0.050359712230215826	0.0	0.05555555555555555	0.05555555555555555	2.0	0.050359712230215826	0.0	3.0	0.0	-5.142857142857142	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.05555555555555555	0.0	0.050359712230215826	0.0	0.0	0.0	0.0	0.0
99	EDMD (AD	0.16753794087427812	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.5	0.0	0.0	0.0	0.0	-2.8571428571428577	0.04	0.04516129032258065	0.0	0.04	0.04	3.0	0.04516129032258065	0.0	1.0	0.0	-2.8571428571428577	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04516129032258065	0.0	0.0	0.0	0.0	0.0
222	39 highly selected patients	0.0287249850841844	-1.5555555555555571	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.4	0.0	-1.5555555555555571	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04265402843601896	0.04265402843601896	4.0	0.045454545454545456	0.25	1.0	0.0	-3.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04265402843601896	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
78	mediated microdeletions around the NF1 gene	0.13590869039667647	-3.25	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.14285714285714285	1.0	-3.25	1.0	1.0	-4.0	0.04	0.047619047619047616	0.0	0.04597701149425287	0.04597701149425287	6.0	0.047619047619047616	0.16666666666666666	1.0	1.0	-4.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.04597701149425287	0.0	0.047619047619047616	0.0	1.0	0.0	0.0	1.0
159	clover leaf skull deformity;Clover leaf skull deformity	0.32261417116341956	-2.75	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0449438202247191	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	4.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
58	effective	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	MCI in majority	0.0793662226340656	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
334	DNA damage in the cell	0.008907573539979922	-1.4444444444444429	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.3333333333333333	0.0	-1.4444444444444429	0.0	0.0	0.0	0.04	0.04	0.0	0.04245283018867924	0.04245283018867924	5.0	0.04	0.8	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04245283018867924	0.0	0.04	0.0	0.0	0.0	0.0	0.0
175	abnormal;ABNORMAL	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	the first primary malignant bone tumor	0.11238352909302805	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
120	inactivation;Inactivation	0.6115547005449775	-2.3999999999999986	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04424778761061947	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04424778761061947	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	leads;???lead	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
148	found;Found	0.10675937573309824	-6.166666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-5.833333333333333	0.04	0.051724137931034475	0.0	0.05263157894736842	0.0531015037593985	1.0	0.05217785843920145	0.0	2.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.053571428571428575	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
318	its kinase inhibitor such as imatinib	0.0916983133607511	-2.2222222222222214	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.2222222222222214	0.0	0.0	-7.692307692307692	0.04	0.05777777777777778	1.0	0.04390243902439024	0.04390243902439024	6.0	0.05777777777777778	0.3333333333333333	1.0	0.0	-7.692307692307692	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04390243902439024	0.0	0.05777777777777778	0.0	0.0	0.16666666666666666	0.0	0.0
73	prokaryotes;Prokaryotes	0.5867894638542289	-5.333333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	-11.166666666666666	0.04	0.07228915662650602	0.0	0.05084745762711865	0.05084745762711865	1.0	0.07228915662650602	0.0	2.0	0.0	-11.166666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.05084745762711865	0.0	0.07228915662650602	0.0	0.0	0.0	0.0	0.0
297	spontaneous cardioversion	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
321	Molecules;molecules	0.048693929415103705	-3.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-16.0	0.04	0.1111111111111111	0.0	0.04587155963302752	0.04587155963302752	1.0	0.1111111111111111	0.0	1.0	0.0	-16.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04587155963302752	0.0	0.1111111111111111	0.0	0.0	0.0	0.0	0.0
137	found;In;in;Found	0.015574654474742043	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8888888888888893	0.0	0.0	-2.6999999999999997	0.04	0.04	0.0	0.04	0.04363439519274835	1.0	0.04529213936655223	0.8	5.0	0.0	-5.1	1.0	0.0	1.0	0.8	1.0	0.0	1.0	0.0	0.0	4.0	1.0	5.0	0.04736842105263158	0.0	0.05025125628140704	1.0	0.0	0.0	0.0	0.0
252	AMI	0.7123617662367117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	beta-contact	0.1595611801486202	-3.375	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-3.375	0.0	0.0	-8.833333333333334	0.04	0.06185567010309279	0.0	0.046242774566473986	0.046242774566473986	3.0	0.06185567010309279	0.6666666666666666	2.0	0.0	-8.833333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.046242774566473986	0.0	0.06185567010309279	0.0	0.0	0.0	0.0	0.0
140	recombinant proteins	0.7268739028102027	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
130	gram-negative bacteria;Gram-Negative Bacteria	0.03449850705212997	-12.0	1.0	-7.444444444444445	0.056962025316455694	0.056962025316455694	0.5	0.5	1.0	-7.4444444444444455	1.0	0.0	-12.0	0.0	0.0	-6.857142857142858	0.056962025316455694	0.05511811023622047	1.0	0.07692307692307693	0.07692307692307693	4.0	0.055118110236220465	1.0	3.0	0.0	-6.857142857142858	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	12.0	0.07692307692307693	0.0	0.05511811023622047	1.0	0.0	0.25	0.0	0.0
158	The syndactyly cases	0.19844371765747773	-2.3999999999999986	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-2.3999999999999986	1.0	1.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04424778761061947	3.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04424778761061947	0.0	0.04	0.0	1.0	0.0	0.0	1.0
80	Caucasian individuals	0.12367659697945912	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
264	the improvement of arterial stiffening	0.09168242431061523	-1.375	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-1.375	0.0	0.0	-5.0	0.04	0.05	0.0	0.042328042328042326	0.042328042328042326	5.0	0.05	0.2	1.0	0.0	-5.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.042328042328042326	0.0	0.05	0.0	0.0	0.0	0.0	0.0
101	Win;WIN	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
132	3,5,3'-D-triiodothyronine	0.8840938362944252	-2.6000000000000014	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.044642857142857144	0.044642857142857144	9.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	18.0	0.044642857142857144	0.0	0.04	0.0	0.0	0.0	0.0	0.0
138	strong cation exchange chromatography	0.2104408332625397	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.375	0.04	0.042328042328042326	0.0	0.04	0.04	4.0	0.042328042328042326	0.0	1.0	0.0	-1.375	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.042328042328042326	0.0	0.0	0.0	0.0	0.0
14	a predominance of beta	0.07084524667171183	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.04	0.04	4.0	0.05405405405405406	0.5	1.0	0.0	-6.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
285	an inherited TP53 mutation	0.4227682396501886	-3.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	C-terminal;C-Terminal	0.7477522913825327	-2.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.75	0.0	0.0	-2.888888888888889	0.04	0.04	0.0	0.04	0.04493150684931507	3.0	0.04559979182930002	0.0	3.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.0547945205479452	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
30	expression;Expression	0.16058626665548642	-0.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-1.85	0.04	0.04	0.0	0.04	0.0408695652173913	1.0	0.044204545454545455	0.0	4.0	0.0	-7.4	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.043478260869565216	0.0	0.056818181818181816	0.0	0.0	0.0	0.0	0.0
37	the effects of two DNA topoisomerase	0.041756068225953284	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	6.0	0.05	0.16666666666666666	1.0	0.0	-5.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
43	The complex pathogen-host-vector system of the tick-borne louping-ill virus	0.03550882044203828	0.0	1.0	0.0	0.04	0.04	0.5294117647058824	0.5294117647058824	0.0	0.0	0.08333333333333333	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	17.0	0.04	0.4117647058823529	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	17.0	0.04	0.0	0.04	0.0	0.0	0.058823529411764705	0.0	0.0
94	help;Help	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
148	chicken;CHICKEN	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
24	Population	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
299	cardiac effects	0.008005156548586875	-3.333333333333332	1.0	-12.0	0.07692307692307693	0.07692307692307693	0.5	0.5	1.0	-12.0	1.0	0.0	-3.333333333333332	0.0	0.0	-12.333333333333332	0.07692307692307693	0.07894736842105263	1.0	0.04615384615384615	0.04615384615384615	2.0	0.07894736842105263	1.0	1.0	0.0	-12.333333333333332	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04615384615384615	0.0	0.07894736842105263	1.0	0.0	0.5	0.0	0.0
312	Hsp90 and/or Hsp70	0.12794239006330396	-2.166666666666668	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.4	1.0	-2.166666666666668	1.0	1.0	0.0	0.04	0.04	0.0	0.043795620437956206	0.043795620437956206	5.0	0.04	0.2	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.043795620437956206	0.0	0.04	0.0	1.0	0.0	0.0	1.0
339	the reduced p16INK4a	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
145	vitro and decrease beta-amyloid	0.29956052836315394	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
208	generalized tonic-clonic and partial-onset epilepsies	0.4552357990760626	-6.75	0.0	0.0	0.04	0.04	0.2222222222222222	0.2222222222222222	0.0	0.0	0.0	1.0	-6.75	1.0	1.0	0.0	0.04	0.04	0.0	0.0547945205479452	0.0547945205479452	9.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.0547945205479452	0.0	0.04	0.0	1.0	0.0	0.0	1.0
343	recognition of incoming viral capsids	0.2760304774354432	-5.166666666666666	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-5.166666666666666	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.050420168067226885	0.050420168067226885	5.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.050420168067226885	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
78	numerous central and peripheral nervous system manifestations	0.06015096991510445	0.0	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	7.0	0.04918032786885245	0.14285714285714285	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
177	endurance sports (long distance running	0.12345732182283334	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
330	the JAK inhibitor CP-690,550 and methotrexate	0.1666615242660352	-1.5555555555555571	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.25	1.0	-1.5555555555555571	1.0	1.0	-3.375	0.04	0.046242774566473986	1.0	0.04265402843601896	0.04265402843601896	6.0	0.046242774566473986	0.3333333333333333	1.0	1.0	-3.375	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.04265402843601896	0.0	0.046242774566473986	0.0	1.0	0.16666666666666666	0.0	1.0
330	myelofibrosis whereas tofacitinib	0.5280818148381968	-5.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-5.0	1.0	1.0	-3.375	0.04	0.046242774566473986	0.0	0.05	0.05	3.0	0.046242774566473986	0.0	1.0	1.0	-3.375	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.05	0.0	0.046242774566473986	0.0	1.0	0.0	0.0	1.0
47	a library for E. coli contamination)	0.1697773434878509	0.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
330	autoimmune disease indications	0.12162574388942697	-3.1111111111111107	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.1111111111111107	0.0	0.0	-7.875	0.04	0.058394160583941604	0.0	0.04568527918781726	0.04568527918781726	3.0	0.058394160583941604	0.0	1.0	0.0	-7.875	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04568527918781726	0.0	0.058394160583941604	0.0	0.0	0.0	0.0	0.0
345	eukaryotic mRNAs	0.5120735351819675	-1.8999999999999986	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.8999999999999986	0.0	0.0	-12.8	0.04	0.0819672131147541	0.0	0.04329004329004329	0.04329004329004329	2.0	0.0819672131147541	0.0	1.0	0.0	-12.8	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04329004329004329	0.0	0.0819672131147541	0.0	0.0	0.0	0.0	0.0
228	8-bromo-	0.3842585586614058	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
11	itaconic acid producer	0.03209155231625845	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.3333333333333333	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.6666666666666666	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	a freely accessible, interactive and flexible software termed Endeavour	0.08630324155159282	0.0	0.0	0.0	0.04	0.04	0.7	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	2;+2	0.6268450230024418	-0.7777777777777786	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	-2.7142857142857144	0.04	0.04	0.0	0.04	0.04132701421800948	1.0	0.04554744525547445	0.0	2.0	0.0	-5.428571428571429	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04265402843601896	0.0	0.05109489051094891	0.0	0.0	0.0	0.0	0.0
189	hormone (GHRH) administration	0.18916618552744635	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
48	the K-Ras oncogene	0.051334859954376665	0.0	1.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.6666666666666666	0.0	0.0	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04	0.04	5.0	0.043478260869565216	0.8	1.0	0.0	-2.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
215	Overexpression;overexpression;overexpressing;overexpress	0.5488215739427651	-1.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-3.0000000000000004	0.04	0.04	0.0	0.04	0.04235294117647059	1.0	0.045916460041960705	0.0	3.0	0.0	-5.4	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.047058823529411764	0.0	0.0510204081632653	0.0	0.0	0.0	0.0	0.0
307	alpha-synuclein immunoreactivity in nigral Lewy bodies	0.210798597343138	0.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.2857142857142857	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.25	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
262	histopathological;histopathology	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	Filters;Filter;filters;filtering	0.3633403100051016	0.0	0.0	0.0	0.04	0.04	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.5	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	other tissues	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	their respective inhibitors	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
82	a valid pharmacogenetic test for SJS/TEN	0.08317543159292975	-2.8571428571428577	0.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.0	1.0	-2.8571428571428577	1.0	1.0	-10.8	0.04	0.07042253521126761	0.0	0.04516129032258065	0.04516129032258065	8.0	0.07042253521126761	0.125	1.0	1.0	-10.8	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04516129032258065	0.0	0.07042253521126761	0.0	1.0	0.0	0.0	1.0
17	Two hyperprolactinemic infertile women	0.1289993902350918	-2.666666666666668	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-6.25	0.04	0.05333333333333334	1.0	0.04477611940298508	0.04477611940298508	4.0	0.05333333333333334	0.25	1.0	0.0	-6.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04477611940298508	0.0	0.05333333333333334	0.0	0.0	0.25	0.0	0.0
129	the mouse (Bestor et al. 1988)	0.19264124897959514	-1.7777777777777786	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	0.0	0.04	0.04	0.0	0.0430622009569378	0.0430622009569378	8.0	0.04	0.375	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.0430622009569378	0.0	0.04	0.0	0.0	0.0	0.0	0.0
344	the reorganization of chromatin structure	0.1338870361537569	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
156	Cu-67, 12 under the assumption	0.12037657915982773	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04	0.04	6.0	0.04819277108433735	0.16666666666666666	1.0	0.0	-4.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
160	OPG	0.7123617662367117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
292	choice	0.08209271579945943	-3.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.04615384615384615	0.04615384615384615	1.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04615384615384615	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
44	far	0.12120633929144269	-3.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	0.0	0.04	0.04	0.0	0.046511627906976744	0.046511627906976744	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.046511627906976744	0.0	0.04	0.0	0.0	0.0	0.0	0.0
196	analog;Analog;analogs	0.052425171549128693	-7.7	1.0	-12.0	0.04	0.05846153846153847	0.0	0.0	1.0	-6.0	1.0	0.0	-15.4	0.0	0.0	-5.833333333333333	0.07692307692307693	0.04	1.0	0.04	0.07208333333333333	1.0	0.05749999999999999	1.0	2.0	0.0	-11.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.10416666666666667	0.0	0.075	1.0	0.0	1.0	0.0	0.0
139	[14,16,17];14,16,17	0.5696628456938159	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.34285714285714286	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	12.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	Drugs;Drug;drugs;drug's	0.26732106119247756	-1.875	0.0	0.0	0.04	0.04	0.5	0.75	0.0	0.0	0.0	1.0	-3.75	1.0	1.0	-4.166666666666667	0.04	0.04	0.0	0.04	0.043529411764705886	1.5	0.05	0.0	2.0	1.0	-8.333333333333334	1.0	1.0	0.5	0.0	1.0	1.0	1.0	1.0	1.0	4.0	1.0	3.0	0.047058823529411764	1.0	0.06000000000000001	0.0	1.0	0.0	1.0	1.0
277	acute;ACUTE	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
260	the hotspots codon 12, 13 and 61 of the H- and K-ras oncogene	0.11958274032949621	-2.571428571428573	1.0	0.0	0.04	0.04	0.29411764705882354	0.29411764705882354	0.0	0.0	0.2222222222222222	1.0	-2.571428571428573	1.0	1.0	0.0	0.04	0.04	1.0	0.0445859872611465	0.0445859872611465	17.0	0.04	0.29411764705882354	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	17.0	0.0445859872611465	0.0	0.04	0.0	1.0	0.058823529411764705	0.0	1.0
163	muscle damage and body fat percent	0.0747829060298053	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
288	a cardiolipin-binding constituent of the Mitofilin/MINOS protein complex	0.09194294901959421	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.1	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	12.0	0.04	0.25	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	12.0	0.04	0.0	0.04	0.0	1.0	0.08333333333333333	0.0	1.0
205	four;Four	0.09044502311397222	-3.875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-7.5	0.04	0.05128205128205128	0.0	0.04597701149425287	0.04737874964956546	1.0	0.05789909015715467	0.0	2.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04878048780487805	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
228	Series;series	0.10672588051118154	-2.3	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.6	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04450980392156863	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04901960784313726	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	Hypopigmented macules;hypopigmented macules	0.9185413616248624	-0.8125	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.625	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.0413903743315508	2.0	0.04	0.0	6.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	12.0	0.0427807486631016	0.0	0.04	0.0	0.0	0.0	0.0	0.0
341	Spontaneous;spontaneous	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	Leonhardt et al.	0.5895611117890552	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.571428571428573	0.04	0.0445859872611465	0.0	0.04	0.04	3.0	0.0445859872611465	0.0	1.0	0.0	-2.571428571428573	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
137	the mid-term results	0.06442911454780277	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	3.0	0.05	0.3333333333333333	1.0	0.0	-5.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
335	the 5' portion	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	the determination	0.04903930253839074	-6.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.053571428571428575	0.053571428571428575	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.053571428571428575	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	Then;then	0.09769828940272403	-1.166666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-2.666666666666667	0.04	0.04	0.0	0.04	0.04205882352941176	1.0	0.04542372881355933	0.0	2.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.044117647058823525	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
86	SR	0.8140968329183348	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
42	the brain	0.029006074720516518	-3.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-9.8	0.04	0.06578947368421052	0.0	0.04672897196261683	0.04672897196261683	2.0	0.06578947368421052	0.5	1.0	0.0	-9.8	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04672897196261683	0.0	0.06578947368421052	0.0	0.0	0.0	0.0	0.0
249	cancer;CANCER	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
49	and;And	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
262	young women with diffuse bilateral bullous emphysema	0.24037628336782133	-5.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	1.0	-5.0	0.0	0.0	-12.333333333333332	0.04	0.07894736842105263	0.0	0.05	0.05	7.0	0.07894736842105263	0.0	1.0	0.0	-12.333333333333332	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.05	0.0	0.07894736842105263	0.0	0.0	0.0	0.0	0.0
75	The lack	0.08475011506885709	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04	0.04	2.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
318	BCR break-points	0.18876116941066978	-1.4444444444444429	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-1.4444444444444429	0.0	0.0	-3.3846153846153832	0.04	0.046263345195729534	0.0	0.04245283018867924	0.04245283018867924	4.0	0.046263345195729534	0.25	1.0	0.0	-3.3846153846153832	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04245283018867924	0.0	0.046263345195729534	0.0	0.0	0.0	0.0	0.0
294	First;first	0.09166003846162973	-2.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.043795620437956206	0.043795620437956206	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043795620437956206	0.0	0.04	0.0	0.0	0.0	0.0	0.0
346	Inducing;inducing	0.8095048688499007	-2.44	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.800000000000001	0.0	0.0	-0.6571428571428569	0.04	0.04	0.0	0.04	0.044551553706095245	1.0	0.041210526315789475	0.0	5.0	0.0	-3.2857142857142847	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04950495049504951	0.0	0.046052631578947366	0.0	0.0	0.0	0.0	0.0
26	three children	0.017096030860203455	0.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
258	constitutive heterochromatin during interphase	0.09524008193280124	0.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
306	Diagnosed;diagnosed	0.057310804300222506	-3.9000000000000004	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-19.0	0.04	0.16666666666666666	0.0	0.04716981132075472	0.04739442946990117	1.0	0.16666666666666666	0.0	2.0	0.0	-19.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.047619047619047616	0.0	0.16666666666666666	0.0	0.0	0.0	0.0	0.0
72	Users;users	0.08890644022379408	-1.3000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.3000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04219409282700422	0.04219409282700422	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04219409282700422	0.0	0.04	0.0	0.0	0.0	0.0	0.0
197	1.25	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
131	Revealed;revealed	0.0019550876375979127	-9.600000000000001	1.0	0.0	0.04	0.04	1.0	1.0	1.0	0.0	1.0	0.0	-15.9	0.0	0.0	-11.4	0.04	0.054945054945054944	0.0	0.04608294930875576	0.07798652959943282	1.0	0.08302808302808302	1.0	2.0	0.0	-16.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.10989010989010989	0.0	0.1111111111111111	1.0	0.0	0.0	0.0	0.0
293	Off-label;off-label	0.019370931077121154	-5.833333333333333	0.3333333333333333	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.16666666666666666	0.0	-9.0	0.0	0.0	-4.666666666666667	0.04	0.04	0.0	0.046511627906976744	0.05300387596899225	3.0	0.05048503611971104	1.0	3.0	0.0	-8.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.0625	0.0	0.058823529411764705	1.0	0.0	0.0	0.0	0.0
318	cells;Cells	0.07833154257539568	-0.7222222222222214	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.4444444444444429	0.0	0.0	-8.115384615384615	0.04	0.05627705627705627	0.0	0.04	0.04122641509433962	1.0	0.059388528138528136	0.0	2.0	0.0	-9.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04245283018867924	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
41	SNF2-like ATPase	0.49517305135213996	-9.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	-9.0	1.0	1.0	-9.333333333333334	0.04	0.06382978723404256	0.0	0.0625	0.0625	4.0	0.06382978723404256	0.0	1.0	1.0	-9.333333333333334	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	4.0	0.0625	0.0	0.06382978723404256	0.0	1.0	0.0	0.0	1.0
220	Leigh's-like and Leigh's syndrome	0.22515379264356167	-3.125	0.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.0	1.0	-3.125	1.0	1.0	-10.666666666666666	0.04	0.06976744186046512	0.0	0.045714285714285714	0.045714285714285714	8.0	0.06976744186046512	0.0	1.0	1.0	-10.666666666666666	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.045714285714285714	0.0	0.06976744186046512	0.0	1.0	0.0	0.0	1.0
188	haploinsufficiency;Haploinsufficiency	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
276	Pathogenic mutations in the MCT8 gene	0.13512549117996134	0.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.2857142857142857	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
295	YEARS;years	0.0938301236000151	-2.833333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.045112781954887216	0.045112781954887216	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045112781954887216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	carriers	0.08084633458897826	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.04	0.04	1.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
310	specific E3 inhibitors in anti-cancer therapy	0.057272227945890285	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.1111111111111111	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
99	fibers;Fibers	0.07545968566628361	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.8571428571428577	0.04	0.04516129032258065	0.0	0.04	0.04	1.0	0.04516129032258065	0.0	1.0	0.0	-2.8571428571428577	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04516129032258065	0.0	0.0	0.0	0.0	0.0
239	some dysmorphic features of the face and limbs	0.042565234018144896	0.0	0.0	0.0	0.04	0.04	0.875	0.875	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.125	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
80	conclusion;CONCLUSIONS;Conclusions;Conclusion	0.3633403100051016	0.0	0.0	0.0	0.04	0.04	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.5	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
127	gefitinib therapy	0.07928746847952328	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
157	CIDOFOVIR;cidofovir;Cidofovir	0.20881434081317315	-1.9333333333333333	1.0	-14.2	0.04	0.04876543209876544	0.0	0.0	1.0	-2.3666666666666667	1.0	1.0	-11.6	1.0	1.0	-2.4	0.09259259259259259	0.04	0.0	0.04	0.045771144278606964	1.0	0.049056603773584916	1.0	6.0	1.0	-14.4	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	3.0	1.0	6.0	0.07462686567164178	0.0	0.09433962264150944	1.0	1.0	0.0	0.0	1.0
330	Study;study	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
119	nucleic acid metabolism;nucleic acids metabolism	0.36943326476259	-2.833333333333332	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-7.199999999999999	0.04	0.056179775280898875	0.0	0.045112781954887216	0.045112781954887216	3.0	0.056179775280898875	0.0	2.0	0.0	-7.199999999999999	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.045112781954887216	0.0	0.056179775280898875	0.0	0.0	0.0	0.0	0.0
7	use of;Use of	0.09536713930007382	-4.375	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-8.75	0.04	0.05970149253731343	0.0	0.04819277108433735	0.0484866294446077	2.0	0.061596778014688464	0.0	2.0	0.0	-9.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04878048780487805	0.0	0.06349206349206349	0.0	0.0	0.0	0.0	0.0
122	position 1639	0.36320156612915566	-3.25	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
215	oncogenic conditions in which	0.05872097523898217	-4.75	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.04938271604938271	0.04938271604938271	4.0	0.05555555555555555	0.25	1.0	0.0	-7.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04938271604938271	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
57	disease course of;course of disease	0.045927204706885216	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-11.4	0.04	0.07352941176470588	0.0	0.04	0.04	3.0	0.07352941176470588	0.0	1.0	0.0	-11.4	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.07352941176470588	0.0	0.0	0.0	0.0	0.0
79	Seventy	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	elements;Elements	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
228	Optimization	0.7123617662367117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
30	defend	0.08698349159641149	-1.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6000000000000014	0.0	0.0	-6.6	0.04	0.05434782608695653	0.0	0.042735042735042736	0.042735042735042736	1.0	0.05434782608695653	0.0	1.0	0.0	-6.6	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.042735042735042736	0.0	0.05434782608695653	0.0	0.0	0.0	0.0	0.0
160	cytokine;Cytokine	0.6883020934619005	-2.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.5	1.0	1.0	-4.571428571428571	0.04	0.048951048951048945	0.0	0.044444444444444446	0.044444444444444446	1.0	0.048951048951048945	0.0	2.0	1.0	-4.571428571428571	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	2.0	0.044444444444444446	0.0	0.048951048951048945	0.0	1.0	0.0	0.0	1.0
320	Protein Binding;protein binding	0.1782065600684761	-2.666666666666668	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04477611940298508	0.04477611940298508	2.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04477611940298508	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
79	diagnostic or therapeutic procedures	0.31396245926583866	-4.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-8.75	0.04	0.06153846153846154	0.0	0.047619047619047616	0.047619047619047616	4.0	0.06153846153846154	0.0	2.0	0.0	-8.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.047619047619047616	0.0	0.06153846153846154	0.0	0.0	0.0	0.0	0.0
48	carcinomas of human exocrine pancreas	0.17857582191945434	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.571428571428573	0.04	0.042682926829268296	0.0	0.04	0.04	5.0	0.042682926829268296	0.2	1.0	0.0	-1.571428571428573	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.042682926829268296	0.0	0.0	0.0	0.0	0.0
122	60;60%	0.6066186994119565	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	esat.kuleuven	0.6668594340272865	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
300	hypoxia-inducible repressor	0.41448125607385766	-2.428571428571427	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.25	1.0	-2.428571428571427	0.0	0.0	0.0	0.04	0.04	0.0	0.04430379746835443	0.04430379746835443	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04430379746835443	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	needed;Needed	0.08448259273477955	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04878048780487805	0.04878048780487805	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04878048780487805	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
242	survived;SURVIVE	0.07433373078784594	-1.7777777777777786	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.0430622009569378	0.0430622009569378	1.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0430622009569378	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
205	Greater;greater	0.08137707406198094	-9.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-9.25	0.0	0.0	-9.0	0.04	0.0625	0.0	0.06349206349206349	0.06349206349206349	1.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.06349206349206349	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
200	deaths	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
267	for;For	0.10799327188373523	-1.3571428571428577	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.7142857142857153	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.042435897435897436	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04487179487179487	0.0	0.04	0.0	0.0	0.0	0.0	0.0
276	four affected males	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
232	Dural ectasia	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
187	VF	0.7279519738093925	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
300	a critical physiological repressor of ho-1	0.14121080567546898	-2.8571428571428577	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.14285714285714285	1.0	-2.8571428571428577	0.0	0.0	0.0	0.04	0.04	0.0	0.04516129032258065	0.04516129032258065	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.04516129032258065	0.0	0.04	0.0	0.0	0.0	0.0	0.0
180	SPINOCEREBELLAR ATAXIA 10;spinocerebellar ataxia type 10	0.4181501657384175	-2.666666666666668	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	-2.666666666666668	1.0	1.0	0.0	0.04	0.04	0.0	0.04477611940298508	0.04477611940298508	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	4.0	0.04477611940298508	0.0	0.04	0.0	1.0	0.0	0.0	1.0
320	acceptor	0.7123617662367117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
48	contribute;Contribute	0.08019732533941384	-1.375	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.375	0.0	0.0	-2.571428571428573	0.04	0.0445859872611465	0.0	0.042328042328042326	0.042328042328042326	1.0	0.0445859872611465	0.0	1.0	0.0	-2.571428571428573	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.042328042328042326	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
15	the co-occurring literature	0.0793662226340656	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	proportion;Proportion	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
125	the typical histological finding	0.05911731365423501	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.04	0.04	4.0	0.0449438202247191	0.25	1.0	0.0	-2.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
144	Site;site;sites;Sites	0.09318658954172426	-1.7000000000000002	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-4.625	0.04	0.04	0.0	0.04	0.043150132898911085	1.0	0.05181818181818182	0.0	4.0	0.0	-10.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	4.0	0.04672897196261683	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
150	gene expression levels	0.10587544128154532	-3.2857142857142847	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.2857142857142847	0.0	0.0	0.0	0.04	0.04	0.0	0.046052631578947366	0.046052631578947366	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.046052631578947366	0.0	0.04	0.0	0.0	0.0	0.0	0.0
194	LARGE gene;large genes	0.08827558983779943	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.04	0.04	2.0	0.05555555555555555	0.0	2.0	0.0	-7.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
222	Preliminary;preliminary	0.09006219608192875	-1.6666666666666679	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6666666666666679	0.0	0.0	0.0	0.04	0.04	0.0	0.04285714285714286	0.04285714285714286	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04285714285714286	0.0	0.04	0.0	0.0	0.0	0.0	0.0
55	Report;report	0.06901263893103253	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
146	6 wk	0.6503788987304104	-1.8333333333333321	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.043165467625899276	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043165467625899276	0.0	0.04	0.0	0.0	0.0	0.0	0.0
291	information collection	0.14684823062145294	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
72	search	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	the extent of the response	0.029169410808932886	-2.833333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.045112781954887216	0.045112781954887216	5.0	0.04	0.6	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.045112781954887216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
74	symptoms;symptom;Symptom	0.06983452888429845	-4.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.5	0.0	0.0	-6.75	0.04	0.04	0.0	0.043795620437956206	0.04892483724600513	1.0	0.06347826086956522	0.0	2.0	0.0	-13.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.05405405405405406	0.0	0.08695652173913043	0.0	0.0	0.0	0.0	0.0
160	function	0.12817146072916036	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04380952380952381	0.0	2.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
103	cytosine residues	0.7533154089973769	-3.555555555555557	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.555555555555557	0.0	0.0	0.0	0.04	0.04	0.0	0.04663212435233161	0.04663212435233161	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04663212435233161	0.0	0.04	0.0	0.0	0.0	0.0	0.0
37	the phosphorylation of Topo II	0.09135233712136266	0.0	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
208	chemoconvulsants pentylenetetrazol	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	No clinically important changes in laboratory assessments	0.03986391100583097	-2.666666666666668	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04477611940298508	0.04477611940298508	7.0	0.05263157894736842	0.14285714285714285	1.0	0.0	-6.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04477611940298508	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
80	G;g%	0.6457332856749624	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-3.6000000000000014	0.04	0.04672897196261683	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04672897196261683	0.0	2.0	0.0	-3.6000000000000014	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.045454545454545456	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
99	variety;Variety	0.06819257804669673	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.2857142857142865	0.04	0.05072463768115942	0.0	0.04	0.04	1.0	0.05072463768115942	0.0	1.0	0.0	-5.2857142857142865	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05072463768115942	0.0	0.0	0.0	0.0	0.0
318	the recognition that the BCR-ABL tyrosine kinase	0.1194664152654357	0.0	0.0	0.0	0.04	0.04	0.4444444444444444	0.4444444444444444	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-4.846153846153847	0.04	0.04961832061068702	1.0	0.04	0.04	9.0	0.04961832061068702	0.5555555555555556	1.0	1.0	-4.846153846153847	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	9.0	0.04	0.0	0.04961832061068702	0.0	1.0	0.1111111111111111	0.0	1.0
11	Study;study	0.10431625273973467	-2.583333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-3.166666666666667	0.04	0.04	0.0	0.043795620437956206	0.04462508294625083	1.0	0.04678571428571429	0.0	2.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.045454545454545456	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
90	PBM	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
224	ALEMTUZUMAB;alemtuzumab	0.6821738115894906	-1.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.0	1.0	1.0	-2.75	0.04	0.044444444444444446	0.0	0.04	0.04173913043478261	1.0	0.04494949494949495	0.0	2.0	1.0	-3.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	2.0	0.043478260869565216	0.0	0.045454545454545456	0.0	1.0	0.0	0.0	1.0
242	young patients	0.06499167683919528	0.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	4.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
24	two blood pressure	0.08204281619631279	-2.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.04424778761061947	0.04424778761061947	3.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04424778761061947	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
104	AU	0.7123617662367117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
231	This model (	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	Chromosomal Rearrangement;chromosome rearrangement	0.4247351894393581	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
287	using;Using	0.09340210751298886	-1.4000000000000004	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	-3.75	0.04	0.04	0.0	0.04	0.042522522522522525	1.0	0.04857142857142857	0.0	2.0	0.0	-7.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04504504504504505	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
323	The following musculoskeletal abnormalities	0.09264195321378159	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
149	Endurance;endurance	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
325	purification method for the proteomic analysis of endogenously ubiquitinated protein;Protein Purification	0.07769975345985417	-13.5	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.16666666666666666	1.0	-13.5	1.0	1.0	-9.666666666666666	0.04	0.06521739130434782	0.0	0.08695652173913043	0.08695652173913043	10.0	0.06521739130434782	0.1	1.0	1.0	-9.666666666666666	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	10.0	0.08695652173913043	0.0	0.06521739130434782	0.0	1.0	0.0	0.0	1.0
44	WHO/UNICEF	0.47109386804614783	-4.75	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04938271604938271	0.04938271604938271	3.0	0.05084745762711865	0.0	2.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04938271604938271	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
160	the initiation of the "vicious cycle	0.06903754052685196	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.42857142857142855	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
185	permanent pacemaker implantation in 1	0.26905681404095005	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	seven normal children	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
183	sequence;Sequence	0.09520971290739387	-3.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
52	the expected molecular mass (30 kDa) for type III	0.16605178225467776	0.0	0.0	0.0	0.04	0.04	0.45454545454545453	0.45454545454545453	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	11.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	11.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
86	sarcoplasmic reticulum adenosine triphosphatase;sarcoplasmic reticulum Ca2+ adenosine triphosphatase	0.5001033104771733	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	a novel source of disease biomarkers	0.05180023626307752	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.7142857142857153	0.04	0.04294478527607362	1.0	0.04	0.04	6.0	0.04294478527607362	0.16666666666666666	1.0	0.0	-1.7142857142857153	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04294478527607362	0.0	0.0	0.16666666666666666	0.0	0.0
321	required program;required by the Catalyst/HypoGen program	0.08914549169467323	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
176	N NOS;n	0.7741036103687066	-0.8333333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.5	0.0	0.0	-2.266666666666667	0.04	0.04	0.0	0.04	0.04148148148148148	1.0	0.04498168498168498	0.0	3.0	0.0	-6.800000000000001	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	3.0	0.044444444444444446	0.0	0.054945054945054944	0.0	0.0	0.0	0.0	0.0
163	a factor in aerobic physical performance	0.04767562201029434	-3.1999999999999993	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04587155963302752	0.04587155963302752	6.0	0.04918032786885245	0.16666666666666666	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04587155963302752	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
166	effects of ACE inhibitor drugs;effect of drugs	0.11408897668172992	-5.800000000000001	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	-5.800000000000001	1.0	1.0	-5.0	0.04	0.05	1.0	0.052083333333333336	0.052083333333333336	5.0	0.05	0.2	1.0	1.0	-5.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	5.0	0.052083333333333336	0.0	0.05	0.0	1.0	0.2	0.0	1.0
200	hockey most common internationally (47%	0.2246359044634622	0.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
327	H3K4	0.8292197277530349	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
311	Huntington disease;Huntington's disease;HUNTINGTON DISEASE	0.8843167213421022	-0.7857142857142853	0.0	0.0	0.04	0.04	0.3333333333333333	0.4047619047619047	0.0	0.0	0.0	1.0	-1.8333333333333321	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.041356628982528267	2.5714285714285716	0.04	0.0	7.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	3.0	1.0	18.0	0.043165467625899276	0.0	0.04	0.0	1.0	0.0	0.0	1.0
73	vaccine;Vaccine	0.11127433333323047	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	1.0	0.047619047619047616	0.0	1.0	1.0	-4.0	1.0	0.5	1.0	0.0	1.0	1.0	1.0	0.5	0.5	2.0	1.0	1.0	0.04	0.0	0.047619047619047616	0.0	1.0	0.0	0.0	1.0
31	cellular immune responses;Immune Responses, Cellular	0.22439048051956362	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.04	0.04	3.0	0.06060606060606061	0.0	3.0	0.0	-8.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.04	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
129	the establishment and maintenance of DNA methylation	0.016432186619148758	0.0	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.7142857142857143	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
177	odds ratio;Odds Ratio	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
231	conclude	0.09747919155575867	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.428571428571427	0.04	0.04430379746835443	0.0	0.04	0.04	1.0	0.04430379746835443	0.0	1.0	0.0	-2.428571428571427	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04430379746835443	0.0	0.0	0.0	0.0	0.0
62	infliximab for Crohn	0.3586362353664308	-2.2222222222222214	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-2.2222222222222214	0.0	0.0	-5.0	0.04	0.05	0.0	0.04390243902439024	0.04390243902439024	3.0	0.05	0.3333333333333333	1.0	0.0	-5.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.04390243902439024	0.0	0.05	0.0	0.0	0.0	0.0	0.0
235	Activation;activation	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
160	OTHER;other	0.07912025531206299	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.7142857142857153	0.04	0.04294478527607362	0.0	0.04	0.04	1.0	0.04294478527607362	0.0	1.0	0.0	-1.7142857142857153	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04294478527607362	0.0	0.0	0.0	0.0	0.0
155	RyR2 or CASQ2 mutations	0.14415098933481596	-2.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.3333333333333333	1.0	-2.0	0.0	0.0	-1.8333333333333321	0.04	0.043165467625899276	0.0	0.043478260869565216	0.043478260869565216	4.0	0.043165467625899276	0.5	1.0	0.0	-1.8333333333333321	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.043478260869565216	0.0	0.043165467625899276	0.0	0.0	0.0	0.0	0.0
144	TREs. Upstream from position -1.5 kb	0.4013899223203642	-2.8000000000000007	0.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.0	1.0	-2.8000000000000007	1.0	1.0	0.0	0.04	0.04	0.0	0.04504504504504505	0.04504504504504505	7.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04504504504504505	0.0	0.04	0.0	1.0	0.0	0.0	1.0
100	inhibition of dna synthesis;inhibition of DNA synthesis	0.0991777181073951	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	4.0	0.045454545454545456	0.25	1.0	0.0	-3.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
50	counts or RPKM values	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
144	Independent;independent	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	this protein present	0.20374293739082183	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	1.0	0.0	1.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
206	administration of L	0.14926582439062372	-6.666666666666666	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.054545454545454536	0.054545454545454536	3.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.054545454545454536	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
73	the development	0.05586793353184874	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.083333333333334	0.04	0.04	0.0	0.04	0.04	2.0	0.04189781021897811	0.5	2.0	0.0	-2.166666666666668	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.043795620437956206	0.0	0.0	0.0	0.0	0.0
111	SECIS binding (5)	0.7163601152334724	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
146	established;Established	0.09059200192985256	-1.8333333333333321	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.043165467625899276	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043165467625899276	0.0	0.04	0.0	0.0	0.0	0.0	0.0
134	a potential candidate	0.07929341420347716	-6.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.054545454545454536	0.054545454545454536	3.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.054545454545454536	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
47	a challenging computational problem	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
91	Meet;met	0.09822722113086536	-4.142857142857142	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.142857142857142	0.0	0.0	0.0	0.04	0.04	0.0	0.04794520547945205	0.04794520547945205	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04794520547945205	0.0	0.04	0.0	0.0	0.0	0.0	0.0
266	Ala92 carriers in hypertensive	0.1405487375957212	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
246	Chinese patient	0.12369241147521627	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.045454545454545456	0.045454545454545456	2.0	0.05555555555555555	0.0	2.0	0.0	-7.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.045454545454545456	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
216	rRNA gene clone libraries	0.17580953932366403	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04	0.04	4.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
334	players	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
120	HSP70;HSP 70	0.7940712023603235	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
330	Research and Development;research and development	0.06876506042795295	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.875	0.04	0.043243243243243246	0.0	0.04	0.04	3.0	0.043243243243243246	0.0	1.0	0.0	-1.875	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.043243243243243246	0.0	0.0	0.0	0.0	0.0
177	1;<1;1+	0.6037376978604453	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.5	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	Human;human	0.33024409880498107	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.2142857142857142	0.04	0.04	0.0	0.04	0.04	1.0	0.042943722943722944	0.0	7.0	0.0	-8.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	7.0	0.04	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
174	two different entities of LQTS	0.05067993172616714	-2.833333333333332	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-5.6	0.04	0.051546391752577324	0.0	0.045112781954887216	0.045112781954887216	5.0	0.051546391752577324	0.2	1.0	0.0	-5.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.045112781954887216	0.0	0.051546391752577324	0.0	0.0	0.0	0.0	0.0
87	Messenger RNA;messenger RNA	0.8007758977422971	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	Primary amebic encephalitis;primary amoebic meningo-encephalitis	0.6784294841111709	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	2.0	1.0	0.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	10.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
84	the indication	0.12176731746802462	-5.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.5	0.0	0.0	0.0	0.04	0.04	0.0	0.05128205128205128	0.05128205128205128	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05128205128205128	0.0	0.04	0.0	0.0	0.0	0.0	0.0
311	a variety	0.10739292592566163	-1.8333333333333321	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.043165467625899276	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043165467625899276	0.0	0.04	0.0	0.0	0.0	0.0	0.0
336	Able;able	0.08093247903275197	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.045454545454545456	0.045454545454545456	1.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
83	CYP2C19 (controls)	0.5053337467359004	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
28	described	0.16146191920102987	-5.666666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.05	0.05178571428571429	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.053571428571428575	0.0	0.04	0.0	0.0	0.0	0.0	0.0
90	usual care	0.07409104590913348	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.04	0.04	2.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
14	Parameters;parameters	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	eukaryotes;Eukaryotes	0.5642252212017876	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.2857142857142847	0.04	0.0440251572327044	0.0	0.04	0.04	1.0	0.0440251572327044	0.0	1.0	0.0	-2.2857142857142847	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.0440251572327044	0.0	0.0	0.0	0.0	0.0
266	modulation;Modulation	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
3	to;TO	0.09281677475089267	-7.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.5	0.0	0.0	-4.2857142857142865	0.04	0.04827586206896552	0.0	0.05714285714285714	0.05714285714285714	1.0	0.04827586206896552	0.0	1.0	0.0	-4.2857142857142865	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05714285714285714	0.0	0.04827586206896552	0.0	0.0	0.0	0.0	0.0
82	a strong association in Han Chinese	0.05068520433959874	-2.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-2.1999999999999993	0.04	0.043859649122807015	0.0	0.043478260869565216	0.043478260869565216	6.0	0.043859649122807015	0.16666666666666666	1.0	0.0	-2.1999999999999993	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.043478260869565216	0.0	0.043859649122807015	0.0	0.0	0.0	0.0	0.0
41	chromatic and regulatory proteins	0.43759267288073395	-7.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-7.0	0.0	0.0	-9.0	0.04	0.0625	1.0	0.05555555555555555	0.05555555555555555	4.0	0.0625	0.25	2.0	0.0	-9.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.05555555555555555	0.0	0.0625	0.0	0.0	0.25	0.0	0.0
144	alpha-cardiac	0.5655713277755647	-2.6000000000000014	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.044642857142857144	0.044642857142857144	3.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.044642857142857144	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
330	pharmacokinetic (PK	0.4047368249196394	-1.3333333333333321	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.3333333333333321	0.0	0.0	-4.625	0.04	0.049079754601226995	0.0	0.04225352112676056	0.04225352112676056	3.0	0.049079754601226995	0.3333333333333333	1.0	0.0	-4.625	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04225352112676056	0.0	0.049079754601226995	0.0	0.0	0.0	0.0	0.0
85	Subset;subset	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	arthritis;ARTHRITIS	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
141	two;Two	0.07046974704668095	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04	0.04	1.0	0.04878048780487805	0.0	1.0	0.0	-4.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
5	Well;well	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
84	a clear need for well designed, long-term	0.04924525863321362	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.1	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	IC	0.7598578648225778	-6.333333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.053571428571428575	0.053571428571428575	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.053571428571428575	0.0	0.04	0.0	0.0	0.0	0.0	0.0
29	improved;Improved	0.09112461233357536	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	oscillation amplitude	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
291	alcohol;ALCOHOL	0.29786980130701657	-0.4	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04069565217391304	1.0	0.04	0.0	5.0	0.0	0.0	1.0	0.3333333333333333	1.0	0.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	5.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
37	ACLARUBICIN;aclarubicin	0.8023042284609121	-1.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-6.0	0.0	0.0	-2.1875	0.04	0.04	0.0	0.04	0.0431578947368421	1.0	0.045384615384615384	0.0	4.0	0.0	-8.75	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	4.0	0.05263157894736842	0.0	0.06153846153846154	0.0	0.0	0.0	0.0	0.0
293	30% of men	0.1405487375957212	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	Ph+;ph+;Ph	0.9908038105695753	-0.09259259259259266	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.6666666666666679	0.0	0.0	-7.128205128205129	0.04	0.04727272727272727	0.0	0.04	0.04015873015873016	1.0555555555555556	0.05617622210109284	0.0	18.0	0.0	-8.307692307692308	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	19.0	0.04285714285714286	0.0	0.059907834101382486	0.0	0.0	0.0	0.0	0.0
310	proteins;PROTEINS	0.7774208603136311	-1.1666666666666667	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.5	1.0	1.0	-2.0	0.04	0.04	0.0	0.04	0.04217054263565891	1.0	0.04421052631578948	0.0	3.0	1.0	-6.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	3.0	0.046511627906976744	0.0	0.05263157894736842	0.0	1.0	0.0	0.0	1.0
210	NCI-H520 cell-line	0.011087555259840268	-4.0	1.0	-3.6000000000000014	0.04672897196261683	0.04672897196261683	0.3333333333333333	0.3333333333333333	1.0	-3.6000000000000014	1.0	0.0	-4.0	0.0	0.0	-4.75	0.04672897196261683	0.04938271604938271	0.0	0.047619047619047616	0.047619047619047616	6.0	0.04938271604938271	1.0	1.0	0.0	-4.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.047619047619047616	0.0	0.04938271604938271	1.0	0.0	0.0	0.0	0.0
44	genomic analysis	0.21548808278075435	-9.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-9.0	0.0	0.0	-11.666666666666666	0.04	0.075	0.0	0.0625	0.0625	2.0	0.075	0.0	1.0	0.0	-11.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.0625	0.0	0.075	0.0	0.0	0.0	0.0	0.0
34	Fold;fold	0.636187340945155	-3.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	species of the genus Plasmodium	0.08252651480240496	-7.75	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-7.75	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.057971014492753624	0.057971014492753624	5.0	0.04918032786885245	0.4	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.057971014492753624	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
322	Murine	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
215	withdrawn;Withdrawn	0.6216147844834947	-3.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	0.0	0.04	0.04	0.0	0.046511627906976744	0.046511627906976744	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046511627906976744	0.0	0.04	0.0	0.0	0.0	0.0	0.0
257	peroxiredoxin 2;Peroxiredoxin-2;peroxiredoxin-2;Peroxiredoxin 2	0.9998771518657054	-3.566666666666667	1.0	-12.571428571428571	0.04	0.04134865900383142	0.0	0.0	1.0	-0.41904761904761906	1.0	1.0	-12.666666666666668	1.0	1.0	-7.0809523809523816	0.08045977011494253	0.04294478527607362	0.0	0.04	0.04749651333302444	1.7	0.057198543733401046	0.7	30.0	1.0	-13.285714285714285	1.0	0.6666666666666666	0.0	0.7	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	4.0	1.0	51.0	0.08108108108108109	0.0	0.08536585365853658	1.0	1.0	0.0	0.0	1.0
199	centromere-specific-DNA-binding factors	0.1674432752636209	-4.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.047619047619047616	0.047619047619047616	8.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.047619047619047616	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
85	blindness;BLINDNESS	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
34	mediated	0.693244583285108	-5.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05	0.05	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.05	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	Call;called	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
78	Gene;gene;genes;Genes	0.03175945184018099	-3.1875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-4.75	1.0	1.0	-3.833333333333333	0.04	0.04	0.0	0.04	0.046168707940309375	1.0	0.049235382308845575	0.75	4.0	1.0	-9.666666666666666	1.0	1.0	1.0	0.75	1.0	1.0	1.0	1.0	1.0	4.0	1.0	4.0	0.04938271604938271	1.0	0.06521739130434782	1.0	1.0	0.0	1.0	1.0
142	the systematic genetic screening of the RET proto-oncogene	0.11235515208756842	0.0	0.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.25	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
270	these two factors in erythropoiesis	0.05833458103272553	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.04	0.04	5.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
68	premature termination	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
28	Primary;primary	0.10357417947446557	-5.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.051724137931034475	0.051724137931034475	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.051724137931034475	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	Waldispühl	0.6087867693893387	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
150	the lysosomal receptor	0.16437548826289292	-2.8571428571428577	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.25	1.0	-2.8571428571428577	0.0	0.0	-2.916666666666667	0.04	0.04	1.0	0.04516129032258065	0.04516129032258065	3.0	0.046086956521739136	0.6666666666666666	2.0	0.0	-5.833333333333334	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04516129032258065	0.0	0.052173913043478265	0.0	0.0	0.3333333333333333	0.0	0.0
28	development	0.13487253549987852	-6.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.054545454545454536	0.054545454545454536	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.054545454545454536	0.0	0.04	0.0	0.0	0.0	0.0	0.0
106	in;In	0.0072785992986508915	-2.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.04477611940298508	0.04477611940298508	1.0	0.04	1.0	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04477611940298508	0.0	0.04	1.0	0.0	0.0	0.0	0.0
239	moyamoya disease by use	0.01965586202842768	0.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.6	1.0	0.0	1.0	1.0	-3.75	0.04	0.047058823529411764	0.0	0.04	0.04	4.0	0.047058823529411764	0.5	1.0	1.0	-3.75	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.047058823529411764	0.0	1.0	0.0	0.0	1.0
85	post;Post	0.6110205555474812	-2.8000000000000007	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04504504504504505	0.04504504504504505	0.0	0.043478260869565216	0.0	1.0	0.0	-2.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04504504504504505	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
231	F-alphaMHC	0.42237869700326597	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.8571428571428577	0.04	0.043209876543209874	0.0	0.04	0.04	3.0	0.043209876543209874	0.3333333333333333	1.0	0.0	-1.8571428571428577	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.043209876543209874	0.0	0.0	0.0	0.0	0.0
265	not;Not;Non;non	0.3629688721628976	-8.0	1.0	-11.333333333333334	0.04	0.04829268292682927	0.0	0.25	1.0	-2.8333333333333335	1.0	0.0	-14.4	0.0	0.0	-8.833333333333332	0.07317073170731708	0.054545454545454536	0.0	0.047619047619047616	0.06299208536011025	0.25	0.0637310606060606	0.0	4.0	0.0	-13.0	1.0	0.0	0.25	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	1.0	0.09433962264150944	0.0	0.08333333333333333	0.0	0.0	0.0	0.0	0.0
16	Sequence similarities;sequence similarity;] sequence similarity;Sequence Similarity	0.4320464806356553	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.9444444444444443	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.625	0.04	0.04	0.0	0.04	0.04	2.1666666666666665	0.041176470588235294	0.0	6.0	0.0	-3.75	1.0	0.0	0.8333333333333334	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	13.0	0.04	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
316	missense mutations in the NOTCH3 gene	0.0935599720416826	-3.09090909090909	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.09090909090909	0.0	0.0	-6.199999999999999	0.04	0.05319148936170213	0.0	0.04564315352697095	0.04564315352697095	6.0	0.05319148936170213	0.3333333333333333	1.0	0.0	-6.199999999999999	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04564315352697095	0.0	0.05319148936170213	0.0	0.0	0.0	0.0	0.0
89	the last 72 hours of life	0.09020609944119357	-6.7	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-6.800000000000001	0.0	0.0	-7.75	0.04	0.05714285714285714	0.0	0.05434782608695653	0.054646440516005736	6.0	0.05798319327731093	0.3333333333333333	2.0	0.0	-8.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	12.0	0.054945054945054944	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
227	dopaminergic systems	0.360802873640141	-2.1999999999999993	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-2.1999999999999993	1.0	1.0	-5.0	0.04	0.05	0.0	0.043859649122807015	0.043859649122807015	2.0	0.05	0.0	2.0	1.0	-5.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.043859649122807015	0.0	0.05	0.0	1.0	0.0	0.0	1.0
269	vector;Vector	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
117	responsible;Responsible	0.09615283682883098	-3.500000000000001	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.428571428571429	0.0	0.0	-5.25	0.04	0.04938271604938271	0.0	0.0445859872611465	0.04659854918612881	1.0	0.05066538399871733	0.0	2.0	0.0	-5.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04861111111111112	0.0	0.05194805194805195	0.0	0.0	0.0	0.0	0.0
13	photoactivated states	0.20491657616916664	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04	0.04	2.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
49	X- linked gene mecp2	0.027050187199943895	-9.0	1.0	-5.800000000000001	0.052083333333333336	0.052083333333333336	0.4	0.4	1.0	-5.800000000000001	1.0	1.0	-9.0	0.0	0.0	-6.800000000000001	0.052083333333333336	0.054945054945054944	0.0	0.0625	0.0625	5.0	0.054945054945054944	1.0	1.0	0.0	-6.800000000000001	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.0625	0.0	0.054945054945054944	1.0	0.0	0.0	0.0	0.0
44	an active production	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	Specificity;specificity	0.626531465053821	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04631578947368421	0.0	2.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
267	a survey	0.10962042463140527	-2.428571428571427	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.428571428571427	0.0	0.0	0.0	0.04	0.04	0.0	0.04430379746835443	0.04430379746835443	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04430379746835443	0.0	0.04	0.0	0.0	0.0	0.0	0.0
9	Agent;agent	0.0829984369065127	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.047619047619047616	0.047619047619047616	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
129	processive manner	0.25559623317487906	-1.2222222222222214	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.2222222222222214	0.0	0.0	0.0	0.04	0.04	0.0	0.04205607476635514	0.04205607476635514	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04205607476635514	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	repressor;Repressor	0.7474807555362751	-1.4444444444444429	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-1.4444444444444429	0.0	0.0	-1.7142857142857153	0.04	0.04294478527607362	0.0	0.04245283018867924	0.04245283018867924	0.0	0.04294478527607362	0.0	1.0	0.0	-1.7142857142857153	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	0.0	0.04245283018867924	0.0	0.04294478527607362	0.0	0.0	0.0	0.0	0.0
102	24-h mRNA rhythms	0.4175122847513681	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
216	important members of the microbial community	0.06878094495568174	-4.25	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04819277108433735	0.04819277108433735	6.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04819277108433735	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
85	promise	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
334	H1	0.6185188451018651	-2.2222222222222214	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.2222222222222214	0.0	0.0	-5.0	0.04	0.05	0.0	0.04390243902439024	0.04390243902439024	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04390243902439024	0.0	0.05	0.0	0.0	0.0	0.0	0.0
93	most troublesome	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
203	320	0.6382896180728992	-3.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04597701149425287	0.04597701149425287	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04597701149425287	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
104	several methods	0.12633707273757303	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	1.0	0.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
321	3D;three dimensional;3-Dimensional	0.5054967753143053	-2.6666666666666665	0.0	0.0	0.04	0.04	0.0	0.16666666666666666	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-13.0	0.04	0.04	0.0	0.04	0.04507936507936508	2.0	0.13555555555555557	0.0	3.0	0.0	-20.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	6.0	0.047619047619047616	0.0	0.2	0.0	0.0	0.0	0.0	0.0
228	new SAR efforts	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
10	androgen depletion-independent (ADI	0.44877667098388957	-2.2857142857142847	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	0.0	-2.2857142857142847	0.0	0.0	0.0	0.04	0.04	0.0	0.0440251572327044	0.0440251572327044	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.0440251572327044	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	a complex)	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	de novo biosynthesis for survival	0.29650254911354357	-3.5	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	0.0	0.04	0.04	0.0	0.046511627906976744	0.046511627906976744	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.046511627906976744	0.0	0.04	0.0	0.0	0.0	0.0	0.0
52	Northern blot analysis	0.35490565103101407	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	congenital hypothyroidism;Congenital Hypothyroidism	0.9576277754899374	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	7.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	14.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
198	11x	0.6748536755795161	-2.8000000000000007	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04504504504504505	0.04504504504504505	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04504504504504505	0.0	0.04	0.0	0.0	0.0	0.0	0.0
299	a consequence	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
131	several glycolytic enzymes	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
52	uptake into TR	0.45407459901601915	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
160	bone disease	0.1501559195128374	-2.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-1.7142857142857153	0.04	0.04294478527607362	0.0	0.04477611940298508	0.04477611940298508	2.0	0.04294478527607362	0.0	2.0	0.0	-1.7142857142857153	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04477611940298508	0.0	0.04294478527607362	0.0	0.0	0.0	0.0	0.0
39	diminished;Diminished	0.06412985706885646	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.75	0.04	0.0547945205479452	0.0	0.04	0.04	1.0	0.0547945205479452	0.0	1.0	0.0	-6.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.0547945205479452	0.0	0.0	0.0	0.0	0.0
192	LRRK2	0.7041033446812871	-6.333333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.053571428571428575	0.053571428571428575	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.053571428571428575	0.0	0.04	0.0	0.0	0.0	0.0	0.0
34	hepatic LDLr gene	0.3695948059603905	-4.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	1.0	0.047619047619047616	0.047619047619047616	3.0	0.04	0.3333333333333333	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.3333333333333333	0.0	0.0
279	the development of harmatomatous polyps	0.0762136562681382	-3.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-2.5	0.04	0.044444444444444446	0.0	0.045454545454545456	0.045454545454545456	5.0	0.044444444444444446	0.4	1.0	0.0	-2.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.045454545454545456	0.0	0.044444444444444446	0.0	0.0	0.0	0.0	0.0
16	Genomes;Genomic;genomes;genome;genomic;Genome	0.9990485903896348	-1.791245791245791	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-5.454545454545455	0.0	0.0	-2.435185185185185	0.04	0.04	0.0	0.04	0.043367603003933546	1.0	0.045118202195293354	0.0	27.0	0.0	-9.25	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	6.0	1.0	27.0	0.05116279069767442	0.0	0.06349206349206349	0.0	0.0	0.0	0.0	0.0
4	the MEN1 gene	0.45228436098479763	-0.65	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04111278883550675	3.0	0.04	0.3333333333333333	5.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	15.0	0.043010752688172046	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	processive enzyme	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
198	the insertion (D1795	0.3841113528079596	-3.1999999999999993	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.04587155963302752	0.04587155963302752	4.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04587155963302752	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
322	the presence of three core components (RbBP5, Ash2L and WDR5)	0.12368720970366201	0.0	0.0	0.0	0.04	0.04	0.5384615384615384	0.5384615384615384	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	13.0	0.04	0.15384615384615385	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	13.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
155	RyR2;RYR2;ryanodine receptor 2;Ryanodine Receptor 2	0.9490607927660836	-6.1060606060606055	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-8.0	0.0	0.0	-6.409090909090909	0.04	0.043795620437956206	0.0	0.045112781954887216	0.05330193519458978	1.3636363636363635	0.059306830623644884	0.0606060606060606	11.0	0.0	-15.333333333333332	1.0	0.0	0.0	0.18181818181818182	0.0	0.0	1.0	0.0	0.0	4.0	1.0	15.0	0.058823529411764705	0.0	0.10344827586206895	0.0	0.0	0.0	0.0	0.0
164	the results of loss	0.003231672298021785	-9.666666666666666	1.0	-17.0	0.125	0.125	1.0	1.0	1.0	-17.0	1.0	0.0	-9.666666666666666	0.0	0.0	-14.0	0.125	0.09090909090909091	1.0	0.06521739130434782	0.06521739130434782	4.0	0.09090909090909091	1.0	1.0	0.0	-14.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.06521739130434782	0.0	0.09090909090909091	1.0	0.0	0.25	0.0	0.0
74	Action Potentials;action potentials	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
173	increases;Increases	0.09463812751514648	-4.7	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.4	0.0	0.0	-5.75	0.04	0.051724137931034475	0.0	0.045454545454545456	0.04960899315738025	1.0	0.05194902548725637	0.0	2.0	0.0	-5.833333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.05376344086021505	0.0	0.052173913043478265	0.0	0.0	0.0	0.0	0.0
332	this time	0.10801258077044511	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
228	paper;Paper	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	chromosome 17 in Japanese cases	0.08550919171361716	-3.333333333333332	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.04615384615384615	0.04615384615384615	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04615384615384615	0.0	0.04	0.0	0.0	0.0	0.0	0.0
317	Specific;specific	0.09934135892293233	-3.5999999999999996	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-5.166666666666667	0.04	0.048387096774193554	0.0	0.04587155963302752	0.04674530362603757	1.0	0.05050933786078099	0.0	2.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.047619047619047616	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
317	a time	0.09076291200622663	-3.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04587155963302752	0.04587155963302752	2.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04587155963302752	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
8	pericentrin	0.870567909640462	-5.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-5.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05	0.05	1.0	0.04	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	0.05	1.0	0.04	0.0	0.0	0.0	1.0	0.0
200	young athletes from commotio cordis	0.03586832636837647	0.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.375	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
188	600 mg/kg valproic acid (VPA600)	0.4011059145413672	0.0	0.0	0.0	0.04	0.04	0.125	0.125	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.25	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
259	lower mortality	0.1229212177975574	-5.777777777777779	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.777777777777779	0.0	0.0	0.0	0.04	0.04	0.0	0.05202312138728324	0.05202312138728324	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05202312138728324	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	reaction;REACTION;reactions	0.11221859445966362	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
179	TOR activity;TOR-dependent increase of S6K activity;Tor activity	0.44323566870106795	-2.444444444444445	0.0	0.0	0.04	0.04	0.5	0.5238095238095238	0.0	0.0	0.0	1.0	-3.666666666666668	0.3333333333333333	0.0	-4.0	0.04	0.04	0.0	0.04	0.044583333333333336	3.6666666666666665	0.04842105263157895	0.0	3.0	0.3333333333333333	-6.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.3333333333333333	1.0	0.3333333333333333	0.3333333333333333	3.0	1.0	11.0	0.046875	0.0	0.05263157894736842	0.0	1.0	0.0	0.0	1.0
80	Coexistence	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
286	Botulinum neurotoxin detection and differentiation by mass spectrometry	0.2395056895281673	0.0	0.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	8.0	0.04	0.25	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.125	0.0	0.0
88	SOX2	0.7798236020386071	-5.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-5.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.05	0.05	1.0	0.053571428571428575	0.0	2.0	0.0	-6.333333333333334	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.05	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
14	interstrand	0.6701549522680516	-1.125	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.25	0.0	0.0	-4.25	0.04	0.04	0.0	0.04	0.04197802197802198	1.0	0.05030303030303031	0.0	2.0	0.0	-8.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04395604395604396	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
47	a special-purpose variant	0.1714248733621507	-2.333333333333332	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.044117647058823525	0.044117647058823525	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.044117647058823525	0.0	0.04	0.0	0.0	0.0	0.0	0.0
125	Mutations, Missense;Missense Mutation;missense mutations;missense mutation	0.5896385614128622	-1.8888888888888886	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-1.5833333333333333	0.04	0.04	0.0	0.04	0.0439080459770115	1.6666666666666667	0.04312757201646091	0.0	3.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	5.0	0.051724137931034475	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
90	calcium	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
76	the questionnaire	0.04076602525710992	-1.3333333333333321	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.3333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.04225352112676056	0.04225352112676056	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04225352112676056	0.0	0.04	0.0	0.0	0.0	0.0	0.0
160	bone;BONE	0.3060901313078056	-0.33333333333333315	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-1.4693877551020407	0.04	0.04	0.0	0.04	0.04058823529411765	1.0	0.04295991778006166	0.0	7.0	0.0	-5.142857142857142	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	7.0	0.044117647058823525	0.0	0.050359712230215826	0.0	0.0	0.0	0.0	0.0
8	to;TO	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
137	this report	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
6	N NOS;n	0.7890508551441878	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
247	Life;life	0.07822110795180048	-2.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.044117647058823525	0.044117647058823525	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.044117647058823525	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
216	Firmicutes	0.8707516195184781	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-1.25	0.04	0.04	0.0	0.04	0.04	1.0	0.0425	0.0	4.0	1.0	-5.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	4.0	0.04	0.0	0.05	0.0	1.0	0.0	0.0	1.0
322	var)3-9	0.8446957850941408	-2.166666666666667	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04419354838709678	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	6.0	0.048387096774193554	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	FMMD	0.6034246534847905	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04	0.04	1.0	0.04878048780487805	0.0	1.0	0.0	-4.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
247	The success	0.03210364438068526	-5.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-9.25	0.04	0.06349206349206349	0.0	0.051724137931034475	0.051724137931034475	2.0	0.06349206349206349	0.5	1.0	0.0	-9.25	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.051724137931034475	0.0	0.06349206349206349	0.0	0.0	0.0	0.0	0.0
24	Defined;defined	0.06084121386126052	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.04	0.04	1.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
176	eukaryotic histone H1	0.539985556381831	-1.875	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-1.875	1.0	1.0	-8.6	0.04	0.06097560975609757	0.0	0.043243243243243246	0.043243243243243246	3.0	0.06097560975609757	0.3333333333333333	1.0	1.0	-8.6	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.043243243243243246	0.0	0.06097560975609757	0.0	1.0	0.0	0.0	1.0
41	Defined;defined	0.07096173573097679	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.04	0.04	1.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
260	mutations C742T, G746T, G747T	0.36114411624674364	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	-2.3999999999999986	0.04	0.04424778761061947	0.0	0.04	0.04	6.0	0.04424778761061947	0.0	1.0	0.0	-2.3999999999999986	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04424778761061947	0.0	0.0	0.0	0.0	0.0
124	treatment planning than traditional methods	0.08279735195665178	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
74	Later;later	0.07046974704668095	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04	0.04	1.0	0.04878048780487805	0.0	1.0	0.0	-4.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
302	thieno[3,2-d]pyrimidines	0.578291200343264	-7.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05555555555555555	0.05555555555555555	9.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.05555555555555555	0.0	0.04	0.0	0.0	0.0	0.0	0.0
327	Alternative;alternative	0.07195524223024728	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
30	Contributing;contributing	0.0793222524109724	-1.1000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.1000000000000014	0.0	0.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.041841004184100423	0.041841004184100423	1.0	0.044642857142857144	0.0	1.0	0.0	-2.6000000000000014	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.041841004184100423	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
225	blunted;Blunted	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	reminiscence;reminiscent	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
316	Reported;Report;reported;report	0.003914059406328346	-5.484848484848485	1.0	-15.2	0.04	0.06068027210884353	1.0	1.0	1.0	-5.066666666666666	1.0	0.0	-14.90909090909091	0.0	0.0	-6.133333333333333	0.1020408163265306	0.04	0.0	0.04	0.06057825267127593	1.0	0.06209876543209877	1.0	3.0	0.0	-15.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.09909909909909911	0.0	0.1	1.0	0.0	0.0	0.0	0.0
46	disease;Disease;diseases;Diseases	0.014393646529173507	-0.5333333333333338	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-1.6000000000000014	1.0	1.0	-2.6666666666666665	0.04	0.04	0.0	0.04	0.04091168091168091	1.0	0.04507936507936508	1.0	3.0	1.0	-4.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	4.0	1.0	3.0	0.042735042735042736	1.0	0.047619047619047616	1.0	1.0	0.0	1.0	1.0
102	Cytoplasmic	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
74	the same as the classical sodium channels	0.06192649133362651	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.2857142857142857	1.0	0.0	0.0	1.0	0.3333333333333333	1.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
227	primary iron insufficiency	0.26113418882512857	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
5	MG patients	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
31	used	0.0026330738724817133	-19.0	1.0	0.0	0.04	0.04	1.0	1.0	1.0	0.0	1.0	0.0	-19.0	0.0	0.0	-19.5	0.04	0.18181818181818182	0.0	0.16666666666666666	0.16666666666666666	1.0	0.18181818181818182	1.0	1.0	0.0	-19.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.16666666666666666	0.0	0.18181818181818182	1.0	0.0	0.0	0.0	0.0
198	4 (16%)	0.6244906610275859	-7.6	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.6	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.0574712643678161	0.0574712643678161	4.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.0574712643678161	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
84	associations;Associations	0.10477763557992177	-6.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05263157894736842	0.05263157894736842	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05263157894736842	0.0	0.04	0.0	0.0	0.0	0.0	0.0
264	pharmacological treatment of subclinical hypothyroidism	0.020122747819252492	-11.75	1.0	-6.6	0.05434782608695653	0.05434782608695653	0.4	0.4	1.0	-6.6	1.0	1.0	-11.75	0.0	0.0	-6.4	0.05434782608695653	0.05376344086021505	0.0	0.07547169811320754	0.07547169811320754	5.0	0.05376344086021505	1.0	1.0	0.0	-6.4	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.07547169811320754	0.0	0.05376344086021505	1.0	0.0	0.0	0.0	0.0
346	expression;Expression	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
306	the constellation of periodic hypothermia and hyperhidrosis	0.10350051444098844	-3.8000000000000007	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-16.0	0.04	0.1111111111111111	0.0	0.04716981132075472	0.04716981132075472	7.0	0.1111111111111111	0.14285714285714285	1.0	0.0	-16.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04716981132075472	0.0	0.1111111111111111	0.0	0.0	0.0	0.0	0.0
276	a thyroid hormone transporter	0.20392792817938546	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
306	Remote;remote	0.05302843716024918	-3.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-14.0	0.04	0.09090909090909091	0.0	0.04587155963302752	0.04587155963302752	1.0	0.09090909090909091	0.0	1.0	0.0	-14.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04587155963302752	0.0	0.09090909090909091	0.0	0.0	0.0	0.0	0.0
100	developmental and proliferative diseases	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
213	KCNE1 (locus name LQT5)	0.4902000256366937	0.0	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
294	HairMax LaserComb;HairMax LaserComb®	0.6895504317445005	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	1.5	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
206	L-DOPA methyl ester;L-Dopa methyl ester;L-dopa methyl ester	0.9573272665797934	-5.333333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-5.333333333333334	1.0	1.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.05084745762711865	0.05084745762711865	5.0	0.048387096774193554	0.0	4.0	1.0	-4.333333333333334	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	3.0	1.0	20.0	0.05084745762711865	0.0	0.048387096774193554	0.0	1.0	0.0	0.0	1.0
180	T lymphocytes;T-Lymphocytes	0.7589563682959148	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
215	c-myc oncogene	0.5748402689212965	-9.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-9.75	0.0	0.0	-10.2	0.04	0.06756756756756756	1.0	0.06557377049180328	0.06557377049180328	4.0	0.06756756756756756	0.25	1.0	0.0	-10.2	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.06557377049180328	0.0	0.06756756756756756	0.0	0.0	0.25	0.0	0.0
288	Generated;generated	0.06968530985843588	-4.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.048387096774193554	0.048387096774193554	1.0	0.06060606060606061	0.0	1.0	0.0	-8.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.048387096774193554	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
297	Patient Outcome;outcome for patients	0.07435842344587819	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
19	United Stateswww.worldexpress	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
150	the LAMP-2A (Lysosome-associated membrane protein type 2A) receptor	0.13740942341302206	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.1111111111111111	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	12.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	12.0	0.04	0.0	0.04	0.0	0.0	0.08333333333333333	0.0	0.0
319	traditional;Traditional	0.06904021280116383	-2.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.044117647058823525	0.044117647058823525	1.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.044117647058823525	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
195	cDNA	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	the causative agent of the most lethal form	0.8783946241611974	-3.6666666666666665	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.3333333333333333	0.0	-5.0	0.0	0.0	-5.055555555555556	0.04	0.04	1.0	0.04	0.0471285140562249	8.0	0.05068295739348371	0.625	6.0	0.0	-6.333333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	48.0	0.05	0.0	0.053571428571428575	0.0	0.0	0.125	0.0	0.0
41	HPC2;hPc2	0.6745902003792813	-9.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-9.5	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.06451612903225806	0.06451612903225806	1.0	0.053571428571428575	0.0	2.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.06451612903225806	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
229	a web resource for the prioritization	0.028285042372325223	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
213	Sequencing;sequencing	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
211	1 (CK1)	0.03838177008214942	-13.11111111111111	1.0	0.0	0.04	0.04	0.0	0.0	1.0	0.0	1.0	0.0	-13.11111111111111	0.0	0.0	-10.11111111111111	0.04	0.06716417910447761	0.0	0.08411214953271028	0.08411214953271028	4.0	0.06716417910447761	1.0	1.0	0.0	-10.11111111111111	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.08411214953271028	0.0	0.06716417910447761	1.0	0.0	0.0	0.0	0.0
129	full methylation at CpG dyads	0.10082692137484979	0.0	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.2222222222222222	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
145	apoptosis;Apoptosis	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
24	patients with similar conditions	0.13193036697555843	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	1.0	0.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	therapeutic;Therapeutic	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	its interaction with the enzyme	0.057961055114664525	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
134	50%;50	0.5762447390149564	-5.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.05	0.05	1.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
335	Active;active	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
198	122 family members	0.25539283242413136	-2.6000000000000014	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.044642857142857144	0.044642857142857144	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.044642857142857144	0.0	0.04	0.0	0.0	0.0	0.0	0.0
303	DNA-binding protein;DNA Binding Protein	0.23131134964988714	-2.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	-2.0	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.043478260869565216	0.043478260869565216	4.0	0.043478260869565216	0.0	2.0	0.0	-2.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	8.0	0.043478260869565216	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
82	0;0%	0.576735923540325	-2.1428571428571423	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.1428571428571423	0.0	0.0	-4.6	0.04	0.04901960784313726	0.0	0.04375	0.04375	0.0	0.04901960784313726	0.0	1.0	0.0	-4.6	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04375	0.0	0.04901960784313726	0.0	0.0	0.0	0.0	0.0
168	finger;FINGER	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	women with early breast cancer	0.08279735195665178	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	first-in-class proteasome inhibitor	0.13937217758493078	-5.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.05	0.05	7.0	0.06451612903225806	0.14285714285714285	1.0	0.0	-9.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.05	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
129	AT Gene;at imprinted genes	0.14978559282231352	-3.666666666666668	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-3.666666666666668	1.0	1.0	-2.8571428571428577	0.04	0.04516129032258065	0.0	0.046875	0.046875	3.0	0.04516129032258065	0.0	1.0	1.0	-2.8571428571428577	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	3.0	0.046875	0.0	0.04516129032258065	0.0	1.0	0.0	0.0	1.0
258	a chromatin sequence	0.21502134065069065	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
212	long QT Jervell	0.040240899867283235	-9.625	1.0	-11.571428571428571	0.07446808510638298	0.07446808510638298	0.3333333333333333	0.3333333333333333	1.0	-11.571428571428571	1.0	1.0	-9.625	0.0	0.0	-12.571428571428571	0.07446808510638298	0.08045977011494253	0.0	0.06504065040650407	0.06504065040650407	3.0	0.08045977011494253	1.0	2.0	0.0	-12.571428571428571	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.06504065040650407	0.0	0.08045977011494253	1.0	0.0	0.0	0.0	0.0
311	associated with;Associated with	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	metazoan nuclear pore complexes	0.25047422376555	-4.25	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	that of the parent compounds	0.04969885078083397	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04	0.04	5.0	0.043478260869565216	0.2	1.0	0.0	-2.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
75	Human galactocerebrosidase	0.35380759468342526	-12.75	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.25	1.0	-12.75	1.0	1.0	-12.5	0.04	0.08	0.0	0.08163265306122448	0.08163265306122448	2.0	0.08	0.0	2.0	1.0	-12.5	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	4.0	0.08163265306122448	1.0	0.08	0.0	1.0	0.0	1.0	1.0
88	result;results;Result	0.08016248664043972	-4.625	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-5.5	0.04	0.05	0.0	0.04819277108433735	0.04909638554216868	1.0	0.05131578947368421	0.0	2.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.05	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
100	(ZCyt) residues in DNA	0.09388513828565795	-3.25	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.2	1.0	-3.25	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.04597701149425287	0.04597701149425287	6.0	0.05128205128205128	0.5	1.0	0.0	-5.5	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04597701149425287	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
306	periodic hypothermia	0.7118655552831625	-3.2666666666666657	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-14.0	0.04	0.07692307692307693	0.0	0.045454545454545456	0.04601571268237934	2.0	0.09508547008547008	0.0	3.0	0.0	-17.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.046296296296296294	0.0	0.125	0.0	0.0	0.0	0.0	0.0
329	15ns unrestrained molecular dynamics (MD	0.4270145456548483	0.0	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	due to;Due To	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
103	Entire;entire	0.0774519579292926	-2.2222222222222214	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.2222222222222214	0.0	0.0	-4.142857142857142	0.04	0.04794520547945205	0.0	0.04390243902439024	0.04390243902439024	1.0	0.04794520547945205	0.0	1.0	0.0	-4.142857142857142	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04390243902439024	0.0	0.04794520547945205	0.0	0.0	0.0	0.0	0.0
134	the viability of the surface epithelium	0.06492807365026797	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
169	Gfi-1b	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
336	romodomain factor 1	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	milliseconds;Millisecond	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
236	m/z	0.6171953679194666	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	anticoagulant drug	0.20229091453947343	-5.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.05	0.05	2.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
194	powerful tools for functional delineation	0.04030660777394785	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.04	0.04	5.0	0.06060606060606061	0.2	1.0	0.0	-8.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
200	a recent study	0.048894972933717654	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
317	imetelstat decreased cell growth of esophageal cancer cells	0.03165759267553614	0.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.125	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
151	linear-time algorithm	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
346	broadly attenuated immune gene activation	0.27984083011048483	-1.3999999999999986	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-1.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.0423728813559322	0.0423728813559322	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.0423728813559322	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	potent;Potential	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	function	0.10856752160203037	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04587155963302752	0.0	1.0	0.0	-3.1999999999999993	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.047619047619047616	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
312	mature unliganded AhR complexes	0.4762006355366632	-2.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	-2.0	1.0	1.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.043478260869565216	0.0	0.04	0.0	1.0	0.0	0.0	1.0
342	the MLL/SET1 family histone methyltransferase	0.33699535454440716	0.0	0.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.2857142857142857	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	7.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
5	one small and inconclusive trial of intranasal neostigmine	0.18987710039913896	-3.25	0.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.0	1.0	-3.25	1.0	1.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	8.0	0.04	0.125	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.04597701149425287	0.0	0.04	0.0	1.0	0.0	0.0	1.0
26	Chronic Inflammation;chronic inflammation	0.22557507682339922	-3.7142857142857153	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.7142857142857153	0.0	0.0	0.0	0.04	0.04	0.0	0.04697986577181208	0.04697986577181208	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04697986577181208	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	European Medicine Evaluation Agency	0.07369997182962514	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.045454545454545456	0.045454545454545456	4.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.045454545454545456	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
319	the protein-protein interaction (PPI)	0.13427422243737003	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.125	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
117	the effects	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	the association	0.1645579002791815	-4.166666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.046875	0.04802766393442623	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04918032786885245	0.0	0.04	0.0	0.0	0.0	0.0	0.0
322	C-terminal;C-Terminal	0.5017846818416422	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	3.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
301	decision trees, k nearest neighbors	0.18075018850285893	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
26	based;Based	0.09112461233357536	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
189	Poor growth;poor growth	0.24184804238823163	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.3333333333333333	1.0	0.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	SAXS	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	testosterone;TESTOSTERONE	0.7492855162222997	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	transcription factors;Transcription Factors	0.37770396827940755	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
200	Research	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	their membrane spanning segments	0.18578719679164934	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.833333333333334	0.04	0.04958677685950414	0.0	0.04	0.04	4.0	0.04958677685950414	0.0	1.0	0.0	-4.833333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04958677685950414	0.0	0.0	0.0	0.0	0.0
73	discriminating beta barrel membrane proteins	0.08328281948849203	0.0	1.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.25	0.0	0.0	0.0	0.0	-2.5	0.04	0.044444444444444446	0.0	0.04	0.04	5.0	0.044444444444444446	0.6	1.0	0.0	-2.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.044444444444444446	0.0	0.0	0.0	0.0	0.0
252	Creatine Kinase B-Type;creatine kinase-B with an M-type	0.31085454107603766	0.0	0.0	0.0	0.04	0.04	0.2222222222222222	0.2222222222222222	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.1111111111111111	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
287	the HDM2 protein level	0.10445656913048328	-3.8000000000000007	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04716981132075472	0.04716981132075472	4.0	0.04878048780487805	0.0	1.0	0.0	-4.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04716981132075472	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
114	Maize;maize	0.5563204661405409	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	1.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
206	the antinociceptive effect of L-DOPA	0.41538142295063396	-5.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	1.0	-5.0	1.0	1.0	0.0	0.04	0.04	0.0	0.05	0.05	7.0	0.04	0.0	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	7.0	0.05	0.0	0.04	0.0	1.0	0.0	0.0	1.0
176	Well;well	0.12500702948907558	-2.125	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	-4.6	0.04	0.045454545454545456	0.0	0.0425531914893617	0.04373217698714349	1.0	0.04952300785634119	0.0	3.0	0.0	-7.4	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.044444444444444446	0.0	0.056818181818181816	0.0	0.0	0.0	0.0	0.0
222	shown;showed;Show	0.18193668447178582	-2.333333333333333	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.7777777777777786	0.0	0.0	-0.5200000000000002	0.04	0.04	0.0	0.04	0.04426340989485352	1.0	0.04092857142857143	0.0	5.0	0.0	-2.6000000000000014	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	5.0	0.04712041884816754	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
4	familial MEN1	0.6837658835016016	-2.25	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.25	1.0	-2.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04395604395604396	0.04395604395604396	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04395604395604396	0.0	0.04	0.0	0.0	0.0	0.0	0.0
84	common;Common	0.09577883264672099	-10.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-10.0	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.06666666666666667	0.06666666666666667	1.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.06666666666666667	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
60	its intracellular localization at a higher resolution	0.10057254967379158	0.0	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
242	adverse cardiac outcomes	0.21607152753448505	-1.3333333333333321	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-1.3333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.04225352112676056	0.04225352112676056	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04225352112676056	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	balanced translocation;balanced genetic translocation	0.6753835489173879	0.0	0.0	0.0	0.04	0.04	0.5	0.5555555555555555	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.2051282051282057	0.04	0.043478260869565216	0.0	0.04	0.04	2.3333333333333335	0.045953299472223465	0.0	6.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	14.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
163	Relative;relative	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
331	insufficiency;Insufficiency	0.6411202810688934	-5.666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.051724137931034475	0.051724137931034475	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.051724137931034475	0.0	0.04	0.0	0.0	0.0	0.0	0.0
49	R168X	0.6828657932045992	-3.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	0.0	0.04	0.04	0.0	0.047058823529411764	0.047058823529411764	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.047058823529411764	0.0	0.04	0.0	0.0	0.0	0.0	0.0
152	inhibitor;Inhibitor	0.5520083876424131	-2.8000000000000007	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	-5.800000000000001	0.04	0.052083333333333336	0.0	0.04504504504504505	0.04504504504504505	1.0	0.052083333333333336	0.0	1.0	0.0	-5.800000000000001	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04504504504504505	0.0	0.052083333333333336	0.0	0.0	0.0	0.0	0.0
14	large data sets	0.08963633461151385	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.043478260869565216	0.043478260869565216	3.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043478260869565216	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
38	mutations in EP300	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	Attempt;attempt	0.06084121386126052	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.04	0.04	1.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
67	the study	0.003539905884114913	-13.0	1.0	-16.5	0.11764705882352941	0.11764705882352941	1.0	1.0	1.0	-16.5	1.0	0.0	-13.0	0.0	0.0	-16.0	0.11764705882352941	0.1111111111111111	0.0	0.08333333333333333	0.08333333333333333	2.0	0.1111111111111111	1.0	1.0	0.0	-16.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.08333333333333333	0.0	0.1111111111111111	1.0	0.0	0.0	0.0	0.0
34	hepatic lipogenesis	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	human diseases	0.4891578454836395	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	6.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	12.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
286	endopeptidase;Endopeptidase	0.6920711031484804	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
258	contribute;Contribute	0.09139544003704729	-5.800000000000001	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.800000000000001	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.052083333333333336	0.052083333333333336	1.0	0.04587155963302752	0.0	1.0	0.0	-3.1999999999999993	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.052083333333333336	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
302	discovered;Discover	0.07255748982549837	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04	0.04	1.0	0.04716981132075472	0.0	1.0	0.0	-3.8000000000000007	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
15	much flexibility for the biologists	0.03923441045266047	-1.6999999999999993	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-1.6999999999999993	0.0	0.0	-2.1999999999999993	0.04	0.043859649122807015	0.0	0.04291845493562232	0.04291845493562232	5.0	0.043859649122807015	0.4	1.0	0.0	-2.1999999999999993	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04291845493562232	0.0	0.043859649122807015	0.0	0.0	0.0	0.0	0.0
215	the first time that the expression	0.07748277985570153	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	Nuclear Localization Signal;nuclear localization signal	0.1187176919696614	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
188	NR1(neo	0.5620911066205747	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	1.0	0.0	1.0	0.5	0.0	1.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	3.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
60	new;NEW	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
206	IMPACT;impact	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
345	a detailed experimental study	0.0884415052403157	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
270	1b;1B	0.6748625439795969	-1.6666666666666667	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04296354825115887	0.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.044642857142857144	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	member;Member	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	the basis of existing knowledge	0.028457748517818557	-2.1111111111111107	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1111111111111107	0.0	0.0	-8.333333333333334	0.04	0.06000000000000001	0.0	0.043689320388349516	0.043689320388349516	5.0	0.06000000000000001	0.4	1.0	0.0	-8.333333333333334	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.043689320388349516	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
150	the lysosomal receptor for CMA	0.07617122278498838	0.0	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.42857142857142855	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	5.0	0.04	0.6	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.2	0.0	0.0
181	cases;Cases	0.1154150085184402	-1.9285714285714288	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.2857142857142847	0.0	0.0	0.0	0.04	0.04	0.0	0.042682926829268296	0.04335404203098635	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.0440251572327044	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	cleavage-stage preimplantation embryos	0.3123795294827484	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	female;FEMALE	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
17	the most likely cause	0.021573617925616104	-2.666666666666668	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.3333333333333333	0.0	-2.666666666666668	0.0	0.0	-5.75	0.04	0.05194805194805195	0.0	0.04477611940298508	0.04477611940298508	4.0	0.05194805194805195	0.25	1.0	0.0	-5.75	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04477611940298508	0.0	0.05194805194805195	0.0	0.0	0.0	0.0	0.0
233	Contraindication;contraindication	0.631171108207499	-4.555555555555555	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.555555555555555	0.0	0.0	0.0	0.04	0.04	0.0	0.04891304347826087	0.04891304347826087	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04891304347826087	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	Bortezomib (PS-341)	0.27160621689142417	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	specific interaction partner	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
101	rapid and irreversible parasite death	0.1206950686301722	-4.5	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-11.0	0.04	0.07142857142857142	0.0	0.04878048780487805	0.04878048780487805	5.0	0.07142857142857142	0.0	1.0	0.0	-11.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04878048780487805	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0
247	strong;Strong	0.08535525031897467	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.04878048780487805	0.04878048780487805	1.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04878048780487805	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
223	a humanized monoclonal antibody against the end terminus	0.16880462991768527	-1.4545454545454533	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-1.4545454545454533	0.0	0.0	0.0	0.04	0.04	0.0	0.04247104247104247	0.04247104247104247	8.0	0.04	0.25	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04247104247104247	0.0	0.04	0.0	0.0	0.0	0.0	0.0
274	anti-amyloid-beta	0.0966773583443111	-12.181818181818182	1.0	-2.7142857142857153	0.04487179487179487	0.04487179487179487	0.0	0.0	1.0	-2.7142857142857153	1.0	1.0	-12.181818181818182	0.0	0.0	-5.571428571428571	0.04487179487179487	0.051470588235294115	0.0	0.07801418439716312	0.07801418439716312	3.0	0.051470588235294115	1.0	1.0	0.0	-5.571428571428571	1.0	0.5	0.0	1.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	3.0	0.07801418439716312	0.0	0.051470588235294115	1.0	0.0	0.0	0.0	0.0
285	67% of the tumors	0.11859582082123679	-3.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	*Number;number	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	17q25-ter region	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
246	Association;association	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	the docking approach	0.0793662226340656	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
61	p62/SQSTM1	0.6953702119729792	-2.3999999999999986	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.3999999999999986	1.0	1.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04424778761061947	3.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04424778761061947	0.0	0.04	0.0	1.0	0.0	0.0	1.0
93	ataxia, nystagmus, tremor and headache	0.3529863159933563	-2.5	0.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.0	1.0	-2.5	1.0	1.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.044444444444444446	0.044444444444444446	7.0	0.048387096774193554	0.0	1.0	1.0	-4.333333333333334	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.044444444444444446	0.0	0.048387096774193554	0.0	1.0	0.0	0.0	1.0
140	Epigenetics;epigenetics	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	id;ID	0.5995424123544066	-1.1000000000000014	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.1000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.041841004184100423	0.041841004184100423	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.041841004184100423	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	gastrinomas and insulinomas	0.45407459901601915	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
43	Europe	0.5908180149730494	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04	0.04	1.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
270	Cells, Erythroid;erythroid cells	0.4061732433257255	-3.6000000000000014	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.04672897196261683	0.04672897196261683	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04672897196261683	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	refractory disease;Refractory Disease	0.07340129594247638	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.800000000000001	0.04	0.04950495049504951	1.0	0.04	0.04	2.0	0.04950495049504951	0.5	1.0	0.0	-4.800000000000001	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04950495049504951	0.0	0.0	0.5	0.0	0.0
253	to;TO	0.1253380054261629	-6.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-8.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04878048780487805	0.05380200860832138	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.058823529411764705	0.0	0.04	0.0	0.0	0.0	0.0	0.0
307	clarify;Clarify	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
285	an;AN	0.5651716832235251	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.04	0.043859649122807015	0.0	0.04	0.04	1.0	0.043859649122807015	0.0	1.0	0.0	-2.1999999999999993	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.043859649122807015	0.0	0.0	0.0	0.0	0.0
341	a 400 mg/kg dosage of ethylnitrosourea	0.1228829177909773	-4.75	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.3333333333333333	0.0	-4.75	0.0	0.0	-2.375	0.04	0.04419889502762431	0.0	0.04938271604938271	0.04938271604938271	8.0	0.04419889502762431	0.25	1.0	0.0	-2.375	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04938271604938271	0.0	0.04419889502762431	0.0	0.0	0.0	0.0	0.0
28	three;Three	0.10357417947446557	-5.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.051724137931034475	0.051724137931034475	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.051724137931034475	0.0	0.04	0.0	0.0	0.0	0.0	0.0
125	muscular;muscle;MUSCLE;Muscle;Muscular	0.3682607984013765	-3.4444444444444446	0.0	0.0	0.04	0.04	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	-4.5	0.04	0.04	0.0	0.04	0.046949152542372884	0.6666666666666666	0.05042682926829268	0.0	3.0	0.0	-9.0	1.0	0.0	0.3333333333333333	0.0	1.0	0.0	1.0	0.0	0.0	5.0	1.0	2.0	0.05084745762711865	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
16	database [11] as a reference	0.15253371083258746	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
177	survival;Survival	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	ac;AC	0.5740415423384372	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	0.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
317	thio;THIO	0.705562907775317	-1.866666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-1.4444444444444446	0.04	0.04	0.0	0.04	0.04337311574788233	1.0	0.04279569892473118	0.0	3.0	0.0	-4.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04587155963302752	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
145	paired helical filament;paired helical filaments	0.248812461736406	-5.2857142857142865	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-5.2857142857142865	0.0	0.0	-9.25	0.04	0.06349206349206349	0.0	0.05072463768115942	0.05072463768115942	3.0	0.06349206349206349	0.0	1.0	0.0	-9.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.05072463768115942	0.0	0.06349206349206349	0.0	0.0	0.0	0.0	0.0
30	expansions	0.094472773144196	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.04	0.04	1.0	0.04587155963302752	0.0	1.0	0.0	-3.1999999999999993	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
258	Compared;compared	0.11149157825147085	-7.800000000000001	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.800000000000001	0.0	0.0	0.0	0.04	0.04	0.0	0.05813953488372093	0.05813953488372093	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05813953488372093	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	malaria agents P. gallinaceum	0.19048149519767668	0.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.4	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	4.0	0.04	0.25	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.25	0.0	1.0
207	broader clinical settings	0.07656528516173172	-3.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-8.333333333333334	0.04	0.06000000000000001	0.0	0.047058823529411764	0.047058823529411764	3.0	0.06000000000000001	0.0	1.0	0.0	-8.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.047058823529411764	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
138	lifecycle stages;Life Cycle Stages	0.18400227799156635	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.5	0.04	0.044444444444444446	0.0	0.04	0.04	2.0	0.044444444444444446	0.0	1.0	0.0	-2.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.044444444444444446	0.0	0.0	0.0	0.0	0.0
207	the treatment	0.007024991894153531	-4.875	1.0	-17.333333333333332	0.04	0.08521739130434783	1.0	1.0	1.0	-8.666666666666666	1.0	0.0	-9.75	0.0	0.0	-9.666666666666668	0.13043478260869565	0.05084745762711865	0.0	0.04	0.05278688524590164	2.0	0.07087827426810478	1.0	2.0	0.0	-14.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.06557377049180328	0.0	0.09090909090909091	1.0	0.0	0.0	0.0	0.0
302	led to the identification of 8-bromo-4;led to the identification of 4;Lead 4+	0.09824077322187408	0.0	0.0	0.0	0.04	0.04	0.625	0.7291666666666667	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.35416666666666663	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	14.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
265	gene mutations	0.010744531550486585	-10.4	1.0	-17.333333333333332	0.13043478260869565	0.13043478260869565	0.5	0.5	1.0	-17.333333333333332	1.0	0.0	-10.4	0.0	0.0	-15.0	0.13043478260869565	0.1	1.0	0.0684931506849315	0.0684931506849315	2.0	0.1	1.0	1.0	0.0	-15.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.0684931506849315	0.0	0.1	1.0	0.0	0.5	0.0	0.0
246	loss;Loss;loss-	0.45418474458940306	0.0	0.0	0.0	0.04	0.04	0.5	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.3333333333333333	0.04	0.0	6.0	0.0	0.0	1.0	0.0	0.6666666666666666	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
328	sporadic;Sporadic	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
103	mammalian DNA MTases	0.1073581231025634	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.3333333333333333	1.0	0.0	1.0	1.0	-1.7142857142857153	0.04	0.04294478527607362	0.0	0.04	0.04	3.0	0.04294478527607362	0.6666666666666666	1.0	1.0	-1.7142857142857153	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.04	0.0	0.04294478527607362	0.0	1.0	0.0	0.0	1.0
13	femtosecond serial X-ray crystallography results	0.3123795294827484	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
180	OPA1 gene;OPA1 GENE;OPA1) gene	0.2647199597645853	-1.333333333333334	0.0	0.0	0.04	0.04	0.3333333333333333	0.41666666666666663	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-5.166666666666667	0.04	0.04	0.0	0.04	0.042388059701492536	2.5	0.05409090909090909	0.0	2.0	0.0	-10.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	5.0	0.04477611940298508	0.0	0.06818181818181819	0.0	0.0	0.0	0.0	0.0
339	cell of bone marrow;bone marrow cells;bone marrow cells of	0.19438352414757826	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6944444444444443	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.133333333333333	0.04	0.05555555555555555	0.0	0.04	0.04	3.3333333333333335	0.05597643097643098	0.0	3.0	0.0	-7.4	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	10.0	0.04	0.0	0.056818181818181816	0.0	0.0	0.0	0.0	0.0
294	a novel device	0.09110855165691337	-6.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.053571428571428575	0.053571428571428575	3.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.053571428571428575	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
120	These results	0.09419740013660208	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.045454545454545456	0.045454545454545456	2.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.045454545454545456	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
142	Families;families;familial;Familial;Family;family	0.5313149656147208	-0.2916666666666665	0.0	0.0	0.04	0.04	0.0	0.75	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-1.5138888888888888	0.04	0.04	0.0	0.04	0.04051470588235294	1.0	0.042762480777334244	0.0	8.0	0.0	-4.0	1.0	0.0	0.75	0.0	1.0	0.0	1.0	0.0	0.0	6.0	1.0	8.0	0.044117647058823525	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
48	early in the progression of the disease;disease early	0.020682809945105882	-1.375	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	-1.375	0.0	0.0	-2.1428571428571423	0.04	0.04375	0.0	0.042328042328042326	0.042328042328042326	7.0	0.04375	0.42857142857142855	1.0	0.0	-2.1428571428571423	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	7.0	0.042328042328042326	0.0	0.04375	0.0	0.0	0.0	0.0	0.0
257	cellular signalling pathways	0.7409201488454747	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
340	normal;NORMAL	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	few;Few	0.10238296519538877	-5.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.05084745762711865	0.05084745762711865	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05084745762711865	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	effect;Effect	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	Gene Expression;expression of genes	0.06783605017951891	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.04	0.043859649122807015	0.0	0.04	0.04	3.0	0.043859649122807015	0.0	1.0	0.0	-2.1999999999999993	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.043859649122807015	0.0	0.0	0.0	0.0	0.0
264	various classes of age	0.045835433082335744	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.04	0.04	4.0	0.046296296296296294	0.25	1.0	0.0	-3.3999999999999986	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
163	soy proteins in the treatment	0.13491704661187107	-3.3999999999999986	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	-3.3999999999999986	1.0	1.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.046296296296296294	0.046296296296296294	5.0	0.048387096774193554	0.4	1.0	1.0	-4.333333333333334	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.046296296296296294	0.0	0.048387096774193554	0.0	1.0	0.0	0.0	1.0
44	evidence;Evidence	0.09501291563137106	-3.875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.75	0.0	0.0	-2.5	0.04	0.04	0.0	0.04	0.04898550724637681	1.0	0.045	0.0	2.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.057971014492753624	0.0	0.05	0.0	0.0	0.0	0.0	0.0
189	the elevated levels of prolactin	0.228462092954257	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
257	a typical 2-cys	0.28826790559932985	-2.833333333333332	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	-2.833333333333332	0.0	0.0	-10.142857142857142	0.04	0.0673076923076923	0.0	0.045112781954887216	0.045112781954887216	5.0	0.0673076923076923	0.2	1.0	0.0	-10.142857142857142	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.045112781954887216	0.0	0.0673076923076923	0.0	0.0	0.0	0.0	0.0
264	a consensus	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
83	Gain;gain	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
12	lack	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
313	cytoplasmic PABP4 and PABP5 in cultured human cells	0.12494255139312753	0.0	1.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.1	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.0	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
4	Papillary Thyroid Carcinoma;papillary thyroid carcinoma	0.8595762898543627	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	3.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
155	bidirectional and polymorphic tachycardias	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
137	the venous system	0.04194783129456333	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.1000000000000014	0.04	0.041841004184100423	0.0	0.04	0.04	3.0	0.041841004184100423	0.6666666666666666	1.0	0.0	-1.1000000000000014	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.041841004184100423	0.0	0.0	0.0	0.0	0.0
256	Transversion;transversion	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
94	the “FDA-approved orphan use” category after February 2002	0.08714233627997614	-3.3999999999999986	1.0	0.0	0.04	0.04	0.4166666666666667	0.4166666666666667	0.0	0.0	0.1	0.0	-3.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.046296296296296294	0.046296296296296294	12.0	0.04	0.08333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	12.0	0.046296296296296294	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	a single family	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	BOR treatment	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
199	entromere proteins Cenpa, Cenpb, and Bub3	0.3869705955420719	0.0	1.0	0.0	0.04	0.04	0.125	0.125	0.0	0.0	0.25	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.125	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
83	prognosis in clopidogrel-treated patients	0.061447209084649665	-4.25	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.16666666666666666	0.0	-4.25	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.04819277108433735	0.04819277108433735	6.0	0.06060606060606061	0.16666666666666666	1.0	0.0	-8.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04819277108433735	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
239	Down's syndrome;DOWN SYNDROME	0.19847188049679856	-3.333333333333332	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-3.333333333333332	1.0	1.0	-7.75	0.04	0.057971014492753624	0.0	0.04615384615384615	0.04615384615384615	3.0	0.057971014492753624	0.0	2.0	1.0	-7.75	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.04615384615384615	0.0	0.057971014492753624	0.0	1.0	0.0	0.0	1.0
318	myeloid cell;Myeloid cell	0.17912457499688095	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.23076923076923	0.04	0.045936395759717315	0.0	0.04	0.04	2.0	0.045936395759717315	0.0	1.0	0.0	-3.23076923076923	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.045936395759717315	0.0	0.0	0.0	0.0	0.0
13	reaction dynamics in biological systems	0.08279735195665178	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
145	some ways	0.003898055353927883	-12.428571428571429	1.0	-18.0	0.14285714285714285	0.14285714285714285	1.0	1.0	1.0	-18.0	1.0	0.0	-12.428571428571429	0.0	0.0	-16.0	0.14285714285714285	0.1111111111111111	1.0	0.07954545454545454	0.07954545454545454	2.0	0.1111111111111111	1.0	1.0	0.0	-16.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.07954545454545454	0.0	0.1111111111111111	1.0	0.0	0.5	0.0	0.0
127	Mutations in which gene;gene mutations	0.016624305798792437	-3.458333333333333	1.0	0.0	0.04	0.04	0.5	0.5625	1.0	0.0	1.0	0.0	-9.0	0.0	0.0	-5.083333333333333	0.04	0.04	0.0	0.04	0.047780003270111185	2.5	0.0565953947368421	1.0	4.0	0.0	-14.333333333333332	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	10.0	0.0625	0.0	0.09374999999999999	1.0	0.0	0.0	0.0	0.0
154	Mutations;mutations	0.12056396797998489	-3.886363636363636	1.0	-13.8	0.04	0.052321428571428574	0.0	0.0	1.0	-3.45	1.0	0.0	-12.363636363636363	0.0	0.0	-5.15	0.08928571428571429	0.04	0.0	0.04	0.051145409464283774	1.0	0.055477517765253614	1.0	4.0	0.0	-13.8	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.07913669064748201	0.0	0.08928571428571429	1.0	0.0	0.0	0.0	0.0
44	Africa	0.6863713820630953	-4.125	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-6.166666666666667	0.04	0.05263157894736842	0.0	0.047619047619047616	0.047905909351692484	1.0	0.0531015037593985	0.0	2.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04819277108433735	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
86	inhibitor;Inhibitor	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
38	Rubinstein-Taybi syndrome (RSTS;Rubinstein-Taybi syndrome (RSTS)	0.39050342569660806	0.0	1.0	0.0	0.04	0.04	0.14285714285714285	0.15079365079365079	0.0	0.0	0.5	0.0	0.0	0.0	0.0	-1.25	0.04	0.04	0.0	0.04	0.04	6.666666666666667	0.04235294117647059	0.6031746031746031	3.0	0.0	-3.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	20.0	0.04	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
198	Insertion;insertion	0.5820204521242	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04597701149425287	0.0	1.0	0.0	-3.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
205	retained;Retained	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	The virtual hits	0.048894972933717654	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
9	like repeats	0.1041905550607364	-9.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-9.666666666666666	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.06521739130434782	0.06521739130434782	2.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.06521739130434782	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
334	resistant cells	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
26	three;Three	0.107896796115963	-1.4285714285714288	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.8571428571428577	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04258064516129033	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04516129032258065	0.0	0.04	0.0	0.0	0.0	0.0	0.0
321	Subset;subsets	0.4601948403474247	-2.8000000000000007	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	-14.0	0.04	0.09090909090909091	0.0	0.04504504504504505	0.04504504504504505	1.0	0.09090909090909091	0.0	1.0	0.0	-14.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04504504504504505	0.0	0.09090909090909091	0.0	0.0	0.0	0.0	0.0
331	-mediated transmission of pericentromeric heterochromatin	0.29956052836315394	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	a billion humans	0.10666279720273474	-3.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	0.0	0.04	0.04	0.0	0.046511627906976744	0.046511627906976744	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.046511627906976744	0.0	0.04	0.0	0.0	0.0	0.0	0.0
141	Autosomal Recessive Inheritance;Autosomal recessive inheritance;autosomal recessive inheritance	0.8576417884798601	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	5.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	3.0	1.0	15.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
155	Synonym;synonymous	0.613365458995008	-5.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.5	0.0	0.0	-2.5	0.04	0.044444444444444446	0.0	0.05128205128205128	0.05128205128205128	1.0	0.044444444444444446	0.0	1.0	0.0	-2.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05128205128205128	0.0	0.044444444444444446	0.0	0.0	0.0	0.0	0.0
310	clinical activity	0.11893882458661169	-4.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.04938271604938271	0.04938271604938271	2.0	0.06451612903225806	0.0	2.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04938271604938271	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
285	arising	0.094472773144196	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.04	0.04	1.0	0.04587155963302752	0.0	1.0	0.0	-3.1999999999999993	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
286	BoNT endopeptidase assays	0.8175108201392002	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	A group;a group	0.0976833756768823	-2.2222222222222214	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.2222222222222214	0.0	0.0	-6.428571428571429	0.04	0.05384615384615385	0.0	0.04390243902439024	0.04390243902439024	2.0	0.05384615384615385	0.0	2.0	0.0	-6.428571428571429	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04390243902439024	0.0	0.05384615384615385	0.0	0.0	0.0	0.0	0.0
72	the related genes	0.05147616602583505	-1.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.0423728813559322	0.0423728813559322	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.0423728813559322	0.0	0.04	0.0	0.0	0.0	0.0	0.0
258	Chromosome Arm;chromosomes arms	0.21550586778815967	-2.1999999999999993	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.043859649122807015	0.043859649122807015	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.043859649122807015	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	cells mosaicism;mosaicism in which 17% of the cells	0.03863161959715782	0.0	0.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04	0.04	8.0	0.04878048780487805	0.375	1.0	0.0	-4.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.04	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
4	cutaneous manifestations of;manifestation of skin	0.18176021947280274	-2.5	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	0.0	0.04	0.04	0.0	0.044444444444444446	0.044444444444444446	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.044444444444444446	0.0	0.04	0.0	0.0	0.0	0.0	0.0
179	rapamycin (mTOR	0.5585035174765755	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.4	0.04	0.0510204081632653	0.0	0.04	0.04	3.0	0.0510204081632653	0.0	1.0	0.0	-5.4	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.0510204081632653	0.0	0.0	0.0	0.0	0.0
95	three potential RNA	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
131	breast cancer-specific potential biomarkers	0.07360665648931922	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.5	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	'component' proteins;component' proteins)	0.47433311329254874	-2.5	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-2.25	0.04	0.04	0.0	0.04	0.045	4.0	0.04439024390243902	0.0	2.0	0.0	-4.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.05	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
79	two hours after administration	0.087841140447183	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.045454545454545456	0.045454545454545456	4.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.045454545454545456	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
78	the International Consortium	0.16050557032848847	-8.5	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-8.5	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.06060606060606061	0.06060606060606061	3.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.06060606060606061	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
267	displays	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
72	information retrieval;Information Retrieval	0.20146510080365157	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
269	base	0.08777881280371597	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
16	a threshold	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
256	the gene	0.04969694317218909	-4.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	0.0	0.04	0.04	1.0	0.04918032786885245	0.04918032786885245	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04918032786885245	0.0	0.04	0.0	0.0	0.5	0.0	0.0
124	T1	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
71	lipogenesis	0.6336246714524139	-3.6000000000000014	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04672897196261683	0.04672897196261683	1.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04672897196261683	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
318	the BCR-ABL fusion protein	0.7072446261980223	-1.0740740740740737	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-3.2222222222222214	1.0	1.0	-4.641025641025641	0.04	0.043478260869565216	0.0	0.04	0.04197278911564626	6.0	0.049599136601911814	0.3333333333333333	3.0	1.0	-6.923076923076923	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	18.0	0.04591836734693877	0.0	0.055319148936170216	0.0	1.0	0.0	0.0	1.0
332	Short-term;short-term	0.1187176919696614	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
215	expression of such an oncogene	0.0730476202762195	0.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.4	1.0	0.0	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	1.0	0.04	0.04	5.0	0.04587155963302752	0.2	1.0	0.0	-3.1999999999999993	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04587155963302752	0.0	0.0	0.2	0.0	0.0
339	Bmi-1-mediated repression	0.5253291347928023	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
214	the central timing mechanism for cellular aging	0.041002170299109554	0.0	1.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.375	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.2857142857142857	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
338	negative t wave;negative T waves	0.1187176919696614	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
137	Accuracy;accuracy	0.07880109090742628	-2.8888888888888893	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.8888888888888893	0.0	0.0	-4.300000000000001	0.04	0.04830917874396135	0.0	0.04522613065326633	0.04522613065326633	1.0	0.04830917874396135	0.0	1.0	0.0	-4.300000000000001	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04522613065326633	0.0	0.04830917874396135	0.0	0.0	0.0	0.0	0.0
6	NALOXONE;naloxone	0.9972319524397681	-1.8421052631578951	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-6.222222222222221	1.0	1.0	-3.5526315789473686	0.04	0.04	0.0	0.04	0.04353176724174188	1.0	0.047977054239218414	0.0	19.0	1.0	-9.25	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	19.0	0.05325443786982248	0.0	0.06349206349206349	0.0	1.0	0.0	0.0	1.0
77	COMT activity	0.168134693299177	-2.833333333333332	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.045112781954887216	0.045112781954887216	2.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.045112781954887216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	Entire;entire	0.09563291488491976	-3.545454545454546	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.909090909090908	0.0	0.0	-3.75	0.04	0.045454545454545456	0.0	0.04198473282442748	0.04718284260268993	1.0	0.04711751662971175	0.0	2.0	0.0	-4.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.052380952380952375	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
121	4-8%	0.7203283124501944	-2.333333333333333	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.044590163934426226	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04918032786885245	0.0	0.04	0.0	0.0	0.0	0.0	0.0
146	caused;cause	0.07227637838306812	-2.833333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.045112781954887216	0.045112781954887216	1.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045112781954887216	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
68	FGFR1, -2 and -3	0.4587563843366077	-4.333333333333334	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	-4.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.048387096774193554	0.048387096774193554	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.048387096774193554	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	DNMT1 to DNA replication foci	0.08993964274477871	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.2857142857142865	0.04	0.04827586206896552	0.0	0.04	0.04	5.0	0.04827586206896552	0.2	1.0	0.0	-4.2857142857142865	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04827586206896552	0.0	0.0	0.0	0.0	0.0
170	the cause	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
175	dysmorphic features;Dysmorphic features	0.8864682077241409	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	9.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	18.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
213	the first evidence	0.07549202322387845	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-9.75	0.04	0.06557377049180328	0.0	0.05	0.05	3.0	0.06557377049180328	0.0	1.0	0.0	-9.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05	0.0	0.06557377049180328	0.0	0.0	0.0	0.0	0.0
13	mixtures	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
227	low;Low	0.07319930470284083	-2.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04504504504504505	0.04504504504504505	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04504504504504505	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
82	Thai	0.8405898912061389	-0.37142857142857155	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.8571428571428577	0.0	0.0	-0.9600000000000002	0.04	0.04	0.0	0.04	0.04064197530864198	1.0	0.041900990099009904	0.0	5.0	0.0	-4.800000000000001	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.043209876543209874	0.0	0.04950495049504951	0.0	0.0	0.0	0.0	0.0
111	translation elongation	0.4952523736829887	-4.428571428571429	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-4.428571428571429	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.04861111111111112	0.04861111111111112	2.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	2.0	0.04861111111111112	1.0	0.046875	0.0	0.0	0.0	1.0	0.0
317	Reduction;reduction	0.07579733177231056	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.045454545454545456	0.045454545454545456	1.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
60	roles;Roles	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	control	0.11648037891071825	-2.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.044117647058823525	0.044117647058823525	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.044117647058823525	0.0	0.04	0.0	0.0	0.0	0.0	0.0
297	postoperative AF in CABG patients	0.26905681404095005	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	one of the largest membrane protein complexes	0.09813896789270846	0.0	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
343	80K-H	0.7544880182025683	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	acute light-induced suppression of pineal melatonin	0.3971334488454135	-4.25	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	8.0	0.04	0.125	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
283	High;high	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
5	conducted;Conduct	0.0719371432101151	-7.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.25	0.0	0.0	-10.25	0.04	0.06779661016949153	0.0	0.056338028169014086	0.056338028169014086	1.0	0.06779661016949153	0.0	1.0	0.0	-10.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.056338028169014086	0.0	0.06779661016949153	0.0	0.0	0.0	0.0	0.0
71	the down-regulation	0.05431365102545339	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04	0.04	4.0	0.04938271604938271	0.25	1.0	0.0	-4.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
71	to;TO	0.13708235242003722	-1.6666666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	-1.1666666666666667	0.04	0.04	0.0	0.04	0.04296354825115887	1.0	0.04217054263565891	0.0	3.0	0.0	-3.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.044642857142857144	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
71	Response;response	0.09241438672407117	-2.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04424778761061947	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04424778761061947	0.0	0.04	0.0	0.0	0.0	0.0	0.0
89	both drugs in the last 72 hours	0.04325478180066842	-6.4	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	1.0	-6.4	1.0	1.0	-7.0	0.04	0.05555555555555555	0.0	0.05376344086021505	0.05376344086021505	7.0	0.05555555555555555	0.2857142857142857	1.0	1.0	-7.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.05376344086021505	0.0	0.05555555555555555	0.0	1.0	0.0	0.0	1.0
46	HES7;HES7 gene	0.8795895813860097	-0.6000000000000002	0.0	0.0	0.04	0.04	0.0	0.16666666666666666	0.0	0.0	0.0	1.0	-3.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.041121495327102804	1.3333333333333333	0.04	0.0	6.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	8.0	0.04672897196261683	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	rheumatoid arthritis (RA)	0.7675682475748582	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
149	miR-146a	0.6828657932045992	-3.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	0.0	0.04	0.04	0.0	0.047058823529411764	0.047058823529411764	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.047058823529411764	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	AR;AR+	0.6838931890066016	-3.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	Bestor	0.6209430422576171	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.8571428571428577	0.04	0.04516129032258065	0.0	0.04	0.04	1.0	0.04516129032258065	0.0	1.0	0.0	-2.8571428571428577	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04516129032258065	0.0	0.0	0.0	0.0	0.0
320	the generation of queries	0.060333253658522656	-4.333333333333334	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-4.333333333333334	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.048387096774193554	0.048387096774193554	4.0	0.05263157894736842	0.25	1.0	0.0	-6.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.048387096774193554	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
61	E2	0.8368037222183511	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.0	1.0	1.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	0.045454545454545456	1.0	0.04	0.0	1.0	0.0	1.0	1.0
125	a well-defined subtype	0.12593395154532125	-6.333333333333334	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-11.5	0.04	0.07407407407407407	0.0	0.053571428571428575	0.053571428571428575	5.0	0.07407407407407407	0.0	1.0	0.0	-11.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.053571428571428575	0.0	0.07407407407407407	0.0	0.0	0.0	0.0	0.0
258	established;Established	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
216	the dominant members	0.08749660280130565	-3.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04597701149425287	0.04597701149425287	3.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04597701149425287	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
58	Treating;treating	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
80	about 1%	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
6	a high mortality	0.07496124148260859	-4.222222222222221	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.222222222222221	0.0	0.0	-9.25	0.04	0.06349206349206349	0.0	0.0481283422459893	0.0481283422459893	3.0	0.06349206349206349	0.0	1.0	0.0	-9.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.0481283422459893	0.0	0.06349206349206349	0.0	0.0	0.0	0.0	0.0
257	whose main function	0.110498966788307	-9.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-9.666666666666666	0.0	0.0	-4.428571428571429	0.04	0.04861111111111112	0.0	0.06521739130434782	0.06521739130434782	3.0	0.04861111111111112	0.0	1.0	0.0	-4.428571428571429	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.06521739130434782	0.0	0.04861111111111112	0.0	0.0	0.0	0.0	0.0
204	Evaluate;evaluate	0.09254454525082689	-2.125	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-3.75	0.04	0.04	0.0	0.04	0.04409638554216867	1.0	0.04857142857142857	0.0	2.0	0.0	-7.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04819277108433735	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
198	a novel SCN5A mutation (c.664C>T	0.17535057131296286	-6.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.14285714285714285	1.0	-6.0	1.0	1.0	-3.25	0.04	0.04597701149425287	1.0	0.05263157894736842	0.05263157894736842	8.0	0.04597701149425287	0.25	1.0	1.0	-3.25	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.05263157894736842	0.0	0.04597701149425287	0.0	1.0	0.125	0.0	1.0
200	Recent;recent	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	Old;old;older	0.07810582532983804	-1.583333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	-2.166666666666667	0.04	0.04	0.0	0.04	0.042900763358778626	1.0	0.04419354838709678	0.0	2.0	0.0	-4.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.04580152671755725	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
6	acute;ACUTE	0.044472802078662436	-14.0	1.0	-13.0	0.08333333333333333	0.08333333333333333	0.0	0.0	1.0	-13.0	1.0	0.0	-14.0	0.0	0.0	-14.25	0.08333333333333333	0.09302325581395349	0.0	0.09090909090909091	0.09090909090909091	1.0	0.09302325581395349	1.0	1.0	0.0	-14.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.09090909090909091	0.0	0.09302325581395349	1.0	0.0	0.0	0.0	0.0
67	a well-studied disease	0.06085164612027579	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04	0.04	5.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
137	Series;series	0.09624214068422196	-1.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-3.0	0.04	0.04	0.0	0.04	0.042388059701492536	1.0	0.04631578947368421	0.0	2.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04477611940298508	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
247	CIN 2	0.8150276822448651	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	2.0	0.047619047619047616	0.0	3.0	1.0	-4.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.047619047619047616	0.0	1.0	0.0	0.0	1.0
124	Molecular tests such as the Oncotype DX(®) breast cancer test	0.04296764186638008	0.0	1.0	0.0	0.04	0.04	0.6363636363636364	0.6363636363636364	0.0	0.0	0.18181818181818182	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	11.0	0.04	0.18181818181818182	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	11.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
163	exercise induced free radical production and depletion of non-enzymatic antioxidant	0.06627952384040033	0.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.1	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	10.0	0.04	0.1	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.04	0.0	0.04	0.0	1.0	0.1	0.0	1.0
256	an amino acid substitution p.Pro250Arg	0.4270145456548483	0.0	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	10%;10	0.9470685574295372	-2.875	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-5.166666666666666	0.0	0.0	-3.125	0.04	0.04	0.0	0.04	0.04543346909943882	1.0	0.04626390433815351	0.0	8.0	0.0	-5.666666666666666	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	8.0	0.050420168067226885	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
75	disease patient	0.03123536915842036	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	2.0	0.05	0.5	1.0	0.0	-5.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
334	the linker histone HHO1	0.20958378185546678	0.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.3333333333333333	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	significant variations in the success	0.047545002611609204	-2.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04477611940298508	0.04477611940298508	5.0	0.05084745762711865	0.2	1.0	0.0	-5.333333333333334	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04477611940298508	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
204	position 1138 (G1138A)	0.4270145456548483	0.0	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
244	a benefit	0.003901659103163024	-14.25	1.0	-16.25	0.11428571428571428	0.11428571428571428	1.0	1.0	1.0	-16.25	1.0	0.0	-14.25	0.0	0.0	-16.5	0.11428571428571428	0.11764705882352941	1.0	0.09302325581395349	0.09302325581395349	2.0	0.11764705882352941	1.0	1.0	0.0	-16.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.09302325581395349	0.0	0.11764705882352941	1.0	0.0	0.5	0.0	0.0
311	The discovery that expansion	0.052997877725278884	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
208	antinociceptive potential	0.33464996046184486	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
180	Major;major	0.07790659436323155	-1.8333333333333321	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.043165467625899276	0.043165467625899276	1.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043165467625899276	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
255	Facial weakness;weakness of the face;face weakness;facial weakness	0.27700201317377354	-1.7142857142857153	0.0	0.0	0.04	0.04	0.5	0.75	0.0	0.0	0.0	0.0	-1.8571428571428577	0.0	0.0	-1.4375	0.04	0.04	0.0	0.042682926829268296	0.04294640168623909	3.0	0.04259887005649718	0.25	4.0	0.0	-2.875	1.0	0.0	0.5	0.5	1.0	0.0	1.0	0.0	0.0	4.0	1.0	12.0	0.043209876543209874	0.0	0.04519774011299435	0.0	0.0	0.0	0.0	0.0
274	ponezumab;PONEZUMAB	0.7010706096384343	-2.6363636363636367	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.6363636363636367	1.0	1.0	-2.0	0.04	0.043478260869565216	0.0	0.044715447154471545	0.044715447154471545	1.0	0.043478260869565216	0.0	1.0	1.0	-2.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	1.0	0.044715447154471545	0.0	0.043478260869565216	0.0	1.0	0.0	0.0	1.0
206	previous levels within 90 min	0.15627876199961344	-5.666666666666666	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.051724137931034475	0.051724137931034475	5.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.051724137931034475	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
203	rule;Rule	0.09773875734391521	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	Chronic myelogenous leukemia (CML);chronic myelogenous leukemia (CML;chronic myelogenous leukemia (CML)	0.9860980831744631	-0.23611111111111116	0.0	0.0	0.04	0.04	0.16666666666666666	0.17083333333333334	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-2.6634615384615383	0.04	0.041401273885350316	0.0	0.04	0.040408653846153844	5.875	0.04497911134100214	0.8291666666666667	8.0	0.0	-5.153846153846153	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	47.0	0.04326923076923077	0.0	0.050387596899224806	0.0	0.0	0.0	0.0	0.0
99	limbs	0.09952666359733718	-3.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-4.7142857142857135	0.04	0.04929577464788733	0.0	0.04597701149425287	0.04597701149425287	1.0	0.04929577464788733	0.0	1.0	0.0	-4.7142857142857135	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04597701149425287	0.0	0.04929577464788733	0.0	0.0	0.0	0.0	0.0
13	Complexes;complexes	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	potential therapeutic targets for human neurodegenerative diseases	0.0930885588100642	0.0	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-1.571428571428573	0.04	0.042682926829268296	1.0	0.04	0.04	7.0	0.042682926829268296	0.14285714285714285	1.0	1.0	-1.571428571428573	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.042682926829268296	0.0	1.0	0.14285714285714285	0.0	1.0
329	several state-of-	0.08095225848218429	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-17.0	0.04	0.125	0.0	0.04	0.04	5.0	0.125	0.0	1.0	0.0	-17.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.125	0.0	0.0	0.0	0.0	0.0
277	tests;test;Test;Tests	0.006331353925401743	-16.0	1.0	-18.0	0.14285714285714285	0.14285714285714285	1.0	1.0	1.0	-18.0	1.0	1.0	-17.2	1.0	1.0	-17.333333333333336	0.14285714285714285	0.12	1.0	0.09803921568627452	0.11312217194570137	1.0	0.13142857142857142	1.0	2.0	1.0	-18.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	4.0	1.0	2.0	0.12820512820512822	1.0	0.14285714285714285	1.0	1.0	1.0	1.0	1.0
129	5;>5	0.6325581163846815	-0.8333333333333339	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.6666666666666679	0.0	0.0	-1.2857142857142865	0.04	0.04	0.0	0.04	0.041428571428571426	0.5	0.04229299363057325	0.0	2.0	0.0	-2.571428571428573	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04285714285714286	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
183	Eight;eight	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
345	a SEC incorporation sequence (SECIS	0.26457481880538564	-1.8000000000000007	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-1.8000000000000007	0.0	0.0	-5.4	0.04	0.0510204081632653	0.0	0.04310344827586207	0.04310344827586207	6.0	0.0510204081632653	0.0	1.0	0.0	-5.4	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04310344827586207	0.0	0.0510204081632653	0.0	0.0	0.0	0.0	0.0
10	human ADI prostate cancer samples validates TPL2	0.1369806811604078	-2.2857142857142847	1.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.3333333333333333	1.0	-2.2857142857142847	1.0	1.0	0.0	0.04	0.04	0.0	0.0440251572327044	0.0440251572327044	7.0	0.04	0.2857142857142857	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	7.0	0.0440251572327044	0.0	0.04	0.0	1.0	0.0	0.0	1.0
24	a randomised controlled trial of a cardiovascular preventive polypill	0.061401401076986675	0.0	0.0	0.0	0.04	0.04	0.5555555555555556	0.5555555555555556	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.5	0.04	0.05405405405405406	1.0	0.04	0.04	9.0	0.05405405405405406	0.3333333333333333	1.0	0.0	-6.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.05405405405405406	0.0	0.0	0.1111111111111111	0.0	0.0
144	the proximal MEF-2 and CArG box sites	0.05795659193630144	0.0	1.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.16666666666666666	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.2857142857142857	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
152	antihyperglycemic	0.8588053726862677	-2.3999999999999986	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04424778761061947	1.0	0.04	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	0.04424778761061947	1.0	0.04	0.0	0.0	0.0	1.0	0.0
49	Analyzed;analyzed	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
147	0.15-1.45 pmol/min/mg protein	0.4287814295309841	0.0	0.0	0.0	0.04	0.04	0.14285714285714285	0.14285714285714285	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
159	14 percent)	0.6171953679194666	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
134	Pattern;pattern	0.07268327190128901	-6.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.054545454545454536	0.054545454545454536	1.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.054545454545454536	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
342	only one Set1	0.16098910437715522	-2.3999999999999986	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04424778761061947	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04424778761061947	0.0	0.04	0.0	0.0	0.0	0.0	0.0
40	a measure	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
291	available;Available	0.14328748919075074	-1.8571428571428577	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.8571428571428577	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.0433443617314585	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04516129032258065	0.0	0.04	0.0	0.0	0.0	0.0	0.0
264	Association;association	0.07439220883492599	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.04	0.04	1.0	0.04587155963302752	0.0	1.0	0.0	-3.1999999999999993	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
16	domain addition	0.08830009882221537	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.04	0.04	2.0	0.04597701149425287	0.0	1.0	0.0	-3.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
62	Class;class	0.07270877609889996	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.04	0.04	1.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
137	mid;Mid	0.5552720225538386	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.699999999999999	0.04	0.04926108374384236	0.0	0.04	0.04	0.0	0.04926108374384236	0.0	1.0	0.0	-4.699999999999999	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04926108374384236	0.0	0.0	0.0	0.0	0.0
341	based;Based	0.09192881091266093	-2.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04395604395604396	0.04395604395604396	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04395604395604396	0.0	0.04	0.0	0.0	0.0	0.0	0.0
236	allows;allow	0.09773875734391521	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
207	children and adolescents with a schizophrenic disorder	0.058850935362318293	0.0	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-12.333333333333332	0.04	0.07894736842105263	0.0	0.04	0.04	7.0	0.07894736842105263	0.0	1.0	0.0	-12.333333333333332	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.07894736842105263	0.0	0.0	0.0	0.0	0.0
125	men;Men	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
25	Gene;gene	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
77	doses of 200 mg	0.09449520402217644	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.04	0.04	4.0	0.06666666666666667	0.25	1.0	0.0	-10.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
78	350 kb	0.7005679068017071	-3.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04597701149425287	0.04597701149425287	2.0	0.051724137931034475	0.0	2.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04597701149425287	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
140	MS	0.9263592967991707	-0.32638888888888906	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-1.8888888888888893	0.0	0.0	-0.375	0.04	0.04	0.0	0.04	0.04056146978021978	1.0	0.04078947368421053	0.0	16.0	0.0	-6.0	1.0	0.3333333333333333	1.0	0.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	16.0	0.04326923076923077	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
121	patients from distinct ethnic groups	0.09872279333683555	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05	0.05	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.05	0.0	0.04	0.0	0.0	0.0	0.0	0.0
286	a single assay	0.16521351046954758	-3.1999999999999993	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04587155963302752	0.04587155963302752	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04587155963302752	0.0	0.04	0.0	0.0	0.0	0.0	0.0
227	Haemoglobin;hemoglobin	0.7538662181232895	-2.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.043859649122807015	0.043859649122807015	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	1.0	0.043859649122807015	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	a portion of PGCs	0.07290228621211126	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-3.428571428571427	0.04	0.04635761589403973	0.0	0.04	0.04	4.0	0.04635761589403973	0.25	1.0	1.0	-3.428571428571427	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04635761589403973	0.0	1.0	0.0	0.0	1.0
25	deterioration;Deterioration	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	a clinically acceptable performance	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
243	this family	0.07515054812957878	-2.428571428571427	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.428571428571427	0.0	0.0	-9.25	0.04	0.06349206349206349	0.0	0.04430379746835443	0.04430379746835443	2.0	0.06349206349206349	0.0	1.0	0.0	-9.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04430379746835443	0.0	0.06349206349206349	0.0	0.0	0.0	0.0	0.0
96	8 of 22 evaluable patients	0.21943955076009722	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	5.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
257	Residue;residues	0.5644136078667382	-4.166666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.166666666666666	0.0	0.0	-5.857142857142858	0.04	0.05223880597014925	0.0	0.047999999999999994	0.047999999999999994	1.0	0.05223880597014925	0.0	1.0	0.0	-5.857142857142858	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047999999999999994	0.0	0.05223880597014925	0.0	0.0	0.0	0.0	0.0
239	with;With	0.14012588572699589	-0.708333333333333	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-4.75	0.04	0.045454545454545456	0.0	0.04	0.0412781954887218	1.0	0.049816217820397225	0.0	4.0	0.0	-7.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.045112781954887216	0.0	0.057971014492753624	0.0	0.0	0.0	0.0	0.0
124	recommendation;Recommendation	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	conjunction with interaction specific keywords	0.10699058841176723	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
287	the metaphase plate (% aligned spindles	0.3180303740973211	0.0	0.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
94	micro-GIST	0.7447325817147706	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
74	impaired;Impaired	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
199	the formation	0.038180903688450236	-2.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-2.666666666666668	0.04	0.04477611940298508	0.0	0.04477611940298508	0.04477611940298508	2.0	0.04477611940298508	0.5	1.0	0.0	-2.666666666666668	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04477611940298508	0.0	0.04477611940298508	0.0	0.0	0.0	0.0	0.0
79	Clinical Signs;clinical signs	0.10075325633103507	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.04	0.04	2.0	0.047058823529411764	0.0	2.0	0.0	-3.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
85	neural dysfunction in Alzheimer	0.2733452152211173	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
164	a range	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
75	galactosylceramide;Galactosylceramide	0.6261537547779711	-4.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	the absence of a human pituitary tumor;Tumor of the Pituitary	0.025701815469035178	0.0	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04	0.04	7.0	0.043478260869565216	0.2857142857142857	1.0	0.0	-2.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	7.0	0.04	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
230	NCCM with HCM	0.2048101199328353	-2.6000000000000014	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.044642857142857144	0.044642857142857144	3.0	0.044642857142857144	0.3333333333333333	1.0	0.0	-2.6000000000000014	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.044642857142857144	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
276	a better understanding of MCT8 pathophysiology	0.15253371083258746	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
314	LC-MS/MS;LC/MS/MS	0.13963600986850355	-3.75	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.047058823529411764	0.047058823529411764	5.0	0.05128205128205128	0.2	1.0	0.0	-5.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.047058823529411764	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
44	the course	0.04296396418161898	-2.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0449438202247191	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	X-ray protein nanocrystallography	0.158721371904578	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.3333333333333333	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	RORβ or Reverb α/β	0.46282727798635953	-3.75	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	0.0	0.04	0.04	0.0	0.047058823529411764	0.047058823529411764	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.047058823529411764	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	Cross;cross	0.5015943809237053	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.04	0.04	0.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
242	30 mm)	0.6343064309408614	-1.8888888888888893	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	0.0	0.04	0.04	0.0	0.04326923076923077	0.04326923076923077	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04326923076923077	0.0	0.04	0.0	0.0	0.0	0.0	0.0
88	positive;% Positive	0.0791872741477725	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.05	0.05	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
89	an analgesic in a wide range	0.10924569603414379	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
199	key element	0.10739292592566163	-1.8333333333333321	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.043165467625899276	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043165467625899276	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	responsible;Responsible	0.09400652772384117	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.875	0.04	0.046511627906976744	0.0	0.04	0.04	1.0	0.04735219949565705	0.0	2.0	0.0	-4.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
12	Localization of PR-	0.3258643752149569	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.04	0.04	4.0	0.054545454545454536	0.0	1.0	0.0	-6.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
74	the symptom of muscular weakness	0.04388534082058867	-2.166666666666668	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.043795620437956206	0.043795620437956206	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.043795620437956206	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	contact with;Contact with;contact	0.0750294470663063	-7.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-14.5	0.0	0.0	-2.166666666666667	0.04	0.04	0.0	0.04	0.06761904761904762	1.5	0.04419354838709678	0.0	2.0	0.0	-4.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	3.0	0.09523809523809523	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
318	I-;i	0.07540643116033252	-2.1111111111111107	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1111111111111107	0.0	0.0	-4.692307692307692	0.04	0.04924242424242425	0.0	0.043689320388349516	0.043689320388349516	1.0	0.04924242424242425	0.0	1.0	0.0	-4.692307692307692	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043689320388349516	0.0	0.04924242424242425	0.0	0.0	0.0	0.0	0.0
318	the molecular juxtaposition	0.1904006680078167	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.3846153846153832	0.04	0.04421768707482993	0.0	0.04	0.04	3.0	0.04421768707482993	0.3333333333333333	1.0	0.0	-2.3846153846153832	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04421768707482993	0.0	0.0	0.0	0.0	0.0
160	SRE	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	the molecular imaging of biochemical reactions	0.2405067407608541	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
29	A. niger	0.7799781877622837	-2.7222222222222228	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-5.222222222222222	0.04	0.048387096774193554	0.0	0.043795620437956206	0.04490157044901571	2.0	0.050622044449560206	0.0	3.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.045454545454545456	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
222	anti-leukocyte (CD52) monoclonal antibody	0.6298252015668352	-5.777777777777779	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-5.777777777777779	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.05202312138728324	0.05202312138728324	6.0	0.04587155963302752	0.3333333333333333	1.0	0.0	-3.1999999999999993	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.05202312138728324	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
30	a novel therapeutic strategy	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
219	Biofilms;biofilm;Biofilm;biofilms	0.4782304507584641	-3.166666666666667	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-3.75	0.04	0.045454545454545456	0.0	0.04	0.04678571428571429	1.0	0.04711751662971175	0.0	2.0	0.0	-4.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.053571428571428575	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
221	anatomical data	0.19651003599540007	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.04	0.04	2.0	0.05405405405405406	0.0	1.0	0.0	-6.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
86	different;Different	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	The chromodomain;the chromodomain	0.8860131269660589	-1.875	1.0	-12.666666666666668	0.04	0.04256756756756757	0.5	0.5	1.0	-0.7916666666666667	0.84375	0.0	-10.0	0.0	0.0	-2.2708333333333335	0.08108108108108109	0.04	0.0	0.04	0.044449147343884186	2.0	0.045776050348889215	1.0	16.0	0.0	-12.666666666666668	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	32.0	0.06666666666666667	0.0	0.08108108108108109	1.0	0.0	0.0	0.0	0.0
94	considered	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
267	ARM;arm	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
286	plate immuno-biochemical assay;Plate assay	0.5664343590146205	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
339	raised;Raised	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
343	a role for TRIM5alpha	0.0295323965441501	0.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.16666666666666666	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	4.0	0.04	0.5	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.25	0.0	1.0
217	Perform;perform	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
254	the response to cigarette smoke	0.05411772315431602	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
101	malaria parasite histone methyltransferases	0.25960436899559464	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.6	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
26	18	0.650588319820874	-1.8571428571428577	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.8571428571428577	0.0	0.0	0.0	0.04	0.04	0.0	0.043209876543209874	0.043209876543209874	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043209876543209874	0.0	0.04	0.0	0.0	0.0	0.0	0.0
155	cardiac ryanodine receptor type 2 (RyR2	0.2998674221714949	-6.5	0.0	0.0	0.04	0.04	0.14285714285714285	0.14285714285714285	0.0	0.0	0.0	1.0	-6.5	0.0	0.0	-14.333333333333332	0.04	0.09374999999999999	0.0	0.05405405405405406	0.05405405405405406	7.0	0.09374999999999999	0.2857142857142857	1.0	0.0	-14.333333333333332	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.05405405405405406	0.0	0.09374999999999999	0.0	0.0	0.0	0.0	0.0
319	molecular docking for further refinement	0.26905681404095005	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
206	UNILATERAL;unilateral	0.6261537547779711	-4.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	6%)	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
83	known associations	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
163	result;Results;results;Result	0.14689062660028399	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	5.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
9	increasing GC	0.44456809294902566	-5.333333333333333	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-6.0	0.0	0.0	-3.625	0.04	0.04	0.0	0.04918032786885245	0.05090595340811044	2.0	0.04816901408450704	0.0	2.0	0.0	-7.25	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.05263157894736842	0.0	0.056338028169014086	0.0	0.0	0.0	0.0	0.0
95	the 2–5A system	0.0793662226340656	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
333	The presence	0.0459204914933268	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-6.75	0.04	0.0547945205479452	0.0	0.04	0.04	2.0	0.0547945205479452	0.5	1.0	1.0	-6.75	1.0	0.5	1.0	1.0	1.0	1.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04	0.0	0.0547945205479452	0.0	1.0	0.0	0.0	1.0
111	donor;DONOR	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
223	Aβ) monoclonal antibody	0.3507101515926323	-3.136363636363636	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.5	1.0	-4.818181818181818	0.0	0.0	-8.0	0.04	0.05511811023622047	0.0	0.04247104247104247	0.04601029601029601	4.0	0.059090586649641764	0.5	2.0	0.0	-9.142857142857142	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04954954954954956	0.0	0.06306306306306306	0.0	0.0	0.0	0.0	0.0
220	the highly tissue-specific disease	0.028006175165402082	-3.875	1.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.25	1.0	-3.875	1.0	1.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.047337278106508875	0.047337278106508875	6.0	0.054545454545454536	0.16666666666666666	1.0	1.0	-6.666666666666666	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.047337278106508875	0.0	0.054545454545454536	0.0	1.0	0.0	0.0	1.0
122	genetic variants	0.49467062392022465	-1.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-1.875	0.04	0.04	0.0	0.04	0.0419047619047619	2.0	0.04428571428571429	0.0	4.0	0.0	-7.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.047619047619047616	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
103	new methylation patterns	0.14725888175039187	-1.6666666666666679	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.6666666666666679	0.0	0.0	-1.7142857142857153	0.04	0.04294478527607362	0.0	0.04285714285714286	0.04285714285714286	3.0	0.04294478527607362	0.0	1.0	0.0	-1.7142857142857153	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04285714285714286	0.0	0.04294478527607362	0.0	0.0	0.0	0.0	0.0
96	NEUTROPENIA;neutropenia);neutropenia	0.5664209609219264	-3.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-6.066666666666666	0.04	0.046296296296296294	0.0	0.046511627906976744	0.046511627906976744	1.3333333333333333	0.05331088664421998	0.16666666666666666	3.0	0.0	-7.4	1.0	0.0	0.0	0.3333333333333333	0.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.046511627906976744	0.0	0.056818181818181816	0.0	0.0	0.0	0.0	0.0
146	Myofibroblasts;myofibroblasts	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	structural;Structural	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	some;Some	0.07553433605392222	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.04	0.045112781954887216	0.0	0.04	0.04	1.0	0.045112781954887216	0.0	1.0	0.0	-2.833333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.045112781954887216	0.0	0.0	0.0	0.0	0.0
25	all;ALL	0.003345127765420692	-12.0	1.0	-17.0	0.125	0.125	1.0	1.0	1.0	-17.0	1.0	0.0	-12.0	0.0	0.0	-12.5	0.125	0.08	0.0	0.07692307692307693	0.07692307692307693	1.0	0.08	1.0	1.0	0.0	-12.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.07692307692307693	0.0	0.08	1.0	0.0	0.0	0.0	0.0
138	analyses;Analysis	0.003637046003106238	-13.846153846153847	1.0	-11.0	0.07142857142857142	0.07142857142857142	1.0	1.0	1.0	-11.0	1.0	0.0	-13.846153846153847	0.0	0.0	-10.375	0.07142857142857142	0.06837606837606838	1.0	0.0896551724137931	0.0896551724137931	1.0	0.06837606837606838	1.0	1.0	0.0	-10.375	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0896551724137931	0.0	0.06837606837606838	1.0	0.0	1.0	0.0	0.0
158	the linker between the IgII and IgIII extracellular immunoglobulin	0.19216892518420584	0.0	0.0	0.0	0.04	0.04	0.4444444444444444	0.4444444444444444	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	relevant abstracts	0.1444916985839097	-1.3499999999999996	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.6999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04242152466367713	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04484304932735426	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	recognition;Recognition	0.06064407243489838	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.076923076923077	0.04	0.05909090909090909	0.0	0.04	0.04	1.0	0.05909090909090909	0.0	1.0	0.0	-8.076923076923077	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05909090909090909	0.0	0.0	0.0	0.0	0.0
230	alpha-tropomyosin;alpha-Tropomyosin	0.5436127861625231	-9.6	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-9.6	0.0	0.0	-9.2	0.04	0.06329113924050632	0.0	0.06493506493506493	0.06493506493506493	3.0	0.06329113924050632	0.0	1.0	0.0	-9.2	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.06493506493506493	0.0	0.06329113924050632	0.0	0.0	0.0	0.0	0.0
288	protein i;protein 1	0.1927664075827681	-4.333333333333334	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-4.333333333333334	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.048387096774193554	0.048387096774193554	2.0	0.05405405405405406	0.5	1.0	0.0	-6.5	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	2.0	1.0	2.0	0.048387096774193554	1.0	0.05405405405405406	0.0	0.0	0.0	1.0	0.0
231	familial hypertrophic cardiomyopathy (FHC)	0.6256510756841772	-0.8571428571428577	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.7142857142857153	0.0	0.0	-0.7857142857142865	0.04	0.04	0.0	0.04	0.041472392638036815	6.0	0.04134146341463415	0.3333333333333333	2.0	0.0	-1.571428571428573	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	12.0	0.04294478527607362	0.0	0.042682926829268296	0.0	0.0	0.0	0.0	0.0
227	the pathophysiological consequences of L-ferritin deficiency	0.13882909715338607	0.0	1.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.1111111111111111	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	8.0	0.04	0.375	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.125	0.0	1.0
303	Cenpa;CENPA;CENPA gene;Cenpa gene;CENP-A	0.9078515220568302	-1.5104166666666667	1.0	-15.0	0.04	0.043750000000000004	0.0	0.09375	1.0	-0.9375	0.9270833333333334	1.0	-15.666666666666668	0.0	0.0	-2.229166666666667	0.1	0.04	0.0	0.04	0.04515602453102453	1.4375	0.04687745483110762	0.78125	16.0	0.0	-16.0	1.0	0.3333333333333333	0.0	0.8125	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	5.0	1.0	23.0	0.10714285714285715	0.0	0.1111111111111111	1.0	0.0	0.0	0.0	0.0
108	zeta-associated protein	0.3075309072386389	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
198	DIIS2	0.6816077504306556	-3.6000000000000014	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.04672897196261683	0.04672897196261683	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04672897196261683	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	Which	0.004685332100067405	-11.090909090909092	1.0	-12.0	0.07692307692307693	0.07692307692307693	1.0	1.0	1.0	-12.0	1.0	0.0	-11.090909090909092	0.0	0.0	-7.0	0.07692307692307693	0.05555555555555555	0.0	0.07189542483660132	0.07189542483660132	1.0	0.05555555555555555	1.0	1.0	0.0	-7.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.07189542483660132	0.0	0.05555555555555555	1.0	0.0	0.0	0.0	0.0
206	treated with;Treated with	0.012772379387339324	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-2.166666666666667	0.04	0.04	0.0	0.04	0.04380952380952381	1.5	0.04419354838709678	0.75	2.0	0.0	-4.333333333333334	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.047619047619047616	0.0	0.048387096774193554	1.0	0.0	0.0	0.0	0.0
326	defects in the GBA gene	0.08720606243878175	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	5.0	0.04	0.6	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.2	0.0	0.0
37	lung cancer;Lung Cancer	0.08843544119223093	-2.333333333333333	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	-6.25	0.04	0.05194805194805195	0.0	0.04	0.044590163934426226	2.0	0.05337128624799858	0.0	2.0	0.0	-6.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04918032786885245	0.0	0.0547945205479452	0.0	0.0	0.0	0.0	0.0
46	69	0.6663079774610844	-1.8000000000000007	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04310344827586207	0.04310344827586207	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04310344827586207	0.0	0.04	0.0	0.0	0.0	0.0	0.0
68	The breakpoint on chromosome 11p15	0.26905681404095005	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
6	heroin users	0.692187927472083	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.04	0.04	2.0	0.047058823529411764	0.0	2.0	0.0	-3.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
67	EAE) mice	0.15016031096262084	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.75	0.04	0.06153846153846154	0.0	0.04	0.04	3.0	0.06153846153846154	0.3333333333333333	1.0	0.0	-8.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.06153846153846154	0.0	0.0	0.0	0.0	0.0
237	their ligand-induced degradation	0.2934143002038108	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04	0.04	5.0	0.043478260869565216	0.2	1.0	0.0	-2.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
144	the muscle-specific subunit	0.10699058841176723	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	salt-sensitive hypertension	0.4017262670882926	-3.75	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	0.0	0.04	0.04	0.0	0.047058823529411764	0.047058823529411764	4.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.047058823529411764	0.0	0.04	0.0	0.0	0.0	0.0	0.0
237	the cytoplasm by inhibitory IkappaB proteins	0.17600010830780824	-2.2857142857142847	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.25	1.0	-2.2857142857142847	0.0	0.0	-3.8571428571428577	0.04	0.0472972972972973	1.0	0.0440251572327044	0.0440251572327044	6.0	0.0472972972972973	0.16666666666666666	1.0	0.0	-3.8571428571428577	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.0440251572327044	0.0	0.0472972972972973	0.0	0.0	0.16666666666666666	0.0	0.0
306	*Number;number	0.04769814230468426	-3.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-17.0	0.04	0.125	0.0	0.04716981132075472	0.04716981132075472	1.0	0.125	0.0	1.0	0.0	-17.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04716981132075472	0.0	0.125	0.0	0.0	0.0	0.0	0.0
26	The data	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
231	a single R403Q missense allele	0.27440800858149755	-2.571428571428573	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	-2.571428571428573	1.0	1.0	-7.2857142857142865	0.04	0.056451612903225805	0.0	0.0445859872611465	0.0445859872611465	5.0	0.056451612903225805	0.0	1.0	1.0	-7.2857142857142865	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.0445859872611465	0.0	0.056451612903225805	0.0	1.0	0.0	0.0	1.0
39	the methyl donor	0.0044600459032874545	-5.0	1.0	-13.0	0.08333333333333333	0.08333333333333333	0.6666666666666666	0.6666666666666666	1.0	-13.0	1.0	0.0	-5.0	0.0	0.0	-13.5	0.08333333333333333	0.08695652173913043	1.0	0.05	0.05	3.0	0.08695652173913043	1.0	1.0	0.0	-13.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05	0.0	0.08695652173913043	1.0	0.0	0.3333333333333333	0.0	0.0
66	Echogenic bowel coexistent with other abnormalities	0.08097122598359083	-2.833333333333332	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.2	0.0	-2.833333333333332	0.0	0.0	-5.75	0.04	0.05194805194805195	0.0	0.045112781954887216	0.045112781954887216	6.0	0.05194805194805195	0.3333333333333333	1.0	0.0	-5.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.045112781954887216	0.0	0.05194805194805195	0.0	0.0	0.0	0.0	0.0
163	peak speed	0.14684823062145294	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
134	the eye	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
331	including;Including	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
78	1 (NF1) gene	0.3159133652729954	-2.25	1.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.5	1.0	-4.5	0.0	0.0	-9.5	0.04	0.053571428571428575	0.0	0.04	0.04439024390243902	5.0	0.06732625482625483	0.2	2.0	0.0	-12.666666666666668	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.04878048780487805	0.0	0.08108108108108109	0.0	0.0	0.0	0.0	0.0
129	the mammalian de novo DNA methyltransferases DNMT3A and DNMT3B	0.3340007256755536	-1.8888888888888893	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-1.8888888888888893	1.0	1.0	-2.1428571428571423	0.04	0.04375	0.0	0.04326923076923077	0.04326923076923077	9.0	0.04375	0.2222222222222222	1.0	1.0	-2.1428571428571423	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	9.0	0.04326923076923077	1.0	0.04375	0.0	1.0	0.0	1.0	1.0
247	84-98% during year 50	0.2886404539004225	-1.8333333333333321	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.043165467625899276	0.043165467625899276	6.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.043165467625899276	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
276	X-linked intellectual	0.27754247601577436	-4.125	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.125	0.0	0.0	0.0	0.04	0.04	0.0	0.04790419161676647	0.04790419161676647	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04790419161676647	0.0	0.04	0.0	0.0	0.0	0.0	0.0
101	combination with an HDAC inhibitor	0.38241455901066934	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.2	0.0	0.0
193	Sequencing of GATA1	0.30413320252407877	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.04	0.04	3.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
137	month;/month	0.09253473875839575	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.300000000000001	0.04	0.04566210045662101	0.0	0.04	0.04	1.0	0.04847207586933615	0.0	2.0	0.0	-5.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
254	Differential;differential	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
196	3;<3	0.5535533979137006	-1.4000000000000004	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	-8.5	0.04	0.05084745762711865	0.0	0.04	0.042522522522522525	0.5	0.06292372881355932	0.0	2.0	0.0	-11.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04504504504504505	0.0	0.075	0.0	0.0	0.0	0.0	0.0
79	significant morbidity and mortality	0.10329611321278091	-5.800000000000001	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-5.800000000000001	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.052083333333333336	0.052083333333333336	4.0	0.05405405405405406	0.0	1.0	0.0	-6.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.052083333333333336	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
14	k-nearest neighbour algorithm	0.38521385782495926	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-2.833333333333332	0.04	0.045112781954887216	0.0	0.04	0.04	5.0	0.045112781954887216	0.2	1.0	0.0	-2.833333333333332	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.045112781954887216	0.0	0.0	0.0	0.0	0.0
85	bad;Bad	0.11844307456772747	-2.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.043859649122807015	0.043859649122807015	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.043859649122807015	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	Integration;Integrated;integrated	0.13947587164708436	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.9375	0.04	0.04	0.0	0.04	0.04	1.0	0.04176470588235294	0.0	4.0	0.0	-3.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.04	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
16	known function	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	an increasing problem in countries	0.0814122563129206	-5.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.05	0.05	5.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.05	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
130	P. aeruginosa	0.8007535282219717	-3.5454545454545467	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.5454545454545467	0.0	0.0	-3.428571428571427	0.04	0.04635761589403973	0.0	0.046610169491525424	0.04661016949152543	2.0	0.04635761589403973	0.0	3.0	0.0	-3.428571428571427	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.046610169491525424	0.0	0.04635761589403973	0.0	0.0	0.0	0.0	0.0
217	cleavage sites	0.33464996046184486	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
80	11 of these individuals	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
148	the deiodinases	0.40008902616873204	-6.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-6.0	1.0	1.0	-5.0	0.04	0.05	0.0	0.05263157894736842	0.05263157894736842	2.0	0.05	0.0	1.0	1.0	-5.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	2.0	0.05263157894736842	0.0	0.05	0.0	1.0	0.0	0.0	1.0
236	ew strategies	0.3699386730264902	-4.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
160	breast cancer;-- Breast Cancer	0.08532525651825018	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
215	p53 levels	0.3390675980923809	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
78	region of chromosome;region of human chromosome;Region of chromosome	0.09132185893509626	-2.8333333333333335	0.0	0.0	0.04	0.04	0.6666666666666666	0.6944444444444443	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04546184738955824	3.3333333333333335	0.04	0.611111111111111	3.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	10.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
53	Activities;activities	0.08398521665073785	-4.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.048387096774193554	0.048387096774193554	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.048387096774193554	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
129	Down-Regulation;down-regulation	0.09442927886143973	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.7142857142857153	0.04	0.04487179487179487	0.0	0.04	0.04	3.0	0.04487179487179487	0.3333333333333333	2.0	0.0	-2.7142857142857153	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04487179487179487	0.0	0.0	0.0	0.0	0.0
207	The handwriting	0.10549951416075809	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
90	DOUBLE BLIND;double-blind	0.2567163064178416	-1.3333333333333333	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-2.8333333333333335	0.04	0.04	0.0	0.04	0.042539682539682544	3.0	0.04686868686868687	0.0	3.0	0.0	-8.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.047619047619047616	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
16	43]	0.6040032001905211	-1.6363636363636367	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.6363636363636367	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.042801556420233464	0.042801556420233464	2.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.042801556420233464	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
183	genetic disorders with autosomal dominant;autosomal dominant genetic disorders	0.03931369876541249	-3.75	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.047058823529411764	0.047058823529411764	5.0	0.05405405405405406	0.2	1.0	0.0	-6.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.047058823529411764	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
138	to;TO	0.105207643689521	-0.5769230769230766	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.1538461538461533	0.0	0.0	-0.9375	0.04	0.04	0.0	0.04	0.04096774193548387	1.0	0.04162162162162163	0.0	2.0	0.0	-1.875	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04193548387096774	0.0	0.043243243243243246	0.0	0.0	0.0	0.0	0.0
72	implicit protein-protein interactions in the cell cycle	0.012328383269373229	0.0	1.0	0.0	0.04	0.04	0.7777777777777778	0.7777777777777778	0.0	0.0	0.16666666666666666	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.5555555555555556	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
78	characterized;Characterized	0.08259581799486503	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.04819277108433735	0.04819277108433735	1.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04819277108433735	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
215	proliferative;Proliferative	0.6566710521881185	-5.916666666666667	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-9.25	0.0	0.0	-7.599999999999999	0.04	0.04587155963302752	0.0	0.04	0.0546993746993747	1.0	0.059218616519488454	0.0	3.0	0.0	-10.4	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.06349206349206349	0.0	0.0684931506849315	0.0	0.0	0.0	0.0	0.0
66	10th	0.614122746982315	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.04	0.04	1.0	0.046511627906976744	0.0	1.0	0.0	-3.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
149	sustained training (miR-21	0.29924008597507823	-4.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-4.0	1.0	1.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.047619047619047616	0.0	0.04	0.0	1.0	0.0	0.0	1.0
292	sodium salt	0.18172550543004778	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	1.0	0.0	1.0	0.3333333333333333	1.0	0.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
93	oppositional behavior	0.28046081069200013	-4.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	0.0	0.04	0.04	0.0	0.04878048780487805	0.04878048780487805	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04878048780487805	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	WS versus controls	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
255	facial weakness in more than 50%	0.21784819916122078	-1.571428571428573	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	1.0	-1.571428571428573	0.0	0.0	-1.625	0.04	0.0427807486631016	0.0	0.042682926829268296	0.042682926829268296	7.0	0.0427807486631016	0.0	1.0	0.0	-1.625	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.042682926829268296	0.0	0.0427807486631016	0.0	0.0	0.0	0.0	0.0
104	the output	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
180	the CD40 ligand molecule	0.3075309072386389	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	Web networks analysis algorithms	0.04628324329982474	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.04	0.04	4.0	0.06060606060606061	0.25	1.0	0.0	-8.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
196	3,5,3',5'-tetraiodothyroacetic acid (tetrac)	0.5089708160505398	-3.3999999999999986	0.0	0.0	0.04	0.04	0.07692307692307693	0.07692307692307693	0.0	0.0	0.0	1.0	-3.3999999999999986	1.0	1.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.046296296296296294	0.046296296296296294	13.0	0.054545454545454536	0.0	1.0	1.0	-6.666666666666666	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	13.0	0.046296296296296294	0.0	0.054545454545454536	0.0	1.0	0.0	0.0	1.0
318	The first oral inhibitor	0.061645578908033176	-1.8888888888888893	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-3.3846153846153832	0.04	0.046263345195729534	0.0	0.04326923076923077	0.04326923076923077	4.0	0.046263345195729534	0.25	1.0	0.0	-3.3846153846153832	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04326923076923077	0.0	0.046263345195729534	0.0	0.0	0.0	0.0	0.0
84	HT2A	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
132	KB -	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
143	lead;???lead	0.0805615830914637	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.043478260869565216	0.043478260869565216	1.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
144	coimmunoprecipitation;Co-Immunoprecipitation	0.617407047096964	-3.8000000000000007	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.04716981132075472	0.04716981132075472	1.0	0.05555555555555555	0.0	2.0	0.0	-7.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04716981132075472	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
249	these studies	0.09483669110025629	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.5	0.04	0.0425531914893617	0.0	0.04	0.04	2.0	0.0425531914893617	0.0	1.0	0.0	-1.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.0425531914893617	0.0	0.0	0.0	0.0	0.0
137	a scientific and mass media	0.07717977619458698	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.6999999999999993	0.04	0.04291845493562232	0.0	0.04	0.04	5.0	0.04291845493562232	0.0	1.0	0.0	-1.6999999999999993	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04291845493562232	0.0	0.0	0.0	0.0	0.0
56	single;Single	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
76	routine screening for depression	0.011739366705008662	-3.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.2	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	4.0	0.04	0.75	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
77	PLASMA;plasma	0.7578933955103357	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.9285714285714284	0.04	0.04	0.0	0.04	0.04	1.0	0.04446280991735537	0.0	4.0	0.0	-7.7142857142857135	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.05785123966942149	0.0	0.0	0.0	0.0	0.0
334	phosphorylated forms	0.20921882941915587	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04	0.04	2.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
140	identification;Identification	0.0943797958812142	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
249	lysine 27	0.8288212964097635	-0.6666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.0	0.0	0.0	-5.333333333333333	0.04	0.043478260869565216	0.0	0.04	0.04115942028985507	2.0	0.05157449762396094	0.0	3.0	0.0	-7.625	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.043478260869565216	0.0	0.05755395683453238	0.0	0.0	0.0	0.0	0.0
53	The ratio	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
331	important roles	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	fatal cerebral malaria	0.26250043207460855	-6.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-6.0	1.0	1.0	-4.0	0.04	0.047619047619047616	0.0	0.05263157894736842	0.05263157894736842	3.0	0.047619047619047616	0.3333333333333333	1.0	1.0	-4.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.05263157894736842	0.0	0.047619047619047616	0.0	1.0	0.0	0.0	1.0
124	correlated;Correlated	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
209	reveal;reveals	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
144	Active transport;active calcium transport	0.1187176919696614	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
101	Small-molecule histone methyltransferase inhibitors	0.16035427500595922	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.6	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.16666666666666666	0.0	1.0
46	transmembrane	0.5799157786571394	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.04	0.04	1.0	0.054545454545454536	0.0	1.0	0.0	-6.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
247	provided;Provided	0.08139733981397564	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.043478260869565216	0.043478260869565216	1.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
209	worm;WORM	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
293	numerous reports on the off-label use	0.0075836795742285695	-5.0	1.0	0.0	0.04	0.04	0.875	0.875	0.0	0.0	0.3333333333333333	0.0	-5.0	0.0	0.0	-7.0	0.04	0.05555555555555555	1.0	0.05	0.05	8.0	0.05555555555555555	0.625	1.0	0.0	-7.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.05	0.0	0.05555555555555555	0.0	0.0	0.125	0.0	0.0
83	CYP2C19*17	0.70659157795286	-3.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.75	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.047058823529411764	0.047058823529411764	1.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	1.0	0.047058823529411764	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
304	genetic inactivation or ibrutinib in the TCL1 mouse	0.1677242011298581	-2.0	0.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.0	1.0	-2.0	1.0	1.0	-2.2857142857142847	0.04	0.0440251572327044	0.0	0.043478260869565216	0.043478260869565216	8.0	0.0440251572327044	0.125	1.0	1.0	-2.2857142857142847	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.043478260869565216	0.0	0.0440251572327044	0.0	1.0	0.0	0.0	1.0
207	DSM-III-R diagnoses	0.5906925702979919	0.0	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.666666666666666	0.04	0.05769230769230768	0.0	0.04	0.04	6.0	0.05769230769230768	0.0	2.0	0.0	-7.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	12.0	0.04	0.0	0.05769230769230768	0.0	0.0	0.0	0.0	0.0
334	form;Form;forms	0.07906718059195925	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.375	0.04	0.04	0.0	0.04	0.04	1.0	0.04469135802469136	0.0	2.0	0.0	-4.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.04	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
48	EGFR (75	0.6386576352327225	-2.375	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.375	0.0	0.0	0.0	0.04	0.04	0.0	0.04419889502762431	0.04419889502762431	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04419889502762431	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	0.89 sensitivity	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
330	Jak1/2	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
69	The autosomal recessive polycystic kidney disease protein	0.269280268648595	-3.166666666666668	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	1.0	-3.166666666666668	1.0	1.0	-5.333333333333334	0.04	0.05084745762711865	1.0	0.04580152671755725	0.04580152671755725	7.0	0.05084745762711865	0.2857142857142857	1.0	1.0	-5.333333333333334	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	7.0	0.04580152671755725	1.0	0.05084745762711865	0.0	1.0	0.14285714285714285	1.0	1.0
205	healthy men;Health, Men's	0.24623414266233423	-2.0625	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04370786516853933	2.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
256	minor;Minor	0.10599342158052662	-6.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.053571428571428575	0.053571428571428575	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.053571428571428575	0.0	0.04	0.0	0.0	0.0	0.0	0.0
42	Glycoprotein;glycoprotein	0.7192683232253412	-2.6000000000000014	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.6000000000000014	1.0	1.0	0.0	0.04	0.04	0.0	0.044642857142857144	0.044642857142857144	1.0	0.04	0.0	1.0	1.0	0.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	1.0	0.044642857142857144	0.0	0.04	0.0	1.0	0.0	0.0	1.0
99	a partial expression of this myopathic disorder	0.06521127719289034	0.0	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-2.1428571428571423	0.04	0.04375	0.0	0.04	0.04	7.0	0.04375	0.14285714285714285	1.0	0.0	-2.1428571428571423	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04375	0.0	0.0	0.0	0.0	0.0
204	atypical;Atypical	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
62	azathioprine in a patient	0.07964978640412375	-4.222222222222221	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	-4.222222222222221	0.0	0.0	-9.25	0.04	0.06349206349206349	0.0	0.0481283422459893	0.0481283422459893	4.0	0.06349206349206349	0.25	1.0	0.0	-9.25	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.0481283422459893	0.0	0.06349206349206349	0.0	0.0	0.0	0.0	0.0
91	49.3%	0.6480714513906395	-1.571428571428573	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.042682926829268296	0.042682926829268296	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.042682926829268296	0.0	0.04	0.0	0.0	0.0	0.0	0.0
266	Components;components	0.08784720324583804	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-2.833333333333332	0.04	0.045112781954887216	0.0	0.04819277108433735	0.04819277108433735	1.0	0.045112781954887216	0.0	1.0	0.0	-2.833333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04819277108433735	0.0	0.045112781954887216	0.0	0.0	0.0	0.0	0.0
25	caused;cause	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
245	Cardiac Troponin I;cardiac troponin I	0.7139288668500362	-1.1785714285714297	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-1.571428571428573	0.0	0.0	-2.8500000000000005	0.04	0.04	0.0	0.04	0.04201219512195122	3.0	0.04537735849056604	0.3333333333333333	4.0	0.0	-3.8000000000000007	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	12.0	0.042682926829268296	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
40	Percentage;percentage	0.10847678871570474	-1.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04173913043478261	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
82	MPE in Chinese Han population	0.08272429375307237	-1.571428571428573	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.14285714285714285	1.0	-1.571428571428573	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	1.0	0.042682926829268296	0.042682926829268296	5.0	0.04716981132075472	0.2	1.0	0.0	-3.8000000000000007	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.042682926829268296	0.0	0.04716981132075472	0.0	0.0	0.2	0.0	0.0
93	3;<3	0.6881067895782358	-1.8333333333333333	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-1.8888888888888886	0.04	0.04	0.0	0.04	0.0432996632996633	0.6666666666666666	0.0439080459770115	0.0	3.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.045454545454545456	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
215	Loss of Cdk2	0.1698921060574518	-3.75	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-3.75	1.0	1.0	-5.4	0.04	0.0510204081632653	0.0	0.047058823529411764	0.047058823529411764	3.0	0.0510204081632653	0.0	1.0	1.0	-5.4	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.047058823529411764	0.0	0.0510204081632653	0.0	1.0	0.0	0.0	1.0
47	other information	0.1252572347225709	-6.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.053571428571428575	0.053571428571428575	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.053571428571428575	0.0	0.04	0.0	0.0	0.0	0.0	0.0
345	critical;Critical	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
106	Five;five	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
151	stretches;Stretches	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
194	List	0.003189111506543702	-17.0	1.0	0.0	0.04	0.04	1.0	1.0	1.0	0.0	1.0	0.0	-17.0	0.0	0.0	-13.5	0.04	0.08695652173913043	0.0	0.125	0.125	1.0	0.08695652173913043	1.0	1.0	0.0	-13.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.125	0.0	0.08695652173913043	1.0	0.0	0.0	0.0	0.0
126	discontinuation of abacavir	0.08616828055252898	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.5	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.6666666666666666	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
25	children with moderate ASD symptoms	0.08848691453375389	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
258	var)3-9	0.5914232087311193	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.04	0.04424778761061947	0.0	0.04	0.04	3.0	0.04424778761061947	0.0	1.0	0.0	-2.3999999999999986	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04424778761061947	0.0	0.0	0.0	0.0	0.0
169	the known GATA-1/FOG-1 and GATA-1/TAL-1 complexes	0.08194575648527978	0.0	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.36363636363636365	1.0	0.0	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.04	0.04	10.0	0.06666666666666667	0.1	1.0	0.0	-10.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.04	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
262	neurofibromas and angiofibromas	0.4065610553183088	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
44	our findings	0.09730331827754438	-3.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.04597701149425287	0.04597701149425287	2.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04597701149425287	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
177	APPEAR;appears	0.09006219608192875	-1.6666666666666679	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6666666666666679	0.0	0.0	0.0	0.04	0.04	0.0	0.04285714285714286	0.04285714285714286	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04285714285714286	0.0	0.04	0.0	0.0	0.0	0.0	0.0
315	the extracellular domain of Notch3 receptor (N3ECD)	0.41045341309109956	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.0	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	9.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
227	L-ferritin gene	0.37248998561286595	-2.6000000000000014	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.044642857142857144	0.044642857142857144	4.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.044642857142857144	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
14	Improved identification	0.08738872634494546	-2.125	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.125	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04371584699453552	0.04371584699453552	2.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04371584699453552	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
80	HCM disease	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
120	Pathway;pathway	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	the maintenance DNA methyltransferase Dnmt1;the maintenance DNA methyltransferase (DNMT) 1;the maintenance DNA methyltransferase (DNMT1)	0.43092497800188645	0.0	0.6666666666666666	0.0	0.04	0.04	0.375	0.4678571428571428	0.0	0.0	0.15	1.0	0.0	0.6666666666666666	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.666666666666667	0.04	0.6464285714285715	3.0	0.6666666666666666	0.0	1.0	1.0	0.0	1.0	0.0	0.6666666666666666	1.0	0.6666666666666666	0.8888888888888888	3.0	1.0	20.0	0.04	1.0	0.04	0.0	1.0	0.0	0.6666666666666666	1.0
307	alpha-synuclein antibodies	0.7470231925501633	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.25	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	2.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
231	the mouse model for FHC	0.07458175138361864	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.142857142857142	0.04	0.04794520547945205	0.0	0.04	0.04	5.0	0.04794520547945205	0.0	1.0	0.0	-4.142857142857142	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04794520547945205	0.0	0.0	0.0	0.0	0.0
175	the characteristics of Andersen syndrome	0.0028088315347964614	0.0	1.0	-9.5	0.06451612903225806	0.06451612903225806	0.8	0.8	1.0	-9.5	1.0	1.0	0.0	1.0	1.0	-10.0	0.06451612903225806	0.06666666666666667	1.0	0.04	0.04	5.0	0.06666666666666667	1.0	1.0	1.0	-10.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.06666666666666667	1.0	1.0	0.2	0.0	1.0
199	HP1	0.6516014816830702	-5.333333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.05084745762711865	0.05084745762711865	1.0	0.04878048780487805	0.0	1.0	0.0	-4.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.05084745762711865	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
90	mg;MG	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	1 aged 7;1-7	0.5539805818120941	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
216	from;From	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
103	Pattern;patterns;pattern;Patterns	0.18197550590782963	-1.2777777777777775	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-1.166666666666667	0.04	0.04	0.0	0.04	0.04218230963466058	1.0	0.042191276156793404	0.0	6.0	0.0	-4.2857142857142865	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	6.0	0.04326923076923077	0.0	0.04827586206896552	0.0	0.0	0.0	0.0	0.0
264	LEVOTHYROXINE;thyroxine;levothyroxine;Thyroxin	0.8154997934212992	-0.7083333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-1.5	1.0	1.0	-0.5333333333333332	0.04	0.04	0.0	0.04	0.04120154602424106	1.0	0.04097859327217126	0.0	6.0	1.0	-3.1999999999999993	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	4.0	1.0	6.0	0.0425531914893617	0.0	0.04587155963302752	0.0	1.0	0.0	0.0	1.0
16	a query against the other 23 (reference) genomes	0.18064291466790003	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.1	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
86	larger I(f) current densities	0.08848691453375389	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	v2;V2	0.6066186994119565	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
221	a new possibility to target	0.028380182314930405	-1.3333333333333321	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.2	0.0	-1.3333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.04225352112676056	0.04225352112676056	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04225352112676056	0.0	0.04	0.0	0.0	0.0	0.0	0.0
206	30 min;/30 min	0.6091244520208251	-4.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
208	Article;article	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
282	XAPC7;PSMA7	0.8482854836895888	-1.0999999999999996	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04192982456140351	1.0	0.04	0.0	2.0	0.0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	2.0	1.0	2.0	0.043859649122807015	1.0	0.04	0.0	0.0	0.0	1.0	0.0
70	0.7	0.8471672674973125	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	0.04	1.0	0.04	0.0	0.0	0.0	1.0	0.0
285	patients;Patients	0.3173074255262165	-1.5999999999999999	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-0.8571428571428571	0.04	0.04	0.0	0.04	0.043015664981588965	1.0	0.04155844155844156	0.0	7.0	0.0	-3.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	7.0	0.047619047619047616	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
73	1–6)	0.6058715606445525	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.04	0.04477611940298508	0.0	0.04	0.04	2.0	0.04477611940298508	0.0	1.0	0.0	-2.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04477611940298508	0.0	0.0	0.0	0.0	0.0
225	a child	0.12542147098915343	-3.333333333333333	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	-3.166666666666667	0.04	0.04	0.0	0.04	0.04727272727272727	2.0	0.04678571428571429	0.0	2.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.054545454545454536	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
52	homeostasis;Homeostasis	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
189	a familiar setting	0.11623532555108591	-6.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05263157894736842	0.05263157894736842	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05263157894736842	0.0	0.04	0.0	0.0	0.0	0.0	0.0
66	two anomalies	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
75	Model;model	0.08433728630968447	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.045454545454545456	0.045454545454545456	1.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
46	11 JAG1 mutation-negative probands	0.29165841153745936	-1.6000000000000014	1.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.16666666666666666	1.0	-1.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.042735042735042736	0.042735042735042736	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.042735042735042736	0.0	0.04	0.0	0.0	0.0	0.0	0.0
267	T';T	0.7053837780841078	-1.1428571428571435	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.7142857142857153	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.041963190184049086	0.6666666666666666	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04294478527607362	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	Cancer of the Colon;of the 12 gene Oncotype DX Colon Cancer	0.06256363093727844	-3.666666666666668	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.25	1.0	-3.666666666666668	1.0	1.0	0.0	0.04	0.04	0.0	0.046875	0.046875	8.0	0.04	0.25	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	8.0	0.046875	0.0	0.04	0.0	1.0	0.0	0.0	1.0
345	form;Form	0.06786708935270133	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.4	0.04	0.0510204081632653	0.0	0.04	0.04	1.0	0.0510204081632653	0.0	1.0	0.0	-5.4	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.0510204081632653	0.0	0.0	0.0	0.0	0.0
14	search;searching	0.08036544946468747	-2.125	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.125	0.0	0.0	-3.166666666666668	0.04	0.04580152671755725	0.0	0.04371584699453552	0.04371584699453552	1.0	0.04580152671755725	0.0	1.0	0.0	-3.166666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04371584699453552	0.0	0.04580152671755725	0.0	0.0	0.0	0.0	0.0
91	Some specificity	0.263502844553945	-2.2857142857142847	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.2857142857142847	0.0	0.0	0.0	0.04	0.04	0.0	0.0440251572327044	0.0440251572327044	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.0440251572327044	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	These results	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	Model;model	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
262	pulmonary lymphangioleiomyomatosis (LAM) in patients	0.29353947441920153	-4.75	0.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.0	1.0	-4.75	1.0	1.0	-12.333333333333332	0.04	0.07894736842105263	0.0	0.04938271604938271	0.04938271604938271	7.0	0.07894736842105263	0.0	1.0	1.0	-12.333333333333332	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04938271604938271	0.0	0.07894736842105263	0.0	1.0	0.0	0.0	1.0
48	used	0.09976090384562859	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.8571428571428577	0.04	0.043209876543209874	0.0	0.04	0.04	1.0	0.043209876543209874	0.0	1.0	0.0	-1.8571428571428577	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.043209876543209874	0.0	0.0	0.0	0.0	0.0
298	/12 hours;12 hours	0.27926268070552995	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	a biological process	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
235	children and adults	0.08649854234610437	-1.2222222222222214	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.2222222222222214	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.04205607476635514	0.04205607476635514	3.0	0.04587155963302752	0.0	1.0	0.0	-3.1999999999999993	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04205607476635514	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
49	Gene;gene	0.01818390220112388	-2.375	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-2.375	0.0	0.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.04419889502762431	0.04419889502762431	1.0	0.046296296296296294	1.0	1.0	0.0	-3.3999999999999986	1.0	1.0	1.0	1.0	1.0	0.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04419889502762431	1.0	0.046296296296296294	1.0	0.0	0.0	1.0	0.0
107	an optimal structure-sequence alignment in O(21C NM) time	0.07296620898613436	-1.5	1.0	0.0	0.04	0.04	0.3076923076923077	0.3076923076923077	0.0	0.0	0.16666666666666666	1.0	-1.5	0.0	0.0	-4.428571428571429	0.04	0.04861111111111112	1.0	0.0425531914893617	0.0425531914893617	13.0	0.04861111111111112	0.46153846153846156	1.0	0.0	-4.428571428571429	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	13.0	0.0425531914893617	0.0	0.04861111111111112	0.0	0.0	0.07692307692307693	0.0	0.0
31	systematic	0.6539152986658473	-8.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-8.5	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.06060606060606061	0.06060606060606061	1.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.06060606060606061	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
44	Attractive;attractive	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	the last therapy	0.026700136328971828	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.6666666666666666	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
150	Pathway;pathway	0.7538357242333268	-2.928571428571429	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.142857142857142	0.0	0.0	-3.2916666666666665	0.04	0.045454545454545456	0.0	0.04430379746835443	0.045355244367524875	1.0	0.04609090909090909	0.0	4.0	0.0	-4.166666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04794520547945205	0.0	0.047999999999999994	0.0	0.0	0.0	0.0	0.0
303	mouse;Mouse, NOS	0.10061331068723725	-4.166666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-4.083333333333333	0.04	0.044444444444444446	0.0	0.04477611940298508	0.04825012866700978	1.0	0.048084291187739464	0.0	2.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.051724137931034475	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
44	the afro-tropical belt	0.11141222362937633	-3.5	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-3.5	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.046511627906976744	0.046511627906976744	3.0	0.04918032786885245	0.3333333333333333	1.0	0.0	-4.666666666666666	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.046511627906976744	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
239	ACTA2	0.6455390126956184	-9.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-9.0	0.0	0.0	-8.25	0.04	0.05970149253731343	0.0	0.0625	0.0625	1.0	0.05970149253731343	0.0	1.0	0.0	-8.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.0625	0.0	0.05970149253731343	0.0	0.0	0.0	0.0	0.0
199	proximal region	0.2448181140445629	-2.833333333333332	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-2.666666666666668	0.04	0.04477611940298508	0.0	0.045112781954887216	0.045112781954887216	2.0	0.04477611940298508	0.0	1.0	0.0	-2.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.045112781954887216	0.0	0.04477611940298508	0.0	0.0	0.0	0.0	0.0
14	bioinformatics;Bio-Informatics	0.5482359547385697	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04	0.04	0.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
111	tRNASec	0.7442990038364407	-0.7619047619047615	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.2857142857142847	0.0	0.0	-1.777777777777778	0.04	0.04	0.0	0.04	0.04134171907756814	1.0	0.04361581920903954	0.0	3.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.0440251572327044	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
14	known 3D structures with respect	0.10466150681997585	-1.375	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.375	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.042328042328042326	0.042328042328042326	6.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.042328042328042326	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
158	simple;Simple	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
251	the aggregation	0.09731681661586292	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04	0.04	2.0	0.043478260869565216	0.5	1.0	0.0	-2.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
188	ID/ASD	0.25513903025327866	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
346	RNAPII	0.6742526532786811	-1.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-3.8571428571428568	0.04	0.04	0.0	0.04	0.04173913043478261	1.0	0.04892561983471075	0.0	2.0	0.0	-7.7142857142857135	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043478260869565216	0.0	0.05785123966942149	0.0	0.0	0.0	0.0	0.0
176	Aggregate;aggregate	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
80	muscle LIM protein	0.21502134065069065	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
127	the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene	0.7996736697625093	-2.5	0.0	0.0	0.04	0.04	0.4117647058823529	0.4117647058823529	0.0	0.0	0.0	1.0	-3.0	1.0	1.0	-1.833333333333334	0.04	0.04	0.0	0.043478260869565216	0.044466403162055336	17.0	0.043437500000000004	0.058823529411764705	2.0	1.0	-3.666666666666668	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	34.0	0.045454545454545456	1.0	0.046875	0.0	1.0	0.0	1.0	1.0
126	0.02) as	0.3735595348537071	-3.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
177	their mortality	0.1219973486267542	-5.555555555555555	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.555555555555555	0.0	0.0	0.0	0.04	0.04	0.0	0.051428571428571435	0.051428571428571435	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.051428571428571435	0.0	0.04	0.0	0.0	0.0	0.0	0.0
241	properties	0.10288288254215792	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-5.4	0.04	0.0510204081632653	0.0	0.05	0.05	1.0	0.0510204081632653	0.0	1.0	0.0	-5.4	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.05	0.0	0.0510204081632653	0.0	0.0	0.0	0.0	0.0
82	CBZ in Han Chinese	0.2132491732910392	-1.8571428571428577	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.8571428571428577	0.0	0.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.043209876543209874	0.043209876543209874	4.0	0.044642857142857144	0.0	1.0	0.0	-2.6000000000000014	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.043209876543209874	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
140	Analysis;analysis	0.012814217235885819	-3.5333333333333328	1.0	-17.666666666666668	0.04	0.059272727272727276	1.0	1.0	1.0	-3.5333333333333337	1.0	0.0	-16.444444444444443	0.0	0.0	-5.066666666666667	0.13636363636363635	0.04	0.0	0.04	0.0557878383298944	1.0	0.06804761904761905	1.0	5.0	0.0	-19.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.11688311688311688	0.0	0.16666666666666666	1.0	0.0	0.0	0.0	0.0
9	classes;Class	0.10477763557992177	-6.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05263157894736842	0.05263157894736842	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05263157894736842	0.0	0.04	0.0	0.0	0.0	0.0	0.0
169	List interaction partners	0.0032176315409645864	-7.6	1.0	0.0	0.04	0.04	1.0	1.0	1.0	0.0	1.0	0.0	-7.6	0.0	0.0	-16.5	0.04	0.11764705882352941	1.0	0.0574712643678161	0.0574712643678161	3.0	0.11764705882352941	1.0	2.0	0.0	-16.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.0574712643678161	0.0	0.11764705882352941	1.0	0.0	0.3333333333333333	0.0	0.0
7	the association between valproic acid and spina bifida	0.04722589277869818	0.0	1.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.25	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.25	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
125	three families	0.11836147927516229	-4.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.04918032786885245	0.04918032786885245	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04918032786885245	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	malignant disease;Malignant disease	0.18530285642228747	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.3076923076923066	0.04	0.04406779661016949	0.0	0.04	0.04	2.0	0.04406779661016949	0.0	1.0	0.0	-2.3076923076923066	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04406779661016949	0.0	0.0	0.0	0.0	0.0
140	yeast chromatin	0.6552111842891357	-3.555555555555557	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.555555555555557	0.0	0.0	-11.0	0.04	0.07142857142857142	0.0	0.04663212435233161	0.04663212435233161	2.0	0.07142857142857142	0.0	1.0	0.0	-11.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04663212435233161	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0
152	Alternative;alternative	0.08606857918774892	-3.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.046296296296296294	0.046296296296296294	1.0	0.044642857142857144	0.0	1.0	0.0	-2.6000000000000014	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046296296296296294	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
160	breast cancer patients	0.16655715489468143	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	feature;Feature	0.07711773492129331	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.04	0.044117647058823525	0.0	0.04	0.04	1.0	0.044117647058823525	0.0	1.0	0.0	-2.333333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.044117647058823525	0.0	0.0	0.0	0.0	0.0
339	prevents;PREVENT	0.08172817083669874	-3.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04615384615384615	0.04615384615384615	1.0	0.04716981132075472	0.0	1.0	0.0	-3.8000000000000007	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04615384615384615	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
16	predicted links between the proteins	0.027263547278438074	-1.0	1.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.14285714285714285	0.0	-1.0	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.041666666666666664	0.041666666666666664	5.0	0.0449438202247191	0.2	1.0	0.0	-2.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.041666666666666664	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
222	relapse and accumulation of disability	0.21859075224649543	-0.9444444444444446	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04163461538461538	5.0	0.04	0.2	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04326923076923077	0.0	0.04	0.0	0.0	0.0	0.0	0.0
245	Ca(2+) binding properties	0.38888048691632143	-2.0	0.0	0.0	0.04	0.04	0.14285714285714285	0.14285714285714285	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-5.4	0.04	0.0510204081632653	0.0	0.043478260869565216	0.043478260869565216	7.0	0.0510204081632653	0.0	1.0	0.0	-5.4	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.043478260869565216	0.0	0.0510204081632653	0.0	0.0	0.0	0.0	0.0
93	4 or 3) with minimal adverse effects	0.06113883571947049	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.16666666666666666	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	8.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.125	0.0	0.0
62	side effect;side-effect;Treatment Side Effects;Side Effect;side-effects in the treatment	0.21980510397058292	-1.3888888888888888	1.0	-11.5	0.04	0.04340740740740741	0.6666666666666666	0.8833333333333332	1.0	-1.15	1.0	0.0	-10.555555555555555	0.0	0.0	-2.6	0.07407407407407407	0.04	1.0	0.04	0.04353846153846154	2.7	0.047009026995044	1.0	10.0	0.0	-13.25	1.0	0.0	0.6	1.0	1.0	0.0	1.0	0.0	0.0	5.0	1.0	27.0	0.06923076923076923	0.0	0.0851063829787234	1.0	0.0	0.41666666666666663	0.0	0.0
9	a maximum	0.09153587619514349	-5.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-7.25	0.04	0.056338028169014086	0.0	0.051724137931034475	0.051724137931034475	2.0	0.056338028169014086	0.0	1.0	0.0	-7.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.051724137931034475	0.0	0.056338028169014086	0.0	0.0	0.0	0.0	0.0
88	factor nanog	0.051472778215414114	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
149	2;+2	0.6495096729360774	-4.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04938271604938271	0.04938271604938271	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04938271604938271	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	described	0.14864026338549263	-2.3125	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.375	0.0	0.0	0.0	0.04	0.04	0.0	0.04395604395604396	0.04407746949183414	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04419889502762431	0.0	0.04	0.0	0.0	0.0	0.0	0.0
243	cases;Cases	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
200	Commotio cordis;Commotio Cordis;commotio cordis	0.9561385594995754	-2.505882352941176	1.0	-5.666666666666666	0.04	0.04206896551724138	0.0	0.0	1.0	-1.0	1.0	0.0	-14.2	0.0	0.0	-1.1764705882352942	0.051724137931034475	0.04	0.0	0.04	0.04928104575163399	2.0	0.042566844919786094	1.0	17.0	0.0	-6.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	34.0	0.09259259259259259	0.0	0.054545454545454536	1.0	0.0	0.0	0.0	0.0
237	Inhibited;inhibited	0.5474664348801399	-4.7142857142857135	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.7142857142857135	0.0	0.0	-7.857142857142858	0.04	0.058333333333333334	0.0	0.04929577464788733	0.04929577464788733	1.0	0.058333333333333334	0.0	1.0	0.0	-7.857142857142858	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04929577464788733	0.0	0.058333333333333334	0.0	0.0	0.0	0.0	0.0
103	binding	0.09579857005895791	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.8571428571428577	0.04	0.04516129032258065	0.0	0.04	0.04	1.0	0.04516129032258065	0.0	1.0	0.0	-2.8571428571428577	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04516129032258065	0.0	0.0	0.0	0.0	0.0
77	Stalevo (Orion	0.5855787032046066	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-2.8571428571428577	0.04	0.04516129032258065	0.0	0.04	0.04	3.0	0.04516129032258065	0.3333333333333333	1.0	1.0	-2.8571428571428577	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.04	0.0	0.04516129032258065	0.0	1.0	0.0	0.0	1.0
329	Four	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
26	the behavioral problems of the non-verbal autistic patients	0.02591538832996011	0.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.125	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	cytotoxic drugs	0.33464996046184486	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	Autosomal Dominant Inherited Disorder;autosomal dominant inherited disorder	0.10175064184447732	-2.25	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	-2.25	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.04395604395604396	0.04395604395604396	4.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	4.0	0.04395604395604396	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
41	the reading	0.04844140450535912	-6.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05263157894736842	0.05263157894736842	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05263157894736842	0.0	0.04	0.0	0.0	0.0	0.0	0.0
265	the genetic heterogeneity	0.1408972522922567	-2.6000000000000014	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.044642857142857144	0.044642857142857144	3.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.044642857142857144	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
41	canonical MYST HAT catalytic domain	0.26905681404095005	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
242	the only predictive risk factor	0.03036962329116638	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	5.0	0.04	0.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.2	0.0	0.0
321	DATA SET;data set;dataset	0.5950123312198848	-1.9199999999999995	0.0	0.0	0.04	0.04	0.0	0.8	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	-4.8	0.04	0.04	0.0	0.04	0.043399616297380615	1.8	0.05476923076923077	0.0	5.0	0.0	-12.0	1.0	0.0	0.8	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	9.0	0.044642857142857144	0.0	0.07692307692307693	0.0	0.0	0.0	0.0	0.0
62	onset;Onset	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
256	familial;Familial	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
86	stress;Stress	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	Gleevec in CML treatment	0.04180994096112458	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.2222222222222222	0.0	0.0	0.0	0.0	-2.6153846153846168	0.04	0.044673539518900345	0.0	0.04	0.04	4.0	0.044673539518900345	0.5	1.0	0.0	-2.6153846153846168	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.044673539518900345	0.0	0.0	0.0	0.0	0.0
161	Mutations;mutations	0.5517000746854124	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.045454545454545456	0.045454545454545456	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
44	cases;case;Cases;Case	0.09318315845576952	-6.9375	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-10.75	0.0	0.0	-6.75	0.04	0.05	0.0	0.04819277108433735	0.05671254750575501	1.0	0.055154220779220775	0.0	4.0	0.0	-9.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	4.0	0.07017543859649122	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
109	attenuate;Attenuate	0.5239798901500994	-3.6000000000000014	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04672897196261683	0.04672897196261683	1.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04672897196261683	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
77	entacapone (OR-611)	0.4420236619688417	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-7.142857142857142	0.04	0.056	0.0	0.04	0.04	4.0	0.056	0.5	1.0	1.0	-7.142857142857142	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04	0.0	0.056	0.0	1.0	0.0	0.0	1.0
89	one;ONE	0.09346942263454319	-4.4	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-8.8	0.0	0.0	-2.75	0.04	0.04	0.0	0.04	0.0508641975308642	1.0	0.04564102564102564	0.0	2.0	0.0	-5.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.0617283950617284	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
7	neurotubular defects (NTDs)	0.5825924784454449	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
125	mutations in MTM1	0.15871913199778065	-6.333333333333334	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.5	0.0	-6.333333333333334	0.0	0.0	-9.75	0.04	0.06557377049180328	0.0	0.053571428571428575	0.053571428571428575	3.0	0.06557377049180328	0.0	1.0	0.0	-9.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.053571428571428575	0.0	0.06557377049180328	0.0	0.0	0.0	0.0	0.0
200	Fatal;fatal	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	the surface of the invasive merozoite	0.04543380983578637	-3.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.045454545454545456	0.045454545454545456	6.0	0.047619047619047616	0.5	1.0	0.0	-4.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.045454545454545456	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
216	expression;Expression	0.06901263893103253	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
44	Imidazole;imidazol	0.6066186994119565	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	a wide spectrum	0.10020684515669617	-1.6999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04291845493562232	0.04291845493562232	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04291845493562232	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	the aggregated controlled and uncontrolled patients	0.12345732182283334	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	cytosolic;cytosol;Cytosolic;Cytosol	0.5604009651461532	-10.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-18.0	0.0	0.0	-3.222222222222222	0.04	0.04	0.0	0.05263157894736842	0.08270676691729323	1.0	0.04840579710144927	0.0	3.0	0.0	-9.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.14285714285714285	0.0	0.06521739130434782	0.0	0.0	0.0	0.0	0.0
100	[29];29+;29	0.7295172595177106	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.333333333333333	0.04	0.04	0.0	0.04	0.04	1.5	0.04727272727272727	0.0	4.0	0.0	-6.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	6.0	0.04	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
124	77 cases	0.19922165536581327	-5.666666666666666	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-11.0	0.04	0.07142857142857142	0.0	0.051724137931034475	0.051724137931034475	2.0	0.07142857142857142	0.0	1.0	0.0	-11.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.051724137931034475	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0
195	DNA nucleases;Nucleases, DNA	0.016654508031630644	-14.0	1.0	-11.666666666666666	0.075	0.075	0.5	0.5	1.0	-11.666666666666666	1.0	1.0	-14.0	0.0	0.0	-9.0	0.075	0.0625	1.0	0.09090909090909091	0.09090909090909091	2.0	0.0625	1.0	1.0	0.0	-9.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	2.0	0.09090909090909091	0.0	0.0625	1.0	0.0	0.5	0.0	0.0
225	higher mean baseline calcium;high calcium	0.17925568444504877	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	two NRs	0.33894568817070503	-5.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-5.0	1.0	1.0	0.0	0.04	0.04	0.0	0.05	0.05	2.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.05	0.0	0.04	0.0	1.0	0.0	0.0	1.0
102	trough ratio for females	0.12055986058605486	-2.75	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0449438202247191	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
81	14	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	the risk	0.08248153890691289	-4.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04938271604938271	0.04938271604938271	2.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04938271604938271	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
190	synthesis;Synthesis	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	Stavru et al.	0.6171953679194666	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	chromosome;Chromosome	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	Finding;finding	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	Notch transmembrane receptor	0.4428526554640303	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
247	13.04 years	0.23135362065576898	-3.333333333333332	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04615384615384615	0.04615384615384615	2.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04615384615384615	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
319	Reported;Report;reported;report	0.05997763963770689	-1.416666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-2.75	0.04	0.04	0.0	0.04	0.04255639097744361	1.0	0.04564102564102564	0.0	2.0	0.0	-5.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.045112781954887216	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
274	Burden;burden	0.07819017530269318	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04	0.04	1.0	0.043478260869565216	0.0	1.0	0.0	-2.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
50	Model;model	0.1367242697966818	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.8666666666666671	0.04	0.04	0.0	0.04	0.04	1.0	0.04154761904761905	0.0	3.0	0.0	-2.6000000000000014	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
281	PROTEIN;protein	0.08216533862763503	-1.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.1999999999999993	0.0	0.0	-1.8333333333333321	0.04	0.043165467625899276	0.0	0.04201680672268907	0.04201680672268907	1.0	0.043165467625899276	0.0	1.0	0.0	-1.8333333333333321	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04201680672268907	0.0	0.043165467625899276	0.0	0.0	0.0	0.0	0.0
324	3 generations	0.17286278339857372	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.04	0.04	2.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
69	Diabetes;diabetes	0.2605422894552913	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	4.0	1.0	0.0	1.0	0.5	1.0	0.0	1.0	1.0	1.0	0.5	0.5	2.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
115	enriched	0.7083937739152718	-1.375	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.042471910112359554	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
144	the SERCA1	0.1599885323184273	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	1.0	0.0	1.0	0.5	0.0	1.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
307	the overall distribution pattern	0.052997877725278884	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
24	Pill;pill	0.20382763300206855	-1.2	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-1.8	0.04	0.04	0.0	0.04	0.04218332093561451	1.0	0.0445	0.0	5.0	0.0	-9.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04587155963302752	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
120	dephosphorylation;Dephosphorylation	0.6817986055309837	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
148	Co-expression of the deiodinases	0.3660198413175458	-6.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-6.0	1.0	1.0	-5.0	0.04	0.05	0.0	0.05263157894736842	0.05263157894736842	4.0	0.05	0.0	1.0	1.0	-5.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.05263157894736842	0.0	0.05	0.0	1.0	0.0	0.0	1.0
7	Fisher p value	0.3195316589152992	-3.5	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-5.75	0.04	0.05194805194805195	0.0	0.046511627906976744	0.046511627906976744	3.0	0.05194805194805195	0.0	1.0	0.0	-5.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.046511627906976744	0.0	0.05194805194805195	0.0	0.0	0.0	0.0	0.0
199	Specific;specific	0.20145722796976737	-4.966666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-6.3	0.04	0.044117647058823525	0.0	0.04580152671755725	0.05007999587418597	1.0	0.05428782602452027	0.0	5.0	0.0	-9.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.05263157894736842	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
326	the presence	0.03787686402666429	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.047619047619047616	0.047619047619047616	2.0	0.047619047619047616	0.5	1.0	0.0	-4.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047619047619047616	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
96	relapsed and refractory myeloma	0.48344251894492923	-2.75	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	-2.75	1.0	1.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0449438202247191	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.0449438202247191	0.0	0.04	0.0	1.0	0.0	0.0	1.0
96	these transcripts in their MM cells	0.12345732182283334	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
226	nonspecific symptoms	0.2896969004897457	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	2.0	0.04918032786885245	0.0	2.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
44	the malaria-infected donor	0.08699248725342917	-3.75	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.2	1.0	-3.75	1.0	1.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.047058823529411764	0.047058823529411764	5.0	0.048387096774193554	0.4	1.0	1.0	-4.333333333333334	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.047058823529411764	0.0	0.048387096774193554	0.0	1.0	0.0	0.0	1.0
125	Population;population	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
104	existing;Exist	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	Biochemical;biochemical	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
90	the findings of GEMINI	0.04250011404863432	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	5;>5	0.5056394874148484	-3.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-10.333333333333334	0.04	0.06818181818181819	0.0	0.04597701149425287	0.04597701149425287	1.0	0.06818181818181819	0.0	1.0	0.0	-10.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04597701149425287	0.0	0.06818181818181819	0.0	0.0	0.0	0.0	0.0
7	the clinical phenotype	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
82	northern China	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
337	a significant multivariable predictor	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
48	pancreatic carcinomas	0.48271456975848637	-3.125	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.125	0.0	0.0	-3.2857142857142847	0.04	0.046052631578947366	0.0	0.045714285714285714	0.045714285714285714	2.0	0.046052631578947366	0.5	2.0	0.0	-3.2857142857142847	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.045714285714285714	0.0	0.046052631578947366	0.0	0.0	0.0	0.0	0.0
212	inheritance of long QT Jervell	0.015411742674260312	-7.375	1.0	-8.571428571428571	0.0608695652173913	0.0608695652173913	0.4	0.4	1.0	-8.571428571428571	1.0	1.0	-7.375	0.0	0.0	-9.857142857142858	0.0608695652173913	0.0660377358490566	0.0	0.05673758865248227	0.05673758865248227	5.0	0.0660377358490566	1.0	1.0	0.0	-9.857142857142858	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.05673758865248227	0.0	0.0660377358490566	1.0	0.0	0.0	0.0	0.0
267	Alternative;alternative	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
330	a new option for RA treatment	0.038213829618688515	-1.6666666666666679	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-1.6666666666666679	0.0	0.0	-1.5	0.04	0.0425531914893617	0.0	0.04285714285714286	0.04285714285714286	6.0	0.0425531914893617	0.3333333333333333	1.0	0.0	-1.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04285714285714286	0.0	0.0425531914893617	0.0	0.0	0.0	0.0	0.0
28	positive;% Positive	0.10477763557992177	-6.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05263157894736842	0.05263157894736842	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05263157894736842	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	the daughter strands	0.0800372784612452	-3.2222222222222214	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.2222222222222214	0.0	0.0	-2.571428571428573	0.04	0.0445859872611465	0.0	0.04591836734693877	0.04591836734693877	3.0	0.0445859872611465	0.3333333333333333	1.0	0.0	-2.571428571428573	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04591836734693877	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
40	relationships;Relationships	0.06273486572701678	-3.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.04580152671755725	0.04580152671755725	1.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04580152671755725	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
77	ropinirole;ROPINIROLE	0.7940712023603235	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
181	16%)	0.6530968235031614	-2.1428571428571423	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.1428571428571423	0.0	0.0	0.0	0.04	0.04	0.0	0.04375	0.04375	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04375	0.0	0.04	0.0	0.0	0.0	0.0	0.0
334	Response;response;responses	0.22049957556429636	-0.7407407407407405	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.2222222222222214	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04130081300813008	1.0	0.04	0.0	6.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	6.0	0.04390243902439024	0.0	0.04	0.0	0.0	0.0	0.0	0.0
6	the primary cause	0.07562716531635386	-3.8888888888888893	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8888888888888893	0.0	0.0	-8.75	0.04	0.06153846153846154	0.0	0.04736842105263158	0.04736842105263158	3.0	0.06153846153846154	0.0	1.0	0.0	-8.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04736842105263158	0.0	0.06153846153846154	0.0	0.0	0.0	0.0	0.0
301	computer-based diagnosis	0.04628324329982474	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.04	0.04	4.0	0.06060606060606061	0.25	1.0	0.0	-8.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
86	function	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
213	the most common type	0.1115603911395928	-6.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.054545454545454536	0.054545454545454536	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.054545454545454536	0.0	0.04	0.0	0.0	0.0	0.0	0.0
274	Anti-Antibodies;anti-amyloid-beta monoclonal antibodies	0.05792259845470385	-9.545454545454545	1.0	0.0	0.04	0.04	0.0	0.0	1.0	0.0	1.0	1.0	-9.545454545454545	0.0	0.0	0.0	0.04	0.04	0.0	0.06470588235294117	0.06470588235294117	5.0	0.04	1.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	5.0	0.06470588235294117	0.0	0.04	1.0	0.0	0.0	0.0	0.0
68	several syndromic forms of craniosynostosis	0.07759101695086873	0.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.4	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
112	Types;types	0.08799582267933755	-5.499999999999999	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.666666666666666	0.0	0.0	-7.75	0.04	0.05263157894736842	0.0	0.04615384615384615	0.05192307692307692	1.0	0.05857385398981324	0.0	2.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.05769230769230768	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
246	Cytochrome 2C19 (CYP2C19	0.7252033656837734	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
321	resulting	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	relapsed/;relapsed,;Relapsed;relapsed	0.7978069392386973	-0.9583333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-1.0666666666666667	0.04	0.04	0.0	0.04	0.04173306094654409	1.3333333333333333	0.04229390681003584	0.0	6.0	0.0	-6.4	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	8.0	0.045454545454545456	0.0	0.05376344086021505	0.0	0.0	0.0	0.0	0.0
127	Mutations;mutation;mutations;Mutation	0.3153735781029832	-1.4487179487179487	1.0	0.0	0.04	0.04	0.0	0.0	1.0	0.0	1.0	0.0	-9.0	0.0	0.0	-0.6153846153846154	0.04	0.04	0.0	0.04	0.043146427912614964	1.0	0.04144796380090498	1.0	13.0	0.0	-8.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	13.0	0.0625	0.0	0.058823529411764705	1.0	0.0	0.0	0.0	0.0
213	drug-	0.10549951416075809	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	its chromodomain with the corresponding transcripts.T	0.10793650749311251	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
3	sequence;Sequence	0.0938301236000151	-2.833333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.045112781954887216	0.045112781954887216	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045112781954887216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
286	an ideal and highly sensitive platform	0.0747829060298053	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	genetic algorithms for gene prioritization	0.026611379378718894	0.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
267	SaO2);SaO2	0.6641753767711227	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.5	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
38	the main clinical features	0.052997877725278884	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
103	the maintenance DNA nucleotide methyltransferases	0.075021071550968	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-7.571428571428571	0.04	0.05737704918032786	0.0	0.04	0.04	5.0	0.05737704918032786	0.6	1.0	1.0	-7.571428571428571	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.04	0.0	0.05737704918032786	0.0	1.0	0.0	0.0	1.0
320	significant variations	0.09117171979811073	-2.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.043795620437956206	0.043795620437956206	2.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043795620437956206	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
11	biotechnological processes with the fungus Aspergillus terreus	0.08327710921451308	-3.333333333333332	1.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.14285714285714285	1.0	-3.333333333333332	1.0	1.0	-5.0	0.04	0.05	0.0	0.04615384615384615	0.04615384615384615	7.0	0.05	0.2857142857142857	1.0	1.0	-5.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04615384615384615	0.0	0.05	0.0	1.0	0.0	0.0	1.0
125	the early postnatal period	0.06637442787073183	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
163	Recommended;recommended	0.09773875734391521	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	the interaction	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
74	a paraneoplastic autoimmune disorder	0.23734505527195437	-3.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-3.0	0.0	0.0	-10.5	0.04	0.06896551724137931	0.0	0.045454545454545456	0.045454545454545456	4.0	0.06896551724137931	0.0	1.0	0.0	-10.5	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.045454545454545456	0.0	0.06896551724137931	0.0	0.0	0.0	0.0	0.0
290	Transabdominal ultrasonography with a high-frequency probe	0.23539794165218209	-3.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-3.0	1.0	1.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	8.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.045454545454545456	0.0	0.04	0.0	1.0	0.0	0.0	1.0
305	insulin receptor gene mutations	0.43522476564368545	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
160	Neutralizing Antibody;neutralizing monoclonal antibody	0.6189400846413728	-3.333333333333332	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.333333333333332	1.0	1.0	-2.571428571428573	0.04	0.0445859872611465	0.0	0.04615384615384615	0.04615384615384615	3.0	0.0445859872611465	0.0	1.0	1.0	-2.571428571428573	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	3.0	0.04615384615384615	0.0	0.0445859872611465	0.0	1.0	0.0	0.0	1.0
80	Two non-synonymous polymorphisms in exon 2 (rs17851524) and exon 5 (rs7687613)	0.12137595334978094	0.0	1.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	15.0	0.04	0.13333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	15.0	0.04	0.0	0.04	0.0	0.0	0.06666666666666667	0.0	0.0
60	another study	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
138	High;high	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	hydrophobicity and amphipathicity	0.45518818288803	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.04	0.04477611940298508	0.0	0.04	0.04	3.0	0.04477611940298508	0.0	2.0	0.0	-2.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04477611940298508	0.0	0.0	0.0	0.0	0.0
144	potential binding sites	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
187	the net outward K current	0.10699058841176723	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
344	the entire Xi chromosome	0.20392792817938546	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	fostamatinib-inhibitor of Syk and idelalisib (GS-1101	0.15860407474425556	0.0	1.0	0.0	0.04	0.04	0.2222222222222222	0.2222222222222222	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.1111111111111111	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
24	Greater;greater	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	general outperforms	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	Consolidation Therapy;consolidation therapy	0.3730670842758065	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
26	performed;Performed	0.6118172489320058	-2.428571428571427	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.428571428571427	0.0	0.0	0.0	0.04	0.04	0.0	0.04430379746835443	0.04430379746835443	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04430379746835443	0.0	0.04	0.0	0.0	0.0	0.0	0.0
66	Percentile;percentile	0.547989743176474	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.04	0.04	1.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
108	prognostic markers;Prognostic Marker	0.16986316741365498	-2.7142857142857153	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.7142857142857153	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.04487179487179487	0.04487179487179487	2.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04487179487179487	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
171	homozygous;Homozygous	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	ddm1 plants to NaCl	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	two hit" hypothesis	0.16182494360968655	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	precipitates;precipitate;PRECIPITATE	0.5951013416514221	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
185	17.5%	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	relevant;Relevant	0.08449918812814772	-5.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-5.0	0.04	0.05	0.0	0.051724137931034475	0.051724137931034475	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.051724137931034475	0.0	0.05	0.0	0.0	0.0	0.0	0.0
30	the most commonly reported pathological states	0.002894306904980798	-10.5	1.0	-11.8	0.07575757575757576	0.07575757575757576	0.8333333333333334	0.8333333333333334	1.0	-11.8	1.0	0.0	-10.5	0.0	0.0	-10.0	0.07575757575757576	0.06666666666666667	1.0	0.06896551724137931	0.06896551724137931	6.0	0.06666666666666667	1.0	1.0	0.0	-10.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.06896551724137931	0.0	0.06666666666666667	1.0	0.0	0.16666666666666666	0.0	0.0
222	high levels	0.08614834192668631	-1.3333333333333321	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.3333333333333321	0.0	0.0	-5.0	0.04	0.05	0.0	0.04225352112676056	0.04225352112676056	2.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04225352112676056	0.0	0.05	0.0	0.0	0.0	0.0	0.0
247	most;Most	0.07962725485541655	-2.833333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.045112781954887216	0.045112781954887216	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045112781954887216	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
225	cause	0.10557031470339825	-5.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.051724137931034475	0.051724137931034475	1.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.051724137931034475	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
7	A statistically significant association between Spina Bifida and Valproic Acid	0.05107500588290606	0.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.125	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.2	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
93	the reports	0.015329951910576421	-2.166666666666668	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.5	0.0	-2.166666666666668	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.043795620437956206	0.043795620437956206	2.0	0.048387096774193554	0.5	1.0	0.0	-4.333333333333334	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043795620437956206	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
180	splicing regulatory elements	0.11072801078596244	-2.833333333333332	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.045112781954887216	0.045112781954887216	3.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.045112781954887216	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
62	one developed hepatotoxicity	0.15549288186894164	-1.3333333333333321	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.3333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.04225352112676056	0.04225352112676056	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04225352112676056	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	a means	0.11438363182305503	-3.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.046875	0.046875	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.046875	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	expected properties	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
150	lysosomes through the LAMP-2A (Lysosome-associated membrane protein type 2A) receptor	0.11870322165415358	0.0	1.0	0.0	0.04	0.04	0.35714285714285715	0.35714285714285715	0.0	0.0	0.08333333333333333	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	14.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	14.0	0.04	0.0	0.04	0.0	0.0	0.07142857142857142	0.0	0.0
189	Delayed;delayed	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
230	CARDIOMYOPATHIES;CARDIOMYOPATHY;cardiomyopathy;cardiomyopathies	0.3452775451231854	-5.32	1.0	-18.428571428571427	0.04	0.06243478260869566	0.0	0.0	1.0	-3.6857142857142855	1.0	1.0	-15.2	1.0	1.0	-6.359999999999999	0.15217391304347827	0.04	0.0	0.04	0.057295609152752	1.0	0.06743233336891927	0.6	5.0	1.0	-18.2	1.0	0.5	0.0	0.6	0.0	1.0	1.0	0.5	0.5	4.0	1.0	5.0	0.1020408163265306	0.0	0.14705882352941177	1.0	1.0	0.0	0.0	1.0
78	the neurofibromatosis type;the Neurofibromatosis Type	0.06252143249683137	-6.5	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-8.25	0.0	0.0	-2.333333333333333	0.04	0.04	0.0	0.04938271604938271	0.054542104293348076	3.0	0.044590163934426226	0.6666666666666666	2.0	0.0	-4.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.05970149253731343	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
222	naive patients	0.04319222991893299	-2.1111111111111107	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.6666666666666666	0.0	-2.1111111111111107	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.043689320388349516	0.043689320388349516	2.0	0.045454545454545456	0.5	1.0	0.0	-3.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043689320388349516	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
154	cardiac ryanodine receptor;RYANODINE RECEPTOR, CARDIAC	0.5313074736200274	-1.8181818181818166	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.8181818181818166	0.0	0.0	-3.6000000000000014	0.04	0.04672897196261683	0.0	0.043137254901960784	0.043137254901960784	3.0	0.04672897196261683	0.0	1.0	0.0	-3.6000000000000014	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.043137254901960784	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
227	decreased inhibition function	0.14505802927659867	-5.800000000000001	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-5.800000000000001	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.052083333333333336	0.052083333333333336	3.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.052083333333333336	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
209	model system;Model System	0.029206448236891253	-1.2666666666666668	1.0	-18.0	0.04	0.06057142857142857	1.0	1.0	1.0	-3.6	1.0	0.0	-6.333333333333334	0.0	0.0	-5.2666666666666675	0.14285714285714285	0.04	0.0	0.04	0.04271428571428572	2.0	0.05986863711001642	1.0	5.0	0.0	-16.666666666666668	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	10.0	0.053571428571428575	0.0	0.12	1.0	0.0	0.0	0.0	0.0
334	a role in the DNA damage reponse	0.0012470559802011763	-7.777777777777779	1.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	1.0	0.0	1.0	0.0	-7.777777777777779	0.0	0.0	-14.25	0.04	0.09302325581395349	0.0	0.05806451612903226	0.05806451612903226	7.0	0.09302325581395349	1.0	1.0	0.0	-14.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.05806451612903226	0.0	0.09302325581395349	1.0	0.0	0.0	0.0	0.0
91	their primary anxiety disorder	0.03505393174035634	-1.7857142857142865	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.25	0.0	-1.8571428571428577	0.0	0.0	0.0	0.04	0.04	0.0	0.04294478527607362	0.04307733090964175	4.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.043209876543209874	0.0	0.04	0.0	0.0	0.0	0.0	0.0
71	responses stress;stress responses	0.07591977348906996	-2.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.043859649122807015	0.043859649122807015	2.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.043859649122807015	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
175	The patient	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
82	A case	0.03218922516849726	-2.428571428571427	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.428571428571427	0.0	0.0	-6.4	0.04	0.05376344086021505	0.0	0.04430379746835443	0.04430379746835443	2.0	0.05376344086021505	0.5	1.0	0.0	-6.4	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04430379746835443	0.0	0.05376344086021505	0.0	0.0	0.0	0.0	0.0
13	snapshot wide-angle x-ray	0.0998415402646795	0.0	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
163	Population;populations	0.0943797958812142	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
3	(m5C	0.31743187487387103	-6.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-11.714285714285714	0.04	0.07526881720430108	0.0	0.05263157894736842	0.05263157894736842	2.0	0.07526881720430108	0.5	1.0	0.0	-11.714285714285714	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05263157894736842	0.0	0.07526881720430108	0.0	0.0	0.0	0.0	0.0
127	lung cancers to gefitinib (Iressa), kinase inhibitor	0.10181274590841999	0.0	1.0	0.0	0.04	0.04	0.3	0.3	0.0	0.0	0.125	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
156	an autosomal recessive gene	0.35785133400450425	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.04	0.04	4.0	0.046511627906976744	0.0	1.0	0.0	-3.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
41	a mammalian model system	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
71	OXPHOS to glycolysis	0.10749485034526722	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
315	hereditary microangiopathy	0.731774248612654	-10.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-10.0	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.06666666666666667	0.06666666666666667	2.0	0.06060606060606061	0.0	1.0	0.0	-8.5	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.06666666666666667	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
109	Isoforms;isoforms	0.757997151446668	-3.6000000000000014	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.6000000000000014	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.04672897196261683	0.04672897196261683	1.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04672897196261683	1.0	0.06666666666666667	0.0	0.0	0.0	1.0	0.0
75	an autosomal recessive inherited disorder	0.3798078458534252	-4.75	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	-4.75	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.04938271604938271	0.04938271604938271	5.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04938271604938271	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
16	this study	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
343	PRY-SPRY domain;PRY/SPRY) domain	0.1792957120057686	0.0	1.0	0.0	0.04	0.04	0.2	0.225	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.5	0.04	0.45	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
271	MCT8 mutations	0.675353243834414	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
254	resident, fibroblast-like cells	0.19706491701828815	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
48	occurring;Occur	0.08151049270873185	-1.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	-2.2857142857142847	0.04	0.0440251572327044	0.0	0.0425531914893617	0.0425531914893617	1.0	0.0440251572327044	0.0	1.0	0.0	-2.2857142857142847	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0425531914893617	0.0	0.0440251572327044	0.0	0.0	0.0	0.0	0.0
213	Ward	0.09804222057814141	-3.333333333333333	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	-9.75	0.04	0.06557377049180328	0.0	0.04	0.04727272727272727	1.0	0.06557377049180328	1.0	2.0	0.0	-9.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.054545454545454536	0.0	0.06557377049180328	1.0	0.0	0.0	0.0	0.0
225	Revealed;revealed	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	YEMEN;Yemen	0.6301335793616649	-6.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.75	0.0	0.0	-8.333333333333334	0.04	0.06000000000000001	0.0	0.0547945205479452	0.0547945205479452	1.0	0.06000000000000001	0.0	2.0	0.0	-8.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.0547945205479452	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
68	clinical feature	0.08595384806607849	-5.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.05084745762711865	0.05084745762711865	2.0	0.06060606060606061	0.0	1.0	0.0	-8.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05084745762711865	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
15	techniques	0.1429533939537771	-0.39999999999999974	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.1999999999999993	0.0	0.0	-4.933333333333334	0.04	0.047619047619047616	0.0	0.04	0.04067226890756303	1.0	0.05006105006105006	0.0	3.0	0.0	-6.800000000000001	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04201680672268907	0.0	0.054945054945054944	0.0	0.0	0.0	0.0	0.0
195	Cell Disease, Sickle;Sickle cell disease	0.18207988110640164	-4.75	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04938271604938271	0.04938271604938271	3.0	0.051724137931034475	0.0	2.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04938271604938271	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
342	BRE2 homolog ASH2L	0.6378484812406789	-6.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.05263157894736842	0.05263157894736842	3.0	0.04587155963302752	0.0	1.0	0.0	-3.1999999999999993	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05263157894736842	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
44	tropical malaria	0.7296673797262491	-7.9	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	1.0	-12.0	1.0	1.0	-6.8	0.04	0.05263157894736842	0.0	0.04878048780487805	0.060293635903392005	2.0	0.055438596491228065	0.5	10.0	1.0	-10.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	20.0	0.07692307692307693	0.0	0.06666666666666667	0.0	1.0	0.0	0.0	1.0
144	Presence;presence	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
3	Formation of the complex	0.03398505574920441	-2.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-1.8571428571428577	0.04	0.043209876543209874	0.0	0.044117647058823525	0.044117647058823525	4.0	0.043209876543209874	0.5	1.0	0.0	-1.8571428571428577	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.044117647058823525	0.0	0.043209876543209874	0.0	0.0	0.0	0.0	0.0
124	tumor gene expression profiles	0.11125583418232861	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	1.0	0.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
189	thyrotropin-releasing hormone	0.20392792817938546	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	the cell-cycle regulator	0.06177025413297616	-1.75	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-1.75	0.0	0.0	0.0	0.04	0.04	0.0	0.043010752688172046	0.043010752688172046	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.043010752688172046	0.0	0.04	0.0	0.0	0.0	0.0	0.0
43	causes;cause	0.0761040329363386	-3.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.046511627906976744	0.046511627906976744	1.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046511627906976744	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
104	comparative analysis	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	reactivation of expression (26)	0.17412860300851346	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	Reside;resides	0.5789605572576604	-1.5555555555555571	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	-2.2857142857142847	0.04	0.0440251572327044	0.0	0.04265402843601896	0.04265402843601896	1.0	0.0440251572327044	0.0	1.0	0.0	-2.2857142857142847	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04265402843601896	0.0	0.0440251572327044	0.0	0.0	0.0	0.0	0.0
31	Reverse vaccinology and vaccines for serogroup B Neisseria meningitidis	0.10160812982368221	0.0	1.0	0.0	0.04	0.04	0.4444444444444444	0.4444444444444444	0.0	0.0	0.125	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.2222222222222222	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	0.91 specificity	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	the presence of a chromodomain	0.0514827321854772	-6.5	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-6.5	0.0	0.0	0.0	0.04	0.04	0.0	0.05405405405405406	0.05405405405405406	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.05405405405405406	0.0	0.04	0.0	0.0	0.0	0.0	0.0
345	selenoprotein genes	0.1482473861637048	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.25	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	2.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
170	described	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
218	Mass Measurement;mass-to-charge measurements	0.1750828146556497	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.16666666666666666	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	6.0	0.04	0.3333333333333333	3.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	18.0	0.04	0.0	0.04	0.0	0.0	0.16666666666666666	0.0	0.0
276	hypothyroidism;HYPOTHYROIDISM	0.7786266455789895	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
41	methylammonium	0.6725853747975624	-9.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-9.5	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.06451612903225806	0.06451612903225806	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.06451612903225806	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
237	binding	0.10614779450106017	-2.2857142857142847	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.2857142857142847	0.0	0.0	-2.2857142857142847	0.04	0.0440251572327044	0.0	0.0440251572327044	0.0440251572327044	1.0	0.0440251572327044	0.0	1.0	0.0	-2.2857142857142847	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.0440251572327044	0.0	0.0440251572327044	0.0	0.0	0.0	0.0	0.0
150	characteristics;Characteristics	0.09876652432094947	-6.428571428571429	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.428571428571429	0.0	0.0	-1.8333333333333321	0.04	0.043165467625899276	0.0	0.05384615384615385	0.05384615384615385	1.0	0.043165467625899276	0.0	1.0	0.0	-1.8333333333333321	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05384615384615385	0.0	0.043165467625899276	0.0	0.0	0.0	0.0	0.0
155	p.Y55C (c.164A	0.4123774837188738	-3.166666666666668	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.04580152671755725	0.04580152671755725	3.0	0.05128205128205128	0.3333333333333333	1.0	0.0	-5.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04580152671755725	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
269	PROSTATE;prostate	0.5424206546460479	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04	0.04	1.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
10	two-stage skin carcinogenesis	0.38143345677735296	-1.7142857142857153	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	-1.7142857142857153	1.0	1.0	0.0	0.04	0.04	0.0	0.04294478527607362	0.04294478527607362	5.0	0.04	0.0	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.04294478527607362	0.0	0.04	0.0	1.0	0.0	0.0	1.0
322	SET domain methyltransferases	0.03822931787773738	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	1.0	0.04	0.04	3.0	0.05	0.6666666666666666	1.0	0.0	-5.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.05	0.0	0.0	0.3333333333333333	0.0	0.0
4	3p	0.8781654314241669	-0.625	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.875	0.0	0.0	-0.7333333333333331	0.04	0.04	0.0	0.04	0.041081081081081085	1.0	0.04128654970760234	0.0	6.0	0.0	-2.1999999999999993	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.043243243243243246	0.0	0.043859649122807015	0.0	0.0	0.0	0.0	0.0
122	the main proportion of the genetic effect	0.08068270443508034	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
208	MES)-induced seizures	0.5825924784454449	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	therapeutic efficacy;Therapeutic Efficacy	0.5485196403767039	-2.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.044444444444444446	0.044444444444444446	2.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.044444444444444446	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
223	-moderate Alzheimer disease	0.03570378971746359	-1.09090909090909	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.5	1.0	-1.09090909090909	0.0	0.0	-4.2857142857142865	0.04	0.04827586206896552	0.0	0.04182509505703422	0.04182509505703422	4.0	0.04827586206896552	0.75	1.0	0.0	-4.2857142857142865	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04182509505703422	0.0	0.04827586206896552	0.0	0.0	0.0	0.0	0.0
130	CLOACA;cloacae	0.6085503851587286	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.571428571428572	0.04	0.04827586206896552	0.0	0.04	0.04	1.0	0.04896062606994375	0.0	2.0	0.0	-4.857142857142858	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04964539007092199	0.0	0.0	0.0	0.0	0.0
114	progenitor species	0.2325990452582905	-1.7142857142857153	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.7142857142857153	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.04294478527607362	0.04294478527607362	2.0	0.04587155963302752	0.0	1.0	0.0	-3.1999999999999993	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04294478527607362	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
310	global decrease	0.08126180589735557	-3.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.047058823529411764	0.047058823529411764	2.0	0.06060606060606061	0.0	1.0	0.0	-8.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047058823529411764	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
102	the clock component cryptochrome	0.08402103040534491	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
37	BD 16	0.7268739028102027	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
305	Mutations;mutation;mutations;Mutation	0.7800526575998575	-0.816326530612245	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.1428571428571423	0.0	0.0	-5.6190476190476195	0.04	0.046875	0.0	0.04	0.04141495168846907	1.0	0.05205931942952432	0.0	7.0	0.0	-9.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	7.0	0.04375	0.0	0.06382978723404256	0.0	0.0	0.0	0.0	0.0
44	1. Insect development regulators	0.12558460973598554	-17.5	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-17.5	0.0	0.0	-11.666666666666666	0.04	0.075	0.0	0.13333333333333333	0.13333333333333333	4.0	0.075	0.0	1.0	0.0	-11.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.13333333333333333	0.0	0.075	0.0	0.0	0.0	0.0	0.0
152	mild NIDDM, gliclazide, tolbutamide or acetohexamide	0.49705407514705807	-2.8000000000000007	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	-2.8000000000000007	1.0	1.0	-2.3999999999999986	0.04	0.04424778761061947	0.0	0.04504504504504505	0.04504504504504505	8.0	0.04424778761061947	0.0	1.0	1.0	-2.3999999999999986	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.04504504504504505	0.0	0.04424778761061947	0.0	1.0	0.0	0.0	1.0
291	Index	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	distribute;Distribute	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
301	Great;great	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
39	MTA	0.9116772232598684	-1.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.5	0.0	0.0	-1.5	0.04	0.04	0.0	0.04	0.042926829268292686	1.0	0.042926829268292686	0.0	6.0	0.0	-4.5	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04878048780487805	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
41	a signal for H3-lysine9	0.19706491701828815	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
312	promote;Promote	0.09273938256784227	-2.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	0.0	0.04	0.04	0.0	0.044444444444444446	0.044444444444444446	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.044444444444444446	0.0	0.04	0.0	0.0	0.0	0.0	0.0
323	craniofacial	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
330	The recent disclosure of the clinical efficacy	0.06283549102272032	-1.4444444444444429	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	0.0	-1.4444444444444429	0.0	0.0	-4.875	0.04	0.049689440993788817	0.0	0.04245283018867924	0.04245283018867924	7.0	0.049689440993788817	0.14285714285714285	1.0	0.0	-4.875	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04245283018867924	0.0	0.049689440993788817	0.0	0.0	0.0	0.0	0.0
200	3 cases of commotio cordis	0.06623553422447677	0.0	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.42857142857142855	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	software;Software	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
43	one;ONE	0.07672085388629256	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04878048780487805	0.04878048780487805	1.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04878048780487805	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
79	ten;TEN	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	Neural Networks (22,23)	0.5471566752889261	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	Thyrotropin level;thyrotrophin level;thyrotropin levels;TSH) levels;TSH level	0.44055595314033064	-2.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.4666666666666666	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-1.8000000000000003	0.04	0.04	0.0	0.04	0.044022246941045604	2.2	0.04354449152542373	0.0	5.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	5.0	1.0	11.0	0.051724137931034475	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
269	Affinity;affinity	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	core;Core	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
82	This allele	0.07609998904676137	-2.571428571428573	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.6666666666666666	1.0	-2.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.0445859872611465	0.0445859872611465	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.0445859872611465	0.0	0.04	0.0	0.0	0.0	0.0	0.0
144	Complete;complete	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
311	mental retardation (FRAXA and FRAXE), myotonic dystrophy	0.40906780896023665	-1.8333333333333321	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	-1.8333333333333321	1.0	1.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.043165467625899276	10.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.043165467625899276	0.0	0.04	0.0	1.0	0.0	0.0	1.0
230	lethal;Lethal	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
284	the cellular targets	0.0045201694379748665	-5.0	1.0	-13.5	0.08695652173913043	0.08695652173913043	0.6666666666666666	0.6666666666666666	1.0	-13.5	1.0	0.0	-5.0	0.0	0.0	-13.5	0.08695652173913043	0.08695652173913043	1.0	0.05	0.05	3.0	0.08695652173913043	1.0	1.0	0.0	-13.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05	0.0	0.08695652173913043	1.0	0.0	0.3333333333333333	0.0	0.0
286	equal;Equal	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
172	boy;Boy	0.08047004051092009	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
228	4-nitroanilines	0.6171953679194666	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
237	the nucleus	0.21863145328585623	-1.571428571428573	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.571428571428573	0.0	0.0	-4.857142857142858	0.04	0.04964539007092199	0.0	0.042682926829268296	0.042682926829268296	2.0	0.04964539007092199	0.0	1.0	0.0	-4.857142857142858	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.042682926829268296	0.0	0.04964539007092199	0.0	0.0	0.0	0.0	0.0
229	human disease gene;Human gene	0.024649331038662792	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.04	0.04	3.0	0.06666666666666667	0.3333333333333333	1.0	0.0	-10.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
11	ATCC 20542	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
286	and;And	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
243	Panel;panel	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	N-terminal domain	0.45610951138841727	-6.5	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-6.5	0.0	0.0	0.0	0.04	0.04	0.0	0.05405405405405406	0.05405405405405406	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.05405405405405406	0.0	0.04	0.0	0.0	0.0	0.0	0.0
198	First;first	0.1696136117654301	-3.2	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.800000000000001	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.046471052096052096	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.054945054945054944	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	Affected;affected	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	time and space	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	Vidaza��������) and 5-azadeoxycytidine (5-aza-CdR	0.1891862169435285	0.0	0.0	0.0	0.04	0.04	0.08333333333333333	0.08333333333333333	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-8.833333333333334	0.04	0.06185567010309279	0.0	0.04	0.04	12.0	0.06185567010309279	0.4166666666666667	1.0	1.0	-8.833333333333334	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	12.0	0.04	0.0	0.06185567010309279	0.0	1.0	0.0	0.0	1.0
200	the U.S. experience	0.11295539573058341	-3.8000000000000007	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-10.333333333333334	0.04	0.06818181818181819	0.0	0.04716981132075472	0.04716981132075472	3.0	0.06818181818181819	0.0	1.0	0.0	-10.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04716981132075472	0.0	0.06818181818181819	0.0	0.0	0.0	0.0	0.0
321	ligands;Ligand;Ligands;ligand	0.6678881606468173	-1.7999999999999994	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-6.4	0.04	0.04	0.0	0.04	0.04328312870798866	1.0	0.06899999999999999	0.0	5.0	0.0	-17.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	5.0	0.046296296296296294	0.0	0.125	0.0	0.0	0.0	0.0	0.0
121	HLA-B*57:01 detection	0.7014808686443303	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	the number of candidate genes	0.05411772315431602	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
253	this disease	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
327	H3 Lys36 trimethylation	0.4609072747901809	-4.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-4.0	0.04	0.047619047619047616	1.0	0.04878048780487805	0.04878048780487805	3.0	0.047619047619047616	0.3333333333333333	1.0	0.0	-4.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04878048780487805	0.0	0.047619047619047616	0.0	0.0	0.3333333333333333	0.0	0.0
176	other bacterial "histone	0.21722610567580708	-2.375	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.3333333333333333	1.0	-2.375	1.0	1.0	-7.199999999999999	0.04	0.056179775280898875	0.0	0.04419889502762431	0.04419889502762431	4.0	0.056179775280898875	0.25	1.0	1.0	-7.199999999999999	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04419889502762431	0.0	0.056179775280898875	0.0	1.0	0.0	0.0	1.0
103	possess	0.09453211184076174	-1.4444444444444429	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.4444444444444429	0.0	0.0	-4.428571428571429	0.04	0.04861111111111112	0.0	0.04245283018867924	0.04245283018867924	1.0	0.04861111111111112	0.0	1.0	0.0	-4.428571428571429	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04245283018867924	0.0	0.04861111111111112	0.0	0.0	0.0	0.0	0.0
235	children;Children	0.0777143416150908	-1.2222222222222214	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.2222222222222214	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.04205607476635514	0.04205607476635514	1.0	0.04587155963302752	0.0	1.0	0.0	-3.1999999999999993	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04205607476635514	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
26	I-E;i.e	0.6223281282727403	-1.7142857142857153	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.7142857142857153	0.0	0.0	0.0	0.04	0.04	0.0	0.04294478527607362	0.04294478527607362	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04294478527607362	0.0	0.04	0.0	0.0	0.0	0.0	0.0
137	the means of the uni- or bilateral jugular vein angioplasty	0.12378232383322979	-3.0	0.0	0.0	0.04	0.04	0.45454545454545453	0.45454545454545453	0.0	0.0	0.0	1.0	-3.0	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.045454545454545456	0.045454545454545456	11.0	0.04587155963302752	0.36363636363636365	1.0	0.0	-3.1999999999999993	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	11.0	0.045454545454545456	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
83	Platelet genotype;genotype to platelet	0.2902992189427334	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
152	already decreased insulin secretion	0.21789802225334434	-2.8000000000000007	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	-2.8000000000000007	0.04	0.04504504504504505	0.0	0.04504504504504505	0.04504504504504505	4.0	0.04504504504504505	0.0	1.0	0.0	-2.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04504504504504505	0.0	0.04504504504504505	0.0	0.0	0.0	0.0	0.0
317	reduced;Reduced	0.07788599199078707	-2.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.044642857142857144	0.044642857142857144	1.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.044642857142857144	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
127	the tyrosine kinase domain	0.36442445707985704	-0.9166666666666661	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.041582733812949635	4.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.043165467625899276	0.0	0.04	0.0	0.0	0.0	0.0	0.0
322	adjacent cysteine-rich regions to;Adjacent to	0.12453917887594247	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04	0.04	6.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
188	Frequently;frequently	0.06943623324127332	-7.833333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.833333333333334	0.0	0.0	-11.6	0.04	0.07462686567164178	0.0	0.05825242718446603	0.05825242718446603	1.0	0.07462686567164178	0.0	1.0	0.0	-11.6	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05825242718446603	0.0	0.07462686567164178	0.0	0.0	0.0	0.0	0.0
304	shows;shown;Show;showing	0.09242230203900968	-3.6875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.625	0.0	0.0	-7.535714285714286	0.04	0.04430379746835443	0.0	0.043243243243243246	0.0470362811089569	1.0	0.0587160673611889	0.0	4.0	0.0	-10.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	4.0	0.049079754601226995	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
303	centromere formation	0.31902286680780856	-2.666666666666668	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-2.666666666666668	1.0	1.0	0.0	0.04	0.04	0.0	0.04477611940298508	0.04477611940298508	2.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04477611940298508	0.0	0.04	0.0	1.0	0.0	0.0	1.0
102	circadian cycle	0.27851317418550164	-4.25	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
290	in;In	0.07505787584857218	-3.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.046511627906976744	0.046511627906976744	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046511627906976744	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
71	NF-κB inhibition	0.5846574733428169	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.045454545454545456	0.045454545454545456	4.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.045454545454545456	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
231	offspring;Offspring	0.6039131868305536	-1.571428571428573	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.042682926829268296	0.042682926829268296	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.042682926829268296	0.0	0.04	0.0	0.0	0.0	0.0	0.0
321	the basis	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
42	kDa	0.6331031144304925	-3.6000000000000014	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-4.800000000000001	0.04	0.04950495049504951	0.0	0.04672897196261683	0.04672897196261683	1.0	0.04950495049504951	0.0	1.0	0.0	-4.800000000000001	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04672897196261683	0.0	0.04950495049504951	0.0	0.0	0.0	0.0	0.0
320	the docking studies	0.0793662226340656	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
254	the pDC response	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	Combine;combining;combines;combine	0.0808453825898573	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.3333333333333335	0.04	0.04	0.0	0.04	0.04	1.0	0.04434854040191541	0.0	3.0	0.0	-3.833333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.04	0.0	0.047244094488188976	0.0	0.0	0.0	0.0	0.0
304	ibrutinib in relapsed chronic lymphocytic leukemia	0.27408316943402955	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.5	1.0	1.0	0.0	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	6.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
125	The responsible gene	0.01587037036201925	-6.333333333333334	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.3333333333333333	0.0	-6.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.053571428571428575	0.053571428571428575	3.0	0.04	0.6666666666666666	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.053571428571428575	0.0	0.04	0.0	0.0	0.0	0.0	0.0
178	cellular cap methylation and cell viability	0.19706491701828815	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	the ZDOCK program for rigid-body protein-protein docking	0.05455567418497514	0.0	0.0	0.0	0.04	0.04	0.5454545454545454	0.5454545454545454	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	11.0	0.04	0.45454545454545453	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	11.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
29	itaconic acid;Itaconic acid	0.9999936245376253	-1.670940170940171	1.0	-11.333333333333334	0.04	0.0425515947467167	0.5	0.5	1.0	-0.8717948717948718	1.0	1.0	-14.666666666666668	0.0	0.0	-1.3846153846153848	0.07317073170731708	0.04	0.0	0.04	0.04535556495846287	2.0	0.04399450297755383	1.0	39.0	0.0	-12.666666666666668	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	78.0	0.09677419354838711	0.0	0.08108108108108109	1.0	0.0	0.0	0.0	0.0
281	Mutations in the Parkin gene (PARK2)	0.19632083045131135	0.0	0.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-4.833333333333334	0.04	0.04958677685950414	0.0	0.04	0.04	8.0	0.04958677685950414	0.125	1.0	1.0	-4.833333333333334	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04958677685950414	0.0	1.0	0.0	0.0	1.0
344	20s proteasome inhibitor;inhibitor of the 20S proteasome	0.15234436933947787	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
305	postnatal growth retardation;Postnatal growth retardation	0.43671254323333936	-1.7142857142857153	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-1.7142857142857153	0.0	0.0	0.0	0.04	0.04	0.0	0.04294478527607362	0.04294478527607362	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04294478527607362	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	integrase structures	0.28760851283812056	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04	0.04	2.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
73	the alternating hydrophobicity	0.1750979055759304	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	3.0	0.04918032786885245	0.3333333333333333	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
150	associated with;Associated;Associated with;associated	0.6405072336490607	-2.483516483516484	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.428571428571429	0.0	0.0	-1.5897435897435896	0.04	0.04	0.0	0.04	0.04463293035136191	1.0769230769230769	0.042900331408351575	0.0	13.0	0.0	-5.166666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	14.0	0.04861111111111112	0.0	0.050420168067226885	0.0	0.0	0.0	0.0	0.0
77	contribution;Contribution	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	pharmacogenomic	0.6765491644525918	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
274	The first passive immunotherapy trial with bapineuzumab	0.11294469657828378	0.0	1.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.14285714285714285	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	7.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
297	oxygen consumption;Oxygen Consumption	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	Decreased;decreased	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
137	included	0.10758553629077393	-2.1111111111111107	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1111111111111107	0.0	0.0	-1.8000000000000007	0.04	0.04310344827586207	0.0	0.043689320388349516	0.043689320388349516	1.0	0.04310344827586207	0.0	1.0	0.0	-1.8000000000000007	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.043689320388349516	0.0	0.04310344827586207	0.0	0.0	0.0	0.0	0.0
329	simplified GB model	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
99	the nuclear membrane protein emerin	0.07955580535505852	-4.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-10.714285714285714	0.04	0.06999999999999999	0.0	0.047619047619047616	0.047619047619047616	5.0	0.06999999999999999	0.2	1.0	0.0	-10.714285714285714	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.047619047619047616	0.0	0.06999999999999999	0.0	0.0	0.0	0.0	0.0
74	diagnosis mediastinoscopy;diagnosis after mediastinoscopy	0.10116822635245053	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	3.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
100	the DNA (cytosine-5	0.01108262925504959	-5.0	1.0	-12.571428571428571	0.08045977011494253	0.08045977011494253	0.5	0.5	1.0	-12.571428571428571	1.0	1.0	-5.0	0.0	0.0	-11.833333333333334	0.08045977011494253	0.0759493670886076	0.0	0.05	0.05	4.0	0.0759493670886076	1.0	1.0	0.0	-11.833333333333334	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.05	0.0	0.0759493670886076	1.0	0.0	0.0	0.0	0.0
90	Effects of a polypill	0.04250011404863432	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	orthosteric binding site	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	quick	0.09589125431898023	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.04	0.045112781954887216	0.0	0.04	0.04	1.0	0.045112781954887216	0.0	1.0	0.0	-2.833333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.045112781954887216	0.0	0.0	0.0	0.0	0.0
131	PROTEIN;proteins;protein;PROTEINS	0.23671486852158288	-3.9250000000000003	1.0	-12.0	0.04	0.04764290755116443	0.0	0.5	1.0	-2.678571428571429	1.0	1.0	-17.4	1.0	1.0	-4.7	0.07692307692307693	0.04	0.0	0.04	0.05637731643677471	1.0	0.05146459027300149	0.5	8.0	1.0	-12.4	1.0	0.3333333333333333	0.5	0.5	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	4.0	1.0	8.0	0.13157894736842105	0.0	0.07936507936507936	1.0	1.0	0.0	0.0	1.0
215	evidence for Myc	0.13207775160317603	-5.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-7.4	0.04	0.056818181818181816	0.0	0.05	0.05	3.0	0.056818181818181816	0.0	1.0	0.0	-7.4	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05	0.0	0.056818181818181816	0.0	0.0	0.0	0.0	0.0
225	glucose;GLUCOSE	0.8754206800076672	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	5.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
280	Which	0.005059893764717775	-18.25	1.0	-16.6	0.11904761904761904	0.11904761904761904	1.0	1.0	1.0	-16.6	1.0	0.0	-18.25	0.0	0.0	-14.2	0.11904761904761904	0.09259259259259259	0.0	0.14814814814814814	0.14814814814814814	1.0	0.09259259259259259	1.0	1.0	0.0	-14.2	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.14814814814814814	0.0	0.09259259259259259	1.0	0.0	0.0	0.0	0.0
5	Support, NOS;support	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	Chuang et al.	0.5988449027329927	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.7142857142857153	0.04	0.04294478527607362	0.0	0.04	0.04	3.0	0.04294478527607362	0.0	1.0	0.0	-1.7142857142857153	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04294478527607362	0.0	0.0	0.0	0.0	0.0
61	specific interactions	0.08325341122728958	-2.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	-6.75	0.04	0.0547945205479452	0.0	0.04424778761061947	0.04424778761061947	2.0	0.0547945205479452	0.0	1.0	0.0	-6.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04424778761061947	0.0	0.0547945205479452	0.0	0.0	0.0	0.0	0.0
227	Human;human	0.0970575386009698	-3.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.046296296296296294	0.046296296296296294	1.0	0.05263157894736842	0.0	2.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.046296296296296294	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
316	due to;Due To	0.0674342893131309	-1.4545454545454533	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.4545454545454533	0.0	0.0	-5.199999999999999	0.04	0.050505050505050504	0.0	0.04247104247104247	0.04247104247104247	2.0	0.050505050505050504	0.0	1.0	0.0	-5.199999999999999	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04247104247104247	0.0	0.050505050505050504	0.0	0.0	0.0	0.0	0.0
13	the pulsed beam of a hard-X-	0.10219421050054414	-6.666666666666666	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.054545454545454536	0.054545454545454536	9.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.054545454545454536	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
300	transcriptional repressor of the HO-1 gene;transcriptional repressor gene	0.19667283738252517	-2.8571428571428577	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.225	1.0	-2.8571428571428577	0.0	0.0	0.0	0.04	0.04	0.0	0.04516129032258065	0.04516129032258065	6.0	0.04	0.5	2.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	12.0	0.04516129032258065	0.0	0.04	0.0	0.0	0.0	0.0	0.0
90	small;SMALL	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
57	steroids in an isolated form	0.15898064341854684	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	the main causative agent of malaria	0.04258803954879115	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.5	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	6.0	0.04	0.8333333333333334	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	12.0	0.04	0.0	0.04	0.0	1.0	0.16666666666666666	0.0	1.0
82	OXCARBAZEPINE;oxcarbazepine	0.5838104498829724	-1.571428571428573	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.571428571428573	0.0	0.0	-8.2	0.04	0.05952380952380952	0.0	0.042682926829268296	0.042682926829268296	1.0	0.05952380952380952	0.0	2.0	0.0	-8.2	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.042682926829268296	0.0	0.05952380952380952	0.0	0.0	0.0	0.0	0.0
115	Role;role;roles;Roles	0.09647932920713201	-0.9375	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-2.0833333333333335	0.04	0.04	0.0	0.04	0.04176470588235294	1.0	0.045000000000000005	0.0	4.0	0.0	-8.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	4.0	0.047058823529411764	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
127	resistant sublines	0.5665502748420537	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.043478260869565216	0.043478260869565216	2.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043478260869565216	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
331	aggressive cancer;aggressive breast cancers	0.02938218438138263	0.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	2.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
250	Major;major	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
299	(1)AM	0.2856949230194996	-5.166666666666666	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-5.166666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.050420168067226885	0.050420168067226885	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.050420168067226885	0.0	0.04	0.0	0.0	0.0	0.0	0.0
212	associated with;Associated with	0.07402265930747533	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.7142857142857153	0.04	0.04294478527607362	0.0	0.04	0.04	2.0	0.04294478527607362	0.0	1.0	0.0	-1.7142857142857153	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04294478527607362	0.0	0.0	0.0	0.0	0.0
302	expression;Expression	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
6	illicit;Illicit	0.600532333250611	-4.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-8.75	0.04	0.06153846153846154	0.0	0.047619047619047616	0.047619047619047616	1.0	0.06153846153846154	0.0	2.0	0.0	-8.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.047619047619047616	0.0	0.06153846153846154	0.0	0.0	0.0	0.0	0.0
41	their C-terminus	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
145	the potential of GSK-3 inhibitors	0.228462092954257	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
251	inhibition of aPKC	0.19336097056861962	-2.1111111111111107	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.1111111111111107	0.0	0.0	-3.7777777777777786	0.04	0.04712041884816754	0.0	0.043689320388349516	0.043689320388349516	3.0	0.04712041884816754	0.3333333333333333	1.0	0.0	-3.7777777777777786	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043689320388349516	0.0	0.04712041884816754	0.0	0.0	0.0	0.0	0.0
307	the study of Parkinson	0.04160612577473199	-3.1999999999999993	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.04587155963302752	0.04587155963302752	4.0	0.04597701149425287	0.5	1.0	0.0	-3.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04587155963302752	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
151	quantify;Quantify	0.5522721460345835	-2.2857142857142847	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.2857142857142847	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.0440251572327044	0.0440251572327044	1.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0440251572327044	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
79	Suspected;suspected	0.09566457187138204	-3.1333333333333333	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-9.4	0.0	0.0	-5.416666666666667	0.04	0.04	0.0	0.04	0.04803418803418804	1.0	0.05503861600247143	0.0	3.0	0.0	-12.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.06410256410256411	0.0	0.07692307692307693	0.0	0.0	0.0	0.0	0.0
119	roles;Roles	0.06620831473592713	-2.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.044117647058823525	0.044117647058823525	1.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.044117647058823525	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
14	bbtm proteins	0.5877845202168249	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.7777777777777773	0.04	0.04	0.0	0.04	0.04	2.0	0.041372549019607845	0.5	3.0	0.0	-2.333333333333332	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.044117647058823525	0.0	0.0	0.0	0.0	0.0
14	pseudo amino acid compositions	0.3012583000067758	-1.75	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-1.75	0.0	0.0	-2.166666666666668	0.04	0.043795620437956206	0.0	0.043010752688172046	0.043010752688172046	4.0	0.043795620437956206	0.0	1.0	0.0	-2.166666666666668	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.043010752688172046	0.0	0.043795620437956206	0.0	0.0	0.0	0.0	0.0
62	After-Treatment;after the onset of treatment	0.02182019951289562	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
126	the symptoms	0.0029063397590464004	-7.6	1.0	-17.333333333333332	0.13043478260869565	0.13043478260869565	1.0	1.0	1.0	-17.333333333333332	1.0	0.0	-7.6	0.0	0.0	-18.0	0.13043478260869565	0.14285714285714285	1.0	0.0574712643678161	0.0574712643678161	2.0	0.14285714285714285	1.0	1.0	0.0	-18.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.0574712643678161	0.0	0.14285714285714285	1.0	0.0	0.5	0.0	0.0
242	most;Most	0.10750096913076461	-1.7222222222222214	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.444444444444443	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04319587628865979	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04639175257731958	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	mt genome	0.7972314214056003	-15.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-15.0	0.0	0.0	-9.666666666666666	0.04	0.06521739130434782	0.0	0.1	0.1	2.0	0.06521739130434782	0.0	1.0	0.0	-9.666666666666666	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	2.0	0.1	0.0	0.06521739130434782	0.0	0.0	0.0	0.0	0.0
85	a subset of tauopathies	0.26782860435995465	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
296	heart failure patients	0.0027635545388488367	-10.727272727272727	1.0	-16.0	0.1111111111111111	0.1111111111111111	1.0	1.0	1.0	-16.0	1.0	0.0	-10.727272727272727	0.0	0.0	-17.666666666666668	0.1111111111111111	0.13636363636363635	0.0	0.07006369426751592	0.07006369426751592	3.0	0.13636363636363635	1.0	1.0	0.0	-17.666666666666668	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.07006369426751592	0.0	0.13636363636363635	1.0	0.0	0.0	0.0	0.0
140	This unequivocal identification	0.16414914424738913	-3.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	the major cause	0.0914532474299032	-5.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.051724137931034475	0.051724137931034475	3.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.051724137931034475	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
147	r;R-	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
43	Currently;currently	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
247	vaccine regimes	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	clinical;Clinical	0.10173282058684235	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04380952380952381	0.0	2.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
189	high prevalence of impaired glucose regulation	0.2340622223270213	-5.666666666666666	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.051724137931034475	0.051724137931034475	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.051724137931034475	0.0	0.04	0.0	0.0	0.0	0.0	0.0
297	Group A;a group	0.11707437433269925	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	essential interactions in a receptor	0.09716881556782975	-2.666666666666668	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.04477611940298508	0.04477611940298508	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04477611940298508	0.0	0.04	0.0	0.0	0.0	0.0	0.0
68	coronal craniosynostosis from 20 unrelated families	0.2239823304551331	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
221	cingulate gyrus;Cingulate Gyrus	0.7722440861748706	-0.9166666666666679	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-0.9166666666666679	1.0	1.0	0.0	0.04	0.04	0.0	0.041522491349480974	0.041522491349480974	2.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	2.0	1.0	2.0	0.041522491349480974	1.0	0.04	0.0	1.0	0.0	1.0	1.0
4	several endocrine organs	0.0594483178219732	-1.625	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-1.625	1.0	1.0	0.0	0.04	0.04	0.0	0.0427807486631016	0.0427807486631016	3.0	0.04	0.6666666666666666	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.0427807486631016	0.0	0.04	0.0	1.0	0.0	0.0	1.0
145	AF102B	0.7950597898506954	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
215	ARF/p53 tumor suppressor pathway	0.5139837652823258	0.0	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-2.1999999999999993	0.04	0.043859649122807015	0.0	0.04	0.04	6.0	0.043859649122807015	0.0	1.0	0.0	-2.1999999999999993	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.043859649122807015	0.0	0.0	0.0	0.0	0.0
85	involvement;involved;Involvement;Involved	0.06612206976874314	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.7857142857142865	0.04	0.04	0.0	0.04	0.04	1.0	0.04134146341463415	0.0	2.0	0.0	-1.571428571428573	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.04	0.0	0.042682926829268296	0.0	0.0	0.0	0.0	0.0
188	used as a model of;Use of	0.013747825750832353	-6.333333333333334	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.3333333333333333	0.0	-6.333333333333334	0.0	0.0	-13.8	0.04	0.08928571428571429	0.0	0.053571428571428575	0.053571428571428575	5.0	0.08928571428571429	0.2	1.0	0.0	-13.8	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.053571428571428575	0.0	0.08928571428571429	0.0	0.0	0.0	0.0	0.0
330	10 mg	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
189	common;Common	0.004138295022629688	-9.666666666666666	1.0	-18.0	0.04	0.09142857142857143	1.0	1.0	1.0	-9.0	1.0	0.0	-19.333333333333332	0.0	0.0	-13.5	0.14285714285714285	0.058823529411764705	0.0	0.04	0.10823529411764705	1.0	0.11274509803921567	1.0	2.0	0.0	-19.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.1764705882352941	0.0	0.16666666666666666	1.0	0.0	0.0	0.0	0.0
95	Nocturnin;nocturnin	0.8356772553054208	-1.1666666666666667	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-2.0	0.04	0.04	0.0	0.04	0.04217054263565891	1.0	0.04421052631578948	0.0	6.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.046511627906976744	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
307	a presynaptic terminal molecule	0.23588152540502058	-2.1999999999999993	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.043859649122807015	0.043859649122807015	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.043859649122807015	0.0	0.04	0.0	0.0	0.0	0.0	0.0
220	a candidate mutation	0.027304061087622646	-4.125	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.6666666666666666	0.0	-4.125	0.0	0.0	-8.333333333333334	0.04	0.06000000000000001	0.0	0.04790419161676647	0.04790419161676647	3.0	0.06000000000000001	0.3333333333333333	1.0	0.0	-8.333333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04790419161676647	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
256	Pro250Arg mutation in FGFR3;FGFR3, PRO250ARG	0.3932819752712341	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
139	BBB[21]	0.6000186669162998	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	its relevance	0.2027943129459911	-4.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.04878048780487805	0.04878048780487805	2.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04878048780487805	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
228	initial SAR	0.2643617943626036	-2.3999999999999986	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04424778761061947	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04424778761061947	0.0	0.04	0.0	0.0	0.0	0.0	0.0
187	QT	0.11717834148852534	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	1.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	1.0	0.0	0.0	0.0	0.0
156	the disease;The disease	0.01331445224595989	-1.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-2.5	0.0	0.0	-1.75	0.04	0.04	0.0	0.04	0.042222222222222223	2.0	0.043255813953488376	1.0	2.0	0.0	-3.5	1.0	0.3333333333333333	1.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	4.0	0.044444444444444446	0.0	0.046511627906976744	1.0	0.0	0.0	0.0	0.0
267	a vital sign telemonitor (VST)	0.2246359044634622	0.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	its calculated molecular mass	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	Per3;PER3	0.7840886777084175	-4.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.25	1.0	1.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	1.0	0.04	0.0	2.0	1.0	0.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	2.0	0.04819277108433735	0.0	0.04	0.0	1.0	0.0	0.0	1.0
329	protein-protein interface predictor (PS-HomPPI)	0.24056069176140132	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	bio;BIO	0.6066186994119565	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	Chromatin;chromatin	0.9146624082355713	-0.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-1.6666666666666679	0.0	0.0	-1.0714285714285718	0.04	0.04	0.0	0.04	0.04085177733065057	1.0	0.041879020778986926	0.0	6.0	0.0	-2.571428571428573	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	6.0	0.04285714285714286	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
298	induces;Induce;induced;Induced	0.5147871143298631	-1.3888888888888893	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.7777777777777786	0.0	0.0	-1.0625	0.04	0.04	0.0	0.04	0.042499999999999996	1.0	0.04185792349726776	0.0	2.0	0.0	-2.125	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.045	0.0	0.04371584699453552	0.0	0.0	0.0	0.0	0.0
41	Catalytic;catalytic	0.5303196997977364	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04	0.04	1.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
48	substitution;Substitution	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
147	adult livers	0.07564204404927363	0.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	direct;Direct	0.09520971290739387	-3.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	City	0.13788667872565594	-4.833333333333333	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04918032786885245	0.049590163934426224	1.0	0.047619047619047616	0.0	2.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
269	MC	0.5980375689166192	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
13	Detailed simulations	0.22899556082833078	-3.666666666666668	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.666666666666668	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.046875	0.046875	2.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.046875	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
152	HM (3.87	0.4055670094373542	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.04	0.04	3.0	0.046296296296296294	0.3333333333333333	1.0	0.0	-3.3999999999999986	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
49	occurring;Occur	0.09273938256784227	-2.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	0.0	0.04	0.04	0.0	0.044444444444444446	0.044444444444444446	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.044444444444444446	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	a clinically useful proof of principal	0.061981303024729775	-3.5	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.046511627906976744	0.046511627906976744	6.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.046511627906976744	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
144	the heart	0.003281176315533017	-14.4	1.0	-17.5	0.13333333333333333	0.13333333333333333	1.0	1.0	1.0	-17.5	1.0	0.0	-14.4	0.0	0.0	-19.5	0.13333333333333333	0.18181818181818182	0.0	0.09433962264150944	0.09433962264150944	2.0	0.18181818181818182	1.0	1.0	0.0	-19.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.09433962264150944	0.0	0.18181818181818182	1.0	0.0	0.0	0.0	0.0
25	aspects;Aspect	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
63	Start;starting	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
90	CTRI/2010/091/000250	0.7680584476903463	-3.8000000000000007	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.8000000000000007	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.04716981132075472	0.04716981132075472	3.0	0.06666666666666667	0.0	2.0	0.0	-10.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04716981132075472	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
290	quantify;Quantify	0.5153786367494709	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.04	0.04	1.0	0.054545454545454536	0.0	1.0	0.0	-6.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
343	the lattice of the retrovirus capsid	0.08934795376219641	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	6.0	0.04918032786885245	0.3333333333333333	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
66	euploid and aneuploid fetuses	0.2025151577214892	-5.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.25	0.0	-5.0	0.0	0.0	-8.75	0.04	0.06153846153846154	0.0	0.05	0.05	4.0	0.06153846153846154	0.0	1.0	0.0	-8.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.05	0.0	0.06153846153846154	0.0	0.0	0.0	0.0	0.0
333	A, Protein;a temperature-specific surface protein;a Tetrahymena thermophila surface protein	0.5528905141949427	-2.7142857142857144	0.0	0.0	0.04	0.04	0.6	0.7166666666666667	0.0	0.0	0.0	0.0	-5.428571428571429	0.0	0.0	-2.25	0.04	0.04	0.0	0.04	0.04554744525547445	5.5	0.04439024390243902	0.0	4.0	0.0	-4.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	22.0	0.05109489051094891	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
52	the brain	0.016723553997800653	-7.5	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.6666666666666666	0.0	-7.5	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.05714285714285714	0.05714285714285714	2.0	0.05128205128205128	0.5	1.0	0.0	-5.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05714285714285714	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
68	mother;Mother	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	within;Within	0.09837694886137573	-1.0555555555555554	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1111111111111107	0.0	0.0	-2.428571428571429	0.04	0.043478260869565216	0.0	0.04	0.04184466019417476	1.0	0.04431977559607293	0.0	2.0	0.0	-2.8571428571428577	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.043689320388349516	0.0	0.04516129032258065	0.0	0.0	0.0	0.0	0.0
226	2;+2	0.5191175287450296	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04	0.04	1.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
228	novel 8-substituted-4	0.2733452152211173	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
343	zebrafish genes	0.23975491413016814	-2.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-2.5	1.0	1.0	-8.666666666666666	0.04	0.06122448979591836	0.0	0.044444444444444446	0.044444444444444446	2.0	0.06122448979591836	0.0	1.0	1.0	-8.666666666666666	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.044444444444444446	0.0	0.06122448979591836	0.0	1.0	0.0	0.0	1.0
10	LYMPHOCYTOSIS;lymphocytosis	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
250	low free T3 index/reverse T3 ratio	0.1799521384931718	0.0	0.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	Some of these methods	0.030408942284881064	-3.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-7.166666666666666	0.04	0.05607476635514018	1.0	0.046511627906976744	0.046511627906976744	4.0	0.05607476635514018	0.5	1.0	0.0	-7.166666666666666	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.046511627906976744	0.0	0.05607476635514018	0.0	0.0	0.25	0.0	0.0
60	the known inner nuclear membrane protein	0.029751400968091906	0.0	1.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.16666666666666666	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
71	glutamine metabolism	0.8956979795776072	-2.4	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-2.85	0.04	0.04	0.0	0.04	0.044571428571428574	2.0	0.04562962962962963	0.0	5.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.047619047619047616	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
177	its 95% confidence	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
97	Recently;recently	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
345	Specified;Specific;specific;specified	0.08548920984683146	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04181818181818182	0.0	3.0	0.0	-3.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
11	Mold;mould	0.7612861464274979	-2.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.5	1.0	1.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.044444444444444446	0.044444444444444446	1.0	0.048387096774193554	0.0	1.0	1.0	-4.333333333333334	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	2.0	1.0	1.0	0.044444444444444446	1.0	0.048387096774193554	0.0	1.0	0.0	1.0	1.0
125	single strand conformation polymorphism	0.732397473935698	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	12.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	Widespread;widespread	0.10454364005385683	-3.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-4.500000000000001	0.04	0.046875	0.0	0.047058823529411764	0.047058823529411764	1.0	0.048861228813559324	0.0	2.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.047058823529411764	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
81	many clinical trials for off	0.002799319347044161	-9.88888888888889	1.0	-10.666666666666666	0.06976744186046512	0.06976744186046512	1.0	1.0	1.0	-10.666666666666666	1.0	0.0	-9.88888888888889	0.0	0.0	-12.0	0.06976744186046512	0.07692307692307693	1.0	0.0661764705882353	0.0661764705882353	5.0	0.07692307692307693	1.0	1.0	0.0	-12.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.0661764705882353	0.0	0.07692307692307693	1.0	0.0	0.2	0.0	0.0
101	Human;human	0.0774087620515286	-4.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04938271604938271	0.04938271604938271	1.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04938271604938271	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
241	injections	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
267	heart failure;FAILURE, HEART	0.3324485764881345	-1.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-2.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04173913043478261	2.0	0.04	0.0	4.0	1.0	0.0	1.0	0.5	1.0	0.0	1.0	1.0	1.0	0.5	0.5	2.0	1.0	8.0	0.043478260869565216	0.0	0.04	0.0	1.0	0.0	0.0	1.0
72	Human;human	0.07157431434064654	-3.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-7.4	0.04	0.056818181818181816	0.0	0.04716981132075472	0.04716981132075472	1.0	0.056818181818181816	0.0	1.0	0.0	-7.4	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04716981132075472	0.0	0.056818181818181816	0.0	0.0	0.0	0.0	0.0
329	Relative;relative	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
301	induced;Induced	0.5172483241542533	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.04	0.04	1.0	0.05405405405405406	0.0	1.0	0.0	-6.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
146	Osteoclast-specific inactivation	0.37611416909289724	-3.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.045454545454545456	0.045454545454545456	4.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.045454545454545456	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
279	involved;Involved	0.0032966498250109793	-18.2	1.0	-16.166666666666668	0.11320754716981131	0.11320754716981131	1.0	1.0	1.0	-16.166666666666668	1.0	0.0	-18.2	0.0	0.0	-17.666666666666668	0.11320754716981131	0.13636363636363635	0.0	0.14705882352941177	0.14705882352941177	1.0	0.13636363636363635	1.0	1.0	0.0	-17.666666666666668	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.14705882352941177	0.0	0.13636363636363635	1.0	0.0	0.0	0.0	0.0
37	VP-16;VP 16	0.9617772335688446	-3.666666666666667	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-5.0	0.0	0.0	-5.15	0.04	0.04	0.0	0.04	0.04719090428344791	1.0	0.05276722617516381	0.0	10.0	0.0	-10.25	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	10.0	0.05	0.0	0.06779661016949153	0.0	0.0	0.0	0.0	0.0
241	found;Found	0.09059200192985256	-1.8333333333333321	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.043165467625899276	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043165467625899276	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	DNA-binding activity	0.04250011404863432	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	short notice	0.08740021058552934	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.04	0.04	2.0	0.046511627906976744	0.0	1.0	0.0	-3.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
318	STI571 (imatinib mesylate	0.33826534395556374	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.23076923076923	0.04	0.042071197411003236	0.0	0.04	0.04	4.0	0.042071197411003236	0.5	1.0	0.0	-1.23076923076923	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.042071197411003236	0.0	0.0	0.0	0.0	0.0
151	%MinMax;MinMax	0.9465706130628461	-2.8571428571428577	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-2.888888888888889	0.04	0.04	0.0	0.04	0.04543194670058285	1.3333333333333333	0.04585070991409917	0.0	9.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	12.0	0.05	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
159	Status;status	0.07886920816155821	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04878048780487805	0.04878048780487805	1.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04878048780487805	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
233	udden death in young competitive athletes	0.010007966378502733	0.0	1.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.6666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
55	taurine and/or coenzyme Q10(CoQ10) on coxsackievirus B3 (CVB3	0.2603130566854493	0.0	0.0	0.0	0.04	0.04	0.21428571428571427	0.21428571428571427	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	14.0	0.05263157894736842	0.0	1.0	1.0	-6.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	14.0	0.04	0.0	0.05263157894736842	0.0	1.0	0.0	0.0	1.0
137	receiving;Receive	0.07394051950963014	-3.7777777777777786	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.7777777777777786	0.0	0.0	-6.6	0.04	0.05434782608695653	0.0	0.04712041884816754	0.04712041884816754	1.0	0.05434782608695653	0.0	1.0	0.0	-6.6	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04712041884816754	0.0	0.05434782608695653	0.0	0.0	0.0	0.0	0.0
88	Elevated	0.6309135963812361	-4.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04938271604938271	0.04938271604938271	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04938271604938271	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
44	blood;Blood	0.2539050807333312	-5.041666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-9.25	0.0	0.0	-2.3333333333333335	0.04	0.04	0.0	0.04	0.052025974844859074	1.0	0.044607805519169784	0.0	6.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.06349206349206349	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
270	central;CENTRAL	0.0963825651646273	-3.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.04672897196261683	0.04672897196261683	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04672897196261683	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	Structural insight	0.09046102551149687	-1.8888888888888893	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-4.2857142857142865	0.04	0.04827586206896552	0.0	0.04326923076923077	0.04326923076923077	2.0	0.04827586206896552	0.0	1.0	0.0	-4.2857142857142865	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04326923076923077	0.0	0.04827586206896552	0.0	0.0	0.0	0.0	0.0
41	a phosphorylation site	0.16168674699454558	-9.5	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-9.5	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.06451612903225806	0.06451612903225806	3.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.06451612903225806	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
102	erba;ERBA	0.7786266455789895	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
30	the family	0.033485039726558814	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.04	0.04	2.0	0.046296296296296294	0.5	1.0	0.0	-3.3999999999999986	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
339	ink4a locus;INK4a locus	0.7440944701293303	-1.583333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.166666666666668	0.0	0.0	-1.8000000000000007	0.04	0.04	0.0	0.04	0.042900763358778626	2.0	0.04336448598130842	0.0	2.0	0.0	-3.6000000000000014	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	4.0	0.04580152671755725	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
16	85%	0.6171953679194666	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
212	dominant Romano-Ward (RW) syndrome	0.17466484034837929	-2.375	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-2.375	0.0	0.0	-8.428571428571429	0.04	0.060344827586206906	0.0	0.04419889502762431	0.04419889502762431	8.0	0.060344827586206906	0.25	1.0	0.0	-8.428571428571429	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04419889502762431	0.0	0.060344827586206906	0.0	0.0	0.0	0.0	0.0
13	up new opportunities	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	mental retardation;MENTAL RETARDATION	0.27926268070552995	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
131	quantitative;Quantitative	0.5643156491182817	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.043478260869565216	0.043478260869565216	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
176	in vitro;In Vitro	0.11777543566786747	-1.875	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.875	0.0	0.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.043243243243243246	0.043243243243243246	2.0	0.044642857142857144	0.5	2.0	0.0	-2.6000000000000014	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.043243243243243246	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
245	) binding properties	0.31040353585539054	-2.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-5.4	0.04	0.0510204081632653	0.0	0.043478260869565216	0.043478260869565216	3.0	0.0510204081632653	0.0	1.0	0.0	-5.4	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043478260869565216	0.0	0.0510204081632653	0.0	0.0	0.0	0.0	0.0
320	the field of natural products	0.05411772315431602	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
159	treated;Treated	0.0829984369065127	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.047619047619047616	0.047619047619047616	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
112	a unique and important class of human genomic diversity	0.020745968951945404	0.0	1.0	0.0	0.04	0.04	0.8888888888888888	0.8888888888888888	0.0	0.0	0.2857142857142857	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	9.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.1111111111111111	0.0	0.0
195	a robust process	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
74	to;TO;To	0.12178350449217908	-1.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-4.1875	0.04	0.04	0.0	0.04	0.042388059701492536	1.0	0.05065372829417773	0.0	4.0	0.0	-11.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.04477611940298508	0.0	0.07272727272727272	0.0	0.0	0.0	0.0	0.0
129	used	0.09326511648759082	-1.8888888888888893	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-5.142857142857142	0.04	0.050359712230215826	0.0	0.04326923076923077	0.04326923076923077	1.0	0.050359712230215826	0.0	1.0	0.0	-5.142857142857142	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04326923076923077	0.0	0.050359712230215826	0.0	0.0	0.0	0.0	0.0
140	most PTMs	0.3390675980923809	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
137	Hemodynamics	0.6109243617108919	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04	0.04	1.0	0.04716981132075472	0.0	1.0	0.0	-3.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
75	the deficiency of galactocerebrosidase	0.23398223253108133	-3.75	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	1.0	-3.75	1.0	1.0	-4.25	0.04	0.04819277108433735	0.0	0.047058823529411764	0.047058823529411764	4.0	0.04819277108433735	0.0	1.0	1.0	-4.25	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	4.0	0.047058823529411764	1.0	0.04819277108433735	0.0	1.0	0.0	1.0	1.0
215	Capability;capable	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	the ubiquitin-proteasome pathway;The ubiquitin-proteasome pathway	0.6860135854173491	-3.5	0.0	0.0	0.04	0.04	0.2	0.20000000000000004	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.046540563791059496	5.0	0.04	0.20000000000000004	3.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	15.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
293	conclude	0.09108616487577634	-11.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-11.5	0.0	0.0	-14.0	0.04	0.09090909090909091	0.0	0.07407407407407407	0.07407407407407407	1.0	0.09090909090909091	0.0	1.0	0.0	-14.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.07407407407407407	0.0	0.09090909090909091	0.0	0.0	0.0	0.0	0.0
332	patients with recurrent B-cell non-Hodgkin lymphoma (B-NHL)	0.2805898618287035	-1.8333333333333321	0.0	0.0	0.04	0.04	0.23076923076923078	0.23076923076923078	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.043165467625899276	13.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	13.0	0.043165467625899276	0.0	0.04	0.0	0.0	0.0	0.0	0.0
140	reveal	0.11603873095218603	-2.2222222222222214	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.2222222222222214	0.0	0.0	0.0	0.04	0.04	0.0	0.04390243902439024	0.04390243902439024	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04390243902439024	0.0	0.04	0.0	0.0	0.0	0.0	0.0
217	Substrates;SUBSTRATE;substrates;substrate	0.9646155619699788	-2.0625	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-4.428571428571429	0.04	0.04	0.0	0.04	0.04384019447005242	1.0	0.04975087643048637	0.0	14.0	0.0	-8.857142857142858	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	14.0	0.04878048780487805	0.0	0.061946902654867256	0.0	0.0	0.0	0.0	0.0
48	mutation frequency;Mutation Frequency	0.21015891483686405	-1.375	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.375	0.0	0.0	0.0	0.04	0.04	0.0	0.042328042328042326	0.042328042328042326	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.042328042328042326	0.0	0.04	0.0	0.0	0.0	0.0	0.0
284	clinical management;Clinical Management	0.07157871935253304	-3.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-5.75	0.04	0.05194805194805195	0.0	0.047058823529411764	0.047058823529411764	2.0	0.05194805194805195	0.0	1.0	0.0	-5.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.047058823529411764	0.0	0.05194805194805195	0.0	0.0	0.0	0.0	0.0
211	Acidic;acidic	0.6470400686513061	-1.666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.1111111111111107	0.0	0.0	-1.8888888888888893	0.04	0.04	0.0	0.04205607476635514	0.04287269757735233	1.0	0.04356020942408377	0.0	2.0	0.0	-3.7777777777777786	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.043689320388349516	0.0	0.04712041884816754	0.0	0.0	0.0	0.0	0.0
88	a role for Nanog;A role for NANOG	0.04924118919607133	0.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.325	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
31	the identification of vaccine candidates	0.1159290568701375	-8.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-8.5	0.0	0.0	-9.0	0.04	0.0625	0.0	0.06060606060606061	0.06060606060606061	5.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.3333333333333333	1.0	0.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.06060606060606061	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
41	Mutant Proteins;mutant MRG15 proteins	0.7325659330056594	-9.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-9.5	1.0	1.0	-5.0	0.04	0.05	1.0	0.06451612903225806	0.06451612903225806	3.0	0.05	0.3333333333333333	2.0	1.0	-5.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	6.0	0.06451612903225806	0.0	0.05	0.0	1.0	0.3333333333333333	0.0	1.0
304	MoAbs or chemotherapy	0.3634319382639375	-1.875	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-1.875	0.0	0.0	0.0	0.04	0.04	0.0	0.043243243243243246	0.043243243243243246	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043243243243243246	0.0	0.04	0.0	0.0	0.0	0.0	0.0
180	deletion;Deletion	0.566410624396259	-1.8333333333333321	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.043165467625899276	0.043165467625899276	1.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043165467625899276	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
27	Opposite;opposite	0.0886630067295803	-1.2222222222222214	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.2222222222222214	0.0	0.0	0.0	0.04	0.04	0.0	0.04205607476635514	0.04205607476635514	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04205607476635514	0.0	0.04	0.0	0.0	0.0	0.0	0.0
29	amounts	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	nM;NM	0.5138825742971316	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.800000000000001	0.04	0.054945054945054944	0.0	0.04	0.04	1.0	0.054945054945054944	0.0	1.0	0.0	-6.800000000000001	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.054945054945054944	0.0	0.0	0.0	0.0	0.0
255	include	0.08103407497452206	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-11.25	0.04	0.07272727272727272	0.0	0.05	0.05	1.0	0.07272727272727272	0.0	1.0	0.0	-11.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.05	0.0	0.07272727272727272	0.0	0.0	0.0	0.0	0.0
17	5 (3.7	0.5848947341975446	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	3.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
7	rate;Rate	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	Late;late	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
147	35 weeks) absent D3 activity	0.29956052836315394	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
288	mitofilin/Fcj1 (formation of crista junction protein	0.11813124080413695	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.14285714285714285	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.2222222222222222	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
93	a higher risk of behavioural side-effects	0.026305271881250085	0.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.2857142857142857	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	8.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.125	0.0	0.0
93	no;NO	0.09166003846162973	-2.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.043795620437956206	0.043795620437956206	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043795620437956206	0.0	0.04	0.0	0.0	0.0	0.0	0.0
101	parasite;parasites;Parasites;PARASITE	0.5492681335836025	-1.3333333333333333	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-3.0	0.04	0.04	0.0	0.04	0.042539682539682544	1.0	0.04750000000000001	0.0	3.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.047619047619047616	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
221	deterioration;Deterioration	0.6032519955435052	-1.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	0.0	0.04	0.04	0.0	0.0425531914893617	0.0425531914893617	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0425531914893617	0.0	0.04	0.0	0.0	0.0	0.0	0.0
257	a major role in the cell	0.07748277985570153	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
326	from;From	0.09945790750549682	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	0.0	0.04	0.04	0.0	0.04878048780487805	0.04878048780487805	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04878048780487805	0.0	0.04	0.0	0.0	0.0	0.0	0.0
144	a direct MEF2 target gene	0.03568310284594695	0.0	1.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.5	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	5.0	0.04	0.2	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	1.0	0.2	0.0	1.0
265	homozygous;Homozygous	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
42	the novel expression	0.043233156510447825	-3.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-5.800000000000001	0.04	0.052083333333333336	0.0	0.046296296296296294	0.046296296296296294	3.0	0.052083333333333336	0.3333333333333333	1.0	0.0	-5.800000000000001	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.046296296296296294	0.0	0.052083333333333336	0.0	0.0	0.0	0.0	0.0
287	HDM2	0.6406061742371958	-3.8000000000000007	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04716981132075472	0.04716981132075472	1.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04716981132075472	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
345	consensus;Consensus	0.08890644022379408	-1.3000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.3000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04219409282700422	0.04219409282700422	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04219409282700422	0.0	0.04	0.0	0.0	0.0	0.0	0.0
346	factors;Factor;factor	0.04555882901254917	-3.03	1.0	-11.857142857142858	0.04	0.043608695652173915	1.0	1.0	1.0	-1.1857142857142857	1.0	0.0	-10.4	0.0	0.0	-1.4857142857142855	0.07608695652173914	0.04	1.0	0.04	0.0464730266372335	1.0	0.04357802729778794	1.0	10.0	0.0	-9.714285714285714	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	10.0	0.0684931506849315	0.0	0.06542056074766354	1.0	0.0	1.0	0.0	0.0
30	telomestatin (SOT-095)	0.7948157637171623	-1.6500000000000004	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-1.6999999999999993	0.0	0.0	-6.199999999999999	0.04	0.05319148936170213	0.0	0.042735042735042736	0.04282674883533252	4.0	0.05319148936170213	0.0	2.0	0.0	-6.199999999999999	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04291845493562232	0.0	0.05319148936170213	0.0	0.0	0.0	0.0	0.0
178	methyl cap formation	0.15570467386727818	-1.375	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.375	0.0	0.0	0.0	0.04	0.04	0.0	0.042328042328042326	0.042328042328042326	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.042328042328042326	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	our approaches	0.051793661601365934	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-16.0	0.04	0.1111111111111111	0.0	0.04	0.04	2.0	0.1111111111111111	0.0	1.0	0.0	-16.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.1111111111111111	0.0	0.0	0.0	0.0	0.0
77	Report;report	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
159	lacks;lack	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	BCR-ABL inhibitors;BCRABL- inhibitors	0.7242107250601193	-2.2222222222222214	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.5	-2.2222222222222214	0.5	0.0	-2.615384615384615	0.04	0.04421768707482993	0.0	0.04390243902439024	0.04390243902439024	3.5	0.04467828798185941	0.29166666666666663	2.0	0.5	-2.8461538461538467	1.0	0.6666666666666666	0.0	1.0	0.0	0.5	1.0	0.0	0.3333333333333333	2.0	1.0	7.0	0.04390243902439024	0.0	0.04513888888888889	0.0	1.0	0.0	0.0	1.0
245	PRE data	0.21033580006942168	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.6	0.04	0.04901960784313726	0.0	0.04	0.04	2.0	0.04901960784313726	0.0	1.0	0.0	-4.6	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04901960784313726	0.0	0.0	0.0	0.0	0.0
63	conjunction;Conjunction	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
323	d: pectus	0.5887662009866453	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04	0.04	2.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
14	the structural nature	0.03888351592295589	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04	0.04	3.0	0.05084745762711865	0.3333333333333333	1.0	0.0	-5.333333333333334	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
101	identification of histone lysine methyltransferase inhibitors	0.11231860983489873	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.2	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	6.0	0.04	0.5	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.16666666666666666	0.0	0.0
102	Typical;typical	0.09520971290739387	-3.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
242	appropriate device discharges	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
294	Recently;recently	0.1291737152742728	-5.666666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.05	0.05178571428571429	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.053571428571428575	0.0	0.04	0.0	0.0	0.0	0.0	0.0
337	displayed	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
183	point mutations in NF1 affected individuals	0.08097652235318023	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.2	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
205	MILD;mild	0.1454935354220319	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04585365853658537	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04878048780487805	0.0	0.04	0.0	0.0	0.0	0.0	0.0
137	the debate about CCSVI	0.022105159112686346	-1.7777777777777786	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.25	0.0	-1.7777777777777786	0.0	0.0	0.0	0.04	0.04	0.0	0.0430622009569378	0.0430622009569378	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.0430622009569378	0.0	0.04	0.0	0.0	0.0	0.0	0.0
276	two;Two	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
254	PMN;PMN)	0.7138342435708049	-6.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05263157894736842	0.05263157894736842	1.5	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.05263157894736842	0.0	0.04	0.0	0.0	0.0	0.0	0.0
10	with;With	0.006569821387325964	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	1.0	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	1.0	0.0	0.0	0.0	0.0
129	its high affinity for hemimethylated DNA	0.08514808737734124	-1.7777777777777786	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.0430622009569378	0.0430622009569378	6.0	0.043478260869565216	0.16666666666666666	1.0	0.0	-2.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.0430622009569378	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
122	0;0%	0.6066186994119565	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
226	fatigue, musculoskeletel and joint pains	0.12345732182283334	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
78	chromosomal losses or gains	0.10131249277664076	-3.5	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-5.0	0.04	0.05	0.0	0.046511627906976744	0.046511627906976744	4.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.046511627906976744	0.0	0.05	0.0	0.0	0.0	0.0	0.0
7	1.1-4.5) in the United States	0.12345732182283334	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	one gene	0.09547137627356765	-1.6999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6999999999999993	0.0	0.0	-2.8000000000000007	0.04	0.04504504504504505	0.0	0.04291845493562232	0.04291845493562232	2.0	0.04504504504504505	0.0	1.0	0.0	-2.8000000000000007	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04291845493562232	0.0	0.04504504504504505	0.0	0.0	0.0	0.0	0.0
318	molecular-targeted therapy;molecular-targeted therapies;Molecular Targeted Therapies;Molecular Targeted Therapy;molecularly targeted therapy	0.4583997123337248	-1.0444444444444443	0.0	0.0	0.04	0.04	0.5	0.5333333333333333	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-2.6	0.04	0.04248366013071895	0.0	0.04	0.041802519301097116	3.8	0.04472236597473789	0.2	5.0	0.0	-3.53846153846154	1.0	0.0	0.0	0.8	0.0	0.0	1.0	0.0	0.0	5.0	1.0	19.0	0.043478260869565216	0.0	0.04659498207885305	0.0	0.0	0.0	0.0	0.0
332	active rheumatoid arthritis (RA)	0.4270145456548483	0.0	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
205	tiredness;fatigue;FATIGUE;TIREDNESS	0.5014489744004214	-2.5	0.0	0.0	0.04	0.04	0.0	0.6666666666666666	0.0	0.0	0.0	1.0	-3.75	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04470588235294118	1.0	0.04	0.0	3.0	1.0	0.0	1.0	0.5	0.6666666666666666	0.0	1.0	1.0	1.0	0.5	0.5	4.0	1.0	3.0	0.047058823529411764	0.0	0.04	0.0	1.0	0.0	0.0	1.0
251	the transcriptional repression of E-cadherin	0.28198269796122194	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
340	early disease than LGE imaging	0.15898064341854684	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	ACTH	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	Ultrasound examination;ultrasound examination	0.3730670842758065	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
5	profiles;Profile	0.09520971290739387	-3.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	human forebrain	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	common;Common	0.07214662784210014	-9.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-9.75	0.0	0.0	-12.333333333333332	0.04	0.07894736842105263	0.0	0.06557377049180328	0.06557377049180328	1.0	0.07894736842105263	0.0	1.0	0.0	-12.333333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.06557377049180328	0.0	0.07894736842105263	0.0	0.0	0.0	0.0	0.0
206	Administration;treatment;treatment nos;administration	0.09695420070562244	-2.5833333333333335	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-2.5	0.04	0.04	0.0	0.04	0.04525466893039049	1.0	0.045	0.0	4.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	4.0	0.05263157894736842	0.0	0.05	0.0	0.0	0.0	0.0	0.0
276	only;Only	0.09233329774971386	-2.375	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.375	0.0	0.0	0.0	0.04	0.04	0.0	0.04419889502762431	0.04419889502762431	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04419889502762431	0.0	0.04	0.0	0.0	0.0	0.0	0.0
37	Support, NOS;supports	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
179	Cell Size;cell size	0.0993921282342399	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-3.3	0.04	0.04	0.0	0.04	0.04631578947368421	2.0	0.04717391304347826	0.0	2.0	0.0	-6.6	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.05263157894736842	0.0	0.05434782608695653	0.0	0.0	0.0	0.0	0.0
332	a first clinical trial with R788 (fostamatinib)	0.05251133885563105	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
254	synovial;Synovial	0.6846150258274698	-4.333333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-11.333333333333334	0.0	0.0	-5.666666666666666	0.04	0.04	0.0	0.04	0.05145057766367138	1.0	0.05713768115942029	0.0	4.0	0.0	-13.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.07317073170731708	0.0	0.08333333333333333	0.0	0.0	0.0	0.0	0.0
293	trazodone;Trazodone;TRAZODONE	0.8394929556962729	-2.8333333333333335	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-9.0	0.0	0.0	-2.5833333333333335	0.04	0.04	0.0	0.04	0.04688725490196078	1.0	0.04602693602693603	0.0	6.0	0.0	-8.5	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	3.0	1.0	6.0	0.0625	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
155	truncating mutations	0.3842585586614058	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
339	human telomerase reverse transcriptase activity	0.1909319629271677	-2.166666666666668	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	-2.166666666666668	1.0	1.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.043795620437956206	0.043795620437956206	5.0	0.044642857142857144	0.0	1.0	1.0	-2.6000000000000014	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.043795620437956206	0.0	0.044642857142857144	0.0	1.0	0.0	0.0	1.0
285	Prevalence	0.6765491644525918	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
319	hypothesis;Hypothesis	0.0631150644679098	-3.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.04615384615384615	0.04615384615384615	1.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04615384615384615	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
86	m mice	0.3390675980923809	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	refractory and relapsed multiple myeloma	0.35004466862373734	-3.25	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	-3.25	1.0	1.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	5.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04597701149425287	0.0	0.04	0.0	1.0	0.0	0.0	1.0
305	various;Various	0.06901263893103253	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
85	short	0.0891628622796912	-2.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	-6.857142857142858	0.04	0.05511811023622047	0.0	0.044642857142857144	0.044642857142857144	1.0	0.05511811023622047	0.0	1.0	0.0	-6.857142857142858	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.044642857142857144	0.0	0.05511811023622047	0.0	0.0	0.0	0.0	0.0
204	an arginine residue	0.675353243834414	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
334	Drug;drug	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
216	in situ uranium bioremediation	0.3037622969819622	0.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.525	0.0	0.0	0.0	0.0	-4.75	0.04	0.04	0.0	0.04	0.04	4.0	0.05020376175548589	0.75	4.0	0.0	-6.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	16.0	0.04	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
200	Twenty-two (28%) participants	0.2246359044634622	0.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	the result of a reciprocal translocation	0.10334572744811249	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.115384615384616	0.04	0.04744525547445255	0.0	0.04	0.04	6.0	0.04788619651046047	0.5	2.0	0.0	-4.307692307692308	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	12.0	0.04	0.0	0.0483271375464684	0.0	0.0	0.0	0.0	0.0
256	chromosome;Chromosome	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
279	the physiological role of LKB1	0.007342678009350002	-3.8000000000000007	1.0	-9.333333333333334	0.06382978723404256	0.06382978723404256	0.6	0.6	1.0	-9.333333333333334	1.0	1.0	-3.8000000000000007	0.0	0.0	-10.833333333333334	0.06382978723404256	0.07058823529411765	1.0	0.04716981132075472	0.04716981132075472	5.0	0.07058823529411765	1.0	1.0	0.0	-10.833333333333334	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04716981132075472	0.0	0.07058823529411765	1.0	0.0	0.2	0.0	0.0
96	Pre-clinical studies	0.2469515378072284	-3.75	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.047058823529411764	0.047058823529411764	2.0	0.04587155963302752	0.0	1.0	0.0	-3.1999999999999993	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047058823529411764	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
222	First;first	0.10777988320218135	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.222222222222221	0.0	0.0	-1.6999999999999993	0.04	0.04	0.0	0.0430622009569378	0.04559527160146355	1.0	0.043148148148148144	0.0	2.0	0.0	-3.3999999999999986	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.0481283422459893	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
100	provide;provided;Provided;Provide	0.06577621736754351	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.9166666666666661	0.04	0.04	0.0	0.04	0.04	1.0	0.041582733812949635	0.0	2.0	0.0	-1.8333333333333321	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.04	0.0	0.043165467625899276	0.0	0.0	0.0	0.0	0.0
189	marker;Marker	0.07268327190128901	-6.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.054545454545454536	0.054545454545454536	1.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.054545454545454536	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
204	denaturing gradient gel electrophoresis;DGGE;Denaturing Gradient Gel Electrophoresis	0.8174936873463107	-3.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-2.75	0.04	0.04	0.0	0.04597701149425287	0.04651791751183232	2.5	0.04564102564102564	0.0	4.0	0.0	-5.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	10.0	0.047058823529411764	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
10	Alternative activation of the MEK/ERK pathway and NF-κB	0.1729616100857676	-2.8571428571428577	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.8571428571428577	0.0	0.0	0.0	0.04	0.04	0.0	0.04516129032258065	0.04516129032258065	12.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	12.0	0.04516129032258065	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	disease biomarkers in epilepsy	0.12472071038975358	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	4.0	0.04	0.5	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.25	0.0	1.0
329	electrostatic	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
262	Progressive;progressive	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
214	to;TO	0.06943718229211664	-6.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.75	0.0	0.0	-10.666666666666666	0.04	0.06976744186046512	0.0	0.0547945205479452	0.0547945205479452	1.0	0.06976744186046512	0.0	1.0	0.0	-10.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0547945205479452	0.0	0.06976744186046512	0.0	0.0	0.0	0.0	0.0
330	Well;well	0.10629848669759494	-3.2222222222222214	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-3.5625	0.04	0.042328042328042326	0.0	0.04568527918781726	0.04591956267083171	1.0	0.04713804713804714	0.0	2.0	0.0	-5.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04615384615384615	0.0	0.05194805194805195	0.0	0.0	0.0	0.0	0.0
78	anticipation of clinical use	0.06637442787073183	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
334	a double-strand break (DSB)	0.1904371556388782	0.0	0.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.125	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
254	Functional;functional	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	'component' proteins [1,3].The accuracy of this approach	0.15194358560027726	0.0	0.0	0.0	0.04	0.04	0.35714285714285715	0.35714285714285715	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	14.0	0.04	0.07142857142857142	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	14.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	central nervous system	0.07592821667365907	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-8.75	0.04	0.06153846153846154	0.0	0.047619047619047616	0.047619047619047616	3.0	0.06153846153846154	0.0	1.0	0.0	-8.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.047619047619047616	0.0	0.06153846153846154	0.0	0.0	0.0	0.0	0.0
338	. DCE extent	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
128	counterparts to the eukaryotic siRNA mechanism	0.06201559754339281	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.09090909090909	0.04	0.04182509505703422	0.0	0.04	0.04	6.0	0.04182509505703422	0.3333333333333333	1.0	0.0	-1.09090909090909	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04182509505703422	0.0	0.0	0.0	0.0	0.0
152	used	0.13390824951636288	-3.3000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-3.3000000000000007	0.04	0.04504504504504505	0.0	0.045454545454545456	0.04609175870858114	1.0	0.04610742818289988	0.0	2.0	0.0	-3.8000000000000007	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04672897196261683	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
10	the MEK/ERK pathway and NF-κB by TPL2	0.149494731266084	0.0	1.0	0.0	0.04	0.04	0.2727272727272727	0.2727272727272727	0.0	0.0	0.2857142857142857	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	11.0	0.04	0.18181818181818182	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	11.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
88	establish;establishes	0.07816942110256009	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04819277108433735	0.04819277108433735	1.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04819277108433735	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
193	a unique combination	0.08800126528842174	-3.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-5.0	0.04	0.05	0.0	0.04716981132075472	0.04716981132075472	3.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04716981132075472	0.0	0.05	0.0	0.0	0.0	0.0	0.0
243	Novel Mutation;novel mutations	0.13113953826408678	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	2.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.5	0.0	0.0
189	Thyroid Hormone;thyroid hormone;thyroid hormones;THYROID HORMONES	0.3969154876297852	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.125	4.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.25	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	4.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	pipeline	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
57	Isolated;isolated	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
91	65	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	portion;Portion	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
21	analyses;Analysis;analysis	0.07248642951064561	-2.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-3.75	0.04	0.04	0.0	0.04	0.045	1.0	0.04857142857142857	0.0	2.0	0.0	-7.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.05	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
67	abnormalities;Abnormalities	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
219	fumarate reductase inhibitor	0.6261043960236499	-5.333333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.05084745762711865	0.05084745762711865	3.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05084745762711865	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
192	restless leg syndrome (RLS	0.05069310368003688	-5.666666666666666	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.75	0.0	-5.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.051724137931034475	0.051724137931034475	5.0	0.04	0.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.051724137931034475	0.0	0.04	0.0	0.0	0.0	0.0	0.0
304	MACROGLOBULINEMIA, WALDENSTROM;Waldenstrom macroglobulinemia	0.8314281821237175	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	Functional;functional	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	sequence homology-based;Sequence Homology, Base	0.17925568444504877	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
316	loss or gain	0.09018054202732614	-2.6363636363636367	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.6363636363636367	0.0	0.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.044715447154471545	0.044715447154471545	3.0	0.046296296296296294	0.0	1.0	0.0	-3.3999999999999986	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.044715447154471545	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
62	this class of drugs	0.04467101376168318	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	4.0	0.047619047619047616	0.25	1.0	0.0	-4.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
94	drug for the treatment;drug treatment	0.045170256728743	-2.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04424778761061947	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04424778761061947	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	bound	0.10347035404028014	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-8.5	0.0	0.0	-6.0	0.04	0.05084745762711865	0.0	0.04	0.05030303030303031	1.0	0.05269645608628659	0.0	2.0	0.0	-6.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.06060606060606061	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
47	a training set	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	Xenopus laevis	0.8988862710341744	-0.6799999999999997	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.6999999999999993	0.0	0.0	-1.2799999999999998	0.04	0.04	0.0	0.04	0.04116738197424893	2.0	0.04234862385321101	0.0	5.0	0.0	-3.1999999999999993	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04291845493562232	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
330	health status;Health Status	0.10696658918272292	-0.9444444444444446	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-2.0625	0.04	0.04	0.0	0.04	0.04163461538461538	2.0	0.04395209580838323	0.0	2.0	0.0	-4.125	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04326923076923077	0.0	0.04790419161676647	0.0	0.0	0.0	0.0	0.0
180	an early primate genome	0.32916223319829147	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04	0.04	4.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
202	young athletes	0.013540982108224624	-9.0	1.0	-16.666666666666668	0.04	0.06666666666666667	1.0	1.0	1.0	-5.555555555555556	1.0	0.0	-12.75	0.0	0.0	-12.222222222222223	0.12	0.0625	0.0	0.05555555555555555	0.0645087455952647	2.0	0.088510101010101	1.0	3.0	0.0	-17.666666666666668	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.08163265306122448	0.0	0.13636363636363635	1.0	0.0	0.0	0.0	0.0
2	TSH receptor (TSHR)	0.12675817268944842	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.5	1.0	0.0	1.0	1.0	-2.0	0.04	0.043478260869565216	0.0	0.04	0.04	5.0	0.043478260869565216	0.8	1.0	1.0	-2.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.043478260869565216	0.0	1.0	0.0	0.0	1.0
139	NEP) gene therapy	0.18188242935920979	-3.875	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.875	0.0	0.0	-8.75	0.04	0.06153846153846154	0.0	0.047337278106508875	0.047337278106508875	4.0	0.06153846153846154	0.0	1.0	0.0	-8.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.047337278106508875	0.0	0.06153846153846154	0.0	0.0	0.0	0.0	0.0
334	BMI1 to damage sites	0.14853596085192747	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	topoisomerases I and II	0.3075309072386389	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	tail;TAIL	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
188	autism;Autism;-- Autism	0.728313664122446	-1.4285714285714288	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-3.4714285714285715	0.04	0.04	0.0	0.04	0.042581895716224075	1.0	0.04686505125340156	1.0	14.0	0.0	-6.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	14.0	0.045454545454545456	0.0	0.05376344086021505	1.0	0.0	0.0	0.0	0.0
216	Geobacter-mediated bioremediation	0.3307455349420201	-5.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.2	1.0	-5.0	1.0	1.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.05	0.05	4.0	0.053571428571428575	0.25	1.0	1.0	-6.333333333333334	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.05	0.0	0.053571428571428575	0.0	1.0	0.0	0.0	1.0
320	test;Test	0.15181293947485874	-1.3333333333333335	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	-1.0	0.04	0.04	0.0	0.04	0.04271186440677966	1.0	0.0419047619047619	0.0	4.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.05084745762711865	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
150	Substrate;SUBSTRATE;substrates;substrate	0.6880525742303675	-3.9047619047619047	1.0	-13.833333333333332	0.04	0.04330348258706467	0.0	0.0	1.0	-0.9222222222222222	1.0	0.0	-13.571428571428571	0.0	0.0	-3.622222222222222	0.08955223880597014	0.04	0.0	0.04	0.04965971258056616	1.0	0.04976768308998132	1.0	15.0	0.0	-14.833333333333332	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	15.0	0.0875	0.0	0.0983606557377049	1.0	0.0	0.0	0.0	0.0
135	Difficult;difficult	0.07562479814146228	-1.8235294117647065	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8235294117647065	0.0	0.0	-4.375	0.04	0.048484848484848485	0.0	0.043147208121827416	0.043147208121827416	1.0	0.048484848484848485	0.0	1.0	0.0	-4.375	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043147208121827416	0.0	0.048484848484848485	0.0	0.0	0.0	0.0	0.0
164	lack	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
230	dilated;Dilated	0.10232096293358318	-11.4	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-11.4	0.0	0.0	-7.4	0.04	0.056818181818181816	0.0	0.07352941176470588	0.07352941176470588	1.0	0.056818181818181816	1.0	1.0	0.0	-7.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.07352941176470588	0.0	0.056818181818181816	1.0	0.0	0.0	0.0	0.0
238	Objective;objective	0.08913876932536269	-4.083333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.083333333333334	0.0	0.0	-2.333333333333332	0.04	0.044117647058823525	0.0	0.04780876494023905	0.04780876494023905	1.0	0.044117647058823525	0.0	1.0	0.0	-2.333333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04780876494023905	0.0	0.044117647058823525	0.0	0.0	0.0	0.0	0.0
160	receptor ligand;ligand of which receptors	0.00644374832934648	-9.5	1.0	-12.428571428571429	0.07954545454545454	0.07954545454545454	0.5	0.5	1.0	-12.428571428571429	1.0	0.0	-9.5	0.0	0.0	-12.0	0.07954545454545454	0.07692307692307693	0.0	0.06451612903225806	0.06451612903225806	4.0	0.07692307692307693	1.0	1.0	0.0	-12.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.06451612903225806	0.0	0.07692307692307693	1.0	0.0	0.0	0.0	0.0
44	the live culture of Synochocystis sp. cyanobacteria	0.08847539364637376	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.2857142857142857	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
312	SUCROSE;sucrose	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	mg;MG	0.8657168469615415	-0.457142857142857	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-2.0714285714285716	0.04	0.04	0.0	0.04	0.04083879423328964	1.0	0.04444757849801596	0.0	7.0	0.0	-8.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	7.0	0.04587155963302752	0.0	0.05970149253731343	0.0	0.0	0.0	0.0	0.0
207	HALLUCINATIONS;hallucinations	0.8274585586689456	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	2.0	1.0	1.0	0.045454545454545456	1.0	0.04	0.0	0.0	0.0	1.0	0.0
232	its systemic score	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
128	mechanism of action;mechanisms of action	0.03259458643733104	-1.4166666666666679	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.4166666666666679	0.0	0.0	-4.818181818181818	0.04	0.04954954954954956	0.0	0.04240282685512368	0.04240282685512368	3.0	0.04954954954954956	0.3333333333333333	1.0	0.0	-4.818181818181818	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04240282685512368	0.0	0.04954954954954956	0.0	0.0	0.0	0.0	0.0
146	specific genetic ablation	0.06806720847785398	-3.333333333333332	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.25	1.0	-3.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.04615384615384615	0.04615384615384615	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04615384615384615	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	a group of seven normal children	0.07748277985570153	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
274	the course of this devastating disease	0.03513983755434284	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.8571428571428577	0.04	0.04516129032258065	0.0	0.04	0.04	6.0	0.04516129032258065	0.3333333333333333	1.0	0.0	-2.8571428571428577	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04516129032258065	0.0	0.0	0.0	0.0	0.0
115	a specific set of paralogous genes;Genes, A	0.21044333836276696	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	12.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
71	signaling pathway	0.6218454566268321	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.045454545454545456	0.045454545454545456	2.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.045454545454545456	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
85	Target Gene;target genes	0.20621630823629286	-3.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-3.6000000000000014	0.0	0.0	-2.8571428571428577	0.04	0.04516129032258065	0.0	0.04672897196261683	0.04672897196261683	2.0	0.04516129032258065	0.0	1.0	0.0	-2.8571428571428577	1.0	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	2.0	1.0	2.0	0.04672897196261683	1.0	0.04516129032258065	0.0	0.0	0.0	1.0	0.0
37	topoisomerase II;Topoisomerase 2;DNA topoisomerase II;DNA-topoisomerase II;Topo II;DNA Topoisomerase II	0.9999903919564611	-1.1414141414141414	1.0	-9.25	0.04	0.041423761423761425	0.0	0.12878787878787878	1.0	-0.5606060606060606	0.9545454545454546	0.0	-12.333333333333332	0.0	0.0	-1.5	0.06349206349206349	0.04	0.0	0.04	0.04321247333209055	2.4242424242424243	0.043530883225095095	0.7878787878787878	33.0	0.0	-9.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	6.0	1.0	80.0	0.07894736842105263	0.0	0.06349206349206349	1.0	0.0	0.0	0.0	0.0
102	Period (Per1	0.43721631812092165	-3.25	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-3.25	1.0	1.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	3.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04597701149425287	0.0	0.04	0.0	1.0	0.0	0.0	1.0
231	STRIP;strips	0.08986356239051486	-3.428571428571427	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.428571428571427	0.0	0.0	-1.571428571428573	0.04	0.042682926829268296	0.0	0.04635761589403973	0.04635761589403973	1.0	0.042682926829268296	0.0	1.0	0.0	-1.571428571428573	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04635761589403973	0.0	0.042682926829268296	0.0	0.0	0.0	0.0	0.0
231	mouse hearts;Mouse Heart	0.15764447056609038	-4.2857142857142865	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.2857142857142865	0.0	0.0	-5.571428571428572	0.04	0.051470588235294115	0.0	0.04827586206896552	0.048275862068965524	2.0	0.05147058823529412	0.0	3.0	0.0	-5.571428571428571	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04827586206896552	0.0	0.051470588235294115	0.0	0.0	0.0	0.0	0.0
156	11 patients	0.21640102224572125	-6.333333333333334	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-9.25	0.04	0.06349206349206349	0.0	0.053571428571428575	0.053571428571428575	2.0	0.06349206349206349	0.0	1.0	0.0	-9.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.053571428571428575	0.0	0.06349206349206349	0.0	0.0	0.0	0.0	0.0
307	patients with PD	0.1378445365820045	-3.1999999999999993	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04587155963302752	0.04587155963302752	3.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04587155963302752	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
122	Identified;identified	0.12980886962058	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.3333333333333335	0.04	0.04	0.0	0.04	0.04	1.0	0.04518518518518518	0.0	3.0	0.0	-7.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
123	70	0.9999295509235407	-4.818181818181818	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.800000000000001	0.0	0.0	-4.909090909090909	0.04	0.04	0.0	0.04	0.050486523481168694	1.0	0.052048682650286934	0.0	33.0	0.0	-10.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	33.0	0.05813953488372093	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
151	sequence;Sequence	0.012876130888143048	-2.142857142857143	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.2857142857142865	0.0	0.0	-3.333333333333334	0.04	0.04	0.0	0.04	0.04394482004280878	1.0	0.046527388600328054	1.0	4.0	0.0	-5.333333333333334	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04827586206896552	0.0	0.05084745762711865	1.0	0.0	0.0	0.0	0.0
256	Point A;a single defining point	0.06249983855426335	-6.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.053571428571428575	0.053571428571428575	4.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.053571428571428575	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
293	symptoms of vasomotor dysregulation (hot flashes	0.11272340449087064	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
270	LDB1 proteins	0.5491908485101622	-3.8000000000000007	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.3333333333333333	1.0	-3.8000000000000007	1.0	1.0	-9.5	0.04	0.06451612903225806	0.0	0.04716981132075472	0.04716981132075472	2.0	0.06451612903225806	0.0	1.0	1.0	-9.5	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	2.0	0.04716981132075472	0.0	0.06451612903225806	0.0	1.0	0.0	0.0	1.0
287	P53	0.644616819729308	-2.8000000000000007	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04504504504504505	0.04504504504504505	1.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04504504504504505	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
82	Screening;screening	0.06799652177494313	-2.1428571428571423	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1428571428571423	0.0	0.0	-7.199999999999999	0.04	0.056179775280898875	0.0	0.04375	0.04375	1.0	0.056179775280898875	0.0	1.0	0.0	-7.199999999999999	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04375	0.0	0.056179775280898875	0.0	0.0	0.0	0.0	0.0
208	recent findings that the atypical antidepressant tianeptine	0.11272340449087064	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
222	CD52	0.9629821867643227	-1.7272727272727273	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.2222222222222214	0.0	0.0	-5.7272727272727275	0.04	0.04	0.0	0.04	0.04299483969887255	1.0	0.052746916647766026	0.0	11.0	0.0	-7.4	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	11.0	0.04390243902439024	0.0	0.056818181818181816	0.0	0.0	0.0	0.0	0.0
264	most patients with subclinical hypothyroidism	0.053982075088060556	0.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.42857142857142855	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
304	impressive responses in heavily pre-treated high-risk CLL	0.060433147334721826	-2.375	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.1	1.0	-2.375	0.0	0.0	-9.428571428571429	0.04	0.06422018348623854	0.0	0.04419889502762431	0.04419889502762431	9.0	0.06422018348623854	0.0	1.0	0.0	-9.428571428571429	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04419889502762431	0.0	0.06422018348623854	0.0	0.0	0.0	0.0	0.0
139	Convection-enhanced delivery	0.4000706556134335	-2.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-2.5	1.0	1.0	-4.75	0.04	0.04938271604938271	0.0	0.044444444444444446	0.044444444444444446	4.0	0.04938271604938271	0.0	2.0	1.0	-4.75	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.044444444444444446	0.0	0.04938271604938271	0.0	1.0	0.0	0.0	1.0
229	the utility	0.029904342675853603	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	2.0	0.05263157894736842	0.5	1.0	0.0	-6.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
30	G-quadruplexes;G-quadruplex;G-Quadruplex;Guanine-Quadruplexes	0.9267403482368538	-0.9916666666666667	1.0	-5.800000000000001	0.04	0.04100694444444444	0.0	0.0	1.0	-0.4833333333333334	1.0	0.0	-11.9	0.0	0.0	-3.1833333333333336	0.052083333333333336	0.04	0.0	0.04	0.043027989821882946	3.0	0.04644288483890887	0.7777777777777777	12.0	0.0	-6.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	36.0	0.07633587786259542	0.0	0.05434782608695653	1.0	0.0	0.0	0.0	0.0
175	sex;Sex	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
344	during;DURING	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
199	characterized;Characterized	0.09059200192985256	-1.8333333333333321	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.043165467625899276	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043165467625899276	0.0	0.04	0.0	0.0	0.0	0.0	0.0
254	Increased;increased	0.10120390444143419	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05	0.05	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05	0.0	0.04	0.0	0.0	0.0	0.0	0.0
293	Review, Systematic;Systematic review	0.27926268070552995	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
24	all;ALL	0.0029354013517620832	-11.4	1.0	-18.0	0.14285714285714285	0.14285714285714285	1.0	1.0	1.0	-18.0	1.0	0.0	-11.4	0.0	0.0	-15.5	0.14285714285714285	0.10526315789473684	0.0	0.07352941176470588	0.07352941176470588	1.0	0.10526315789473684	1.0	1.0	0.0	-15.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.07352941176470588	0.0	0.10526315789473684	1.0	0.0	0.0	0.0	0.0
121	rollout	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
341	Ethylnitrosourea;ethylnitrosourea;ENU	0.23203437336706392	-4.017857142857143	1.0	-15.0	0.04	0.04857142857142858	0.0	0.0	1.0	-2.142857142857143	1.0	0.0	-13.75	0.0	0.0	-3.625	0.1	0.04	0.0	0.04	0.05075461646890218	1.0	0.05239978724557209	1.0	7.0	0.0	-15.875	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	7.0	0.08888888888888889	0.0	0.1095890410958904	1.0	0.0	0.0	0.0	0.0
90	1000 in Europe	0.28393614933701766	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.04	0.04	3.0	0.05405405405405406	0.0	1.0	0.0	-6.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
27	Social;social	0.07992707372589007	-1.7777777777777786	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.0430622009569378	0.0430622009569378	1.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0430622009569378	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
62	Pancreatitis in a patient	0.07472150953262546	-2.2222222222222214	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	-2.2222222222222214	1.0	1.0	-4.75	0.04	0.04938271604938271	0.0	0.04390243902439024	0.04390243902439024	4.0	0.04938271604938271	0.25	1.0	1.0	-4.75	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04390243902439024	0.0	0.04938271604938271	0.0	1.0	0.0	0.0	1.0
291	laboratory references	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
145	increased GAD activity;increased activity	0.1187176919696614	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
301	The objective	0.11010083760971255	-2.555555555555557	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.555555555555557	0.0	0.0	0.0	0.04	0.04	0.0	0.04455445544554456	0.04455445544554456	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04455445544554456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
25	A family-based, cognitive behavioural treatment	0.09277645774468193	0.0	0.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.125	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
144	MEF2D	0.8112365623029894	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	1.0	0.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
115	nervous system development;Nervous System Development	0.12471761596165726	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
281	YEARS;years	0.21038165575636644	-1.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-1.1999999999999993	0.0	0.0	-1.8333333333333321	0.04	0.043165467625899276	0.0	0.04201680672268907	0.04201680672268907	1.0	0.043165467625899276	0.0	1.0	0.0	-1.8333333333333321	1.0	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04201680672268907	1.0	0.043165467625899276	0.0	0.0	0.0	1.0	0.0
276	female MCT8 mutation carriers	0.28454260835056683	-2.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
10	the Tpl2/Cot oncogene	0.2666320011077242	0.0	1.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.25	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
107	fractional;Fraction	0.7887113346321589	-1.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-1.5	0.0	0.0	-4.2857142857142865	0.04	0.04827586206896552	0.0	0.0425531914893617	0.0425531914893617	1.0	0.04827586206896552	0.0	1.0	0.0	-4.2857142857142865	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	2.0	1.0	1.0	0.0425531914893617	1.0	0.04827586206896552	0.0	0.0	0.0	1.0	0.0
318	ph- chronic myeloid leukemia;Ph+) chronic myeloid leukaemia	0.3755267060547676	-1.4444444444444429	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	0.0	-1.4444444444444429	0.0	0.0	-6.846153846153847	0.04	0.05508474576271186	0.0	0.04245283018867924	0.04245283018867924	6.0	0.05508474576271186	0.3333333333333333	2.0	0.0	-6.846153846153847	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	12.0	0.04245283018867924	0.0	0.05508474576271186	0.0	0.0	0.0	0.0	0.0
140	discovery;Discovery	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
127	the first-line treatment with gefitinib	0.03416699530006928	0.0	1.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	difficult task	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
37	DNA Binding;DNA binding	0.17869741582974974	-6.333333333333334	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-8.75	0.04	0.06153846153846154	0.0	0.053571428571428575	0.053571428571428575	2.0	0.06153846153846154	0.0	1.0	0.0	-8.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.053571428571428575	0.0	0.06153846153846154	0.0	0.0	0.0	0.0	0.0
52	Neurons;neurons	0.6465500797805931	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04631578947368421	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.05263157894736842	0.0	0.04	0.0	0.0	0.0	0.0	0.0
127	therapeutic target	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
9	significant losses	0.07332431934141369	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.75	0.04	0.057971014492753624	0.0	0.04	0.04	2.0	0.057971014492753624	0.0	1.0	0.0	-7.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.057971014492753624	0.0	0.0	0.0	0.0	0.0
67	models;Model;model;Models	0.018632104242269718	-3.75	1.0	-16.5	0.04	0.049705882352941176	1.0	1.0	1.0	-2.0625	1.0	0.0	-18.5	0.0	0.0	-8.53125	0.11764705882352941	0.04	1.0	0.04	0.05723752598752599	1.0	0.06359441452907023	0.875	8.0	0.0	-13.0	1.0	0.0	1.0	0.875	1.0	0.0	1.0	0.0	0.0	4.0	1.0	8.0	0.15384615384615385	0.0	0.08333333333333333	1.0	0.0	1.0	0.0	0.0
151	protein targeting	0.35209249160753997	-2.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
188	a mouse model	0.04924055088460717	0.0	0.3333333333333333	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.1111111111111111	0.0	0.0	0.0	0.0	-5.8	0.04	0.04	0.0	0.04	0.04	3.0	0.05449494949494949	0.6666666666666666	3.0	0.0	-10.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
313	cytoplasmic PABP4 and PABP5	0.3930219589312583	0.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.16666666666666666	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
26	High;Elevated;elevated;higher	0.36033278109380695	-0.9285714285714288	0.0	0.0	0.04	0.04	0.0	0.5	0.0	0.0	0.0	0.0	-1.8571428571428577	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04160493827160494	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.5	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.043209876543209874	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	the malignant phenotype	0.17991386544424184	-2.2222222222222214	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.2222222222222214	0.0	0.0	-5.846153846153847	0.04	0.052208835341365466	0.0	0.04390243902439024	0.04390243902439024	3.0	0.052208835341365466	0.3333333333333333	1.0	0.0	-5.846153846153847	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04390243902439024	0.0	0.052208835341365466	0.0	0.0	0.0	0.0	0.0
4	within;of;Of;Within	0.014686259452156843	-2.6875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.375	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.044860517718019605	1.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	1.0	0.5	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.046242774566473986	0.0	0.04	1.0	0.0	0.0	0.0	0.0
14	amino acid composition based method	0.07675655056931481	-5.375	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	1.0	-5.375	0.0	0.0	-9.666666666666666	0.04	0.06521739130434782	1.0	0.050955414012738856	0.050955414012738856	5.0	0.06521739130434782	0.2	1.0	0.0	-9.666666666666666	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.050955414012738856	0.0	0.06521739130434782	0.0	0.0	0.2	0.0	0.0
224	MONTHS;months	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
317	Efficacy;efficacy	0.5610012079290777	-3.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04587155963302752	0.04587155963302752	1.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04587155963302752	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
329	simple;Simple	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
341	damage;Damage	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	Family;family	0.0937097016095048	-7.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-14.0	0.0	0.0	-1.833333333333334	0.04	0.04	0.0	0.04	0.06545454545454546	1.0	0.043437500000000004	0.0	2.0	0.0	-3.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.09090909090909091	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
128	molecular invaders	0.6170704071952036	-1.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	-2.90909090909091	0.04	0.04526748971193416	0.0	0.0425531914893617	0.0425531914893617	2.0	0.04526748971193416	0.0	1.0	0.0	-2.90909090909091	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.0425531914893617	0.0	0.04526748971193416	0.0	0.0	0.0	0.0	0.0
10	gastric;Gastric	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	this residue	0.2570570889728846	-8.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-8.0	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.058823529411764705	0.058823529411764705	2.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.058823529411764705	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
294	1 mg	0.6518436242247154	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	apical membrane;Apical membrane	0.5717231683879584	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
343	find;Find	0.06998091245582899	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	1.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
244	enhanced;Enhance;Enhanced;enhance	0.06823289703526167	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
149	results;Result	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
50	locus;Locus	0.8326044662201431	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
94	the treatment of chronic myelogenous leukemia	0.19490873953746635	-2.3999999999999986	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-2.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04424778761061947	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04424778761061947	0.0	0.04	0.0	0.0	0.0	0.0	0.0
144	no;NO	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
185	including;Including	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	the discovery of polymorphisms	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
217	natural protein	0.019479252773705224	-1.625	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.3333333333333333	1.0	-1.625	1.0	1.0	-5.571428571428571	0.04	0.051470588235294115	0.0	0.0427807486631016	0.0427807486631016	2.0	0.051470588235294115	0.5	1.0	1.0	-5.571428571428571	1.0	0.3333333333333333	1.0	1.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.0427807486631016	0.0	0.051470588235294115	0.0	1.0	0.0	0.0	1.0
293	Preliminary results	0.14268360973571956	-9.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-9.0	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.0625	0.0625	2.0	0.06060606060606061	0.0	2.0	0.0	-8.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.0625	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
176	HU Protein;protein HU;HU protein;HU proteins	0.9500318741040822	-2.225	0.0	0.0	0.04	0.04	0.0	0.45	0.0	0.0	0.0	1.0	-6.375	1.0	1.0	-6.44	0.04	0.044642857142857144	0.1	0.04	0.04413355479117683	2.0	0.05538320103007075	0.05	10.0	1.0	-12.8	1.0	0.6666666666666666	0.0	0.1	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	4.0	1.0	20.0	0.053691275167785234	0.0	0.0819672131147541	0.0	1.0	0.05	0.0	1.0
217	TAILS) strategy	0.10749485034526722	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
11	itaconic acid producing level via enhanced glycolytic flux	0.06000154574780222	0.0	1.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.1	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.25	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	an inhibitor of the Bcr-Abl tyrosine kinase	0.17836895186572665	-2.2222222222222214	1.0	0.0	0.04	0.04	0.2222222222222222	0.2222222222222222	0.0	0.0	0.14285714285714285	1.0	-2.2222222222222214	1.0	1.0	-1.46153846153846	0.04	0.04248366013071895	1.0	0.04390243902439024	0.04390243902439024	9.0	0.04248366013071895	0.5555555555555556	1.0	1.0	-1.46153846153846	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	9.0	0.04390243902439024	1.0	0.04248366013071895	0.0	1.0	0.1111111111111111	1.0	1.0
134	Surface of epithelium;of the surface epithelium	0.05192381467612613	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
94	the development	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
211	two;Two	0.08324054938051959	-1.8888888888888893	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-2.1111111111111107	0.04	0.043689320388349516	0.0	0.04326923076923077	0.04326923076923077	1.0	0.043689320388349516	0.0	1.0	0.0	-2.1111111111111107	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04326923076923077	0.0	0.043689320388349516	0.0	0.0	0.0	0.0	0.0
90	Care	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
256	Achondroplasia;ACHONDROPLASIA	0.7424326016890371	-10.666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-10.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.06976744186046512	0.06976744186046512	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.06976744186046512	0.0	0.04	0.0	0.0	0.0	0.0	0.0
63	ADA	0.6560282309242312	-7.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.0	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.05555555555555555	0.05555555555555555	1.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.05555555555555555	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
65	K4 and K9	0.3400733075918026	-3.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.045454545454545456	0.045454545454545456	3.0	0.04597701149425287	0.0	1.0	0.0	-3.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.045454545454545456	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
122	Anticoagulant effect;anticoagulant effect	0.16652327756564753	-5.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.05	0.05	2.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.05	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
7	the neural tube to close	0.1009081261668759	-3.75	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	0.0	0.04	0.04	0.0	0.047058823529411764	0.047058823529411764	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.047058823529411764	0.0	0.04	0.0	0.0	0.0	0.0	0.0
163	judo-training session	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	Literature;literature;LIterature	0.6132207351421316	-1.2923076923076924	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.199999999999999	0.0	0.0	-4.9692307692307685	0.04	0.04	0.0	0.04	0.04230278782920233	1.0	0.0507171201018064	0.0	13.0	0.0	-7.800000000000001	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	13.0	0.04807692307692307	0.0	0.05813953488372093	0.0	0.0	0.0	0.0	0.0
313	sperm maturation and fitness	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	critical residues	0.20008054889233162	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	2.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
143	tRNA;tRNAs	0.8954518966470775	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-1.3599999999999994	0.04	0.04	0.0	0.04	0.04	1.0	0.04251851851851852	0.0	5.0	1.0	-3.3999999999999986	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	5.0	0.04	0.0	0.046296296296296294	0.0	1.0	0.0	0.0	1.0
137	the study	0.033880952506419725	-3.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04615384615384615	0.04615384615384615	2.0	0.05263157894736842	0.5	1.0	0.0	-6.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04615384615384615	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
5	their poorer pharmacodynamic profiles and tolerability	0.200496330682082	-3.75	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.047058823529411764	0.047058823529411764	6.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.047058823529411764	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
47	Complete;complete	0.10297704762030026	-5.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.5	0.0	0.0	0.0	0.04	0.04	0.0	0.05128205128205128	0.05128205128205128	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05128205128205128	0.0	0.04	0.0	0.0	0.0	0.0	0.0
103	5mC	0.6329493246644857	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.7142857142857153	0.04	0.04294478527607362	0.0	0.04	0.04	1.0	0.04294478527607362	0.0	1.0	0.0	-1.7142857142857153	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04294478527607362	0.0	0.0	0.0	0.0	0.0
122	clearance of S-warfarin	0.1464833758691662	-4.0	1.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.2	0.0	-4.0	0.0	0.0	-9.0	0.04	0.0625	0.0	0.047619047619047616	0.047619047619047616	5.0	0.0625	0.2	1.0	0.0	-9.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.047619047619047616	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
267	Prosthesis;prosthesis	0.6144391413036169	-2.7142857142857153	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.7142857142857153	0.0	0.0	0.0	0.04	0.04	0.0	0.04487179487179487	0.04487179487179487	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04487179487179487	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	a set of implicitly interacting proteins	0.11514302976799319	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	6.0	0.045454545454545456	0.16666666666666666	1.0	0.0	-3.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
82	HLA-B*1502, human;human leukocyte antigen HLA-B*1502	0.26625041125728066	0.0	1.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.25	1.0	0.0	0.0	0.0	-3.299999999999999	0.04	0.04587155963302752	0.0	0.04	0.04	6.0	0.0460839279646619	0.5	2.0	0.0	-3.3999999999999986	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	12.0	0.04	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
137	Mean;mean	0.08005832124839517	-3.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-4.300000000000001	0.04	0.04830917874396135	0.0	0.04615384615384615	0.04615384615384615	1.0	0.04830917874396135	0.0	1.0	0.0	-4.300000000000001	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04615384615384615	0.0	0.04830917874396135	0.0	0.0	0.0	0.0	0.0
102	B)	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
180	caused;cause	0.16980238649898283	-1.2	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	-6.733333333333334	0.04	0.04	0.0	0.04	0.042182861734488895	1.0	0.05802585141058784	0.0	5.0	0.0	-11.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04580152671755725	0.0	0.075	0.0	0.0	0.0	0.0	0.0
26	to;TO	0.06541548776389379	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.043478260869565216	0.043478260869565216	1.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
41	the binding specificity	0.20746220121390285	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	the 300–500 million episodes	0.05985171777715778	-4.5	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04878048780487805	0.04878048780487805	4.0	0.053571428571428575	0.25	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04878048780487805	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
174	QT interval;Q-T interval	0.08725658240480252	-4.333333333333334	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.333333333333334	0.0	0.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.048387096774193554	0.048387096774193554	2.0	0.044642857142857144	0.5	1.0	0.0	-2.6000000000000014	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.048387096774193554	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
228	potent;Potential	0.6443030853801779	-3.7	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.4	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04840909090909091	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.056818181818181816	0.0	0.04	0.0	0.0	0.0	0.0	0.0
322	structural data on the catalytic subunit	0.08680331008994818	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	named	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
137	2009a) PTA	0.4066504182730994	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.3000000000000007	0.04	0.04608294930875576	0.0	0.04	0.04	3.0	0.04608294930875576	0.3333333333333333	1.0	0.0	-3.3000000000000007	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04608294930875576	0.0	0.0	0.0	0.0	0.0
4	associated disease	0.035627626323753124	-2.125	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.125	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04371584699453552	0.04371584699453552	2.0	0.04716981132075472	0.5	1.0	0.0	-3.8000000000000007	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04371584699453552	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
41	the embryonic development	0.0793662226340656	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	conservation;Conservation	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
343	biological pathways	0.04214881779845902	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	2.0	0.04918032786885245	0.5	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
44	the course of infection	0.04774866386403132	-2.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-2.75	1.0	1.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0449438202247191	4.0	0.04	0.5	1.0	1.0	0.0	1.0	0.3333333333333333	1.0	1.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.0449438202247191	0.0	0.04	0.0	1.0	0.0	0.0	1.0
41	the C-terminus	0.28224119294005345	-8.5	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-8.5	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.06060606060606061	0.06060606060606061	4.0	0.053571428571428575	0.25	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.06060606060606061	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
208	derivatives	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
185	o	0.6668594340272865	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
157	indicated;Indicated	0.0028683000767767996	-14.4	1.0	-18.0	0.14285714285714285	0.14285714285714285	1.0	1.0	1.0	-18.0	1.0	0.0	-14.4	0.0	0.0	-18.6	0.14285714285714285	0.15625	0.0	0.09433962264150944	0.09433962264150944	1.0	0.15625	1.0	1.0	0.0	-18.6	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.09433962264150944	0.0	0.15625	1.0	0.0	0.0	0.0	0.0
94	More micro-GIST	0.3390675980923809	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
99	AD	0.14457393631498155	-4.875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-2.8571428571428577	0.04	0.04516129032258065	0.0	0.04938271604938271	0.04969135802469136	1.0	0.04516129032258065	0.0	2.0	0.0	-2.8571428571428577	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05	0.0	0.04516129032258065	0.0	0.0	0.0	0.0	0.0
102	Cry2) genes	0.5935496375073458	-4.75	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-4.75	1.0	1.0	0.0	0.04	0.04	0.0	0.04938271604938271	0.04938271604938271	3.0	0.04	0.0	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04938271604938271	0.0	0.04	0.0	1.0	0.0	0.0	1.0
60	hydrophobic;Hydrophobic	0.5633992331163501	-5.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.05	0.05	1.0	0.054545454545454536	0.0	1.0	0.0	-6.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
97	MYOTONIC DYSTROPHY 1;Myotonic dystrophy type 1	0.7090148129426996	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	4.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	16.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
177	46.6 expected)	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
242	17 of 26 [65%])	0.44285976656303544	-1.6666666666666679	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	0.0	-1.6666666666666679	0.0	0.0	0.0	0.04	0.04	0.0	0.04285714285714286	0.04285714285714286	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04285714285714286	0.0	0.04	0.0	0.0	0.0	0.0	0.0
68	exons IIIa and IIIc)	0.4175122847513681	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
274	pathogenesis	0.6370676435341989	-1.4545454545454533	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.4545454545454533	0.0	0.0	-2.571428571428573	0.04	0.0445859872611465	0.0	0.04247104247104247	0.04247104247104247	1.0	0.0445859872611465	0.0	1.0	0.0	-2.571428571428573	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04247104247104247	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
93	limited;Limited	0.07639673289877087	-2.833333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-5.0	0.04	0.05	0.0	0.045112781954887216	0.045112781954887216	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045112781954887216	0.0	0.05	0.0	0.0	0.0	0.0	0.0
155	familial disorder	0.41227547929223474	-5.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-5.5	1.0	1.0	-8.0	0.04	0.058823529411764705	0.0	0.05128205128205128	0.05128205128205128	2.0	0.058823529411764705	0.0	2.0	1.0	-8.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	4.0	0.05128205128205128	0.0	0.058823529411764705	0.0	1.0	0.0	0.0	1.0
264	various;Various	0.0737759439625356	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.04	0.04	1.0	0.046296296296296294	0.0	1.0	0.0	-3.3999999999999986	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
41	a chromodomain gene	0.10009656297378071	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
225	d: glucose tolerance	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	US	0.12896630872103812	-5.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.05084745762711865	0.05084745762711865	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.05084745762711865	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	Introduction;introduction	0.07830623048825934	-8.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-8.75	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.06153846153846154	0.06153846153846154	1.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.06153846153846154	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
222	reduced;Reduced	0.22790703293456077	-2.1111111111111107	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04379174484052532	1.0	0.04	0.0	5.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04615384615384615	0.0	0.04	0.0	0.0	0.0	0.0	0.0
297	The Pediatric Risk of Mortality (PRISM	0.08847539364637376	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.2857142857142857	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
83	Study;study	0.13370823494013684	-0.9166666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04164794007490637	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	the catalytic nuclease domain	0.1405487375957212	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	-methyltransferases by oligodeoxyribonucleotides	0.2274688024954199	-4.5	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	-4.5	0.0	0.0	-8.833333333333334	0.04	0.06185567010309279	0.0	0.04878048780487805	0.04878048780487805	4.0	0.06185567010309279	0.5	1.0	0.0	-8.833333333333334	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04878048780487805	0.0	0.06185567010309279	0.0	0.0	0.0	0.0	0.0
163	inflammatory signaling	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
304	either;Either	0.07635997672716116	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.571428571428573	0.04	0.0445859872611465	0.0	0.04	0.04	1.0	0.0445859872611465	0.0	1.0	0.0	-2.571428571428573	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
137	PP	0.6290600606552499	-2.2222222222222214	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.2222222222222214	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04390243902439024	0.04390243902439024	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04390243902439024	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
322	zest and trithorax) domain (ESET)	0.13465341111409246	0.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.25	0.0	0.0	0.0	0.0	-3.666666666666668	0.04	0.046875	1.0	0.04	0.04	8.0	0.046875	0.125	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.046875	0.0	0.0	0.125	0.0	0.0
225	connective tissue abnormalities	0.2206642834143794	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.3333333333333333	0.0	0.0
101	the BZLF1 transcription	0.20746220121390285	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
249	provide;Provide	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	the Plasmodium genus	0.17946556669241012	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	3.0	0.047619047619047616	0.3333333333333333	1.0	0.0	-4.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
96	A regimen	0.2509539782363395	-5.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.05	0.05	2.0	0.04716981132075472	0.0	1.0	0.0	-3.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
62	Leukopenia and thrombocytopenia	0.4232555327302723	-1.7777777777777786	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-1.7777777777777786	1.0	1.0	0.0	0.04	0.04	0.0	0.0430622009569378	0.0430622009569378	3.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.0430622009569378	0.0	0.04	0.0	1.0	0.0	0.0	1.0
227	membrane;Membrane;membrane-	0.5489580343886917	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	1.5	0.05	0.0	2.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	3.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
232	ANNULOAORTIC ECTASIA;annuloaortic ectasia	0.7516174327205302	-2.166666666666668	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.043795620437956206	0.043795620437956206	2.0	0.0449438202247191	0.0	3.0	0.0	-2.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.043795620437956206	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
155	inherited CPVT	0.2856949230194996	-5.166666666666666	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-5.166666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.050420168067226885	0.050420168067226885	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.050420168067226885	0.0	0.04	0.0	0.0	0.0	0.0	0.0
328	an autosomal recessive (AR) mode	0.40151405552860553	-3.0	0.0	0.0	0.04	0.04	0.14285714285714285	0.14285714285714285	0.0	0.0	0.0	1.0	-3.0	1.0	1.0	-4.75	0.04	0.04938271604938271	1.0	0.045454545454545456	0.045454545454545456	7.0	0.04938271604938271	0.14285714285714285	1.0	1.0	-4.75	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.045454545454545456	0.0	0.04938271604938271	0.0	1.0	0.14285714285714285	0.0	1.0
7	Increased risk for MCMs	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	Degree;level;degree;Level	0.06533847367292667	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.083333333333334	0.04	0.04	0.0	0.04	0.04	1.0	0.04189781021897811	0.0	2.0	0.0	-2.166666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.04	0.0	0.043795620437956206	0.0	0.0	0.0	0.0	0.0
13	generation;Generation	0.08174206851709978	-6.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.054545454545454536	0.054545454545454536	1.0	0.054545454545454536	0.0	1.0	0.0	-6.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.054545454545454536	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
88	A role;a role	0.1068892846337702	-4.875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04938271604938271	0.04969135802469136	2.0	0.053571428571428575	0.0	2.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.05	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
40	an equivalent	0.2176338410667971	-2.166666666666668	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.043795620437956206	0.043795620437956206	2.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043795620437956206	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
313	nuclear poly(A) binding protein PABPN1	0.38268668319109683	-1.571428571428573	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-1.571428571428573	1.0	1.0	0.0	0.04	0.04	0.0	0.042682926829268296	0.042682926829268296	6.0	0.04	0.16666666666666666	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.042682926829268296	0.0	0.04	0.0	1.0	0.0	0.0	1.0
46	single family	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
89	5 of the 6 girls	0.07594933472817433	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
177	was;WAS	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
199	Cenpb;CENPB	0.9627643774427966	-3.9833333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-6.166666666666666	0.0	0.0	-3.7	0.04	0.045112781954887216	0.0	0.04580152671755725	0.04775778647919032	1.0	0.047122941448060465	0.0	10.0	0.0	-6.166666666666666	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	10.0	0.053097345132743355	0.0	0.053097345132743355	0.0	0.0	0.0	0.0	0.0
31	represents;Represent	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
170	Gene;gene	0.008895319768391918	-14.25	1.0	-17.0	0.125	0.125	1.0	1.0	1.0	-17.0	1.0	1.0	-14.25	1.0	1.0	-14.25	0.125	0.09302325581395349	1.0	0.09302325581395349	0.09302325581395349	1.0	0.09302325581395349	1.0	1.0	1.0	-14.25	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	2.0	1.0	1.0	0.09302325581395349	1.0	0.09302325581395349	1.0	1.0	1.0	1.0	1.0
122	dosage;dosages;Dosage;Dosages;dose;DOSE	0.6076810667001991	-2.3333333333333335	0.0	0.0	0.04	0.04	0.0	0.6666666666666666	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-4.888888888888889	0.04	0.04	0.0	0.04	0.04449556918019642	1.0	0.05217086378376701	0.0	9.0	0.0	-10.0	1.0	0.0	0.6666666666666666	0.0	1.0	0.0	1.0	0.0	0.0	6.0	1.0	9.0	0.04938271604938271	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
76	Heart Association (AHA) Prevention Committee report recommended depression screening of all coronary heart disease;coronary heart disease screening	0.00858471818417384	0.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	16.0	0.04	0.375	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	16.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
188	executive abilities in the BTBR mouse model	0.013239039710707097	0.0	1.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.125	0.0	0.0	0.0	0.0	-7.4	0.04	0.056818181818181816	0.0	0.04	0.04	7.0	0.056818181818181816	0.2857142857142857	1.0	0.0	-7.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.056818181818181816	0.0	0.0	0.0	0.0	0.0
8	three;Three	0.0943797958812142	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	AdoMet	0.8585817679397963	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	2.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
318	The BCR-ABL inhibitor imatinib i	0.13748129014143262	0.0	1.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.16666666666666666	1.0	0.0	1.0	1.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	7.0	0.047619047619047616	0.42857142857142855	1.0	1.0	-4.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	7.0	0.04	0.0	0.047619047619047616	0.0	1.0	0.0	0.0	1.0
41	Brd4;BRD4	0.7832012734625726	-16.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-16.5	1.0	1.0	-10.666666666666666	0.04	0.06976744186046512	0.0	0.11764705882352941	0.11764705882352941	1.0	0.06976744186046512	0.0	2.0	1.0	-10.666666666666666	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	2.0	0.11764705882352941	0.0	0.06976744186046512	0.0	1.0	0.0	0.0	1.0
203	proximal;PROXIMAL	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
90	1107 patients	0.17938023233523773	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04	0.04	2.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
156	dietary Copper intake;dietary intake of copper	0.33766173604840966	-3.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	4.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
74	three percent	0.26637297321726805	-2.666666666666668	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.04477611940298508	0.04477611940298508	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04477611940298508	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	mCAF1;MCAF1	0.8131784978644663	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	4.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
199	host chromosome	0.4661098175071109	-2.166666666666668	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-2.166666666666668	1.0	1.0	0.0	0.04	0.04	0.0	0.043795620437956206	0.043795620437956206	2.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	2.0	0.043795620437956206	1.0	0.04	0.0	1.0	0.0	1.0	1.0
198	collapse	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
80	a very rare cause of HCM responsible	0.06495544270537182	0.0	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	Swi6	0.6649840092894851	-9.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-9.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.0625	0.0625	1.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.0625	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
104	HMMGene;HMMgene	0.771351746239246	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
183	direct sequence analysis	0.140411099756115	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	1.0	0.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	newly	0.13557789676843682	-1.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.042727272727272725	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	the regimen of bortezomib	0.08371090020959861	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.25	1.0	0.0	0.0	0.0	-6.4	0.04	0.05376344086021505	0.0	0.04	0.04	4.0	0.05376344086021505	0.25	1.0	0.0	-6.4	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.05376344086021505	0.0	0.0	0.0	0.0	0.0
121	A fast, sensitive and specific test for HLA-B*57:01 detection	0.1386816507093202	-4.0	0.0	0.0	0.04	0.04	0.5833333333333334	0.5833333333333334	0.0	0.0	0.0	1.0	-4.0	0.0	0.0	0.0	0.04	0.04	1.0	0.047619047619047616	0.047619047619047616	12.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	12.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.08333333333333333	0.0	0.0
185	ventricular segments	0.19819500992824804	-5.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-5.5	0.0	0.0	-11.0	0.04	0.07142857142857142	0.0	0.05128205128205128	0.05128205128205128	2.0	0.07142857142857142	0.0	1.0	0.0	-11.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05128205128205128	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0
226	include;included	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
77	a combination tablet	0.13934482505877643	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.7142857142857153	0.04	0.04294478527607362	0.0	0.04	0.04	3.0	0.04294478527607362	0.0	1.0	0.0	-1.7142857142857153	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04294478527607362	0.0	0.0	0.0	0.0	0.0
255	autosomal dominant FSHD1	0.5485702210171871	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
74	Lower Limbs;lower limbs	0.07089622972933286	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.04	0.04	2.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
295	devices;DEVICES	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	the neuronal splicing factor	0.21890620975158648	-7.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-7.0	0.0	0.0	-6.2857142857142865	0.04	0.05343511450381679	0.0	0.05555555555555555	0.05555555555555555	4.0	0.05343511450381679	0.0	1.0	0.0	-6.2857142857142865	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.05555555555555555	0.0	0.05343511450381679	0.0	0.0	0.0	0.0	0.0
260	mutations C742T, G746T, G747T in the TP53 gene	0.13327918478002526	0.0	1.0	0.0	0.04	0.04	0.3	0.3	0.0	0.0	0.1111111111111111	1.0	0.0	1.0	1.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.04	0.04	10.0	0.04587155963302752	0.1	1.0	1.0	-3.1999999999999993	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.04	0.0	0.04587155963302752	0.0	1.0	0.0	0.0	1.0
88	a key transcription factor in the maintenance	0.059639064218366906	-5.0	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.05	0.05	7.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.05	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
96	disease;Disease	0.004520218715869529	-14.25	1.0	-18.0	0.14285714285714285	0.14285714285714285	1.0	1.0	1.0	-18.0	1.0	0.0	-14.25	0.0	0.0	-16.4	0.14285714285714285	0.11627906976744186	1.0	0.09302325581395349	0.09302325581395349	1.0	0.11627906976744186	1.0	2.0	0.0	-16.4	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.09302325581395349	0.0	0.11627906976744186	1.0	0.0	1.0	0.0	0.0
126	(OR = 17.1	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	the discovery of several small-molecule inhibitors	0.034652235981356486	-2.2222222222222214	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-2.2222222222222214	0.0	0.0	-5.461538461538462	0.04	0.05118110236220472	0.0	0.04390243902439024	0.04390243902439024	8.0	0.05118110236220472	0.375	1.0	0.0	-5.461538461538462	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04390243902439024	0.0	0.05118110236220472	0.0	0.0	0.0	0.0	0.0
123	a set of 70 genes;Genes, A	0.159674109594513	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	5.0	0.04	0.2	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.2	0.0	0.0
298	nonthyroidal illness (NTI);nonthyroidal illness (NTI	0.5454370929545768	0.0	0.0	0.0	0.04	0.04	0.2	0.225	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.5	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
313	a growth advantage in cells	0.08279735195665178	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
86	Responsive;responsive	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	a custom-designed set	0.057961055114664525	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
24	2;+2	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	these regions	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
34	Gene;genes;gene;Genes	0.009096089980172153	-6.875	1.0	-18.75	0.04	0.1	1.0	1.0	1.0	-9.375	1.0	1.0	-13.75	1.0	1.0	-7.875	0.16	0.04	1.0	0.04	0.06444444444444444	1.0	0.07405405405405406	1.0	2.0	1.0	-15.75	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	4.0	1.0	2.0	0.08888888888888889	1.0	0.10810810810810811	1.0	1.0	1.0	1.0	1.0
129	the next generation via its preferential methylation	0.026159799377058854	-1.6666666666666679	1.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.2857142857142857	0.0	-1.6666666666666679	0.0	0.0	-2.571428571428573	0.04	0.0445859872611465	0.0	0.04285714285714286	0.04285714285714286	7.0	0.0445859872611465	0.2857142857142857	1.0	0.0	-2.571428571428573	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04285714285714286	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
72	the co-occurrence of genes or proteins	0.0980990838150757	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
339	the tumor	0.0984025346268932	-2.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.044117647058823525	0.044117647058823525	2.0	0.044642857142857144	0.0	1.0	0.0	-2.6000000000000014	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.044117647058823525	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
222	the comparator group	0.0793662226340656	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
38	and;And	0.07270877609889996	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.04	0.04	1.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
218	mass calibrants	0.05211087670879709	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.5	0.0	0.0
222	B-Cell Chronic Lymphocytic Leukemia;B-cell chronic lymphocytic leukaemia	0.48879078415250377	-1.5555555555555571	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	0.0	0.04	0.04	0.0	0.04265402843601896	0.04265402843601896	6.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	12.0	0.04265402843601896	0.0	0.04	0.0	0.0	0.0	0.0	0.0
249	K9	0.6924134078733853	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.125	0.04	0.04371584699453552	0.0	0.04	0.04	1.0	0.04371584699453552	0.0	2.0	0.0	-2.125	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04371584699453552	0.0	0.0	0.0	0.0	0.0
151	%MinMax output	0.36327212797715464	-1.8571428571428577	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-1.8571428571428577	0.0	0.0	0.0	0.04	0.04	0.0	0.043209876543209874	0.043209876543209874	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043209876543209874	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	the updated versions	0.05230089262579014	-1.8333333333333321	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.043165467625899276	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043165467625899276	0.0	0.04	0.0	0.0	0.0	0.0	0.0
264	the strongest evidence	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
304	idelalisib (GS	0.7307823555398101	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
165	Unusual frequencies of certain alternating purine-pyrimidine runs	0.14109668803572545	0.0	0.0	0.0	0.04	0.04	0.5555555555555556	0.5555555555555556	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
174	JLNS	0.6976115664626104	-1.083333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	-1.3000000000000007	0.04	0.04	0.0	0.04	0.04189781021897811	1.0	0.04232142857142857	0.0	2.0	0.0	-2.6000000000000014	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043795620437956206	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
177	LE);LE	0.6775004026255331	-1.4074074074074072	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.1111111111111107	0.0	0.0	-6.333333333333333	0.04	0.04	0.0	0.04	0.04245954692556634	1.3333333333333333	0.056344086021505375	0.0	3.0	0.0	-9.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.043689320388349516	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
17	investigated	0.0996719102175413	-3.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04615384615384615	0.04615384615384615	1.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04615384615384615	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
69	at;At	0.08763830215664516	-1.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-5.166666666666667	0.04	0.05	0.0	0.04	0.042388059701492536	1.0	0.050423728813559325	0.0	2.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04477611940298508	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
100	nucleic acid metabolism	0.6006896831855117	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.04	0.044117647058823525	0.0	0.04	0.04	3.0	0.04411764705882352	0.0	3.0	0.0	-2.333333333333332	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.044117647058823525	0.0	0.0	0.0	0.0	0.0
274	results;Result	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	detection method	0.2546308556974498	-1.09090909090909	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.09090909090909	0.0	0.0	0.0	0.04	0.04	0.0	0.04182509505703422	0.04182509505703422	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04182509505703422	0.0	0.04	0.0	0.0	0.0	0.0	0.0
178	CTD	0.8268705814765251	-3.625	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.625	1.0	1.0	-4.166666666666666	0.04	0.047999999999999994	0.0	0.04678362573099415	0.04678362573099415	1.0	0.047999999999999994	0.0	2.0	1.0	-4.166666666666666	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	2.0	0.04678362573099415	0.0	0.047999999999999994	0.0	1.0	0.0	0.0	1.0
206	peripheral DDC inhibitors (carbidopa	0.7331174186654269	-6.666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-6.666666666666666	1.0	1.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.054545454545454536	0.054545454545454536	5.0	0.053571428571428575	0.0	1.0	1.0	-6.333333333333334	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.054545454545454536	0.0	0.053571428571428575	0.0	1.0	0.0	0.0	1.0
335	their promoters	0.22097148672146344	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.04	0.04	2.0	0.04587155963302752	0.0	1.0	0.0	-3.1999999999999993	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
341	showed;Show	0.09150127164625485	-4.875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.875	0.0	0.0	-2.375	0.04	0.04419889502762431	0.0	0.049689440993788817	0.049689440993788817	1.0	0.04419889502762431	0.0	1.0	0.0	-2.375	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.049689440993788817	0.0	0.04419889502762431	0.0	0.0	0.0	0.0	0.0
46	those in Alagille syndrome	0.08402103040534491	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
97	19q13.3	0.7123617662367117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	pharmacogenomics;Pharmacogenomics	0.6231301874478336	-3.666666666666668	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.046875	0.046875	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046875	0.0	0.04	0.0	0.0	0.0	0.0	0.0
319	mechanism;Mechanism	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
317	targeted therapy	0.03423684701935181	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.047619047619047616	0.047619047619047616	2.0	0.053571428571428575	0.5	1.0	0.0	-6.333333333333334	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047619047619047616	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
340	LGE	0.6349312870229323	-3.571428571428573	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.571428571428573	0.0	0.0	-4.6	0.04	0.04901960784313726	0.0	0.04666666666666667	0.04666666666666667	1.0	0.04901960784313726	0.0	1.0	0.0	-4.6	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04666666666666667	0.0	0.04901960784313726	0.0	0.0	0.0	0.0	0.0
145	Levels;levels	0.1264590317974233	-0.8571428571428577	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.571428571428573	0.0	0.0	-1.6666666666666667	0.04	0.04	0.0	0.04	0.04152866242038217	1.0	0.043333333333333335	0.0	3.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.0445859872611465	0.0	0.05	0.0	0.0	0.0	0.0	0.0
82	ethnicity-specific	0.17146355153724904	-2.2857142857142847	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.2857142857142847	0.0	0.0	-7.199999999999999	0.04	0.056179775280898875	0.0	0.0440251572327044	0.0440251572327044	3.0	0.056179775280898875	0.3333333333333333	1.0	0.0	-7.199999999999999	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.0440251572327044	0.0	0.056179775280898875	0.0	0.0	0.0	0.0	0.0
35	the liver	0.007424348431787605	-6.166666666666666	1.0	-17.75	0.04	0.08896551724137931	1.0	1.0	1.0	-8.875	1.0	0.0	-12.333333333333332	0.0	0.0	-8.75	0.13793103448275862	0.04	0.0	0.04	0.05947368421052632	2.0	0.08666666666666667	1.0	2.0	0.0	-17.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.07894736842105263	0.0	0.13333333333333333	1.0	0.0	0.0	0.0	0.0
163	Some studies	0.12554009857066784	-6.4	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.4	0.0	0.0	0.0	0.04	0.04	0.0	0.05376344086021505	0.05376344086021505	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05376344086021505	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	intragenic mutations	0.21912854100443127	-1.1000000000000014	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.5	0.0	-1.1000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.041841004184100423	0.041841004184100423	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.041841004184100423	0.0	0.04	0.0	0.0	0.0	0.0	0.0
201	due to;Due To	0.08021854220857808	-10.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-20.0	0.0	0.0	-6.5	0.04	0.04	0.0	0.04	0.12000000000000001	2.0	0.061666666666666654	0.0	2.0	0.0	-13.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.2	0.0	0.08333333333333333	0.0	0.0	0.0	0.0	0.0
247	cervical screening programs	0.12653495187865305	-2.666666666666668	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.04477611940298508	0.04477611940298508	3.0	0.046511627906976744	0.3333333333333333	2.0	0.0	-3.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04477611940298508	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
122	the amount of this protein present	0.1708780801870013	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	1.0	0.0	1.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
91	Control;control	0.1083799334806924	-1.0714285714285712	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1428571428571423	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.041874999999999996	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04375	0.0	0.04	0.0	0.0	0.0	0.0	0.0
249	Drosophila Polycomb protein;Polycomb protein, Drosophila	0.2985086602987126	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-6.125	0.04	0.052980132450331126	0.0	0.04	0.04	3.0	0.052980132450331126	0.3333333333333333	2.0	0.0	-6.125	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.04	0.0	0.052980132450331126	0.0	0.0	0.0	0.0	0.0
41	a variety of animal and plant proteins	0.07670806698226675	0.0	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.14285714285714285	0.0	0.0
212	RWS	0.6084977118945804	-2.125	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.125	0.0	0.0	-5.857142857142858	0.04	0.05223880597014925	0.0	0.04371584699453552	0.04371584699453552	1.0	0.05223880597014925	0.0	1.0	0.0	-5.857142857142858	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04371584699453552	0.0	0.05223880597014925	0.0	0.0	0.0	0.0	0.0
307	The identification of the alpha-synuclein gene	0.08037996809102946	0.0	0.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	8.0	0.045454545454545456	0.375	1.0	0.0	-3.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
310	at least two prior therapies	0.08279735195665178	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
305	Novel;novel	0.07673902555986478	-2.571428571428573	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.571428571428573	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.0445859872611465	0.0445859872611465	1.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0445859872611465	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
14	extent;Extent	0.07679707865717114	-1.625	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.625	0.0	0.0	-3.833333333333332	0.04	0.047244094488188976	0.0	0.0427807486631016	0.0427807486631016	1.0	0.047244094488188976	0.0	1.0	0.0	-3.833333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0427807486631016	0.0	0.047244094488188976	0.0	0.0	0.0	0.0	0.0
251	mis-localization of Par3 and aPKC	0.3039745723062024	-1.8888888888888893	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	-1.8888888888888893	1.0	1.0	-3.333333333333332	0.04	0.04615384615384615	0.0	0.04326923076923077	0.04326923076923077	5.0	0.04615384615384615	0.2	1.0	1.0	-3.333333333333332	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.04326923076923077	0.0	0.04615384615384615	0.0	1.0	0.0	0.0	1.0
79	4.5 to 10.7	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	Thirty	0.12752460253404646	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05	0.05	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.05	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	now;Now	0.09773875734391521	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
338	global;Global	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
80	at least one of MLP	0.08848691453375389	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	the remaining 51 patients	0.07031476259204332	-1.6000000000000014	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-1.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.042735042735042736	0.042735042735042736	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.042735042735042736	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	likelihood for recurrence.[1	0.18916618552744635	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	biomedical;Biomedical	0.6088152588407234	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.04	0.04	0.0	0.04	0.04	1.0	0.052258064516129035	0.0	2.0	0.0	-9.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
266	0.02)	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	pairs;Pair	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
253	active drugs	0.0628356219103949	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	2.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.5	0.0	0.0
307	CLBs) in the brains	0.10042946025195948	-3.3999999999999986	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.046296296296296294	0.046296296296296294	5.0	0.04878048780487805	0.2	1.0	0.0	-4.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.046296296296296294	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
241	The association;the association	0.03822512677051816	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-3.3	0.04	0.04	0.0	0.04	0.04631578947368421	2.0	0.04717391304347826	0.5	2.0	0.0	-6.6	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.05263157894736842	0.0	0.05434782608695653	0.0	0.0	0.0	0.0	0.0
129	regulatory	0.09635587892128761	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.7142857142857153	0.04	0.04487179487179487	0.0	0.04	0.04	1.0	0.04487179487179487	0.0	1.0	0.0	-2.7142857142857153	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04487179487179487	0.0	0.0	0.0	0.0	0.0
149	miR-494 content	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
219	fumarate reductase (Frd) activity in some pathogenic bacteria	0.18722935946905236	-5.333333333333334	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.05084745762711865	0.05084745762711865	10.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.05084745762711865	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
256	Saethre-Chotzen syndrome;SAETHRE-CHOTZEN SYNDROME	0.5242671068583076	-5.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.05	0.05000000000000001	4.0	0.05405405405405406	0.25	3.0	0.0	-6.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	12.0	0.05	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
78	The NFI gene	0.10009656297378071	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
310	US Food	0.14684823062145294	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	cluster in the vicinity	0.06637442787073183	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
231	alpha-myosin heavy chain Arg403Gln	0.17024006782975287	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.3333333333333333	1.0	0.0	0.0	0.0	-4.7142857142857135	0.04	0.04929577464788733	0.0	0.04	0.04	6.0	0.04929577464788733	0.8333333333333334	2.0	0.0	-4.7142857142857135	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	12.0	0.04	0.0	0.04929577464788733	0.0	0.0	0.0	0.0	0.0
88	S-phase transition and proliferation in the developing embryo	0.1103142225603473	-5.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.05	0.05	10.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.05	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
38	molecular lesions	0.7749933655185222	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04	0.04	2.0	0.04819277108433735	0.0	2.0	0.0	-4.25	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
160	Both;both	0.09059200192985256	-1.8333333333333321	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.043165467625899276	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043165467625899276	0.0	0.04	0.0	0.0	0.0	0.0	0.0
266	an excess of Ala92 carriers	0.26905681404095005	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
48	T substitution at nucleotide position	0.26905681404095005	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
267	mobile phones;Phones, Mobile	0.127755607801729	-2.571428571428573	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.0445859872611465	0.0445859872611465	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.0445859872611465	0.0	0.04	0.0	0.0	0.0	0.0	0.0
306	postmortem;Postmortem	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	circadian rhythm protein cryptochrome	0.3075309072386389	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	phase I studies;Phase I Study	0.07435842344587819	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
246	genotyping evaluated polymorphisms	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
293	Preferred;preferred	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
340	Infiltration;infiltration	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
74	DIAGNOSIS;diagnosis;Diagnosed;diagnosed	0.05333437968909729	-1.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-5.625	0.04	0.04	0.0	0.04	0.042727272727272725	1.0	0.056363636363636366	0.0	2.0	0.0	-11.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.045454545454545456	0.0	0.07272727272727272	0.0	0.0	0.0	0.0	0.0
41	A Southern blot analysis	0.1486353009273346	-9.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-9.0	0.0	0.0	0.0	0.04	0.04	0.0	0.0625	0.0625	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.0625	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	the possibility	0.038095688819985186	-1.6666666666666679	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6666666666666679	0.0	0.0	-1.8571428571428577	0.04	0.043209876543209874	0.0	0.04285714285714286	0.04285714285714286	2.0	0.043209876543209874	0.5	1.0	0.0	-1.8571428571428577	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04285714285714286	0.0	0.043209876543209874	0.0	0.0	0.0	0.0	0.0
318	Give;giving;gives	0.08956578898492124	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.615384615384616	0.04	0.04868913857677902	0.0	0.04	0.04	1.0	0.05167990859620342	0.0	3.0	0.0	-6.384615384615385	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	3.0	0.04	0.0	0.05371900826446282	0.0	0.0	0.0	0.0	0.0
332	further clinical development	0.09108938679413384	-2.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.043795620437956206	0.043795620437956206	3.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043795620437956206	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
205	Selected;selected	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
168	MILD;mild	0.10309550514092947	-4.125	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-5.0	0.04	0.04918032786885245	0.0	0.047619047619047616	0.047905909351692484	1.0	0.05001389274798555	0.0	2.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04819277108433735	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
89	Improvement;improvement	0.14095469534932045	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
91	23.37%	0.6580882950339034	-2.7142857142857153	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.7142857142857153	0.0	0.0	0.0	0.04	0.04	0.0	0.04487179487179487	0.04487179487179487	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04487179487179487	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	density;Density	0.08071865271530183	-1.8888888888888893	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-2.8571428571428577	0.04	0.04516129032258065	0.0	0.04326923076923077	0.04326923076923077	1.0	0.04516129032258065	0.0	1.0	0.0	-2.8571428571428577	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04326923076923077	0.0	0.04516129032258065	0.0	0.0	0.0	0.0	0.0
125	a severe congenital disorder	0.08675908384807575	-6.333333333333334	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-11.25	0.04	0.07272727272727272	0.0	0.053571428571428575	0.053571428571428575	4.0	0.07272727272727272	0.0	1.0	0.0	-11.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.053571428571428575	0.0	0.07272727272727272	0.0	0.0	0.0	0.0	0.0
86	T3	0.7670749621955456	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	the propagation	0.10097750912902405	-1.8888888888888893	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-2.7142857142857153	0.04	0.04487179487179487	0.0	0.04326923076923077	0.04326923076923077	2.0	0.04487179487179487	0.5	1.0	0.0	-2.7142857142857153	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04326923076923077	0.0	0.04487179487179487	0.0	0.0	0.0	0.0	0.0
342	MLL1 and MLL2 H3K4 methyltransferase complexes	0.21474813359700387	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.2857142857142857	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
9	Frequency;frequency	0.06973767273598451	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04	0.04	1.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
13	) from mixtures	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
238	subgroups	0.6382400837040426	-2.083333333333332	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.083333333333332	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04363636363636363	0.04363636363636363	1.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04363636363636363	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
276	liver and kidney	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
305	the insulin receptor gene (INSR	0.20579808899180146	-1.8571428571428577	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-1.8571428571428577	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.043209876543209874	0.043209876543209874	6.0	0.047619047619047616	0.16666666666666666	1.0	0.0	-4.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.043209876543209874	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
14	standard;Standard	0.07449537880140875	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.04	0.04580152671755725	0.0	0.04	0.04	1.0	0.04580152671755725	0.0	1.0	0.0	-3.166666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04580152671755725	0.0	0.0	0.0	0.0	0.0
109	myocardial growth	0.2117097423392894	-3.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.045454545454545456	0.045454545454545456	2.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.045454545454545456	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
207	agitation;AGITATION	0.6147664148175173	-2.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0449438202247191	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
103	Genome-wide patterns	0.14906379476629825	-1.7777777777777786	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	0.0	0.04	0.04	0.0	0.0430622009569378	0.0430622009569378	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.0430622009569378	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	specific enhancers	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	Per1;PER1	0.9337588313961382	-2.09375	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-5.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.044045319207865946	0.875	0.04	0.0	8.0	1.0	0.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	7.0	0.05	0.0	0.04	0.0	1.0	0.0	0.0	1.0
72	literature mining techniques	0.0793662226340656	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
301	higher accuracy	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
287	an investigational small-molecule inhibitor	0.5199146324670044	-3.5	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-4.375	0.04	0.047619047619047616	0.0	0.04587155963302752	0.046520685476891116	6.0	0.048500881834215165	0.0	2.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	12.0	0.04716981132075472	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
249	lysine;LYSINE	0.874995668110393	-0.3333333333333333	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.0	0.0	0.0	-4.854166666666667	0.04	0.043478260869565216	0.0	0.04	0.04057971014492754	1.0	0.050120129896710754	0.0	6.0	0.0	-6.875	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.043478260869565216	0.0	0.05517241379310345	0.0	0.0	0.0	0.0	0.0
115	Nature;nature	0.07783442501517307	-8.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-8.0	0.0	0.0	-9.0	0.04	0.0625	0.0	0.058823529411764705	0.058823529411764705	1.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.058823529411764705	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
132	Compound;compounds;compound	0.004789128193194968	-5.2	1.0	-18.0	0.04	0.09142857142857143	1.0	1.0	1.0	-9.0	1.0	0.0	-10.4	0.0	0.0	-7.666666666666666	0.14285714285714285	0.04	1.0	0.04	0.054246575342465755	1.0	0.07172413793103448	1.0	2.0	0.0	-15.333333333333332	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.0684931506849315	0.0	0.10344827586206895	1.0	0.0	1.0	0.0	0.0
258	H3S10P	0.7061267520380323	-3.0999999999999996	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-3.0	0.04	0.04504504504504505	0.0	0.04504504504504505	0.04567067067067067	1.0	0.045458302339036284	0.0	2.0	0.0	-3.1999999999999993	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.046296296296296294	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
189	39.2 kilograms per square metre	0.30055321193494106	-4.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
140	Understand;understand	0.0707070590989606	-2.2222222222222214	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.2222222222222214	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04390243902439024	0.04390243902439024	1.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04390243902439024	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
231	uncertain etiology	0.21811270488131979	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.571428571428573	0.04	0.04666666666666667	0.0	0.04	0.04	2.0	0.04666666666666667	0.0	1.0	0.0	-3.571428571428573	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04666666666666667	0.0	0.0	0.0	0.0	0.0
99	Recently	0.09691608242490507	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.571428571428573	0.04	0.0445859872611465	0.0	0.04	0.04	1.0	0.0445859872611465	0.0	1.0	0.0	-2.571428571428573	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
189	T';T	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	two unrelated patients	0.23673926941830228	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
149	regulated;Regulated	0.6450935443069199	-4.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	problem;Problem	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
125	the myotubularin 1 gene (MTM1)	0.10129985818715309	0.0	1.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.2857142857142857	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	maintenance of methylation	0.005341700318105725	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	1.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	1.0	0.0	0.0	0.0	0.0
247	genital wart incidence	0.5962621892906477	-2.666666666666668	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04477611940298508	0.04477611940298508	3.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04477611940298508	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
247	the assumption	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
189	raised;Raised	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	biomedical knowledge	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
132	occurring;Occur	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
86	2 mRNA	0.77499487114738	-6.666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.054545454545454536	0.054545454545454536	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.054545454545454536	0.0	0.04	0.0	0.0	0.0	0.0	0.0
266	subjects;Subject	0.12502256015305793	-1.1666666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-1.3888888888888882	0.04	0.04	0.0	0.04	0.04217054263565891	1.0	0.0424277048949076	0.0	3.0	0.0	-2.333333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.046511627906976744	0.0	0.044117647058823525	0.0	0.0	0.0	0.0	0.0
334	domains;Domain	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
189	the response of hGH	0.16182494360968655	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
38	cyclic-AMP-regulated gene expression	0.33024779718480995	0.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.2857142857142857	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	14.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
127	ADENOCARCINOMA;adenocarcinoma;Adenocarcinomas	0.7755729783954826	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	5.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	Usage;usage	0.6078722860890746	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
140	Approach;Approaches;approaches;approach	0.12947091470757896	-1.9555555555555557	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.111111111111111	0.0	0.0	-2.6	0.04	0.04	0.0	0.04	0.04353640660425314	1.0	0.04562337662337662	0.0	5.0	0.0	-6.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	5.0	0.047872340425531915	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
151	Possible;possible	0.09746669181166712	-3.3571428571428577	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8571428571428577	0.0	0.0	-5.333333333333333	0.04	0.047619047619047616	0.0	0.04516129032258065	0.046229293809938975	1.0	0.051082251082251076	0.0	2.0	0.0	-6.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.0472972972972973	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
311	Spinal;spinal	0.5534003149595746	-5.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.5	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.05128205128205128	0.05128205128205128	1.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05128205128205128	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
134	Immunoglobulin Lambda Chain;immunoglobulin lambda chain	0.5073579874918589	-5.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-5.0	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.05	0.05	3.0	0.05405405405405406	0.0	2.0	0.0	-6.5	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.05	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
119	heterodimer	0.6885765529881176	-2.583333333333333	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.166666666666666	0.0	0.0	-1.8000000000000007	0.04	0.04	0.0	0.04	0.04521008403361344	1.0	0.04336448598130842	0.0	2.0	0.0	-3.6000000000000014	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.050420168067226885	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
337	Mortality;mortality	0.1090205839635794	-0.5999999999999996	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.041008403361344536	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04201680672268907	0.0	0.04	0.0	0.0	0.0	0.0	0.0
222	lymphoid malignancies	0.7164442871371576	-1.4444444444444429	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.4444444444444429	0.0	0.0	-2.3999999999999986	0.04	0.04424778761061947	0.0	0.04245283018867924	0.04245283018867924	2.0	0.04424778761061947	0.0	2.0	0.0	-2.3999999999999986	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04245283018867924	0.0	0.04424778761061947	0.0	0.0	0.0	0.0	0.0
265	component;Component	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
312	Triage;triage	0.6078722860890746	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
205	absolute weight	0.11084004513643027	-2.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0449438202247191	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
37	ATP/	0.669190721745788	-4.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	the development of a program	0.03776773949451835	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
38	thumbs	0.1728938398120744	-2.777777777777778	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.0	0.0	-1.0833333333333333	0.04	0.04	0.0	0.04	0.04533538146441372	1.0	0.04199233716475096	0.0	3.0	0.0	-3.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.048387096774193554	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
170	Jejunal;jejunal	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
330	the FDA for rheumatoid arthritis	0.050360272310354025	-2.2222222222222214	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.42857142857142855	0.0	-2.2222222222222214	0.0	0.0	0.0	0.04	0.04	0.0	0.04390243902439024	0.04390243902439024	5.0	0.04	0.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04390243902439024	0.0	0.04	0.0	0.0	0.0	0.0	0.0
25	family CBT (FCBT) than individual CBT (ICBT	0.2637062250856764	0.0	0.0	0.0	0.04	0.04	0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	25,26	0.6171953679194666	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
150	a selective type	0.14444859464360416	-5.2857142857142865	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-5.2857142857142865	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.05072463768115942	0.05072463768115942	3.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05072463768115942	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
340	aim;Aim	0.07472131446368781	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-7.4	0.04	0.056818181818181816	0.0	0.05	0.05	1.0	0.056818181818181816	0.0	1.0	0.0	-7.4	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05	0.0	0.056818181818181816	0.0	0.0	0.0	0.0	0.0
236	strategies;strategy	0.10712771428609377	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04380952380952381	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
99	Seventeen families	0.18573471189062707	-4.75	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-12.142857142857142	0.04	0.07777777777777778	0.0	0.04938271604938271	0.04938271604938271	2.0	0.07777777777777778	0.0	1.0	0.0	-12.142857142857142	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04938271604938271	0.0	0.07777777777777778	0.0	0.0	0.0	0.0	0.0
242	alone;only;Only;Alone	0.06656758898780447	-1.8888888888888893	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.7777777777777786	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04356020942408377	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.04712041884816754	0.0	0.04	0.0	0.0	0.0	0.0	0.0
25	moderate ASD symptoms	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
131	List	0.004474463926971182	-16.4	1.0	-14.0	0.09090909090909091	0.09090909090909091	1.0	1.0	1.0	-14.0	1.0	0.0	-16.4	0.0	0.0	-13.8	0.09090909090909091	0.08928571428571429	0.0	0.11627906976744186	0.11627906976744186	1.0	0.08928571428571429	1.0	1.0	0.0	-13.8	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.11627906976744186	0.0	0.08928571428571429	1.0	0.0	0.0	0.0	0.0
278	tgf-beta receptor ii;TGF-beta-II-receptor	0.7432621818714767	-7.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.75	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.057971014492753624	0.057971014492753624	7.0	0.05555555555555555	0.0	2.0	0.0	-7.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	14.0	0.057971014492753624	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
75	results;Result	0.08789743481165169	-4.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.04938271604938271	0.04938271604938271	1.0	0.04597701149425287	0.0	1.0	0.0	-3.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04938271604938271	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
317	represents;Represent	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	this agent	0.09641842798361447	-1.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.75	0.0	0.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.043010752688172046	0.043010752688172046	2.0	0.044642857142857144	0.0	1.0	0.0	-2.6000000000000014	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043010752688172046	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
115	genomic neighborhood	0.3390675980923809	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
40	Mean;mean	0.14095469534932045	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
87	genes;Genes	0.018028487652152623	-8.75	1.0	-18.75	0.04	0.1	1.0	1.0	1.0	-9.375	1.0	1.0	-13.75	1.0	1.0	-7.875	0.16	0.04	1.0	0.047058823529411764	0.06797385620915034	1.0	0.07405405405405406	1.0	2.0	1.0	-15.75	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	2.0	1.0	2.0	0.08888888888888889	1.0	0.10810810810810811	1.0	1.0	1.0	1.0	1.0
127	smokers	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	GC-donor splice site models for Arabidopsis and rice	0.13643660009768455	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.1	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	5 Azacytidine;5-azacytidine;azacytidine;AZACITIDINE;5-aza;5-Aza	0.999091280354143	-0.3611111111111111	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.25	1.0	1.0	-4.648148148148148	0.04	0.04	0.0	0.04	0.04066411238825032	2.4444444444444446	0.05112240221610619	0.24074074074074073	18.0	1.0	-9.666666666666666	1.0	0.3333333333333333	0.0	0.7222222222222222	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	6.0	1.0	44.0	0.04597701149425287	0.0	0.06521739130434782	0.0	1.0	0.0	0.0	1.0
79	the patients in comatose	0.047139750780863514	-3.3999999999999986	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-11.0	0.04	0.07142857142857142	0.0	0.046296296296296294	0.046296296296296294	4.0	0.07142857142857142	0.25	1.0	0.0	-11.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.046296296296296294	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0
204	380	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
267	A new, phonocardiography-	0.26905681404095005	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	a very efficacious competitive antagonist	0.13248033364974673	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04	0.04	5.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
47	ee.nthu.edu.tw	0.7581991220944404	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
338	/-7% of left ventricle)	0.2596311811658064	-1.6363636363636367	0.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.0	0.0	-1.6363636363636367	0.0	0.0	0.0	0.04	0.04	0.0	0.042801556420233464	0.042801556420233464	7.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.042801556420233464	0.0	0.04	0.0	0.0	0.0	0.0	0.0
326	characterized;Characterized	0.0991977202585733	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-2.0	0.04	0.04	0.0	0.04	0.04380952380952381	1.0	0.04380952380952381	0.0	2.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.047619047619047616	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
304	Highly;highly	0.07041737765661071	-4.375	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.375	0.0	0.0	-8.285714285714286	0.04	0.059829059829059825	0.0	0.048484848484848485	0.048484848484848485	1.0	0.059829059829059825	0.0	1.0	0.0	-8.285714285714286	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.048484848484848485	0.0	0.059829059829059825	0.0	0.0	0.0	0.0	0.0
231	Gene Mutation;mutation into the alpha cardiac myosin heavy chain (MHC) gene	0.06853703751202217	0.0	1.0	0.0	0.04	0.04	0.4166666666666667	0.4166666666666667	0.0	0.0	0.25	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	12.0	0.04	0.5	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	12.0	0.04	0.0	0.04	0.0	0.0	0.08333333333333333	0.0	0.0
277	the evaluation of changes	0.0884415052403157	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
26	gastrointestinal endoscopy	0.7413928297720063	-3.2857142857142856	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.2857142857142865	0.0	0.0	0.0	0.04	0.04	0.0	0.0440251572327044	0.04615050965083496	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04827586206896552	0.0	0.04	0.0	0.0	0.0	0.0	0.0
271	Syndromes;syndromes	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
119	p54nrb (non	0.7163601152334724	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
125	ubiquitously expressed MTM1 gene	0.1405487375957212	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
294	the use	0.1130837801952978	-3.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.04615384615384615	0.04615384615384615	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04615384615384615	0.0	0.04	0.0	0.0	0.0	0.0	0.0
71	cellular respiratory systems	0.47580460586823914	-3.3999999999999986	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.046296296296296294	0.046296296296296294	3.0	0.047058823529411764	0.0	2.0	0.0	-3.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.046296296296296294	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
120	held	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
132	the receptor	0.3747664949792554	-9.466666666666667	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-11.0	0.0	0.0	-12.0	0.04	0.07692307692307693	0.0	0.05376344086021505	0.06554019457245264	2.0	0.07692307692307693	0.0	3.0	0.0	-12.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.07142857142857142	0.0	0.07692307692307693	0.0	0.0	0.0	0.0	0.0
192	The association between RLS and LRRK2 gene mutation	0.08154138307832161	-6.666666666666666	1.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.2222222222222222	1.0	-6.666666666666666	1.0	1.0	0.0	0.04	0.04	1.0	0.054545454545454536	0.054545454545454536	8.0	0.04	0.125	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.054545454545454536	0.0	0.04	0.0	1.0	0.125	0.0	1.0
173	Replacement Therapy;replacement therapy	0.07365694677170874	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.04	0.043165467625899276	0.0	0.04	0.04	2.0	0.043165467625899276	0.0	1.0	0.0	-1.8333333333333321	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.043165467625899276	0.0	0.0	0.0	0.0	0.0
152	glibenclamide therapy	0.07834558736064173	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	S/T) motifs	0.7465505366720792	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.666666666666667	0.04	0.04	0.0	0.04	0.04	5.0	0.04542372881355933	0.0	2.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
177	Thirty	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	elevated thyrotropin (TSH) levels	0.8327933039386114	-5.333333333333334	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	1.0	-5.333333333333334	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.05084745762711865	0.05084745762711865	6.0	0.04918032786885245	0.0	2.0	0.0	-4.666666666666666	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	12.0	0.05084745762711865	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
29	gpdA	0.6052148580033511	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.04	0.04	1.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
85	Liver Disease (ALD)Alcoholic liver;hepatic hepatic	0.04476900917269013	0.0	1.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.3333333333333333	1.0	0.0	1.0	1.0	-5.142857142857142	0.04	0.050359712230215826	1.0	0.04	0.04	7.0	0.050359712230215826	0.42857142857142855	1.0	1.0	-5.142857142857142	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	7.0	0.04	0.0	0.050359712230215826	0.0	1.0	0.14285714285714285	0.0	1.0
43	member;Member	0.0834028399885045	-3.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.047058823529411764	0.047058823529411764	1.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047058823529411764	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
96	relapsed or	0.24992123698374794	-3.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-2.1999999999999993	0.04	0.043859649122807015	0.0	0.045454545454545456	0.045454545454545456	2.0	0.043859649122807015	0.0	1.0	0.0	-2.1999999999999993	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.045454545454545456	0.0	0.043859649122807015	0.0	0.0	0.0	0.0	0.0
199	Primary;primary	0.082982109540416	-2.833333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.045112781954887216	0.045112781954887216	1.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045112781954887216	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
142	future;Future	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	clearance of calcium;Calcium Clearance	0.5319516836830203	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	the transmembrane β-strands of the outer membrane proteins	0.06833223035315693	-2.375	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-2.375	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04419889502762431	0.04419889502762431	10.0	0.045454545454545456	0.6	1.0	0.0	-3.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04419889502762431	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
318	kinase inhibitors;Kinase Inhibitors	0.3968579929853613	-1.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-4.076923076923077	0.04	0.04421768707482993	1.0	0.04	0.04173913043478261	2.0	0.04810884353741497	0.5	2.0	0.0	-5.76923076923077	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.043478260869565216	0.0	0.052000000000000005	0.0	0.0	0.5	0.0	0.0
342	the histone methyltransferase	0.2144827666958868	-6.800000000000001	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-6.800000000000001	1.0	1.0	-6.6	0.04	0.05434782608695653	0.0	0.054945054945054944	0.054945054945054944	3.0	0.05434782608695653	0.6666666666666666	1.0	1.0	-6.6	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.054945054945054944	0.0	0.05434782608695653	0.0	1.0	0.0	0.0	1.0
30	First;first	0.10291425863238464	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.6999999999999993	0.04	0.04	0.0	0.04	0.04	1.0	0.043148148148148144	0.0	2.0	0.0	-3.3999999999999986	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
46	for;For	0.08859356489706434	-1.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04201680672268907	0.04201680672268907	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04201680672268907	0.0	0.04	0.0	0.0	0.0	0.0	0.0
157	CMV	0.6560236501476947	-3.3999999999999986	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-2.3999999999999986	0.04	0.04424778761061947	0.0	0.046296296296296294	0.046296296296296294	1.0	0.04424778761061947	0.0	1.0	0.0	-2.3999999999999986	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.046296296296296294	0.0	0.04424778761061947	0.0	0.0	0.0	0.0	0.0
122	he;He	0.07179027434645972	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.047619047619047616	0.047619047619047616	1.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
256	Arg	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	drug targets;drug target	0.11707437433269925	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
158	planning;Planning	0.10834121266201877	-1.0999999999999996	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04192982456140351	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.043859649122807015	0.0	0.04	0.0	0.0	0.0	0.0	0.0
59	concentrations;Concentrations	0.06899870749423251	-5.800000000000001	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.800000000000001	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.052083333333333336	0.052083333333333336	1.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.052083333333333336	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
15	structural;Structural;structures	0.09113937642668107	-1.4499999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	0.0	0.04	0.04	0.0	0.0423728813559322	0.042463036422646955	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.0425531914893617	0.0	0.04	0.0	0.0	0.0	0.0	0.0
198	7x	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	plants;Plants	0.13391980531752765	-0.48148148148148096	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.4444444444444429	0.0	0.0	-0.6666666666666666	0.04	0.04	0.0	0.04	0.040817610062893084	1.0	0.04115942028985507	0.0	3.0	0.0	-2.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04245283018867924	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
223	Immunotherapy, Passive;passive immunotherapy	0.5463567257356108	-1.8181818181818166	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.8181818181818166	0.0	0.0	-3.8571428571428577	0.04	0.0472972972972973	0.0	0.043137254901960784	0.043137254901960784	2.0	0.0472972972972973	0.0	1.0	0.0	-3.8571428571428577	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.043137254901960784	0.0	0.0472972972972973	0.0	0.0	0.0	0.0	0.0
28	concomitant development	0.29768314582036853	-6.666666666666666	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.054545454545454536	0.054545454545454536	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.054545454545454536	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	the-art predictors transFold and PRED-TMBB	0.17235484180680655	-2.555555555555557	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-2.555555555555557	1.0	1.0	-3.333333333333332	0.04	0.04615384615384615	0.0	0.04455445544554456	0.04455445544554456	9.0	0.04615384615384615	0.3333333333333333	1.0	1.0	-3.333333333333332	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04455445544554456	0.0	0.04615384615384615	0.0	1.0	0.0	0.0	1.0
174	the dominant Romano-Ward (RW) syndrome	0.061461898419698534	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.4444444444444444	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
213	LQT12;SNTA1	0.8449074909366465	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	4.0	1.0	0.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
242	exercise testing	0.1619925499503854	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	chromosome 9 and 22	0.9276810435394425	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.2820512820512822	0.04	0.041666666666666664	0.0	0.04	0.04	4.0	0.042174234034699144	0.25	6.0	0.0	-1.8461538461538467	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	24.0	0.04	0.0	0.04318936877076412	0.0	0.0	0.0	0.0	0.0
58	olecular tests	0.3310541326979445	-5.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.05	0.05	2.0	0.04918032786885245	0.0	2.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.05	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
332	Novel;novel	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	the USA	0.20123518407215368	-4.25	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.04819277108433735	0.04819277108433735	2.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04819277108433735	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
203	deletion;Deletion	0.6354731764423084	-8.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-8.75	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.06153846153846154	0.06153846153846154	1.0	0.04587155963302752	0.0	1.0	0.0	-3.1999999999999993	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.06153846153846154	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
193	GATA1, ARG216GLN;GATA1 Arg216Gln	0.7460250911297006	-3.3999999999999986	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.3999999999999986	1.0	1.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.046296296296296294	0.046296296296296294	2.0	0.05084745762711865	0.0	1.0	1.0	-5.333333333333334	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	2.0	1.0	2.0	0.046296296296296294	1.0	0.05084745762711865	0.0	1.0	0.0	1.0	1.0
4	rare inherited cancer syndromes	0.13367526090752366	-3.875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-3.875	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.047337278106508875	0.047337278106508875	4.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.3333333333333333	1.0	0.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.047337278106508875	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
189	Report;report	0.09121137094188815	-2.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-4.0	0.04	0.04	0.0	0.04	0.045	1.0	0.04941176470588235	0.0	2.0	0.0	-8.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.05	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
229	functional analyses;Functional analysis	0.169188290062278	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
293	the only SSRI	0.054993901939855594	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.5	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
346	the elongation of transcripts	0.1491728768675033	-1.8000000000000007	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04310344827586207	0.04310344827586207	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04310344827586207	0.0	0.04	0.0	0.0	0.0	0.0	0.0
77	membrane;Membrane	0.5658023944960809	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.1428571428571423	0.04	0.04375	0.0	0.04	0.04	1.0	0.04375	0.0	1.0	0.0	-2.1428571428571423	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04375	0.0	0.0	0.0	0.0	0.0
345	proposed;Proposed	0.09016793342309946	-1.6999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04291845493562232	0.04291845493562232	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04291845493562232	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	Inducing;inducing	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
140	G;g;g%	0.5708519976379184	-1.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-2.5	0.04	0.04	0.0	0.04205607476635514	0.04255913786164647	0.5	0.045	0.0	2.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	1.0	0.0430622009569378	0.0	0.05	0.0	0.0	0.0	0.0	0.0
66	adverse pregnancy outcome	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
142	C620S);C620S	0.5242626052800212	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.666666666666666	0.04	0.04225352112676056	0.0	0.04	0.04	1.5	0.04286589099816289	0.25	2.0	0.0	-2.0	1.0	0.0	0.0	0.5	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
334	Foci;foci	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	the complete structure	0.029148962528673918	-2.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.044117647058823525	0.044117647058823525	3.0	0.04	0.6666666666666666	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.044117647058823525	0.0	0.04	0.0	0.0	0.0	0.0	0.0
38	psychomotor development delay;Psychomotor delay	0.27235294941819344	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	31 adults	0.2110828741927123	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04	0.04	2.0	0.04878048780487805	0.0	1.0	0.0	-4.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
276	p24) in a female patient	0.10516088727088753	-2.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	multi-view text mining	0.26602968377748804	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.04	0.04	3.0	0.06060606060606061	0.0	1.0	0.0	-8.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
110	thyroid state	0.09093537330198001	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.04	0.04	2.0	0.046875	0.5	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
218	to;TO;To	0.0868068106467973	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	minor;Minor	0.06503543752352588	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-9.0	0.04	0.0625	0.0	0.045454545454545456	0.045454545454545456	1.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
227	primary fibroblasts	0.35740574937482544	-2.6000000000000014	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.044642857142857144	0.044642857142857144	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.044642857142857144	0.0	0.04	0.0	0.0	0.0	0.0	0.0
38	caused;causes;cause	0.18234416333381107	-2.8888888888888893	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-5.25	0.04	0.04	0.0	0.04	0.046053864168618265	1.0	0.058583509513742076	0.0	6.0	0.0	-14.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	6.0	0.053571428571428575	0.0	0.09302325581395349	0.0	0.0	0.0	0.0	0.0
198	its mutant	0.22911560116869722	-6.199999999999999	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-6.199999999999999	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.05319148936170213	0.05319148936170213	2.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05319148936170213	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
216	a metal resistant Pseudomonas aeruginosa strain;a metal-resistant Pseudomonas aeruginosa strain	0.3902040791293009	-5.625	0.0	0.0	0.04	0.04	0.42857142857142855	0.4642857142857143	0.0	0.0	0.0	1.0	-7.25	1.0	1.0	-8.5	0.04	0.05263157894736842	0.0	0.047619047619047616	0.051978537894030855	6.5	0.06203007518796992	0.0	2.0	1.0	-11.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	13.0	0.056338028169014086	0.0	0.07142857142857142	0.0	1.0	0.0	0.0	1.0
238	the best conventional treatment option	0.05411772315431602	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
104	GN	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
24	paper;Paper	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
51	an anti-PD1 antibody	0.4851016569281921	-1.5833333333333321	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-1.5833333333333321	1.0	1.0	-5.0	0.04	0.05	1.0	0.042704626334519574	0.042704626334519574	3.0	0.05	0.3333333333333333	1.0	1.0	-5.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.042704626334519574	0.0	0.05	0.0	1.0	0.3333333333333333	0.0	1.0
211	Five;five	0.08334631552010782	-1.6666666666666679	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6666666666666679	0.0	0.0	-1.8888888888888893	0.04	0.04326923076923077	0.0	0.04285714285714286	0.04285714285714286	1.0	0.04326923076923077	0.0	1.0	0.0	-1.8888888888888893	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04285714285714286	0.0	0.04326923076923077	0.0	0.0	0.0	0.0	0.0
107	Matrix;matrix	0.6733470869749268	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
241	Nerve root impingement;impingement of the nerve root	0.10083661990240139	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
149	Increased;increased	0.09355636499425246	-2.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0449438202247191	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
156	treatable movement disorder	0.19988753634654213	-6.333333333333334	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-6.333333333333334	0.0	0.0	-12.5	0.04	0.08	0.0	0.053571428571428575	0.053571428571428575	3.0	0.08	0.0	1.0	0.0	-12.5	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	3.0	0.053571428571428575	0.0	0.08	0.0	0.0	0.0	0.0	0.0
176	ACT;act	0.00219341785398262	-17.875	1.0	0.0	0.04	0.04	1.0	1.0	1.0	0.0	1.0	0.0	-17.875	0.0	0.0	-16.8	0.04	0.12195121951219513	0.0	0.14035087719298245	0.14035087719298245	1.0	0.12195121951219513	1.0	1.0	0.0	-16.8	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.14035087719298245	0.0	0.12195121951219513	1.0	0.0	0.0	0.0	0.0
49	62 patients from UK	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
163	*Number;number	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
197	5,473	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
262	MUCOSA;mucosas	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
127	cases of non-small cell lung cancer (NSCLC)	0.14109668803572545	0.0	0.0	0.0	0.04	0.04	0.5555555555555556	0.5555555555555556	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
144	the human SERCA2 gene	0.10539247980758439	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.25	0.0	0.0
328	the mode	0.0030087844685724894	-7.800000000000001	1.0	-16.25	0.11428571428571428	0.11428571428571428	1.0	1.0	1.0	-16.25	1.0	0.0	-7.800000000000001	0.0	0.0	-16.75	0.11428571428571428	0.12121212121212122	1.0	0.05813953488372093	0.05813953488372093	2.0	0.12121212121212122	1.0	1.0	0.0	-16.75	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05813953488372093	0.0	0.12121212121212122	1.0	0.0	0.5	0.0	0.0
311	two fragile X syndromes of mental retardation (FRAXA and FRAXE), myotonic dystrophy	0.21448301023824204	-4.333333333333334	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	-4.333333333333334	1.0	1.0	0.0	0.04	0.04	0.0	0.048387096774193554	0.048387096774193554	15.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	15.0	0.048387096774193554	0.0	0.04	0.0	1.0	0.0	0.0	1.0
9	the present results	0.07769621043602098	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04	0.04	3.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
310	II trials in a variety	0.057961055114664525	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	a means	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
67	DEMYELINATION;demyelination	0.6660574965505912	-1.055555555555556	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	-4.166666666666667	0.04	0.04	0.0	0.04	0.041933842239185753	1.0	0.05333333333333334	0.0	3.0	0.0	-12.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04580152671755725	0.0	0.08	0.0	0.0	0.0	0.0	0.0
158	age;AGE	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	mantle cell lymphoma treatment	0.4327616304371275	-3.25	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-3.25	1.0	1.0	-2.3999999999999986	0.04	0.04424778761061947	0.0	0.04597701149425287	0.04597701149425287	4.0	0.04424778761061947	0.0	2.0	1.0	-2.3999999999999986	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04597701149425287	0.0	0.04424778761061947	0.0	1.0	0.0	0.0	1.0
96	50%;50	0.6079068508843011	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.04	0.0	0.04	0.04	0.5	0.04941176470588235	0.0	2.0	0.0	-8.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
220	the ND6 subunit	0.19189207790644303	-2.125	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.125	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04371584699453552	0.04371584699453552	3.0	0.047619047619047616	0.3333333333333333	1.0	0.0	-4.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04371584699453552	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
13	good qualitative agreement	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
344	histone H3;Histone H3	0.7317527096351648	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	4.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	None of our patients	0.0884415052403157	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
291	water;WATER	0.13032270437917173	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	1.0	0.0	1.0	0.5	1.0	0.0	1.0	1.0	1.0	0.5	0.5	2.0	1.0	1.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
256	a female patient with a Pro250Arg mutation	0.07315313996107475	0.0	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
291	general;General	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
265	Cardiac Muscle;cardiac muscle	0.20146510080365157	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	the growth failure	0.11858912668535745	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	1.0	0.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
270	Ski;Ski's	0.2983790098811893	-2.16	0.0	0.0	0.04	0.04	0.5	0.9	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-10.7	0.04	0.06060606060606061	0.0	0.04	0.04405662805662806	1.2	0.0766911045943304	0.0	5.0	0.0	-17.5	1.0	0.0	0.8	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.047619047619047616	0.0	0.13333333333333333	0.0	0.0	0.0	0.0	0.0
29	cultures with the largest difference;culture difference	0.03590599394892387	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.045454545454545456	0.045454545454545456	5.0	0.053571428571428575	0.2	1.0	0.0	-6.333333333333334	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.045454545454545456	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
303	histone variant CENPA	0.08662900692159335	-3.333333333333332	1.0	-9.166666666666666	0.06315789473684211	0.06315789473684211	0.0	0.0	1.0	-9.166666666666666	1.0	1.0	-3.333333333333332	0.0	0.0	-9.5	0.06315789473684211	0.06451612903225806	0.0	0.04615384615384615	0.04615384615384615	3.0	0.06451612903225806	1.0	1.0	0.0	-9.5	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.04615384615384615	0.0	0.06451612903225806	1.0	0.0	0.0	0.0	0.0
299	Which	0.004779762126416741	-17.5	1.0	-18.0	0.14285714285714285	0.14285714285714285	1.0	1.0	1.0	-18.0	1.0	0.0	-17.5	0.0	0.0	-15.666666666666668	0.14285714285714285	0.10714285714285715	0.0	0.13333333333333333	0.13333333333333333	1.0	0.10714285714285715	1.0	1.0	0.0	-15.666666666666668	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.13333333333333333	0.0	0.10714285714285715	1.0	0.0	0.0	0.0	0.0
44	its mosquito vector	0.3712989995534217	-2.75	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0449438202247191	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
171	an MYH7-associated spectrum of NCCM	0.2443019888294256	-3.6000000000000014	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	1.0	-3.6000000000000014	1.0	1.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04672897196261683	0.04672897196261683	7.0	0.053571428571428575	0.0	1.0	1.0	-6.333333333333334	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04672897196261683	0.0	0.053571428571428575	0.0	1.0	0.0	0.0	1.0
229	ORIENT (neighbor-favoring weight reinforcement)	0.2437065367195448	0.0	0.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
103	the establishment	0.03794072029440384	-1.8888888888888893	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-2.1428571428571423	0.04	0.04375	0.0	0.04326923076923077	0.04326923076923077	2.0	0.04375	0.5	1.0	0.0	-2.1428571428571423	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04326923076923077	0.0	0.04375	0.0	0.0	0.0	0.0	0.0
137	the appropriate subsequent antithrombotic regimen	0.0987050025177782	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04	0.04	5.0	0.043478260869565216	0.2	1.0	0.0	-2.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
21	three;Three	0.08513976243786738	-4.428571428571429	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.428571428571429	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.04861111111111112	0.04861111111111112	1.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04861111111111112	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
225	deleted;Deleted	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	experiment;Experiment	0.06901263893103253	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
265	phenotype;Phenotype	0.5500338339103773	-3.6000000000000014	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.04672897196261683	0.04672897196261683	1.0	0.054545454545454536	0.0	1.0	0.0	-6.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04672897196261683	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
285	in-situ carcinoma;in situ carcinomas	0.35257886982690934	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.04	0.04	3.0	0.0462962962962963	0.3333333333333333	3.0	0.0	-3.3999999999999986	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.04	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
31	intracellular	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	one of 14 placebo patients	0.15898064341854684	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	outer loops	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
68	the human MSX2 gene	0.10151919661888018	-5.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	-5.333333333333334	1.0	1.0	-6.5	0.04	0.05405405405405406	1.0	0.04918032786885245	0.05001389274798555	4.0	0.05405405405405406	0.5	2.0	1.0	-6.5	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.05084745762711865	0.0	0.05405405405405406	0.0	1.0	0.25	0.0	1.0
287	apoptosis in T-NHL cell lines	0.15898064341854684	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
213	Channel;channel	0.09350770744665571	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047058823529411764	0.0	0.04	0.04	1.0	0.04762579730687456	0.0	2.0	0.0	-4.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
231	the Gly203Ser cardiac troponin I (TnI-203) and Arg403Gln alpha-myosin heavy chain	0.11730136634292135	-2.428571428571427	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.14285714285714285	1.0	-2.428571428571427	0.0	0.0	-2.2857142857142847	0.04	0.0440251572327044	0.0	0.04430379746835443	0.04430379746835443	15.0	0.0440251572327044	0.3333333333333333	1.0	0.0	-2.2857142857142847	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	15.0	0.04430379746835443	0.0	0.0440251572327044	0.0	0.0	0.0	0.0	0.0
14	folding;Folding	0.7984172794811444	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-3.750000000000001	0.04	0.04477611940298508	0.0	0.04	0.04	1.0	0.04718144813124461	0.0	2.0	1.0	-4.833333333333334	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	2.0	1.0	2.0	0.04	1.0	0.04958677685950414	0.0	1.0	0.0	1.0	1.0
287	ABK with a selectivity	0.20955370180513044	-3.1999999999999993	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04587155963302752	0.04587155963302752	4.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04587155963302752	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
307	major protein	0.04725571327906539	-1.9000000000000004	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.3333333333333333	1.0	-3.8000000000000007	1.0	1.0	-4.5	0.04	0.04878048780487805	1.0	0.04	0.04358490566037736	2.0	0.04878048780487805	0.5	2.0	1.0	-4.5	1.0	0.6666666666666666	1.0	1.0	1.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04716981132075472	0.0	0.04878048780487805	0.0	1.0	0.5	0.0	1.0
95	conjunction;Conjunction	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
137	ET) of CCSVI	0.10121403571828586	-1.2222222222222214	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.5	0.0	-1.2222222222222214	0.0	0.0	-4.199999999999999	0.04	0.04587155963302752	0.0	0.04205607476635514	0.04205607476635514	4.0	0.04818830506903901	0.75	2.0	0.0	-5.199999999999999	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04205607476635514	0.0	0.050505050505050504	0.0	0.0	0.0	0.0	0.0
96	rate;Rate	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
56	treat;TREAT	0.003321318345123271	-18.666666666666668	1.0	-18.0	0.14285714285714285	0.14285714285714285	1.0	1.0	1.0	-18.0	1.0	0.0	-18.666666666666668	0.0	0.0	-19.0	0.14285714285714285	0.16666666666666666	0.0	0.15789473684210528	0.15789473684210528	1.0	0.16666666666666666	1.0	1.0	0.0	-19.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.15789473684210528	0.0	0.16666666666666666	1.0	0.0	0.0	0.0	0.0
72	Literature;literature	0.5581829451268915	-1.7454545454545458	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-4.545454545454546	0.04	0.04	0.0	0.04	0.04314429541893811	1.0	0.04975129973708323	0.0	11.0	0.0	-7.6	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	11.0	0.04716981132075472	0.0	0.0574712643678161	0.0	0.0	0.0	0.0	0.0
82	described	0.07956918104696434	-2.571428571428573	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.571428571428573	0.0	0.0	-9.6	0.04	0.06493506493506493	0.0	0.0445859872611465	0.0445859872611465	1.0	0.06493506493506493	0.0	1.0	0.0	-9.6	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.0445859872611465	0.0	0.06493506493506493	0.0	0.0	0.0	0.0	0.0
262	Balloon cells	0.14684823062145294	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
30	the primary candidate for this anti-amyloidogenic activity	0.04674180248996833	0.0	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
145	-induced cell death and apoptosis in PC12 cells	0.10960826902211158	0.0	0.0	0.0	0.04	0.04	0.5555555555555556	0.5555555555555556	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.1111111111111111	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	org/cgi/content	0.6668594340272865	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
78	occurring;occurred;Occur;Occurred	0.07519348356259158	-2.875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.04519918283963228	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	Mutations in CHD7	0.31729632132624763	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-5.666666666666667	0.04	0.05084745762711865	0.0	0.04	0.04	3.0	0.05173951828724353	0.3333333333333333	2.0	1.0	-6.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.05263157894736842	0.0	1.0	0.0	0.0	1.0
95	the DnaQ family	0.022381827982806697	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	3.0	0.04	0.6666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.3333333333333333	0.0	0.0
319	potential concerns	0.08391605666937475	-2.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.044117647058823525	0.044117647058823525	2.0	0.05405405405405406	0.0	1.0	0.0	-6.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.044117647058823525	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
118	in vitro;In Vitro	0.06982605562841729	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04	0.04	2.0	0.04819277108433735	0.5	1.0	0.0	-4.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
129	the maintenance methyltransferase;the “maintenance” methyltransferase	0.2516070164290077	-0.7222222222222214	0.0	0.0	0.04	0.04	0.4	0.5333333333333333	0.0	0.0	0.0	1.0	-1.4444444444444429	0.0	0.0	-3.6428571428571423	0.04	0.04375	0.0	0.04	0.04122641509433962	4.0	0.047054856115107915	0.5333333333333333	2.0	0.0	-5.142857142857142	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	8.0	0.04245283018867924	0.0	0.050359712230215826	0.0	0.0	0.0	0.0	0.0
256	Nortriptyline;NORTRIPTYLINE;Nortriptyline.	0.6037376978604453	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.5	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	E-box-driven gene expression	0.3322032343541392	-2.75	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0449438202247191	5.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	one of the two reports	0.08279735195665178	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	likely;Likely	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
188	C57BL	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
270	The zinc finger transcription factor GATA-1	0.14123094956265012	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.16666666666666666	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
131	Combination;combination	0.05881994638986471	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.8	0.04	0.0617283950617284	0.0	0.04	0.04	1.0	0.0617283950617284	0.0	1.0	0.0	-8.8	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.0617283950617284	0.0	0.0	0.0	0.0	0.0
129	S adenosylmethionine;S-adenosyl methionine;S-adenosylmethionine	0.5344687953107041	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-5.5	0.04	0.05109489051094891	0.0	0.04	0.04	3.5	0.051282739373121514	0.29166666666666663	2.0	0.0	-5.571428571428571	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	3.0	1.0	7.0	0.04	0.0	0.051470588235294115	0.0	0.0	0.0	0.0	0.0
4	1 vipoma	0.4867152409007567	-3.625	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.625	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04678362573099415	0.04678362573099415	2.0	0.04716981132075472	0.5	1.0	0.0	-3.8000000000000007	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04678362573099415	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
17	a right ectopic pregnancy	0.16182494360968655	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
54	considered	0.08424784999938828	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
93	RECEIVED;receive;receiving;Receive;received	0.1307833049511516	-6.472222222222221	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-10.833333333333334	0.0	0.0	-4.111111111111111	0.04	0.04	0.0	0.04615384615384615	0.055157383466206994	1.0	0.04875653082549634	0.0	6.0	0.0	-6.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	5.0	1.0	6.0	0.07058823529411765	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
4	Transcript;transcript	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
216	an important model organism for bioremediation studies	0.03791853630730369	0.0	1.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.125	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
270	Using	0.09729340743684152	-1.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-8.75	0.04	0.04	0.0	0.04	0.042727272727272725	1.0	0.08666666666666667	0.0	2.0	0.0	-17.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.045454545454545456	0.0	0.13333333333333333	0.0	0.0	0.0	0.0	0.0
16	The top scoring hits	0.06637442787073183	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
214	the protein component	0.048894972933717654	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
163	health care professional	0.10410971754935001	-2.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04504504504504505	0.04504504504504505	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04504504504504505	0.0	0.04	0.0	0.0	0.0	0.0	0.0
192	function	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	Formula	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
132	the receptor on alphavbeta3	0.1748045286132811	-6.4	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-6.4	0.0	0.0	-12.0	0.04	0.07692307692307693	0.0	0.05376344086021505	0.05376344086021505	4.0	0.07692307692307693	0.0	1.0	0.0	-12.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.05376344086021505	0.0	0.07692307692307693	0.0	0.0	0.0	0.0	0.0
299	inotropic agents;Inotropic agent	0.16155752320049063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	2.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
84	mirtazapine 15 mg;Mirtazapine 15 MG	0.5206405992735543	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
215	p53/Pten-deficient cells and tumour regression	0.4024317464198247	-4.75	0.0	0.0	0.04	0.04	0.2222222222222222	0.2222222222222222	0.0	0.0	0.0	1.0	-4.75	0.0	0.0	-7.4	0.04	0.056818181818181816	0.0	0.04938271604938271	0.04938271604938271	9.0	0.056818181818181816	0.0	1.0	0.0	-7.4	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04938271604938271	0.0	0.056818181818181816	0.0	0.0	0.0	0.0	0.0
277	diagnostic tests	0.016403524008620923	-7.0	1.0	-12.0	0.07692307692307693	0.07692307692307693	0.5	0.5	1.0	-12.0	1.0	1.0	-7.0	1.0	1.0	-10.0	0.07692307692307693	0.06666666666666667	1.0	0.05555555555555555	0.05555555555555555	2.0	0.06666666666666667	1.0	1.0	1.0	-10.0	1.0	0.5	0.0	1.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	2.0	0.05555555555555555	0.0	0.06666666666666667	1.0	1.0	0.5	0.0	1.0
44	blood suction	0.33464996046184486	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
78	microdeletions	0.6891157495153456	-4.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	0.0	0.04	0.04	0.0	0.04878048780487805	0.04878048780487805	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04878048780487805	0.0	0.04	0.0	0.0	0.0	0.0	0.0
189	more than 5 years	0.12720679518873382	-4.333333333333334	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-4.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.048387096774193554	0.048387096774193554	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.048387096774193554	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	discrete models (Chou	0.3664983532337138	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.04	0.04477611940298508	0.0	0.04	0.04	4.0	0.04477611940298508	0.0	1.0	0.0	-2.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04477611940298508	0.0	0.0	0.0	0.0	0.0
14	the detection of transmembrane β-barrel chains	0.06382136539459875	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	8.0	0.045454545454545456	0.625	1.0	1.0	-3.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.045454545454545456	0.0	1.0	0.0	0.0	1.0
102	the C3H strain	0.16424500826351182	-4.75	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04938271604938271	0.04938271604938271	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04938271604938271	0.0	0.04	0.0	0.0	0.0	0.0	0.0
165	the history	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	Form;form	0.957413728880686	-12.083333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-16.5	0.0	0.0	-9.968253968253968	0.04	0.047619047619047616	0.0	0.04819277108433735	0.07941393989924703	1.0	0.06803700457918616	0.0	21.0	0.0	-11.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	21.0	0.11764705882352941	0.0	0.075	0.0	0.0	0.0	0.0	0.0
257	ovulatory;Ovulatory	0.5294601312752852	-4.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-9.285714285714286	0.04	0.06363636363636364	0.0	0.04878048780487805	0.04878048780487805	1.0	0.06363636363636364	0.0	1.0	0.0	-9.285714285714286	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04878048780487805	0.0	0.06363636363636364	0.0	0.0	0.0	0.0	0.0
344	genome;genomic;Genome;Genomic	0.26100573202529914	-6.5625	1.0	-14.166666666666668	0.04	0.06615384615384616	0.0	0.0	1.0	-7.083333333333334	1.0	1.0	-13.125	0.0	0.0	-6.25	0.09230769230769231	0.04	0.0	0.04	0.06210526315789473	1.0	0.06	0.5	2.0	0.0	-12.5	1.0	1.0	0.0	0.5	0.0	0.0	1.0	1.0	1.0	4.0	1.0	2.0	0.08421052631578947	1.0	0.08	1.0	0.0	0.0	1.0	0.0
46	the Alagille syndrome critical region within 20p12	0.07419469783834164	0.0	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04	0.04	7.0	0.05084745762711865	0.14285714285714285	1.0	1.0	-5.333333333333334	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.05084745762711865	0.0	1.0	0.0	0.0	1.0
137	endovascular treatment;Endovascular treatment	0.9997128975179351	-2.9786324786324787	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.111111111111111	0.0	0.0	-5.288461538461538	0.04	0.04310344827586207	0.0	0.04265402843601896	0.04546647854054752	2.0	0.05138308488238094	0.5	26.0	0.0	-10.1	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	52.0	0.047872340425531915	0.0	0.06711409395973154	0.0	0.0	0.0	0.0	0.0
250	Sixteen	0.6699299063304603	-2.2222222222222214	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.2222222222222214	0.0	0.0	0.0	0.04	0.04	0.0	0.04390243902439024	0.04390243902439024	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04390243902439024	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	second-generation	0.06190133028052652	-2.1111111111111107	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.1111111111111107	0.0	0.0	-7.76923076923077	0.04	0.05803571428571429	0.0	0.043689320388349516	0.043689320388349516	3.0	0.05803571428571429	0.3333333333333333	1.0	0.0	-7.76923076923077	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043689320388349516	0.0	0.05803571428571429	0.0	0.0	0.0	0.0	0.0
115	HCNE sequences	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	Mutant;mutant	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	somatic divisions.In mammals	0.5942114260970301	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.1428571428571423	0.04	0.04375	0.0	0.04	0.04	3.0	0.04375	0.0	1.0	0.0	-2.1428571428571423	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04375	0.0	0.0	0.0	0.0	0.0
274	the pathogenesis of AD	0.0622503756697894	-1.5454545454545467	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-1.5454545454545467	0.0	0.0	-2.8571428571428577	0.04	0.04516129032258065	0.0	0.04263565891472868	0.04263565891472868	4.0	0.04516129032258065	0.25	1.0	0.0	-2.8571428571428577	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04263565891472868	0.0	0.04516129032258065	0.0	0.0	0.0	0.0	0.0
225	The great majority of patients	0.08279735195665178	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
48	11 different mutant alleles	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	is;IS	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
201	cause of death;Cause of Death	0.10948305048399379	-11.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-11.0	0.0	0.0	0.0	0.04	0.04	0.0	0.07142857142857142	0.07142857142857142	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.07142857142857142	0.0	0.04	0.0	0.0	0.0	0.0	0.0
316	a family	0.09809298157107384	-3.6363636363636367	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.6363636363636367	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04680851063829787	0.04680851063829787	2.0	0.04716981132075472	0.0	1.0	0.0	-3.8000000000000007	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04680851063829787	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
25	Sample;sample	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
111	trans-acting proteins	0.7171460201729598	-4.428571428571429	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.428571428571429	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04861111111111112	0.04861111111111112	2.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04861111111111112	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
297	hospitalization;HOSPITALIZATION	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
261	pivotal;PIVOT	0.4827284791382184	-2.428571428571427	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.428571428571427	0.0	0.0	-11.666666666666666	0.04	0.075	0.0	0.04430379746835443	0.04430379746835443	1.0	0.075	0.0	1.0	0.0	-11.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04430379746835443	0.0	0.075	0.0	0.0	0.0	0.0	0.0
40	use;uses	0.09273938256784227	-2.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	0.0	0.04	0.04	0.0	0.044444444444444446	0.044444444444444446	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.044444444444444446	0.0	0.04	0.0	0.0	0.0	0.0	0.0
135	databases;database;Databases;Database	0.00269617767794052	-3.9705882352941178	1.0	-10.727272727272727	0.04	0.05503184713375795	1.0	1.0	1.0	-5.363636363636363	1.0	0.0	-6.8235294117647065	0.0	0.0	-5.25	0.07006369426751592	0.044444444444444446	0.0	0.04187192118226601	0.04844405120601973	1.0	0.05163398692810457	1.0	2.0	0.0	-8.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.05501618122977346	0.0	0.058823529411764705	1.0	0.0	0.0	0.0	0.0
232	mitral valve prolapse;MITRAL VALVE PROLAPSE	0.9990655773431614	-1.6666666666666667	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-8.666666666666666	1.0	1.0	-1.8846153846153846	0.04	0.04	0.0	0.04	0.043849247728288396	3.0	0.04445332445332446	0.0	13.0	1.0	-9.25	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	39.0	0.06122448979591836	0.0	0.06349206349206349	0.0	1.0	0.0	0.0	1.0
186	-function mutations;function mutations	0.517781353677114	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.38888888888888884	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.6666666666666665	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
311	ataxia type 1 (SCA1	0.4175122847513681	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
123	40	0.6799262331530457	-3.3999999999999986	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.046296296296296294	0.046296296296296294	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.046296296296296294	0.0	0.04	0.0	0.0	0.0	0.0	0.0
183	Missense Mutation;missense mutation	0.5717231683879584	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
346	and;And	0.10468833200630674	-7.800000000000001	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.800000000000001	0.0	0.0	-1.571428571428573	0.04	0.042682926829268296	0.0	0.05813953488372093	0.05813953488372093	1.0	0.042682926829268296	0.0	1.0	0.0	-1.571428571428573	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05813953488372093	0.0	0.042682926829268296	0.0	0.0	0.0	0.0	0.0
318	associated with;Associated with;Associated;associated	0.17541837685354794	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.1076923076923073	0.04	0.04153354632587859	0.0	0.04	0.04	1.6	0.04378659761370211	0.0	5.0	0.0	-3.9230769230769234	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	8.0	0.04	0.0	0.04744525547445255	0.0	0.0	0.0	0.0	0.0
63	higher risk;HIGH RISK	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	adjuvant chemotherapy in ER-positive breast cancer	0.21515302129199834	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
7	Maternal;maternal	0.6136107594599689	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-3.625	0.04	0.04	0.0	0.04	0.04380952380952381	1.0	0.04816901408450704	0.0	2.0	0.0	-7.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.047619047619047616	0.0	0.056338028169014086	0.0	0.0	0.0	0.0	0.0
32	H3.4;4 of H3	0.31059685447332874	-2.6000000000000014	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-2.6000000000000014	1.0	1.0	0.0	0.04	0.04	0.0	0.044642857142857144	0.044642857142857144	2.0	0.04	0.0	1.0	1.0	0.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	2.0	0.044642857142857144	0.0	0.04	0.0	1.0	0.0	0.0	1.0
200	2;+2	0.5912746201715742	-1.9000000000000004	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-5.833333333333333	0.04	0.04	0.0	0.04	0.04358490566037736	1.0	0.057499999999999996	0.0	2.0	0.0	-11.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04716981132075472	0.0	0.075	0.0	0.0	0.0	0.0	0.0
50	each cell line	0.08628475506433098	-2.7777777777777786	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.7777777777777786	0.0	0.0	-4.6	0.04	0.04901960784313726	0.0	0.045	0.045	3.0	0.04901960784313726	0.0	1.0	0.0	-4.6	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.045	0.0	0.04901960784313726	0.0	0.0	0.0	0.0	0.0
80	Septal hypertrophy;septal hypertrophy	0.6721500832556117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
150	LOCALIZED;localized	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
171	severe early-onset heart failure	0.09846887059279563	-6.199999999999999	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-6.199999999999999	0.0	0.0	-11.0	0.04	0.07142857142857142	0.0	0.05319148936170213	0.05319148936170213	6.0	0.07142857142857142	0.0	1.0	0.0	-11.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.05319148936170213	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0
15	a broader set of entity types	0.053643096511266454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	Reporter;reporter	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	awakening;Awakening	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	an equivalent potential	0.12968440049186578	-2.25	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.25	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.04395604395604396	0.04395604395604396	3.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04395604395604396	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
284	the clinical management	0.042957945515577155	-3.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-6.25	0.04	0.05333333333333334	0.0	0.047058823529411764	0.047058823529411764	3.0	0.05333333333333334	0.3333333333333333	1.0	0.0	-6.25	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.047058823529411764	0.0	0.05333333333333334	0.0	0.0	0.0	0.0	0.0
251	cell migration and proliferation	0.06153028083556889	-1.7777777777777786	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-3.333333333333332	0.04	0.04615384615384615	0.0	0.0430622009569378	0.0430622009569378	4.0	0.04615384615384615	0.25	1.0	0.0	-3.333333333333332	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.0430622009569378	0.0	0.04615384615384615	0.0	0.0	0.0	0.0	0.0
111	Binding Protein;binding protein	0.15389151507653545	-1.8571428571428577	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-1.8571428571428577	0.0	0.0	0.0	0.04	0.04	0.0	0.043209876543209874	0.043209876543209874	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.5	1.0	0.0	1.0	0.0	1.0	0.5	0.5	2.0	1.0	2.0	0.043209876543209874	0.0	0.04	0.0	0.0	0.0	0.0	0.0
168	less;Less	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	collisional;collisions;Collision	0.6361475894110491	-2.6666666666666665	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-3.3333333333333335	0.04	0.04	0.0	0.04	0.04507936507936508	1.0	0.046750208855472014	0.0	3.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	3.0	0.047619047619047616	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
134	Restricted;restricted	0.07398315959944811	-6.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.05263157894736842	0.05263157894736842	1.0	0.06060606060606061	0.0	1.0	0.0	-8.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05263157894736842	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
14	SEGMENT;segment;segments	0.38285140278141117	0.0	0.0	0.0	0.04	0.04	0.0	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.7777777777777772	0.04	0.04	0.0	0.04	0.04	0.6666666666666666	0.04812898387701537	0.0	3.0	0.0	-7.5	1.0	0.0	0.6666666666666666	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.04	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
171	-1 specific region	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
175	A 19;a 19	0.20146510080365157	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	THALIDOMIDE;thalidomide;THAL;Thalidomide	0.9578108430568376	-0.3958333333333333	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.75	0.0	0.0	-2.183333333333333	0.04	0.04	0.0	0.04	0.04078189300411523	1.0	0.044935050300161865	0.0	12.0	0.0	-8.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	4.0	1.0	12.0	0.04938271604938271	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
41	euchromatic genes	0.3096553377005689	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-3.666666666666668	0.04	0.046875	0.0	0.04	0.04	2.0	0.046875	0.0	1.0	1.0	-3.666666666666668	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04	0.0	0.046875	0.0	1.0	0.0	0.0	1.0
269	human non-small cell lung cancer (NSCLC) cell lines (adenocarcinoma	0.11127255608116232	-2.8000000000000007	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-2.8000000000000007	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04504504504504505	0.04504504504504505	12.0	0.0625	0.16666666666666666	1.0	0.0	-9.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	12.0	0.04504504504504505	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
4	miRNAs	0.7891545342678937	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.5	0.04	0.046296296296296294	0.0	0.04	0.04	1.0	0.04651263412945656	0.0	4.0	0.0	-3.6000000000000014	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
9	Alus and CpG islands	0.3075309072386389	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	EBV	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
183	due to;resulting;Due To	0.08577203951269795	-3.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04777777777777778	1.5	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	3.0	0.05555555555555555	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	particular promoter motifs	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
82	CARBAMAZEPINE;carbamazepine	0.8774169461705401	-2.1250000000000004	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.8571428571428577	0.0	0.0	-9.75	0.04	0.051546391752577324	0.0	0.04	0.04377244641418813	1.0	0.06722877418402541	0.0	8.0	0.0	-13.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.04516129032258065	0.0	0.08333333333333333	0.0	0.0	0.0	0.0	0.0
114	any adenine methylated GATC sites	0.36572603755531863	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
131	TNBC invasive potential	0.44037917272134386	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	3.0	0.047619047619047616	0.0	2.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
195	ranscription activator-like effector nuclease	0.46009738556829655	0.0	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.16666666666666666	0.0	0.0
225	15%) of subclinical hypothyroidism	0.4804707422996111	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
14	two top-performing methods	0.03864589478517516	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.04	0.045112781954887216	1.0	0.04	0.04	5.0	0.045112781954887216	0.4	1.0	0.0	-2.833333333333332	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.045112781954887216	0.0	0.0	0.2	0.0	0.0
172	> 100 males	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
61	membranes;Membranes	0.6097150563298547	-2.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.043859649122807015	0.043859649122807015	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043859649122807015	0.0	0.04	0.0	0.0	0.0	0.0	0.0
75	twitcher mutant mouse cells	0.18978369224310088	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04	0.04	4.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
140	Complete;complete	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	Animal genomes;Animal genome	0.3671602026239327	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	2.0	0.05263157894736842	0.0	2.0	0.0	-6.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	4.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
278	the mismatch repair	0.1069625850806212	-8.5	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-8.5	0.0	0.0	0.0	0.04	0.04	0.0	0.06060606060606061	0.06060606060606061	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.06060606060606061	0.0	0.04	0.0	0.0	0.0	0.0	0.0
83	affecting;Affecting	0.08886423477814463	-2.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-4.75	0.04	0.04	0.0	0.04	0.04439024390243902	1.0	0.052258064516129035	0.0	2.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04878048780487805	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
44	ATP production	0.2670034613288844	-2.75	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0449438202247191	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
330	patients with rheumatoid arthritis	0.07780759710847121	-1.3333333333333321	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.4642857142857143	0.0	-1.3333333333333321	0.0	0.0	-3.0	0.04	0.0425531914893617	0.0	0.04225352112676056	0.04225352112676056	4.0	0.04566683964711987	0.5	2.0	0.0	-4.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04225352112676056	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
195	modification of 54%	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
195	endogenous;Endogenous	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	gene/protein relationship networ	0.15801935105881773	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
56	swallowed fluticasone	0.39355556332182906	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
84	1.83) and epilepsy/seizures (2.24, 95% CI 1.60	0.3775797174280728	0.0	0.0	0.0	0.04	0.04	0.07692307692307693	0.07692307692307693	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	13.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	13.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	orthochromatic cells	0.38585307056551166	-5.75	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-5.75	0.0	0.0	0.0	0.04	0.04	0.0	0.05194805194805195	0.05194805194805195	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.05194805194805195	0.0	0.04	0.0	0.0	0.0	0.0	0.0
58	the best treatment options	0.0025067221689655957	-6.333333333333334	1.0	-17.333333333333332	0.13043478260869565	0.13043478260869565	1.0	1.0	1.0	-17.333333333333332	1.0	0.0	-6.333333333333334	0.0	0.0	-17.0	0.13043478260869565	0.125	1.0	0.053571428571428575	0.053571428571428575	4.0	0.125	1.0	1.0	0.0	-17.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.053571428571428575	0.0	0.125	1.0	0.0	0.25	0.0	0.0
129	intracellular	0.549428503684414	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9.428571428571429	0.04	0.06422018348623854	0.0	0.04	0.04	1.0	0.06422018348623854	0.0	1.0	0.0	-9.428571428571429	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.06422018348623854	0.0	0.0	0.0	0.0	0.0
14	Sensitivity;sensitivity	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
114	Plant;plants;plant;Plants	0.02821003439861613	-1.690476190476191	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.7142857142857153	0.0	0.0	-2.1999999999999997	0.04	0.04	0.0	0.04	0.04301326283412271	1.0	0.044782608695652176	0.6666666666666666	6.0	0.0	-6.6	1.0	0.0	1.0	0.6666666666666666	1.0	0.0	1.0	0.0	0.0	4.0	1.0	6.0	0.04487179487179487	0.0	0.05434782608695653	1.0	0.0	0.0	0.0	0.0
4	Manifestation of;of the three major manifestations	0.01155079364952168	-2.0	1.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.2	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	5.0	0.04	0.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	20%;20;[20]	0.7678226496253387	-0.8222222222222222	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.7777777777777786	0.0	0.0	-1.9142857142857146	0.04	0.04	0.0	0.04	0.04145070422535212	1.2	0.0443012912482066	0.0	5.0	0.0	-8.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	6.0	0.045	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
274	Drug;drug	0.17714959336165964	-1.7272727272727266	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-1.7272727272727266	1.0	1.0	-2.7142857142857153	0.04	0.04487179487179487	0.0	0.04296875	0.04296875	1.0	0.04487179487179487	0.0	1.0	1.0	-2.7142857142857153	1.0	1.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04296875	1.0	0.04487179487179487	0.0	1.0	0.0	1.0	1.0
129	disease result;result in development of disease	0.02804697228897317	-1.7777777777777786	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-2.571428571428573	0.04	0.0445859872611465	0.0	0.0430622009569378	0.0430622009569378	5.0	0.0445859872611465	0.4	1.0	0.0	-2.571428571428573	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.0430622009569378	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
305	deletion;Deletion	0.5020167372656013	-1.7142857142857153	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.7142857142857153	0.0	0.0	-9.333333333333334	0.04	0.06382978723404256	0.0	0.04294478527607362	0.04294478527607362	1.0	0.06382978723404256	0.0	1.0	0.0	-9.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04294478527607362	0.0	0.06382978723404256	0.0	0.0	0.0	0.0	0.0
208	a dual mode	0.23800283539259467	-4.25	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-2.75	0.04	0.04	0.0	0.046511627906976744	0.04825581395348837	3.0	0.04564102564102564	0.0	2.0	0.0	-5.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.05	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
228	inhibitors of Tpl2 kinase	0.0868901941420567	0.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.8	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	4.0	0.04	0.75	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.25	0.0	0.0
131	he results	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
145	Alzheimer's disease-like phenotype	0.35559061041433926	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
92	8	0.5978176668429032	-3.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-8.25	0.04	0.05970149253731343	0.0	0.047058823529411764	0.047058823529411764	1.0	0.05970149253731343	0.0	1.0	0.0	-8.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.047058823529411764	0.0	0.05970149253731343	0.0	0.0	0.0	0.0	0.0
149	mitochondrial biogenesis;Mitochondrial Biogenesis	0.6721500832556117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
248	0.01	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
6	Evaluated;evaluated	0.072636225092711	-5.777777777777779	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.777777777777779	0.0	0.0	-8.75	0.04	0.06153846153846154	0.0	0.05202312138728324	0.05202312138728324	1.0	0.06153846153846154	0.0	1.0	0.0	-8.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05202312138728324	0.0	0.06153846153846154	0.0	0.0	0.0	0.0	0.0
205	large;LARGE	0.0748863687108654	-7.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.5	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.05714285714285714	0.05714285714285714	1.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05714285714285714	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
209	yeast, worm, fly and fish	0.2246359044634622	0.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
176	nucleoprotein;Nucleoprotein	0.7528621404874102	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.04	0.04	1.0	0.04587155963302752	0.0	1.0	1.0	-3.1999999999999993	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04	1.0	0.04587155963302752	0.0	1.0	0.0	1.0	1.0
7	1/5;1.1-4.5;1.1-4.5)	0.6037376978604453	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.5	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
231	-old, male mice with and without a FHC (R403Q) mutation	0.04508554571678581	-2.8571428571428577	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.09090909090909091	0.0	-2.8571428571428577	0.0	0.0	-5.142857142857142	0.04	0.050359712230215826	1.0	0.04516129032258065	0.04516129032258065	14.0	0.050359712230215826	0.14285714285714285	1.0	0.0	-5.142857142857142	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	14.0	0.04516129032258065	0.0	0.050359712230215826	0.0	0.0	0.07142857142857142	0.0	0.0
231	enhanced;enhancing;Enhance;Enhanced	0.059411113652183364	-1.1428571428571423	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.2857142857142847	0.0	0.0	-3.000000000000001	0.04	0.042682926829268296	0.0	0.04	0.0420125786163522	1.0	0.045647018970189704	0.0	2.0	0.0	-4.428571428571429	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.0440251572327044	0.0	0.04861111111111112	0.0	0.0	0.0	0.0	0.0
142	Identified;identified	0.1026067986604508	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.7777777777777786	0.04	0.04	0.0	0.04	0.04	1.0	0.04331606217616581	0.0	2.0	0.0	-3.555555555555557	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04663212435233161	0.0	0.0	0.0	0.0	0.0
26	Association;association	0.06302707763732564	-2.7142857142857153	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.7142857142857153	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.04487179487179487	0.04487179487179487	1.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04487179487179487	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
90	Australian;Australia (n ;AUSTRALIAN	0.6580167507588025	-2.400000000000001	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-4.333333333333333	0.04	0.04	0.0	0.04	0.04448598130841122	1.6666666666666667	0.04939571150097466	0.0	3.0	0.0	-7.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	5.0	0.04672897196261683	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
204	affected individuals	0.11179683534245334	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	the overall topology	0.07656470720519508	-3.25	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.04597701149425287	0.04597701149425287	3.0	0.046875	0.3333333333333333	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04597701149425287	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
257	Major;major	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	the most potent noncovalent inhibitor	0.26905681404095005	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	standard;Standard	0.06990157853528768	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-9.0	0.04	0.0625	0.0	0.05	0.05	1.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
168	the more severe cases	0.052997877725278884	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
68	third immunoglobulin-like domain	0.15898064341854684	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
163	MELATONIN;melatonin	0.7111192058369022	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
111	selenoprotein biosynthesis through interaction	0.1127087240762076	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.14285714285714285	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
127	Mutant;mutant	0.566410624396259	-1.8333333333333321	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.043165467625899276	0.043165467625899276	1.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043165467625899276	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
95	two highly homologous regions	0.12158908048401756	-3.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
137	A total	0.09445178373837723	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.6000000000000014	0.04	0.042735042735042736	0.0	0.04	0.04	2.0	0.042735042735042736	0.0	1.0	0.0	-1.6000000000000014	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.042735042735042736	0.0	0.0	0.0	0.0	0.0
258	HMTases);HMTases	0.6641753767711227	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.5	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
106	FBXW7	0.7850128565492788	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	cyclic antidepressant intoxication	0.7867749175372906	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
244	transfusions;Transfusions	0.5368409442571505	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04	0.04	1.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
71	angiogenesis, erythropoiesis and glycolysis	0.18245260804734748	0.0	1.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.16666666666666666	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
342	lack	0.09441019167357716	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-5.800000000000001	0.04	0.052083333333333336	0.0	0.045454545454545456	0.045454545454545456	1.0	0.052083333333333336	0.0	1.0	0.0	-5.800000000000001	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.045454545454545456	0.0	0.052083333333333336	0.0	0.0	0.0	0.0	0.0
49	RECURRENT;recurrent	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
61	autophagy protein	0.21476565869143777	-2.6000000000000014	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	-6.25	0.04	0.05333333333333334	0.0	0.044642857142857144	0.044642857142857144	2.0	0.05333333333333334	0.0	1.0	0.0	-6.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.044642857142857144	0.0	0.05333333333333334	0.0	0.0	0.0	0.0	0.0
44	vitro intraerythrocytic development	0.36405326364753815	-7.75	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-7.75	0.0	0.0	-5.0	0.04	0.05	0.0	0.057971014492753624	0.057971014492753624	3.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.057971014492753624	0.0	0.05	0.0	0.0	0.0	0.0	0.0
94	even when surgery	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	promising data	0.0973851774680859	-2.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.044444444444444446	0.044444444444444446	2.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.044444444444444446	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
246	Events;events	0.0873730171143011	-4.375	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-9.0	0.04	0.06060606060606061	0.0	0.047619047619047616	0.048500881834215165	1.0	0.06256109481915934	0.0	2.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04938271604938271	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
8	the cell	0.003979133266937442	-13.25	1.0	-18.0	0.14285714285714285	0.14285714285714285	1.0	1.0	1.0	-18.0	1.0	0.0	-13.25	0.0	0.0	-14.5	0.14285714285714285	0.09523809523809523	0.0	0.0851063829787234	0.0851063829787234	2.0	0.09523809523809523	1.0	1.0	0.0	-14.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.0851063829787234	0.0	0.09523809523809523	1.0	0.0	0.0	0.0	0.0
104	Pombe	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	the first case	0.04483852909073928	-3.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04580152671755725	0.04580152671755725	3.0	0.04938271604938271	0.3333333333333333	1.0	0.0	-4.75	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04580152671755725	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
132	Order;order	0.07745982320287048	-9.8	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-9.8	0.0	0.0	-10.666666666666666	0.04	0.06976744186046512	0.0	0.06578947368421052	0.06578947368421052	1.0	0.06976744186046512	0.0	1.0	0.0	-10.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.06578947368421052	0.0	0.06976744186046512	0.0	0.0	0.0	0.0	0.0
271	TH resistance	0.15335597305980264	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
293	medication use;MEDICATION USE	0.03253789412915662	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.5	0.0	0.0
220	Encephalomyopathy;encephalomyopathy	0.5447445755659535	-1.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.0425531914893617	0.0425531914893617	1.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0425531914893617	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
49	cognitive;Cognitive	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	I-E;i.e	0.6066186994119565	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
206	ip;i.p.)	0.8534279858323878	-3.7333333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-3.4666666666666672	0.04	0.04	0.0	0.04	0.04795488721804512	1.8	0.04726463700234192	0.0	5.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.053571428571428575	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
159	type II (25 percent)	0.5192046187491082	-3.0	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	1.0	-3.0	1.0	1.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	6.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.045454545454545456	0.0	0.04	0.0	1.0	0.0	0.0	1.0
204	the efficacy	0.219892774791927	-4.25	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.04819277108433735	0.04819277108433735	2.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04819277108433735	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
253	a phenotypic variant of RLS	0.26905681404095005	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
6	Long;long	0.07132975072983481	-4.111111111111111	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.111111111111111	0.0	0.0	-7.75	0.04	0.057971014492753624	0.0	0.047872340425531915	0.047872340425531915	1.0	0.057971014492753624	0.0	1.0	0.0	-7.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047872340425531915	0.0	0.057971014492753624	0.0	0.0	0.0	0.0	0.0
93	discontinuing treatment	0.3825367454022693	-3.333333333333332	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-3.333333333333332	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.04615384615384615	0.04615384615384615	2.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04615384615384615	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
102	critical regulators	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	an hour-	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
49	Causative mutations	0.30602499233237646	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
270	a direct physical interaction	0.0608799968776418	-3.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04716981132075472	0.04716981132075472	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04716981132075472	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	European Medicines Agency	0.18553312764366373	-5.666666666666666	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-5.666666666666666	1.0	1.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.051724137931034475	0.051724137931034475	3.0	0.04918032786885245	0.0	1.0	1.0	-4.666666666666666	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.051724137931034475	0.0	0.04918032786885245	0.0	1.0	0.0	0.0	1.0
74	A 53 year-old heavy smoker	0.07683108456371458	-3.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-12.0	0.04	0.07692307692307693	0.0	0.045454545454545456	0.045454545454545456	7.0	0.07692307692307693	0.14285714285714285	1.0	0.0	-12.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.045454545454545456	0.0	0.07692307692307693	0.0	0.0	0.0	0.0	0.0
73	β-barrel transmembrane segments [13]	0.17021991467726666	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.04	0.043165467625899276	0.0	0.04	0.04	8.0	0.043165467625899276	0.375	1.0	0.0	-1.8333333333333321	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.043165467625899276	0.0	0.0	0.0	0.0	0.0
41	a conserved serine in the chromodomain	0.09628532242635444	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.16666666666666666	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.5	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
180	DM gene	0.22818712165473648	-2.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.043478260869565216	0.043478260869565216	2.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043478260869565216	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
94	2001Y42	0.6765491644525918	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
345	the name	0.003928822157881648	-8.9	1.0	-5.0	0.05	0.05	1.0	1.0	1.0	-5.0	1.0	0.0	-8.9	0.0	0.0	-5.0	0.05	0.05	1.0	0.06211180124223602	0.06211180124223602	2.0	0.05	1.0	1.0	0.0	-5.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.06211180124223602	0.0	0.05	1.0	0.0	0.5	0.0	0.0
326	aucher disease results	0.08984044017081744	-3.5	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	0.0	0.04	0.04	0.0	0.046511627906976744	0.046511627906976744	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.046511627906976744	0.0	0.04	0.0	0.0	0.0	0.0	0.0
5	for;For	0.00782842751459247	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-1.875	0.04	0.04	0.0	0.04	0.04380952380952381	1.0	0.043529411764705886	1.0	2.0	0.0	-3.75	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.047619047619047616	0.0	0.047058823529411764	1.0	0.0	0.0	0.0	0.0
249	recognition;Recognition	0.07230402029378052	-2.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	-5.75	0.04	0.05194805194805195	0.0	0.043795620437956206	0.043795620437956206	1.0	0.05194805194805195	0.0	1.0	0.0	-5.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043795620437956206	0.0	0.05194805194805195	0.0	0.0	0.0	0.0	0.0
163	a higher increase	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
114	new;NEW;Novel;novel	0.05527453284642815	-3.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.857142857142858	0.0	0.0	-6.6000000000000005	0.04	0.044642857142857144	0.0	0.04375	0.04669769503546099	1.0	0.0570436507936508	0.0	2.0	0.0	-10.6	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.04964539007092199	0.0	0.06944444444444445	0.0	0.0	0.0	0.0	0.0
254	inflammation status	0.29231928288067943	-6.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05263157894736842	0.05263157894736842	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05263157894736842	0.0	0.04	0.0	0.0	0.0	0.0	0.0
66	Loop;loop	0.07058225711986772	-9.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-9.333333333333334	0.0	0.0	-12.5	0.04	0.08	0.0	0.06382978723404256	0.06382978723404256	1.0	0.08	0.0	1.0	0.0	-12.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.06382978723404256	0.0	0.08	0.0	0.0	0.0	0.0	0.0
66	the most commonly identified (7.6	0.09478263623695089	-2.5	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	0.0	0.04	0.04	0.0	0.044444444444444446	0.044444444444444446	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.044444444444444446	0.0	0.04	0.0	0.0	0.0	0.0	0.0
254	to;TO	0.010224334715078187	-5.583333333333334	1.0	-18.333333333333332	0.04	0.0675	1.0	1.0	1.0	-4.583333333333333	1.0	0.0	-18.666666666666668	0.0	0.0	-5.166666666666667	0.15	0.04	0.0	0.04	0.07119243421052632	1.0	0.06296875	1.0	4.0	0.0	-17.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.15789473684210528	0.0	0.125	1.0	0.0	0.0	0.0	0.0
206	12.5	0.6321971851245842	-5.666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.051724137931034475	0.051724137931034475	1.0	0.054545454545454536	0.0	1.0	0.0	-6.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.051724137931034475	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
62	serious infections	0.14684823062145294	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	complete genomes	0.4151036879671975	-4.727272727272727	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-4.727272727272727	0.0	0.0	-6.5	0.04	0.04819277108433735	0.0	0.04932735426008968	0.04932735426008968	2.0	0.05486561631139945	0.0	2.0	0.0	-8.75	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04932735426008968	0.0	0.06153846153846154	0.0	0.0	0.0	0.0	0.0
301	paper;Paper	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
241	Radiographic investigation	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
86	Myosin;myosin	0.7377347907742027	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
111	[Ser]Sec	0.56382698762603	-1.571428571428573	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.571428571428573	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.042682926829268296	0.042682926829268296	4.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.042682926829268296	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
239	a combination of aCGH	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
177	Increased;increased	0.09598639454599986	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.7777777777777786	0.0	0.0	-9.333333333333334	0.04	0.0625	0.0	0.04	0.043674285957519265	1.0	0.06384408602150538	0.0	3.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04712041884816754	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
24	blood pressure and cholesterol	0.06755949139669983	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.04	0.04	4.0	0.05405405405405406	0.0	1.0	0.0	-6.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
121	a known genetic risk factor for abacavir hypersensitivity	0.049209157435370035	0.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.2222222222222222	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.25	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
277	Renal biomarkers	0.7268739028102027	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
75	the normal	0.11471062143466125	-3.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	0.0	0.04	0.04	0.0	0.047058823529411764	0.047058823529411764	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047058823529411764	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	the gene structure prediction	0.005666201593407132	-1.166666666666666	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.3333333333333333	0.0	-2.333333333333332	0.0	0.0	-2.75	0.04	0.04	0.0	0.04	0.04205882352941176	4.0	0.04564102564102564	1.0	2.0	0.0	-5.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.044117647058823525	0.0	0.05128205128205128	1.0	0.0	0.0	0.0	0.0
305	rare autosomal recessive condition;rare condition;Rare Disorder;rare, recessively inherited disorder	0.30980300878025935	-2.5	0.0	0.0	0.04	0.04	0.5	0.55	0.0	0.0	0.0	1.0	-2.571428571428573	0.0	0.0	-4.166666666666667	0.04	0.04	0.0	0.04430379746835443	0.044444892364750466	4.5	0.05	0.0	2.0	0.0	-8.333333333333334	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.41666666666666663	4.0	1.0	9.0	0.0445859872611465	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
329	the basis	0.05887357819561126	-4.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	-17.0	0.04	0.125	0.0	0.04918032786885245	0.04918032786885245	2.0	0.125	0.0	1.0	0.0	-17.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04918032786885245	0.0	0.125	0.0	0.0	0.0	0.0	0.0
343	Enhance;enhance	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
274	's two Phase	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
290	patients with bladder outlet obstruction	0.1471746314615874	-3.25	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	-3.25	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04597701149425287	0.04597701149425287	5.0	0.04918032786885245	0.2	1.0	0.0	-4.666666666666666	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04597701149425287	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
204	insufficient bony development;insufficient development	0.420472123462711	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	adult;ADULT	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
58	new;NEW	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	linkage	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
8	a core structure within the proximal lumen	0.058636061390565875	-3.75	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.047058823529411764	0.047058823529411764	7.0	0.06060606060606061	0.14285714285714285	1.0	0.0	-8.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.047058823529411764	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
85	the immunoglobulin heavy chain variable genes	0.09025906883740656	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-5.428571428571429	0.04	0.05109489051094891	0.0	0.04	0.04	6.0	0.05109489051094891	0.0	1.0	0.0	-5.428571428571429	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.05109489051094891	0.0	0.0	0.0	0.0	0.0
124	ScenarioOncotype DX	0.3842585586614058	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
25	FXS	0.7123617662367117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
172	high doses of LT(4)	0.15501955476832016	-3.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.045454545454545456	0.045454545454545456	5.0	0.04597701149425287	0.0	1.0	0.0	-3.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.045454545454545456	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
239	her mother	0.08475011506885709	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04	0.04	2.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
330	% total;total	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	interactions from the co-occurring literature	0.04049964488517651	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	Lesion;lesion	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
125	birth leading	0.11438363182305503	-3.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.046875	0.046875	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.046875	0.0	0.04	0.0	0.0	0.0	0.0	0.0
284	Platelet Derived Growth Factor Receptor;platelet-derived growth factor receptor	0.7744385018276583	-3.6666666666666665	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-3.75	1.0	1.0	-3.25	0.04	0.0449438202247191	0.0	0.046511627906976744	0.04687642498860009	6.0	0.0459890253462242	0.0	3.0	1.0	-3.5	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	2.0	1.0	18.0	0.047058823529411764	1.0	0.046511627906976744	0.0	1.0	0.0	1.0	1.0
229	bioinformatics;Bio-Informatics	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	beta barrel membrane proteins;beta-barrel membrane proteins	0.9990623327903487	-0.8846153846153846	1.0	0.0	0.04	0.04	0.2	0.2076923076923077	0.0	0.0	0.28205128205128205	0.0	-2.375	0.0	0.0	-2.9487179487179485	0.04	0.04	0.0	0.04	0.041559526229235574	4.846153846153846	0.045802337562157916	0.7923076923076924	13.0	0.0	-5.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	63.0	0.04419889502762431	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
251	MCF7	0.6287982870600954	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.1111111111111107	0.04	0.043689320388349516	0.0	0.04	0.04	1.0	0.043689320388349516	0.0	1.0	0.0	-2.1111111111111107	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.043689320388349516	0.0	0.0	0.0	0.0	0.0
163	the Mediterranean diet	0.0793662226340656	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
37	doxorubicin and etoposide	0.6979788095316466	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
181	25%	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
227	Reflex latency;reflex latency	0.6939204082851139	-2.6000000000000014	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.044642857142857144	0.044642857142857144	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.044642857142857144	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	ligand free protein	0.22514884479460656	-5.666666666666666	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.051724137931034475	0.051724137931034475	3.0	0.053571428571428575	0.0	2.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.051724137931034475	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
17	resumed;Resume	0.07891352058763418	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.043478260869565216	0.043478260869565216	1.0	0.046511627906976744	0.0	1.0	0.0	-3.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
38	frameshift mutations;Mutations, Frame Shift	0.6392094361268081	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.04	0.04	2.0	0.04597701149425287	0.0	2.0	0.0	-3.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
199	regulatory	0.1145044042437165	-1.8333333333333321	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.043165467625899276	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.043165467625899276	0.0	0.04	0.0	0.0	0.0	0.0	0.0
152	diazoxide;DIAZOXIDE	0.7377347907742027	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
293	an earlier and more severe menopausal syndrome than the general female population	0.05071401516600713	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	12.0	0.04	0.08333333333333333	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	12.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
49	affects;Affect	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
175	patient;*^patient	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
82	-induced MPE	0.44205997552858906	-4.571428571428571	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.571428571428571	0.0	0.0	-14.0	0.04	0.09090909090909091	0.0	0.048951048951048945	0.048951048951048945	3.0	0.09090909090909091	0.3333333333333333	1.0	0.0	-14.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.048951048951048945	0.0	0.09090909090909091	0.0	0.0	0.0	0.0	0.0
303	fluorescent protein (GFP	0.4111430216956384	-4.666666666666666	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	-2.5	0.04	0.044444444444444446	0.0	0.04918032786885245	0.04918032786885245	4.0	0.044444444444444446	0.0	1.0	0.0	-2.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04918032786885245	0.0	0.044444444444444446	0.0	0.0	0.0	0.0	0.0
67	studied disease;study disease	0.05806490519156825	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.04	0.04	2.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
322	Drosophila melanogaster	0.6342833664652986	-4.666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04918032786885245	0.04918032786885245	2.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04918032786885245	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
79	Maximum;maximum	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
160	osteoclast function	0.33464996046184486	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
116	patients;Patients	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
7	the full-blown fetal hydantoin syndrome	0.36930540695932285	0.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	7.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
2	the orbit	0.11412262484845027	-3.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.04672897196261683	0.04672897196261683	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04672897196261683	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	The developed BioMap system	0.058002921571208864	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.04	0.04	4.0	0.04587155963302752	0.25	1.0	0.0	-3.1999999999999993	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
71	Ets-1;ETS-1	0.7549583354935522	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	1.0	0.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
190	clinical trials for prevention;prevention clinical Trials	0.0011737399296596076	-9.833333333333334	1.0	0.0	0.04	0.04	1.0	1.0	1.0	0.0	1.0	0.0	-9.833333333333334	0.0	0.0	-19.0	0.04	0.16666666666666666	0.0	0.06593406593406594	0.06593406593406594	4.0	0.16666666666666666	1.0	1.0	0.0	-19.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.06593406593406594	0.0	0.16666666666666666	1.0	0.0	0.0	0.0	0.0
229	Training;training	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	Integration;integration	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
199	Element;element	0.09059200192985256	-1.8333333333333321	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.043165467625899276	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043165467625899276	0.0	0.04	0.0	0.0	0.0	0.0	0.0
246	LOF; *2, *3)	0.5292343719920116	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	the "proof	0.06947521157381996	-3.25	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04597701149425287	0.04597701149425287	3.0	0.05263157894736842	0.3333333333333333	1.0	0.0	-6.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04597701149425287	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
236	the selection of candidate proteotypic peptides	0.10885742480127332	-3.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
206	Returned;returned	0.08205452680050998	-6.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.05263157894736842	0.05263157894736842	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05263157894736842	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
281	disease;Disease	0.020665995785898696	-1.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-1.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04310344827586207	0.04310344827586207	1.0	0.04	1.0	1.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	0.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04310344827586207	1.0	0.04	1.0	0.0	0.0	1.0	0.0
122	important determinants	0.1760978019587062	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.04	0.04	2.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
4	tumors from 31 patients	0.05317963529948374	-2.125	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.14285714285714285	1.0	-2.125	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	1.0	0.04371584699453552	0.04371584699453552	4.0	0.04587155963302752	0.25	1.0	0.0	-3.1999999999999993	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04371584699453552	0.0	0.04587155963302752	0.0	0.0	0.25	0.0	0.0
72	The developed BioMap system	0.058002921571208864	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.04	0.04	4.0	0.04587155963302752	0.25	1.0	0.0	-3.1999999999999993	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
88	Early;early	0.07816942110256009	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04819277108433735	0.04819277108433735	1.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04819277108433735	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
79	benzodiazepine-induced sedation	0.7538326743307358	-3.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.1999999999999993	1.0	1.0	-6.25	0.04	0.05333333333333334	0.0	0.04587155963302752	0.04587155963302752	4.0	0.05333333333333334	0.25	2.0	1.0	-6.25	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.04587155963302752	0.0	0.05333333333333334	0.0	1.0	0.0	0.0	1.0
44	the main causative agent of this parasitic disease	0.022501711218165316	0.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.14285714285714285	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	8.0	0.04	0.5	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.125	0.0	1.0
241	an;AN	0.7172728766843438	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
94	imatinib for chronic myeloid leukaemia	0.2958066272429287	-3.6000000000000014	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	-3.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.04672897196261683	0.04672897196261683	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04672897196261683	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	genetic studies;Genetic Study	0.07597150276901225	-1.5555555555555571	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	-2.428571428571427	0.04	0.04430379746835443	0.0	0.04265402843601896	0.04265402843601896	2.0	0.04430379746835443	0.0	1.0	0.0	-2.428571428571427	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04265402843601896	0.0	0.04430379746835443	0.0	0.0	0.0	0.0	0.0
246	R;R-	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
257	pathogenesis	0.666594640831735	-1.8333333333333321	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.043165467625899276	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.043165467625899276	0.0	0.04	0.0	0.0	0.0	0.0	0.0
266	0.011)	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
99	familial background;Family Background	0.3368614056990859	-7.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-7.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05555555555555555	0.05555555555555555	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.05555555555555555	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	FAINTING;fainting	0.23225864430778811	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-3.166666666666668	1.0	1.0	-2.5	0.04	0.04	0.0	0.045112781954887216	0.04545715433622223	1.0	0.045	0.0	2.0	1.0	-5.0	1.0	1.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	2.0	1.0	2.0	0.04580152671755725	1.0	0.05	0.0	1.0	0.0	1.0	1.0
37	anticancer drugs;Anticancer Drugs	0.013638708488929273	-12.0	1.0	-14.0	0.09090909090909091	0.09090909090909091	0.5	0.5	1.0	-14.0	1.0	0.0	-12.0	0.0	0.0	-12.75	0.09090909090909091	0.08163265306122448	1.0	0.07692307692307693	0.07692307692307693	2.0	0.08163265306122448	1.0	2.0	0.0	-12.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.07692307692307693	0.0	0.08163265306122448	1.0	0.0	0.5	0.0	0.0
61	truncated DeltaN63 Atg4D	0.762768751538929	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.0	1.0	1.0	-7.25	0.04	0.056338028169014086	0.0	0.045454545454545456	0.045454545454545456	4.0	0.056338028169014086	0.0	2.0	1.0	-7.25	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.045454545454545456	0.0	0.056338028169014086	0.0	1.0	0.0	0.0	1.0
7	Failure of the neural tube	0.09916666906596389	-3.25	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	the connectivity of PFAM domains	0.07594933472817433	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
221	Potential;potential	0.003577978198305373	-14.083333333333332	1.0	-9.0	0.0625	0.0625	1.0	1.0	1.0	-9.0	1.0	0.0	-14.083333333333332	0.0	0.0	-8.0	0.0625	0.058823529411764705	0.0	0.09160305343511449	0.09160305343511449	1.0	0.058823529411764705	1.0	1.0	0.0	-8.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.09160305343511449	0.0	0.058823529411764705	1.0	0.0	0.0	0.0	0.0
114	Potential;potential	0.06407384901433494	-5.142857142857142	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.142857142857142	0.0	0.0	-11.2	0.04	0.07246376811594203	0.0	0.050359712230215826	0.050359712230215826	1.0	0.07246376811594203	0.0	1.0	0.0	-11.2	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.050359712230215826	0.0	0.07246376811594203	0.0	0.0	0.0	0.0	0.0
310	in myeloma therapy	0.0351492122420075	-5.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.05	0.05	3.0	0.06451612903225806	0.6666666666666666	1.0	0.0	-9.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
139	signal peptide;Peptide, Signal	0.23636300837699326	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	2.0	0.05	0.0	2.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
7	High;higher	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
91	for;For	0.009549145852050859	-3.6428571428571432	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.571428571428571	0.0	0.0	0.0	0.04	0.04	0.0	0.04487179487179487	0.046911421911421905	1.0	0.04	1.0	2.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.048951048951048945	0.0	0.04	1.0	0.0	0.0	0.0	0.0
332	phase 3 trials;phase 3 trial	0.11365857771042086	-2.5	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.044444444444444446	0.044444444444444446	3.0	0.04597701149425287	0.0	1.0	0.0	-3.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.044444444444444446	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
78	DIAGNOSIS;diagnosis;Diagnosed;diagnosed	0.0644896458137448	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-5.666666666666667	0.04	0.05084745762711865	0.0	0.05	0.05	1.0	0.05173951828724353	0.0	2.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.05	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
204	investigate	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
114	different;Different	0.07358476254593886	-2.7142857142857153	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.7142857142857153	0.0	0.0	-5.800000000000001	0.04	0.052083333333333336	0.0	0.04487179487179487	0.04487179487179487	1.0	0.052083333333333336	0.0	1.0	0.0	-5.800000000000001	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04487179487179487	0.0	0.052083333333333336	0.0	0.0	0.0	0.0	0.0
251	decrease in E-cadherin	0.27371153970076617	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-2.8888888888888893	0.04	0.04522613065326633	0.0	0.04	0.04	3.0	0.04522613065326633	0.0	1.0	0.0	-2.8888888888888893	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.04	0.0	0.04522613065326633	0.0	0.0	0.0	0.0	0.0
225	thyroid function in WS	0.11863767202876557	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.04	0.04	4.0	0.048387096774193554	0.25	1.0	0.0	-4.333333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
271	TH cell-membrane	0.3425203445704429	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	4.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
121	the safety and efficacy of drug treatment	0.06495544270537182	0.0	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
127	Some 90%	0.3720518909872365	-2.833333333333332	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.045112781954887216	0.045112781954887216	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.045112781954887216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
202	100,000	0.7270576515203546	-5.875	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.5	0.0	0.0	-2.833333333333333	0.04	0.04	0.0	0.05063291139240506	0.052343482723229556	1.0	0.04586206896551724	0.0	2.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05405405405405406	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
229	the validation studies	0.0793662226340656	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
333	the temperatures of 20	0.0437739739532124	-4.571428571428571	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-4.571428571428571	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.048951048951048945	0.048951048951048945	4.0	0.04597701149425287	0.5	1.0	0.0	-3.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.048951048951048945	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
77	fixed-dose combinations	0.101839377289391	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.8571428571428577	0.04	0.043209876543209874	0.0	0.04	0.04	4.0	0.043209876543209874	0.0	1.0	0.0	-1.8571428571428577	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.043209876543209874	0.0	0.0	0.0	0.0	0.0
229	consists;CONSIST	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
231	CARDIOMYOPATHY;cardiomyopathy	0.08316523593593649	-1.7142857142857153	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.7142857142857153	0.0	0.0	-4.142857142857142	0.04	0.04794520547945205	0.0	0.04294478527607362	0.04294478527607362	1.0	0.04794520547945205	1.0	1.0	0.0	-4.142857142857142	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04294478527607362	0.0	0.04794520547945205	1.0	0.0	0.0	0.0	0.0
223	pharmacodynamics (plasma total Aβ1-40 concentration	0.30999271175055826	-1.2727272727272734	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-1.2727272727272734	0.0	0.0	0.0	0.04	0.04	0.0	0.0421455938697318	0.0421455938697318	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.0421455938697318	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	Ubiquitination;ubiquitination	0.7462496189437826	-4.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	0.04	0.04	0.0	0.046511627906976744	0.04883720930232558	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.05	0.0	0.04	0.0	0.0	0.0	0.0	0.0
127	Somatic mutations in the tyrosine kinase (TK) domain	0.18500222701980948	0.0	0.0	0.0	0.04	0.04	0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
264	an unresolved clinical challenge--	0.26905681404095005	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	a target-oriented isolation of potentially bioactive secondary metabolites	0.1164565672642326	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
176	bacterial	0.5860045571200567	-4.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-10.2	0.04	0.06756756756756756	0.0	0.04938271604938271	0.04938271604938271	1.0	0.06756756756756756	0.0	1.0	0.0	-10.2	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04938271604938271	0.0	0.06756756756756756	0.0	0.0	0.0	0.0	0.0
189	calcium loading	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
256	12) on the basis	0.12128954683570312	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.04	0.04	5.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
97	intron 1	0.8625817397481141	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
206	Present;present	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
289	progressed	0.11835126447297398	-2.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04504504504504505	0.04504504504504505	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04504504504504505	0.0	0.04	0.0	0.0	0.0	0.0	0.0
291	apps addressed alcohol	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
308	raf Kinases;Raf kinase	0.6397992040028528	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	3.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
8	a microtubule-associated protein	0.18258251903059658	-4.5	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	-4.5	0.0	0.0	0.0	0.04	0.04	0.0	0.04878048780487805	0.04878048780487805	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04878048780487805	0.0	0.04	0.0	0.0	0.0	0.0	0.0
24	Trial;CLINICAL TRIALS;trial;clinical trials	0.0628736033643804	-1.8166666666666664	1.0	-18.0	0.04	0.04857142857142857	1.0	1.0	1.0	-1.5	1.0	0.0	-15.6	0.0	0.0	-6.541666666666667	0.14285714285714285	0.04	1.0	0.04	0.04647575698424811	1.0833333333333333	0.06051474734942477	1.0	12.0	0.0	-17.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	13.0	0.10638297872340426	0.0	0.13333333333333333	1.0	0.0	0.9583333333333334	0.0	0.0
137	endovascular treatment (ET)	0.3015882842222794	-3.833333333333334	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	-3.8888888888888893	0.0	0.0	-6.8	0.04	0.05235602094240837	0.0	0.04712041884816754	0.04724441995039956	5.0	0.05507974457525043	0.6	2.0	0.0	-7.699999999999999	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04736842105263158	0.0	0.057803468208092484	0.0	0.0	0.0	0.0	0.0
281	a protein named DJ-1	0.12298502492082247	-1.1999999999999993	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	-1.1999999999999993	1.0	1.0	-3.833333333333332	0.04	0.047244094488188976	0.0	0.04201680672268907	0.04201680672268907	4.0	0.047244094488188976	0.0	1.0	1.0	-3.833333333333332	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04201680672268907	0.0	0.047244094488188976	0.0	1.0	0.0	0.0	1.0
199	conventional;Conventional	0.07159712843280118	-5.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-9.0	0.04	0.0625	0.0	0.051724137931034475	0.051724137931034475	1.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.051724137931034475	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
287	Investigation;Evaluated;investigation;evaluated	0.06673240632712302	-1.6999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.043148148148148144	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.046296296296296294	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	a given protein	0.047856057621882435	-2.8999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.8999999999999986	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04524886877828054	0.04524886877828054	3.0	0.045454545454545456	0.3333333333333333	1.0	0.0	-3.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04524886877828054	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
187	paroxysmal atrial	0.5696091342400936	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	2.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
199	centromere binding;centromere-specific-DNA-binding	0.1744191832111764	-4.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.047619047619047616	0.047619047619047616	7.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	7.0	0.047619047619047616	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
102	marked;Marked	0.6897570128485616	-4.125	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047905909351692484	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
91	62) treatment	0.2206642834143794	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.3333333333333333	0.0	0.0
124	Response;response	0.10004837004925869	-1.833333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.0	0.0	-1.833333333333334	0.04	0.04	0.0	0.04	0.043437500000000004	1.0	0.043437500000000004	0.0	2.0	0.0	-3.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.046875	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
72	link;Link	0.08240170788004741	-3.1000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.1000000000000014	0.0	0.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.04566210045662101	0.04566210045662101	1.0	0.046296296296296294	0.0	1.0	0.0	-3.3999999999999986	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04566210045662101	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
86	PKC alpha overexpression	0.8175108201392002	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
80	heart of HCM patients;heart patients	0.08671490994812284	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
195	common genetic disorders	0.0854031573309914	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04878048780487805	0.04878048780487805	3.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04878048780487805	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
19	blue;BLUE	0.6066186994119565	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
223	white patients	0.19887326249353984	-1.5757575757575744	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8181818181818166	0.0	0.0	-2.4761904761904767	0.04	0.0440251572327044	0.0	0.04182509505703422	0.042699868286985264	2.0	0.044399043918332465	0.0	3.0	0.0	-2.571428571428573	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.043137254901960784	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
346	II (Pol II	0.36815668834974896	-4.2	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.5	1.0	-6.6	0.0	0.0	-6.5	0.04	0.04516129032258065	0.0	0.04310344827586207	0.0487256371814093	4.0	0.05623449131513648	0.5	2.0	0.0	-10.142857142857142	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.05434782608695653	0.0	0.0673076923076923	0.0	0.0	0.0	0.0	0.0
331	replication;Replication	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
331	anticancer activity	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
233	the most common cause;The most common cause	0.9692388688070425	-5.11965811965812	1.0	-17.5	0.04	0.047179487179487174	1.0	1.0	1.0	-1.3461538461538463	0.9743589743589743	0.0	-11.11111111111111	0.0	0.0	-6.730769230769231	0.13333333333333333	0.04	1.0	0.04	0.05208347471099593	4.0	0.0588663967611336	1.0	13.0	0.0	-15.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	52.0	0.072	0.0	0.10526315789473684	1.0	0.0	0.25	0.0	0.0
10	Related;related	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
48	38% of the overall series	0.070573803746527	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	6.0	0.05	0.16666666666666666	1.0	0.0	-5.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
200	a chest protector	0.0793662226340656	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
77	an adjunct	0.5331167240388152	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9.285714285714286	0.04	0.06363636363636364	0.0	0.04	0.04	2.0	0.06363636363636364	0.0	1.0	0.0	-9.285714285714286	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.06363636363636364	0.0	0.0	0.0	0.0	0.0
25	HOME;home	0.0648071641734773	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.04	0.04	1.0	0.05405405405405406	0.0	1.0	0.0	-6.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
320	Specs	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
297	a significant inverse relationship	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
138	a simple derivatization procedure	0.10125390641716234	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04	0.04	4.0	0.043478260869565216	0.0	1.0	0.0	-2.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
183	the somatic mutational spectrum	0.11627961912072131	-4.25	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.04819277108433735	0.04819277108433735	4.0	0.06060606060606061	0.25	1.0	0.0	-8.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04819277108433735	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
174	associated with;Associated with;Associated;associated	0.06558793241642799	-1.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-1.5	0.04	0.04	0.0	0.04	0.04173913043478261	1.5	0.042727272727272725	0.0	2.0	0.0	-3.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.043478260869565216	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
319	potential concerns about the undesirable effects	0.04268159245627423	-2.333333333333332	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.044117647058823525	0.044117647058823525	6.0	0.05405405405405406	0.16666666666666666	1.0	0.0	-6.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.044117647058823525	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
99	is;IS	0.006569821387325964	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	1.0	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	1.0	0.0	0.0	0.0	0.0
143	only;Only	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
284	other forms of cancer therapy	0.05411772315431602	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	Frequency;frequency	0.08001929770067369	-2.7777777777777786	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.7777777777777786	0.0	0.0	-3.833333333333332	0.04	0.047244094488188976	0.0	0.045	0.045	1.0	0.047244094488188976	0.0	1.0	0.0	-3.833333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045	0.0	0.047244094488188976	0.0	0.0	0.0	0.0	0.0
158	Apert syndrome (syndromic craniosynostosis with symmetrical syndactyly	0.13805913340829173	-3.6000000000000014	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.2	1.0	-3.6000000000000014	1.0	1.0	0.0	0.04	0.04	0.0	0.04672897196261683	0.04672897196261683	8.0	0.04	0.375	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04672897196261683	0.0	0.04	0.0	1.0	0.0	0.0	1.0
9	the Alu I family of man	0.05172733387632983	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
8	centrosome;Centrosome	0.9352791264278334	-2.375	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.0	1.0	1.0	-3.9375	0.04	0.04	0.0	0.04	0.044486622235100935	1.0	0.04846615846615847	0.0	8.0	1.0	-7.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	8.0	0.047619047619047616	0.0	0.05555555555555555	0.0	1.0	0.0	0.0	1.0
90	a polypill (Polycap)	0.3123795294827484	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
213	Brother;brother	0.06163186670033532	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-12.0	0.04	0.07692307692307693	0.0	0.05	0.05	1.0	0.07692307692307693	0.0	1.0	0.0	-12.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05	0.0	0.07692307692307693	0.0	0.0	0.0	0.0	0.0
251	modulation;Modulation	0.5864306174254299	-1.8888888888888893	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-1.8888888888888893	0.04	0.04326923076923077	0.0	0.04326923076923077	0.04326923076923077	1.0	0.04326923076923077	0.0	1.0	0.0	-1.8888888888888893	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04326923076923077	0.0	0.04326923076923077	0.0	0.0	0.0	0.0	0.0
303	Suppressed;suppressed	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
290	Transvaginal Ultrasound;Transvaginal ultrasound;transvaginal ultrasound	0.8753567618681075	-12.05	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-13.25	1.0	1.0	-10.133333333333335	0.04	0.06382978723404256	0.0	0.07272727272727272	0.077678916827853	2.0	0.06756616502335237	0.0	5.0	1.0	-11.333333333333334	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	3.0	1.0	10.0	0.0851063829787234	0.0	0.07317073170731708	0.0	1.0	0.0	0.0	1.0
307	NAC	0.8429963764608942	-2.6000000000000014	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.044642857142857144	0.044642857142857144	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	2.0	0.044642857142857144	0.0	0.04	0.0	0.0	0.0	0.0	0.0
334	variants;Variant;variant	0.42300889093569516	-2.0606060606060606	1.0	-13.75	0.04	0.044444444444444446	0.0	0.0	1.0	-1.25	1.0	0.0	-15.444444444444445	0.0	0.0	-3.6136363636363638	0.08888888888888889	0.04	1.0	0.04	0.04707629320908436	1.0	0.04811262733038632	1.0	11.0	0.0	-11.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	11.0	0.10465116279069768	0.0	0.07272727272727272	1.0	0.0	1.0	0.0	0.0
332	Development, Other;others in clinical development	0.14273768740513829	-2.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.043795620437956206	0.043795620437956206	4.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.043795620437956206	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	mature;Mature	0.5748709684159367	-3.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.046511627906976744	0.046511627906976744	1.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046511627906976744	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
84	histamine receptor blockade	0.675353243834414	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
127	single;Single	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	most patients	0.08638154344256214	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-7.23076923076923	0.04	0.05627705627705627	0.0	0.047619047619047616	0.047619047619047616	2.0	0.05627705627705627	0.0	1.0	0.0	-7.23076923076923	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047619047619047616	0.0	0.05627705627705627	0.0	0.0	0.0	0.0	0.0
15	the PPIs	0.07617774091422008	-2.6000000000000014	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.6666666666666666	1.0	-2.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.044642857142857144	0.044642857142857144	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.044642857142857144	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	inflammation;INFLAMMATION	0.632331070958031	-2.833333333333332	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.045112781954887216	0.045112781954887216	1.0	0.04938271604938271	0.0	2.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.045112781954887216	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
31	E. granulosus tegumental membrane protein	0.38167609431531685	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-9.0	0.04	0.0625	0.0	0.04	0.04	5.0	0.0625	0.0	1.0	1.0	-9.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.0625	0.0	1.0	0.0	0.0	1.0
79	Antagonist;antagonist	0.5508360854501932	-3.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-6.25	0.04	0.05333333333333334	0.0	0.04587155963302752	0.04587155963302752	1.0	0.05333333333333334	0.0	1.0	0.0	-6.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04587155963302752	0.0	0.05333333333333334	0.0	0.0	0.0	0.0	0.0
82	Reach;reach	0.08976070477377668	-1.571428571428573	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.042682926829268296	0.042682926829268296	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.042682926829268296	0.0	0.04	0.0	0.0	0.0	0.0	0.0
227	Thermoregulation;thermoregulation	0.5667095527189704	-3.8000000000000007	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04716981132075472	0.04716981132075472	1.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04716981132075472	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
129	hemi;Hemi	0.6537338403760867	-0.6666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-0.8571428571428577	0.04	0.04	0.0	0.04	0.04115942028985507	0.0	0.04152866242038217	0.0	3.0	0.0	-2.571428571428573	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.043478260869565216	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
292	the treatment of neuropathic pain or fibromyalgia	0.016458693239357728	0.0	1.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.5714285714285714	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
118	cells;Cells	0.08788994715838552	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.625	0.04	0.045454545454545456	0.0	0.04	0.04	1.0	0.05257801899592944	0.0	2.0	0.0	-8.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.05970149253731343	0.0	0.0	0.0	0.0	0.0
183	Neurofibromatosis type 1 and Noonan syndrome	0.05239664237856806	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.2	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.5	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
198	Amino acid change;amino acid changes	0.3448418541079625	-5.599999999999999	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-5.6	0.0	0.0	0.0	0.04	0.04	0.0	0.051546391752577324	0.051546391752577324	3.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.051546391752577324	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	Retarded growth and development	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	ultrashort;ultrashort (	0.6594167495771752	-4.666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	-4.5	0.04	0.048387096774193554	0.0	0.04918032786885245	0.04918032786885245	1.5	0.048783712321523	0.0	2.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04918032786885245	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
255	Facioscapulohumeral muscular dystrophy;Facioscapulohumeral dystrophy;Facio-Scapulo-Humeral Dystrophy;FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY;facioscapulohumeral dystrophy	0.855870061544843	-4.0	1.0	-10.375	0.04	0.04472934472934473	0.0	0.0	1.0	-1.7291666666666667	1.0	0.0	-11.0	0.0	0.0	-8.0	0.06837606837606838	0.055944055944055944	0.0	0.04	0.04925392558457075	2.6666666666666665	0.05950815967224613	1.0	12.0	0.0	-11.625	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	5.0	1.0	32.0	0.07142857142857142	0.0	0.07476635514018691	1.0	0.0	0.0	0.0	0.0
4	appear;APPEAR	0.09731312944392172	-3.875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.875	0.0	0.0	0.0	0.04	0.04	0.0	0.047337278106508875	0.047337278106508875	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047337278106508875	0.0	0.04	0.0	0.0	0.0	0.0	0.0
65	established;Established	0.08385716819963272	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.047619047619047616	0.047619047619047616	1.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
276	Thyroid, NOS;thyroid	0.710456880121112	-0.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04085106382978723	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.0425531914893617	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	3D;three-dimensional;3-Dimensional	0.4978262399444654	-1.5416666666666667	0.0	0.0	0.04	0.04	0.0	0.1111111111111111	0.0	0.0	0.0	0.0	-4.625	0.0	0.0	-7.666666666666667	0.04	0.05	0.0	0.04	0.04302658486707567	2.0	0.058887667216419276	0.1111111111111111	3.0	0.0	-10.833333333333334	1.0	0.0	0.0	0.3333333333333333	0.0	0.0	1.0	0.0	0.0	3.0	1.0	6.0	0.049079754601226995	0.0	0.07058823529411765	0.0	0.0	0.0	0.0	0.0
79	two hours	0.10010591781947384	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.045454545454545456	0.045454545454545456	2.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.045454545454545456	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
252	Troponin T	0.7725917477983353	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
149	12 weeks of endurance training	0.15898064341854684	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
159	occurred;Occurred	0.08074746464470092	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
229	unified;Unified	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
19	Phillippineswww.genericviagra.com	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	human infectious diseases	0.20739962860420155	-9.25	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-9.25	1.0	1.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.06349206349206349	0.06349206349206349	3.0	0.04918032786885245	0.0	1.0	1.0	-4.666666666666666	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.06349206349206349	0.0	0.04918032786885245	0.0	1.0	0.0	0.0	1.0
186	genetic analysis;Genetic analysis	0.11707437433269925	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
282	Assay;assay	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	an antidote in comatose patients	0.051857292521984386	-3.3999999999999986	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.2857142857142857	1.0	-3.3999999999999986	1.0	1.0	-7.25	0.04	0.056338028169014086	0.0	0.046296296296296294	0.046296296296296294	5.0	0.056338028169014086	0.6	1.0	1.0	-7.25	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.046296296296296294	0.0	0.056338028169014086	0.0	1.0	0.0	0.0	1.0
304	prognostic markers;Prognostic Marker	0.27926268070552995	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
257	protein and lipid protection	0.31459820278721756	-6.833333333333334	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	-6.833333333333334	0.0	0.0	-2.571428571428573	0.04	0.0445859872611465	0.0	0.05504587155963304	0.05504587155963304	4.0	0.0445859872611465	0.0	2.0	0.0	-2.571428571428573	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.05504587155963304	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
73	new;NEW;Novel;novel	0.24084323358958004	-1.0694444444444446	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8888888888888893	0.0	0.0	-3.2708333333333335	0.04	0.04	0.0	0.04	0.04191655281680908	1.0	0.04708984583239843	0.0	8.0	0.0	-8.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	8.0	0.04736842105263158	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
121	equal efficacy and cost	0.10652174914513579	-5.333333333333334	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.05084745762711865	0.05084745762711865	4.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.05084745762711865	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
184	196	0.6194314411086717	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	1.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
41	SET-domain histone methyltransferase	0.30256944470268476	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04	0.04	5.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
14	terms;Term;termed	0.07132231594113096	-1.875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-4.249999999999999	0.04	0.044117647058823525	0.0	0.04	0.043529411764705886	1.0	0.04860749609578344	0.0	2.0	0.0	-6.166666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.047058823529411764	0.0	0.053097345132743355	0.0	0.0	0.0	0.0	0.0
75	Autosomal recessive;autosomal recessive	0.7734118636713873	-4.833333333333333	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-2.25	0.04	0.04	0.0	0.04938271604938271	0.049588477366255136	2.0	0.04418762261458891	0.0	3.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.05	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
102	organs	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
71	upregulation of glycolysis	0.10137062042812169	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
336	acetyllysine residues in histones	0.5318879688173874	-2.75	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0449438202247191	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
215	induces;Inducing;induction;induced;inducing;Induction;induce;Induce;Induced	0.9714765488581708	-3.22	1.0	-14.2	0.04	0.0421037037037037	0.0	0.0	1.0	-0.568	1.0	0.0	-14.0	0.0	0.0	-5.984000000000001	0.09259259259259259	0.04	0.0	0.04	0.04791072083746654	1.0	0.055439573136783	0.32	25.0	0.0	-14.8	1.0	0.0	0.0	0.32	0.0	0.0	1.0	0.0	0.0	9.0	1.0	25.0	0.09090909090909091	0.0	0.09803921568627452	1.0	0.0	0.0	0.0	0.0
260	the mutational hotspots	0.02589915046037807	-8.0	1.0	-10.4	0.0684931506849315	0.0684931506849315	0.3333333333333333	0.3333333333333333	1.0	-10.4	1.0	1.0	-8.0	0.0	0.0	-9.6	0.0684931506849315	0.06493506493506493	1.0	0.058823529411764705	0.058823529411764705	3.0	0.06493506493506493	1.0	1.0	0.0	-9.6	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.058823529411764705	0.0	0.06493506493506493	1.0	0.0	0.3333333333333333	0.0	0.0
44	biosynthesis	0.7149191177847443	-3.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-2.333333333333333	0.04	0.04	0.0	0.045454545454545456	0.0459830866807611	1.0	0.044590163934426226	0.0	2.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.046511627906976744	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
41	chromodomain gene	0.1599885323184273	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	1.0	0.0	1.0	0.5	0.0	1.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
14	approach [13]	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	CHROMODOMAIN HELICASE DNA-BINDING PROTEIN 1;CHD1;CHD-1;Chd1;chromodomain helicase DNA-binding protein 1	0.8789104043988389	-2.25	0.0	0.0	0.04	0.04	0.0	0.05357142857142857	0.0	0.0	0.0	1.0	-9.0	1.0	1.0	-3.041666666666667	0.04	0.04	0.0	0.04	0.045625	1.75	0.0461110437383782	0.017857142857142856	8.0	1.0	-6.0	1.0	0.3333333333333333	0.0	0.125	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	5.0	1.0	14.0	0.0625	0.0	0.05263157894736842	0.0	1.0	0.0	0.0	1.0
333	the surface	0.028137037961783785	-1.571428571428573	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.571428571428573	0.0	0.0	-8.75	0.04	0.06153846153846154	0.0	0.042682926829268296	0.042682926829268296	2.0	0.06153846153846154	0.5	1.0	0.0	-8.75	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.042682926829268296	0.0	0.06153846153846154	0.0	0.0	0.0	0.0	0.0
60	membrane-integral Nups	0.7544880182025683	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	the kinetic analysis	0.08156053277362822	-4.25	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04819277108433735	0.04819277108433735	3.0	0.045454545454545456	0.3333333333333333	1.0	0.0	-3.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04819277108433735	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
137	patients with Chronic Cerebro-Spinal Venous Insufficiency (CCSVI) and multiple sclerosis (MS)	0.013468393374397132	0.0	1.0	0.0	0.04	0.04	0.35294117647058826	0.35294117647058826	0.0	0.0	0.5555555555555556	0.0	0.0	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04	0.04	17.0	0.04878048780487805	0.7647058823529411	1.0	0.0	-4.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	17.0	0.04	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
342	trithorax homolog;homolog of Drosophila trithorax	0.32798665695044926	-3.1999999999999993	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.04587155963302752	0.04587155963302752	4.0	0.046296296296296294	0.0	1.0	0.0	-3.3999999999999986	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04587155963302752	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
144	the enhancer region	0.08642089434510923	-2.3999999999999986	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04424778761061947	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04424778761061947	0.0	0.04	0.0	0.0	0.0	0.0	0.0
89	the cause	0.04336341107169938	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
9	the known higher selective disadvantage of recombination products	0.10855132711580304	-5.666666666666666	0.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.051724137931034475	0.051724137931034475	8.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.051724137931034475	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
239	strong;Strong	0.07753425935432966	-2.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04477611940298508	0.04477611940298508	1.0	0.04878048780487805	0.0	1.0	0.0	-4.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04477611940298508	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
74	a Ca2	0.1856814120775366	-2.833333333333332	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-10.5	0.04	0.06896551724137931	0.0	0.045112781954887216	0.045112781954887216	2.0	0.06896551724137931	0.0	1.0	0.0	-10.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.045112781954887216	0.0	0.06896551724137931	0.0	0.0	0.0	0.0	0.0
330	joints;Joints	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
99	inner surface membrane	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
300	a repressor of the oxidative stress response	0.10654776137565483	-2.8571428571428577	1.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.2857142857142857	1.0	-2.8571428571428577	0.0	0.0	0.0	0.04	0.04	0.0	0.04516129032258065	0.04516129032258065	7.0	0.04	0.42857142857142855	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	14.0	0.04516129032258065	0.0	0.04	0.0	0.0	0.0	0.0	0.0
30	relaxin expression	0.4995477368232526	-1.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-3.7	0.04	0.04	0.0	0.04	0.04173913043478261	2.0	0.04840909090909091	0.0	4.0	0.0	-7.4	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.043478260869565216	0.0	0.056818181818181816	0.0	0.0	0.0	0.0	0.0
72	text-mining packages	0.03646305658772403	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.75	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
257	's oxidative defenses	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
281	Carry;carry	0.08985105651687028	-1.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.042735042735042736	0.042735042735042736	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.042735042735042736	0.0	0.04	0.0	0.0	0.0	0.0	0.0
28	probable autoimmune origin	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	circadian rhythmicity in mice	0.07346520742530743	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
163	inflammation;INFLAMMATION	0.7430894477265151	-1.8000000000000007	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-3.0	0.04	0.04	0.0	0.04	0.04336448598130842	1.0	0.04631578947368421	0.0	4.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04672897196261683	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
239	lesions	0.6312264565632238	-3.333333333333332	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04615384615384615	0.04615384615384615	1.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04615384615384615	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
156	The inheritance	0.022807555783436507	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	1.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	1.0	0.0	0.0	0.0	0.0
221	electrode positioning	0.650094923347479	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.04	0.04	2.0	0.058823529411764705	0.0	2.0	0.0	-8.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
331	binding	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
82	risk for CBZ	0.13439755706104684	-1.571428571428573	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.571428571428573	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.042682926829268296	0.042682926829268296	3.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.042682926829268296	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
71	a candidate transcription factor	0.045390990944635654	0.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.6666666666666666	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.25	0.0	0.0
130	methodology	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
307	Mutations in the alpha	0.15214303617228242	-2.3999999999999986	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04424778761061947	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04424778761061947	0.0	0.04	0.0	0.0	0.0	0.0	0.0
151	RCC	0.6796887997262264	-2.3571428571428568	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.7142857142857135	0.0	0.0	-2.833333333333333	0.04	0.04	0.0	0.04	0.04464788732394366	1.0	0.04586206896551724	0.0	2.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04929577464788733	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
120	anisomycin and arsenite	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
104	Prediction;prediction;predictions	0.14389719953845406	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
216	situ bioremediation	0.23369295192928355	-3.25	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.5	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	the global minimum energy structure	0.048996420590420954	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.04	0.044117647058823525	0.0	0.04	0.04	5.0	0.044117647058823525	0.2	1.0	0.0	-2.333333333333332	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.044117647058823525	0.0	0.0	0.0	0.0	0.0
78	distal;DISTAL	0.6298694339012535	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.666666666666667	0.04	0.04	0.0	0.04	0.04	1.0	0.04542372881355933	0.0	2.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
254	proportion;Proportion	0.10238296519538877	-5.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.05084745762711865	0.05084745762711865	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05084745762711865	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	old;Old	0.10820578548762314	-1.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04212389380530973	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04424778761061947	0.0	0.04	0.0	0.0	0.0	0.0	0.0
222	the development	0.045182001847346574	-4.111111111111111	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.111111111111111	0.0	0.0	0.0	0.04	0.04	0.0	0.047872340425531915	0.047872340425531915	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047872340425531915	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	critical;Critical	0.06345914824668802	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.04	0.04	1.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
318	production;Production	0.0712441514969011	-1.7777777777777786	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-5.76923076923077	0.04	0.052000000000000005	0.0	0.0430622009569378	0.0430622009569378	1.0	0.052000000000000005	0.0	1.0	0.0	-5.76923076923077	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0430622009569378	0.0	0.052000000000000005	0.0	0.0	0.0	0.0	0.0
72	data analysis algorithms from the necessity	0.044468376246253064	-1.6999999999999993	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-1.6999999999999993	0.0	0.0	-5.0	0.04	0.05	0.0	0.04291845493562232	0.04291845493562232	6.0	0.05	0.16666666666666666	1.0	0.0	-5.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04291845493562232	0.0	0.05	0.0	0.0	0.0	0.0	0.0
73	Model;model	0.12251854446386425	-1.7037037037037048	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-4.944444444444445	0.04	0.043795620437956206	0.0	0.04265402843601896	0.04292680068746419	1.0	0.050384146025049224	0.0	3.0	0.0	-7.166666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04326923076923077	0.0	0.05607476635514018	0.0	0.0	0.0	0.0	0.0
49	features;characteristics;Characteristics;Feature	0.06723646459694888	-1.125	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04197802197802198	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.04395604395604396	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	majority of patients	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
90	CARPE-M study	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
27	Advanced;advanced	0.07474515735363976	-2.2222222222222214	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.2222222222222214	0.0	0.0	-5.0	0.04	0.05	0.0	0.04390243902439024	0.04390243902439024	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04390243902439024	0.0	0.05	0.0	0.0	0.0	0.0	0.0
115	the function	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
327	a feature of introns	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
111	proper selenocysteine synthesis	0.20746220121390285	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
267	analog;Analog	0.6157476116558734	-2.8571428571428577	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.8571428571428577	0.0	0.0	0.0	0.04	0.04	0.0	0.04516129032258065	0.04516129032258065	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04516129032258065	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	significant predictor variables	0.12720614182431092	-4.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.047619047619047616	0.047619047619047616	3.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.047619047619047616	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
90	eg;EG	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
289	inhibitor idelalisib	0.22307950623343603	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
242	Measured	0.11603873095218603	-2.2222222222222214	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.2222222222222214	0.0	0.0	0.0	0.04	0.04	0.0	0.04390243902439024	0.04390243902439024	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04390243902439024	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	gabapentin-related rash in this population	0.05885709927362253	0.0	1.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.125	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.2857142857142857	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
252	the control group	0.08356593022561223	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	2.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
150	direct;Direct	0.0925071381544399	-2.428571428571427	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.428571428571427	0.0	0.0	0.0	0.04	0.04	0.0	0.04430379746835443	0.04430379746835443	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04430379746835443	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	the successful completion	0.09545766202980806	-18.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-18.0	0.0	0.0	-11.0	0.04	0.07142857142857142	0.0	0.14285714285714285	0.14285714285714285	3.0	0.07142857142857142	0.3333333333333333	1.0	0.0	-11.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.14285714285714285	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0
336	Chromatin Remodeling;chromatin remodelling;chromatin remodeling	0.5867006441844541	-1.875	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-1.875	0.04	0.04	0.0	0.04	0.043529411764705886	2.0	0.043529411764705886	0.0	2.0	0.0	-3.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.047058823529411764	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
89	partial seizures;Partial seizures	0.2983279104863945	-2.3999999999999986	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04424778761061947	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04424778761061947	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	low;Low	0.07744319849939259	-1.5555555555555571	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	-3.571428571428573	0.04	0.04666666666666667	0.0	0.04265402843601896	0.04265402843601896	1.0	0.04666666666666667	0.0	1.0	0.0	-3.571428571428573	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04265402843601896	0.0	0.04666666666666667	0.0	0.0	0.0	0.0	0.0
79	1,4-imidazobenzodiazepine	0.653905375881782	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.04	0.04	5.0	0.04597701149425287	0.0	1.0	0.0	-3.25	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
267	tighter;Tight	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
151	output;Output	0.10694814515923642	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.142857142857142	0.0	0.0	-2.0	0.04	0.04	0.0	0.043209876543209874	0.04557754101133096	1.0	0.04380952380952381	0.0	2.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04794520547945205	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
176	found;in;In;Present;Found;present	0.01038445855663031	-3.2916666666666665	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.25	0.0	0.0	-7.8	0.04	0.05376344086021505	0.0	0.04	0.04670565302144249	1.0	0.058868139210701026	0.3333333333333333	3.0	0.0	-10.4	1.0	0.0	1.0	0.3333333333333333	1.0	0.0	1.0	0.0	0.0	6.0	1.0	3.0	0.05333333333333334	0.0	0.0684931506849315	1.0	0.0	0.0	0.0	0.0
16	Interaction;interactions	0.07937667460309614	-2.4545454545454533	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.4545454545454533	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.044354838709677415	0.044354838709677415	1.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.044354838709677415	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
320	Validity;validity	0.07227637838306812	-2.833333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.045112781954887216	0.045112781954887216	1.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045112781954887216	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
13	the system	0.07884817754029713	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	2.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
41	mice	0.08777881280371597	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
143	evaluation;Evaluation	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
257	the relative abundance of peroxiredoxin 2	0.07340111551508247	-2.833333333333332	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.42857142857142855	1.0	-2.833333333333332	1.0	1.0	-2.428571428571427	0.04	0.04430379746835443	0.0	0.045112781954887216	0.045112781954887216	6.0	0.04430379746835443	0.5	1.0	1.0	-2.428571428571427	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.045112781954887216	0.0	0.04430379746835443	0.0	1.0	0.0	0.0	1.0
215	p53/Pten-deficient cells	0.5015318213943798	-4.75	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	1.0	-4.75	0.0	0.0	-7.4	0.04	0.056818181818181816	0.0	0.04938271604938271	0.04938271604938271	6.0	0.056818181818181816	0.0	1.0	0.0	-7.4	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04938271604938271	0.0	0.056818181818181816	0.0	0.0	0.0	0.0	0.0
122	most;Most	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	Peak;peak	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
72	set;Set	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
28	These findings	0.12107946463151989	-5.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.05084745762711865	0.05084745762711865	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05084745762711865	0.0	0.04	0.0	0.0	0.0	0.0	0.0
144	induced;Induced	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	Meet;met	0.06936315925490025	-6.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-10.333333333333334	0.04	0.06818181818181819	0.0	0.053571428571428575	0.053571428571428575	1.0	0.06818181818181819	0.0	1.0	0.0	-10.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.053571428571428575	0.0	0.06818181818181819	0.0	0.0	0.0	0.0	0.0
183	eight somatic (1888delG, 4374-4375delCC, R2129S, 2088delG, 2341del18, IVS27b-5C>T, 4083insT, Q519P)	0.27306369672684816	0.0	0.0	0.0	0.04	0.04	0.047619047619047616	0.047619047619047616	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	21.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	21.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	dysregulation in disease	0.21502134065069065	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
130	VIM-;VIM;vim	0.9659670418462208	-1.2727272727272727	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.8181818181818166	0.0	0.0	-2.520408163265306	0.04	0.04	0.0	0.04	0.04221238114849273	0.6428571428571429	0.04475779841419179	0.03571428571428571	14.0	0.0	-5.571428571428571	1.0	0.3333333333333333	0.0	0.07142857142857142	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	3.0	1.0	9.0	0.047210300429184546	0.0	0.051470588235294115	0.0	0.0	0.0	0.0	0.0
73	feed-forward Neural Networks	0.18916618552744635	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
322	enzyme activity	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	CNOT7	0.876110163107776	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	4.0	1.0	0.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
121	the use	0.14382469478585125	-6.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-5.333333333333333	0.04	0.05	0.0	0.051724137931034475	0.052647783251231525	2.0	0.05086206896551724	0.0	2.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.053571428571428575	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
195	a pair of highly active TALENs	0.0747829060298053	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
77	given;GIVEN	0.07028389026566616	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-6.2857142857142865	0.04	0.05343511450381679	0.0	0.043478260869565216	0.043478260869565216	1.0	0.05343511450381679	0.0	1.0	0.0	-6.2857142857142865	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.05343511450381679	0.0	0.0	0.0	0.0	0.0
80	previous;Previous	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	Prognosis;prognosis	0.6894258364443007	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	-3.777777777777778	0.04	0.04	0.0	0.04	0.04585580821434867	1.0	0.04818910256410256	0.0	3.0	0.0	-7.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04918032786885245	0.0	0.05769230769230768	0.0	0.0	0.0	0.0	0.0
44	synthesis;Synthesis	0.6295532543684198	-1.625	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-2.166666666666667	0.04	0.04	0.0	0.04	0.04298850574712644	1.0	0.04419354838709678	0.0	2.0	0.0	-4.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04597701149425287	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
318	expression;Expression	0.09965593807309824	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.4615384615384617	0.04	0.042622950819672135	0.0	0.04	0.04	1.0	0.044443148007700835	0.0	2.0	0.0	-3.3846153846153832	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.046263345195729534	0.0	0.0	0.0	0.0	0.0
160	osteoclastogenesis and cytokine production	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
216	U(VI;U(VI)	0.9982123550507611	-1.3125	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-12.25	0.0	0.0	-4.361111111111112	0.04	0.04	0.0	0.04	0.0437452500379997	3.3333333333333335	0.052160586124401914	0.0	12.0	0.0	-15.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	40.0	0.0784313725490196	0.0	0.1	0.0	0.0	0.0	0.0	0.0
168	lacks;lack	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
143	their targets by a short complementary region	0.06495544270537182	0.0	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
307	sporadic cases	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
331	low level of p53 and Bcl-2 expression	0.12608336148160756	0.0	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
109	an inevitable, concomitant overexpression of TRalpha1	0.2635015070829394	-3.6000000000000014	0.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04672897196261683	0.04672897196261683	7.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04672897196261683	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
107	Sequence Alignment;sequence alignment;alignment of two sequences;sequence-sequence alignment	0.06003509329931733	-5.0	1.0	-11.571428571428571	0.04	0.053787234042553186	0.5	0.6	1.0	-4.628571428571428	1.0	0.4	-9.833333333333334	0.0	0.0	-9.17142857142857	0.07446808510638298	0.04516129032258065	0.0	0.04	0.052384379061798415	3.2	0.06526806388120641	1.0	5.0	0.0	-11.142857142857142	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.0	0.13333333333333333	4.0	1.0	16.0	0.06593406593406594	0.0	0.07216494845360824	1.0	0.0	0.0	0.0	0.0
267	MHR	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
89	the few reports	0.048894972933717654	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
171	features of non-compaction cardiomyopathy	0.04486934437691037	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
37	Poisons;poison;Poison;poisons	0.47901539351531475	-6.166666666666667	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-9.75	0.04	0.06557377049180328	0.0	0.05263157894736842	0.0531015037593985	1.0	0.06557377049180328	0.0	2.0	0.0	-9.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.053571428571428575	0.0	0.06557377049180328	0.0	0.0	0.0	0.0	0.0
130	CFU/ml;CFU/mL	0.5717231683879584	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	Part of;part of	0.07876710831831964	-5.166666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.166666666666666	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.050420168067226885	0.050420168067226885	2.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.050420168067226885	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
5	another observational study of 69 patients	0.08680331008994818	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
161	the equal number	0.048894972933717654	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
341	homozygous, heterozygous, and wild-type mice (3.2 x	0.1518146031386049	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04	0.04	12.0	0.04878048780487805	0.08333333333333333	1.0	0.0	-4.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	12.0	0.04	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
251	Transcriptional and post-transcriptional regulatory mechanisms	0.30773780101229764	-1.7777777777777786	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-1.6666666666666679	0.04	0.04285714285714286	0.0	0.0430622009569378	0.0430622009569378	5.0	0.04285714285714286	0.0	2.0	0.0	-1.6666666666666679	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.0430622009569378	0.0	0.04285714285714286	0.0	0.0	0.0	0.0	0.0
89	admission;Admission	0.09241438672407117	-2.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04424778761061947	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04424778761061947	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	the antitumor efficacy	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
63	a subcutaneous injection	0.48501901710734213	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	the current status of bortezomib as well as	0.013452118426957753	0.0	1.0	0.0	0.04	0.04	0.875	0.875	0.0	0.0	0.16666666666666666	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.375	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
118	proliferation;Proliferation	0.5296114464834385	-1.571428571428573	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.571428571428573	0.0	0.0	-6.75	0.04	0.0547945205479452	0.0	0.042682926829268296	0.042682926829268296	1.0	0.0547945205479452	0.0	1.0	0.0	-6.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.042682926829268296	0.0	0.0547945205479452	0.0	0.0	0.0	0.0	0.0
269	60-90%	0.6743089891211831	-4.6	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.6	0.0	0.0	0.0	0.04	0.04	0.0	0.04901960784313726	0.04901960784313726	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04901960784313726	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	profile;profiles;Profile	0.15156045096539913	-1.05	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.375	0.0	0.0	-3.2666666666666657	0.04	0.04	0.0	0.04	0.041897203561943444	1.0	0.04631794871794871	0.0	5.0	0.0	-5.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	5.0	0.046242774566473986	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
258	mouse fibroblast cells;mouse fibroblast cell	0.2604100930014654	-3.8000000000000007	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-7.400000000000001	0.04	0.056818181818181816	0.0	0.04716981132075472	0.04716981132075473	3.0	0.056818181818181816	0.0	3.0	0.0	-7.4	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.04716981132075472	0.0	0.056818181818181816	0.0	0.0	0.0	0.0	0.0
41	conserved residues	0.5769349379675445	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04	0.04	2.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
249	binding of polycomb repressive complex 2 (PRC2)	0.2647684370239564	0.0	0.0	0.0	0.04	0.04	0.2222222222222222	0.2222222222222222	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-1.5	0.04	0.0425531914893617	0.0	0.04	0.04	9.0	0.0425531914893617	0.3333333333333333	1.0	0.0	-1.5	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04	0.0	0.0425531914893617	0.0	0.0	0.0	0.0	0.0
85	Sequences;sequences	0.0861695891560261	-3.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-2.571428571428573	0.04	0.0445859872611465	0.0	0.046296296296296294	0.046296296296296294	1.0	0.0445859872611465	0.0	1.0	0.0	-2.571428571428573	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046296296296296294	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
186	SQTS	0.8856263537131194	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	6.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	Reduced dosage of Dnmt1	0.1405487375957212	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
10	Tumorigenesis;tumorigenesis	0.9639494312085589	-1.585714285714286	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.7142857142857153	1.0	1.0	-2.9	0.04	0.04	0.0	0.04	0.042798365441164395	1.0	0.046539682539682534	0.0	10.0	1.0	-7.5	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	10.0	0.04487179487179487	0.0	0.05714285714285714	0.0	1.0	0.0	0.0	1.0
103	DNA methyltransferase 3B;DNA Methyltransferase 3B	0.3208103607331125	-1.8888888888888893	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-1.8888888888888893	0.0	0.0	-5.428571428571429	0.04	0.05109489051094891	0.0	0.04326923076923077	0.04326923076923077	3.0	0.05109489051094891	0.3333333333333333	2.0	0.0	-5.428571428571429	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.04326923076923077	0.0	0.05109489051094891	0.0	0.0	0.0	0.0	0.0
151	membrane;Membrane	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	luminal domain	0.20491657616916664	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04	0.04	2.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
285	the cohort of young onset breast cancer cases	0.07090241696188426	-3.1999999999999993	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04587155963302752	0.04587155963302752	8.0	0.04	0.125	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04587155963302752	0.0	0.04	0.0	0.0	0.0	0.0	0.0
321	3D QSAR Pharmacophore Generation module	0.11154164189996178	-3.3999999999999986	1.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.16666666666666666	0.0	-3.3999999999999986	0.0	0.0	-18.0	0.04	0.14285714285714285	0.0	0.046296296296296294	0.046296296296296294	6.0	0.14285714285714285	0.16666666666666666	1.0	0.0	-18.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.046296296296296294	0.0	0.14285714285714285	0.0	0.0	0.0	0.0	0.0
288	To;TO	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	their N-terminal end	0.25804463447651876	-5.5	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-5.5	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.05128205128205128	0.05128205128205128	5.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.05128205128205128	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
103	their substrate specificity	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
111	eubacteria;EUBACTERIA	0.625681486939812	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.043478260869565216	0.043478260869565216	1.0	0.04918032786885245	0.0	2.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.043478260869565216	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
152	Preferred;preferred	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
94	individualized;Individualized	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	30%;30	0.8006110598095644	-2.666666666666668	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.666666666666668	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.04477611940298508	0.04477611940298508	1.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04477611940298508	1.0	0.046875	0.0	0.0	0.0	1.0	0.0
236	queries sample sets	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	Combination;combination	0.08953518362259696	-1.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	0.0	0.04	0.04	0.0	0.0425531914893617	0.0425531914893617	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0425531914893617	0.0	0.04	0.0	0.0	0.0	0.0	0.0
37	biomarker status	0.18779502699181239	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.75	0.04	0.057971014492753624	0.0	0.04	0.04	2.0	0.057971014492753624	0.0	1.0	0.0	-7.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.057971014492753624	0.0	0.0	0.0	0.0	0.0
115	the majority of those tested	0.06091014631561395	-7.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.5	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.05714285714285714	0.05714285714285714	5.0	0.046875	0.2	1.0	0.0	-3.666666666666668	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.05714285714285714	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
38	Taybi syndrome	0.01483872079936603	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9.75	0.04	0.06557377049180328	0.0	0.04	0.04	2.0	0.06557377049180328	1.0	1.0	0.0	-9.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.06557377049180328	1.0	0.0	0.0	0.0	0.0
122	the role	0.12338921334505663	-3.375	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-7.25	0.04	0.05555555555555555	0.0	0.04597701149425287	0.04624431970061481	2.0	0.05634920634920634	0.0	2.0	0.0	-7.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.046511627906976744	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
96	only;Only	0.07984484430335967	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-5.800000000000001	0.04	0.052083333333333336	0.0	0.05	0.05	1.0	0.052083333333333336	0.0	1.0	0.0	-5.800000000000001	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05	0.0	0.052083333333333336	0.0	0.0	0.0	0.0	0.0
101	Specific;specific	0.09966873012460924	-1.625	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-2.0	0.04	0.04	0.0	0.04	0.04298850574712644	1.0	0.04380952380952381	0.0	2.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04597701149425287	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
116	drug ingestion;ingestion of these drugs	0.1082236968763137	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	4.0	0.04	0.25	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.25	0.0	0.0
74	five months	0.08217313876208321	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	2.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
95	only two of the members of this family;Family only	0.021353001656280485	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	8.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.125	0.0	0.0
13	Dependent;dependent	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
159	less;Less	0.09520971290739387	-3.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
288	inner membrane architecture	0.27860063094266696	-5.666666666666666	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.051724137931034475	0.051724137931034475	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.051724137931034475	0.0	0.04	0.0	0.0	0.0	0.0	0.0
193	BEACH;Beach	0.09504320880292803	-3.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04587155963302752	0.04587155963302752	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04587155963302752	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	elevation of TSH serum concentration	0.26905681404095005	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
176	pool;Pool	0.07232053266286834	-5.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.25	0.0	0.0	-8.4	0.04	0.06024096385542168	0.0	0.05063291139240506	0.05063291139240506	1.0	0.06024096385542168	0.0	1.0	0.0	-8.4	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05063291139240506	0.0	0.06024096385542168	0.0	0.0	0.0	0.0	0.0
155	missense;Missense	0.6021623042919048	-5.833333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.833333333333334	0.0	0.0	-3.833333333333332	0.04	0.047244094488188976	0.0	0.052173913043478265	0.052173913043478265	1.0	0.047244094488188976	0.0	1.0	0.0	-3.833333333333332	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.052173913043478265	0.0	0.047244094488188976	0.0	0.0	0.0	0.0	0.0
330	JAK3 inhibitor	0.4126905570794827	-0.9629629629629631	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.3333333333333333	0.0	-1.5555555555555571	0.0	0.0	-1.1666666666666667	0.04	0.04	1.0	0.04	0.04163584985425984	2.0	0.04217054263565891	0.5	3.0	0.0	-3.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04265402843601896	0.0	0.046511627906976744	0.0	0.0	0.5	0.0	0.0
332	LFM-A13;LFM A13	0.7962401126268869	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
82	A strong association between human leukocyte antigen (HLA	0.06682488676989234	0.0	0.0	0.0	0.04	0.04	0.5555555555555556	0.5555555555555556	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.4	0.04	0.056818181818181816	0.0	0.04	0.04	9.0	0.056818181818181816	0.2222222222222222	1.0	0.0	-7.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.056818181818181816	0.0	0.0	0.0	0.0	0.0
177	the life expectancy	0.007250602597737151	-10.777777777777779	1.0	-9.5	0.06451612903225806	0.06451612903225806	0.6666666666666666	0.6666666666666666	1.0	-9.5	1.0	0.0	-10.777777777777779	0.0	0.0	-5.5	0.06451612903225806	0.05128205128205128	1.0	0.0703125	0.0703125	3.0	0.05128205128205128	1.0	1.0	0.0	-5.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.0703125	0.0	0.05128205128205128	1.0	0.0	0.3333333333333333	0.0	0.0
61	protein i;protein 1	0.3309398283126476	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
126	gastrointestinal symptoms (OR	0.15030023518951927	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.25	0.0	0.0
287	cyclin-A expression	0.4122001344688689	-3.8000000000000007	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-3.8000000000000007	1.0	1.0	-4.75	0.04	0.04938271604938271	0.0	0.04716981132075472	0.04716981132075472	4.0	0.04938271604938271	0.0	2.0	1.0	-4.75	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04716981132075472	0.0	0.04938271604938271	0.0	1.0	0.0	0.0	1.0
14	protein annotation;Protein Annotation	0.18626111985201205	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.04	0.043795620437956206	0.0	0.04	0.04	2.0	0.043795620437956206	0.0	1.0	0.0	-2.166666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.043795620437956206	0.0	0.0	0.0	0.0	0.0
24	Latin America	0.5426096569324456	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
216	dissimilatory Fe(III) reduction	0.4556218236364278	-3.0	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	rule based approaches	0.07636552907076562	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.166666666666666	0.04	0.050420168067226885	0.0	0.04	0.04	3.0	0.050420168067226885	0.0	1.0	0.0	-5.166666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.050420168067226885	0.0	0.0	0.0	0.0	0.0
312	repeat;Repeat	0.08386298154252271	-2.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.04477611940298508	0.04477611940298508	1.0	0.044642857142857144	0.0	1.0	0.0	-2.6000000000000014	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04477611940298508	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
174	cause	0.09010892839657728	-2.833333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-6.800000000000001	0.04	0.054945054945054944	0.0	0.045112781954887216	0.045112781954887216	1.0	0.054945054945054944	0.0	1.0	0.0	-6.800000000000001	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.045112781954887216	0.0	0.054945054945054944	0.0	0.0	0.0	0.0	0.0
343	100;100%	0.5399967066495627	-2.166666666666668	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.043795620437956206	0.043795620437956206	1.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043795620437956206	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
89	aged;Aged	0.5265999206447548	-3.9000000000000004	0.0	0.0	0.04	0.04	0.0	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04716981132075472	0.04739442946990117	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.5	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	daily clinical practice	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
270	multiple proteins including FOG-1, EKLF, SP1, CBP/p300 and PU.1	0.19022025649724753	0.0	1.0	0.0	0.04	0.04	0.21428571428571427	0.21428571428571427	0.0	0.0	0.07142857142857142	1.0	0.0	1.0	1.0	-10.0	0.04	0.06666666666666667	0.0	0.04	0.04	14.0	0.06666666666666667	0.0	1.0	1.0	-10.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	14.0	0.04	0.0	0.06666666666666667	0.0	1.0	0.0	0.0	1.0
31	Transmitted;transmitted	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	Moderate;moderate	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
328	three families	0.0990987915079186	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.045454545454545456	0.045454545454545456	2.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.045454545454545456	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
58	Satisfactory;satisfactory	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	hGH therapy	0.44067785631379464	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
133	Vanadate;vanadate	0.5997803753697614	-1.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.0425531914893617	0.0425531914893617	1.0	0.054545454545454536	0.0	2.0	0.0	-6.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.0425531914893617	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
78	mutation in chromosome;chromosome mutation	0.099161288927248	-4.75	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	1.0	0.04938271604938271	0.04938271604938271	3.0	0.05084745762711865	0.6666666666666666	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04938271604938271	0.0	0.05084745762711865	0.0	0.0	0.3333333333333333	0.0	0.0
247	Introduction;introduction	0.12416481820703902	-1.5555555555555547	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-3.1666666666666665	0.04	0.04	0.0	0.04	0.04275941652692883	1.0	0.04625514403292181	0.0	3.0	0.0	-4.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.045112781954887216	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
121	a success by pharmacogenetics researchers	0.10660291969480827	-5.333333333333334	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.05084745762711865	0.05084745762711865	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.05084745762711865	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	Bias;bias	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	First;first	0.09979047448650916	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.5	0.04	0.04	0.0	0.04	0.04	1.0	0.045	0.0	2.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
209	Gasterosteus aculeatus	0.7268739028102027	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
165	The dinucleotide CpG	0.19194442734575876	-2.7142857142857153	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.7142857142857153	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04487179487179487	0.04487179487179487	3.0	0.04878048780487805	0.3333333333333333	1.0	0.0	-4.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04487179487179487	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
79	often;Often	0.07046974704668095	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04	0.04	1.0	0.04878048780487805	0.0	1.0	0.0	-4.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
318	identification of the Philadelphia chromosome	0.03269948436828299	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	5.0	0.045454545454545456	0.8	1.0	0.0	-3.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
307	an initial attempt	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
66	three;Three	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	dynamic programming	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	the discrimination of these proteins	0.0221173848544024	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.04	0.04	5.0	0.05128205128205128	0.6	1.0	0.0	-5.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
79	a potent benzodiazepine antagonist	0.2954895154622228	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-3.25	0.04	0.04597701149425287	0.0	0.04	0.04	4.0	0.04597701149425287	0.25	1.0	1.0	-3.25	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04597701149425287	0.0	1.0	0.0	0.0	1.0
16	Tool, Software;software tool	0.027560117351753947	-1.09090909090909	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.09090909090909	0.0	0.0	-4.75	0.04	0.04938271604938271	1.0	0.04182509505703422	0.04182509505703422	2.0	0.04938271604938271	0.5	1.0	0.0	-4.75	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04182509505703422	0.0	0.04938271604938271	0.0	0.0	0.5	0.0	0.0
242	massive left ventricular hypertrophy	0.3186234145671068	-1.3333333333333321	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-1.3333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.04225352112676056	0.04225352112676056	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04225352112676056	0.0	0.04	0.0	0.0	0.0	0.0	0.0
222	10 years from disease onset	0.18014247444734957	-3.8888888888888893	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-3.8888888888888893	0.0	0.0	0.0	0.04	0.04	0.0	0.04736842105263158	0.04736842105263158	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04736842105263158	0.0	0.04	0.0	0.0	0.0	0.0	0.0
336	three;Three	0.08584314190398114	-3.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.046511627906976744	0.046511627906976744	1.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046511627906976744	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
14	Local;local	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	in vitro;In Vitro	0.3575941624548449	-1.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04181818181818182	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	girl;Girl	0.08189816193974862	-6.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.053571428571428575	0.053571428571428575	1.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.053571428571428575	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
291	PRONE;prone	0.6065541339399907	-1.8571428571428577	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.8571428571428577	0.0	0.0	0.0	0.04	0.04	0.0	0.043209876543209874	0.043209876543209874	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043209876543209874	0.0	0.04	0.0	0.0	0.0	0.0	0.0
293	suffer	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
5	the use	0.062002909750726816	-2.9166666666666665	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-8.75	0.0	0.0	-4.166666666666667	0.04	0.04	0.0	0.04	0.04717948717948719	2.0	0.05333333333333334	0.5	3.0	0.0	-12.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.06153846153846154	0.0	0.08	0.0	0.0	0.0	0.0	0.0
246	receiving;Receive	0.06703689305732215	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.05	0.05	1.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
309	the almost universal cause of the characteristic neurologic symptoms and pathology	0.037423737905785064	0.0	0.0	0.0	0.04	0.04	0.8181818181818182	0.8181818181818182	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	11.0	0.04	0.18181818181818182	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	11.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
330	the first such drug	0.10463273532488362	-3.2222222222222214	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-3.2222222222222214	0.0	0.0	-8.625	0.04	0.061068702290076333	0.0	0.04591836734693877	0.04591836734693877	4.0	0.061068702290076333	0.0	1.0	0.0	-8.625	1.0	0.3333333333333333	1.0	0.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04591836734693877	0.0	0.061068702290076333	0.0	0.0	0.0	0.0	0.0
247	Exhibit;exhibit	0.0793834640757368	-2.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.043795620437956206	0.043795620437956206	1.0	0.046511627906976744	0.0	1.0	0.0	-3.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043795620437956206	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
78	locus;Locus	0.8056675805851616	-4.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.25	1.0	1.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	1.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04819277108433735	1.0	0.04	0.0	1.0	0.0	1.0	1.0
177	survive;SURVIVE	0.10558678416595335	-6.222222222222221	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.222222222222221	0.0	0.0	0.0	0.04	0.04	0.0	0.05325443786982248	0.05325443786982248	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05325443786982248	0.0	0.04	0.0	0.0	0.0	0.0	0.0
224	Fifteen	0.1134810616120774	-1.571428571428573	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.042682926829268296	0.042682926829268296	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.042682926829268296	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	a maintenance enzyme	0.031740894723935195	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.3333333333333333	1.0	0.0	0.0	0.0	-2.0	0.04	0.043478260869565216	1.0	0.04	0.04	3.0	0.043478260869565216	0.6666666666666666	1.0	0.0	-2.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.043478260869565216	0.0	0.0	0.3333333333333333	0.0	0.0
163	athletes;Athletes	0.2617983565413769	-3.7818181818181817	1.0	-17.333333333333332	0.04	0.05644268774703558	0.0	0.9090909090909091	1.0	-3.1515151515151514	1.0	0.0	-14.8	0.0	0.0	-5.03030303030303	0.13043478260869565	0.04	0.0	0.04	0.05253742188442674	1.0	0.06631028983116097	1.0	11.0	0.0	-19.0	1.0	0.0	0.9090909090909091	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	11.0	0.09803921568627452	0.0	0.16666666666666666	1.0	0.0	0.0	0.0	0.0
281	to;TO	0.08922031232866688	-1.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.0423728813559322	0.0423728813559322	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0423728813559322	0.0	0.04	0.0	0.0	0.0	0.0	0.0
215	-induced senescence	0.3990861901186097	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	3.0	0.047619047619047616	0.3333333333333333	1.0	0.0	-4.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
344	mouse liver chromatin	0.21502134065069065	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
109	ARB2	0.7999733836848668	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	1.0	0.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
131	various grades of atypia	0.09336613325538692	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	4.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
199	properties	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
118	2;+2	0.5004100325766299	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.04	0.04	1.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
93	discontinuation of GBP	0.10137062042812169	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	therapy in children	0.010164879882858734	-2.166666666666668	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.5	0.0	-2.166666666666668	0.0	0.0	-5.0	0.04	0.05	0.0	0.043795620437956206	0.043795620437956206	3.0	0.05	0.6666666666666666	1.0	0.0	-5.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043795620437956206	0.0	0.05	0.0	0.0	0.0	0.0	0.0
44	from;From	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
222	disease onset	0.36494319713356677	-3.444444444444443	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.444444444444443	0.0	0.0	0.0	0.04	0.04	0.0	0.04639175257731958	0.04639175257731958	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04639175257731958	0.0	0.04	0.0	0.0	0.0	0.0	0.0
128	Evolution;evolutionary	0.5614071504503167	-1.1666666666666679	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.1666666666666679	0.0	0.0	-3.5454545454545467	0.04	0.046610169491525424	0.0	0.04195804195804196	0.04195804195804196	1.0	0.046610169491525424	0.0	1.0	0.0	-3.5454545454545467	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04195804195804196	0.0	0.046610169491525424	0.0	0.0	0.0	0.0	0.0
129	DNMTs;DNA methyltransferases;DNMT;DNA Methyltransferase;(DNMTs;DNA 5-cytosine methyltransferase;Dnmts;DNA methyltransferase;dna methyltransferases;methyltransferase DNA;Dnmts);Dnmt;DNMTs)	0.9999999965703756	-1.0448343079922027	0.017543859649122806	0.0	0.04	0.04000000000000001	0.0	0.3719298245614035	0.0	0.0	0.005847953216374269	1.0	-3.666666666666668	0.0	0.0	-4.461152882205513	0.04	0.04	0.0	0.04	0.041862799174752705	1.8771929824561404	0.04986252566438389	0.4105263157894737	57.0	0.0	-9.714285714285714	1.0	0.6666666666666666	0.0	0.8245614035087719	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	13.0	1.0	107.0	0.046875	0.0	0.06542056074766354	0.0	0.0	0.0	0.0	0.0
239	indicated;Indicated	0.07579614674277428	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.04	0.04	1.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
40	Sousa	0.6680261073497243	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
112	UNDERSTOOD;understood	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
114	The Dnmt3 family of de novo DNA methyltransferases	0.07572811893334244	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.125	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	8.0	0.04	0.375	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.125	0.0	0.0
103	poorly;Poorly	0.583646157341767	-1.5555555555555571	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	-1.8571428571428577	0.04	0.043209876543209874	0.0	0.04265402843601896	0.04265402843601896	1.0	0.043209876543209874	0.0	1.0	0.0	-1.8571428571428577	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04265402843601896	0.0	0.043209876543209874	0.0	0.0	0.0	0.0	0.0
15	Part of;part-of;part of	0.30378292697477266	-1.4666666666666661	0.0	0.0	0.04	0.04	0.0	0.6666666666666666	0.0	0.0	0.0	0.0	-2.6999999999999993	0.0	0.0	-1.0	0.04	0.04	0.0	0.04	0.04258716808765886	1.6666666666666667	0.04181818181818182	0.3333333333333333	3.0	0.0	-3.0	1.0	0.0	0.6666666666666666	0.6666666666666666	1.0	0.0	1.0	0.0	0.0	3.0	1.0	5.0	0.04484304932735426	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
47	multiple;MULTIPLE	0.14035012602113567	-2.4444444444444446	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.044613880742913004	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.048387096774193554	0.0	0.04	0.0	0.0	0.0	0.0	0.0
72	other aspects	0.1050666840344068	-1.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04201680672268907	0.04201680672268907	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04201680672268907	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	methyltransferase family	0.41732188366318956	-2.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-2.0	0.0	0.0	-4.2857142857142865	0.04	0.04827586206896552	0.0	0.043478260869565216	0.043478260869565216	2.0	0.04827586206896552	0.0	1.0	0.0	-4.2857142857142865	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	2.0	0.043478260869565216	0.0	0.04827586206896552	0.0	0.0	0.0	0.0	0.0
68	a deletion	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
267	oxygen	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
324	Recently;recently	0.09166003846162973	-2.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.043795620437956206	0.043795620437956206	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043795620437956206	0.0	0.04	0.0	0.0	0.0	0.0	0.0
83	a pharmacogenetic approach to dual antiplatelet treatment	0.15253371083258746	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
99	Emery-Dreyfus myodystrophy	0.5253291347928023	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
302	the therapeutic inhibition of Tpl2	0.07333139700025225	0.0	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.3333333333333333	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.6	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
69	gene product;PROTEIN;proteins;protein;PROTEINS	0.6082649726701338	-0.791666666666667	0.0	0.0	0.04	0.04	0.0	0.75	0.0	0.0	0.0	1.0	-3.166666666666668	0.0	0.0	-1.3333333333333335	0.04	0.04	0.0	0.04	0.04145038167938932	1.25	0.04271186440677966	0.0	4.0	0.0	-5.333333333333334	1.0	1.0	0.75	0.0	1.0	0.0	1.0	1.0	1.0	5.0	1.0	5.0	0.04580152671755725	1.0	0.05084745762711865	0.0	0.0	0.0	1.0	0.0
121	HLA-B*57	0.9293407425320609	-3.266666666666667	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-5.666666666666666	0.0	0.0	-3.2	0.04	0.04	0.0	0.04	0.04668381063705436	2.0	0.04652631578947368	0.0	5.0	0.0	-6.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.051724137931034475	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
320	0.82);0.82	0.6641753767711227	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.5	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
215	DNA damage response	0.23559127910584088	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-4.0	0.0	0.0	-3.6000000000000014	0.04	0.04672897196261683	0.0	0.047619047619047616	0.047619047619047616	3.0	0.04672897196261683	0.0	1.0	0.0	-3.6000000000000014	1.0	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	3.0	0.047619047619047616	1.0	0.04672897196261683	0.0	0.0	0.0	1.0	0.0
240	Which	0.005012492046401155	-16.857142857142858	1.0	-17.5	0.13333333333333333	0.13333333333333333	1.0	1.0	1.0	-17.5	1.0	0.0	-16.857142857142858	0.0	0.0	-13.75	0.13333333333333333	0.08888888888888889	0.0	0.12280701754385966	0.12280701754385966	1.0	0.08888888888888889	1.0	1.0	0.0	-13.75	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.12280701754385966	0.0	0.08888888888888889	1.0	0.0	0.0	0.0	0.0
310	the use of chemically active agents	0.023031819582450607	-5.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-9.0	0.04	0.0625	0.0	0.05	0.05	6.0	0.0625	0.5	1.0	0.0	-9.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.05	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
6	respiratory depression of <10 breaths/min	0.2437065367195448	0.0	0.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
212	Prolonged QTc;prolonged QTc	0.8007758977422971	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	this compound	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
88	Human Development;human tumor development	0.18455256540445159	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-6.333333333333333	0.04	0.053571428571428575	0.0	0.04878048780487805	0.04878048780487806	3.0	0.053571428571428575	0.0	3.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.04878048780487805	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
129	subsequent silencing of a handful	0.05953823385557763	-3.8888888888888893	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-3.8888888888888893	0.0	0.0	-2.7142857142857153	0.04	0.04487179487179487	0.0	0.04736842105263158	0.04736842105263158	5.0	0.04487179487179487	0.2	1.0	0.0	-2.7142857142857153	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04736842105263158	0.0	0.04487179487179487	0.0	0.0	0.0	0.0	0.0
25	based;Based	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
160	the approval of denosumab	0.015773352235753386	0.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.4	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.75	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
228	potent inhibitors	0.40299053651032263	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.5	0.0	0.0
99	propositus;Propositus	0.6817986055309837	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
305	heart failure;FAILURE, HEART	0.15683667790635714	-2.571428571428573	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-2.571428571428573	0.0	0.0	-9.666666666666666	0.04	0.06521739130434782	0.0	0.0445859872611465	0.0445859872611465	2.0	0.06521739130434782	0.0	2.0	0.0	-9.666666666666666	1.0	0.5	1.0	0.0	1.0	0.0	1.0	0.5	0.5	2.0	1.0	4.0	0.0445859872611465	0.0	0.06521739130434782	0.0	0.0	0.0	0.0	0.0
310	a promising strategy	0.11231982977445785	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05	0.05	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05	0.0	0.04	0.0	0.0	0.0	0.0	0.0
245	Comprehensive open reading frame/splice site mutation analysis	0.10605821001865433	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	9.0	0.04	0.1111111111111111	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04	0.0	0.04	0.0	1.0	0.1111111111111111	0.0	1.0
317	introduced;introduce	0.0774394940176665	-3.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04672897196261683	0.04672897196261683	1.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04672897196261683	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
267	Weekly;weekly	0.09066791716240748	-1.8571428571428577	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8571428571428577	0.0	0.0	0.0	0.04	0.04	0.0	0.043209876543209874	0.043209876543209874	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043209876543209874	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	amino-acid propensities	0.3517733592013261	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-1.8333333333333321	0.04	0.043165467625899276	0.0	0.04	0.04	4.0	0.043165467625899276	0.25	1.0	0.0	-1.8333333333333321	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.043165467625899276	0.0	0.0	0.0	0.0	0.0
84	prescribed dosages	0.6860897275446812	-6.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05263157894736842	0.05263157894736842	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05263157894736842	0.0	0.04	0.0	0.0	0.0	0.0	0.0
84	strong cholinergic activity	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
125	generalized hypotonia and weakness at birth	0.10859021879746622	-4.666666666666666	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	-7.25	0.04	0.056338028169014086	0.0	0.04918032786885245	0.04918032786885245	6.0	0.056338028169014086	0.0	1.0	0.0	-7.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04918032786885245	0.0	0.056338028169014086	0.0	0.0	0.0	0.0	0.0
86	The bradycardia and prolonged QT(	0.2239823304551331	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
188	the C58/J mouse model	0.04483093884741645	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04	0.04	6.0	0.04716981132075472	0.3333333333333333	1.0	0.0	-3.8000000000000007	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
231	Understand;understand	0.0715278920969546	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.142857142857142	0.04	0.04794520547945205	0.0	0.04	0.04	1.0	0.04794520547945205	0.0	1.0	0.0	-4.142857142857142	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04794520547945205	0.0	0.0	0.0	0.0	0.0
161	complete penetrance	0.1976948307573782	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04	0.04	2.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
139	gene transfer;Gene Transfer	0.14822232056369256	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.04	0.04	2.0	0.046511627906976744	0.0	3.0	0.0	-3.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
332	TIME;time	0.09112461233357536	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	not;Not;non;Non	0.35248443219896636	-0.9444444444444441	0.0	0.0	0.04	0.04	0.0	0.6666666666666666	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-1.0	0.04	0.04	0.0	0.04	0.04170426065162908	1.0	0.04181818181818182	0.0	3.0	0.0	-3.0	1.0	0.0	0.6666666666666666	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.045112781954887216	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
17	bromocriptine treatment	0.2883753834919048	-2.833333333333332	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-7.25	0.04	0.056338028169014086	0.0	0.045112781954887216	0.045112781954887216	2.0	0.056338028169014086	0.0	2.0	0.0	-7.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.045112781954887216	0.0	0.056338028169014086	0.0	0.0	0.0	0.0	0.0
25	CONFLICT;conflict	0.0950782807120467	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.75	0.04	0.04	0.0	0.04	0.04	1.0	0.04857142857142857	0.0	2.0	0.0	-7.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
96	PRs;Partial Response;PRs);partial responses	0.655929567287805	-1.3571428571428572	0.0	0.0	0.04	0.04	0.0	0.42857142857142855	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-6.114285714285714	0.04	0.047619047619047616	0.0	0.04	0.04268077601410935	1.2857142857142858	0.053442066481765124	0.07142857142857142	7.0	0.0	-8.0	1.0	0.0	0.42857142857142855	0.14285714285714285	1.0	0.0	1.0	0.0	0.0	4.0	1.0	9.0	0.04938271604938271	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
257	host factors	0.09301657471062728	-5.833333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.833333333333334	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.052173913043478265	0.052173913043478265	2.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.052173913043478265	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
310	effective	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	a specific input	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
69	proper tissue organization	0.08773717292688622	-2.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.043795620437956206	0.043795620437956206	3.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043795620437956206	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
332	undesirable side effects;undesirable effects	0.1270546614416131	-2.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
66	5 patients	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
90	previous;Previous	0.06213730858761587	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.04	0.04	1.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
78	LOCALIZED;localized	0.525194806633319	-4.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-9.666666666666666	0.04	0.06521739130434782	0.0	0.04878048780487805	0.04878048780487805	1.0	0.06521739130434782	0.0	1.0	0.0	-9.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04878048780487805	0.0	0.06521739130434782	0.0	0.0	0.0	0.0	0.0
274	approximately;Approximately	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	a synteny-maintaining array of HCNEs	0.15253371083258746	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
8	two;Two	0.09773875734391521	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
150	Degradation Pathway;pathway for the degradation	0.07409880232876695	-5.2857142857142865	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-5.2857142857142865	0.0	0.0	-4.166666666666666	0.04	0.047999999999999994	0.0	0.05072463768115942	0.05072463768115942	4.0	0.047999999999999994	0.5	1.0	0.0	-4.166666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.05072463768115942	0.0	0.047999999999999994	0.0	0.0	0.0	0.0	0.0
120	the down-regulation of JNK phosphatases	0.1476333548316879	-2.1999999999999993	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.043859649122807015	0.043859649122807015	7.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.043859649122807015	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
156	The overall sex ratio	0.06734465880121233	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	1.0	0.0	1.0	0.3333333333333333	1.0	1.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
156	autosomal-recessive pattern	0.34505381696061316	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04	0.04	4.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
26	the duodenal crypts	0.2185783508022366	-1.7142857142857153	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-1.7142857142857153	0.0	0.0	0.0	0.04	0.04	0.0	0.04294478527607362	0.04294478527607362	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04294478527607362	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	the livers	0.08688841195730564	-3.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-6.571428571428571	0.04	0.05426356589147286	0.0	0.046296296296296294	0.046296296296296294	2.0	0.05426356589147286	0.0	1.0	0.0	-6.571428571428571	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.046296296296296294	0.0	0.05426356589147286	0.0	0.0	0.0	0.0	0.0
160	likely;Likely	0.0702598612648431	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.571428571428571	0.04	0.048951048951048945	0.0	0.04	0.04	1.0	0.048951048951048945	0.0	1.0	0.0	-4.571428571428571	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.048951048951048945	0.0	0.0	0.0	0.0	0.0
101	blood stage	0.10655097644493881	-6.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.25	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.05333333333333334	0.05333333333333334	2.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05333333333333334	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
259	the life expectancy	0.007250602597737151	-10.777777777777779	1.0	-9.5	0.06451612903225806	0.06451612903225806	0.6666666666666666	0.6666666666666666	1.0	-9.5	1.0	0.0	-10.777777777777779	0.0	0.0	-5.5	0.06451612903225806	0.05128205128205128	1.0	0.0703125	0.0703125	3.0	0.05128205128205128	1.0	1.0	0.0	-5.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.0703125	0.0	0.05128205128205128	1.0	0.0	0.3333333333333333	0.0	0.0
99	Tendon contractures;Tendon contracture	0.7589563682959148	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
288	MitOS for mitochondrial organizing structure	0.1438704740932317	-5.666666666666666	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.051724137931034475	0.051724137931034475	5.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.051724137931034475	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
128	the hypothesis	0.03502486228147467	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.3636363636363633	0.04	0.04417670682730924	0.0	0.04	0.04	2.0	0.04417670682730924	0.5	1.0	0.0	-2.3636363636363633	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04417670682730924	0.0	0.0	0.0	0.0	0.0
209	AGING;aging	0.9115223141058357	-1.5925925925925926	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-8.333333333333334	0.0	0.0	-0.5185185185185185	0.04	0.04	0.0	0.04	0.04362573099415205	1.0	0.041020036429872495	0.0	9.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.06000000000000001	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
237	Bs;BS	0.6446624335782378	-2.3333333333333335	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.142857142857142	0.0	0.0	-3.0476190476190474	0.04	0.04	0.0	0.04	0.04452319625780857	0.3333333333333333	0.04596896191966615	0.0	3.0	0.0	-4.7142857142857135	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.050359712230215826	0.0	0.04929577464788733	0.0	0.0	0.0	0.0	0.0
153	histamine (H1)	0.6000186669162998	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
8	centriole assembly	0.435809293607436	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
159	finger and toe abnormalities	0.20159137434488644	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
91	Some specificity in the form	0.044782923504221785	-2.7142857142857153	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-2.7142857142857153	0.0	0.0	0.0	0.04	0.04	0.0	0.04487179487179487	0.04487179487179487	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04487179487179487	0.0	0.04	0.0	0.0	0.0	0.0	0.0
94	Accelerated;accelerated	0.12323026575185474	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.199999999999999	0.0	0.0	0.0	0.04	0.04	0.0	0.04716981132075472	0.05018065034122843	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.05319148936170213	0.0	0.04	0.0	0.0	0.0	0.0	0.0
262	a cohort of patients	0.06637442787073183	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
130	laser desorption ionization-time	0.15194742445971668	-1.6363636363636367	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-1.6363636363636367	0.0	0.0	-7.2857142857142865	0.04	0.056451612903225805	0.0	0.042801556420233464	0.042801556420233464	5.0	0.056451612903225805	0.2	1.0	0.0	-7.2857142857142865	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.042801556420233464	0.0	0.056451612903225805	0.0	0.0	0.0	0.0	0.0
44	the most ubiquitous and destructive tropical	0.08460807799421208	-10.5	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-10.5	0.0	0.0	-9.666666666666666	0.04	0.06521739130434782	0.0	0.06896551724137931	0.06896551724137931	6.0	0.06521739130434782	0.16666666666666666	1.0	0.0	-9.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.06896551724137931	0.0	0.06521739130434782	0.0	0.0	0.0	0.0	0.0
307	neurological disorders of the elderly	0.038669580349387264	-3.3999999999999986	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.046296296296296294	0.046296296296296294	5.0	0.047619047619047616	0.4	1.0	0.0	-4.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.046296296296296294	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
40	the branch support analyses of the independent data sets	0.03632847356037841	-3.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.04580152671755725	0.04580152671755725	9.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04580152671755725	0.0	0.04	0.0	0.0	0.0	0.0	0.0
145	decarboxylase enzyme activity	0.30018662919745615	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04	0.04	3.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
146	the localization of podocin and synaptopodin	0.1593359254589332	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	Knowledge;knowledge	0.3093103214023273	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.2857142857142856	0.04	0.04	0.0	0.04	0.04	1.0	0.04765873015873016	0.0	7.0	0.0	-9.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	7.0	0.04	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
117	subsequent;Subsequent	0.08095876138724122	-2.428571428571427	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.428571428571427	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.04430379746835443	0.04430379746835443	1.0	0.04597701149425287	0.0	1.0	0.0	-3.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04430379746835443	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
222	the risk of sustained disability accumulation	0.0383206353764479	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
101	Embryo Development;embryo development	0.27926268070552995	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
276	progresses;progress	0.08953518362259696	-1.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	0.0	0.04	0.04	0.0	0.0425531914893617	0.0425531914893617	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0425531914893617	0.0	0.04	0.0	0.0	0.0	0.0	0.0
285	hormone receptor and HER-2 positive	0.1269925391546701	0.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.16666666666666666	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	a poor outcome	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
235	associated with;Associated with;Associated;associated	0.05150683732452489	-3.0555555555555554	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.111111111111111	0.0	0.0	-8.9	0.04	0.05813953488372093	0.0	0.043478260869565216	0.045675300647548565	1.5	0.0624031007751938	0.0	2.0	0.0	-10.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.047872340425531915	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
119	complex;Complex	0.0737759439625356	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.04	0.04	1.0	0.046296296296296294	0.0	1.0	0.0	-3.3999999999999986	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
44	Plasmodium sp. claims	0.6570007956065655	-18.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-18.0	0.0	0.0	-11.666666666666666	0.04	0.075	0.0	0.14285714285714285	0.14285714285714285	3.0	0.075	0.0	1.0	0.0	-11.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.14285714285714285	0.0	0.075	0.0	0.0	0.0	0.0	0.0
229	an;AN	0.5004100325766299	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.04	0.04	1.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
318	the Philadelphia chromosome and Bcr-Abl oncogene	0.18506431816588167	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.5	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
13	ranging;Range	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
66	a significant risk	0.08342514015280957	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.043478260869565216	0.043478260869565216	3.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043478260869565216	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
312	an E3 ubiquitin ligase	0.24322352733579253	-2.833333333333332	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.75	1.0	-2.833333333333332	1.0	1.0	0.0	0.04	0.04	1.0	0.045112781954887216	0.045112781954887216	4.0	0.04	0.75	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.045112781954887216	0.0	0.04	0.0	1.0	0.25	0.0	1.0
79	Cyclic;cyclic	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
87	KCND3 expression	0.2970403598762433	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
124	likelihood of disease	0.05267714337970258	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.3333333333333333	0.0	0.0
41	methyltransferase 1	0.5878595553704155	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.04	0.04	2.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
32	Human;human	0.06435489027425928	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.04	0.04	1.0	0.054545454545454536	0.0	1.0	0.0	-6.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
138	stable isotope labeling;Isotope Labeling, Stable	0.411577855448261	-1.23076923076923	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-1.23076923076923	0.0	0.0	-1.875	0.04	0.043243243243243246	0.0	0.042071197411003236	0.042071197411003236	3.0	0.043243243243243246	0.0	2.0	0.0	-1.875	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.042071197411003236	0.0	0.043243243243243246	0.0	0.0	0.0	0.0	0.0
318	treated with;Treated with	0.0684105809253574	-1.8888888888888893	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-5.23076923076923	0.04	0.05058365758754864	0.0	0.04326923076923077	0.04326923076923077	2.0	0.05058365758754864	0.0	1.0	0.0	-5.23076923076923	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04326923076923077	0.0	0.05058365758754864	0.0	0.0	0.0	0.0	0.0
80	Screening of the other family members	0.053643096511266454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	a 6-month period	0.16960094411545815	-2.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
150	transmembrane import	0.263502844553945	-2.2857142857142847	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.2857142857142847	0.0	0.0	0.0	0.04	0.04	0.0	0.0440251572327044	0.0440251572327044	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.0440251572327044	0.0	0.04	0.0	0.0	0.0	0.0	0.0
303	demonstrates;Demonstrates	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
140	H4	0.6661168002123584	-1.7777777777777786	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	0.0	0.04	0.04	0.0	0.0430622009569378	0.0430622009569378	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.0430622009569378	0.0	0.04	0.0	0.0	0.0	0.0	0.0
1	box;Box	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
160	Activation;activation	0.5706759929842535	-3.333333333333332	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-4.571428571428571	0.04	0.048951048951048945	0.0	0.04615384615384615	0.04615384615384615	1.0	0.048951048951048945	0.0	1.0	0.0	-4.571428571428571	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04615384615384615	0.0	0.048951048951048945	0.0	0.0	0.0	0.0	0.0
237	a discrete nuclear import sequence in IkappaB alpha	0.20233452909222638	-2.428571428571427	0.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.0	1.0	-2.428571428571427	0.0	0.0	-8.857142857142858	0.04	0.061946902654867256	0.0	0.04430379746835443	0.04430379746835443	8.0	0.061946902654867256	0.0	1.0	0.0	-8.857142857142858	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.04430379746835443	0.0	0.061946902654867256	0.0	0.0	0.0	0.0	0.0
74	motor nerve;Motor nerve	0.0965413298455764	-1.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	-4.625	0.04	0.04	0.0	0.04	0.042222222222222223	2.0	0.05174603174603175	0.0	2.0	0.0	-9.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.044444444444444446	0.0	0.06349206349206349	0.0	0.0	0.0	0.0	0.0
3	[5-methyl]cytosine to thymine	0.36473482249229416	0.0	0.0	0.0	0.04	0.04	0.125	0.125	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-3.428571428571427	0.04	0.04635761589403973	0.0	0.04	0.04	8.0	0.04635761589403973	0.25	1.0	0.0	-3.428571428571427	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04635761589403973	0.0	0.0	0.0	0.0	0.0
32	Localisation;Localization	0.5966292673647423	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04	0.04	1.0	0.051724137931034475	0.0	2.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
215	inappropriate;Inappropriate	0.6181062576094165	-2.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-3.0999999999999996	0.04	0.04	0.0	0.04	0.04439024390243902	1.0	0.046595744680851064	0.0	2.0	0.0	-6.199999999999999	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04878048780487805	0.0	0.05319148936170213	0.0	0.0	0.0	0.0	0.0
91	several forms	0.11070394741772184	-2.7142857142857153	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.7142857142857153	0.0	0.0	0.0	0.04	0.04	0.0	0.04487179487179487	0.04487179487179487	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04487179487179487	0.0	0.04	0.0	0.0	0.0	0.0	0.0
281	PD (EOPD	0.581803771744138	-1.8000000000000007	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.8000000000000007	0.0	0.0	-4.833333333333334	0.04	0.04958677685950414	0.0	0.04310344827586207	0.04310344827586207	3.0	0.04958677685950414	0.0	1.0	0.0	-4.833333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04310344827586207	0.0	0.04958677685950414	0.0	0.0	0.0	0.0	0.0
332	proximal B-cell receptor (BCR) signaling pathway	0.3978503145860548	-2.666666666666668	0.0	0.0	0.04	0.04	0.1	0.1	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.04477611940298508	0.04477611940298508	10.0	0.046511627906976744	0.0	1.0	0.0	-3.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04477611940298508	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
112	poorly;Poorly	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
168	the presence	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
215	protein kinase p38	0.35888423384371676	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.04	0.04	4.0	0.046296296296296294	0.0	1.0	0.0	-3.3999999999999986	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
258	preimplantation embryos;Preimplantation Embryos	0.5589106688367875	-2.6000000000000014	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.044642857142857144	0.044642857142857144	2.0	0.046296296296296294	0.0	1.0	0.0	-3.3999999999999986	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.044642857142857144	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
16	the observation	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
189	this feature	0.07884817754029713	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	2.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
189	participants	0.16741938802497427	-6.333333333333333	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.05263157894736842	0.05358851674641148	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.054545454545454536	0.0	0.04	0.0	0.0	0.0	0.0	0.0
2	High;higher	0.0963825651646273	-3.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.04672897196261683	0.04672897196261683	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04672897196261683	0.0	0.04	0.0	0.0	0.0	0.0	0.0
194	enable;enables	0.06270148594792964	-2.571428571428573	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.571428571428573	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.0445859872611465	0.0445859872611465	1.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0445859872611465	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
326	lysosomal acid beta	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
251	a greater EMT via actin depolymerisation	0.09106462578775723	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.2857142857142857	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
48	-function mutations in ras genes;function genes;function mutations in ras genes	0.051347306135056336	0.0	1.0	0.0	0.04	0.04	0.5	0.55	0.0	0.0	0.17142857142857143	0.0	0.0	0.0	0.0	-4.928571428571429	0.04	0.04964539007092199	0.0	0.04	0.04	5.5	0.049822695035460995	0.45	2.0	0.0	-5.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	11.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
16	Sequence similarities for all proteins	0.057961055114664525	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	synthesizes melatonin	0.760121147545931	-4.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	gene fusion events in entire genome sequences	0.03331204115790728	-1.6363636363636367	1.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.4	1.0	-1.6363636363636367	0.0	0.0	0.0	0.04	0.04	0.0	0.042801556420233464	0.042801556420233464	7.0	0.04	0.42857142857142855	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.042801556420233464	0.0	0.04	0.0	0.0	0.0	0.0	0.0
330	the first oral Janus kinase inhibitor	0.04213461355537097	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	6.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.16666666666666666	0.0	0.0
211	a single phosphorylated side chain at position n-3 or n-4 relative	0.06929999533405784	0.0	0.0	0.0	0.04	0.04	0.7272727272727273	0.7272727272727273	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.6666666666666679	0.04	0.04285714285714286	0.0	0.04	0.04	11.0	0.04285714285714286	0.0	1.0	0.0	-1.6666666666666679	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	11.0	0.04	0.0	0.04285714285714286	0.0	0.0	0.0	0.0	0.0
14	the exposure status of transmembrane beta barrel residues	0.019622246615909122	0.0	1.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.1111111111111111	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.625	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	hydrophobic-hydrophilic residues	0.6077102462983993	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	4.0	0.045454545454545456	0.25	2.0	0.0	-3.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
129	PGCs;PGC	0.8187346230451952	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-4.2142857142857135	0.04	0.04635761589403973	0.0	0.04	0.04	1.0	0.048180083522304316	0.0	4.0	1.0	-5.142857142857142	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	4.0	0.04	0.0	0.050359712230215826	0.0	1.0	0.0	0.0	1.0
103	an independent origin in the prokaryotic DNA methyltransferase sequence space	0.11071301812504472	-3.8888888888888893	0.0	0.0	0.04	0.04	0.7	0.7	0.0	0.0	0.0	1.0	-3.8888888888888893	1.0	1.0	-2.7142857142857153	0.04	0.04487179487179487	0.0	0.04736842105263158	0.04736842105263158	10.0	0.04487179487179487	0.2	1.0	1.0	-2.7142857142857153	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	10.0	0.04736842105263158	0.0	0.04487179487179487	0.0	1.0	0.0	0.0	1.0
287	consistent with;Consistent with	0.06520178078287343	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04	0.04	2.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
331	the effects of missense or truncation mutations	0.15253371083258746	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
231	cardiac electrophysiology;Cardiac Electrophysiology	0.5503496639737773	-1.571428571428573	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.571428571428573	0.0	0.0	-3.2857142857142847	0.04	0.046052631578947366	0.0	0.042682926829268296	0.042682926829268296	2.0	0.046052631578947366	0.0	1.0	0.0	-3.2857142857142847	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.042682926829268296	0.0	0.046052631578947366	0.0	0.0	0.0	0.0	0.0
238	dependency;Dependency	0.590167073129298	-2.416666666666668	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.416666666666668	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04428044280442805	0.04428044280442805	1.0	0.043478260869565216	0.0	1.0	0.0	-2.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04428044280442805	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
102	a heterodimer of the transcription factors circadian locomotor output cycles	0.11571702264895531	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.2	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
213	Mutations;mutation;mutations;Mutation	0.9628228968653545	-1.7857142857142858	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-2.8214285714285716	0.04	0.04	0.0	0.04	0.043621218224131765	1.0	0.04544535725613915	0.0	14.0	0.0	-6.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	14.0	0.053571428571428575	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
339	of lung adenocarcinoma;ADENOCARCINOMA OF LUNG	0.11441966787216687	-3.333333333333332	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04615384615384615	0.04615384615384615	3.0	0.04716981132075472	0.0	1.0	0.0	-3.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04615384615384615	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
66	bleeding;BLEEDING	0.7400570541038045	-2.8333333333333335	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.166666666666666	0.0	0.0	-3.6875	0.04	0.04	0.0	0.04	0.0454190600598324	1.0	0.04792603407286107	0.0	4.0	0.0	-8.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.050420168067226885	0.0	0.05970149253731343	0.0	0.0	0.0	0.0	0.0
13	studies	0.10216305401141904	-4.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.0	0.0	-5.0	0.04	0.05	0.0	0.048387096774193554	0.048387096774193554	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.048387096774193554	0.0	0.05	0.0	0.0	0.0	0.0	0.0
30	the formation	0.003423644806289946	-12.9	1.0	-16.4	0.11627906976744186	0.11627906976744186	1.0	1.0	1.0	-16.4	1.0	0.0	-12.9	0.0	0.0	-16.6	0.11627906976744186	0.11904761904761904	0.0	0.08264462809917356	0.08264462809917356	2.0	0.11904761904761904	1.0	1.0	0.0	-16.6	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.08264462809917356	0.0	0.11904761904761904	1.0	0.0	0.0	0.0	0.0
73	positive predictive value;PPV	0.6544233052635458	0.0	0.0	0.0	0.04	0.04	0.0	0.2222222222222222	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.6666666666666667	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
307	phosphorylated tau	0.6473055970525935	-7.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.05555555555555555	0.05555555555555555	2.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05555555555555555	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
334	the formation of DNA double strand	0.034019045952398554	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.04	0.04	6.0	0.0449438202247191	0.3333333333333333	1.0	0.0	-2.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
176	hydroxybutyrate;Hydroxybutyrate	0.6501669397152106	-1.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-1.5	1.0	1.0	-6.199999999999999	0.04	0.05319148936170213	0.0	0.0425531914893617	0.0425531914893617	1.0	0.05319148936170213	0.0	1.0	1.0	-6.199999999999999	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	1.0	0.0425531914893617	0.0	0.05319148936170213	0.0	1.0	0.0	0.0	1.0
198	D1795	0.6404330101264002	-3.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.04587155963302752	0.04587155963302752	1.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04587155963302752	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
74	Large Cell Neuroendocrine Carcinoma of the Lung;large-cell neuroendocrine carcinoma (LCNEC) of the lung	0.370566821569009	-3.333333333333332	0.0	0.0	0.04	0.04	0.45454545454545453	0.45454545454545453	0.0	0.0	0.0	1.0	-3.333333333333332	1.0	1.0	0.0	0.04	0.04	0.0	0.04615384615384615	0.04615384615384615	11.0	0.04	0.36363636363636365	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	22.0	0.04615384615384615	0.0	0.04	0.0	1.0	0.0	0.0	1.0
93	OAB refractory	0.6481597390548374	-7.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.05555555555555555	0.05555555555555555	2.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05555555555555555	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
94	contrast;Contrast	0.09241438672407117	-2.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04424778761061947	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04424778761061947	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	Rapid synthesis of new DNMT inhibitors derivatives	0.2220297054976667	0.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	1.0	0.14285714285714285	0.0	1.0
270	Ldb-1;Ldb1;LDB1	0.7984746827254445	-2.8000000000000003	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-6.6	0.0	0.0	-5.1	0.04	0.04	0.0	0.04	0.04564932187406562	1.0	0.05261726242371404	0.0	5.0	0.0	-9.5	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	3.0	1.0	5.0	0.05434782608695653	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
317	Two weeks	0.09080429612026643	-3.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04672897196261683	0.04672897196261683	2.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04672897196261683	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
16	consists;CONSIST	0.08797079493650918	-1.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.0	0.0	0.0	0.0	0.04	0.04	0.0	0.041666666666666664	0.041666666666666664	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.041666666666666664	0.0	0.04	0.0	0.0	0.0	0.0	0.0
179	studies	0.14649287110372652	-1.8888888888888886	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-2.1999999999999997	0.04	0.04	0.0	0.04	0.0439080459770115	1.0	0.044782608695652176	0.0	3.0	0.0	-6.6	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.051724137931034475	0.0	0.05434782608695653	0.0	0.0	0.0	0.0	0.0
156	an autosomal recessive disorder	0.4071385432210068	-3.166666666666668	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	-3.166666666666668	1.0	1.0	-7.25	0.04	0.056338028169014086	0.0	0.04580152671755725	0.04580152671755725	4.0	0.056338028169014086	0.0	1.0	1.0	-7.25	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04580152671755725	0.0	0.056338028169014086	0.0	1.0	0.0	0.0	1.0
91	overall anxiety	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	2 (Cry1	0.6301717994890276	-5.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.5	1.0	-5.0	1.0	1.0	0.0	0.04	0.04	0.0	0.05	0.05	3.0	0.04	0.0	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.05	0.0	0.04	0.0	1.0	0.0	0.0	1.0
100	competitive	0.08367204276257814	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.166666666666666	0.04	0.053097345132743355	0.0	0.04	0.04	1.0	0.053097345132743355	0.0	1.0	0.0	-6.166666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.053097345132743355	0.0	0.0	0.0	0.0	0.0
106	a subunit of the spliceosomal U2 small nuclear ribonucleoprotein (snRNP)	0.26615099703406286	-2.5	0.0	0.0	0.04	0.04	0.4166666666666667	0.4166666666666667	0.0	0.0	0.0	1.0	-2.5	0.0	0.0	0.0	0.04	0.04	0.0	0.044444444444444446	0.044444444444444446	12.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	12.0	0.044444444444444446	0.0	0.04	0.0	0.0	0.0	0.0	0.0
223	treat;TREAT	0.05803694780784468	-3.1818181818181834	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.1818181818181834	0.0	0.0	-11.857142857142858	0.04	0.07608695652173914	0.0	0.04583333333333334	0.04583333333333334	1.0	0.07608695652173914	0.0	1.0	0.0	-11.857142857142858	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04583333333333334	0.0	0.07608695652173914	0.0	0.0	0.0	0.0	0.0
311	myotonic dystrophy;DYSTROPHY, MYOTONIC	0.8356500628501066	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	1.0	0.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
108	costs;Costs	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
242	blood pressure decrease	0.10125818247400414	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
321	multiple alignment methods	0.09679557010844424	-3.6000000000000014	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-14.0	0.04	0.09090909090909091	0.0	0.04672897196261683	0.04672897196261683	3.0	0.09090909090909091	0.0	1.0	0.0	-14.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04672897196261683	0.0	0.09090909090909091	0.0	0.0	0.0	0.0	0.0
203	including;Including	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
330	a manageable safety profile	0.5053910450313833	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.9375	0.04	0.04	0.0	0.04	0.04	4.0	0.04176470588235294	0.0	4.0	0.0	-3.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	16.0	0.04	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
19	case series;CASE SERIES	0.073845319421843	-2.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.043859649122807015	0.043859649122807015	2.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.043859649122807015	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
318	development	0.1421301883446616	-0.5925925925925929	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-4.717948717948718	0.04	0.048872180451127824	0.0	0.04	0.0410207336523126	1.0	0.04930671961883055	0.0	3.0	0.0	-4.846153846153847	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.0430622009569378	0.0	0.04961832061068702	0.0	0.0	0.0	0.0	0.0
246	a gene dose effect	0.06221915849785899	-2.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-2.75	1.0	1.0	-6.0	0.04	0.05263157894736842	1.0	0.0449438202247191	0.0449438202247191	4.0	0.05263157894736842	0.25	1.0	1.0	-6.0	1.0	0.3333333333333333	1.0	1.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.0449438202247191	0.0	0.05263157894736842	0.0	1.0	0.25	0.0	1.0
115	Inspection of other HCNE-dense regions	0.10057254967379158	0.0	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	allele and hypersensitivity reaction	0.14081375544905314	-6.666666666666666	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	1.0	-6.666666666666666	1.0	1.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.054545454545454536	0.054545454545454536	4.0	0.053571428571428575	0.0	1.0	1.0	-6.333333333333334	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.054545454545454536	0.0	0.053571428571428575	0.0	1.0	0.0	0.0	1.0
222	the names	0.0036114245454130266	-10.11111111111111	1.0	-9.8	0.06578947368421052	0.06578947368421052	1.0	1.0	1.0	-9.8	1.0	0.0	-10.11111111111111	0.0	0.0	-10.8	0.06578947368421052	0.07042253521126761	1.0	0.06716417910447761	0.06716417910447761	2.0	0.07042253521126761	1.0	1.0	0.0	-10.8	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.06716417910447761	0.0	0.07042253521126761	1.0	0.0	0.5	0.0	0.0
160	a nuclear factor-β ligand (RANKL) inhibitor	0.2767670121527794	-3.333333333333332	0.0	0.0	0.04	0.04	0.3	0.3	0.0	0.0	0.0	1.0	-3.333333333333332	1.0	1.0	-2.7142857142857153	0.04	0.04487179487179487	0.0	0.04615384615384615	0.04615384615384615	10.0	0.04487179487179487	0.3	1.0	1.0	-2.7142857142857153	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	10.0	0.04615384615384615	0.0	0.04487179487179487	0.0	1.0	0.0	0.0	1.0
79	agonists	0.8671147669071669	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-4.75	0.04	0.04819277108433735	0.0	0.04	0.04	1.0	0.04939759036144579	0.0	3.0	1.0	-5.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	3.0	0.04	1.0	0.05	0.0	1.0	0.0	1.0	1.0
213	the proband	0.1978963993171017	-4.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-9.75	0.04	0.06557377049180328	0.0	0.047619047619047616	0.047619047619047616	2.0	0.06557377049180328	0.0	1.0	0.0	-9.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047619047619047616	0.0	0.06557377049180328	0.0	0.0	0.0	0.0	0.0
249	mediates;Mediate	0.6647079483199937	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.583333333333333	0.04	0.0425531914893617	0.0	0.04	0.04	1.0	0.05255370171947549	0.0	3.0	0.0	-7.625	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.05755395683453238	0.0	0.0	0.0	0.0	0.0
297	SERUM;serum	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	run	0.09851914128946967	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.04	0.043795620437956206	0.0	0.04	0.04	1.0	0.043795620437956206	0.0	1.0	0.0	-2.166666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.043795620437956206	0.0	0.0	0.0	0.0	0.0
188	sing	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	the only effective agent in the treatment of plasma cell;the cell plasma	0.026919050030461057	-5.0	0.0	0.0	0.04	0.04	0.9	0.9	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-11.0	0.04	0.07142857142857142	0.0	0.05	0.05	10.0	0.07142857142857142	0.0	1.0	0.0	-11.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	10.0	0.05	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0
324	GD	0.6129928655598147	-3.166666666666668	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04580152671755725	0.04580152671755725	1.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04580152671755725	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
129	its maintenance activity in association	0.03776773949451835	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
144	Calsequestrin;calsequestrin	0.7890508551441878	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
30	C9orf72 gene;C9ORF72 gene;C9orf72 Gene	0.39971057621355705	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.3000000000000007	0.04	0.04	0.0	0.04	0.04	2.0	0.04232142857142857	0.0	4.0	0.0	-2.6000000000000014	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	8.0	0.04	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
101	Format;formats;format	0.09554621842794984	-3.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.04711751662971175	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.04878048780487805	0.0	0.04	0.0	0.0	0.0	0.0	0.0
258	these findings	0.1102694175351909	-2.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.044642857142857144	0.044642857142857144	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.044642857142857144	0.0	0.04	0.0	0.0	0.0	0.0	0.0
128	the mechanism of eukaryotic RNA interference (RNAi)	0.02249469563684119	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.375	0.0	0.0	0.0	0.0	-3.5454545454545467	0.04	0.046610169491525424	0.0	0.04	0.04	9.0	0.046610169491525424	0.8888888888888888	1.0	0.0	-3.5454545454545467	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.046610169491525424	0.0	0.0	0.0	0.0	0.0
227	high iron;high incidence of iron	0.11287250265048183	-3.6000000000000014	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	-3.6000000000000014	1.0	1.0	0.0	0.04	0.04	0.0	0.04672897196261683	0.04672897196261683	4.0	0.04	0.25	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	4.0	0.04672897196261683	0.0	0.04	0.0	1.0	0.0	0.0	1.0
37	conclusion;Conclusion	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	atomic;Atom	0.6367764156676019	-8.777777777777777	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-17.333333333333332	0.0	0.0	-5.888888888888888	0.04	0.04	0.0	0.04	0.07764492753623188	1.0	0.05457482993197279	0.0	3.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.13043478260869565	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
228	enzyme	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
257	Add;adding	0.08396399813714008	-2.833333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-2.7142857142857153	0.04	0.04487179487179487	0.0	0.045112781954887216	0.045112781954887216	1.0	0.04487179487179487	0.0	1.0	0.0	-2.7142857142857153	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045112781954887216	0.0	0.04487179487179487	0.0	0.0	0.0	0.0	0.0
56	esophageal disease;Esophageal Disease	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
151	Present;present	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
175	ventricular tachycardia	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
27	antibiotic-resistant bacteria	0.2537529149325188	-1.5555555555555571	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.25	0.0	-1.5555555555555571	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04265402843601896	0.04265402843601896	4.0	0.045454545454545456	0.25	2.0	0.0	-3.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04265402843601896	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
58	to;TO	0.006249575000362858	-5.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.051724137931034475	0.051724137931034475	1.0	0.05263157894736842	1.0	1.0	0.0	-6.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.051724137931034475	0.0	0.05263157894736842	1.0	0.0	0.0	0.0	0.0
287	This single-arm phase II study	0.10057254967379158	0.0	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
68	a tyrosine kinase receptor gene	0.382286078448733	-5.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	-5.0	1.0	1.0	0.0	0.04	0.04	1.0	0.05	0.05	5.0	0.04	0.2	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.05	0.0	0.04	0.0	1.0	0.2	0.0	1.0
127	a significant correlation	0.1018464788191369	-2.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.043795620437956206	0.043795620437956206	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043795620437956206	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	a phase I trial of bortezomib and pegylated liposomal doxorubicin (PLD)	0.0784133433002118	-2.75	1.0	0.0	0.04	0.04	0.46153846153846156	0.46153846153846156	0.0	0.0	0.2	1.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0449438202247191	13.0	0.04	0.23076923076923078	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	13.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	all results with an E-value higher	0.12345732182283334	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
137	A total of 564 endovascular procedures	0.07994112237479052	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04	0.04	6.0	0.043478260869565216	0.16666666666666666	1.0	0.0	-2.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
91	self-report;Self-Report	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	Box	0.138062657829642	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
59	free T3;Free T3	0.17918435268158972	-4.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.047619047619047616	0.047619047619047616	2.0	0.054545454545454536	0.0	1.0	0.0	-6.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.047619047619047616	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
117	globotriaosylceramide (Gb	0.6035910523198296	-1.7142857142857153	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.7142857142857153	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.04294478527607362	0.04294478527607362	3.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04294478527607362	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
318	monitoring;Monitoring	0.07687056671605019	-1.6666666666666679	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6666666666666679	0.0	0.0	-3.8461538461538467	0.04	0.04727272727272727	0.0	0.04285714285714286	0.04285714285714286	1.0	0.04727272727272727	0.0	1.0	0.0	-3.8461538461538467	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04285714285714286	0.0	0.04727272727272727	0.0	0.0	0.0	0.0	0.0
40	sgmjournals	0.6668594340272865	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
282	Interaction;interaction	0.07117688379751735	-2.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.044642857142857144	0.044642857142857144	1.0	0.05405405405405406	0.0	1.0	0.0	-6.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.044642857142857144	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
225	neonatal thyroid screening;neonatal screening;Neonatal Screening	0.3140271133885072	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.41666666666666663	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.5	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
104	the benefits	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
267	Concepts;concepts	0.6039131868305536	-1.571428571428573	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.042682926829268296	0.042682926829268296	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.042682926829268296	0.0	0.04	0.0	0.0	0.0	0.0	0.0
147	type III iodothyronine deiodinase activity	0.3556645721140102	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
1	Site of;site of	0.030155674082559904	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	elements;Elements	0.08378942391171013	-2.1111111111111107	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1111111111111107	0.0	0.0	-2.1428571428571423	0.04	0.04375	0.0	0.043689320388349516	0.043689320388349516	1.0	0.04375	0.0	1.0	0.0	-2.1428571428571423	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043689320388349516	0.0	0.04375	0.0	0.0	0.0	0.0	0.0
235	winter;WINTER	0.06911486176365976	-1.6666666666666679	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6666666666666679	0.0	0.0	-6.4	0.04	0.05376344086021505	0.0	0.04285714285714286	0.04285714285714286	1.0	0.05376344086021505	0.0	1.0	0.0	-6.4	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04285714285714286	0.0	0.05376344086021505	0.0	0.0	0.0	0.0	0.0
226	5;>5	0.5191175287450296	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04	0.04	1.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
99	early onset contractures of elbows	0.09819256139902725	-3.5	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-5.142857142857142	0.04	0.050359712230215826	0.0	0.046511627906976744	0.046511627906976744	5.0	0.050359712230215826	0.2	1.0	0.0	-5.142857142857142	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.046511627906976744	0.0	0.050359712230215826	0.0	0.0	0.0	0.0	0.0
151	Frequencies;frequencies	0.07123340667167213	-2.428571428571427	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.428571428571427	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04430379746835443	0.04430379746835443	1.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04430379746835443	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
121	persons;Individual;Persons;individuals	0.07051949670784499	-5.333333333333333	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-3.166666666666667	0.04	0.04	0.0	0.04918032786885245	0.05090595340811044	1.0	0.04678571428571429	0.0	2.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.05263157894736842	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
88	OCT4;Oct-4;Oct4	0.7867805752284992	-4.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-5.0	0.0	0.0	-6.0	0.04	0.051724137931034475	0.0	0.04878048780487805	0.04939024390243903	1.0	0.052647783251231525	0.0	4.0	0.0	-6.333333333333334	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	3.0	1.0	4.0	0.05	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
137	Twenty-nine;Twenty Nine	0.06185661053130321	-1.5555555555555571	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	-1.5	0.04	0.0425531914893617	0.0	0.04265402843601896	0.04265402843601896	3.0	0.0425531914893617	0.3333333333333333	1.0	0.0	-1.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04265402843601896	0.0	0.0425531914893617	0.0	0.0	0.0	0.0	0.0
147	Which deiodinase	0.01879537990144946	0.0	1.0	0.0	0.04	0.04	0.5	0.5	1.0	0.0	1.0	1.0	0.0	1.0	1.0	-6.5	0.04	0.05405405405405406	0.0	0.04	0.04	2.0	0.05405405405405406	1.0	2.0	1.0	-6.5	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04	0.0	0.05405405405405406	1.0	1.0	0.0	0.0	1.0
137	Our open-label study	0.062333159846523004	-2.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
78	neo;NEO	0.7054974977205541	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	0.0	0.047619047619047616	0.0	2.0	1.0	-4.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	0.0	0.04	0.0	0.047619047619047616	0.0	1.0	0.0	0.0	1.0
204	Residue;residue	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	the chromodomain of Cbx2	0.10954121152848732	-3.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.25	1.0	-6.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04631578947368421	4.0	0.04	0.5	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.05263157894736842	0.0	0.04	0.0	1.0	0.0	0.0	1.0
65	H3	0.5980375689166192	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
44	Balamuthia mandrillaris	0.7268739028102027	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
331	molecular components	0.2765738641103709	-4.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
247	Life expectancy;Life Expectancy	0.2635196711014587	-3.166666666666668	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04580152671755725	0.04580152671755725	2.0	0.04878048780487805	0.0	2.0	0.0	-4.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04580152671755725	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
44	a vertebrate	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
152	findings	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
159	28	0.6175102087792802	-4.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04938271604938271	0.04938271604938271	2.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04938271604938271	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
262	I-E;i.e	0.6066186994119565	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
222	the risk	0.1740059992190957	-2.0444444444444443	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-2.04	0.04	0.04	0.0	0.04	0.04366001220242609	2.0	0.045513513513513515	0.5	5.0	0.0	-10.2	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04615384615384615	0.0	0.06756756756756756	0.0	0.0	0.0	0.0	0.0
122	Includes;including;includes;Including	0.0927759158252801	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-4.0	0.04	0.04	0.0	0.04	0.0438399318859089	1.0	0.049642545771578034	0.0	4.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	4.0	0.04938271604938271	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
236	all the analytes in a biological sample	0.036109513469102066	0.0	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.2857142857142857	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
6	client willingness	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
243	Transcription Start Site;transcription start site	0.17577365439613604	-2.2857142857142847	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.2857142857142847	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.0440251572327044	0.0440251572327044	3.0	0.04878048780487805	0.0	2.0	0.0	-4.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.0440251572327044	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
24	Atorvastatin;atorvastatin;ATORVASTATIN	0.6504772317046449	-0.7333333333333331	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04128654970760234	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	3.0	0.043859649122807015	0.0	0.04	0.0	0.0	0.0	0.0	0.0
270	Stages;stages	0.09372053408889891	-2.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04504504504504505	0.04504504504504505	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04504504504504505	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	Target;Targeted;targeted;target	0.06926260024823326	-2.166666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-1.375	0.04	0.04	0.0	0.043478260869565216	0.04379795396419437	1.0	0.042471910112359554	0.0	2.0	0.0	-2.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.044117647058823525	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
239	genetic association	0.09515997586586059	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.045454545454545456	0.045454545454545456	2.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.045454545454545456	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
293	young patients	0.14684823062145294	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
317	Functional;functional	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
333	expression of a specific immobilization antigen	0.02265220037594283	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.4	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	6.0	0.04	0.6666666666666666	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.16666666666666666	0.0	1.0
30	the first intron	0.10304073418246722	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-3.6000000000000014	0.04	0.04672897196261683	0.0	0.04	0.04	3.0	0.04672897196261683	0.3333333333333333	1.0	0.0	-3.6000000000000014	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
138	the enrichment	0.011220351735895527	-14.076923076923077	1.0	-12.0	0.07692307692307693	0.07692307692307693	0.5	0.5	1.0	-12.0	1.0	0.0	-14.076923076923077	0.0	0.0	-12.25	0.07692307692307693	0.0784313725490196	0.0	0.09154929577464789	0.09154929577464789	2.0	0.0784313725490196	1.0	1.0	0.0	-12.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.09154929577464789	0.0	0.0784313725490196	1.0	0.0	0.0	0.0	0.0
225	TSH B	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	conflicting	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
172	LT	0.6714489485407028	-2.3999999999999986	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04424778761061947	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04424778761061947	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	var gene silencing	0.48501901710734213	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
141	conclude	0.14289025014454645	-8.4	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-8.4	0.0	0.0	0.0	0.04	0.04	0.0	0.06024096385542168	0.06024096385542168	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.06024096385542168	0.0	0.04	0.0	0.0	0.0	0.0	0.0
90	low doses of thiazide	0.06637442787073183	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
205	single;Single	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
336	in vitro;In Vitro	0.19748376476734225	-4.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.047619047619047616	0.047619047619047616	2.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.047619047619047616	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
5	choice	0.09062027317799021	-7.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.0	0.0	0.0	-10.25	0.04	0.06779661016949153	0.0	0.05555555555555555	0.05555555555555555	1.0	0.06779661016949153	0.0	1.0	0.0	-10.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.05555555555555555	0.0	0.06779661016949153	0.0	0.0	0.0	0.0	0.0
44	Toxocara canis	0.8034281960653468	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
156	single gene	0.09711156336589616	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.045454545454545456	0.045454545454545456	2.0	0.046511627906976744	0.0	1.0	0.0	-3.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.045454545454545456	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
204	disproportional short stature	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
66	long segment of Hirschsprung disease;Hirschsprung disease, long-segment	0.04525336347841148	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	the active sites of several proteases.7	0.07063365527665647	-3.75	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-4.6	0.04	0.04901960784313726	0.0	0.047058823529411764	0.047058823529411764	6.0	0.04901960784313726	0.0	1.0	0.0	-4.6	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.047058823529411764	0.0	0.04901960784313726	0.0	0.0	0.0	0.0	0.0
101	chemiluminescence;Chemiluminescence	0.5712075018969801	-3.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.046511627906976744	0.046511627906976744	1.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046511627906976744	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
276	The clinical importance	0.05214132772105638	-1.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.75	0.0	0.0	0.0	0.04	0.04	0.0	0.043010752688172046	0.043010752688172046	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043010752688172046	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	warfarin pharmacokinetics and pharmacodynamics	0.1559710666350906	0.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.16666666666666666	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
176	two overlapping promoters of the gal operon	0.38177924349000525	-1.375	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	1.0	-1.375	1.0	1.0	0.0	0.04	0.04	0.0	0.042328042328042326	0.042328042328042326	7.0	0.04	0.0	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	7.0	0.042328042328042326	0.0	0.04	0.0	1.0	0.0	0.0	1.0
75	neurological disorder	0.24956069822766216	-4.75	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.04938271604938271	0.04938271604938271	2.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04938271604938271	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
235	PRECIPITATE;precipitating	0.5500621530790859	-4.222222222222221	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.222222222222221	0.0	0.0	-7.199999999999999	0.04	0.056179775280898875	0.0	0.0481283422459893	0.0481283422459893	1.0	0.056179775280898875	0.0	1.0	0.0	-7.199999999999999	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0481283422459893	0.0	0.056179775280898875	0.0	0.0	0.0	0.0	0.0
133	a novel target	0.04299556670897608	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	3.0	0.045454545454545456	0.3333333333333333	1.0	0.0	-3.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
281	PARK9	0.8292197277530349	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
231	transverse aortic	0.6160397541830247	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.7142857142857153	0.04	0.04294478527607362	0.0	0.04	0.04	2.0	0.04294478527607362	0.0	1.0	0.0	-1.7142857142857153	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04294478527607362	0.0	0.0	0.0	0.0	0.0
345	(UTR) selenoprotein mRNAs	0.47642063159983283	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.2	1.0	0.0	0.0	0.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.04	0.04	5.0	0.046296296296296294	0.0	1.0	0.0	-3.3999999999999986	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
185	these 10 LVNC patients	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	paper;Paper	0.2029889561093575	-0.275	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.375	0.0	0.0	-1.933333333333333	0.04	0.04	0.0	0.04	0.04046560846560847	1.0	0.04356228437952433	0.0	5.0	0.0	-3.833333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.042328042328042326	0.0	0.047244094488188976	0.0	0.0	0.0	0.0	0.0
41	a family of genes	0.09515213682508193	-7.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.5	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.05714285714285714	0.05714285714285714	4.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.05714285714285714	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
226	problems with thinking, disorientation, balance disturbances	0.14186599671909297	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-6.0	0.04	0.05263157894736842	1.0	0.04	0.04	8.0	0.05263157894736842	0.125	1.0	1.0	-6.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.05263157894736842	0.0	1.0	0.125	0.0	1.0
144	regulatory regions;Regulatory Regions	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
35	down;Lanugo	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	transmembrane segments because NET FGs	0.05469171437767171	-3.25	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.1111111111111111	0.0	-3.25	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.04597701149425287	0.04597701149425287	5.0	0.046875	0.2	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04597701149425287	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
90	12-24 months	0.17286278339857372	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.04	0.04	2.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
91	significant	0.11572415940495655	-2.1428571428571423	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1428571428571423	0.0	0.0	0.0	0.04	0.04	0.0	0.04375	0.04375	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04375	0.0	0.04	0.0	0.0	0.0	0.0	0.0
213	caused by mutations	0.13256159816944668	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	3.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
344	Relative;relative	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	Combine;combines;combining	0.07827688865704281	-2.5500000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-3.5999999999999996	0.04	0.046296296296296294	0.0	0.042735042735042736	0.04462333532100974	1.0	0.04673305380852551	0.0	2.0	0.0	-3.8000000000000007	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.046511627906976744	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
30	agent treatment;treatment with a G-quadruplex-interactive agent	0.12071441662839841	0.0	1.0	0.0	0.04	0.04	0.4444444444444444	0.4444444444444444	0.0	0.0	0.16666666666666666	0.0	0.0	0.0	0.0	-2.1999999999999993	0.04	0.043859649122807015	0.0	0.04	0.04	9.0	0.043859649122807015	0.4444444444444444	2.0	0.0	-2.1999999999999993	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	18.0	0.04	0.0	0.043859649122807015	0.0	0.0	0.0	0.0	0.0
320	one additional hydrogen-bond donor (HBD) features	0.14750239891697606	-5.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.05	0.05	10.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.05	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
175	CLEFT PALATE;cleft palate	0.7535877571557554	-3.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.75	1.0	1.0	0.0	0.04	0.04	0.0	0.047058823529411764	0.047058823529411764	2.0	0.04	0.0	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	4.0	0.047058823529411764	0.0	0.04	0.0	1.0	0.0	0.0	1.0
44	the catalytic subunit gene	0.19370405895445292	-11.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-11.5	0.0	0.0	-11.333333333333334	0.04	0.07317073170731708	0.0	0.07407407407407407	0.07407407407407407	4.0	0.07317073170731708	0.25	1.0	0.0	-11.333333333333334	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.07407407407407407	0.0	0.07317073170731708	0.0	0.0	0.0	0.0	0.0
318	reciprocal translocation between chromosomes;Reciprocal Translocation;reciprocal chromosome translocation;reciprocal translocation	0.9987814903692505	0.0	0.0	0.0	0.04	0.04	0.0	0.014705882352941176	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.619909502262443	0.04	0.04248366013071895	0.0	0.04	0.04	2.1176470588235294	0.04709790975013916	0.0	17.0	0.0	-6.538461538461538	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	36.0	0.04	0.0	0.05416666666666667	0.0	0.0	0.0	0.0	0.0
13	Experimental;experimental	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
281	Mutations in the DJ-1 gene;gene mutations;mutations in the DJ-1 gene;Mutations in other genes	0.5493093281904435	-0.23999999999999985	0.2	0.0	0.04	0.04	0.6	0.6599999999999999	0.0	0.0	0.03333333333333333	0.6	-1.1999999999999993	0.6	0.0	-3.1	0.04	0.04	0.0	0.04	0.040403361344537814	4.6	0.0463183841150291	0.22000000000000003	5.0	0.6	-5.833333333333334	1.0	0.3333333333333333	0.0	1.0	0.0	0.6	1.0	0.0	0.2	4.0	1.0	23.0	0.04201680672268907	0.0	0.052173913043478265	0.0	1.0	0.0	0.0	1.0
318	most CML patients	0.15166961091552508	-1.5555555555555571	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	-0.8461538461538467	0.04	0.041401273885350316	0.0	0.04265402843601896	0.04265402843601896	3.0	0.041401273885350316	0.0	1.0	0.0	-0.8461538461538467	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04265402843601896	0.0	0.041401273885350316	0.0	0.0	0.0	0.0	0.0
31	vaccine candidate	0.18683538205840872	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-6.0	0.0	0.0	-2.75	0.04	0.04	0.0	0.04	0.04631578947368421	2.0	0.04564102564102564	0.0	2.0	0.0	-5.5	1.0	0.3333333333333333	1.0	0.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.05263157894736842	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
124	Good prognosis;good prognosis	0.20146510080365157	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
146	peripheral nervous system	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
178	The RNMT-activating subunit	0.302202152245096	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-2.666666666666668	0.04	0.04477611940298508	0.0	0.04	0.04	5.0	0.04477611940298508	0.4	1.0	0.0	-2.666666666666668	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04477611940298508	0.0	0.0	0.0	0.0	0.0
10	Activation;activation	0.673901346257283	-2.3571428571428577	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.04375	0.04416799363057325	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.0445859872611465	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	Computational identification of beta	0.022788768436599553	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.25	0.0	0.0	0.0	0.0	-5.833333333333334	0.04	0.052173913043478265	0.0	0.04	0.04	4.0	0.052173913043478265	0.75	1.0	0.0	-5.833333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.052173913043478265	0.0	0.0	0.0	0.0	0.0
16	linkage;linkages	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
83	antiplatelet drug;antiplatelet agent;Antiplatelet Agent;Antiplatelet drug	0.13611098941037827	-1.625	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-8.0	0.04	0.05263157894736842	0.0	0.04	0.04298850574712644	2.0	0.05964912280701754	0.0	2.0	0.0	-10.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	4.0	0.04597701149425287	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
155	an;AN	0.5228542808364763	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
44	the water medium	0.048894972933717654	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
110	VIc);VIc;VIC	0.614914799650649	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.111111111111112	0.04	0.05263157894736842	0.0	0.04	0.04	1.3333333333333333	0.05294486215538847	0.0	3.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.04	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
75	inherited deficiency	0.2843809101390708	-5.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05	0.05	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	permits;Permits	0.0826827080311016	-4.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04918032786885245	0.04918032786885245	1.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04918032786885245	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
313	post;Post	0.6066186994119565	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
293	children and adolescents	0.1373751965233737	-1.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-3.0	0.04	0.04	0.0	0.04	0.042727272727272725	3.0	0.04631578947368421	0.0	2.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.045454545454545456	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
127	improved;Improved	0.06572267597863467	-6.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-11.333333333333334	0.04	0.07317073170731708	0.0	0.05263157894736842	0.05263157894736842	1.0	0.07317073170731708	0.0	1.0	0.0	-11.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05263157894736842	0.0	0.07317073170731708	0.0	0.0	0.0	0.0	0.0
149	response to physical activity	0.09998334433488879	-3.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	0.0	0.04	0.04	0.0	0.046511627906976744	0.046511627906976744	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.046511627906976744	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	(WAXS);WAXS	0.7728344913197663	-2.833333333333333	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-3.0833333333333335	0.04	0.04	0.0	0.04	0.04586206896551724	1.5	0.046550751879699245	0.0	4.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.051724137931034475	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
140	PTM	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
235	An autoimmune basis for the disease	0.056249078990898364	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.04	0.04	6.0	0.046296296296296294	0.3333333333333333	1.0	0.0	-3.3999999999999986	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
50	DEGseq and Pyicos	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	The behavioral problems	0.057656976243216716	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	0.0	0.04	0.04	0.0	0.04878048780487805	0.04878048780487805	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04878048780487805	0.0	0.04	0.0	0.0	0.0	0.0	0.0
344	averages;Average	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
24	A further study	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	rapid;Rapid	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
269	fewer colonies	0.10876031267125157	-2.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.043859649122807015	0.043859649122807015	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043859649122807015	0.0	0.04	0.0	0.0	0.0	0.0	0.0
3	Escherichia coli K-12	0.6174198233425533	-5.166666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.166666666666666	0.0	0.0	-4.428571428571429	0.04	0.04861111111111112	0.0	0.050420168067226885	0.050420168067226885	3.0	0.04861111111111112	0.0	1.0	0.0	-4.428571428571429	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.050420168067226885	0.0	0.04861111111111112	0.0	0.0	0.0	0.0	0.0
163	Increasing;increasing	0.06526239486352117	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04	0.04	1.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
288	provide;Provide	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
111	protein factors	0.04755845630732791	0.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.25	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	2.0	0.04	0.5	2.0	0.0	0.0	1.0	0.3333333333333333	1.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.5	0.0	0.0
188	BTBR T+tf/J (BTBR	0.7209342536605978	-4.333333333333333	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-5.5	0.04	0.047619047619047616	0.0	0.045454545454545456	0.048589341692789965	8.0	0.051587301587301584	0.125	2.0	0.0	-7.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	16.0	0.051724137931034475	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
7	birth during 1973	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
175	the characteristics	0.002640737002471037	-5.0	1.0	-17.5	0.13333333333333333	0.13333333333333333	1.0	1.0	1.0	-17.5	1.0	0.0	-5.0	0.0	0.0	-18.0	0.13333333333333333	0.14285714285714285	1.0	0.05	0.05	2.0	0.14285714285714285	1.0	1.0	0.0	-18.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05	0.0	0.14285714285714285	1.0	0.0	0.5	0.0	0.0
189	deficient expression of calcitonin	0.28170367946430735	-4.333333333333334	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-4.333333333333334	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.048387096774193554	0.048387096774193554	4.0	0.05405405405405406	0.0	1.0	0.0	-6.5	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.048387096774193554	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
199	histone H3 in centromeric nucleosomes	0.29542880439825553	0.0	1.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.14285714285714285	1.0	0.0	1.0	1.0	-1.8333333333333321	0.04	0.043165467625899276	0.0	0.04	0.04	5.0	0.043165467625899276	0.2	1.0	1.0	-1.8333333333333321	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.04	0.0	0.043165467625899276	0.0	1.0	0.0	0.0	1.0
137	further investigation	0.09639039448766368	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.1000000000000014	0.04	0.041841004184100423	0.0	0.04	0.04	2.0	0.041841004184100423	0.0	1.0	0.0	-1.1000000000000014	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.041841004184100423	0.0	0.0	0.0	0.0	0.0
211	Side;side	0.08037609202547222	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.3333333333333321	0.04	0.04225352112676056	0.0	0.04	0.04	1.0	0.04225352112676056	0.0	1.0	0.0	-1.3333333333333321	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04225352112676056	0.0	0.0	0.0	0.0	0.0
246	gain-of-function	0.036438909873871196	0.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	proteins Brd2	0.5414715938765099	-7.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-7.5	0.0	0.0	-4.0	0.04	0.047619047619047616	1.0	0.05714285714285714	0.05714285714285714	2.0	0.047619047619047616	0.5	1.0	0.0	-4.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.05714285714285714	0.0	0.047619047619047616	0.0	0.0	0.5	0.0	0.0
110	ATP synthase subunit 6;subunit 6 of ATP synthase	0.5471028257214459	-4.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	-4.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.047619047619047616	0.047619047619047616	5.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	5.0	0.047619047619047616	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
67	MULTIPLE SCLEROSIS;multiple sclerosis	0.9996456187283547	-0.8111111111111112	1.0	-11.75	0.04	0.04236477987421384	0.5	0.5	1.0	-0.7833333333333333	1.0	1.0	-12.166666666666668	0.0	0.0	-6.783333333333333	0.07547169811320754	0.04	0.0	0.04	0.042528138528138526	2.0	0.058216881017640026	1.0	30.0	0.0	-13.75	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	60.0	0.07792207792207793	0.0	0.08888888888888889	1.0	0.0	0.0	0.0	0.0
6	Management of opioid overdose	0.09053211076307498	-1.2222222222222214	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	1.0	-1.2222222222222214	1.0	1.0	0.0	0.04	0.04	0.0	0.04205607476635514	0.04205607476635514	4.0	0.04	0.5	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04205607476635514	0.0	0.04	0.0	1.0	0.0	0.0	1.0
75	Preparation for procedure;procedure for the preparation	0.06954445570481105	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	7.8 (p	0.7014808686443303	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
233	variety;Variety	0.09006219608192875	-1.6666666666666679	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6666666666666679	0.0	0.0	0.0	0.04	0.04	0.0	0.04285714285714286	0.04285714285714286	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04285714285714286	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	probe structural studies	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	software algorithm	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
299	Increased;increased	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
299	exogenous T(1)AM	0.44812380188002016	-5.666666666666666	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.051724137931034475	0.051724137931034475	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.051724137931034475	0.0	0.04	0.0	0.0	0.0	0.0	0.0
186	α(2)	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
207	mental health;Mental Health	0.05765678302330921	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.666666666666666	0.04	0.05769230769230768	0.0	0.04	0.04	2.0	0.05769230769230768	0.0	1.0	0.0	-7.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.05769230769230768	0.0	0.0	0.0	0.0	0.0
332	inhibitors of JAK	0.3279542248135121	-3.333333333333332	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04615384615384615	0.04615384615384615	3.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04615384615384615	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
131	Aldolase1);Aldolase1	0.6641753767711227	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.5	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
246	the TLR incidence	0.18821966034300913	-3.25	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.04597701149425287	0.04597701149425287	3.0	0.05128205128205128	0.3333333333333333	1.0	0.0	-5.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04597701149425287	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
329	source;Source	0.09773875734391521	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
8	structural;Structural;Structure;structure	0.052520328929097325	-3.875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-8.25	0.04	0.05714285714285714	0.0	0.0449438202247191	0.04747191011235955	1.0	0.05982142857142857	0.0	2.0	0.0	-9.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.05	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
156	The autosomal recessive mode	0.10323019028262205	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-4.75	0.04	0.04938271604938271	1.0	0.04	0.04	4.0	0.04938271604938271	0.5	1.0	1.0	-4.75	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04938271604938271	0.0	1.0	0.25	0.0	1.0
128	palindromic repeats	0.2976224694894377	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.8636363636363624	0.04	0.04508196721311475	0.0	0.04	0.04	2.0	0.04742786143461167	0.0	2.0	0.0	-4.909090909090908	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.049773755656108594	0.0	0.0	0.0	0.0	0.0
82	Chinese Han population	0.14042187432648184	-2.5	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.25	0.0	-5.0	0.0	0.0	-8.7	0.04	0.046296296296296294	1.0	0.04	0.045	3.0	0.06860269360269361	0.3333333333333333	4.0	0.0	-14.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	12.0	0.05	0.0	0.09090909090909091	0.0	0.0	0.3333333333333333	0.0	0.0
174	syndrome;Syndromes;syndromes;Syndrome	0.011555822358699605	-1.3888888888888893	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	-3.266666666666667	0.04	0.04424778761061947	0.0	0.04	0.04242462710250714	1.0	0.046048856964663674	0.6666666666666666	3.0	0.0	-3.8000000000000007	1.0	0.0	1.0	0.6666666666666666	1.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.043795620437956206	0.0	0.04716981132075472	1.0	0.0	0.0	0.0	0.0
320	classes;Class;class	0.1092030735996144	-2.6666666666666665	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-1.5555555555555554	0.04	0.04	0.0	0.043165467625899276	0.04486004522763437	1.0	0.04306010928961748	0.0	3.0	0.0	-4.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	3.0	0.047619047619047616	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
194	introduced;introduce	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
226	cluster;clustered;Cluster	0.07972003248656251	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.166666666666667	0.04	0.04	0.0	0.04	0.04	1.0	0.04419354838709678	0.0	2.0	0.0	-4.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.04	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
206	In Vivo;in vivo	0.20146510080365157	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	KCl	0.5903007912167021	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.7142857142857135	0.04	0.05185185185185186	0.0	0.04	0.04	1.0	0.05185185185185186	0.0	1.0	0.0	-5.7142857142857135	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.05185185185185186	0.0	0.0	0.0	0.0	0.0
310	two;Two	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
134	Potential;potential	0.07268327190128901	-6.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.054545454545454536	0.054545454545454536	1.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.054545454545454536	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
3	Mutagenesis;mutagenesis	0.5868109858711043	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.571428571428571	0.04	0.05426356589147286	0.0	0.04	0.04	1.0	0.05426356589147286	0.0	2.0	0.0	-6.571428571428571	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.05426356589147286	0.0	0.0	0.0	0.0	0.0
149	HYPERTROPHY;hypertrophy	0.6261537547779711	-4.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
345	sequence;Sequence	0.10426098756823182	-0.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6000000000000014	0.0	0.0	-1.0999999999999996	0.04	0.04	0.0	0.04	0.041367521367521365	1.0	0.04192982456140351	0.0	2.0	0.0	-2.1999999999999993	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.042735042735042736	0.0	0.043859649122807015	0.0	0.0	0.0	0.0	0.0
220	these mutations	0.042504663403395086	-4.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.6666666666666666	0.0	-4.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.047619047619047616	0.047619047619047616	2.0	0.05	0.5	1.0	0.0	-5.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047619047619047616	0.0	0.05	0.0	0.0	0.0	0.0	0.0
258	whose preferential binding	0.343217921388461	-4.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.047619047619047616	0.047619047619047616	3.0	0.04716981132075472	0.0	1.0	0.0	-3.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.047619047619047616	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
90	and;And	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
10	EBV-related Hodgkin lymphomas	0.4804707422996111	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
72	this study	0.09217160424583312	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.04	0.043859649122807015	0.0	0.04	0.04	2.0	0.043859649122807015	0.0	1.0	0.0	-2.1999999999999993	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.043859649122807015	0.0	0.0	0.0	0.0	0.0
345	UGA as a Sec codon	0.26905681404095005	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
226	operations	0.0889852165802779	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	1.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
291	Pathology;pathology	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
25	The intent	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
37	redox reactions	0.2620460747552078	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.75	0.04	0.057971014492753624	0.0	0.04	0.04	2.0	0.057971014492753624	0.0	2.0	0.0	-7.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.057971014492753624	0.0	0.0	0.0	0.0	0.0
238	following;Following	0.09192881091266093	-2.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04395604395604396	0.04395604395604396	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04395604395604396	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	genes;Genes	0.10011189313233033	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.416666666666667	0.04	0.04	0.0	0.04	0.04	1.0	0.04479338842975207	0.0	2.0	0.0	-4.833333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04958677685950414	0.0	0.0	0.0	0.0	0.0
85	Nine miRNAs (miR-22, miR-29c, miR-128, miR-132, miR-138, miR-218, miR-222, miR-344, and miR-674*)	0.15773138915052054	0.0	1.0	0.0	0.04	0.04	0.09090909090909091	0.09090909090909091	0.0	0.0	0.08333333333333333	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	22.0	0.04	0.09090909090909091	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	22.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
66	Early;early	0.08389013872897774	-6.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-5.75	0.04	0.05194805194805195	0.0	0.053571428571428575	0.053571428571428575	1.0	0.05194805194805195	0.0	1.0	0.0	-5.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.053571428571428575	0.0	0.05194805194805195	0.0	0.0	0.0	0.0	0.0
43	sole;SOLE	0.07886920816155821	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04878048780487805	0.04878048780487805	1.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04878048780487805	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
129	evidence;Evidence	0.10485281931303403	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.2142857142857135	0.04	0.04	0.0	0.04	0.04	1.0	0.04215189873417721	0.0	2.0	0.0	-2.428571428571427	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04430379746835443	0.0	0.0	0.0	0.0	0.0
96	the treatment of AL amyloidosis	0.15898064341854684	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
62	Analysis	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
90	ACTRN 12607000099426	0.6640320957831716	-3.3999999999999986	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.046296296296296294	0.046296296296296294	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.046296296296296294	0.0	0.04	0.0	0.0	0.0	0.0	0.0
142	2A	0.5713814349011338	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.444444444444445	0.04	0.056962025316455694	0.0	0.04	0.04	1.0	0.056962025316455694	0.0	1.0	0.0	-7.444444444444445	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.056962025316455694	0.0	0.0	0.0	0.0	0.0
274	Aβ peptide immunotherapy	0.8096883860458677	-1.8181818181818166	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-1.8181818181818166	0.0	0.0	-2.7142857142857153	0.04	0.04487179487179487	0.0	0.043137254901960784	0.043137254901960784	3.0	0.04487179487179487	0.0	2.0	0.0	-2.7142857142857153	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.043137254901960784	0.0	0.04487179487179487	0.0	0.0	0.0	0.0	0.0
330	DMARD)-IR	0.5296720961263451	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-4.125	0.04	0.04790419161676647	0.0	0.04	0.04	4.0	0.04790419161676647	0.25	1.0	0.0	-4.125	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04790419161676647	0.0	0.0	0.0	0.0	0.0
228	Tumor Progression Loci-2 (Tpl2) kinase inhibitors	0.24510996065441604	0.0	1.0	0.0	0.04	0.04	0.125	0.125	0.0	0.0	0.4	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	8.0	0.04	0.25	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.125	0.0	0.0
332	R788 (fostamatinib disodium)	0.5324049938541512	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	12.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
17	PRL	0.5939359646348814	-3.333333333333332	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-8.25	0.04	0.05970149253731343	0.0	0.04615384615384615	0.04615384615384615	1.0	0.05970149253731343	0.0	1.0	0.0	-8.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04615384615384615	0.0	0.05970149253731343	0.0	0.0	0.0	0.0	0.0
185	heart failure in 2	0.13720615534077008	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
78	function mutations in the NF1 gene	0.13522169460316852	-4.25	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-4.25	1.0	1.0	0.0	0.04	0.04	1.0	0.04819277108433735	0.04819277108433735	6.0	0.04	0.16666666666666666	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04819277108433735	0.0	0.04	0.0	1.0	0.16666666666666666	0.0	1.0
83	response to clopidogrel and several platelet function tests	0.03748155261815098	-3.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.25	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	1.0	0.045454545454545456	0.045454545454545456	8.0	0.04	0.125	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.125	0.0	0.0
146	the function	0.034374514706478614	-3.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04615384615384615	0.04615384615384615	2.0	0.051724137931034475	0.5	1.0	0.0	-5.666666666666666	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04615384615384615	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
121	pharmacogenetic test;Pharmacogenetic Test	0.11090791728643912	-5.333333333333333	1.0	-12.333333333333332	0.04	0.05298245614035088	0.5	0.5	1.0	-4.111111111111111	1.0	0.0	-6.333333333333334	0.0	0.0	-5.222222222222222	0.07894736842105263	0.04	1.0	0.048387096774193554	0.050935327657580264	2.0	0.05353629976580796	1.0	6.0	0.0	-11.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	12.0	0.053571428571428575	0.0	0.07142857142857142	1.0	0.0	0.5	0.0	0.0
206	RECEIVED;received	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	only;Only	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
131	endothelial cell growth factor	0.10023743251947323	-1.8000000000000007	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-1.8000000000000007	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04310344827586207	0.04310344827586207	4.0	0.04716981132075472	0.0	1.0	0.0	-3.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04310344827586207	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
290	of ultrasonography (US)-derived bladder;Ultrasonography of Bladder	0.17451496640628403	-4.75	0.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.0	1.0	-4.75	1.0	1.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04938271604938271	0.04938271604938271	8.0	0.053571428571428575	0.125	1.0	1.0	-6.333333333333334	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	8.0	0.04938271604938271	0.0	0.053571428571428575	0.0	1.0	0.0	0.0	1.0
255	third;Third	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
38	Chromosomal	0.5812411368485914	-6.333333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-12.0	0.04	0.07692307692307693	0.0	0.053571428571428575	0.053571428571428575	1.0	0.07692307692307693	0.0	1.0	0.0	-12.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.053571428571428575	0.0	0.07692307692307693	0.0	0.0	0.0	0.0	0.0
24	parallel-group	0.27939186888792705	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.04	0.04	3.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
68	distal 5q-trisomy	0.7014808686443303	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
63	period;/period	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
149	miR- 107, 1 and 181 in the skeletal muscle	0.1734420436621283	0.0	0.0	0.0	0.04	0.04	0.36363636363636365	0.36363636363636365	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	11.0	0.04	0.09090909090909091	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	11.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
276	thyroid hormone levels	0.2816181176975252	-0.75	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.6666666666666666	-2.25	0.0	0.0	-0.7333333333333331	0.04	0.04	0.0	0.04	0.04131868131868132	3.0	0.04128654970760234	0.3333333333333333	3.0	0.0	-2.1999999999999993	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.0	0.2222222222222222	1.0	1.0	9.0	0.04395604395604396	0.0	0.043859649122807015	0.0	0.0	0.0	0.0	0.0
198	a novel double missense mutation (K1527R	0.19250521054311895	-6.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-3.5	0.04	0.046511627906976744	1.0	0.05263157894736842	0.05263157894736842	7.0	0.046511627906976744	0.14285714285714285	1.0	0.0	-3.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.05263157894736842	0.0	0.046511627906976744	0.0	0.0	0.14285714285714285	0.0	0.0
69	neonatal diabetes;Neonatal diabetes	0.3821377028101954	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	2.0	1.0	2.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
203	in;In	0.007473709270285086	-8.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-8.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.058823529411764705	0.058823529411764705	1.0	0.047619047619047616	1.0	1.0	0.0	-4.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.058823529411764705	0.0	0.047619047619047616	1.0	0.0	0.0	0.0	0.0
334	the earliest response	0.04838272729154254	-3.7777777777777786	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.7777777777777786	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.04712041884816754	0.04712041884816754	3.0	0.046511627906976744	0.3333333333333333	1.0	0.0	-3.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04712041884816754	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
251	Transcriptional;transcriptional	0.6457427373028604	-1.4444444444444446	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	-1.3333333333333321	0.04	0.04205607476635514	0.0	0.04225352112676056	0.04245377478138976	0.5	0.04225445247751719	0.0	2.0	0.0	-1.4444444444444429	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04265402843601896	0.0	0.04245283018867924	0.0	0.0	0.0	0.0	0.0
176	prokaryotes and mitochondria	0.07897487389805641	-1.75	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.25	0.0	-1.75	0.0	0.0	-9.8	0.04	0.06578947368421052	0.0	0.043010752688172046	0.043010752688172046	3.0	0.06578947368421052	0.3333333333333333	1.0	0.0	-9.8	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043010752688172046	0.0	0.06578947368421052	0.0	0.0	0.0	0.0	0.0
313	PABPC4 (p(Het)	0.4490390798013828	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.3333333333333333	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
24	Group;group	0.06345914824668802	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.04	0.04	1.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
304	treated;Treated	0.5651705499912848	-3.875	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.875	0.0	0.0	-7.142857142857142	0.04	0.056	0.0	0.047337278106508875	0.047337278106508875	0.0	0.056	0.0	1.0	0.0	-7.142857142857142	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.047337278106508875	0.0	0.056	0.0	0.0	0.0	0.0	0.0
305	autophosphorylation	0.6398228829472737	-2.2142857142857135	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.428571428571427	0.0	0.0	-9.166666666666666	0.04	0.054545454545454536	0.0	0.043478260869565216	0.04389102916895982	1.0	0.06477272727272726	0.0	2.0	0.0	-11.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04430379746835443	0.0	0.075	0.0	0.0	0.0	0.0	0.0
61	elongation	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	Lymphoma, Non-Hodgkin;non-Hodgkin's lymphoma	0.8970300861683589	-3.625	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.25	1.0	1.0	-3.0	0.04	0.04424778761061947	0.0	0.045454545454545456	0.046823658269441404	3.0	0.04548837978661815	0.0	4.0	1.0	-3.6000000000000014	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	12.0	0.04819277108433735	0.0	0.04672897196261683	0.0	1.0	0.0	0.0	1.0
73	analysis of variance;Analysis of Variance	0.05642852335308313	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.04	0.044117647058823525	0.0	0.04	0.04	3.0	0.044117647058823525	0.3333333333333333	1.0	0.0	-2.333333333333332	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.044117647058823525	0.0	0.0	0.0	0.0	0.0
178	the nascent transcript	0.2058819839525017	-5.75	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-5.75	0.0	0.0	-5.166666666666666	0.04	0.050420168067226885	0.0	0.05194805194805195	0.05194805194805195	3.0	0.050420168067226885	0.3333333333333333	1.0	0.0	-5.166666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05194805194805195	0.0	0.050420168067226885	0.0	0.0	0.0	0.0	0.0
82	MPE	0.8576842643670352	-3.071428571428572	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.571428571428571	0.0	0.0	-9.0	0.04	0.04716981132075472	0.0	0.042682926829268296	0.04581698789015862	1.0	0.06988120195667366	0.0	4.0	0.0	-14.2	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	4.0	0.048951048951048945	0.0	0.09259259259259259	0.0	0.0	0.0	0.0	0.0
14	protein modifications;Protein Modification	0.20146510080365157	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
319	vivo validation studies	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
174	two different entities	0.08474185434878188	-2.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	-4.800000000000001	0.04	0.04950495049504951	0.0	0.044444444444444446	0.044444444444444446	3.0	0.04950495049504951	0.0	1.0	0.0	-4.800000000000001	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.044444444444444446	0.0	0.04950495049504951	0.0	0.0	0.0	0.0	0.0
231	the beta-isoform	0.3256705856779179	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-4.428571428571429	0.04	0.04861111111111112	0.0	0.04	0.04	4.0	0.04861111111111112	0.25	1.0	0.0	-4.428571428571429	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04861111111111112	0.0	0.0	0.0	0.0	0.0
126	most;Most	0.07101356386477531	-6.6	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.6	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.05434782608695653	0.05434782608695653	1.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05434782608695653	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
15	PPI detection to two tasks	0.08086706676759925	0.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.2857142857142857	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	an alteration	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
150	70 kD)	0.749050968877833	-3.428571428571427	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.428571428571427	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04635761589403973	0.04635761589403973	3.0	0.043478260869565216	0.0	2.0	0.0	-2.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04635761589403973	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
61	PROTEIN;proteins;protein;PROTEINS	0.9293847984872905	-1.56	0.0	0.0	0.04	0.04	0.0	0.1	0.0	0.0	0.0	1.0	-3.8000000000000007	0.0	0.0	-2.125	0.04	0.04	0.0	0.04	0.04287136885402011	1.0	0.04519279472088461	0.0	10.0	0.0	-9.25	1.0	0.3333333333333333	0.1	0.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	4.0	1.0	10.0	0.04716981132075472	0.0	0.06349206349206349	0.0	0.0	0.0	0.0	0.0
197	320	0.6017169099142065	-7.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.75	0.0	0.0	-11.333333333333334	0.04	0.07317073170731708	0.0	0.057971014492753624	0.057971014492753624	1.0	0.07317073170731708	0.0	1.0	0.0	-11.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.057971014492753624	0.0	0.07317073170731708	0.0	0.0	0.0	0.0	0.0
41	its ATPase/helicase	0.4345871006611708	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04	0.04	4.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
265	confirm	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
339	Deficient;deficient	0.5452066125383197	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
183	an excess of café-au-lait spots	0.3376091172853318	-3.75	0.0	0.0	0.04	0.04	0.2222222222222222	0.2222222222222222	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.047058823529411764	0.047058823529411764	9.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.047058823529411764	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
46	Notch signaling pathway;Notch signalling pathway;Notch Signaling Pathway	0.8159604030398151	-0.8999999999999998	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04152333273735026	3.0	0.04	0.6666666666666666	6.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	18.0	0.0425531914893617	0.0	0.04	0.0	0.0	0.0	0.0	0.0
192	homogeneous;Homogeneous	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
144	regulated;Regulated	0.001960544752225273	-15.2	1.0	0.0	0.04	0.04	1.0	1.0	1.0	0.0	1.0	0.0	-15.2	0.0	0.0	-17.0	0.04	0.125	0.0	0.1020408163265306	0.1020408163265306	1.0	0.125	1.0	1.0	0.0	-17.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.1020408163265306	0.0	0.125	1.0	0.0	0.0	0.0	0.0
73	house	0.6668594340272865	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
271	Three	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
276	normal thyroid hormone levels	0.100205178302844	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
40	Confidence;confidence	0.14095469534932045	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
330	further activity in this area	0.08279735195665178	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	Includes;includes;included	0.08983788974802799	-1.450000000000001	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.041841004184100423	0.042472226229981244	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.04310344827586207	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	now;Now	0.07634680496314203	-1.3636363636363633	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.3636363636363633	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.04230769230769231	0.04230769230769231	1.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04230769230769231	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
95	adenosine;ADENOSINE	0.5004100325766299	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.04	0.04	1.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
198	The substitution (D1790G	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
346	several eukaryotic promoters	0.2920984049808776	-1.1000000000000014	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.25	1.0	-1.1000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.041841004184100423	0.041841004184100423	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.041841004184100423	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	(18)	0.5939535099351959	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.04	0.043795620437956206	0.0	0.04	0.04	3.0	0.043795620437956206	0.0	1.0	0.0	-2.166666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.043795620437956206	0.0	0.0	0.0	0.0	0.0
199	A specific histone	0.07048461629607436	-6.166666666666666	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-6.166666666666666	0.0	0.0	-8.166666666666666	0.04	0.059405940594059396	0.0	0.053097345132743355	0.053097345132743355	3.0	0.059405940594059396	0.3333333333333333	1.0	0.0	-8.166666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.053097345132743355	0.0	0.059405940594059396	0.0	0.0	0.0	0.0	0.0
16	genes in E. coli	0.3075309072386389	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
150	misfolded cargo proteins	0.45407459901601915	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	Rosetta Stone method;Rosetta stone" method)	0.30833264112858305	0.0	0.0	0.0	0.04	0.04	0.4	0.5333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.75	0.04	0.04	0.0	0.04	0.04	4.0	0.043255813953488376	0.0	2.0	0.0	-3.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.04	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
172	Psychomotor retardation, severe;severe psychomotor retardation	0.5627327101894029	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
12	to;TO	0.06998091245582899	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	1.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
29	performed;Performed	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	State;state	0.047144794329146894	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-14.0	0.04	0.09090909090909091	0.0	0.04	0.04	1.0	0.09090909090909091	0.0	1.0	0.0	-14.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.09090909090909091	0.0	0.0	0.0	0.0	0.0
14	Gram;GRAM	0.5111724589278831	-1.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	-8.333333333333334	0.04	0.06000000000000001	0.0	0.0425531914893617	0.0425531914893617	1.0	0.06000000000000001	0.0	1.0	0.0	-8.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0425531914893617	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
327	investigated	0.10937306177143596	-3.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-2.8000000000000007	0.04	0.04504504504504505	0.0	0.047058823529411764	0.047058823529411764	1.0	0.04504504504504505	0.0	1.0	0.0	-2.8000000000000007	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.047058823529411764	0.0	0.04504504504504505	0.0	0.0	0.0	0.0	0.0
343	TRIM5α SPRY domain	0.07657452512946615	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.3333333333333333	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.6666666666666666	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
236	a biological sample for which	0.08279735195665178	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	these four methods	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	vitro and	0.2689006085096079	-3.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
125	myotubularin (MTM1) gene	0.23469318043664547	0.0	1.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.5	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
200	events);Events;events	0.24127672429902156	-0.9000000000000004	0.0	0.0	0.04	0.04	0.5	0.875	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-3.25	0.04	0.04	0.0	0.04	0.041682242990654206	1.25	0.050833333333333335	0.0	4.0	0.0	-13.0	1.0	0.0	0.75	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	5.0	0.04672897196261683	0.0	0.08333333333333333	0.0	0.0	0.0	0.0	0.0
215	ARF-p53-p21Cip1	0.6629463091944346	-4.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.0	0.0	0.0	-5.800000000000001	0.04	0.052083333333333336	0.0	0.047619047619047616	0.047619047619047616	5.0	0.052083333333333336	0.0	1.0	0.0	-5.800000000000001	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.047619047619047616	0.0	0.052083333333333336	0.0	0.0	0.0	0.0	0.0
225	hypothalamic-pituitary-thyroid (HPT) axis;hypothalamic-pituitary-thyroid axis	0.38096297931162626	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	9.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
229	The traditional approach	0.048894972933717654	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
75	Galactosylceramide beta-galactosidase cross reacting	0.3254116081305337	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.3333333333333333	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	6.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
312	binds;Bind	0.08649893108445883	-5.166666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.166666666666666	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.050420168067226885	0.050420168067226885	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.050420168067226885	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
66	the second trimester	0.10011306112922536	-5.583333333333333	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-8.166666666666666	0.0	0.0	-8.875	0.04	0.06060606060606061	0.0	0.045454545454545456	0.05243024302430242	3.0	0.06204906204906205	0.3333333333333333	2.0	0.0	-9.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.059405940594059396	0.0	0.06349206349206349	0.0	0.0	0.0	0.0	0.0
317	the reverse transcriptase activity of telomerase	0.14798972895764598	-3.1999999999999993	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-3.1999999999999993	1.0	1.0	-5.0	0.04	0.05	0.0	0.04587155963302752	0.04587155963302752	6.0	0.05	0.16666666666666666	1.0	1.0	-5.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.04587155963302752	0.0	0.05	0.0	1.0	0.0	0.0	1.0
251	EGF-mediated EMT	0.2489052770119481	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.25	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
201	type of blunt cardiac injury;Type of injury	0.14639378418672647	-17.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-17.0	0.0	0.0	-11.0	0.04	0.07142857142857142	0.0	0.125	0.125	5.0	0.07142857142857142	0.0	1.0	0.0	-11.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.125	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0
129	cooperation with the maintenenace DNA methyltransferase	0.14557840684705667	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
246	P2Y12 and occurrence of neurological adverse events	0.2087678151888562	0.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
150	the receptor	0.034657635960991015	-8.642857142857142	1.0	-13.166666666666668	0.04	0.06225352112676056	0.5	0.5	1.0	-6.583333333333334	1.0	1.0	-10.428571428571429	0.0	0.0	-10.666666666666668	0.08450704225352114	0.05825242718446603	1.0	0.05511811023622047	0.06187278060830632	2.0	0.07260447446179823	1.0	2.0	0.0	-13.5	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.06862745098039216	0.0	0.08695652173913043	1.0	0.0	0.5	0.0	0.0
199	Functional;functional	0.08379256115055554	-2.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-2.333333333333332	0.04	0.044117647058823525	0.0	0.044117647058823525	0.044117647058823525	1.0	0.044117647058823525	0.0	1.0	0.0	-2.333333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.044117647058823525	0.0	0.044117647058823525	0.0	0.0	0.0	0.0	0.0
307	Show;showing	0.07964297945723156	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.047619047619047616	0.047619047619047616	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.05	0.0	0.0	0.0	0.0	0.0
221	NAcc	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	the others	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
103	the wide distribution of the Dnmt1, Dnmt2 and Dnmt3 enzyme families	0.04030747339221833	0.0	1.0	0.0	0.04	0.04	0.5833333333333334	0.5833333333333334	0.0	0.0	0.09090909090909091	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	12.0	0.04	0.3333333333333333	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	12.0	0.04	0.0	0.04	0.0	1.0	0.08333333333333333	0.0	1.0
14	the alternating patterns	0.06397929847248758	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.166666666666666	0.04	0.050420168067226885	0.0	0.04	0.04	3.0	0.050420168067226885	0.3333333333333333	1.0	0.0	-5.166666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.050420168067226885	0.0	0.0	0.0	0.0	0.0
260	the mutation hotspots of the K-ras proto-oncogene	0.11203927744862821	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.5714285714285714	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	9.0	0.04	0.4444444444444444	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	9.0	0.04	0.0	0.04	0.0	1.0	0.1111111111111111	0.0	1.0
96	safety;Safety	0.1656382819023157	-4.125	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-5.449999999999999	0.04	0.04424778761061947	0.0	0.047058823529411764	0.047912782509418696	1.0	0.05277754586016719	0.0	4.0	0.0	-10.6	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04878048780487805	0.0	0.06944444444444445	0.0	0.0	0.0	0.0	0.0
146	the effects of ILK ablation	0.011004203828192862	0.0	1.0	-6.333333333333334	0.053571428571428575	0.053571428571428575	0.6	0.6	1.0	-6.333333333333334	1.0	1.0	0.0	0.0	0.0	-6.666666666666666	0.053571428571428575	0.054545454545454536	1.0	0.04	0.04	5.0	0.054545454545454536	1.0	1.0	0.0	-6.666666666666666	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.04	0.0	0.054545454545454536	1.0	0.0	0.2	0.0	0.0
13	Sample;sample;samples	0.1422534646359871	-2.8666666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-8.0	0.0	0.0	-3.2	0.04	0.04	0.0	0.04	0.04647899159663866	1.0	0.04651431911163063	0.0	5.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	5.0	0.058823529411764705	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
88	Clonal Expansion;clonal expansion	0.2713016503344617	-4.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.047619047619047616	0.047619047619047616	2.0	0.048387096774193554	0.0	2.0	0.0	-4.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.047619047619047616	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
26	cultures;Cultures	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
65	Which	0.0049874135092890055	-17.25	1.0	-18.0	0.14285714285714285	0.14285714285714285	1.0	1.0	1.0	-18.0	1.0	0.0	-17.25	0.0	0.0	-14.5	0.14285714285714285	0.09523809523809523	0.0	0.12903225806451613	0.12903225806451613	1.0	0.09523809523809523	1.0	1.0	0.0	-14.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.12903225806451613	0.0	0.09523809523809523	1.0	0.0	0.0	0.0	0.0
318	) acute lymphoblastic leukemia cells;acute lymphoblastic leukemia cells	0.30098288931635725	-1.4444444444444429	0.0	0.0	0.04	0.04	0.2	0.225	0.0	0.0	0.0	0.0	-1.4444444444444429	0.0	0.0	-8.692307692307693	0.04	0.05909090909090909	0.0	0.04245283018867924	0.04245283018867924	4.5	0.06140819964349377	0.325	2.0	0.0	-9.307692307692308	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.04245283018867924	0.0	0.06372549019607844	0.0	0.0	0.0	0.0	0.0
158	The protocol	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	low;Low	0.09888188928863312	-4.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.048387096774193554	0.048387096774193554	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.048387096774193554	0.0	0.04	0.0	0.0	0.0	0.0	0.0
188	The Autism ProSAP1/Shank2 mouse model	0.13345871311136495	0.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.42857142857142855	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
334	SNF	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
297	atrial fibrillation;ATRIAL FIBRILLATION	0.8813260198542912	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	5.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	a set of downregulated genes	0.1439517984230646	-2.6000000000000014	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	1.0	-2.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.044642857142857144	0.044642857142857144	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.044642857142857144	0.0	0.04	0.0	0.0	0.0	0.0	0.0
192	very early disease onset	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
254	stimuli;Stimuli	0.09773875734391521	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	the telomere	0.10549951416075809	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
147	not;Not	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
345	detailed;Detailed	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
251	kinase inhibitor;Kinase Inhibitor	0.597894608824963	-1.8888888888888893	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-8.777777777777779	0.04	0.06164383561643836	0.0	0.04326923076923077	0.04326923076923077	2.0	0.06164383561643836	0.0	2.0	0.0	-8.777777777777779	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04326923076923077	0.0	0.06164383561643836	0.0	0.0	0.0	0.0	0.0
287	ABK	0.698416640830183	-3.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04587155963302752	0.04587155963302752	1.0	0.04819277108433735	0.0	2.0	0.0	-4.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04587155963302752	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
93	the reported adverse effects of gabapentin	0.0039784587746964336	-3.166666666666668	1.0	-6.333333333333334	0.053571428571428575	0.053571428571428575	0.6666666666666666	0.6666666666666666	1.0	-6.333333333333334	1.0	0.0	-3.166666666666668	0.0	0.0	-5.666666666666666	0.053571428571428575	0.051724137931034475	1.0	0.04580152671755725	0.04580152671755725	6.0	0.051724137931034475	1.0	1.0	0.0	-5.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04580152671755725	0.0	0.051724137931034475	1.0	0.0	0.16666666666666666	0.0	0.0
199	facultative proteins such as CENPE, CENPF and INCENP	0.45631924338607627	-2.333333333333332	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-2.333333333333332	0.0	0.0	-2.166666666666668	0.04	0.043795620437956206	0.0	0.044117647058823525	0.044117647058823525	9.0	0.043795620437956206	0.0	1.0	0.0	-2.166666666666668	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	9.0	0.044117647058823525	0.0	0.043795620437956206	0.0	0.0	0.0	0.0	0.0
49	resulting	0.12485849184122304	-4.375	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.375	0.0	0.0	0.0	0.04	0.04	0.0	0.048484848484848485	0.048484848484848485	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.048484848484848485	0.0	0.04	0.0	0.0	0.0	0.0	0.0
78	deletion;Deletion	0.6157327180405838	-7.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.5	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.05714285714285714	0.05714285714285714	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05714285714285714	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
129	nucleosomes in chromatin regions	0.20392792817938546	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
188	oxytocin;OXYTOCIN	0.6545550503120147	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04	0.04	1.0	0.04716981132075472	0.0	1.0	0.0	-3.8000000000000007	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	1.0	0.04	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
232	To;TO;to	0.0653989809830218	-3.750000000000001	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.833333333333334	0.0	0.0	-8.875	0.04	0.0547945205479452	0.0	0.04477611940298508	0.04718144813124461	1.0	0.06311154598825831	0.0	2.0	0.0	-11.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.04958677685950414	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0
312	Smad1;SMAD1	0.7844059961876467	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.0	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04587155963302752	0.0	2.0	0.0	-3.1999999999999993	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	2.0	0.045454545454545456	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
256	a defining point mutation in the Fibroblast Growth Factor Receptor3 (FGFR3) gene	0.09918249118540903	-5.0	1.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.125	1.0	-5.0	1.0	1.0	-5.5	0.04	0.05128205128205128	1.0	0.05	0.05	14.0	0.05128205128205128	0.07142857142857142	1.0	1.0	-5.5	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	14.0	0.05	1.0	0.05128205128205128	0.0	1.0	0.07142857142857142	1.0	1.0
345	eukaryotic selenoprotein-encoding genes	0.14167927541018346	0.0	1.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.5	1.0	0.0	0.0	0.0	-5.4	0.04	0.0510204081632653	0.0	0.04	0.04	5.0	0.0510204081632653	0.4	1.0	0.0	-5.4	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.0510204081632653	0.0	0.0	0.0	0.0	0.0
156	Mortality;mortality	0.07423770024208881	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.04	0.04	1.0	0.04597701149425287	0.0	1.0	0.0	-3.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
121	several independent researchers	0.0927050193367411	-5.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.051724137931034475	0.051724137931034475	3.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.051724137931034475	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
16	protein annotation;Protein Annotation	0.20146510080365157	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
203	PWS (deletion	0.41295641580552406	-4.5	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.5	0.0	-4.5	0.0	0.0	-3.6000000000000014	0.04	0.04672897196261683	0.0	0.04878048780487805	0.04878048780487805	3.0	0.04672897196261683	0.0	1.0	0.0	-3.6000000000000014	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04878048780487805	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
278	the main defects	0.13722609848918177	-8.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-8.0	0.0	0.0	-9.0	0.04	0.0625	0.0	0.058823529411764705	0.058823529411764705	3.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.058823529411764705	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
117	HEART;heart	0.09228016637083075	-4.571428571428571	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.571428571428571	0.0	0.0	-8.25	0.04	0.05970149253731343	0.0	0.048951048951048945	0.048951048951048945	1.0	0.05970149253731343	0.0	2.0	0.0	-8.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.048951048951048945	0.0	0.05970149253731343	0.0	0.0	0.0	0.0	0.0
137	A potential shift in the treatment paradigm	0.028580854751701003	-2.2222222222222214	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	-2.2222222222222214	0.0	0.0	-1.3000000000000007	0.04	0.04219409282700422	0.0	0.04390243902439024	0.04390243902439024	7.0	0.04219409282700422	0.42857142857142855	1.0	0.0	-1.3000000000000007	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04390243902439024	0.0	0.04219409282700422	0.0	0.0	0.0	0.0	0.0
183	including;Including	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
29	SUCROSE;sucrose	0.658909094894199	-2.666666666666668	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.666666666666668	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04477611940298508	0.04477611940298508	1.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	1.0	0.04477611940298508	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
343	the TRIM50 C-terminal region to phosphatidylinositol species	0.14941448032378812	0.0	0.0	0.0	0.04	0.04	0.4444444444444444	0.4444444444444444	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	9.0	0.05263157894736842	0.1111111111111111	1.0	1.0	-6.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04	0.0	0.05263157894736842	0.0	1.0	0.0	0.0	1.0
96	therapy-related toxicity	0.2241066619573677	-3.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.046511627906976744	0.046511627906976744	4.0	0.044642857142857144	0.0	1.0	0.0	-2.6000000000000014	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.046511627906976744	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
111	one;ONE;One	0.07681560958372223	-3.2142857142857135	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-4.833333333333334	0.04	0.048387096774193554	0.0	0.04430379746835443	0.045961422543701023	1.0	0.049617277200656104	0.0	2.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.047619047619047616	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
79	2 to 4	0.2917670531335801	-3.6000000000000014	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-8.75	0.04	0.06153846153846154	0.0	0.04672897196261683	0.04672897196261683	3.0	0.06153846153846154	0.0	1.0	0.0	-8.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04672897196261683	0.0	0.06153846153846154	0.0	0.0	0.0	0.0	0.0
62	association with inflammatory bowel disease	0.1441738185708021	-2.2222222222222214	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	-2.2222222222222214	1.0	1.0	0.0	0.04	0.04	0.0	0.04390243902439024	0.04390243902439024	5.0	0.04	0.2	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04390243902439024	0.0	0.04	0.0	1.0	0.0	0.0	1.0
71	stimuli;Stimuli	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
140	intact proteins	0.3390675980923809	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	the tumorigenesis	0.13761019108142256	-2.25	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-2.25	0.0	0.0	-5.199999999999999	0.04	0.050505050505050504	0.0	0.04395604395604396	0.04395604395604396	2.0	0.050505050505050504	0.5	1.0	0.0	-5.199999999999999	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04395604395604396	0.0	0.050505050505050504	0.0	0.0	0.0	0.0	0.0
342	H3 K4 methyltransferase MLL1	0.6346488147816525	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.2	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	2.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
85	qPCR	0.6973995532021896	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
286	intoxication;INTOXICATION	0.6152244233353865	-2.8000000000000007	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04504504504504505	0.04504504504504505	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04504504504504505	0.0	0.04	0.0	0.0	0.0	0.0	0.0
312	The E3 ubiquitin ligase CHIP (C-terminus	0.16710620388169709	0.0	1.0	0.0	0.04	0.04	0.2222222222222222	0.2222222222222222	0.0	0.0	0.3333333333333333	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	9.0	0.04	0.4444444444444444	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	9.0	0.04	0.0	0.04	0.0	1.0	0.1111111111111111	0.0	1.0
257	antioxidant enzyme	0.24253690197788988	-9.5	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.3333333333333333	1.0	-9.5	1.0	1.0	-11.428571428571429	0.04	0.0736842105263158	0.0	0.06451612903225806	0.06451612903225806	2.0	0.0736842105263158	0.5	1.0	1.0	-11.428571428571429	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.06451612903225806	0.0	0.0736842105263158	0.0	1.0	0.0	0.0	1.0
122	S;/s	0.5060247871650599	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.04	0.04	1.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
16	Then;then	0.22075174410328105	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.65	0.04	0.04	0.0	0.04	0.04	1.0	0.041195402298850575	0.0	5.0	0.0	-3.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
100	Dependent;dependent	0.06853316678232349	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.166666666666666	0.04	0.050420168067226885	0.0	0.04	0.04	1.0	0.050420168067226885	0.0	1.0	0.0	-5.166666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.050420168067226885	0.0	0.0	0.0	0.0	0.0
102	transcriptional/translational feedback loops	0.4655030588053653	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	to;TO	0.07230072927832355	-1.4545454545454546	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-6.090909090909091	0.04	0.04	0.0	0.04	0.04278628001884665	1.0	0.054965905603735515	1.0	11.0	0.0	-10.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	11.0	0.04938271604938271	0.0	0.06666666666666667	1.0	0.0	0.0	0.0	0.0
199	the proposal	0.04256803310992381	-2.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	0.0	0.04	0.04	0.0	0.044444444444444446	0.044444444444444446	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.044444444444444446	0.0	0.04	0.0	0.0	0.0	0.0	0.0
152	now;Now	0.08309336917915155	-3.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04716981132075472	0.04716981132075472	1.0	0.04716981132075472	0.0	1.0	0.0	-3.8000000000000007	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04716981132075472	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
204	Individual;individuals	0.14095469534932045	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	disease characteristic;characteristic lesions of moyamoya disease	0.03400821725486485	0.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.5	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	5.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
251	nicotinamide adenine dinucleotide;Nicotinamide Adenine Dinucleotide	0.6365365591371616	-1.6666666666666679	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-1.6666666666666679	0.0	0.0	-3.7777777777777786	0.04	0.04712041884816754	0.0	0.04285714285714286	0.04285714285714286	3.0	0.04712041884816754	0.0	1.0	0.0	-3.7777777777777786	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	3.0	0.04285714285714286	0.0	0.04712041884816754	0.0	0.0	0.0	0.0	0.0
104	the ENCODE regions	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
316	cluster;Cluster	0.08335428368052449	-2.7272727272727266	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.7272727272727266	0.0	0.0	-2.8000000000000007	0.04	0.04504504504504505	0.0	0.044897959183673466	0.044897959183673466	1.0	0.04504504504504505	0.0	1.0	0.0	-2.8000000000000007	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.044897959183673466	0.0	0.04504504504504505	0.0	0.0	0.0	0.0	0.0
140	means;Means	0.074591715811745	-1.7777777777777786	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.0430622009569378	0.0430622009569378	1.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0430622009569378	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
108	Useful;useful	0.09204421579584872	-2.2857142857142847	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.2857142857142847	0.0	0.0	0.0	0.04	0.04	0.0	0.0440251572327044	0.0440251572327044	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0440251572327044	0.0	0.04	0.0	0.0	0.0	0.0	0.0
286	fast;Fast	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	bioinformatic means	0.41604157917582957	-9.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-9.0	0.0	0.0	0.0	0.04	0.04	0.0	0.0625	0.0625	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.0625	0.0	0.04	0.0	0.0	0.0	0.0	0.0
302	nhibitors of tumor progression	0.16030082009795002	-4.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
319	the literatures	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	the aorta	0.10549951416075809	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
216	Anaeromyxobacter dehalogenans	0.7975903447201348	-4.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.25	1.0	1.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04819277108433735	0.04819277108433735	2.0	0.05084745762711865	0.0	1.0	1.0	-5.333333333333334	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	2.0	0.04819277108433735	1.0	0.05084745762711865	0.0	1.0	0.0	1.0	1.0
266	blood pressure;BLOOD PRESSURE	0.3877042734008708	-6.083333333333333	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-11.25	0.0	0.0	-2.6666666666666665	0.04	0.04	0.0	0.04	0.05718760640108955	2.0	0.045169874079353765	0.0	6.0	0.0	-4.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	12.0	0.07272727272727272	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
299	the cardiac effects	0.004290299609671504	-3.333333333333332	1.0	-12.0	0.07692307692307693	0.07692307692307693	0.6666666666666666	0.6666666666666666	1.0	-12.0	1.0	0.0	-3.333333333333332	0.0	0.0	-12.333333333333332	0.07692307692307693	0.07894736842105263	1.0	0.04615384615384615	0.04615384615384615	3.0	0.07894736842105263	1.0	1.0	0.0	-12.333333333333332	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04615384615384615	0.0	0.07894736842105263	1.0	0.0	0.3333333333333333	0.0	0.0
60	any part	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	β-barrel membrane protein prediction [18,19]	0.09014262889284752	0.0	1.0	0.0	0.04	0.04	0.2727272727272727	0.2727272727272727	0.0	0.0	0.16666666666666666	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	11.0	0.04	0.2727272727272727	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	11.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
317	Approach;approach	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
99	(3) cardiomyopathy	0.6175565094348678	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.571428571428573	0.04	0.042682926829268296	0.0	0.04	0.04	2.0	0.042682926829268296	0.0	1.0	0.0	-1.571428571428573	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.042682926829268296	0.0	0.0	0.0	0.0	0.0
183	approximately 1 in 4,000 persons	0.12166253777349303	-3.75	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	0.0	0.04	0.04	0.0	0.047058823529411764	0.047058823529411764	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.047058823529411764	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	patient;patients;Patients;*^patient	0.20470084398218152	-1.2857142857142858	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-2.9285714285714284	0.04	0.04	0.0	0.04	0.04233766233766234	1.0	0.0456298282832326	0.0	7.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	7.0	0.045454545454545456	0.0	0.05	0.0	0.0	0.0	0.0	0.0
304	BTK;Btk	0.9877706329358098	-1.7578125	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.875	0.0	0.0	-3.776785714285714	0.04	0.04	0.0	0.04	0.04320548914672754	1.0	0.05026586817579926	0.0	16.0	0.0	-14.428571428571429	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	16.0	0.049689440993788817	0.0	0.0945945945945946	0.0	0.0	0.0	0.0	0.0
17	Suspected;suspected	0.08276153765018361	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04878048780487805	0.04878048780487805	1.0	0.04878048780487805	0.0	1.0	0.0	-4.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04878048780487805	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
315	Gene;gene	0.018953888313369485	-9.5	1.0	-18.5	0.04	0.09692307692307693	1.0	1.0	1.0	-9.25	1.0	1.0	-9.5	1.0	1.0	-12.75	0.15384615384615385	0.0625	1.0	0.06451612903225806	0.06451612903225806	1.0	0.0900735294117647	1.0	2.0	1.0	-16.5	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	2.0	1.0	2.0	0.06451612903225806	1.0	0.11764705882352941	1.0	1.0	1.0	1.0	1.0
305	the majority	0.0921490896965567	-2.8571428571428577	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.8571428571428577	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04516129032258065	0.04516129032258065	2.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04516129032258065	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
49	responsible;Responsible	0.08061253618895399	-2.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.25	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.04395604395604396	0.04395604395604396	1.0	0.04587155963302752	0.0	1.0	0.0	-3.1999999999999993	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04395604395604396	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
129	chromatin factors	0.31923431393739754	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04	0.04	2.0	0.043478260869565216	0.0	1.0	0.0	-2.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
145	the abnormal hyperphosphorylation	0.19106137873475496	-2.8571428571428577	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.8571428571428577	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04516129032258065	0.04516129032258065	3.0	0.04938271604938271	0.3333333333333333	1.0	0.0	-4.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04516129032258065	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
132	3,5-Dimethyl-3'	0.5825924784454449	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	Missing;missing	0.05710314513152379	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.04	0.04	1.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
144	cis;Cis	0.6066186994119565	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
69	deficiency;Deficiency	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
339	culture;Culture	0.08047563966958526	-2.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-3.6000000000000014	0.04	0.04672897196261683	0.0	0.04477611940298508	0.04477611940298508	1.0	0.04672897196261683	0.0	1.0	0.0	-3.6000000000000014	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04477611940298508	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
163	's positive therapeutic benefits in various oxidative stress-associated diseases	0.07797530871753301	0.0	0.0	0.0	0.04	0.04	0.6363636363636364	0.6363636363636364	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	11.0	0.04	0.09090909090909091	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	11.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
269	immortal bronchial epithelial cell strain HBE4	0.20316590375831495	-2.6000000000000014	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	-5.0	0.04	0.05	0.0	0.044642857142857144	0.044642857142857144	6.0	0.05	0.16666666666666666	1.0	0.0	-5.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.044642857142857144	0.0	0.05	0.0	0.0	0.0	0.0	0.0
274	Preliminary results	0.15495806300586298	-1.6363636363636367	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6363636363636367	0.0	0.0	0.0	0.04	0.04	0.0	0.042801556420233464	0.042801556420233464	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.042801556420233464	0.0	0.04	0.0	0.0	0.0	0.0	0.0
286	data;Data	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
17	pituitary microadenoma in 21 (15.4	0.39354822867414563	0.0	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
49	manifestations	0.6413210707628691	-1.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	-2.1999999999999993	0.04	0.043859649122807015	0.0	0.0425531914893617	0.0425531914893617	1.0	0.043859649122807015	0.0	1.0	0.0	-2.1999999999999993	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.0425531914893617	0.0	0.043859649122807015	0.0	0.0	0.0	0.0	0.0
227	low levels	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
140	reproducible;Reproducibility	0.5489876245017752	-1.5555555555555571	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	-5.0	0.04	0.05	0.0	0.04265402843601896	0.04265402843601896	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04265402843601896	0.0	0.05	0.0	0.0	0.0	0.0	0.0
102	the pathogenesis of a variety	0.04049964488517651	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
161	the responsible gene	0.06393360961060943	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.04	0.04	3.0	0.046875	0.3333333333333333	1.0	0.0	-3.666666666666668	1.0	0.3333333333333333	1.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
241	contralateral;CONTRALATERAL	0.6238856231506495	-2.333333333333333	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	-2.5	0.04	0.04	0.0	0.04	0.044590163934426226	1.0	0.045	0.0	2.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04918032786885245	0.0	0.05	0.0	0.0	0.0	0.0	0.0
189	calcium metabolism	0.7569196033508871	-4.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.047619047619047616	0.047619047619047616	2.0	0.06451612903225806	0.0	3.0	0.0	-9.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.047619047619047616	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
198	most cases	0.10643847661408903	-6.800000000000001	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.800000000000001	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.054945054945054944	0.054945054945054944	2.0	0.04878048780487805	0.0	1.0	0.0	-4.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.054945054945054944	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
229	using;Using;use of;Use of	0.5903430936626293	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0416666666666665	0.04	0.04	0.0	0.04	0.04	1.1666666666666667	0.047783751493428915	0.0	12.0	0.0	-10.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	14.0	0.04	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
132	cardiac effects of 3,5-diiodo-4	0.32828482741769727	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
267	ECG electrodes	0.6568436531426567	-2.571428571428573	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.0445859872611465	0.0445859872611465	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.0445859872611465	0.0	0.04	0.0	0.0	0.0	0.0	0.0
116	Which drugs	0.006929876487067323	-10.4	1.0	-18.666666666666668	0.15789473684210528	0.15789473684210528	1.0	1.0	1.0	-18.666666666666668	1.0	1.0	-10.4	1.0	1.0	-17.0	0.15789473684210528	0.125	1.0	0.0684931506849315	0.0684931506849315	2.0	0.125	1.0	2.0	1.0	-17.0	1.0	0.3333333333333333	1.0	1.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.0684931506849315	0.0	0.125	1.0	1.0	0.5	0.0	1.0
35	any detectable D1 expression	0.26782860435995465	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
90	Guidelines Adherence;Guideline Adherence;adherence to guideline	0.40009388981240535	-3.5999999999999996	0.0	0.0	0.04	0.04	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	-7.199999999999999	0.0	0.0	-4.5	0.04	0.04	0.0	0.04	0.04808988764044944	2.5	0.051250000000000004	0.0	2.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	5.0	0.056179775280898875	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
228	in vivo efficacy	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
294	FDA) for the treatment	0.031684802155577105	-6.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.3333333333333333	0.0	-6.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05263157894736842	0.05263157894736842	5.0	0.04	0.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.05263157894736842	0.0	0.04	0.0	0.0	0.0	0.0	0.0
163	very;Very	0.09705854714792957	-3.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04716981132075472	0.04716981132075472	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04716981132075472	0.0	0.04	0.0	0.0	0.0	0.0	0.0
213	KCNQ1 gene;KCNA9;genes KCNQ1;KVLQT1;Kv7.1;KVLQT1);KCNQ1;KCNQ1 Gene	0.9999363668475244	-1.4414414414414414	0.0	0.0	0.04	0.04	0.0	0.08108108108108109	0.0	0.0	0.0	1.0	-6.666666666666666	1.0	1.0	-1.9594594594594594	0.04	0.04	0.16216216216216217	0.04	0.04295140678580523	1.1891891891891893	0.043652855931529726	0.08108108108108109	37.0	1.0	-4.25	1.0	0.3333333333333333	0.0	0.16216216216216217	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	8.0	1.0	44.0	0.054545454545454536	0.0	0.04819277108433735	0.0	1.0	0.08108108108108109	0.0	1.0
139	a therapeutic function for Aβ	0.1677153304640803	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-4.25	0.04	0.04819277108433735	0.0	0.04	0.04	5.0	0.04819277108433735	0.0	1.0	1.0	-4.25	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04819277108433735	0.0	1.0	0.0	0.0	1.0
75	process;Process	0.07839552138403628	-6.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.75	0.0	0.0	-7.75	0.04	0.057971014492753624	0.0	0.0547945205479452	0.0547945205479452	1.0	0.057971014492753624	0.0	1.0	0.0	-7.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0547945205479452	0.0	0.057971014492753624	0.0	0.0	0.0	0.0	0.0
155	The central role	0.09139978256632278	-2.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	-2.666666666666668	0.04	0.04477611940298508	0.0	0.043795620437956206	0.043795620437956206	3.0	0.04477611940298508	0.0	1.0	0.0	-2.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043795620437956206	0.0	0.04477611940298508	0.0	0.0	0.0	0.0	0.0
16	best;Best	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
63	First;first	0.08019598201867174	-10.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-10.0	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.06666666666666667	0.06666666666666667	1.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.06666666666666667	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
103	Neurons;neurons	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
126	common;Common	0.07094744081837076	-5.800000000000001	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.800000000000001	0.0	0.0	-9.333333333333334	0.04	0.06382978723404256	0.0	0.052083333333333336	0.052083333333333336	1.0	0.06382978723404256	0.0	1.0	0.0	-9.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.052083333333333336	0.0	0.06382978723404256	0.0	0.0	0.0	0.0	0.0
14	The ANN	0.09666111545244421	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.04	0.043795620437956206	0.0	0.04	0.04	2.0	0.043795620437956206	0.5	1.0	0.0	-2.166666666666668	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.043795620437956206	0.0	0.0	0.0	0.0	0.0
103	DNA targeting un-methylated DNA	0.14788259700975337	-2.1111111111111107	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-2.1111111111111107	0.0	0.0	0.0	0.04	0.04	0.0	0.043689320388349516	0.043689320388349516	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.043689320388349516	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	Our data	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	the ‘PubMed Search’ tool	0.11573000002300696	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.16666666666666666	0.0	0.0
63	mg;MG	0.7172728766843438	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
140	occurring;Occur	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
277	Defined;defined	0.0661817914888578	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
177	LOWER;lower	0.13250389035345023	-5.666666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.777777777777779	0.0	0.0	0.0	0.04	0.04	0.0	0.051428571428571435	0.05172584640792734	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.05202312138728324	0.0	0.04	0.0	0.0	0.0	0.0	0.0
256	P250R mutation	0.8690888911690103	-6.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-10.333333333333334	1.0	1.0	-5.125	0.04	0.04	0.0	0.04	0.05618768328445749	2.0	0.051312741312741314	0.0	4.0	1.0	-7.5	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.06818181818181819	0.0	0.05714285714285714	0.0	1.0	0.0	0.0	1.0
151	web;Web	0.09827285573126496	-6.428571428571428	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-9.571428571428571	0.0	0.0	-4.833333333333333	0.04	0.04	0.0	0.046052631578947366	0.055433723196881085	1.0	0.05260869565217391	0.0	2.0	0.0	-9.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.06481481481481481	0.0	0.06521739130434782	0.0	0.0	0.0	0.0	0.0
46	well as in AML-initiating cells;Cells/well	0.07773962113697021	-1.1000000000000014	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	1.0	-1.1000000000000014	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.041841004184100423	0.041841004184100423	7.0	0.046875	0.14285714285714285	1.0	0.0	-3.666666666666668	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	7.0	0.041841004184100423	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
28	breast cancer;-- Breast Cancer	0.833156373891378	-5.8	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.05	0.05212406015037594	2.0	0.04	0.0	10.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	20.0	0.053571428571428575	0.0	0.04	0.0	0.0	0.0	0.0	0.0
249	loss of PRC2 activity	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
125	female carriers	0.14684823062145294	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
110	mitochondrial (II and III) subunits of cytochrome-c oxidase	0.42070898087870634	0.0	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04	0.04	12.0	0.051724137931034475	0.08333333333333333	1.0	0.0	-5.666666666666666	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	12.0	0.04	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
285	Human Epidermal growth factor Receptor (HER2) amplification (83	0.17938903258284775	0.0	1.0	0.0	0.04	0.04	0.2727272727272727	0.2727272727272727	0.0	0.0	0.16666666666666666	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	11.0	0.04	0.09090909090909091	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	11.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	GvHD	0.6404701957580634	-2.333333333333332	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.044117647058823525	0.044117647058823525	1.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.044117647058823525	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
88	the developing embryo	0.1668204292007314	-3.5	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	0.0	0.04	0.04	0.0	0.046511627906976744	0.046511627906976744	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.046511627906976744	0.0	0.04	0.0	0.0	0.0	0.0	0.0
199	other species	0.09189851650362736	-3.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	-5.0	0.04	0.05	0.0	0.04580152671755725	0.04580152671755725	2.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04580152671755725	0.0	0.05	0.0	0.0	0.0	0.0	0.0
41	the histone H3	0.39110789752970754	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
94	indication (December 2008)	0.2129783930596476	-3.8000000000000007	1.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.25	0.0	-3.8000000000000007	0.0	0.0	0.0	0.04	0.04	1.0	0.04716981132075472	0.04716981132075472	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04716981132075472	0.0	0.04	0.0	0.0	0.2	0.0	0.0
121	occurring;Occur	0.10357417947446557	-5.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.051724137931034475	0.051724137931034475	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.051724137931034475	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	testing patients for the allele	0.056503702840828084	-4.333333333333334	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-4.333333333333334	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.048387096774193554	0.048387096774193554	5.0	0.048387096774193554	0.2	1.0	0.0	-4.333333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.048387096774193554	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
49	72% of patients	0.23710398384424036	-2.375	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.375	0.0	0.0	0.0	0.04	0.04	0.0	0.04419889502762431	0.04419889502762431	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04419889502762431	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	Useful;useful	0.07709417515871393	-1.6363636363636367	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6363636363636367	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.042801556420233464	0.042801556420233464	1.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.042801556420233464	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
317	inhibition of telomerase activity	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
71	glucose metabolism	0.9816949507628324	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	9.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	18.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	one to two minutes	0.08660910141723283	-2.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.044642857142857144	0.044642857142857144	4.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.044642857142857144	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
85	miR-132-3p/hsa-miR	0.6000186669162998	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
275	patients with the DOORS syndrome	0.003373346413340707	-7.125	1.0	-9.0	0.0625	0.0625	0.8	0.8	1.0	-9.0	1.0	1.0	-7.125	1.0	1.0	-10.0	0.0625	0.06666666666666667	0.0	0.055944055944055944	0.055944055944055944	5.0	0.06666666666666667	1.0	1.0	1.0	-10.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.055944055944055944	0.0	0.06666666666666667	1.0	1.0	0.0	0.0	1.0
198	ECG NOS;ECG	0.5683010006279064	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04878048780487805	0.0	1.0	0.0	-4.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
142	high-risk areas	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
69	limb digits multiply	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
90	reviews	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	thyroid gland;THYROID GLAND;Thyroid, NOS;thyroid;Thyroid	0.9639287033382705	-1.512820512820513	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-1.2051282051282053	0.04	0.04	0.0	0.04	0.04305824657798342	1.3076923076923077	0.04247216599190284	0.0	13.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	5.0	1.0	17.0	0.05263157894736842	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
241	pseudarthrosis;Pseudarthrosis	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	a framework	0.09043244989180597	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.04	0.04477611940298508	0.0	0.04	0.04	2.0	0.04477611940298508	0.0	1.0	0.0	-2.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04477611940298508	0.0	0.0	0.0	0.0	0.0
317	The role	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
330	the some potent and highly selective JAK1 inhibitors	0.15309426768149323	-1.7777777777777786	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-6.875	0.04	0.05517241379310345	1.0	0.0430622009569378	0.0430622009569378	8.0	0.05517241379310345	0.0	1.0	0.0	-6.875	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.0430622009569378	0.0	0.05517241379310345	0.0	0.0	0.125	0.0	0.0
262	subependymal nodule (SN	0.6736436094673455	-8.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-8.25	0.0	0.0	0.0	0.04	0.04	0.0	0.05970149253731343	0.05970149253731343	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.05970149253731343	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	an important target	0.03856345177978802	-7.5	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.5	0.0	-7.5	0.0	0.0	-6.5	0.04	0.05405405405405406	1.0	0.05714285714285714	0.05714285714285714	3.0	0.05405405405405406	0.3333333333333333	1.0	0.0	-6.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05714285714285714	0.0	0.05405405405405406	0.0	0.0	0.3333333333333333	0.0	0.0
293	tianeptine;Tianeptine	0.7492855162222997	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
5	Reach;reached	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	8], [9]	0.5649575422988644	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
297	T3 concentration (P	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	doses of gabapentin;dose pharmacokinetics of gabapentin;Gabapentin Dose	0.05396327044566282	0.0	0.5	0.0	0.04	0.04	0.5	0.5833333333333333	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.5	0.04	0.5833333333333333	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
158	the great majority of cases	0.08279735195665178	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
165	CpG motifs	0.6518436242247154	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
238	Angiographies;angiographic	0.7243671343496954	-2.3888888888888893	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-0.6111111111111107	0.04	0.04	0.0	0.04195804195804196	0.04428904428904429	1.0	0.04105515587529976	0.0	3.0	0.0	-1.8333333333333321	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.045454545454545456	0.0	0.043165467625899276	0.0	0.0	0.0	0.0	0.0
226	difficulty lifting;Difficulty lifting	0.27926268070552995	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	Recent;Recently;recently;recent	0.08006917468797854	-4.333333333333333	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.25	0.0	0.0	-2.888888888888889	0.04	0.04	0.0	0.04	0.049428693372355344	1.0	0.04559979182930002	0.0	3.0	0.0	-4.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.056338028169014086	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
15	Availability of;available;Available;available biomedical text mining tools for the detection of	0.015403220417481428	-0.7750000000000004	1.0	-6.4	0.04	0.043440860215053764	0.6666666666666666	0.9166666666666666	1.0	-1.6	1.0	0.0	-2.0	0.0	0.0	-1.75	0.05376344086021505	0.04	0.25	0.04	0.04132981626341641	3.0	0.04388888888888889	1.0	4.0	0.0	-7.0	1.0	0.0	0.75	1.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	12.0	0.043478260869565216	0.0	0.05555555555555555	1.0	0.0	0.027777777777777776	0.0	0.0
50	Measures of RNA abundance	0.060781769506690196	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.16666666666666666	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
143	Gerard et al.	0.6171953679194666	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	Local;local	0.07579614674277428	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.04	0.04	1.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
37	Recent;Recently;recently	0.07377347970121963	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.125	0.04	0.04	0.0	0.04	0.04	1.0	0.049850746268656716	0.0	2.0	0.0	-8.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.04	0.0	0.05970149253731343	0.0	0.0	0.0	0.0	0.0
291	aid;Aid	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
90	two blood pressure	0.08204281619631279	-2.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.04424778761061947	0.04424778761061947	3.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04424778761061947	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
334	DNA damage induction	0.06751715744384046	-1.5555555555555571	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04265402843601896	0.04265402843601896	3.0	0.047619047619047616	0.6666666666666666	2.0	0.0	-4.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04265402843601896	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
60	components of the NPC	0.06637442787073183	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
49	atypical;Atypical	0.7087377473349904	-0.625	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.875	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.041081081081081085	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.043243243243243246	0.0	0.04	0.0	0.0	0.0	0.0	0.0
155	Autosomal dominant;autosomal dominant	0.24584486302726247	-9.333333333333334	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-9.333333333333334	0.0	0.0	-2.333333333333332	0.04	0.044117647058823525	0.0	0.06382978723404256	0.06382978723404256	2.0	0.044117647058823525	0.0	1.0	0.0	-2.333333333333332	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.06382978723404256	0.0	0.044117647058823525	0.0	0.0	0.0	0.0	0.0
264	with;With	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
205	to;TO	0.08948373982222868	-3.875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-7.75	0.04	0.05263157894736842	0.0	0.04597701149425287	0.04737874964956546	1.0	0.05857385398981324	0.0	2.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04878048780487805	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
144	post;Post	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	10%;10	0.6377110003425351	-10.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-10.0	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.06666666666666667	0.06666666666666667	0.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.06666666666666667	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
102	mCry2) genes	0.5912142437508239	-4.5	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-4.5	1.0	1.0	0.0	0.04	0.04	0.0	0.04878048780487805	0.04878048780487805	3.0	0.04	0.0	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04878048780487805	0.0	0.04	0.0	1.0	0.0	0.0	1.0
319	through;Through	0.09168043792310962	-1.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-4.25	0.04	0.04	0.0	0.04	0.042388059701492536	1.0	0.05030303030303031	0.0	2.0	0.0	-8.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04477611940298508	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
231	FHC	0.8780177191735039	-1.4081632653061225	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.2857142857142865	0.0	0.0	-4.673469387755103	0.04	0.046052631578947366	0.0	0.04	0.04281081237602976	1.0	0.04927709080492415	0.0	7.0	0.0	-5.571428571428571	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.05072463768115942	0.0	0.051470588235294115	0.0	0.0	0.0	0.0	0.0
310	tumor cell adhesion	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
278	Families;families	0.05590579645193492	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.04	0.04	1.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
307	mostly;Mostly	0.08010107912165296	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.045454545454545456	0.045454545454545456	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
127	gefitinib and erlotinib	0.6062301437018218	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.5944444444444444	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	1.0	9.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	27.0	0.04	0.0	0.04	1.0	0.0	0.0	0.0	0.0
160	other cancers	0.09401360348987844	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.7142857142857153	0.04	0.04294478527607362	0.0	0.04	0.04	2.0	0.04294478527607362	0.0	1.0	0.0	-1.7142857142857153	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04294478527607362	0.0	0.0	0.0	0.0	0.0
337	cardiovascular mortality	0.2561691657660384	-1.3000000000000007	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.3000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04219409282700422	0.04219409282700422	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04219409282700422	0.0	0.04	0.0	0.0	0.0	0.0	0.0
285	Compared;compared	0.14341979440108604	-2.0666666666666664	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.043775368362524325	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04587155963302752	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	the apurinic/apyrimidinic endonuclease	0.3123795294827484	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	proteases.7;protease 7	0.5743070539809633	-3.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-4.6	0.04	0.04901960784313726	0.0	0.047058823529411764	0.047058823529411764	1.0	0.04901960784313726	0.0	1.0	0.0	-4.6	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047058823529411764	0.0	0.04901960784313726	0.0	0.0	0.0	0.0	0.0
222	the generation	0.030871904715132348	-1.7777777777777786	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-6.800000000000001	0.04	0.054945054945054944	0.0	0.0430622009569378	0.0430622009569378	2.0	0.054945054945054944	0.5	1.0	0.0	-6.800000000000001	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.0430622009569378	0.0	0.054945054945054944	0.0	0.0	0.0	0.0	0.0
73	per-residue and per-segment measures of accuracy	0.07994112237479052	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04	0.04	6.0	0.043478260869565216	0.16666666666666666	1.0	0.0	-2.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
90	all clinical trials	0.0028376533070818928	-7.800000000000001	1.0	-18.0	0.14285714285714285	0.14285714285714285	1.0	1.0	1.0	-18.0	1.0	0.0	-7.800000000000001	0.0	0.0	-17.5	0.14285714285714285	0.13333333333333333	1.0	0.05813953488372093	0.05813953488372093	3.0	0.13333333333333333	1.0	1.0	0.0	-17.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05813953488372093	0.0	0.13333333333333333	1.0	0.0	0.3333333333333333	0.0	0.0
247	vaccinated vs 6.29	0.36455145303528796	-2.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
6	discharged;Discharged	0.5330175365015917	-3.666666666666668	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.0	0.0	-8.25	0.04	0.05970149253731343	0.0	0.046875	0.046875	1.0	0.05970149253731343	0.0	1.0	0.0	-8.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046875	0.0	0.05970149253731343	0.0	0.0	0.0	0.0	0.0
44	time-lapse imaging	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
69	those of patients	0.048894972933717654	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
136	children with heart failure	0.0027998535601308615	-9.833333333333334	1.0	-16.0	0.1111111111111111	0.1111111111111111	1.0	1.0	1.0	-16.0	1.0	0.0	-9.833333333333334	0.0	0.0	-15.0	0.1111111111111111	0.1	0.0	0.06593406593406594	0.06593406593406594	4.0	0.1	1.0	1.0	0.0	-15.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.06593406593406594	0.0	0.1	1.0	0.0	0.0	0.0	0.0
228	poor selectivity	0.2765738641103709	-4.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
48	harbored;Harbor	0.5324503336112033	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.142857142857142	0.04	0.050359712230215826	0.0	0.04	0.04	1.0	0.050359712230215826	0.0	1.0	0.0	-5.142857142857142	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.050359712230215826	0.0	0.0	0.0	0.0	0.0
131	Some of these proteins	0.026505735550000735	0.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.25	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
229	modules in gene;Gene Modules	0.06227578876492644	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
111	selenocysteine biosynthesis in eubacteria	0.24787643536769227	-2.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.043478260869565216	0.043478260869565216	4.0	0.04918032786885245	0.25	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.043478260869565216	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
198	the consensus splice site	0.10511182495774415	-3.3999999999999986	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.046296296296296294	0.046296296296296294	4.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.046296296296296294	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
15	protein names	0.05884819660295943	-2.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-2.5	0.0	0.0	-2.3999999999999986	0.04	0.04424778761061947	0.0	0.044444444444444446	0.044444444444444446	2.0	0.04424778761061947	0.5	1.0	0.0	-2.3999999999999986	1.0	0.3333333333333333	1.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.044444444444444446	0.0	0.04424778761061947	0.0	0.0	0.0	0.0	0.0
121	predominantly white populations	0.145761328046283	-6.333333333333334	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.053571428571428575	0.053571428571428575	3.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.053571428571428575	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
14	β-barrel membrane proteins	0.9977483251181354	-0.3	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	-1.5666666666666669	0.04	0.04	0.0	0.04	0.04051063829787234	5.0	0.04305838041431262	0.6	10.0	0.0	-5.333333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	50.0	0.0425531914893617	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
95	RNA-polyA10	0.6171953679194666	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
75	a severe disorder of the peripheral and central nervous system myelin	0.054626100525702374	-9.5	0.0	0.0	0.04	0.04	0.8181818181818182	0.8181818181818182	0.0	0.0	0.0	0.0	-9.5	0.0	0.0	-8.75	0.04	0.06153846153846154	0.0	0.06451612903225806	0.06451612903225806	11.0	0.06153846153846154	0.0	1.0	0.0	-8.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	11.0	0.06451612903225806	0.0	0.06153846153846154	0.0	0.0	0.0	0.0	0.0
39	to;TO	0.07423770024208881	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.04	0.04	1.0	0.04597701149425287	0.0	1.0	0.0	-3.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
73	not;Not;non;Non	0.6153579146312075	-0.4027777777777777	0.0	0.0	0.04	0.04	0.0	0.5	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-3.395833333333333	0.04	0.043478260869565216	0.0	0.04	0.04069034398699892	0.5	0.04642703954695786	0.0	8.0	0.0	-5.5	1.0	0.0	0.5	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	4.0	0.04326923076923077	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
160	osteoclastogenesis and cytokine production by malignant cells	0.15253371083258746	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
103	lacks;lack	0.06157871199222618	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.7142857142857135	0.04	0.05785123966942149	0.0	0.04	0.04	1.0	0.05785123966942149	0.0	1.0	0.0	-7.7142857142857135	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05785123966942149	0.0	0.0	0.0	0.0	0.0
229	experimentally identified phenotypes	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	genome;genomic;Genome;Genomic	0.8246805105544746	-2.1111111111111107	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.2222222222222214	1.0	1.0	-2.6428571428571432	0.04	0.043478260869565216	0.0	0.0430622009569378	0.043692379507527135	1.0	0.04474053295932679	0.0	4.0	1.0	-2.8571428571428577	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	4.0	1.0	4.0	0.04390243902439024	1.0	0.04516129032258065	0.0	1.0	0.0	1.0	1.0
227	L-ferritin deficiency	0.4735008974911581	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.25	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	4.0	0.04	0.25	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.25	0.0	1.0
121	development of HLA	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
322	named	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
300	a transcriptional repressor of HO-1	0.12670805549079892	-2.7142857142857153	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.2	1.0	-2.7142857142857153	0.0	0.0	0.0	0.04	0.04	0.0	0.04487179487179487	0.04487179487179487	5.0	0.04	0.6	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.04487179487179487	0.0	0.04	0.0	0.0	0.0	0.0	0.0
264	the oldest old subjects	0.0884415052403157	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
307	a specific component of Lewy bodies	0.010664251301685565	0.0	1.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.42857142857142855	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	6.0	0.047619047619047616	0.5	1.0	0.0	-4.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
44	the major challenges in the development	0.03759289802576083	-2.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.75	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.0449438202247191	0.0449438202247191	6.0	0.046875	0.3333333333333333	1.0	0.0	-3.666666666666668	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.0449438202247191	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
30	first intron	0.30572516983700904	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.04	0.04	2.0	0.046296296296296294	0.0	1.0	0.0	-3.3999999999999986	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
179	sequence;Sequence	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
197	427	0.6052148580033511	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.04	0.04	1.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
238	2143 patients	0.2958188110487749	-6.25	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-6.583333333333334	0.0	0.0	-9.0	0.04	0.0625	0.0	0.05240174672489082	0.05335019462941374	2.0	0.0625	0.0	2.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.05429864253393666	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
216	initial;Initial	0.07296156602125722	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.04	0.04	1.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
85	expression;Expression	0.38193577398493883	-2.1	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-2.2321428571428577	0.04	0.04	0.0	0.04	0.043898492730971655	1.0	0.04440038500043986	0.0	8.0	0.0	-7.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.04716981132075472	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
235	the narcolepsy cases	0.005532321612617687	-12.555555555555555	1.0	-12.6	0.08064516129032258	0.08064516129032258	0.6666666666666666	0.6666666666666666	1.0	-12.6	1.0	0.0	-12.555555555555555	0.0	0.0	-13.2	0.08064516129032258	0.0847457627118644	0.0	0.08035714285714285	0.08035714285714285	3.0	0.0847457627118644	1.0	1.0	0.0	-13.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.08035714285714285	0.0	0.0847457627118644	1.0	0.0	0.0	0.0	0.0
124	recurrence risk information	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	diagnosis of primary;Diagnosis.primary	0.03809459826425287	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
144	using;Using	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
80	clinical;Clinical	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
223	downstream effects	0.21161768733862668	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.428571428571429	0.04	0.04861111111111112	0.0	0.04	0.04	2.0	0.04861111111111112	0.0	1.0	0.0	-4.428571428571429	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04861111111111112	0.0	0.0	0.0	0.0	0.0
318	an orally available tyrosine kinase inhibitor	0.4585150824766939	-0.7777777777777786	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	-5.346153846153846	0.04	0.04814814814814815	1.0	0.04	0.04132701421800948	6.0	0.05104502843092054	0.3333333333333333	2.0	0.0	-6.461538461538462	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	12.0	0.04265402843601896	0.0	0.05394190871369294	0.0	0.0	0.16666666666666666	0.0	0.0
13	realm;Realm	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
101	Assay;assay;assays	0.6841615498597213	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.04545845905783915	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	3.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
237	p105 and IkappaBgamma	0.29475315584956935	-4.428571428571429	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-4.428571428571429	0.0	0.0	-9.142857142857142	0.04	0.06306306306306306	0.0	0.04861111111111112	0.04861111111111112	3.0	0.06306306306306306	0.0	1.0	0.0	-9.142857142857142	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04861111111111112	0.0	0.06306306306306306	0.0	0.0	0.0	0.0	0.0
226	"phobia-apraxia"), 5	0.38631648802519436	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04	0.04	8.0	0.053571428571428575	0.25	1.0	1.0	-6.333333333333334	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.053571428571428575	0.0	1.0	0.0	0.0	1.0
264	the negative effects of possible overtreatment	0.05172733387632983	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
331	an increased risk	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
71	switches in the energy production	0.03576257893441019	-2.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.044642857142857144	0.044642857142857144	5.0	0.046511627906976744	0.4	1.0	0.0	-3.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.044642857142857144	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
106	More;more	0.0035948627236039965	-17.0	1.0	-15.0	0.1	0.1	1.0	1.0	1.0	-15.0	1.0	0.0	-17.0	0.0	0.0	-14.0	0.1	0.09090909090909091	0.0	0.125	0.125	1.0	0.09090909090909091	1.0	1.0	0.0	-14.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.125	0.0	0.09090909090909091	1.0	0.0	0.0	0.0	0.0
203	defects	0.11222434118231553	-9.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-9.25	0.0	0.0	-10.8	0.04	0.07042253521126761	1.0	0.06349206349206349	0.06349206349206349	1.0	0.07042253521126761	1.0	1.0	0.0	-10.8	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.06349206349206349	0.0	0.07042253521126761	1.0	0.0	1.0	0.0	0.0
332	Small Molecule;small molecule	0.1565898826690608	-0.7222222222222227	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	-1.0833333333333333	0.04	0.04	0.0	0.04	0.04126520681265207	2.0	0.04199233716475096	0.0	3.0	0.0	-3.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.043795620437956206	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
15	biologists;Biologists	0.7268029400891787	-1.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.6999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.041841004184100423	0.04255930468511502	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04291845493562232	0.0	0.04	0.0	0.0	0.0	0.0	0.0
171	truncating mutation	0.40299053651032263	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.5	0.0	0.0
181	High;higher	0.09773875734391521	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
204	diagnose with certainty or	0.06637442787073183	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
274	Several types of Aβ peptide immunotherapy	0.19770074048297512	-1.8181818181818166	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-1.8181818181818166	0.0	0.0	-2.7142857142857153	0.04	0.04487179487179487	0.0	0.043137254901960784	0.043137254901960784	6.0	0.04487179487179487	0.16666666666666666	1.0	0.0	-2.7142857142857153	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.043137254901960784	0.0	0.04487179487179487	0.0	0.0	0.0	0.0	0.0
321	including;Including	0.052641232978087676	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-14.0	0.04	0.09090909090909091	0.0	0.045454545454545456	0.045454545454545456	1.0	0.09090909090909091	0.0	1.0	0.0	-14.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.09090909090909091	0.0	0.0	0.0	0.0	0.0
200	Demographics;demographics	0.4904345345409726	-4.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-12.333333333333332	0.04	0.07894736842105263	0.0	0.047619047619047616	0.047619047619047616	1.0	0.07894736842105263	0.0	1.0	0.0	-12.333333333333332	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.07894736842105263	0.0	0.0	0.0	0.0	0.0
238	3;<3	0.588355044192654	-2.416666666666668	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.416666666666668	0.0	0.0	-2.166666666666668	0.04	0.043795620437956206	0.0	0.04428044280442805	0.04428044280442805	1.0	0.043795620437956206	0.0	1.0	0.0	-2.166666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04428044280442805	0.0	0.043795620437956206	0.0	0.0	0.0	0.0	0.0
257	mammalian enzyme	0.2506483902624089	-2.666666666666668	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.3333333333333333	1.0	-2.666666666666668	1.0	1.0	-4.571428571428571	0.04	0.048951048951048945	0.0	0.04477611940298508	0.04477611940298508	2.0	0.048951048951048945	0.5	1.0	1.0	-4.571428571428571	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04477611940298508	0.0	0.048951048951048945	0.0	1.0	0.0	0.0	1.0
90	Efficacy;efficacy	0.5630247089065323	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.75	0.04	0.06060606060606061	0.0	0.04	0.04	1.0	0.061553030303030304	0.0	2.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
183	Neurofibromatosis Type 1;Neurofibromatosis type 1;neurofibromatosis;NF1);Neurofibromatosis;neurofibromatosis type 1;NF1	0.9993429532497001	-4.018518518518518	1.0	-8.5	0.04	0.042289562289562294	0.0	0.13580246913580246	1.0	-0.9444444444444444	0.9074074074074074	1.0	-14.25	1.0	1.0	-3.2777777777777777	0.06060606060606061	0.04	0.0	0.04	0.05064278243807344	1.8888888888888888	0.047870715429627425	0.4444444444444444	27.0	1.0	-9.75	1.0	0.3333333333333333	0.0	0.4444444444444444	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	7.0	1.0	51.0	0.09302325581395349	0.0	0.06557377049180328	1.0	1.0	0.0	0.0	1.0
207	Only the group	0.048894972933717654	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	acetone;ACETONE	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
78	South African;AFRICAN, SOUTH	0.09149272443147613	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.04878048780487805	0.04878048780487805	2.0	0.06666666666666667	0.0	2.0	0.0	-10.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04878048780487805	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
131	Annexin	0.6947956451881169	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-6.199999999999999	0.04	0.05319148936170213	0.0	0.04	0.04	1.0	0.05319148936170213	0.0	1.0	1.0	-6.199999999999999	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	1.0	0.04	0.0	0.05319148936170213	0.0	1.0	0.0	0.0	1.0
33	cultured cells	0.08575032145139112	-1.6999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6999999999999993	0.0	0.0	-5.428571428571429	0.04	0.05109489051094891	0.0	0.04291845493562232	0.04291845493562232	2.0	0.05109489051094891	0.0	1.0	0.0	-5.428571428571429	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04291845493562232	0.0	0.05109489051094891	0.0	0.0	0.0	0.0	0.0
330	poorly;Poorly	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
58	decade;Decade	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
62	MP	0.5980375689166192	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
285	likelihood;Likelihood	0.09241438672407117	-2.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04424778761061947	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04424778761061947	0.0	0.04	0.0	0.0	0.0	0.0	0.0
324	mutations in ADAMTS10 and FBN1 genes	0.27769503014796065	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
258	late 1- and 2-cell stages	0.17347656523806065	-3.3999999999999986	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.046296296296296294	0.046296296296296294	8.0	0.04587155963302752	0.0	1.0	0.0	-3.1999999999999993	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.046296296296296294	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
291	seven;Seven	0.09390847214108768	-2.8571428571428577	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.8571428571428577	0.0	0.0	0.0	0.04	0.04	0.0	0.04516129032258065	0.04516129032258065	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04516129032258065	0.0	0.04	0.0	0.0	0.0	0.0	0.0
86	increased HCN2 and HCN4 mRNA and protein levels	0.22065826311149114	0.0	0.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.0	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
247	Infrastructure;infrastructures	0.09830884294143961	-4.166666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.166666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.047999999999999994	0.047999999999999994	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047999999999999994	0.0	0.04	0.0	0.0	0.0	0.0	0.0
159	base	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
48	38%	0.5805854009086466	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	2.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
310	the clinic	0.031749923219710215	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.04878048780487805	0.04878048780487805	2.0	0.06060606060606061	0.5	1.0	0.0	-8.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04878048780487805	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
214	senescent human cells	0.23673926941830228	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
141	inheritance of nemaline myopathy	0.019539101492651895	-7.800000000000001	1.0	-4.25	0.04819277108433735	0.04819277108433735	0.25	0.25	1.0	-4.25	1.0	0.0	-7.800000000000001	0.0	0.0	-5.0	0.04819277108433735	0.05	0.0	0.05813953488372093	0.05813953488372093	4.0	0.05	1.0	1.0	0.0	-5.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.05813953488372093	0.0	0.05	1.0	0.0	0.0	0.0	0.0
200	Less Than;less frequently than	0.07435842344587819	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	methyl transfer	0.4046394796276098	-1.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-1.5	0.04	0.04	0.0	0.04	0.04181818181818182	2.0	0.042926829268292686	0.0	3.0	0.0	-4.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.045454545454545456	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
91	findings	0.11743168297592567	-2.571428571428573	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.0445859872611465	0.0445859872611465	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.0445859872611465	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	confirmed	0.11167270141226433	-2.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-4.833333333333333	0.04	0.04	0.0	0.04	0.045	1.0	0.0526086956521739	0.0	2.0	0.0	-9.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05	0.0	0.06521739130434782	0.0	0.0	0.0	0.0	0.0
125	29 independant patients	0.3665824570399672	-6.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.05263157894736842	0.05263157894736842	3.0	0.04597701149425287	0.0	1.0	0.0	-3.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05263157894736842	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
186	KCNQ1 (SQT2) and KCNJ2 (SQT3)	0.5934809433838768	0.0	0.0	0.0	0.04	0.04	0.1111111111111111	0.1111111111111111	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.0	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	9.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
190	physical exercise [in particular	0.08848691453375389	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	a same metabolic pathway	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
246	CYP2C19 G681A single polymorphism	0.45748032674196176	-3.75	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	-3.75	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.047058823529411764	0.047058823529411764	4.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.047058823529411764	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
276	Lesion;lesion	0.6113249175816913	-2.375	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.375	0.0	0.0	0.0	0.04	0.04	0.0	0.04419889502762431	0.04419889502762431	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04419889502762431	0.0	0.04	0.0	0.0	0.0	0.0	0.0
149	biopsies muscle;muscle biopsies	0.3730670842758065	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
269	Oligonucleotide;oligonucleotide	0.5368409442571505	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04	0.04	1.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
324	Show;showing	0.15377716778320888	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-5.0	0.04	0.05	0.0	0.04	0.04	1.0	0.05	0.0	1.0	1.0	-5.0	1.0	1.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04	1.0	0.05	0.0	1.0	0.0	1.0	1.0
149	acute exercise before and after sustained training (miR-146a	0.047659789854206026	-4.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.1	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	9.0	0.04	0.1111111111111111	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
309	an unstable	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
141	autosomal dominant and autosomal recessive inheritance	0.2713526136559406	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
4	A germline mutation of the MEN1 gene	0.08847539364637376	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.2857142857142857	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	neglected	0.6184846423664224	-7.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.25	0.0	0.0	-9.333333333333334	0.04	0.06382978723404256	0.0	0.056338028169014086	0.056338028169014086	1.0	0.06382978723404256	0.0	1.0	0.0	-9.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.056338028169014086	0.0	0.06382978723404256	0.0	0.0	0.0	0.0	0.0
215	Myc style	0.16904303159764897	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-10.6	0.04	0.06944444444444445	0.0	0.04	0.04	2.0	0.06944444444444445	0.0	1.0	0.0	-10.6	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.06944444444444445	0.0	0.0	0.0	0.0	0.0
196	a child with known genetic RTH	0.0747829060298053	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	disease biomarkers	0.16382667686925506	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	2.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.5	0.0	0.0
133	TGF	0.6345454337531042	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.04	0.04580152671755725	0.0	0.04	0.04	0.0	0.04580152671755725	0.0	1.0	0.0	-3.166666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.04	0.0	0.04580152671755725	0.0	0.0	0.0	0.0	0.0
339	Bmi	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
132	tetraiodothyroacetic acid in oligodendrocyte and astrocyte nuclei	0.34269535804449497	-8.6	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	1.0	-8.6	1.0	1.0	0.0	0.04	0.04	0.0	0.06097560975609757	0.06097560975609757	7.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.06097560975609757	0.0	0.04	0.0	1.0	0.0	0.0	1.0
235	The loss	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
276	most;Most	0.10839203622934002	-1.0625	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.125	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04185792349726776	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04371584699453552	0.0	0.04	0.0	0.0	0.0	0.0	0.0
94	Orphan Products Development on January 31, 2001	0.3596970327466207	-3.6000000000000014	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.04672897196261683	0.04672897196261683	8.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04672897196261683	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	a hard-X-	0.4663404074559137	-6.666666666666666	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.054545454545454536	0.054545454545454536	5.0	0.051724137931034475	0.0	2.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.054545454545454536	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
295	behavioral therapy;BEHAVIORAL THERAPY	0.24184804238823163	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.3333333333333333	1.0	0.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
252	primary intervention;primary percutaneous intervention	0.20519111788111277	-2.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
24	the results	0.058369021933077955	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
125	male infants;infants male	0.20019758332268955	-5.333333333333333	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.05084745762711865	0.05084745762711865	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.05084745762711865	0.0	0.04	0.0	0.0	0.0	0.0	0.0
71	metabolic pathway;Metabolic Pathway	0.541244591874057	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.04	0.04	2.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
16	single;Single	0.1743687499134462	-0.2727272727272725	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.09090909090909	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04045627376425855	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04182509505703422	0.0	0.04	0.0	0.0	0.0	0.0	0.0
26	symptoms	0.11515979827696353	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
213	induced LQTS	0.6843841765658943	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	2.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
239	17p11.2	0.6007341582488578	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04	0.04	1.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
203	15q11-q13 deletions	0.6000801800384936	-8.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-8.0	0.0	0.0	-10.6	0.04	0.06944444444444445	0.0	0.058823529411764705	0.058823529411764705	4.0	0.06944444444444445	0.25	2.0	0.0	-10.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.058823529411764705	0.0	0.06944444444444445	0.0	0.0	0.0	0.0	0.0
107	terms;Term	0.07620191937397346	-5.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.25	0.0	0.0	-7.142857142857142	0.04	0.056	0.0	0.05063291139240506	0.05063291139240506	1.0	0.056	0.0	1.0	0.0	-7.142857142857142	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05063291139240506	0.0	0.056	0.0	0.0	0.0	0.0	0.0
144	MEF- 2 by coimmunoprecipitation	0.17604026944421544	-3.8000000000000007	1.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.5	1.0	-3.8000000000000007	1.0	1.0	-7.0	0.04	0.05555555555555555	0.0	0.04716981132075472	0.04716981132075472	5.0	0.05555555555555555	0.2	1.0	1.0	-7.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04716981132075472	0.0	0.05555555555555555	0.0	1.0	0.0	0.0	1.0
44	the causative agent of human malaria	0.7260554041867953	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.41269841269841273	0.8333333333333334	0.0	0.8333333333333334	0.0	0.0	0.04	0.04	1.0	0.04	0.04	6.0	0.04	0.8333333333333334	6.0	0.8333333333333334	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.8333333333333334	1.0	0.0	0.27777777777777773	1.0	1.0	36.0	0.04	0.0	0.04	0.0	1.0	0.16666666666666666	0.0	1.0
86	KCND2 and KCND3 expression	0.26782860435995465	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
86	a reduced expression	0.1097739211481831	-4.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.048387096774193554	0.048387096774193554	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.048387096774193554	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	careful;Care	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
317	driven;Drive	0.09176746255704875	-2.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.043859649122807015	0.043859649122807015	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043859649122807015	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	heterochromatin protein 1 (HP1) family	0.3838893555952242	-7.5	0.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.0	1.0	-7.5	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.05714285714285714	0.05714285714285714	7.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.05714285714285714	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
90	studies	0.2461891299809374	-1.1600000000000001	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-1.6	0.04	0.04	0.0	0.04	0.04211772421708477	1.0	0.04376470588235294	0.0	5.0	0.0	-8.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04672897196261683	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
1	the 2092 nucleotide interval	0.1405487375957212	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	multiple aspects of development	0.0884415052403157	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	Oncotype DX gene assay	0.10044223298483577	0.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	Dnmt1 in the maintenance	0.01274199774005064	-2.1111111111111107	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.2	0.0	-2.1111111111111107	0.0	0.0	-2.7142857142857153	0.04	0.04487179487179487	0.0	0.043689320388349516	0.043689320388349516	4.0	0.04487179487179487	0.75	1.0	0.0	-2.7142857142857153	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.043689320388349516	0.0	0.04487179487179487	0.0	0.0	0.0	0.0	0.0
220	large;LARGE	0.07280419129335008	-1.875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.875	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.043243243243243246	0.043243243243243246	1.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043243243243243246	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
80	genetic defects in PRKAG2	0.17423540272965482	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
16	Buljan et al. 2010)	0.554218138531675	-1.3636363636363633	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.3636363636363633	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.04230769230769231	0.04230769230769231	5.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04230769230769231	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
80	investigating;investigate	0.10491032095851924	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.1999999999999993	0.04	0.04	0.0	0.04	0.04	1.0	0.04212389380530973	0.0	2.0	0.0	-2.3999999999999986	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04424778761061947	0.0	0.0	0.0	0.0	0.0
127	some reports	0.11569647565355703	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	on;On	0.0936378533113963	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.045454545454545456	0.0	0.04	0.04	1.0	0.04772727272727273	0.0	2.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
41	subgroup;Subset;subset	0.5951013416514221	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
80	signs	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
82	the human leukocyte antigen HLA-B*1502	0.23280933671400297	0.0	1.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.2	1.0	0.0	0.0	0.0	-3.299999999999999	0.04	0.04587155963302752	0.0	0.04	0.04	7.0	0.0460839279646619	0.5714285714285714	2.0	0.0	-3.3999999999999986	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	14.0	0.04	0.0	0.046296296296296294	0.0	0.0	0.0	0.0	0.0
44	genome;Genome	0.8906764692818335	-4.45	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-15.0	0.0	0.0	-2.7333333333333334	0.04	0.04	0.0	0.04	0.05526760563380282	1.0	0.04633606557377049	0.0	5.0	0.0	-9.0	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	2.0	1.0	5.0	0.1	1.0	0.0625	0.0	0.0	0.0	1.0	0.0
6	often;Often	0.07139385759650989	-3.555555555555557	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.555555555555557	0.0	0.0	-7.25	0.04	0.056338028169014086	0.0	0.04663212435233161	0.04663212435233161	1.0	0.056338028169014086	0.0	1.0	0.0	-7.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04663212435233161	0.0	0.056338028169014086	0.0	0.0	0.0	0.0	0.0
223	anti-amyloid-beta monoclonal antibody;anti antibody	0.10453423790088633	-4.272727272727273	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.6	1.0	-4.272727272727273	0.0	0.0	-3.8571428571428577	0.04	0.0472972972972973	0.0	0.048245614035087724	0.048245614035087724	5.0	0.0472972972972973	1.0	2.0	0.0	-3.8571428571428577	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	10.0	0.048245614035087724	0.0	0.0472972972972973	1.0	0.0	0.0	0.0	0.0
320	The challenge	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	p300	0.8597409992472947	-2.6000000000000014	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.044642857142857144	0.044642857142857144	1.0	0.04	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	0.044642857142857144	1.0	0.04	0.0	0.0	0.0	1.0	0.0
318	a selective inhibitor of the Bcr-Abl tyrosine kinase	0.4661898082275065	-1.1111111111111107	0.0	0.0	0.04	0.04	0.3	0.3	0.0	0.0	0.0	1.0	-2.2222222222222214	1.0	1.0	-5.5	0.04	0.05118110236220472	1.0	0.04	0.04195121951219512	10.0	0.051282250785845446	0.6	2.0	1.0	-5.538461538461538	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	20.0	0.04390243902439024	0.0	0.05138339920948617	0.0	1.0	0.1	0.0	1.0
227	These results	0.1133427152386913	-3.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.046296296296296294	0.046296296296296294	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.046296296296296294	0.0	0.04	0.0	0.0	0.0	0.0	0.0
142	germline mutations in the RET proto-oncogene	0.22485433377302969	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-2.8888888888888893	0.04	0.04522613065326633	0.0	0.04	0.04	6.0	0.04522613065326633	0.3333333333333333	1.0	0.0	-2.8888888888888893	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04522613065326633	0.0	0.0	0.0	0.0	0.0
74	Presented;presented	0.07412530292335719	-3.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	-12.375	0.04	0.07692307692307693	0.0	0.04580152671755725	0.04580152671755725	1.0	0.0792778649921507	0.0	2.0	0.0	-12.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04580152671755725	0.0	0.08163265306122448	0.0	0.0	0.0	0.0	0.0
331	Genetic;GENETIC	0.10003690870347429	-4.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.04918032786885245	0.04918032786885245	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04918032786885245	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	Illness;illness	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
278	The HNPCC syndrome (hereditary non polyposis colon cancer) or Lynch syndrome	0.21409819151130335	0.0	0.0	0.0	0.04	0.04	0.38461538461538464	0.38461538461538464	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	13.0	0.04	0.07692307692307693	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	13.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
323	protrusion;Protrusion	0.5248509775689362	-3.3999999999999986	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-8.75	0.04	0.06153846153846154	0.0	0.046296296296296294	0.046296296296296294	1.0	0.06153846153846154	0.0	1.0	0.0	-8.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046296296296296294	0.0	0.06153846153846154	0.0	0.0	0.0	0.0	0.0
331	human epidermal growth factor receptor 2;HER2;HER-2	0.9171145255010028	-4.933333333333333	0.0	0.0	0.04	0.04	0.0	0.2	0.0	0.0	0.0	1.0	-6.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.0505078369905956	3.0	0.04	0.0	5.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	3.0	1.0	15.0	0.054545454545454536	0.0	0.04	0.0	0.0	0.0	0.0	0.0
223	downstream effects on the degenerative process	0.1011336258071706	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	6.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
158	P253R)	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	targeted tyrosine kinase inhibition of BCR-ABL kinase	0.14593098814522826	-1.5555555555555571	1.0	0.0	0.04	0.04	0.2222222222222222	0.2222222222222222	0.0	0.0	0.125	1.0	-1.5555555555555571	1.0	1.0	-2.0769230769230766	0.04	0.0436241610738255	1.0	0.04265402843601896	0.04265402843601896	9.0	0.0436241610738255	0.5555555555555556	1.0	1.0	-2.0769230769230766	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	9.0	0.04265402843601896	0.0	0.0436241610738255	0.0	1.0	0.2222222222222222	0.0	1.0
55	electromechanical dissociation;ELECTRO-MECHANICAL DISSOCIATION	0.7031765872398005	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333333	0.04	0.053571428571428575	0.0	0.04	0.04	2.0	0.053571428571428575	0.0	3.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
262	less impaired lung function	0.08925313550474437	-3.75	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-8.333333333333334	0.04	0.06000000000000001	0.0	0.047058823529411764	0.047058823529411764	4.0	0.06000000000000001	0.0	1.0	0.0	-8.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.047058823529411764	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
322	the carboxyl-terminal SET domain	0.09337732095129522	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	1.0	0.04	0.04	6.0	0.05084745762711865	0.3333333333333333	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.05084745762711865	0.0	0.0	0.16666666666666666	0.0	0.0
84	antidepressant treatment with mirtazapine	0.10721518809013725	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.2857142857142857	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	The prediction of the complete structure	0.011589397881592705	-2.333333333333332	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.2	0.0	-2.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.044117647058823525	0.044117647058823525	6.0	0.04	0.6666666666666666	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.044117647058823525	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	iHop;IHOP	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
164	an accumulation of oxidative damage	0.18916618552744635	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
176	mammals;Mammals	0.6358741763154818	-2.125	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.125	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04371584699453552	0.04371584699453552	1.0	0.04716981132075472	0.0	2.0	0.0	-3.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04371584699453552	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
124	Stage II Colon Cancer;stage II colon cancer;Stage-II colon cancer	0.6896989512714151	-2.5	0.0	0.0	0.04	0.04	0.4	0.42500000000000004	0.0	0.0	0.0	1.0	-10.0	1.0	1.0	-2.0833333333333335	0.04	0.04	0.0	0.04	0.04666666666666667	4.75	0.045000000000000005	0.0	4.0	1.0	-8.333333333333334	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	3.0	1.0	19.0	0.06666666666666667	0.0	0.06000000000000001	0.0	1.0	0.0	0.0	1.0
97	ZNF9 gene	0.33464996046184486	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
199	constitutive centromere proteins Cenpa and Cenpb	0.3619572201959538	0.0	1.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.3333333333333333	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	1.0	0.0	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	6.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
101	used	0.15857420918336135	-2.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-3.6666666666666665	0.04	0.04	0.0	0.04	0.045270606234461656	1.0	0.05047619047619047	0.0	3.0	0.0	-11.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04819277108433735	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0
247	health care providers;Providers, Health Care	0.12471761596165726	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	immunoreactivity;I-;I;i	0.470150107910833	0.0	0.0	0.0	0.04	0.04	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.6666666666666666	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.3333333333333333	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	NCBI BLASTp v2	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
53	fasting;FASTING	0.6477660784074714	-4.333333333333333	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	-4.166666666666667	0.04	0.047619047619047616	0.0	0.047619047619047616	0.04839968774395004	1.0	0.04800307219662059	0.0	2.0	0.0	-4.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04918032786885245	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
68	PHP1A;PHP1A)	0.7786486872858972	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.3333333333333333	0.04	0.0	3.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
222	Compared;Comparison;compared	0.27375389010786383	-1.7936507936507944	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.7777777777777786	0.0	0.0	-0.3714285714285716	0.04	0.04	0.0	0.04	0.043176036090961246	1.0	0.04066326530612245	0.0	7.0	0.0	-2.6000000000000014	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	7.0	0.04712041884816754	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
50	Calculated;calculated	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
249	trimethylation of lysine 27	0.41628878427548965	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.04	0.04	4.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
85	Mild Cognitive Impairment;Cognitive impairment, mild	0.0954803892515137	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.428571428571429	0.04	0.05109489051094891	0.0	0.04	0.04	3.0	0.05109489051094891	0.0	1.0	0.0	-5.428571428571429	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.05109489051094891	0.0	0.0	0.0	0.0	0.0
24	the Atorvastatin and Amlodipine in Patients	0.09645534905595755	-3.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	in;In;Found;found;Present;present;presents	0.6612067576803097	-0.9338235294117647	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.875	0.0	0.0	-2.2941176470588234	0.04	0.04	0.0	0.04	0.04166206129570089	1.0	0.04469488075088523	0.0	17.0	0.0	-8.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	7.0	1.0	17.0	0.047337278106508875	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
79	the effect	0.08388307688645308	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04	0.04	2.0	0.04878048780487805	0.0	1.0	0.0	-4.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
145	CMS-exposed old rats	0.15898064341854684	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
262	Role;role	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
245	the last 10 years	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	discriminating beta-barrel	0.05567780282035587	0.0	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	4.0	0.045454545454545456	0.75	1.0	0.0	-3.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
66	Increased;increased	0.08398732547132219	-1.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	-6.375	0.04	0.045454545454545456	0.0	0.04	0.042222222222222223	1.0	0.05551415797317437	0.0	2.0	0.0	-9.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.044444444444444446	0.0	0.06557377049180328	0.0	0.0	0.0	0.0	0.0
102	the SCN	0.15335597305980264	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
198	the characteristic electrocardiographic pattern	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
144	2 factors	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
39	homocysteine;Homocysteine	0.8967714451475501	-2.9	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.0	1.0	1.0	-3.35	0.04	0.0449438202247191	0.0	0.0449438202247191	0.04525025536261491	1.0	0.0462128222075347	0.0	5.0	1.0	-3.75	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	5.0	0.045454545454545456	0.0	0.047058823529411764	0.0	1.0	0.0	0.0	1.0
198	the third mutation	0.041138739198591324	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.3333333333333333	0.0	0.0
44	mosquito contact with DDT	0.25632870559196996	-15.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-15.5	0.0	0.0	-9.0	0.04	0.0625	0.0	0.10526315789473684	0.10526315789473684	4.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.10526315789473684	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
317	a dose-dependent manner	0.07901796014805601	-3.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.045454545454545456	0.045454545454545456	5.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.045454545454545456	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
102	the CRY1 protein	0.2062574147506935	-2.25	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.27777777777777773	1.0	-3.75	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.0441711229946524	3.0	0.04	0.3333333333333333	3.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	9.0	0.047058823529411764	0.0	0.04	0.0	1.0	0.0	0.0	1.0
188	8 weeks	0.19020487190965546	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.4	0.04	0.056818181818181816	0.0	0.04	0.04	2.0	0.056818181818181816	0.0	1.0	0.0	-7.4	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.056818181818181816	0.0	0.0	0.0	0.0	0.0
251	Epithelial-Mesenchymal Transition;epithelial-mesenchymal transition	0.3693216483245728	-5.185185185185184	1.0	-11.5	0.04	0.05135802469135803	0.25	0.25	1.0	-3.8333333333333335	1.0	0.0	-11.11111111111111	0.0	0.0	-9.185185185185185	0.07407407407407407	0.053571428571428575	0.0	0.04390243902439024	0.05326829268292682	4.0	0.06477743271221532	1.0	6.0	0.0	-12.222222222222221	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	24.0	0.072	0.0	0.07826086956521738	1.0	0.0	0.0	0.0	0.0
26	non-autistic control subjects	0.14819872178129567	-3.428571428571427	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.16666666666666666	0.0	-3.428571428571427	0.0	0.0	0.0	0.04	0.04	0.0	0.04635761589403973	0.04635761589403973	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04635761589403973	0.0	0.04	0.0	0.0	0.0	0.0	0.0
78	International	0.11692328678351498	-8.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-8.25	0.0	0.0	-5.0	0.04	0.05	0.0	0.05970149253731343	0.05970149253731343	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.05970149253731343	0.0	0.05	0.0	0.0	0.0	0.0	0.0
95	The other three members	0.052997877725278884	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
30	FANCJ helicase	0.5961790868286974	-1.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.1999999999999993	0.0	0.0	-4.6	0.04	0.04901960784313726	0.0	0.04201680672268907	0.04201680672268907	2.0	0.04901960784313726	0.0	1.0	0.0	-4.6	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04201680672268907	0.0	0.04901960784313726	0.0	0.0	0.0	0.0	0.0
122	The CYP2C9 gene;the CYP2C9 gene	0.11774344343623802	-1.875	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-3.75	1.0	1.0	-4.25	0.04	0.04	1.0	0.04	0.043529411764705886	3.0	0.05030303030303031	0.3333333333333333	2.0	1.0	-8.5	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.047058823529411764	0.0	0.06060606060606061	0.0	1.0	0.3333333333333333	0.0	1.0
268	missense substitution	0.5984638572072157	-4.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-6.800000000000001	0.04	0.054945054945054944	0.0	0.047619047619047616	0.047619047619047616	2.0	0.054945054945054944	0.0	1.0	0.0	-6.800000000000001	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047619047619047616	0.0	0.054945054945054944	0.0	0.0	0.0	0.0	0.0
291	dermatology reference	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
222	Greater;greater	0.09623291921108221	-3.555555555555557	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.555555555555557	0.0	0.0	0.0	0.04	0.04	0.0	0.04663212435233161	0.04663212435233161	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04663212435233161	0.0	0.04	0.0	0.0	0.0	0.0	0.0
140	help;Help	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
345	structures;structure;Structure	0.8200054076084078	-0.3125	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.3999999999999986	0.0	0.0	-1.9	0.04	0.04	0.0	0.04	0.04052654906810787	1.0	0.044128721112416766	0.0	16.0	0.0	-7.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	16.0	0.0423728813559322	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
38	an unusual facial appearance	0.35725927123784706	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
48	the two methods	0.048894972933717654	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
114	condition;conditions	0.06869875470057024	-4.2857142857142865	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.2857142857142865	0.0	0.0	-8.8	0.04	0.0617283950617284	0.0	0.04827586206896552	0.04827586206896552	1.0	0.0617283950617284	0.0	1.0	0.0	-8.8	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04827586206896552	0.0	0.0617283950617284	0.0	0.0	0.0	0.0	0.0
128	apparatus	0.6394303944029475	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.09090909090909	0.04	0.04182509505703422	0.0	0.04	0.04	1.0	0.04182509505703422	0.0	1.0	0.0	-1.09090909090909	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04182509505703422	0.0	0.0	0.0	0.0	0.0
189	Growth hormone stimulation test;GH-stimulation test	0.5071935355371312	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
339	up-regulation;Up-Regulation;upregulation	0.5478998376029306	-1.583333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04	0.042900763358778626	1.0	0.04716981132075472	0.0	2.0	0.0	-3.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.04580152671755725	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
164	the lack	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	Early;early	0.07891352058763418	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.043478260869565216	0.043478260869565216	1.0	0.046511627906976744	0.0	1.0	0.0	-3.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
287	INHIBITION;inhibition;Inhibition	0.13300268597571213	-1.4666666666666661	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04257309941520468	1.0	0.04	1.0	3.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	3.0	0.043859649122807015	0.0	0.04	1.0	0.0	1.0	0.0	0.0
8	a 135-kDa	0.34056237636564574	-5.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.05	0.05	4.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.05	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
28	ultrasonography;Ultrasonography	0.6928830429075297	-4.333333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.048387096774193554	0.048387096774193554	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.048387096774193554	0.0	0.04	0.0	0.0	0.0	0.0	0.0
343	antiviral protein	0.19096525291259003	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
345	decoding	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
33	used	0.11165913706025134	-1.1000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.1000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.041841004184100423	0.041841004184100423	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.041841004184100423	0.0	0.04	0.0	0.0	0.0	0.0	0.0
188	Phenotypes;phenotypes	0.5703089411513254	-2.166666666666668	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	-3.6000000000000014	0.04	0.04672897196261683	0.0	0.043795620437956206	0.043795620437956206	1.0	0.04672897196261683	0.0	1.0	0.0	-3.6000000000000014	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043795620437956206	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
143	Distance	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	uk/TMB-Web/TMB-Hunt2	0.6362798323191099	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	0.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
341	2800 and 840 mutants per 10(6) clonable cells	0.2450470832146663	-1.375	0.0	0.0	0.04	0.04	0.3	0.3	0.0	0.0	0.0	0.0	-1.375	0.0	0.0	-3.375	0.04	0.046242774566473986	0.0	0.042328042328042326	0.042328042328042326	10.0	0.046242774566473986	0.0	1.0	0.0	-3.375	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.042328042328042326	0.0	0.046242774566473986	0.0	0.0	0.0	0.0	0.0
205	external stimuli	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
104	de novo comparative gene predictors	0.19319188879980403	-2.666666666666668	1.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.25	0.0	-2.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.04477611940298508	0.04477611940298508	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04477611940298508	0.0	0.04	0.0	0.0	0.0	0.0	0.0
322	Term;termed	0.07096173573097679	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.04	0.04	1.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
24	The Cluster Randomized Usual Care vs Caduet Investigation Assessing Long-term	0.07389040794853105	-2.6000000000000014	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.044642857142857144	0.044642857142857144	12.0	0.04	0.08333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	12.0	0.044642857142857144	0.0	0.04	0.0	0.0	0.0	0.0	0.0
271	thyroid hormone transporter	0.030861595812712212	-4.0	1.0	-10.6	0.06944444444444445	0.06944444444444445	0.3333333333333333	0.3333333333333333	1.0	-10.6	1.0	1.0	-4.0	0.0	0.0	-12.25	0.06944444444444445	0.0784313725490196	1.0	0.047619047619047616	0.047619047619047616	3.0	0.0784313725490196	1.0	1.0	0.0	-12.25	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.047619047619047616	0.0	0.0784313725490196	1.0	0.0	0.3333333333333333	0.0	0.0
61	MAPK15/ERK8	0.7867749175372906	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
94	imatinib for CML	0.2285543078161175	-3.1999999999999993	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04587155963302752	0.04587155963302752	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04587155963302752	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	Thyroid, NOS;thyroid	0.7786266455789895	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
8	microtubule;Micro-tubule	0.7964204528997417	-2.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.75	1.0	1.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0449438202247191	1.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	2.0	1.0	1.0	0.0449438202247191	1.0	0.04	0.0	1.0	0.0	1.0	1.0
175	female;FEMALE	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	connectivity;Connectivity	0.7172728766843438	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	a crossvalidation accuracy of >95%	0.15452966293551015	0.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.5	0.04	0.044444444444444446	0.0	0.04	0.04	7.0	0.044444444444444446	0.14285714285714285	1.0	0.0	-2.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.044444444444444446	0.0	0.0	0.0	0.0	0.0
101	malaria parasite;malarial parasite	0.474610769556111	-5.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-13.0	0.04	0.08333333333333333	0.0	0.05	0.05	2.0	0.08333333333333333	0.0	1.0	0.0	-13.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.05	0.0	0.08333333333333333	0.0	0.0	0.0	0.0	0.0
102	a circadian-	0.3872359506409451	-4.5	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	0.0	0.04	0.04	0.0	0.04878048780487805	0.04878048780487805	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04878048780487805	0.0	0.04	0.0	0.0	0.0	0.0	0.0
222	difference;*Difference	0.09006219608192875	-1.6666666666666679	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6666666666666679	0.0	0.0	0.0	0.04	0.04	0.0	0.04285714285714286	0.04285714285714286	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04285714285714286	0.0	0.04	0.0	0.0	0.0	0.0	0.0
68	extra copy of MSX2 gene	0.06822936828867342	-6.333333333333334	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	1.0	-6.333333333333334	1.0	1.0	-9.0	0.04	0.0625	1.0	0.053571428571428575	0.053571428571428575	5.0	0.0625	0.2	1.0	1.0	-9.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.053571428571428575	0.0	0.0625	0.0	1.0	0.2	0.0	1.0
127	few;Few	0.0921982914832669	-2.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.044117647058823525	0.044117647058823525	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.044117647058823525	0.0	0.04	0.0	0.0	0.0	0.0	0.0
140	Coupled;coupled	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
6	an opioid overdose	0.2697663064829675	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.5	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.6666666666666666	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
297	highest;Highest	0.1791087318291414	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
242	this finding	0.10636711654898957	-1.5555555555555571	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	0.0	0.04	0.04	0.0	0.04265402843601896	0.04265402843601896	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04265402843601896	0.0	0.04	0.0	0.0	0.0	0.0	0.0
151	the ORFeomes	0.21302111000380491	-2.428571428571427	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.428571428571427	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04430379746835443	0.04430379746835443	2.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04430379746835443	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
227	advanced disease;advanced cystic fibrosis lung disease	0.30125996004770406	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	5.0	0.05	0.0	2.0	0.0	-5.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	10.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
100	Cytotoxicity;cytotoxicity	0.6285966119323192	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.04	0.04477611940298508	0.0	0.04	0.04	1.0	0.04477611940298508	0.0	2.0	0.0	-2.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04477611940298508	0.0	0.0	0.0	0.0	0.0
231	FHC mutant MHC	0.5973023286942135	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.8571428571428577	0.04	0.043209876543209874	0.0	0.04	0.04	3.0	0.043209876543209874	0.0	1.0	0.0	-1.8571428571428577	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.043209876543209874	0.0	0.0	0.0	0.0	0.0
104	ENCODE regions	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	combined treatment	0.10197114810195274	-4.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04938271604938271	0.04938271604938271	2.0	0.04716981132075472	0.0	1.0	0.0	-3.8000000000000007	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04938271604938271	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
225	more complex neuropeptide circuitry for WS features	0.21993439663386755	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
135	some contaminants	0.010268613991812399	-4.647058823529411	1.0	-8.454545454545455	0.06043956043956043	0.06043956043956043	0.5	0.5	1.0	-8.454545454545455	1.0	0.0	-4.647058823529411	0.0	0.0	-4.0	0.06043956043956043	0.047619047619047616	0.0	0.049132947976878616	0.049132947976878616	2.0	0.047619047619047616	1.0	1.0	0.0	-4.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.049132947976878616	0.0	0.047619047619047616	1.0	0.0	0.0	0.0	0.0
256	The Muenke syndrome (MS)	0.07551023476479249	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.5	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
287	single-agent efficacy and safety of the investigational AAK inhibitor MLN8237 (alisertib)	0.09113239560405514	0.0	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.13333333333333333	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	15.0	0.04	0.13333333333333333	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	15.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
68	3 (FGFR1	0.6530355232689208	-4.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
223	Third Party;third-party	0.056971805692376865	-2.3636363636363633	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.3636363636363633	0.0	0.0	-4.142857142857142	0.04	0.04794520547945205	0.0	0.04417670682730924	0.04417670682730924	3.0	0.04794520547945205	0.3333333333333333	1.0	0.0	-4.142857142857142	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04417670682730924	0.0	0.04794520547945205	0.0	0.0	0.0	0.0	0.0
318	This fusion protein	0.17350520080321727	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-5.923076923076923	0.04	0.05241935483870968	0.0	0.04	0.04	3.0	0.05241935483870968	0.0	1.0	0.0	-5.923076923076923	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.05241935483870968	0.0	0.0	0.0	0.0	0.0
13	the most obvious benefit	0.0884415052403157	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	domain (DBD)	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
223	an anti-Aβ monoclonal antibody (cohort 2	0.3220477355135868	-1.09090909090909	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.16666666666666666	1.0	-1.09090909090909	0.0	0.0	-2.1428571428571423	0.04	0.04375	0.0	0.04182509505703422	0.04182509505703422	7.0	0.04375	0.2857142857142857	1.0	0.0	-2.1428571428571423	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04182509505703422	0.0	0.04375	0.0	0.0	0.0	0.0	0.0
93	children, adults	0.038151651419105405	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	six transmembrane segments in its N-terminal half	0.05845033167746186	0.0	1.0	0.0	0.04	0.04	0.5555555555555556	0.5555555555555556	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.1111111111111111	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
335	level of JIL-1;Level 1	0.1187176919696614	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	a domain	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
144	MEF2A	0.876110163107776	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	4.0	1.0	0.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
95	Structure;structure	0.09520971290739387	-3.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
338	the clinical meaning	0.0037888634819865027	-10.0	1.0	-7.25	0.056338028169014086	0.056338028169014086	1.0	1.0	1.0	-7.25	1.0	0.0	-10.0	0.0	0.0	-6.5	0.056338028169014086	0.05405405405405406	1.0	0.06666666666666667	0.06666666666666667	3.0	0.05405405405405406	1.0	1.0	0.0	-6.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.06666666666666667	0.0	0.05405405405405406	1.0	0.0	0.3333333333333333	0.0	0.0
315	receptor;Receptor	0.7486846811788826	-4.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-8.0	0.0	0.0	-4.0	0.04	0.04	0.0	0.04	0.04941176470588235	1.0	0.04941176470588235	0.0	2.0	0.0	-8.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	2.0	0.058823529411764705	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
227	SPINAL CORD;spinal cord	0.37822509235023555	-5.599999999999999	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-5.6	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.051546391752577324	0.051546391752577324	2.0	0.048387096774193554	0.0	3.0	0.0	-4.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.051546391752577324	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
131	a three-tier orthogonal technology approach	0.08772568627793331	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.199999999999999	0.04	0.05319148936170213	0.0	0.04	0.04	7.0	0.05319148936170213	0.14285714285714285	1.0	0.0	-6.199999999999999	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.05319148936170213	0.0	0.0	0.0	0.0	0.0
277	Detected;detected	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
313	traits	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	each genome	0.3390675980923809	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
254	the complex intercellular network of RA	0.09373520192468647	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.2857142857142857	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
343	PRY	0.7671624749706115	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04	0.04	1.0	0.053571428571428575	0.0	4.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
80	high frequency of this mutation	0.08417807339267468	-3.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.045454545454545456	0.045454545454545456	5.0	0.04716981132075472	0.0	1.0	0.0	-3.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.045454545454545456	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
330	findings	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
157	like lobucavir and cidofovir	0.08849098769887236	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
48	codon 12 of the K-ras gene	0.281427793549626	0.0	0.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.7142857142857153	0.04	0.04294478527607362	0.0	0.04	0.04	8.0	0.04294478527607362	0.5	2.0	0.0	-1.7142857142857153	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	16.0	0.04	0.0	0.04294478527607362	0.0	0.0	0.0	0.0	0.0
68	Residue;residue	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
138	a total of 10,096 phosphorylation sites	0.11692727709300345	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.375	0.04	0.042328042328042326	0.0	0.04	0.04	6.0	0.042328042328042326	0.0	1.0	0.0	-1.375	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.042328042328042326	0.0	0.0	0.0	0.0	0.0
16	Pairs;pair;pairs;Pair	0.26984468644531756	-0.125	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.0	0.0	0.0	-1.3125	0.04	0.04	0.0	0.04	0.04020833333333333	1.0	0.042666345999679334	0.0	8.0	0.0	-5.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	8.0	0.041666666666666664	0.0	0.05194805194805195	0.0	0.0	0.0	0.0	0.0
317	mouse;Mouse, NOS	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
114	AtDNMT2	0.5652590635855946	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.04	0.04	1.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
255	mosaicism;MOSAICISM	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
67	EAE) animal model	0.07578179873557331	-3.333333333333332	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-9.5	0.04	0.06451612903225806	1.0	0.04615384615384615	0.04615384615384615	4.0	0.06451612903225806	0.5	1.0	0.0	-9.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04615384615384615	0.0	0.06451612903225806	0.0	0.0	0.25	0.0	0.0
199	the histone H3	0.17621730438704442	-4.833333333333334	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-4.833333333333334	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04958677685950414	0.04958677685950414	3.0	0.04918032786885245	0.6666666666666666	1.0	0.0	-4.666666666666666	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04958677685950414	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
255	FSHD A1	0.36975290730873206	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.375	0.04	0.042328042328042326	0.0	0.04	0.04	2.0	0.042328042328042326	0.5	1.0	0.0	-1.375	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.042328042328042326	0.0	0.0	0.0	0.0	0.0
41	histone methyltransferase	0.9200664907485209	-3.4	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-8.5	0.0	0.0	-3.1333333333333333	0.04	0.04	0.0	0.04	0.04824242424242424	2.0	0.04638641686182669	0.0	5.0	0.0	-6.333333333333334	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.06060606060606061	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
1	mutated;Mutated	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	Willis) to chromosome 17q25	0.12733918156896584	-2.0	1.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.14285714285714285	0.0	-2.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.043478260869565216	0.043478260869565216	5.0	0.045454545454545456	0.4	1.0	0.0	-3.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.043478260869565216	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
197	340	0.6017169099142065	-7.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.75	0.0	0.0	-11.333333333333334	0.04	0.07317073170731708	0.0	0.057971014492753624	0.057971014492753624	1.0	0.07317073170731708	0.0	1.0	0.0	-11.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.057971014492753624	0.0	0.07317073170731708	0.0	0.0	0.0	0.0	0.0
14	a Hidden Markov Model method;A Hidden Markov Model method	0.09789438980869106	-1.0625	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-2.125	0.0	0.0	-2.25	0.04	0.04	1.0	0.04	0.04185792349726776	5.0	0.04439024390243902	0.2	2.0	0.0	-4.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	10.0	0.04371584699453552	0.0	0.04878048780487805	0.0	0.0	0.2	0.0	0.0
326	63%	0.6376335904333617	-7.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.75	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.057971014492753624	0.057971014492753624	2.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.057971014492753624	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
14	stable;STABLE	0.17192052664087962	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.166666666666667	0.04	0.04	0.0	0.04	0.04	1.0	0.04206001622060016	0.0	4.0	0.0	-2.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.044444444444444446	0.0	0.0	0.0	0.0	0.0
297	cardiac surgery;Cardiac surgery	0.3730670842758065	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
339	the rate of proliferation	0.11751721971864434	-2.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
145	MILD;mild	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
242	negative predictive value	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	the most serious form of malaria	0.018526421627128455	-9.25	1.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.3333333333333333	1.0	-9.25	1.0	1.0	-6.0	0.04	0.05263157894736842	0.0	0.06349206349206349	0.06349206349206349	6.0	0.05263157894736842	0.5	1.0	1.0	-6.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.06349206349206349	0.0	0.05263157894736842	0.0	1.0	0.0	0.0	1.0
86	effects;Effects	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
145	0.002)	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
185	presentation;Presentation	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	having 5 or more	0.11701663201111684	-1.875	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-1.875	0.0	0.0	0.0	0.04	0.04	0.0	0.043243243243243246	0.043243243243243246	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.043243243243243246	0.0	0.04	0.0	0.0	0.0	0.0	0.0
134	epithelium	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	module;Module;modules	0.7240400356516099	-1.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.8999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04205632623708867	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.04329004329004329	0.0	0.04	0.0	0.0	0.0	0.0	0.0
319	pharmacophore model_017	0.21193385212824753	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
227	insufficient levels of brain iron	0.0651023337127791	-3.1999999999999993	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04587155963302752	0.04587155963302752	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04587155963302752	0.0	0.04	0.0	0.0	0.0	0.0	0.0
25	a modified version	0.15609162684833364	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	Mechanisms;mechanisms	0.07195524223024728	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
72	BIND data model	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	amino acid composition	0.44601736316715096	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-1.6666666666666667	0.04	0.04	0.0	0.04	0.04	3.0	0.043333333333333335	0.0	3.0	0.0	-5.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
212	autosomal-recessive Jervell and Lange-Nielsen syndrome	0.05527021039251538	0.0	1.0	0.0	0.04	0.04	0.2222222222222222	0.2222222222222222	0.0	0.0	0.3333333333333333	1.0	0.0	1.0	1.0	-1.7142857142857153	0.04	0.04294478527607362	0.0	0.04	0.04	9.0	0.04294478527607362	0.7777777777777778	1.0	1.0	-1.7142857142857153	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04	0.0	0.04294478527607362	0.0	1.0	0.0	0.0	1.0
3	donor;DONOR	0.02374198244298742	-6.238095238095238	1.0	-16.714285714285715	0.04	0.051527093596059115	1.0	1.0	1.0	-2.3877551020408165	1.0	0.0	-18.333333333333332	0.0	0.0	-8.224489795918368	0.12068965517241381	0.04516129032258065	1.0	0.04	0.06333366565443706	1.0	0.06444171839262194	1.0	7.0	0.0	-16.142857142857142	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	7.0	0.15	0.0	0.11290322580645161	1.0	0.0	1.0	0.0	0.0
138	SUBSTRATE;substrate	0.5632388254797537	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.375	0.04	0.04419889502762431	0.0	0.04	0.04	1.0	0.04419889502762431	0.0	1.0	0.0	-2.375	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04419889502762431	0.0	0.0	0.0	0.0	0.0
227	PERIPHERAL NEUROPATHY;peripheral neuropathy	0.8314281821237175	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
227	Generalized seizures;generalized seizure;GENERALIZED SEIZURE;generalized seizures	0.8716381355634388	-3.3999999999999986	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.3999999999999986	0.0	0.0	-3.4	0.04	0.04	0.0	0.046296296296296294	0.046296296296296294	2.0	0.04703448275862069	0.0	5.0	0.0	-5.666666666666666	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	4.0	1.0	10.0	0.046296296296296294	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
330	November	0.6084281165437194	-3.444444444444443	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.444444444444443	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.04639175257731958	0.04639175257731958	1.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04639175257731958	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
176	Report;report	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
271	known;Known	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
281	an autosomal recessive form of early-onset parkinsonism;an autosomal recessive form of early-onset Parkinsonism	0.2594739979114363	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.11805555555555555	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.4444444444444444	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	18.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
204	a mutation in FGFR3	0.1405487375957212	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
259	the other hand	0.051141386904976056	-1.2222222222222214	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.2222222222222214	0.0	0.0	0.0	0.04	0.04	0.0	0.04205607476635514	0.04205607476635514	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04205607476635514	0.0	0.04	0.0	0.0	0.0	0.0	0.0
334	RSC	0.8586977467531047	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	academic use at http://staff.science.uva.nl/~bui/PPIs.zip	0.09518236517780318	-2.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.1	1.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	*Number;number	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
139	a new possibility for NEP delivery	0.0801520288254872	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	6.0	0.047619047619047616	0.0	1.0	1.0	-4.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.047619047619047616	0.0	1.0	0.0	0.0	1.0
96	inhibitor;Inhibitor	0.5937802082403724	-3.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.046511627906976744	0.046511627906976744	1.0	0.044642857142857144	0.0	1.0	0.0	-2.6000000000000014	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046511627906976744	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
58	stable;STABLE	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
330	immunosuppressive	0.7956947304166495	-1.6666666666666679	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-1.6666666666666679	0.0	0.0	0.0	0.04	0.04	0.0	0.04285714285714286	0.04285714285714286	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	1.0	0.04285714285714286	0.0	0.04	0.0	0.0	0.0	0.0	0.0
2	Levels;levels	0.11947908584174295	-3.700000000000001	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-1.0	0.04	0.04	0.0	0.04672897196261683	0.046949391641685774	1.0	0.04173913043478261	0.0	2.0	0.0	-2.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04716981132075472	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
276	de novo translocation	0.6171953679194666	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	for;For	0.006569821387325964	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	1.0	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	1.0	0.0	0.0	0.0	0.0
111	shown;Show	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
20	intermediate;INTERMEDIATE	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	patients of non-White race	0.134539239962029	-6.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05263157894736842	0.05263157894736842	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.05263157894736842	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	the known families of deadenylases	0.0021783404046034354	0.0	1.0	-9.5	0.06451612903225806	0.06451612903225806	0.8	0.8	1.0	-9.5	1.0	0.0	0.0	0.0	0.0	-10.0	0.06451612903225806	0.06666666666666667	1.0	0.04	0.04	5.0	0.06666666666666667	1.0	1.0	0.0	-10.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.06666666666666667	1.0	0.0	0.2	0.0	0.0
207	risk populations);risk population;risk populations	0.12045706100153908	-3.75	0.0	0.0	0.04	0.04	0.6666666666666666	0.8333333333333333	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-8.333333333333334	0.04	0.06000000000000001	0.0	0.047058823529411764	0.047058823529411764	2.5	0.06000000000000001	0.0	2.0	0.0	-8.333333333333334	1.0	0.0	0.5	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	5.0	0.047058823529411764	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
316	deletion;Deletion	0.5884484471950103	-4.090909090909092	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.090909090909092	0.0	0.0	-3.6000000000000014	0.04	0.04672897196261683	0.0	0.04782608695652175	0.04782608695652175	1.0	0.04672897196261683	0.0	1.0	0.0	-3.6000000000000014	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04782608695652175	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
96	disease period	0.041831373405131954	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.5	0.0	0.0
96	a synergistic growth inhibitory and pro-apoptotic activity in different human cancer cells	0.06540777408230372	-4.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.047619047619047616	0.047619047619047616	12.0	0.04587155963302752	0.0	1.0	0.0	-3.1999999999999993	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	12.0	0.047619047619047616	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
332	PP2	0.7123617662367117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
58	emulsification;Emulsification	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
86	potassium	0.6987017868929465	-5.666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.051724137931034475	0.051724137931034475	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.051724137931034475	0.0	0.04	0.0	0.0	0.0	0.0	0.0
83	loss-of-function CYP2C19 genotypes	0.2661990776595722	-3.5	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	1.0	-3.5	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.046511627906976744	0.046511627906976744	7.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.046511627906976744	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
334	Cellular;cells;cellular;cell;Cell;Cells	0.30322609929616484	-1.4722222222222223	0.0	0.0	0.04	0.04	0.0	0.75	0.0	0.0	0.0	0.0	-2.1111111111111107	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04255694548170276	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.75	0.0	1.0	0.0	1.0	0.0	0.0	6.0	1.0	4.0	0.043689320388349516	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	10.93 +/- 3;10^3	0.536099372950064	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
217	cleavage	0.7123617662367117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
163	placebo on mean performance	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
175	Some mutation carriers	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	most;Most;Much;much	0.0684553292224829	-1.6499999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8999999999999986	0.0	0.0	-1.0999999999999996	0.04	0.04	0.0	0.0423728813559322	0.04283146232298775	1.0	0.04192982456140351	0.0	2.0	0.0	-2.1999999999999993	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.04329004329004329	0.0	0.043859649122807015	0.0	0.0	0.0	0.0	0.0
14	beta-barrels;beta-barrel;beta barrel;Beta barrel	0.9999999998328901	-0.8581730769230769	1.0	-11.0	0.04	0.04060439560439561	0.3333333333333333	0.37179487179487175	1.0	-0.21153846153846154	1.0	0.0	-13.5	0.0	0.0	-4.916666666666666	0.07142857142857142	0.04	0.0	0.04	0.041945418328463595	2.769230769230769	0.0508508004924986	0.9807692307692307	52.0	0.0	-12.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	144.0	0.08695652173913043	0.0	0.07692307692307693	1.0	0.0	0.0	0.0	0.0
88	transcription;Transcription	0.6439850776463425	-5.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-5.5	0.04	0.05084745762711865	0.0	0.05	0.05	1.0	0.05128579777907656	0.0	2.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.05	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
255	germline mosaicism in 6	0.5567307435036549	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.375	0.04	0.042328042328042326	0.0	0.04	0.04	4.0	0.042328042328042326	0.0	2.0	0.0	-1.375	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.042328042328042326	0.0	0.0	0.0	0.0	0.0
160	pain;PAIN	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	2 (mCry1	0.66174857174979	-5.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05	0.05	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05	0.0	0.04	0.0	0.0	0.0	0.0	0.0
343	the SPRY domain;The SPRY domain	0.007474406362720043	-6.0	1.0	-10.333333333333334	0.04	0.054090909090909085	0.6666666666666666	0.6666666666666666	1.0	-5.166666666666667	1.0	0.0	-12.0	0.0	0.0	-6.5	0.06818181818181819	0.04	0.0	0.04	0.05846153846153847	3.0	0.061666666666666654	1.0	2.0	0.0	-13.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.07692307692307693	0.0	0.08333333333333333	1.0	0.0	0.0	0.0	0.0
322	G9a;G9A	0.8102538359307317	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04	1.0	0.04	0.0	0.0	0.0	1.0	0.0
186	Related;related	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	normal mice	0.17135388543661767	-9.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-9.0	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.0625	0.0625	2.0	0.046875	0.0	2.0	0.0	-3.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.0625	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
318	hiladelphia chromosome translocation	0.42587509245152366	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.53846153846154	0.04	0.042622950819672135	0.0	0.04	0.04	3.0	0.042622950819672135	0.3333333333333333	1.0	0.0	-1.53846153846154	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.042622950819672135	0.0	0.0	0.0	0.0	0.0
261	an inherited arrhythmogenic disease	0.1933215271520772	-2.428571428571427	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-2.428571428571427	1.0	1.0	-6.0	0.04	0.05263157894736842	1.0	0.04430379746835443	0.04430379746835443	4.0	0.05263157894736842	0.25	1.0	1.0	-6.0	1.0	0.5	0.0	1.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	4.0	0.04430379746835443	0.0	0.05263157894736842	0.0	1.0	0.25	0.0	1.0
89	opioid;Opioid;Opioids;opioids	0.9064947343111633	-4.800000000000001	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-6.199999999999999	1.0	1.0	-4.888888888888889	0.04	0.04	0.0	0.044642857142857144	0.04972569608926896	1.0	0.05107583774250441	0.0	9.0	1.0	-7.5	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	4.0	1.0	9.0	0.05319148936170213	0.0	0.05714285714285714	0.0	1.0	0.0	0.0	1.0
145	glycogen synthase kinase-3;Glycogen Synthase Kinase 3;GSK-3	0.9251631969411005	-0.38095238095238076	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.2857142857142847	0.0	0.0	-0.625	0.04	0.04	0.0	0.04	0.04067085953878407	2.0	0.041176470588235294	0.0	6.0	0.0	-3.75	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	3.0	1.0	12.0	0.0440251572327044	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
276	biochemical tests	0.45012714853077657	-1.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	0.0	0.04	0.04	0.0	0.0425531914893617	0.0425531914893617	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.0425531914893617	0.0	0.04	0.0	0.0	0.0	0.0	0.0
246	ischemic;Ischaemic	0.5997376272171248	-4.375	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04819277108433735	0.0484866294446077	1.0	0.0625	0.0	2.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04878048780487805	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
281	's disease	0.016646664699898485	-6.7	1.0	-14.666666666666668	0.04	0.06838709677419355	0.5	0.5	1.0	-7.333333333333334	1.0	0.0	-11.6	0.0	0.0	-12.166666666666668	0.09677419354838711	0.06976744186046512	0.0	0.04310344827586207	0.05886515697375193	2.0	0.07900136798905609	1.0	2.0	0.0	-13.666666666666668	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.07462686567164178	0.0	0.08823529411764706	1.0	0.0	0.0	0.0	0.0
124	a panel	0.0809600812831366	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-9.666666666666666	0.04	0.06521739130434782	0.0	0.05	0.05	2.0	0.06521739130434782	0.0	1.0	0.0	-9.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05	0.0	0.06521739130434782	0.0	0.0	0.0	0.0	0.0
293	Recommended;recommended	0.06803851930060137	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04819277108433735	0.04819277108433735	1.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04819277108433735	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
131	subtype;Subtype	0.5651716832235251	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.04	0.043859649122807015	0.0	0.04	0.04	1.0	0.043859649122807015	0.0	1.0	0.0	-2.1999999999999993	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.043859649122807015	0.0	0.0	0.0	0.0	0.0
320	the treatment of human tumours	0.057961055114664525	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
160	vitamin D receptor;Receptor, Vitamin D	0.20330048417093763	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-5.428571428571429	0.04	0.05109489051094891	0.0	0.04	0.04	3.0	0.05109489051094891	0.3333333333333333	1.0	1.0	-5.428571428571429	1.0	0.5	0.0	1.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	3.0	0.04	0.0	0.05109489051094891	0.0	1.0	0.0	0.0	1.0
239	disease;Disease	0.025927438666277218	-1.1111111111111107	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-3.333333333333332	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04205128205128205	1.0	0.04	1.0	3.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	2.0	1.0	3.0	0.04615384615384615	1.0	0.04	1.0	1.0	0.0	1.0	1.0
30	breast cancer;-- Breast Cancer	0.062254593174442326	-1.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8000000000000007	0.0	0.0	-7.4	0.04	0.056818181818181816	0.0	0.04310344827586207	0.04310344827586207	2.0	0.056818181818181816	0.0	1.0	0.0	-7.4	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04310344827586207	0.0	0.056818181818181816	0.0	0.0	0.0	0.0	0.0
42	Antigen, Prostate-Specific;prostate-specific antigen	0.49101698692741047	-3.8000000000000003	1.0	-6.800000000000001	0.04	0.04498168498168498	0.25	0.25	1.0	-2.266666666666667	1.0	1.0	-11.4	1.0	1.0	-3.6666666666666665	0.054945054945054944	0.04	0.0	0.04	0.051176470588235295	4.0	0.04800369817224948	1.0	6.0	1.0	-7.800000000000001	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	24.0	0.07352941176470588	0.0	0.05813953488372093	1.0	1.0	0.0	0.0	1.0
57	to;TO	0.004094169532668087	-9.0	1.0	-17.8	0.04	0.08944444444444445	1.0	1.0	1.0	-8.9	1.0	0.0	-18.0	0.0	0.0	-13.6	0.1388888888888889	0.06756756756756756	0.0	0.04	0.09142857142857143	1.0	0.09628378378378377	1.0	2.0	0.0	-17.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.14285714285714285	0.0	0.125	1.0	0.0	0.0	0.0	0.0
14	The similarities and differences between these two potentials	0.0389586752807596	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	8.0	0.05263157894736842	0.125	1.0	0.0	-6.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
327	Part;part	0.07367900731239119	-2.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.75	0.0	0.0	-5.800000000000001	0.04	0.052083333333333336	0.0	0.0449438202247191	0.0449438202247191	1.0	0.052083333333333336	0.0	1.0	0.0	-5.800000000000001	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0449438202247191	0.0	0.052083333333333336	0.0	0.0	0.0	0.0	0.0
166	hypertensive	0.7173578767979144	-8.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-8.0	0.0	0.0	0.0	0.04	0.04	0.0	0.058823529411764705	0.058823529411764705	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.058823529411764705	0.0	0.04	0.0	0.0	0.0	0.0	0.0
235	narcolepsy-cataplexy	0.5469740901637832	-1.3333333333333321	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.3333333333333321	0.0	0.0	-4.6	0.04	0.04901960784313726	0.0	0.04225352112676056	0.04225352112676056	3.0	0.04901960784313726	0.3333333333333333	2.0	0.0	-4.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04225352112676056	0.0	0.04901960784313726	0.0	0.0	0.0	0.0	0.0
318	Oncoprotein;oncoprotein	0.6752411472380111	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-8.076923076923077	0.04	0.05909090909090909	0.0	0.04	0.04	1.0	0.05909090909090909	0.0	2.0	0.0	-8.076923076923077	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	2.0	0.04	0.0	0.05909090909090909	0.0	0.0	0.0	0.0	0.0
33	Haemolytic disease of the newborn	0.39108139630114075	-1.6999999999999993	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-1.6999999999999993	0.0	0.0	-2.428571428571427	0.04	0.04430379746835443	0.0	0.04291845493562232	0.04291845493562232	5.0	0.044303797468354424	0.20000000000000004	3.0	0.0	-2.428571428571427	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	15.0	0.04291845493562232	0.0	0.04430379746835443	0.0	0.0	0.0	0.0	0.0
100	their inhibition	0.2765738641103709	-4.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
270	PIAS3	0.787700577218903	-6.4	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-6.4	0.0	0.0	-11.5	0.04	0.07407407407407407	0.0	0.05376344086021505	0.05376344086021505	1.0	0.07407407407407407	0.0	2.0	0.0	-11.5	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	2.0	0.05376344086021505	0.0	0.07407407407407407	0.0	0.0	0.0	0.0	0.0
245	TNNC1 mutation	0.46550922673215583	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	2.0	0.04	0.5	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	1.0	0.5	0.0	1.0
42	Human kallikrein-related peptidase 3 (hK3)	0.3708237319359728	-3.8000000000000007	0.0	0.0	0.04	0.04	0.2222222222222222	0.2222222222222222	0.0	0.0	0.0	1.0	-3.8000000000000007	1.0	1.0	-8.8	0.04	0.0617283950617284	0.0	0.04716981132075472	0.04716981132075472	9.0	0.0617283950617284	0.1111111111111111	1.0	1.0	-8.8	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	9.0	0.04716981132075472	0.0	0.0617283950617284	0.0	1.0	0.0	0.0	1.0
225	circulating TSH	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	cytosine-C5 methyltransferase;Cytosine-C5) methyltransferase	0.7008034290668756	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.38888888888888884	1.0	0.0	0.0	0.0	-5.277777777777778	0.04	0.043795620437956206	0.0	0.04	0.04	4.666666666666667	0.051373169025877435	0.35000000000000003	3.0	0.0	-7.666666666666666	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.5555555555555555	2.0	1.0	14.0	0.04	0.0	0.05769230769230768	0.0	0.0	0.0	0.0	0.0
330	10%;10	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	edu;EDU	0.7908073788487419	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	2.0	1.0	0.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
150	selective removal of damaged cytosolic proteins (	0.16957824804322913	-2.2857142857142847	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	-2.2857142857142847	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.0440251572327044	0.0440251572327044	7.0	0.043478260869565216	0.14285714285714285	1.0	0.0	-2.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.0440251572327044	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
150	a chaperone complex	0.05968611226739091	-7.857142857142858	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.5	1.0	-7.857142857142858	0.0	0.0	-4.833333333333334	0.04	0.04958677685950414	0.0	0.058333333333333334	0.058333333333333334	3.0	0.04958677685950414	0.3333333333333333	1.0	0.0	-4.833333333333334	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.058333333333333334	0.0	0.04958677685950414	0.0	0.0	0.0	0.0	0.0
47	the standard set (Burset and Guigo, Genomics, 34, 353-367, 1996)	0.1978842973258825	-2.333333333333332	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.044117647058823525	0.044117647058823525	16.0	0.04	0.0625	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	16.0	0.044117647058823525	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	5-aza-CdR;5-Aza-CdR	0.7575048784185421	-1.1666666666666667	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.5	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04217054263565891	5.0	0.04	0.4000000000000001	3.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	15.0	0.046511627906976744	0.0	0.04	0.0	1.0	0.0	0.0	1.0
68	abnormal closure of sutures	0.35518821381225546	-6.666666666666666	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.054545454545454536	0.054545454545454536	4.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.054545454545454536	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
44	the control	0.05610642891502621	-7.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.75	0.0	0.0	-6.666666666666667	0.04	0.05	0.0	0.0547945205479452	0.05638276752034942	2.0	0.05500000000000001	0.5	2.0	0.0	-8.333333333333334	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.057971014492753624	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
40	with;With	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
338	similar;Similar	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	this family	0.09446366255314652	-2.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.044444444444444446	0.044444444444444446	2.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.044444444444444446	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
124	changes	0.09027701568348244	-4.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	-8.333333333333334	0.04	0.06000000000000001	0.0	0.04918032786885245	0.04918032786885245	1.0	0.06000000000000001	0.0	1.0	0.0	-8.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04918032786885245	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
46	other cancers	0.024883635737863112	0.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.6666666666666666	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.3333333333333333	1.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
155	SYNCOPE;syncope	0.7213222551439366	-1.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-2.0	0.04	0.04	0.0	0.04	0.0431578947368421	1.0	0.04380952380952381	0.0	4.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.05263157894736842	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
254	a role	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
276	T(3)) plasma levels	0.6596246050767584	-1.5	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	1.0	-1.5	0.0	0.0	0.0	0.04	0.04	0.0	0.0425531914893617	0.0425531914893617	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.0425531914893617	0.0	0.04	0.0	0.0	0.0	0.0	0.0
128	Protein Analysis;analysis of protein	0.03241211195866082	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.7272727272727266	0.04	0.04700854700854701	0.0	0.04	0.04	3.0	0.04700854700854701	0.3333333333333333	1.0	0.0	-3.7272727272727266	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04700854700854701	0.0	0.0	0.0	0.0	0.0
137	50% (9 of 18)	0.5286420129070891	0.0	0.0	0.0	0.04	0.04	0.14285714285714285	0.14285714285714285	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.8999999999999986	0.04	0.04524886877828054	0.0	0.04	0.04	7.0	0.04524886877828054	0.2857142857142857	2.0	0.0	-2.8999999999999986	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	14.0	0.04	0.0	0.04524886877828054	0.0	0.0	0.0	0.0	0.0
264	normalization;Normalization	0.6690782806642525	-1.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	0.0	0.04	0.04	0.0	0.0425531914893617	0.0425531914893617	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.0425531914893617	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	a single protein;a protein;a larger protein;proteins in organism A;a minimum PROTEIN;A, Protein;protein--a;a pair of non-homologous proteins;a 'composite' protein	0.9910673656637529	0.0	0.0	0.0	0.04	0.04	0.4	0.8012820512820512	0.0	0.0	0.0	0.15384615384615385	0.0	0.0	0.0	-0.8269230769230769	0.04	0.04	0.0	0.04	0.04	3.5384615384615383	0.04168831168831169	0.03076923076923077	13.0	0.0	-5.75	1.0	0.3333333333333333	0.5384615384615384	0.15384615384615385	1.0	0.0	1.0	0.0	0.05128205128205128	9.0	1.0	46.0	0.04	0.0	0.05194805194805195	0.0	0.0	0.0	0.0	0.0
30	Exon;exon	0.6765044620959489	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-6.6	0.04	0.05434782608695653	0.0	0.04	0.04	1.0	0.05434782608695653	0.0	1.0	0.0	-6.6	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	1.0	0.04	0.0	0.05434782608695653	0.0	0.0	0.0	0.0	0.0
37	multidrug-resistant cancer cells	0.27300569064988095	-4.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.047619047619047616	0.047619047619047616	5.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.047619047619047616	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
189	biological;Biological	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
287	the selectivity of alisertib	0.07418138660869551	-2.1999999999999993	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	1.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.043859649122807015	0.043859649122807015	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.043859649122807015	0.0	0.04	0.0	0.0	0.0	0.0	0.0
61	ULK1	0.7794728434345481	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-2.75	0.04	0.0449438202247191	0.0	0.04	0.04	1.0	0.0449438202247191	0.0	2.0	1.0	-2.75	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04	0.0	0.0449438202247191	0.0	1.0	0.0	0.0	1.0
277	the 4-month treatment with pioglitazone	0.21993439663386755	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
200	UNITED STATES;United States;U S;U.S	0.3433559833699239	-1.2666666666666668	0.0	0.0	0.04	0.04	0.0	0.6666666666666666	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-3.222222222222222	0.04	0.04	0.0	0.04	0.04238993710691824	1.3333333333333333	0.04840579710144927	0.0	3.0	0.0	-9.666666666666666	1.0	0.0	0.6666666666666666	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	4.0	0.04716981132075472	0.0	0.06521739130434782	0.0	0.0	0.0	0.0	0.0
239	(two;two;Two	0.27723974813047286	0.0	0.0	0.0	0.04	0.04	0.5	0.875	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.1875	0.04	0.04	0.0	0.04	0.04	1.25	0.04234567901234568	0.0	4.0	0.0	-4.75	1.0	0.0	0.75	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	5.0	0.04	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
80	UTR	0.6310309472271658	-2.666666666666668	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-5.800000000000001	0.04	0.052083333333333336	0.0	0.04477611940298508	0.04477611940298508	0.0	0.052083333333333336	0.0	1.0	0.0	-5.800000000000001	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.04477611940298508	0.0	0.052083333333333336	0.0	0.0	0.0	0.0	0.0
255	weakness;WEAKNESS	0.16564773866750432	-0.8571428571428577	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8571428571428577	0.0	0.0	-1.71875	0.04	0.04	0.0	0.04	0.04147320084311954	1.0	0.0430385654630312	0.0	4.0	0.0	-2.875	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.043209876543209874	0.0	0.04519774011299435	0.0	0.0	0.0	0.0	0.0
246	prodrug clopidogrel	0.22307950623343603	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
25	≥ 1 psychotropic medication	0.5129383043467466	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
252	creatine kinase-MB fraction;Creatine phosphokinase MB fraction	0.5198239124974473	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	important factors	0.08175254515775773	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04878048780487805	0.04878048780487805	2.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04878048780487805	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
122	pharmacogenetic	0.5881824248862525	-4.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.04938271604938271	0.04938271604938271	1.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04938271604938271	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
262	The disease	0.059465498651175355	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.3333333333333333	1.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
335	Pol II;RNA Polymerase II;RNA polymerase II	0.9897393693892754	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-4.177777777777778	0.04	0.04	0.0	0.04	0.04	2.7777777777777777	0.04881231220503538	0.0	9.0	0.0	-7.800000000000001	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	3.0	1.0	25.0	0.04	0.0	0.05813953488372093	0.0	0.0	0.0	0.0	0.0
4	Like;like	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
344	using;Using	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
9	density;densities;Density	0.17076521569552555	-3.533333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	-2.95	0.04	0.04	0.0	0.04	0.046919491525423726	1.0	0.04610156214952087	0.0	5.0	0.0	-7.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	5.0	0.05084745762711865	0.0	0.056338028169014086	0.0	0.0	0.0	0.0	0.0
73	these proteins' construction principles	0.15243928707301652	-1.2222222222222214	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	-1.2222222222222214	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04205607476635514	0.04205607476635514	5.0	0.043478260869565216	0.2	1.0	0.0	-2.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04205607476635514	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
44	suggested;Suggest	0.09321648205984116	-10.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-10.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.06666666666666667	0.06666666666666667	1.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.06666666666666667	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
30	extent;Extent	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	calcitonin function	0.44104891520585965	-5.333333333333334	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-5.333333333333334	0.0	0.0	-5.0	0.04	0.05	0.0	0.05084745762711865	0.05084745762711865	2.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	2.0	0.05084745762711865	0.0	0.05	0.0	0.0	0.0	0.0	0.0
4	the parathyroid	0.09847459708137632	-1.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.0425531914893617	0.0425531914893617	2.0	0.045454545454545456	0.5	1.0	0.0	-3.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.0425531914893617	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
285	controls (n	0.49069857772961073	-3.8000000000000007	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-3.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04716981132075472	0.04716981132075472	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04716981132075472	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	our experience	0.09575376176221045	-5.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.5	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.05128205128205128	0.05128205128205128	2.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05128205128205128	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
38	patients to rest	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
172	kg.d)	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
304	mouse;Mouse, NOS	0.09112461233357536	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
266	large populations;large population	0.07365694677170874	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.04	0.043165467625899276	0.0	0.04	0.04	2.0	0.043165467625899276	0.0	1.0	0.0	-1.8333333333333321	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.043165467625899276	0.0	0.0	0.0	0.0	0.0
80	more specific therapies in the treatment	0.039760689555518106	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	iii;III	0.5636992062267255	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.04	0.044117647058823525	0.0	0.04	0.04	1.0	0.044117647058823525	0.0	1.0	0.0	-2.333333333333332	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.044117647058823525	0.0	0.0	0.0	0.0	0.0
93	The cohort	0.113027285797118	-2.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
132	L-T4 in both cell lines	0.15253371083258746	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
66	Chromosomal Aberrations;chromosomal abnormalities;chromosomal abnormality;Chromosomal Abnormalities;chromosomal/genetic abnormalities;Abnormality, Chromosomal;Chromosomal aberrations	0.9792417037104302	-1.3636363636363635	0.0	0.0	0.04	0.04	0.0	0.06818181818181818	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04247933884297521	2.5454545454545454	0.04	0.0	11.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	7.0	1.0	28.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
116	used drugs;used drug	0.03253789412915662	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.5	0.0	0.0
24	a cardiovascular preventive polypill	0.21930888672299367	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.04	0.04	4.0	0.05405405405405406	0.25	1.0	0.0	-6.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
155	a severe inherited arrhythmic disease	0.05774068831992656	-4.833333333333334	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-4.833333333333334	0.0	0.0	-6.0	0.04	0.05263157894736842	1.0	0.04958677685950414	0.04958677685950414	5.0	0.05263157894736842	0.2	1.0	0.0	-6.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04958677685950414	0.0	0.05263157894736842	0.0	0.0	0.2	0.0	0.0
103	DNMT3a/3b;DNMT3a/3b)	0.7114817109615199	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-7.857142857142858	0.04	0.056451612903225805	0.0	0.04	0.04	3.5	0.05839822024471636	0.125	2.0	1.0	-8.428571428571429	1.0	0.6666666666666666	0.0	0.5	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	7.0	0.04	0.0	0.060344827586206906	0.0	1.0	0.0	0.0	1.0
335	Observed;observed	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
75	the expression	0.09757890387765199	-5.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.75	0.0	0.0	-5.75	0.04	0.05194805194805195	0.0	0.05194805194805195	0.05194805194805195	2.0	0.05194805194805195	0.0	1.0	0.0	-5.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05194805194805195	0.0	0.05194805194805195	0.0	0.0	0.0	0.0	0.0
134	Identified;identified	0.09773875734391521	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
199	ENPA/Cse4	0.7409201488454747	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	this parasite species	0.15630348090617233	-5.75	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-5.75	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.05194805194805195	0.05194805194805195	3.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05194805194805195	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
95	Distributed;distributed	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	the most common clock-related proteins	0.11003177386317028	0.0	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	thyroid morphology in these patients	0.08268961168374454	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04	0.04	5.0	0.053571428571428575	0.2	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
192	lower serum ferritin	0.6277344217976196	-6.666666666666666	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-6.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.054545454545454536	0.054545454545454536	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.054545454545454536	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	several places	0.10653066399039185	-1.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.042735042735042736	0.042735042735042736	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.042735042735042736	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	cause disease;disease cause	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
159	associated with;Associated with	0.11707437433269925	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
39	either;Either	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	50%;50	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
83	Risk;risk	0.0711484454867308	-3.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-7.5	0.04	0.05714285714285714	0.0	0.047058823529411764	0.047058823529411764	1.0	0.05714285714285714	0.0	1.0	0.0	-7.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047058823529411764	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
146	osteoclasts;Osteoclasts;Osteoclast	0.7408929314020548	-2.583333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.044444444444444446	0.04461028192371476	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.04477611940298508	0.0	0.04	0.0	0.0	0.0	0.0	0.0
83	allelic;Allele;allele	0.9930411878518347	-0.8	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.5	0.0	0.0	-1.6	0.04	0.04	0.0	0.04	0.04152741088872683	1.0	0.04381430278204471	0.0	15.0	0.0	-9.5	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	3.0	1.0	15.0	0.04878048780487805	1.0	0.06451612903225806	0.0	0.0	0.0	1.0	0.0
1	critical;Critical	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
175	small mandible;Small mandible	0.39826684138827634	-2.75	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0449438202247191	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
304	an inhibitor	0.3049157608650745	-2.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.044444444444444446	0.044444444444444446	2.0	0.06666666666666667	0.5	1.0	0.0	-10.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.044444444444444446	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
163	a single bout of RE	0.08848691453375389	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
152	efficient;Efficient	0.08517003712039342	-3.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.04716981132075472	0.04716981132075472	1.0	0.04587155963302752	0.0	1.0	0.0	-3.1999999999999993	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04716981132075472	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
290	marked differences in sonographic findings	0.15898064341854684	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
108	the mutational status of immunoglobulin	0.09104998152320747	-2.571428571428573	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-2.571428571428573	0.0	0.0	-6.199999999999999	0.04	0.05319148936170213	0.0	0.0445859872611465	0.0445859872611465	5.0	0.05319148936170213	0.2	1.0	0.0	-6.199999999999999	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.0445859872611465	0.0	0.05319148936170213	0.0	0.0	0.0	0.0	0.0
140	a significant evolutionary step	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
176	spatial point statistics	0.3269915475311465	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	the proteasome inhibitor	0.16853309018830126	-5.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.05	0.05	3.0	0.06666666666666667	0.3333333333333333	1.0	0.0	-10.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
341	PROCARBAZINE;procarbazine	0.6680066813541813	-1.375	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.375	0.0	0.0	0.0	0.04	0.04	0.0	0.042328042328042326	0.042328042328042326	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.042328042328042326	0.0	0.04	0.0	0.0	0.0	0.0	0.0
32	loss;Loss	0.09788117189105187	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04631578947368421	0.0	2.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
317	its class in clinical trials	0.08279735195665178	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
30	ACUTE LEUKEMIA;acute leukemia	0.7666555817950902	-1.1000000000000014	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.1000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.041841004184100423	0.041841004184100423	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.041841004184100423	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	annually worldwide	0.08680490027199582	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.04	0.04	2.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
66	stained;Stained	0.5535468397580197	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.04	0.04	1.0	0.04597701149425287	0.0	1.0	0.0	-3.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
249	with;Addition;With;addition	0.010223632818618468	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.6875	0.04	0.05263157894736842	0.0	0.04	0.04	1.0	0.05468458379992534	0.5	2.0	0.0	-7.375	1.0	0.0	1.0	0.5	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.04	0.0	0.05673758865248227	1.0	0.0	0.0	0.0	0.0
258	a decrease in DNA methylation levels	0.07909346932887608	-5.199999999999999	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	1.0	-5.199999999999999	1.0	1.0	-8.8	0.04	0.0617283950617284	0.0	0.050505050505050504	0.050505050505050504	6.0	0.0617283950617284	0.0	1.0	1.0	-8.8	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.050505050505050504	0.0	0.0617283950617284	0.0	1.0	0.0	0.0	1.0
307	's disease (AD)	0.25902327381875934	-3.6000000000000014	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04672897196261683	0.04672897196261683	5.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04672897196261683	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
242	Extreme;extreme	0.14097399993512674	-0.9629629629629631	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.6666666666666679	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04163773920783267	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04285714285714286	0.0	0.04	0.0	0.0	0.0	0.0	0.0
342	not;Not	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
261	CALM1	0.7867175629115711	-2.571428571428573	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.571428571428573	0.0	0.0	-8.333333333333334	0.04	0.06000000000000001	0.0	0.0445859872611465	0.0445859872611465	1.0	0.06000000000000001	0.0	2.0	0.0	-8.333333333333334	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	2.0	0.0445859872611465	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
24	in individuals;in individual;in people;) in people	0.18513069486123276	-2.2	0.0	0.0	0.04	0.04	0.6666666666666666	0.9166666666666666	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-8.75	0.04	0.058823529411764705	0.0	0.04	0.043990412430779405	2.25	0.06161142976252085	0.0	4.0	0.0	-9.5	1.0	0.0	0.75	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	9.0	0.04587155963302752	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
160	antibody therapies;therapies such as the antibody	0.03672671915523757	-2.833333333333332	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	-7.2857142857142865	0.04	0.056451612903225805	0.0	0.045112781954887216	0.045112781954887216	5.0	0.056451612903225805	0.2	1.0	0.0	-7.2857142857142865	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.045112781954887216	0.0	0.056451612903225805	0.0	0.0	0.0	0.0	0.0
290	Suprapubic;suprapubic	0.6351647238334629	-5.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05	0.05	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	GeneBuilder	0.783975816744278	-2.8888888888888893	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.044444444444444446	0.04523350553884905	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04580152671755725	0.0	0.04	0.0	0.0	0.0	0.0	0.0
138	isobaric tag for the relative and absolute quantitation methodology	0.058358189728567544	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.375	0.04	0.04419889502762431	0.0	0.04	0.04	9.0	0.04419889502762431	0.2222222222222222	1.0	0.0	-2.375	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.04419889502762431	0.0	0.0	0.0	0.0	0.0
325	followed by;Followed by	0.17409998208207356	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	2.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
327	histone lysine methylation;histone H3 lysine 36 tri-methylation	0.34400965173965103	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.16666666666666666	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
146	podocin	0.7850128565492788	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
333	incubated;Incubated	0.5939841198408272	-4.857142857142858	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.857142857142858	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.04964539007092199	0.04964539007092199	1.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04964539007092199	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
86	KCND3 transcription	0.7744579530037519	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
343	Functional;functional	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	the identification of transmembrane beta barrel proteins (TMBs)	0.032213786439663356	-2.25	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.375	0.0	-2.25	0.0	0.0	-2.833333333333332	0.04	0.045112781954887216	0.0	0.04395604395604396	0.04395604395604396	10.0	0.045112781954887216	0.6	1.0	0.0	-2.833333333333332	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04395604395604396	0.0	0.045112781954887216	0.0	0.0	0.0	0.0	0.0
125	The gene responsible	0.01607304422744164	-6.666666666666666	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.3333333333333333	0.0	-6.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.054545454545454536	0.054545454545454536	3.0	0.04	0.6666666666666666	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.054545454545454536	0.0	0.04	0.0	0.0	0.0	0.0	0.0
144	elements;Element;Elements;element	0.5223634971891472	-0.7714285714285717	0.0	0.0	0.04	0.04	0.0	0.7142857142857143	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	-4.214285714285714	0.04	0.04	0.0	0.04	0.04138398602684317	0.7142857142857143	0.04984397931766353	0.0	7.0	0.0	-10.0	1.0	0.0	0.7142857142857143	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	5.0	0.04504504504504505	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
152	decreased insulin secretion;Decreased Insulin Secretion	0.28671660742381944	-2.8000000000000007	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	-2.8000000000000007	0.04	0.04504504504504505	0.0	0.04504504504504505	0.04504504504504505	3.0	0.04504504504504505	0.0	1.0	0.0	-2.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04504504504504505	0.0	0.04504504504504505	0.0	0.0	0.0	0.0	0.0
15	The original system	0.04672120949198022	-5.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.5	0.0	0.0	-5.800000000000001	0.04	0.052083333333333336	0.0	0.05128205128205128	0.05128205128205128	3.0	0.052083333333333336	0.3333333333333333	1.0	0.0	-5.800000000000001	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05128205128205128	0.0	0.052083333333333336	0.0	0.0	0.0	0.0	0.0
46	exon 9	0.7268739028102027	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
29	continuous;CONTINUOUS	0.07213718265255763	-3.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.04580152671755725	0.04580152671755725	1.0	0.054545454545454536	0.0	1.0	0.0	-6.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04580152671755725	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
14	a transmembrane beta strand prediction technique	0.041613311630900526	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.16666666666666666	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
342	Homolog;homolog	0.6089473376649964	-5.6	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.6	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.051546391752577324	0.051546391752577324	1.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.051546391752577324	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
174	the recessive Jervell and Lange	0.16925308362460045	-3.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-5.6	0.04	0.051546391752577324	0.0	0.045454545454545456	0.045454545454545456	5.0	0.051546391752577324	0.2	1.0	0.0	-5.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.045454545454545456	0.0	0.051546391752577324	0.0	0.0	0.0	0.0	0.0
99	nuclear and cell integrity	0.16580377686773543	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
214	DISPLAY;display	0.0968891560091204	-3.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	0.0	0.04	0.04	0.0	0.047058823529411764	0.047058823529411764	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047058823529411764	0.0	0.04	0.0	0.0	0.0	0.0	0.0
293	depression during childhood;Childhood Depression	0.07435842344587819	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
135	MASS SPECTROMETRY;mass spectrometry	0.19876484018062296	-2.1764705882352935	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.1764705882352935	0.0	0.0	-2.25	0.04	0.04395604395604396	0.0	0.04381443298969072	0.04381443298969072	2.0	0.04395604395604396	0.0	1.0	0.0	-2.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04381443298969072	0.0	0.04395604395604396	0.0	0.0	0.0	0.0	0.0
142	Presented;presented	0.07605879023739286	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.04	0.04477611940298508	0.0	0.04	0.04	1.0	0.04477611940298508	0.0	1.0	0.0	-2.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04477611940298508	0.0	0.0	0.0	0.0	0.0
133	transactivation of the c-Jun promoter	0.200950079802553	0.0	0.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.2857142857142857	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
160	available;Available	0.10980600039187233	-2.916666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-2.428571428571429	0.04	0.0440251572327044	0.0	0.045112781954887216	0.045283663704716336	1.0	0.044305572246925454	0.0	2.0	0.0	-2.571428571428573	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.045454545454545456	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
44	female Anopheles mosquitoes	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
227	a dopaminergic abnormality	0.4065610553183088	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
232	Progressive;progressive	0.07033597916367322	-6.333333333333334	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.053571428571428575	0.053571428571428575	1.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.053571428571428575	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
277	the long term	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	Assigned;assigned	0.07448175440629054	-1.8333333333333321	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.043165467625899276	0.043165467625899276	1.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043165467625899276	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
52	Transcriptional;transcriptional	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
126	gastrointestinal (GI) symptoms	0.5279856887322881	-11.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	-11.0	0.0	0.0	-10.333333333333334	0.04	0.06818181818181819	1.0	0.07142857142857142	0.07142857142857142	5.0	0.06818181818181819	0.2	2.0	0.0	-10.333333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.07142857142857142	0.0	0.06818181818181819	0.0	0.0	0.2	0.0	0.0
16	a single transcript in one (	0.12345732182283334	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	non-conserved residues	0.669190721745788	-4.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	adjacent sites by murine DNA	0.09877046048546954	-4.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-5.428571428571429	0.04	0.05109489051094891	0.0	0.047619047619047616	0.047619047619047616	5.0	0.05109489051094891	0.2	1.0	0.0	-5.428571428571429	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.047619047619047616	0.0	0.05109489051094891	0.0	0.0	0.0	0.0	0.0
133	folate uptake	0.6768305462325295	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.04	0.04	2.0	0.05084745762711865	0.0	2.0	0.0	-5.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
16	another organism as a Rosetta Stone protein	0.053705708846318714	0.0	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.04	0.04878048780487805	0.0	0.04	0.04	7.0	0.04878048780487805	0.0	1.0	0.0	-4.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
86	normalization;Normalization	0.547989743176474	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.04	0.04	1.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
132	thyroid hormone;Thyroid Hormone	0.9606383965649484	-3.3	1.0	-12.333333333333332	0.04	0.04216374269005848	0.5	0.5	1.0	-0.6851851851851851	1.0	1.0	-11.4	0.0	0.0	-5.166666666666667	0.07894736842105263	0.04	0.0	0.04	0.046942110177404295	2.0	0.0521043771043771	1.0	18.0	0.0	-13.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	36.0	0.07352941176470588	0.0	0.08333333333333333	1.0	0.0	0.0	0.0	0.0
15	Broad;broader	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
339	cell survival;Cell Survival	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
310	Gene, A;a specific global decrease in estrogen-induced gene	0.04885289289094773	-4.75	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.04938271604938271	0.04938271604938271	9.0	0.06451612903225806	0.1111111111111111	1.0	0.0	-9.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.04938271604938271	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
41	binding of the chromodomain protein;Protein Binding	0.05954709041715501	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
74	TRANSMITTER;transmitter	0.6078722860890746	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
187	a new familial primary electrical disease	0.06522565760309312	-3.166666666666668	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04580152671755725	0.04580152671755725	6.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04580152671755725	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
205	meal;Meal	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
38	DIAGNOSIS;diagnosis	0.216412419129698	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	2.0	1.0	1.0	0.04	1.0	0.04	0.0	0.0	0.0	1.0	0.0
206	experiment 1	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
47	the Human Genome Center at Baylor College	0.11003177386317028	0.0	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
137	CCSVI and balloon dilatation	0.07657558639619376	-1.6666666666666679	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.25	0.0	-1.6666666666666679	0.0	0.0	0.0	0.04	0.04	0.0	0.04285714285714286	0.04285714285714286	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04285714285714286	0.0	0.04	0.0	0.0	0.0	0.0	0.0
221	data;Data	0.0648071641734773	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.04	0.04	1.0	0.05405405405405406	0.0	1.0	0.0	-6.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
41	mouse transcriptome	0.17073233556600292	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-10.333333333333334	0.04	0.06818181818181819	0.0	0.04	0.04	2.0	0.06818181818181819	0.0	1.0	0.0	-10.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.06818181818181819	0.0	0.0	0.0	0.0	0.0
44	a potential drug target for treatment	0.09578787087196253	-6.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05263157894736842	0.05263157894736842	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.05263157894736842	0.0	0.04	0.0	0.0	0.0	0.0	0.0
142	2 (MEN2) syndromes	0.1086870124182969	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.111111111111111	0.04	0.047872340425531915	0.0	0.04	0.04	5.0	0.047872340425531915	0.8	1.0	0.0	-4.111111111111111	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.047872340425531915	0.0	0.0	0.0	0.0	0.0
41	CDYL2	0.8163493760368835	-4.666666666666667	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-7.0	1.0	1.0	-5.333333333333333	0.04	0.04918032786885245	0.0	0.04	0.05037037037037037	1.0	0.05096870342771981	0.0	3.0	1.0	-6.666666666666666	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	3.0	0.05555555555555555	0.0	0.054545454545454536	0.0	1.0	0.0	0.0	1.0
343	Maintained;maintained	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
242	this;This	0.08971054475512508	-1.5555555555555571	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	0.0	0.04	0.04	0.0	0.04265402843601896	0.04265402843601896	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04265402843601896	0.0	0.04	0.0	0.0	0.0	0.0	0.0
149	miR-133b	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
39	effect;Effect	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
188	potential relevance	0.21086444414709735	-3.333333333333332	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-7.4	0.04	0.056818181818181816	0.0	0.04615384615384615	0.04615384615384615	2.0	0.056818181818181816	0.0	1.0	0.0	-7.4	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04615384615384615	0.0	0.056818181818181816	0.0	0.0	0.0	0.0	0.0
102	essential components of the central and peripheral circadian clocks	0.05412528811227409	-4.75	0.0	0.0	0.04	0.04	0.7777777777777778	0.7777777777777778	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04938271604938271	0.04938271604938271	9.0	0.04	0.2222222222222222	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04938271604938271	0.0	0.04	0.0	0.0	0.0	0.0	0.0
185	LVNC	0.7123617662367117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
206	the doses of 0.1, 0.3	0.22047712530770358	-3.666666666666668	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.046875	0.046875	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.046875	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	the rational identification of small molecule inhibitors	0.06516123839059482	-7.166666666666666	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	1.0	-7.166666666666666	0.0	0.0	-8.333333333333334	0.04	0.06000000000000001	0.0	0.05607476635514018	0.05607476635514018	7.0	0.06000000000000001	0.14285714285714285	1.0	0.0	-8.333333333333334	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.05607476635514018	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
41	11)	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
216	U(IV;U(IV)	0.6954727767469708	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.5	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	the same reference sequence	0.052997877725278884	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
12	deposited	0.002414530086439908	-15.4	1.0	0.0	0.04	0.04	1.0	1.0	1.0	0.0	1.0	0.0	-15.4	0.0	0.0	-18.333333333333332	0.04	0.15	0.0	0.10416666666666667	0.10416666666666667	1.0	0.15	1.0	1.0	0.0	-18.333333333333332	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.10416666666666667	0.0	0.15	1.0	0.0	0.0	0.0	0.0
129	some;Some	0.07929265559758812	-1.2222222222222214	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.2222222222222214	0.0	0.0	-2.7142857142857153	0.04	0.04487179487179487	0.0	0.04205607476635514	0.04205607476635514	1.0	0.04487179487179487	0.0	1.0	0.0	-2.7142857142857153	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04205607476635514	0.0	0.04487179487179487	0.0	0.0	0.0	0.0	0.0
321	Three	0.05376557222642715	-3.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-20.0	0.04	0.2	0.0	0.04716981132075472	0.04716981132075472	1.0	0.2	0.0	1.0	0.0	-20.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04716981132075472	0.0	0.2	0.0	0.0	0.0	0.0	0.0
317	Two	0.09757187532598001	-3.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.046296296296296294	0.046296296296296294	1.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.046296296296296294	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
48	C transversion	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
209	the effects of experimental manipulations	0.10908429713738986	-6.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05263157894736842	0.05263157894736842	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.05263157894736842	0.0	0.04	0.0	0.0	0.0	0.0	0.0
188	The inbred BTBR T	0.33247700618611425	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	4.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
198	autosomal-dominant mutations in the SCN5A gene	0.05111124695408217	-2.8000000000000007	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.375	1.0	-2.8000000000000007	1.0	1.0	0.0	0.04	0.04	1.0	0.04504504504504505	0.04504504504504505	8.0	0.04	0.5	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04504504504504505	0.0	0.04	0.0	1.0	0.125	0.0	1.0
91	the youths with depression	0.05761549214277518	-2.2857142857142847	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.2857142857142847	0.0	0.0	0.0	0.04	0.04	0.0	0.0440251572327044	0.0440251572327044	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.0440251572327044	0.0	0.04	0.0	0.0	0.0	0.0	0.0
84	serotonin 5-HT2A or 5-HT2C receptors	0.4193895725701179	0.0	0.0	0.0	0.04	0.04	0.1111111111111111	0.1111111111111111	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
137	1012;1012S	0.5489876245017752	-1.5555555555555571	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	-5.0	0.04	0.05	0.0	0.04265402843601896	0.04265402843601896	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04265402843601896	0.0	0.05	0.0	0.0	0.0	0.0	0.0
215	initial;Initial	0.0943797958812142	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
30	a wide spectrum	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
82	Study;study	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
215	alone;only;Only;Alone	0.06679795353720124	-1.625	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04298850574712644	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
76	PHQ-2	0.7197519684249668	-1.166666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.3333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.041666666666666664	0.04196009389671361	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04225352112676056	0.0	0.04	0.0	0.0	0.0	0.0	0.0
83	clopidogrel 150-mg maintenance dosing	0.1929727888096237	0.0	1.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	Exon;exon	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
58	Triple;triple	0.7172728766843438	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
177	the end of their professional carrier	0.015745876730042647	-1.6666666666666679	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.14285714285714285	0.0	-1.6666666666666679	0.0	0.0	0.0	0.04	0.04	0.0	0.04285714285714286	0.04285714285714286	6.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04285714285714286	0.0	0.04	0.0	0.0	0.0	0.0	0.0
91	GAD in adults [13,14], children and adolescents [15,16	0.08018768515035447	-1.571428571428573	1.0	0.0	0.04	0.04	0.3125	0.3125	0.0	0.0	0.4	0.0	-1.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.042682926829268296	0.042682926829268296	16.0	0.04	0.0625	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	16.0	0.042682926829268296	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	one MEN1 patient	0.11761553365832458	-2.125	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.4	1.0	-2.125	0.0	0.0	0.0	0.04	0.04	0.0	0.04371584699453552	0.04371584699453552	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04371584699453552	0.0	0.04	0.0	0.0	0.0	0.0	0.0
209	manipulations;Manipulation;MANIPULATIONS;manipulation	0.5240185044732714	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04380952380952381	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
94	the development of investigations	0.0884415052403157	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
118	CXCR2 (SB225002)	0.38072217053960583	-2.428571428571427	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.4	1.0	-2.428571428571427	1.0	1.0	-7.5	0.04	0.05714285714285714	0.0	0.04430379746835443	0.04430379746835443	4.0	0.05714285714285714	0.25	1.0	1.0	-7.5	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04430379746835443	0.0	0.05714285714285714	0.0	1.0	0.0	0.0	1.0
145	Shut down;shutdown	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
37	a potential predictor of tumor responsiveness	0.09614233257547584	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.25	0.04	0.05333333333333334	0.0	0.04	0.04	6.0	0.05333333333333334	0.0	1.0	0.0	-6.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.05333333333333334	0.0	0.0	0.0	0.0	0.0
160	a major fracture trial	0.11685018095205689	-1.8333333333333321	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.043165467625899276	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.043165467625899276	0.0	0.04	0.0	0.0	0.0	0.0	0.0
188	tf/J mouse model	0.062046385535207714	-3.333333333333332	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.5	0.0	-3.333333333333332	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04615384615384615	0.04615384615384615	5.0	0.04716981132075472	0.4	1.0	0.0	-3.8000000000000007	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04615384615384615	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
99	Defined;defined	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
162	10	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
246	Required;required	0.0025150849930639756	-18.75	1.0	0.0	0.04	0.04	1.0	1.0	1.0	0.0	1.0	0.0	-18.75	0.0	0.0	-14.5	0.04	0.09523809523809523	0.0	0.16	0.16	1.0	0.09523809523809523	1.0	1.0	0.0	-14.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.16	0.0	0.09523809523809523	1.0	0.0	0.0	0.0	0.0
233	young people	0.27957609866259603	-11.63888888888889	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.25	0.0	-12.777777777777779	0.0	0.0	-8.625	0.04	0.05714285714285714	0.0	0.059602649006622516	0.07626429861529199	2.0	0.061160714285714284	0.5	8.0	0.0	-9.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	16.0	0.08181818181818182	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
84	depression treatment	0.21881624226862767	-6.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-6.0	1.0	1.0	0.0	0.04	0.04	0.0	0.05263157894736842	0.05263157894736842	2.0	0.04	0.0	2.0	1.0	0.0	1.0	0.3333333333333333	1.0	0.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.05263157894736842	0.0	0.04	0.0	1.0	0.0	0.0	1.0
96	the antitumor efficacy of anthracyclines	0.26905681404095005	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	serine;SERINE	0.862844268022805	-9.333333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-10.0	0.0	0.0	-5.4444444444444455	0.04	0.048387096774193554	0.0	0.058823529411764705	0.06405228758169934	0.6666666666666666	0.051216751556310135	0.0	3.0	0.0	-6.0	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	2.0	0.06666666666666667	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
130	GES	0.8868742022709823	-1.2727272727272716	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-1.4545454545454533	0.0	0.0	-2.928571428571427	0.04	0.04430379746835443	0.0	0.04182509505703422	0.04214806876403834	1.0	0.04533070668119708	0.0	4.0	0.0	-3.428571428571427	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	4.0	0.04247104247104247	0.0	0.04635761589403973	0.0	0.0	0.0	0.0	0.0
225	(99m)Tc-pertechnetate thyroid scintigraphy	0.6209940897134617	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	structures of the transmembrane (TM) domains	0.0677340073790982	-2.25	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.25	0.0	0.0	-8.333333333333334	0.04	0.06000000000000001	0.0	0.04395604395604396	0.04395604395604396	8.0	0.06000000000000001	0.375	1.0	0.0	-8.333333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04395604395604396	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
209	Represent;represent	0.0895362429989046	-6.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-13.0	0.0	0.0	-3.166666666666667	0.04	0.04	0.0	0.04	0.061666666666666654	1.0	0.04678571428571429	0.0	2.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.08333333333333333	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
260	the mutation hotspots	0.09544700521883712	-2.571428571428573	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.6666666666666666	1.0	-2.571428571428573	0.0	0.0	0.0	0.04	0.04	1.0	0.0445859872611465	0.0445859872611465	3.0	0.04	0.6666666666666666	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.0445859872611465	0.0	0.04	0.0	0.0	0.3333333333333333	0.0	0.0
333	Tetrahymena thermophila surface protein	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
74	the diagnosis	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
184	0.83	0.82406034615933	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.04	0.04	1.0	0.047058823529411764	0.0	1.0	0.0	-3.75	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	0.04	1.0	0.047058823529411764	0.0	0.0	0.0	1.0	0.0
223	The first passive immunotherapy trial	0.04515257728213146	0.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.25	0.0	0.0	0.0	0.0	-4.142857142857142	0.04	0.04794520547945205	0.0	0.04	0.04	5.0	0.04794520547945205	0.2	1.0	0.0	-4.142857142857142	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04794520547945205	0.0	0.0	0.0	0.0	0.0
14	their amino acid compositions	0.16182494360968655	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	0;0%	0.6155188201867553	-0.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.0	0.0	0.0	-2.25	0.04	0.04	0.0	0.04	0.04083333333333333	0.0	0.04439024390243902	0.0	2.0	0.0	-4.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.041666666666666664	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
16	these associations	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	Active;activity;active;Activity	0.06823289703526167	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
61	the functions of GABARAPL1 (ATG8L) and GABARAPL2 (GATE-16)	0.1212959406055285	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.18181818181818182	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	12.0	0.04	0.08333333333333333	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	12.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
84	treat;TREAT	0.09334503420064146	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-8.5	0.0	0.0	-2.833333333333333	0.04	0.04	0.0	0.04	0.05030303030303031	1.0	0.04586206896551724	0.0	2.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.06060606060606061	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
1	elements;Elements	0.07262545187407575	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.043478260869565216	0.043478260869565216	1.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
72	the gene	0.040414492389381926	-1.1000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.1000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.041841004184100423	0.041841004184100423	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.041841004184100423	0.0	0.04	0.0	0.0	0.0	0.0	0.0
326	mutations in glucocerebrosidase (	0.3267593978100326	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
208	of AED use;Use of	0.06227578876492644	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	represents;Represent	0.0985949953261355	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
288	proteins-components of;Component of protein	0.3781839658396867	-4.666666666666666	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-4.666666666666666	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.04918032786885245	0.04918032786885245	4.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	1.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	2.0	1.0	4.0	0.04918032786885245	1.0	0.05128205128205128	0.0	0.0	0.0	1.0	0.0
44	sugar with pyretroids	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
160	to;TO;To	0.006825829101310074	-5.375	1.0	-14.428571428571429	0.04	0.05364864864864865	1.0	1.0	1.0	-3.607142857142857	1.0	0.0	-17.5	0.0	0.0	-3.0357142857142856	0.0945945945945946	0.04	0.0	0.04	0.06507360534929721	1.0	0.049444444444444444	1.0	4.0	0.0	-12.142857142857142	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.13333333333333333	0.0	0.07777777777777778	1.0	0.0	0.0	0.0	0.0
341	fractionated;Fractionated	0.6101752622896102	-2.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04395604395604396	0.04395604395604396	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04395604395604396	0.0	0.04	0.0	0.0	0.0	0.0	0.0
286	Detection of botulinum neurotoxin-	0.26592474183276726	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	5.0	0.04	0.6	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.2	0.0	0.0
257	more than 2-fold differential expression of 32 oxidative stress	0.11876875228661166	-4.166666666666666	0.0	0.0	0.04	0.04	0.5555555555555556	0.5555555555555556	0.0	0.0	0.0	0.0	-4.166666666666666	0.0	0.0	-1.571428571428573	0.04	0.042682926829268296	0.0	0.047999999999999994	0.047999999999999994	9.0	0.042682926829268296	0.1111111111111111	1.0	0.0	-1.571428571428573	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.047999999999999994	0.0	0.042682926829268296	0.0	0.0	0.0	0.0	0.0
12	PR-	0.562252726575284	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.04	0.04	2.0	0.054545454545454536	0.0	1.0	0.0	-6.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
144	AP-2A	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
69	photoreceptors;Photoreceptors	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
101	H3K4	0.8292197277530349	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
131	triple-negative breast cancer;triple negative breast cancer	0.017819894684523652	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	4.0	0.047619047619047616	1.0	2.0	0.0	-4.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	8.0	0.04	0.0	0.047619047619047616	1.0	0.0	0.0	0.0	0.0
100	and;And	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
151	the codon usage frequency of the sequence	0.02786950418476862	0.0	1.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.2857142857142857	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	a multiple endocrine neoplasia type	0.04067926289818722	-2.375	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-2.375	0.0	0.0	0.0	0.04	0.04	0.0	0.04419889502762431	0.04419889502762431	5.0	0.04	0.8	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04419889502762431	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	tropical, parasitic diseases;Tropical Diseases	0.2285932841359312	-11.75	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-11.75	1.0	1.0	-9.0	0.04	0.0625	0.0	0.07547169811320754	0.07547169811320754	4.0	0.0625	0.0	1.0	1.0	-9.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	4.0	0.07547169811320754	0.0	0.0625	0.0	1.0	0.0	0.0	1.0
4	Related;related	0.09152591734464818	-2.125	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.125	0.0	0.0	0.0	0.04	0.04	0.0	0.04371584699453552	0.04371584699453552	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04371584699453552	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	genome scale discrimination of β-barrel membrane proteins	0.07999387419797808	0.0	0.0	0.0	0.04	0.04	0.4444444444444444	0.4444444444444444	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04	0.04	9.0	0.043478260869565216	0.4444444444444444	1.0	0.0	-2.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
14	an amino acid composition	0.26550371211216156	-3.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-3.0	0.0	0.0	-7.166666666666666	0.04	0.05607476635514018	0.0	0.045454545454545456	0.045454545454545456	4.0	0.05607476635514018	0.0	1.0	0.0	-7.166666666666666	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.045454545454545456	0.0	0.05607476635514018	0.0	0.0	0.0	0.0	0.0
75	absence	0.12433103832656751	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
120	H(2;h 2	0.569342079138643	-3.3999999999999986	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.046296296296296294	0.046296296296296294	1.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046296296296296294	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
11	the cadA gene into the citric acid producing	0.10216363886080948	-2.5	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	-2.5	0.0	0.0	0.0	0.04	0.04	0.0	0.044444444444444446	0.044444444444444446	8.0	0.04	0.375	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.044444444444444446	0.0	0.04	0.0	0.0	0.0	0.0	0.0
215	prototypical markers	0.21636675643052267	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.04	0.04	2.0	0.04716981132075472	0.0	1.0	0.0	-3.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
247	HPV re-infection	0.24114584893347382	-5.333333333333334	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.4	0.0	-5.333333333333334	0.0	0.0	-3.5	0.04	0.046511627906976744	1.0	0.05084745762711865	0.05084745762711865	2.0	0.046511627906976744	0.5	1.0	0.0	-3.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05084745762711865	0.0	0.046511627906976744	0.0	0.0	0.5	0.0	0.0
142	all ethnic groups in South Africa	0.04772014480097293	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.8888888888888893	0.04	0.04326923076923077	0.0	0.04	0.04	6.0	0.04326923076923077	0.16666666666666666	1.0	0.0	-1.8888888888888893	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04326923076923077	0.0	0.0	0.0	0.0	0.0
206	L-dopa;LEVODOPA;levodopa;L-DOPA;l-DOPA;L Dopa;L-Dopa	0.9999999435241073	-2.0625	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-5.333333333333334	1.0	1.0	-1.354166666666667	0.04	0.04	0.0	0.04	0.04407746231352027	2.875	0.04264354295724107	0.0	32.0	1.0	-6.333333333333334	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	7.0	1.0	92.0	0.05084745762711865	0.0	0.053571428571428575	0.0	1.0	0.0	0.0	1.0
225	A WS patient with CPP	0.15898064341854684	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
250	ventricular function	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
161	various deformities	0.27080625539909625	-3.25	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
155	mutations of the CASQ2 gene	0.04304575174121854	-5.333333333333334	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.6	1.0	-5.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.05084745762711865	0.05084745762711865	5.0	0.04	0.6	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.05084745762711865	0.0	0.04	0.0	0.0	0.0	0.0	0.0
209	fish;FISH;fishes	0.18658719790203673	-1.8333333333333333	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	-2.1666666666666665	0.04	0.04	0.0	0.04	0.04382209188660802	1.0	0.04722222222222222	0.0	6.0	0.0	-13.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	6.0	0.054545454545454536	0.0	0.08333333333333333	0.0	0.0	0.0	0.0	0.0
107	O NOS;O	0.6224304543482914	-1.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.0833333333333321	0.0	0.0	-4.071428571428572	0.04	0.04516129032258065	0.0	0.041522491349480974	0.04166716901968822	1.0	0.047942964001870036	0.0	2.0	0.0	-5.2857142857142865	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04181184668989547	0.0	0.05072463768115942	0.0	0.0	0.0	0.0	0.0
318	Currently;currently	0.08904545516552738	-0.9444444444444446	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-4.9230769230769225	0.04	0.04814814814814815	0.0	0.04	0.04163461538461538	1.0	0.049867724867724866	0.0	2.0	0.0	-5.615384615384615	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04326923076923077	0.0	0.051587301587301584	0.0	0.0	0.0	0.0	0.0
200	1982 until 2002	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
131	are;Are	0.07674629533419766	-1.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8000000000000007	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04310344827586207	0.04310344827586207	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04310344827586207	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
178	purified;Purified	0.5563204661405409	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	1.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
96	Further;further	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	Network;network	0.07110288558633066	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.2857142857142865	0.04	0.04827586206896552	0.0	0.04	0.04	1.0	0.04827586206896552	0.0	1.0	0.0	-4.2857142857142865	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04827586206896552	0.0	0.0	0.0	0.0	0.0
276	review of the pertinent literature;Review of Literature	0.03265608861692618	-2.375	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-2.375	0.0	0.0	-9.6	0.04	0.06493506493506493	0.0	0.04419889502762431	0.04419889502762431	5.0	0.06493506493506493	0.2	1.0	0.0	-9.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04419889502762431	0.0	0.06493506493506493	0.0	0.0	0.0	0.0	0.0
44	the malaria	0.010710585904416583	-4.75	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.6666666666666666	1.0	-4.75	1.0	1.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.04938271604938271	0.04938271604938271	2.0	0.054545454545454536	1.0	1.0	1.0	-6.666666666666666	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04938271604938271	0.0	0.054545454545454536	1.0	1.0	0.0	0.0	1.0
124	subtypes	0.7123617662367117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	insect chitin synthesis	0.44037917272134386	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	3.0	0.047619047619047616	0.0	2.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
226	several front-line operations	0.07297391503833127	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	5.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
305	signalling	0.6016316744762409	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	1.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
118	represents;Represent	0.06394986386946587	-4.857142857142858	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.857142857142858	0.0	0.0	-11.0	0.04	0.07142857142857142	0.0	0.04964539007092199	0.04964539007092199	1.0	0.07142857142857142	0.0	1.0	0.0	-11.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04964539007092199	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0
145	CHRONIC;chronic	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
31	work;Work	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
78	central;CENTRAL	0.07096173573097679	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.04	0.04	1.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
96	poor prognosis;Poor prognosis	0.2598118477214766	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.04	0.043859649122807015	0.0	0.04	0.04	2.0	0.043859649122807015	0.0	2.0	0.0	-2.1999999999999993	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.043859649122807015	0.0	0.0	0.0	0.0	0.0
15	the OntoGene project	0.08611593927164138	-2.3000000000000007	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.3000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04405286343612335	0.04405286343612335	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04405286343612335	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	Five patients	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	solution;Solution	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	aminopeptidases;Aminopeptidases	0.716897932404643	-4.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.25	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04819277108433735	0.04819277108433735	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	1.0	0.04819277108433735	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
274	the pathogenesis	0.23586115252234627	-1.4545454545454533	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.4545454545454533	0.0	0.0	-2.571428571428573	0.04	0.0445859872611465	0.0	0.04247104247104247	0.04247104247104247	2.0	0.0445859872611465	0.0	1.0	0.0	-2.571428571428573	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04247104247104247	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
13	Crystalline;crystalline	0.595055177538121	-5.333333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.05084745762711865	0.05084745762711865	0.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.05084745762711865	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
292	included	0.09094416913775388	-2.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.043795620437956206	0.043795620437956206	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.043795620437956206	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
140	quantitative proteomics methods	0.48501901710734213	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	the preferred strategy	0.14416294558450624	-6.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.05263157894736842	0.05263157894736842	3.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.05263157894736842	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
121	Concern;concern	0.10722162528744765	-6.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.054545454545454536	0.054545454545454536	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.054545454545454536	0.0	0.04	0.0	0.0	0.0	0.0	0.0
82	a possible association	0.03910796788039975	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.199999999999999	0.04	0.050505050505050504	0.0	0.04	0.04	3.0	0.050505050505050504	0.3333333333333333	1.0	0.0	-5.199999999999999	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.050505050505050504	0.0	0.0	0.0	0.0	0.0
254	initiation;Initiation	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	monoallelic expressions on chromosome 3	0.17094165745002232	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.04	0.04	5.0	0.0449438202247191	0.2	1.0	0.0	-2.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
304	High risk of;HIGH RISK;of high risk;high-risk	0.07757915399286942	-2.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.8333333333333333	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-2.571428571428571	0.04	0.04	0.0	0.04	0.04380952380952381	3.0	0.045179856115107914	0.16666666666666666	2.0	0.0	-5.142857142857142	1.0	0.0	0.5	0.5	1.0	0.0	1.0	0.0	0.0	4.0	1.0	6.0	0.047619047619047616	0.0	0.050359712230215826	0.0	0.0	0.0	0.0	0.0
89	fentanyl in 20	0.2796536507454495	-3.6000000000000014	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-3.6000000000000014	1.0	1.0	0.0	0.04	0.04	0.0	0.04672897196261683	0.04672897196261683	3.0	0.04	0.3333333333333333	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04672897196261683	0.0	0.04	0.0	1.0	0.0	0.0	1.0
131	cytokeratins	0.8203285026441218	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	0.04	1.0	0.04	0.0	1.0	0.0	1.0	1.0
71	HIF-1 beta/ARNT	0.7811694267454853	-2.3999999999999986	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.3999999999999986	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.04424778761061947	0.04424778761061947	4.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04424778761061947	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
96	CDK inhibition	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	catalytic Dnmt3A/3L complex;catalytic complex	0.3557433020453593	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
304	Recent clinical data	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
25	associated with;Associated with	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
159	based;Based	0.09520971290739387	-3.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	the same time	0.04299556670897608	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	3.0	0.045454545454545456	0.3333333333333333	1.0	0.0	-3.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
47	The GeneBuilder system	0.08879153332293355	-3.166666666666668	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.04580152671755725	0.04580152671755725	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04580152671755725	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	their target genes D site albumin promoter	0.30214178062326646	-4.5	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	1.0	-4.5	1.0	1.0	0.0	0.04	0.04	0.0	0.04878048780487805	0.04878048780487805	7.0	0.04	0.0	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	7.0	0.04878048780487805	0.0	0.04	0.0	1.0	0.0	0.0	1.0
89	Together;together	0.07267611988525721	-2.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.044642857142857144	0.044642857142857144	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.044642857142857144	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
332	a Syk inhibitor	0.1939249068026912	-3.333333333333332	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04615384615384615	0.04615384615384615	3.0	0.04938271604938271	0.3333333333333333	1.0	0.0	-4.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04615384615384615	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
216	genes;Genes	0.06998091245582899	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	1.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
333	I-;I	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
213	autosomal dominant trait	0.17958650231884488	-6.666666666666666	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	-13.5	0.04	0.08695652173913043	0.0	0.054545454545454536	0.054545454545454536	3.0	0.08695652173913043	0.0	2.0	0.0	-13.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.054545454545454536	0.0	0.08695652173913043	0.0	0.0	0.0	0.0	0.0
303	Variant;variant	0.06614693117843777	-9.666666666666666	1.0	-14.666666666666668	0.04	0.06838709677419355	0.0	0.0	1.0	-7.333333333333334	1.0	0.0	-16.0	0.0	0.0	-11.0	0.09677419354838711	0.053571428571428575	0.0	0.04615384615384615	0.07863247863247863	1.0	0.08035714285714286	1.0	2.0	0.0	-15.666666666666668	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.1111111111111111	0.0	0.10714285714285715	1.0	0.0	0.0	0.0	0.0
79	blood concentrations	0.08302410432173131	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04	0.04	2.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
75	amino acid sequence information	0.26910289585721964	-9.75	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-9.75	0.0	0.0	0.0	0.04	0.04	0.0	0.06557377049180328	0.06557377049180328	4.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.06557377049180328	0.0	0.04	0.0	0.0	0.0	0.0	0.0
52	type 2 deiodinase	0.33055370480603813	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.3333333333333333	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
127	Encoding;encoding	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
127	the responses	0.03756837044270065	-5.333333333333334	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.5	0.0	-5.333333333333334	0.0	0.0	-9.333333333333334	0.04	0.06382978723404256	0.0	0.05084745762711865	0.05084745762711865	2.0	0.06382978723404256	0.0	1.0	0.0	-9.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05084745762711865	0.0	0.06382978723404256	0.0	0.0	0.0	0.0	0.0
199	Play;plays	0.08395221217819623	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.043478260869565216	0.043478260869565216	1.0	0.043478260869565216	0.0	1.0	0.0	-2.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
111	vivo studies	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
88	Play;plays	0.10579342670292423	-3.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04631578947368421	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.05263157894736842	0.0	0.04	0.0	0.0	0.0	0.0	0.0
257	chaperone-like protein	0.33729683769386964	-8.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-8.5	0.0	0.0	-4.2857142857142865	0.04	0.04827586206896552	0.0	0.06060606060606061	0.06060606060606061	4.0	0.04827586206896552	0.0	1.0	0.0	-4.2857142857142865	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.06060606060606061	0.0	0.04827586206896552	0.0	0.0	0.0	0.0	0.0
125	The authors	0.03864198971789589	-3.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.046875	0.046875	2.0	0.04597701149425287	0.5	1.0	0.0	-3.25	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.046875	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
281	Early-onset;early-onset;early onset;Early onset	0.9995691026832705	-0.642857142857143	0.0	0.0	0.04	0.04	0.3333333333333333	0.42857142857142855	0.0	0.0	0.0	0.0	-5.699999999999999	0.0	0.0	-6.26984126984127	0.04	0.045112781954887216	0.0	0.04	0.04119672130811169	2.4285714285714284	0.05474895433299468	0.0	21.0	0.0	-15.333333333333332	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	51.0	0.05181347150259067	0.0	0.10344827586206895	0.0	0.0	0.0	0.0	0.0
276	these data	0.1057049778956363	-1.375	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.375	0.0	0.0	0.0	0.04	0.04	0.0	0.042328042328042326	0.042328042328042326	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.042328042328042326	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	assisted;Assisted	0.09211420547218516	-8.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-8.5	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.06060606060606061	0.06060606060606061	1.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.06060606060606061	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
44	Asia	0.6395127511867676	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.045454545454545456	0.045454545454545456	1.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.045454545454545456	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
276	disturbed TH levels	0.15698036943861188	-1.625	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.625	0.0	0.0	0.0	0.04	0.04	0.0	0.0427807486631016	0.0427807486631016	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.0427807486631016	0.0	0.04	0.0	0.0	0.0	0.0	0.0
293	TCAs	0.5520376717368426	-5.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-13.5	0.04	0.08695652173913043	0.0	0.05	0.05	1.0	0.08695652173913043	0.0	1.0	0.0	-13.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.05	0.0	0.08695652173913043	0.0	0.0	0.0	0.0	0.0
181	Study;study	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
38	Variant;variant	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	FUNGICIDES;fungicides	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
68	runx2;RUNX2;Runx2	0.8249883104175709	-2.111111111111111	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-6.333333333333334	1.0	1.0	-2.1666666666666665	0.04	0.04	0.0	0.04	0.04452380952380952	1.0	0.04468468468468469	0.0	6.0	1.0	-6.5	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	3.0	1.0	6.0	0.053571428571428575	0.0	0.05405405405405406	0.0	1.0	0.0	0.0	1.0
71	Increased;increased	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
6	altered mental status in cancer patients	0.04297109086782901	-3.555555555555557	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.555555555555557	0.0	0.0	-8.25	0.04	0.05970149253731343	0.0	0.04663212435233161	0.04663212435233161	6.0	0.05970149253731343	0.16666666666666666	1.0	0.0	-8.25	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04663212435233161	0.0	0.05970149253731343	0.0	0.0	0.0	0.0	0.0
250	0.016) and fT3/fT4 (p	0.5532607392457332	-1.6666666666666679	0.0	0.0	0.04	0.04	0.125	0.125	0.0	0.0	0.0	1.0	-1.6666666666666679	0.0	0.0	0.0	0.04	0.04	0.0	0.04285714285714286	0.04285714285714286	8.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04285714285714286	0.0	0.04	0.0	0.0	0.0	0.0	0.0
63	Risk;risk	0.08233820256999201	-9.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-9.0	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.0625	0.0625	1.0	0.06060606060606061	0.0	1.0	0.0	-8.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0625	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
102	mouse liver;mouse livers;Mouse Liver	0.18818147064983431	-3.9583333333333335	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0475671551163628	2.0	0.04	0.5	6.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	12.0	0.04878048780487805	0.0	0.04	0.0	0.0	0.0	0.0	0.0
118	CXC chemokine receptors 1;CXC Chemokine Receptor 1	0.6126786203986732	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-4.75	0.04	0.04938271604938271	1.0	0.04	0.04	4.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	4.0	0.04	0.0	0.04938271604938271	0.0	0.0	0.25	0.0	0.0
320	more complex workflows in drug discovery campaigns	0.06461677157222477	-4.5	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04878048780487805	0.04878048780487805	7.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04878048780487805	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
329	energy grid including desolvation	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	adrenocorticotropin;Adrenocorticotropin	0.7787913022657665	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
66	two;Two	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
104	TWINSCAN	0.7092381572244214	-1.083333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04189781021897811	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043795620437956206	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	side effects	0.10801258077044511	-2.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
71	lactate overproduction. We	0.3857652096709128	-2.8000000000000007	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.04504504504504505	0.04504504504504505	4.0	0.04597701149425287	0.0	1.0	0.0	-3.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04504504504504505	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
82	Identified;identified	0.07377422342632291	-1.8571428571428577	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8571428571428577	0.0	0.0	-5.0	0.04	0.05	0.0	0.043209876543209874	0.043209876543209874	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043209876543209874	0.0	0.05	0.0	0.0	0.0	0.0	0.0
16	clustering;Clustering	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	The pose prediction success rate of each docking program	0.03949444130838625	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.2222222222222222	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
97	DM	0.6642320293515822	-3.1666666666666665	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-9.5	0.0	0.0	-6.888888888888888	0.04	0.047619047619047616	0.0	0.04	0.048172043010752695	1.0	0.058317837604764604	0.0	3.0	0.0	-12.333333333333332	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.06451612903225806	0.0	0.07894736842105263	0.0	0.0	0.0	0.0	0.0
16	a cut-off E-value of 1 × 10-10	0.12632243189274936	0.0	0.0	0.0	0.04	0.04	0.4444444444444444	0.4444444444444444	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.2222222222222222	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
172	Novel mutation in MCT8 gene	0.1675282090707671	-2.8000000000000007	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-2.8000000000000007	1.0	1.0	-3.75	0.04	0.047058823529411764	0.0	0.04504504504504505	0.04504504504504505	6.0	0.047058823529411764	0.16666666666666666	1.0	1.0	-3.75	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04504504504504505	0.0	0.047058823529411764	0.0	1.0	0.0	0.0	1.0
267	set;Set	0.09343925929430232	-2.7142857142857153	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.7142857142857153	0.0	0.0	0.0	0.04	0.04	0.0	0.04487179487179487	0.04487179487179487	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04487179487179487	0.0	0.04	0.0	0.0	0.0	0.0	0.0
256	the fibroblast growth factor receptor (FGFR	0.2246359044634622	0.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	Approach;approach	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
220	Highly;highly	0.08508850959244306	-6.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.25	0.0	0.0	-5.333333333333334	0.04	0.05084745762711865	0.0	0.05333333333333334	0.05333333333333334	1.0	0.05084745762711865	0.0	1.0	0.0	-5.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05333333333333334	0.0	0.05084745762711865	0.0	0.0	0.0	0.0	0.0
139	Replaced;replaced	0.07579614674277428	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.04	0.04	1.0	0.0449438202247191	0.0	1.0	0.0	-2.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
137	Venous angioplasty;angioplasty of the extracranial veins;venous angioplasty;Angioplasty of vein	0.7992488845484685	-1.0	0.0	0.0	0.04	0.04	0.0	0.06666666666666667	0.0	0.0	0.0	0.3333333333333333	-2.2222222222222214	0.0	0.0	-3.5666666666666664	0.04	0.04484304932735426	0.0	0.04	0.04174015009380863	2.5	0.046750505609615	0.48333333333333334	6.0	0.0	-5.5	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.0	0.1111111111111111	4.0	1.0	15.0	0.04390243902439024	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
74	LYMPH NODE;lymph node	0.6889681780988667	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
75	gel filtration;Gel Filtration	0.8003942904321836	-6.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.25	0.0	0.0	0.0	0.04	0.04	0.0	0.05333333333333334	0.05333333333333334	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.05333333333333334	0.0	0.04	0.0	0.0	0.0	0.0	0.0
78	an important resource for testing DNA blots	0.11546130892300681	-4.0	0.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
274	course of this devastating disease;course of disease	0.025905874190912222	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.8571428571428577	0.04	0.04516129032258065	0.0	0.04	0.04	5.0	0.04516129032258065	0.4	1.0	0.0	-2.8571428571428577	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04	0.0	0.04516129032258065	0.0	0.0	0.0	0.0	0.0
41	Epigenetic Silencing;epigenetic silencing	0.7589563682959148	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
171	the identification	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
74	Lambert-Eaton myasthenic syndrome (LEMS)	0.19965929740498686	0.0	1.0	0.0	0.04	0.04	0.125	0.125	0.0	0.0	0.5	1.0	0.0	0.0	0.0	-2.75	0.04	0.0449438202247191	0.0	0.04	0.04	8.0	0.0449438202247191	0.5	1.0	0.0	-2.75	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.04	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
187	an autosomal dominant mode of inheritance;An autosomal dominant mode of inheritance	0.11360283370842127	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.15476190476190477	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	6.0	0.04	0.5	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	12.0	0.04	0.0	0.04	0.0	1.0	0.16666666666666666	0.0	1.0
226	What memory problems	0.003794408465271785	-11.4	1.0	0.0	0.04	0.04	1.0	1.0	1.0	0.0	1.0	1.0	-11.4	1.0	1.0	-14.0	0.04	0.09090909090909091	1.0	0.07352941176470588	0.07352941176470588	3.0	0.09090909090909091	1.0	1.0	1.0	-14.0	1.0	0.5	1.0	1.0	1.0	1.0	1.0	0.5	0.5	1.0	1.0	3.0	0.07352941176470588	0.0	0.09090909090909091	1.0	1.0	0.3333333333333333	0.0	1.0
337	DE-CMR	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	the VKORC1 -1639G	0.4065610553183088	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
312	Factor;factors	0.09328332288419436	-2.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.04477611940298508	0.04477611940298508	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04477611940298508	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	a total	0.11084004513643027	-2.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0449438202247191	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
245	alters;Altered	0.08500375821646908	-1.2857142857142865	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.571428571428573	0.0	0.0	-6.2	0.04	0.04	0.0	0.04	0.04229299363057325	1.0	0.059682539682539684	0.0	2.0	0.0	-12.4	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.0445859872611465	0.0	0.07936507936507936	0.0	0.0	0.0	0.0	0.0
217	the acronym "TAILS	0.019867825789004617	-9.375	1.0	-12.875	0.08247422680412371	0.08247422680412371	0.25	0.25	1.0	-12.875	1.0	0.0	-9.375	0.0	0.0	-11.142857142857142	0.08247422680412371	0.07216494845360824	0.0	0.064	0.064	4.0	0.07216494845360824	1.0	1.0	0.0	-11.142857142857142	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.064	0.0	0.07216494845360824	1.0	0.0	0.0	0.0	0.0
99	post;Post	0.6066186994119565	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	the domain architecture	0.07160604473843854	-0.7272727272727266	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.4545454545454533	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.04	0.04123552123552124	3.0	0.046511627906976744	0.3333333333333333	2.0	0.0	-3.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04247104247104247	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
33	Disruption	0.6528100491352161	-2.8999999999999986	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.8999999999999986	0.0	0.0	-2.2857142857142847	0.04	0.0440251572327044	0.0	0.04524886877828054	0.04524886877828054	1.0	0.0440251572327044	0.0	1.0	0.0	-2.2857142857142847	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04524886877828054	0.0	0.0440251572327044	0.0	0.0	0.0	0.0	0.0
121	The strong association between HLA-B5701 and abacavir hypersensitivity reaction	0.06562175984958077	0.0	1.0	0.0	0.04	0.04	0.5454545454545454	0.5454545454545454	0.0	0.0	0.25	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	11.0	0.04	0.09090909090909091	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	11.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
37	drug-induced protein-associated DNA breaks	0.08861934241600691	-5.666666666666666	0.0	0.0	0.04	0.04	0.625	0.625	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-7.75	0.04	0.057971014492753624	1.0	0.051724137931034475	0.051724137931034475	8.0	0.057971014492753624	0.125	1.0	0.0	-7.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.051724137931034475	0.0	0.057971014492753624	0.0	0.0	0.125	0.0	0.0
344	bulk;Bulk	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
304	-class covalent inhibitor	0.22137632462134	-4.375	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-4.375	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.048484848484848485	0.048484848484848485	4.0	0.06666666666666667	0.25	1.0	0.0	-10.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.048484848484848485	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
33	antibody	0.11717834148852534	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	1.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	1.0	0.0	0.0	0.0	0.0
44	The gene of an NADP	0.14322653516779063	-6.75	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	-6.75	0.0	0.0	0.0	0.04	0.04	0.0	0.0547945205479452	0.0547945205479452	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.0547945205479452	0.0	0.04	0.0	0.0	0.0	0.0	0.0
323	diagnostic features	0.2327513669110956	-7.6	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-7.6	0.0	0.0	-8.25	0.04	0.05970149253731343	0.0	0.0574712643678161	0.0574712643678161	2.0	0.05970149253731343	0.0	1.0	0.0	-8.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.0574712643678161	0.0	0.05970149253731343	0.0	0.0	0.0	0.0	0.0
212	two;Two	0.07865395790865108	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.8571428571428577	0.04	0.043209876543209874	0.0	0.04	0.04	1.0	0.043209876543209874	0.0	1.0	0.0	-1.8571428571428577	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.043209876543209874	0.0	0.0	0.0	0.0	0.0
20	the central cartwheel	0.08749595014761453	-2.75	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0449438202247191	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
99	the clinical triad	0.060170541303205	-4.75	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	-10.714285714285714	0.04	0.06999999999999999	0.0	0.04938271604938271	0.04938271604938271	3.0	0.06999999999999999	0.3333333333333333	1.0	0.0	-10.714285714285714	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04938271604938271	0.0	0.06999999999999999	0.0	0.0	0.0	0.0	0.0
44	Unusual;unusual	0.09345299033810076	-7.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-7.75	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.057971014492753624	0.057971014492753624	1.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.057971014492753624	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
339	stem cells during development	0.07624269882126641	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.04	0.04672897196261683	0.0	0.04	0.04	4.0	0.04672897196261683	0.0	1.0	0.0	-3.6000000000000014	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
41	critical;Critical	0.09851395978418487	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.833333333333333	0.04	0.04	0.0	0.04	0.04	1.0	0.04586206896551724	0.0	2.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
25	language development;Language Development	0.08300092644550074	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.04	0.04	2.0	0.06060606060606061	0.0	2.0	0.0	-8.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
11	Firstly;firstly	0.5532942644523475	-3.166666666666668	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04580152671755725	0.04580152671755725	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04580152671755725	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
102	METABOLIC;metabolic	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
262	incidence;Incidence	0.7172728766843438	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
324	autosomal recessive (AR) and autosomal dominant (AD) modes of inheritance	0.48701237197969555	0.0	1.0	0.0	0.04	0.04	0.35714285714285715	0.35714285714285715	0.0	0.0	0.1111111111111111	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	14.0	0.04	0.14285714285714285	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	28.0	0.04	0.0	0.04	0.0	1.0	0.07142857142857142	0.0	1.0
44	the vector	0.10815148666477084	-5.75	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-5.75	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.05194805194805195	0.05194805194805195	2.0	0.048387096774193554	0.5	1.0	0.0	-4.333333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05194805194805195	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
206	DOPA decarboxylase inhibitor	0.9470672329603826	-6.166666666666667	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-6.333333333333334	1.0	1.0	-5.5	0.04	0.05	0.0	0.05263157894736842	0.0531015037593985	3.0	0.05131578947368421	0.0	4.0	1.0	-6.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	12.0	0.053571428571428575	0.0	0.05263157894736842	0.0	1.0	0.0	0.0	1.0
120	Components;components	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	nonspecific;Non-specific	0.5738025983553254	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.045454545454545456	0.045454545454545456	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
25	anxiety in autism spectrum disorder	0.002512583927935051	-12.333333333333332	1.0	0.0	0.04	0.04	0.8	0.8	1.0	0.0	1.0	0.0	-12.333333333333332	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.07894736842105263	0.07894736842105263	5.0	0.06666666666666667	1.0	1.0	0.0	-10.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.07894736842105263	0.0	0.06666666666666667	1.0	0.0	0.0	0.0	0.0
144	alpha-cardiac myosin heavy chain;Alpha heavy chain	0.3846341851164455	-3.8000000000000007	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-3.8000000000000007	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04716981132075472	0.04716981132075472	6.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	6.0	0.04716981132075472	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
198	SCN5A mutations	0.06192487975554756	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.8	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	2.0	0.04	1.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	1.0	1.0	0.5	0.0	1.0
274	the brain of AD patients	0.04791159745511333	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.8571428571428577	0.04	0.04516129032258065	0.0	0.04	0.04	5.0	0.04516129032258065	0.2	1.0	0.0	-2.8571428571428577	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04516129032258065	0.0	0.0	0.0	0.0	0.0
2	fibroblasts;Fibroblasts	0.7573700712738862	-0.6500000000000004	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04116071428571429	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.044642857142857144	0.0	0.04	0.0	0.0	0.0	0.0	0.0
313	function of the protein;function protein	0.0039470399335415005	-8.142857142857142	1.0	-16.333333333333332	0.11538461538461539	0.11538461538461539	1.0	1.0	1.0	-16.333333333333332	1.0	1.0	-8.142857142857142	0.0	0.0	-17.0	0.11538461538461539	0.125	1.0	0.059322033898305086	0.059322033898305086	4.0	0.125	1.0	1.0	0.0	-17.0	1.0	0.5	1.0	1.0	1.0	0.0	1.0	0.5	0.5	2.0	1.0	4.0	0.059322033898305086	0.0	0.125	1.0	0.0	0.25	0.0	0.0
248	30	0.7980547076453142	-2.625	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.625	0.0	0.0	-2.3214285714285716	0.04	0.04	0.0	0.04	0.045013318587166486	1.0	0.04456896551724138	0.0	4.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.049079754601226995	0.0	0.05	0.0	0.0	0.0	0.0	0.0
9	he increase in insertions and deletions	0.10582830258752847	-5.666666666666666	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.051724137931034475	0.051724137931034475	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.051724137931034475	0.0	0.04	0.0	0.0	0.0	0.0	0.0
247	depend	0.12538786257993742	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	0.0	0.04	0.04	0.0	0.04878048780487805	0.04878048780487805	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04878048780487805	0.0	0.04	0.0	0.0	0.0	0.0	0.0
87	an improvement	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
26	Relationship;relationship	0.06302707763732564	-2.7142857142857153	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.7142857142857153	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.04487179487179487	0.04487179487179487	1.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04487179487179487	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
149	biopsies;Biopsies	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
334	histone family, member X	0.2219965954299637	-1.2222222222222214	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.25	1.0	-1.2222222222222214	0.0	0.0	0.0	0.04	0.04	0.0	0.04205607476635514	0.04205607476635514	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.04205607476635514	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	Molecular imaging;imaging of biological molecules;Molecular Imaging;molecular imaging	0.8558219048042207	-5.5	0.0	0.0	0.04	0.04	0.0	0.25	0.0	0.0	0.0	1.0	-11.0	1.0	1.0	-5.833333333333333	0.04	0.04	0.0	0.04	0.055714285714285716	2.6666666666666665	0.057499999999999996	0.0	6.0	1.0	-11.666666666666666	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	4.0	1.0	16.0	0.07142857142857142	0.0	0.075	0.0	1.0	0.0	0.0	1.0
40	phylogenetic tree	0.017646883347252475	-6.166666666666667	1.0	-8.5	0.04	0.05030303030303031	0.5	0.5	1.0	-4.25	1.0	0.0	-9.166666666666666	0.0	0.0	-5.0	0.06060606060606061	0.04	0.0	0.04580152671755725	0.054479710727199676	2.0	0.05333333333333333	1.0	2.0	0.0	-10.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.06315789473684211	0.0	0.06666666666666667	1.0	0.0	0.0	0.0	0.0
49	two males	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	eneView	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	the major challenges	0.048894972933717654	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
169	the protein GATA1	0.011057916641107298	-11.2	1.0	-9.0	0.0625	0.0625	0.6666666666666666	0.6666666666666666	1.0	-9.0	1.0	1.0	-11.2	1.0	1.0	-10.0	0.0625	0.06666666666666667	0.0	0.07246376811594203	0.07246376811594203	3.0	0.06666666666666667	1.0	1.0	1.0	-10.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.07246376811594203	0.0	0.06666666666666667	1.0	1.0	0.0	0.0	1.0
82	the HLA-B*1502 allele	0.03757818390809074	-10.571428571428571	1.0	-3.3999999999999986	0.046296296296296294	0.046296296296296294	0.2	0.2	1.0	-3.3999999999999986	1.0	1.0	-10.571428571428571	0.0	0.0	-4.0	0.046296296296296294	0.047619047619047616	0.0	0.0693069306930693	0.0693069306930693	5.0	0.047619047619047616	1.0	1.0	0.0	-4.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.0693069306930693	0.0	0.047619047619047616	1.0	0.0	0.0	0.0	0.0
256	the protein product	0.140411099756115	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	1.0	0.0	1.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
77	Pyridine;pyridine	0.6564993972382017	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-4.2857142857142865	0.04	0.04827586206896552	0.0	0.04	0.04	1.0	0.04827586206896552	0.0	1.0	1.0	-4.2857142857142865	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	1.0	0.04	0.0	0.04827586206896552	0.0	1.0	0.0	0.0	1.0
82	Han Chinese between a genetic marker	0.03925767572124286	-2.2857142857142847	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-2.2857142857142847	0.0	0.0	-8.4	0.04	0.06024096385542168	0.0	0.0440251572327044	0.0440251572327044	6.0	0.06024096385542168	0.16666666666666666	1.0	0.0	-8.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.0440251572327044	0.0	0.06024096385542168	0.0	0.0	0.0	0.0	0.0
306	complaints of altered consciousness	0.052997877725278884	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
312	Ca(2+)/S100A2	0.5471566752889261	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
315	Fas-L)- induced apoptosis	0.5471566752889261	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
37	soluble	0.6327759642334068	-4.666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	-5.75	0.04	0.05194805194805195	0.0	0.04918032786885245	0.04918032786885245	1.0	0.05194805194805195	0.0	1.0	0.0	-5.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04918032786885245	0.0	0.05194805194805195	0.0	0.0	0.0	0.0	0.0
269	PA	0.660717625637253	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.75	0.04	0.047058823529411764	0.0	0.04	0.04	0.0	0.047058823529411764	0.0	2.0	0.0	-3.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.04	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
208	development	0.12328186590527837	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	an evolutionarily conserved member of the CCR4-NOT complex	0.10440258483514453	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
181	controls;control	0.17647251480134965	-1.2857142857142865	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04229299363057325	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.0445859872611465	0.0	0.04	0.0	0.0	0.0	0.0	0.0
249	chromatin domains	0.4510651860948908	-6.166666666666666	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-6.166666666666666	0.0	0.0	-4.375	0.04	0.048484848484848485	0.0	0.053097345132743355	0.053097345132743355	2.0	0.048484848484848485	0.0	2.0	0.0	-4.375	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.053097345132743355	0.0	0.048484848484848485	0.0	0.0	0.0	0.0	0.0
7	The teratogenicity of antiepilepsy drug valproic acid	0.15060155264433275	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	7.0	0.04	0.14285714285714285	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	1.0	0.14285714285714285	0.0	1.0
271	the Allan-Herndon-Dudley syndrome (AHDS)	0.27664082037152155	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.1	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
242	SCD in patients	0.020177879358477896	-2.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.6	0.0	-2.0	0.0	0.0	0.0	0.04	0.04	0.0	0.043478260869565216	0.043478260869565216	3.0	0.04	0.6666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043478260869565216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
342	transcription activation;Activation, Transcription	0.7589563682959148	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
67	experimental autoimmune encephalomyelitis (EAE) mice	0.14934725122618842	0.0	0.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.04	0.04	7.0	0.058823529411764705	0.2857142857142857	1.0	0.0	-8.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
200	the chest	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	VKORC1;VKORC1 gene;VKORC1 Gene;VKORC1 genes	0.9999997454648037	-1.9230769230769231	0.0	0.0	0.04	0.04	0.0	0.07692307692307693	0.0	0.0	0.0	1.0	-4.75	1.0	1.0	-4.5	0.04	0.04	0.15384615384615385	0.04	0.04365137916039318	1.1538461538461537	0.050465282339984645	0.07692307692307693	52.0	1.0	-9.0	1.0	0.3333333333333333	0.0	0.15384615384615385	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	4.0	1.0	60.0	0.04938271604938271	0.0	0.0625	0.0	1.0	0.07692307692307693	0.0	1.0
71	nutrient;Nutrient	0.08145359011905424	-2.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	-3.25	0.04	0.04597701149425287	0.0	0.044642857142857144	0.044642857142857144	1.0	0.04597701149425287	0.0	1.0	0.0	-3.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.044642857142857144	0.0	0.04597701149425287	0.0	0.0	0.0	0.0	0.0
41	such binding interactions	0.11627050112820682	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.04	0.04	3.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
335	the recruitment signal for the Rpd3S histone deacetylase complex (HDAC	0.1231244877342157	0.0	0.0	0.0	0.04	0.04	0.45454545454545453	0.45454545454545453	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.04	0.043859649122807015	0.0	0.04	0.04	11.0	0.043859649122807015	0.09090909090909091	1.0	0.0	-2.1999999999999993	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	11.0	0.04	0.0	0.043859649122807015	0.0	0.0	0.0	0.0	0.0
180	its gene	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	the removal	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
176	Hin invertasome	0.6170856529035521	-1.375	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.375	0.0	0.0	-2.8000000000000007	0.04	0.04504504504504505	0.0	0.042328042328042326	0.042328042328042326	2.0	0.04504504504504505	0.0	1.0	0.0	-2.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.042328042328042326	0.0	0.04504504504504505	0.0	0.0	0.0	0.0	0.0
47	species;Species	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	thalidomide (THAL)	0.4317439057948049	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-2.3999999999999986	0.04	0.04424778761061947	0.0	0.04	0.04	4.0	0.04424778761061947	0.5	1.0	0.0	-2.3999999999999986	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04424778761061947	0.0	0.0	0.0	0.0	0.0
329	Pocket A	0.14684823062145294	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
144	TREs. Upstream	0.6986383063015744	-2.8000000000000007	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.8000000000000007	1.0	1.0	0.0	0.04	0.04	0.0	0.04504504504504505	0.04504504504504505	3.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04504504504504505	0.0	0.04	0.0	1.0	0.0	0.0	1.0
41	Interaction between an integral protein	0.11813387796363928	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.666666666666666	0.04	0.05769230769230768	0.0	0.04	0.04	5.0	0.05769230769230768	0.0	1.0	0.0	-7.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.05769230769230768	0.0	0.0	0.0	0.0	0.0
103	Coordinated;coordinated	0.09720193343991052	-3.4444444444444446	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.222222222222221	0.0	0.0	-4.0	0.04	0.04375	0.0	0.04285714285714286	0.04670947030497592	1.0	0.047994402985074625	0.0	2.0	0.0	-5.857142857142858	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.05056179775280899	0.0	0.05223880597014925	0.0	0.0	0.0	0.0	0.0
176	the distribution of HU	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	DNA methylation within the methylated domains	0.04721466275404589	-1.2222222222222214	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.2222222222222214	0.0	0.0	-1.571428571428573	0.04	0.042682926829268296	0.0	0.04205607476635514	0.04205607476635514	6.0	0.042682926829268296	0.5	1.0	0.0	-1.571428571428573	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04205607476635514	0.0	0.042682926829268296	0.0	0.0	0.0	0.0	0.0
213	four;Four	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
8	Centrosome components;. Centrosome components	0.39524393700766164	-4.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.41666666666666663	0.0	0.0	0.0	1.0	-4.0	1.0	1.0	-7.0	0.04	0.05555555555555555	0.0	0.047619047619047616	0.047619047619047616	2.5	0.05555555555555555	0.0	2.0	1.0	-7.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	5.0	0.047619047619047616	0.0	0.05555555555555555	0.0	1.0	0.0	0.0	1.0
339	the knockdown of BMI-1 expression	0.11725443957386267	-2.666666666666668	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.04477611940298508	0.04477611940298508	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04477611940298508	0.0	0.04	0.0	0.0	0.0	0.0	0.0
3	hhai methyltransferase;HhaI methyltransferase	0.7889120747774685	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-1.8571428571428577	0.04	0.043209876543209874	0.0	0.04	0.04	2.0	0.043209876543209874	0.0	3.0	1.0	-1.8571428571428577	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.04	0.0	0.043209876543209874	0.0	1.0	0.0	0.0	1.0
288	core MINOS subunit	0.31444768546503443	-6.666666666666666	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	-9.0	0.04	0.0625	0.0	0.054545454545454536	0.054545454545454536	3.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.054545454545454536	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
19	PAH	0.6185525926634594	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.045454545454545456	0.045454545454545456	1.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.045454545454545456	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
34	promoter activity	0.3384167564757728	-4.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.04878048780487805	0.04878048780487805	2.0	0.046511627906976744	0.0	2.0	0.0	-3.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04878048780487805	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
195	-mediated gene correction	0.3236802556985892	-4.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-10.333333333333334	0.04	0.06818181818181819	0.0	0.047619047619047616	0.047619047619047616	4.0	0.06818181818181819	0.0	1.0	0.0	-10.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.047619047619047616	0.0	0.06818181818181819	0.0	0.0	0.0	0.0	0.0
82	central and northern China	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
8	M NOS;M	0.7577930117773186	-2.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0449438202247191	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	1.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
168	ankylosis of the elbows;ankylosis of the elbow;Ankylosis, elbow;elbow ankylosis	0.396326428226024	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-2.5	0.04	0.04	0.0	0.04	0.04	3.0	0.045	0.25	4.0	0.0	-5.0	1.0	0.3333333333333333	0.0	0.5	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	4.0	1.0	12.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
222	three;Three	0.09076922656227149	-1.8888888888888893	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	0.0	0.04	0.04	0.0	0.04326923076923077	0.04326923076923077	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04326923076923077	0.0	0.04	0.0	0.0	0.0	0.0	0.0
342	istone H3 lysine	0.7651841453896528	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
230	suggest;Suggest	0.08406795719351395	-3.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04587155963302752	0.04587155963302752	1.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04587155963302752	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
228	)-1H-1	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
315	apoptosis in the pathogenesis	0.1405487375957212	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
146	Essential;essential	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	our data	0.11276083731878535	-3.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
43	a wide range of host species	0.06094728806207198	-3.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	0.0	0.04	0.04	0.0	0.046511627906976744	0.046511627906976744	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.046511627906976744	0.0	0.04	0.0	0.0	0.0	0.0	0.0
238	endovascular coiling	0.05300656185986911	-11.583333333333334	1.0	-10.333333333333334	0.06818181818181819	0.06818181818181819	0.0	0.0	1.0	-10.333333333333334	1.0	0.0	-11.583333333333334	0.0	0.0	-10.666666666666666	0.06818181818181819	0.06976744186046512	0.0	0.07453416149068323	0.07453416149068323	2.0	0.06976744186046512	1.0	1.0	0.0	-10.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.07453416149068323	0.0	0.06976744186046512	1.0	0.0	0.0	0.0	0.0
270	List interaction partners for the protein GATA1	0.0024393919833945706	0.0	1.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	1.0	0.0	1.0	1.0	0.0	1.0	1.0	-10.0	0.04	0.06666666666666667	1.0	0.04	0.04	7.0	0.06666666666666667	1.0	1.0	1.0	-10.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	7.0	0.04	0.0	0.06666666666666667	1.0	1.0	0.14285714285714285	0.0	1.0
58	non-bismuth-	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
80	higher outflow gradients	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
26	DIARRHEA;diarrhea	0.771351746239246	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
125	the MTM1 gene on Xq28	0.08652300562303297	-3.666666666666668	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-3.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.046875	0.046875	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.046875	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	X-linked moyamoya syndrome	0.12689415562641285	-2.333333333333332	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.3333333333333333	1.0	-2.333333333333332	1.0	1.0	-3.5	0.04	0.046511627906976744	0.0	0.044117647058823525	0.044117647058823525	3.0	0.046511627906976744	0.3333333333333333	1.0	1.0	-3.5	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.044117647058823525	0.0	0.046511627906976744	0.0	1.0	0.0	0.0	1.0
257	thiol-dependent hydrogen peroxide scavenger activity	0.27275574003944747	-1.8333333333333321	0.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	-6.428571428571429	0.04	0.05384615384615385	0.0	0.043165467625899276	0.043165467625899276	7.0	0.05384615384615385	0.0	1.0	0.0	-6.428571428571429	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.043165467625899276	0.0	0.05384615384615385	0.0	0.0	0.0	0.0	0.0
313	HPV-16 E6;HPV16 E6	0.8314281821237175	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
229	evaluating and ranking positional candidate genes	0.0747829060298053	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
332	Study;studies	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
49	sporadic;Sporadic	0.7661688949502072	-1.84375	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04332945826551965	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.047058823529411764	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	DEDD superfamily	0.7132058944692273	-2.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.75	1.0	1.0	0.0	0.04	0.04	0.0	0.0449438202247191	0.0449438202247191	2.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.0449438202247191	0.0	0.04	0.0	1.0	0.0	0.0	1.0
99	the lamin A/C gene	0.23594360135705247	-4.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-4.5	0.0	0.0	0.0	0.04	0.04	0.0	0.04878048780487805	0.04878048780487805	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04878048780487805	0.0	0.04	0.0	0.0	0.0	0.0	0.0
107	O(n2log n)	0.3664740981168262	-1.0833333333333321	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.0833333333333321	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04181184668989547	0.04181184668989547	5.0	0.043478260869565216	0.4	1.0	0.0	-2.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04181184668989547	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
267	Activities;activities	0.09343925929430232	-2.7142857142857153	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.7142857142857153	0.0	0.0	0.0	0.04	0.04	0.0	0.04487179487179487	0.04487179487179487	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04487179487179487	0.0	0.04	0.0	0.0	0.0	0.0	0.0
71	a regulator of glucose metabolism	0.15898064341854684	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
101	high-throughput screening;High Throughput Screening	0.20004810970576217	-3.5	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	0.0	0.04	0.04	0.0	0.046511627906976744	0.046511627906976744	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.046511627906976744	0.0	0.04	0.0	0.0	0.0	0.0	0.0
160	bone resorption	0.21054905169133356	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.571428571428571	0.04	0.048951048951048945	0.0	0.04	0.04	2.0	0.048951048951048945	0.0	1.0	0.0	-4.571428571428571	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.048951048951048945	0.0	0.0	0.0	0.0	0.0
204	3(FGFR3) gene in common	0.21525629944567717	-3.25	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	1.0	-3.25	0.0	0.0	-8.0	0.04	0.058823529411764705	1.0	0.04597701149425287	0.04597701149425287	7.0	0.058823529411764705	0.14285714285714285	1.0	0.0	-8.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04597701149425287	0.0	0.058823529411764705	0.0	0.0	0.14285714285714285	0.0	0.0
74	this;This	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
199	PROTEIN;proteins;protein;PROTEINS	0.9674032879943519	-3.142857142857142	0.0	0.0	0.04	0.04	0.0	0.5	0.0	0.0	0.0	1.0	-5.666666666666666	0.0	0.0	-3.0357142857142856	0.04	0.04	0.0	0.043165467625899276	0.04585091527095395	1.0	0.04592070379786704	0.0	14.0	0.0	-6.0	1.0	0.5	0.5	0.0	1.0	0.0	1.0	0.5	0.5	4.0	1.0	14.0	0.051724137931034475	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
89	chronic localized neuropathic pain from a variety	0.029033232617301376	0.0	1.0	0.0	0.04	0.04	0.7142857142857143	0.7142857142857143	0.0	0.0	0.14285714285714285	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.2857142857142857	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
269	Cellular proliferation	0.8188308513378794	-2.6000000000000014	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.044642857142857144	0.044642857142857144	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.044642857142857144	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	the rosetta-stone method;the Rosetta Stone method	0.11173458861802962	-2.590909090909091	0.0	0.0	0.04	0.04	0.6	0.675	0.0	0.0	0.0	0.0	-5.181818181818182	0.0	0.0	-2.25	0.04	0.04	0.0	0.04	0.045229357798165136	4.5	0.04439024390243902	0.325	2.0	0.0	-4.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	9.0	0.05045871559633027	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
246	Not significant;not significant	0.06418407432855582	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04878048780487805	0.04878048780487805	2.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04878048780487805	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
79	the safe and effective use of flumazenil	0.07140050185293742	-3.6000000000000014	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	1.0	-3.6000000000000014	1.0	1.0	-8.75	0.04	0.06153846153846154	0.0	0.04672897196261683	0.04672897196261683	7.0	0.06153846153846154	0.14285714285714285	1.0	1.0	-8.75	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	7.0	0.04672897196261683	0.0	0.06153846153846154	0.0	1.0	0.0	0.0	1.0
181	commonly HER2	0.1936684149443115	-2.1428571428571423	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.5	1.0	-2.1428571428571423	0.0	0.0	0.0	0.04	0.04	0.0	0.04375	0.04375	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04375	0.0	0.04	0.0	0.0	0.0	0.0	0.0
24	co-administration	0.6697397756228205	-2.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.043859649122807015	0.043859649122807015	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.043859649122807015	0.0	0.04	0.0	0.0	0.0	0.0	0.0
317	specimens	0.6258277431200391	-3.8000000000000007	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04716981132075472	0.04716981132075472	1.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04716981132075472	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
129	Dnmt3a and Dnmt3b;DNMT3A and DNMT3B	0.7242987943658942	-2.1944444444444455	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-3.555555555555557	1.0	1.0	-3.0000000000000004	0.04	0.042682926829268296	0.0	0.04285714285714286	0.04390341728083752	3.0	0.04590865753337906	0.0	4.0	1.0	-6.571428571428571	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	12.0	0.04663212435233161	0.0	0.05426356589147286	0.0	1.0	0.0	0.0	1.0
21	Site of;site motif of	0.004530562809867441	-13.428571428571429	1.0	-13.25	0.0851063829787234	0.0851063829787234	0.6666666666666666	0.6666666666666666	1.0	-13.25	1.0	0.0	-13.428571428571429	0.0	0.0	-14.75	0.0851063829787234	0.0975609756097561	1.0	0.08641975308641975	0.08641975308641975	3.0	0.0975609756097561	1.0	1.0	0.0	-14.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.08641975308641975	0.0	0.0975609756097561	1.0	0.0	0.3333333333333333	0.0	0.0
305	result;Result	0.0661817914888578	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	1.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
46	Identified;identified	0.7550725795088521	-1.0499999999999998	0.0	0.0	0.04	0.04	0.0	0.875	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-0.7083333333333333	0.04	0.04	0.0	0.04	0.041803677467493146	1.0	0.04146551724137931	0.0	8.0	0.0	-5.666666666666666	1.0	0.0	0.875	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.043478260869565216	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
71	inducible transcription factor	0.13125894080637227	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	3.0	0.04	0.6666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.3333333333333333	0.0	0.0
262	sporadic and tuberous sclerosis-related forms	0.10184060135271839	-3.5	1.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.16666666666666666	1.0	-3.5	1.0	1.0	0.0	0.04	0.04	0.0	0.046511627906976744	0.046511627906976744	7.0	0.04	0.2857142857142857	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.046511627906976744	0.0	0.04	0.0	1.0	0.0	0.0	1.0
225	baseline calcium concentrations	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
84	Young;younger	0.09411662981084568	-9.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-9.5	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.06451612903225806	0.06451612903225806	1.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.06451612903225806	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
318	pluripotent hematopoietic disorder	0.32897087834091027	-1.7777777777777786	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-3.3076923076923066	0.04	0.04609929078014184	0.0	0.0430622009569378	0.0430622009569378	3.0	0.04609929078014184	0.0	1.0	0.0	-3.3076923076923066	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.0430622009569378	0.0	0.04609929078014184	0.0	0.0	0.0	0.0	0.0
49	eight with variant forms	0.11503274475397703	-1.375	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-1.375	0.0	0.0	0.0	0.04	0.04	0.0	0.042328042328042326	0.042328042328042326	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.042328042328042326	0.0	0.04	0.0	0.0	0.0	0.0	0.0
205	up to 48 hours after the last dose	0.062416197160684854	-3.25	0.0	0.0	0.04	0.04	0.7777777777777778	0.7777777777777778	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	9.0	0.04	0.1111111111111111	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
276	serum T3	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
5	results;Result	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
86	nuclear and cytosolic compartments	0.19151651535707043	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	4.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
329	newly	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
127	including deletion mutations	0.20746220121390285	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
104	Finding;finding	0.1600122642097738	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.5	0.04	0.04	0.0	0.04	0.04	1.0	0.05272727272727273	0.0	4.0	0.0	-14.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.09090909090909091	0.0	0.0	0.0	0.0	0.0
251	actin depolymerisation;actin depolymerization	0.6682915181655399	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-2.1111111111111107	0.04	0.043689320388349516	0.0	0.043478260869565216	0.043478260869565216	2.0	0.043689320388349516	0.0	2.0	0.0	-2.1111111111111107	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.043478260869565216	0.0	0.043689320388349516	0.0	0.0	0.0	0.0	0.0
9	introns from all isochore classes	0.1269925391546701	0.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.16666666666666666	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
84	treatment;treatment nos	0.09321648205984116	-10.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-10.0	0.0	0.0	-6.333333333333334	0.04	0.053571428571428575	0.0	0.06666666666666667	0.06666666666666667	1.0	0.053571428571428575	0.0	1.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.06666666666666667	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
4	MALIGNANT;malignant	0.6044088312951653	-1.625	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.625	0.0	0.0	0.0	0.04	0.04	0.0	0.0427807486631016	0.0427807486631016	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0427807486631016	0.0	0.04	0.0	0.0	0.0	0.0	0.0
317	off‑target effects	0.06080615964598021	-3.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.045454545454545456	0.045454545454545456	4.0	0.04918032786885245	0.25	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.045454545454545456	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
41	the ATP-dependent chromatin remodeling factor chromodomain helicase DNA	0.20307093449148667	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.2	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
315	NOTCH3 (Notch	0.6798601067073301	-7.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-7.5	1.0	1.0	-6.0	0.04	0.05263157894736842	0.0	0.05714285714285714	0.05714285714285714	3.0	0.05263157894736842	0.0	1.0	1.0	-6.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.05714285714285714	0.0	0.05263157894736842	0.0	1.0	0.0	0.0	1.0
185	estimated;Estimated	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	a preference for oligo-adenosine RNA	0.1651118051894242	0.0	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.04	0.04	7.0	0.06060606060606061	0.0	1.0	0.0	-8.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
190	effect;Effect	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
84	Hydrochloride, Paroxetine;paroxetine hydrochloride	0.7989141095016253	-5.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-5.5	0.0	0.0	0.0	0.04	0.04	0.0	0.05128205128205128	0.05128205128205128	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	4.0	0.05128205128205128	0.0	0.04	0.0	0.0	0.0	0.0	0.0
211	targeting;Targeting	0.566152697724998	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.1111111111111107	0.04	0.043689320388349516	0.0	0.04	0.04	1.0	0.043689320388349516	0.0	1.0	0.0	-2.1111111111111107	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.043689320388349516	0.0	0.0	0.0	0.0	0.0
305	syndromes of severe insulin resistance;Insulin resistance syndrome	0.07801479210239513	-2.428571428571427	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	1.0	-2.428571428571427	0.0	0.0	-9.333333333333334	0.04	0.06382978723404256	0.0	0.04430379746835443	0.04430379746835443	5.0	0.06382978723404256	0.0	1.0	0.0	-9.333333333333334	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	5.0	0.04430379746835443	0.0	0.06382978723404256	0.0	0.0	0.0	0.0	0.0
14	the global minimum energy structure by dynamic programming.The space	0.03522083909085574	0.0	0.0	0.0	0.04	0.04	0.8888888888888888	0.8888888888888888	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.04	0.044117647058823525	0.0	0.04	0.04	9.0	0.044117647058823525	0.1111111111111111	1.0	0.0	-2.333333333333332	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.044117647058823525	0.0	0.0	0.0	0.0	0.0
13	following;Following	0.09660742387934279	-3.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.046875	0.046875	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046875	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	CCR4-associated factor 1	0.32338136653821303	-6.75	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	-6.75	0.0	0.0	0.0	0.04	0.04	0.0	0.0547945205479452	0.0547945205479452	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.0547945205479452	0.0	0.04	0.0	0.0	0.0	0.0	0.0
177	Decreased;decreased	0.06084121386126052	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.04	0.04	1.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
258	level;Levels;Level;levels	0.08745319687518081	-2.733333333333333	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-2.0	0.04	0.04	0.0	0.043859649122807015	0.044932934187320146	1.0	0.04365891985774543	0.0	3.0	0.0	-3.6000000000000014	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.046296296296296294	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
75	LRs in the brain	0.06637442787073183	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
320	Lead compounds;lead compounds	0.0721677774095651	-2.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.044117647058823525	0.044117647058823525	2.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.044117647058823525	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
152	an extrapancreatic effect	0.2839402766437367	-3.6000000000000014	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-9.6	0.04	0.06493506493506493	0.0	0.04672897196261683	0.04672897196261683	3.0	0.06493506493506493	0.0	1.0	0.0	-9.6	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04672897196261683	0.0	0.06493506493506493	0.0	0.0	0.0	0.0	0.0
24	middle-	0.19651003599540007	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.04	0.04	2.0	0.05405405405405406	0.0	1.0	0.0	-6.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
118	antagonists	0.062310083318316806	-12.142857142857142	1.0	-14.2	0.09259259259259259	0.09259259259259259	0.0	0.0	1.0	-14.2	1.0	0.0	-12.142857142857142	0.0	0.0	-11.25	0.09259259259259259	0.07272727272727272	0.0	0.07777777777777778	0.07777777777777778	1.0	0.07272727272727272	1.0	1.0	0.0	-11.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.07777777777777778	0.0	0.07272727272727272	1.0	0.0	0.0	0.0	0.0
143	form;Form	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	all the measures	0.048894972933717654	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
222	circulating;Circulating	0.6058211548459367	-1.7777777777777786	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	0.0	0.04	0.04	0.0	0.0430622009569378	0.0430622009569378	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0430622009569378	0.0	0.04	0.0	0.0	0.0	0.0	0.0
287	novel in vivo pharmacodynamic assays	0.26905681404095005	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
7	Valproic Acid;VALPROIC ACID;valproic acid;Valproic acid	0.9997843622395193	-2.36	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-5.0	1.0	1.0	-3.88	0.04	0.04	0.0	0.04	0.04454052111058128	2.0	0.04942914862914863	0.0	25.0	1.0	-9.25	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.33333333333333326	4.0	1.0	50.0	0.05	0.0	0.06349206349206349	0.0	1.0	0.0	0.0	1.0
199	nucleosomal packaging of centromeric;centromeric nucleosomes;centromeric nucleosome	0.7823717789380312	-1.7777777777777786	0.0	0.0	0.04	0.04	0.0	0.08333333333333333	0.0	0.0	0.0	1.0	-2.666666666666668	1.0	1.0	-2.0	0.04	0.04	0.0	0.04	0.043184079601990055	2.6666666666666665	0.04363636363636364	0.0	3.0	1.0	-3.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.4444444444444444	3.0	1.0	8.0	0.04477611940298508	0.0	0.045454545454545456	0.0	1.0	0.0	0.0	1.0
100	Compared;compared	0.07501320457875972	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	1.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
215	addiction;ADDICTION	0.6134417740765289	-7.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-7.25	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.056338028169014086	0.056338028169014086	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.056338028169014086	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
25	a standard cognitive behaviour therapy (CBT) rationale	0.19216892518420584	0.0	0.0	0.0	0.04	0.04	0.4444444444444444	0.4444444444444444	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	9.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	23	0.6581350072783083	-5.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.5	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.05128205128205128	0.05128205128205128	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.05128205128205128	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
207	late onset movement disorders;Late-Onset Disorders	0.16076691099809026	-4.25	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04819277108433735	0.04819277108433735	4.0	0.047619047619047616	0.0	2.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.04819277108433735	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
229	Candidate Genes;disease candidate genes;Candidate Gene;Candidate Disease Gene;candidate gene prioritization approach for complex diseases;disease relevance of candidate genes;candidate gene;candidate disease gene;candidate genes;candidates against the profile of the known genes	0.9997172742606357	0.0	0.038461538461538464	0.0	0.04	0.04	0.8	0.9868131868131869	0.0	0.0	0.005494505494505494	0.0	0.0	0.0	0.0	-3.3846153846153846	0.04	0.04	0.0	0.04	0.04	2.6153846153846154	0.04890508684863523	0.13507326007326007	26.0	0.0	-10.0	1.0	0.0	0.9230769230769231	0.3076923076923077	1.0	0.0	1.0	0.0	0.0	10.0	1.0	68.0	0.04	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
90	middle-	0.19651003599540007	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.04	0.04	2.0	0.05405405405405406	0.0	1.0	0.0	-6.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
101	indirect;Indirect	0.502755950999532	-4.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-11.666666666666666	0.04	0.075	0.0	0.04878048780487805	0.04878048780487805	1.0	0.075	0.0	1.0	0.0	-11.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04878048780487805	0.0	0.075	0.0	0.0	0.0	0.0	0.0
38	big toes;Hallux;halluces	0.7115976454953867	-1.2222222222222225	0.0	0.0	0.04	0.04	0.0	0.6666666666666666	0.0	0.0	0.0	0.0	-3.666666666666668	0.0	0.0	-1.375	0.04	0.04	0.0	0.04	0.04229166666666667	1.6666666666666667	0.04247191011235955	0.0	6.0	0.0	-2.75	1.0	0.0	0.6666666666666666	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	10.0	0.046875	0.0	0.0449438202247191	0.0	0.0	0.0	0.0	0.0
132	triiodothyroacetic acid;triac;Triiodothyroacetic acid;TRIAC	0.7330449616083476	-4.8999999999999995	0.0	0.0	0.04	0.04	0.0	0.25	0.0	0.0	0.0	1.0	-10.4	1.0	1.0	-5.666666666666667	0.04	0.04	0.0	0.04	0.05299365185432676	1.5	0.05675213675213675	0.0	6.0	1.0	-12.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	4.0	1.0	9.0	0.0684931506849315	0.0	0.07692307692307693	0.0	1.0	0.0	0.0	1.0
215	caused;causes;cause	0.13126274296279902	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-5.25	0.04	0.046296296296296294	0.0	0.047619047619047616	0.04821428571428571	1.0	0.05098125377380697	0.0	4.0	0.0	-7.4	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.05	0.0	0.056818181818181816	0.0	0.0	0.0	0.0	0.0
249	K9 and H3K27me3	0.32552544071610034	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.125	0.04	0.04371584699453552	0.0	0.04	0.04	3.0	0.04371584699453552	0.0	1.0	0.0	-2.125	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04371584699453552	0.0	0.0	0.0	0.0	0.0
256	the most common genetic cause	0.08279735195665178	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	an accuracy of 84.2%	0.2239823304551331	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
288	the TOB/SAM complex	0.38241455901066934	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.2	0.0	0.0
88	Role;role	0.19328997740780987	-1.95	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-2.5333333333333337	0.04	0.04	0.0	0.04	0.043876543209876544	1.0	0.04542857142857143	0.0	5.0	0.0	-6.333333333333334	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.05	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
150	CMA) substrate receptor LAMP-2	0.27468938420100986	-2.7142857142857153	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.5	1.0	-2.7142857142857153	0.0	0.0	-5.833333333333334	0.04	0.052173913043478265	1.0	0.04487179487179487	0.04487179487179487	5.0	0.052173913043478265	0.4	1.0	0.0	-5.833333333333334	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04487179487179487	0.0	0.052173913043478265	0.0	0.0	0.2	0.0	0.0
102	the deubiquitination pathway	0.23060711103797382	-3.5	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	0.0	0.04	0.04	0.0	0.046511627906976744	0.046511627906976744	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.046511627906976744	0.0	0.04	0.0	0.0	0.0	0.0	0.0
61	different;Different	0.0648689902162362	-3.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-9.75	0.04	0.06557377049180328	0.0	0.04716981132075472	0.04716981132075472	1.0	0.06557377049180328	0.0	1.0	0.0	-9.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04716981132075472	0.0	0.06557377049180328	0.0	0.0	0.0	0.0	0.0
62	Immunosuppressive drugs;immunosuppressive drugs	0.38724647335360307	-1.5555555555555571	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	0.0	0.04	0.04	0.0	0.04265402843601896	0.04265402843601896	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04265402843601896	0.0	0.04	0.0	0.0	0.0	0.0	0.0
267	based;Based	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	interacting partners	0.09449791463540107	-3.09090909090909	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.09090909090909	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04564315352697095	0.04564315352697095	2.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04564315352697095	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
283	lines	0.138062657829642	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
334	H2AX;histone variant H2AX;Histone H2AX;H2A.X;-H2AX;Histone variant H2AX;histone H2AX	0.9987494040162055	-0.6402116402116403	0.09523809523809523	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.03571428571428571	1.0	-2.1111111111111107	0.0	0.0	-1.9761904761904763	0.04	0.04	0.09523809523809523	0.04	0.04110068792467842	1.619047619047619	0.044403575354586985	0.25396825396825395	21.0	0.0	-9.75	1.0	0.6666666666666666	0.0	0.47619047619047616	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	7.0	1.0	34.0	0.043689320388349516	0.0	0.06557377049180328	0.0	0.0	0.031746031746031744	0.0	0.0
37	induced;Induced	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
250	CHF	0.7853009530308853	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.5	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
270	an explanation	0.2643617943626036	-2.3999999999999986	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.04424778761061947	0.04424778761061947	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04424778761061947	0.0	0.04	0.0	0.0	0.0	0.0	0.0
329	account	0.10011856807660403	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.5	0.04	0.04	0.0	0.04	0.04	1.0	0.0825	0.0	2.0	0.0	-17.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.125	0.0	0.0	0.0	0.0	0.0
90	Asia	0.8140968329183348	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
142	RET exons 10	0.6171953679194666	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	Conventional Therapy;conventional CML therapy	0.18100243440496674	-1.5555555555555571	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	-3.0769230769230766	0.04	0.045614035087719294	0.0	0.04265402843601896	0.04265402843601896	3.0	0.045614035087719294	0.0	2.0	0.0	-3.0769230769230766	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04265402843601896	0.0	0.045614035087719294	0.0	0.0	0.0	0.0	0.0
14	20%;20;[20];20]	0.8027833021749727	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.166666666666667	0.04	0.045454545454545456	0.0	0.04	0.04	1.5	0.04813883417385887	0.0	6.0	0.0	-5.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	9.0	0.04	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
336	acetyllysine residues	0.7051278194919338	-2.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.75	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.0449438202247191	0.0449438202247191	2.0	0.04938271604938271	0.0	2.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.0449438202247191	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
90	the institutional ethics committee of each centre	0.03115498843252499	-3.6000000000000014	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-6.5	0.04	0.05405405405405406	0.0	0.04672897196261683	0.04672897196261683	7.0	0.05405405405405406	0.2857142857142857	1.0	0.0	-6.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04672897196261683	0.0	0.05405405405405406	0.0	0.0	0.0	0.0	0.0
5	patients with severe disease	0.0884415052403157	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
101	hairpin RNAs	0.5647899476745901	-3.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-9.666666666666666	0.04	0.06521739130434782	0.0	0.047058823529411764	0.047058823529411764	2.0	0.06521739130434782	0.0	1.0	0.0	-9.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.047058823529411764	0.0	0.06521739130434782	0.0	0.0	0.0	0.0	0.0
32	Localization of PR-	0.3258643752149569	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.04	0.04	4.0	0.054545454545454536	0.0	1.0	0.0	-6.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
40	www;WWW	0.6066186994119565	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
50	RPKM);RPKM	0.7868382599391397	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.25	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	potent inhibitor of the 26S proteasome	0.2637891933705576	-4.25	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-7.6	0.04	0.0574712643678161	0.0	0.04819277108433735	0.04819277108433735	6.0	0.0574712643678161	0.0	1.0	0.0	-7.6	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04819277108433735	0.0	0.0574712643678161	0.0	0.0	0.0	0.0	0.0
158	MONTHS;months	0.06901263893103253	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	1.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
74	thought;Thought	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	22,23	0.6442187022146988	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
110	clone;Clone	0.6399465807406479	-3.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.04587155963302752	0.04587155963302752	1.0	0.048387096774193554	0.0	2.0	0.0	-4.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04587155963302752	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
25	Results;outcomes;Outcome;results;Result	0.06184089602858452	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.1666666666666665	0.04	0.04	0.0	0.04	0.04	1.0	0.048172043010752695	0.0	3.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	5.0	1.0	3.0	0.04	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
84	attempted suicide;Attempted Suicide	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
133	Reduction;reduction	0.07873149921151852	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.04	0.043165467625899276	0.0	0.04	0.04	1.0	0.043165467625899276	0.0	1.0	0.0	-1.8333333333333321	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.043165467625899276	0.0	0.0	0.0	0.0	0.0
15	two web applications	0.10055620869665338	-1.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04310344827586207	0.04310344827586207	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04310344827586207	0.0	0.04	0.0	0.0	0.0	0.0	0.0
301	proteomics;Proteomics;proteomic	0.5452362734097207	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.04	0.04	0.0	0.04	0.04	1.0	0.052258064516129035	0.0	2.0	0.0	-9.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.04	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
83	CYP2C19 genotypes	0.7307823555398101	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
177	73.9 (72.7, 75.1) yr	0.5471566752889261	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	' box);box;Box	0.6546565925534659	-0.55	0.0	0.0	0.04	0.04	0.0	0.26666666666666666	0.0	0.0	0.0	0.0	-2.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04098876404494382	0.8	0.04	0.0	5.0	0.0	0.0	1.0	0.0	0.2	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.0449438202247191	0.0	0.04	0.0	0.0	0.0	0.0	0.0
285	carriers	0.12244801426913565	-3.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04716981132075472	0.04716981132075472	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04716981132075472	0.0	0.04	0.0	0.0	0.0	0.0	0.0
237	Human T-cell leukemia virus type I	0.11135123869939965	-2.2857142857142847	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.2857142857142847	0.0	0.0	-4.571428571428571	0.04	0.048951048951048945	0.0	0.0440251572327044	0.0440251572327044	6.0	0.048951048951048945	0.0	1.0	0.0	-4.571428571428571	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.0440251572327044	0.0	0.048951048951048945	0.0	0.0	0.0	0.0	0.0
14	*Number;number	0.0975661386858013	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.083333333333333	0.04	0.04	0.0	0.04	0.04	1.0	0.04654867256637168	0.0	2.0	0.0	-6.166666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.053097345132743355	0.0	0.0	0.0	0.0	0.0
96	evaluable patients	0.20008054889233162	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.04	0.04	2.0	0.05263157894736842	0.0	1.0	0.0	-6.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
79	the primary management of benzodiazepine overdose	0.025068611237319093	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.42857142857142855	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	6.0	0.047619047619047616	0.3333333333333333	1.0	0.0	-4.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
227	lead;???lead	0.10262023294040629	-5.4	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.4	0.0	0.0	0.0	0.04	0.04	0.0	0.0510204081632653	0.0510204081632653	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0510204081632653	0.0	0.04	0.0	0.0	0.0	0.0	0.0
277	Donors;donors	0.093065404135075	-2.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.044642857142857144	0.044642857142857144	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.044642857142857144	0.0	0.04	0.0	0.0	0.0	0.0	0.0
163	QC	0.7123617662367117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
178	m-RNA Guanylyltransferase;mRNA guanylyltransferase;RNA guanylyltransferase	0.8533509438475037	-0.40625	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-1.625	1.0	1.0	-0.75	0.04	0.04	0.0	0.04	0.0406951871657754	1.5	0.041363636363636366	0.0	4.0	1.0	-3.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	3.0	1.0	6.0	0.0427807486631016	0.0	0.045454545454545456	0.0	1.0	0.0	0.0	1.0
100	Antineoplastic;cancer drugs;Cancer Drug;antineoplastic	0.4341605280188296	-1.625	0.0	0.0	0.04	0.04	0.0	0.5	0.0	0.0	0.0	1.0	-3.25	1.0	1.0	-3.583333333333332	0.04	0.04615384615384615	0.0	0.04	0.04298850574712644	1.0	0.046698970321017566	0.0	2.0	1.0	-3.833333333333332	1.0	0.5	0.5	0.0	1.0	1.0	1.0	0.5	0.5	4.0	1.0	2.0	0.04597701149425287	0.0	0.047244094488188976	0.0	1.0	0.0	0.0	1.0
122	increased sensitivity	0.08008224099073274	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.04878048780487805	0.04878048780487805	2.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04878048780487805	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
62	Nodular regenerative hyperplasia;nodular regenerative hyperplasia;Hyperplasia, nodular regenerative	0.9384791397291127	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.25	0.04	0.04	0.0	0.04	0.04	3.0	0.04439024390243903	0.0	6.0	0.0	-4.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	18.0	0.04	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
132	3,5-L-diiodothyronine	0.7922439765553148	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	14.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
71	tumor cells from OXPHOS	0.10413029620428409	-4.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.047619047619047616	0.047619047619047616	4.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.047619047619047616	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
238	Care;care	0.08953518362259696	-1.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	0.0	0.04	0.04	0.0	0.0425531914893617	0.0425531914893617	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0425531914893617	0.0	0.04	0.0	0.0	0.0	0.0	0.0
66	second-	0.23209945046593367	-8.666666666666666	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-8.666666666666666	0.0	0.0	-9.25	0.04	0.06349206349206349	0.0	0.06122448979591836	0.06122448979591836	2.0	0.06349206349206349	0.0	1.0	0.0	-9.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.06122448979591836	0.0	0.06349206349206349	0.0	0.0	0.0	0.0	0.0
143	as;AS	0.07690487070876048	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.04	0.04424778761061947	0.0	0.04	0.04	1.0	0.04424778761061947	0.0	1.0	0.0	-2.3999999999999986	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04424778761061947	0.0	0.0	0.0	0.0	0.0
229	evolutionary conservation	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	Isolated;isolated	0.0653399327051652	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-9.75	0.04	0.06557377049180328	0.0	0.047619047619047616	0.047619047619047616	1.0	0.06557377049180328	0.0	1.0	0.0	-9.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.06557377049180328	0.0	0.0	0.0	0.0	0.0
124	Genomic Instability;genomic instability	0.894690066964295	-3.1666666666666665	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-5.833333333333333	0.04	0.04	0.0	0.04	0.04678571428571429	2.0	0.057499999999999996	0.0	6.0	0.0	-11.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	12.0	0.053571428571428575	0.0	0.075	0.0	0.0	0.0	0.0	0.0
31	further research	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	rhythmic clock gene expression	0.13720615534077008	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
125	myotubularin cause	0.25929163454758714	-6.666666666666666	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-6.666666666666666	0.0	0.0	-14.25	0.04	0.09302325581395349	0.0	0.054545454545454536	0.054545454545454536	2.0	0.09302325581395349	0.0	1.0	0.0	-14.25	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	2.0	0.054545454545454536	0.0	0.09302325581395349	0.0	0.0	0.0	0.0	0.0
246	The cytochrome P450 (CYP) 2C19*2 polymorphism	0.41474847133122267	-3.5	0.0	0.0	0.04	0.04	0.125	0.125	0.0	0.0	0.0	1.0	-3.5	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.046511627906976744	0.046511627906976744	8.0	0.05555555555555555	0.125	1.0	0.0	-7.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.046511627906976744	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
46	endothelial-specific deletion	0.5719153017625052	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
314	arginine and lysine methylation sites	0.11226274072929047	-1.375	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.16666666666666666	1.0	-1.375	1.0	1.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.042328042328042326	0.042328042328042326	5.0	0.04918032786885245	0.2	1.0	1.0	-4.666666666666666	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.042328042328042326	0.0	0.04918032786885245	0.0	1.0	0.0	0.0	1.0
38	16p13.3 or mutations	0.30492601422673643	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04	0.04	3.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
93	the actual incidence and severity of gabapentin-related rash	0.06472429664990638	-2.5	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.1	1.0	-2.5	1.0	1.0	0.0	0.04	0.04	0.0	0.044444444444444446	0.044444444444444446	10.0	0.04	0.3	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.044444444444444446	0.0	0.04	0.0	1.0	0.0	0.0	1.0
245	the regulatory N-domain of isolated cardiac troponin C	0.1107777442066811	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	10.0	0.04	0.3	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
13	lipidic;Lipid	0.6231301874478336	-3.666666666666668	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.046875	0.046875	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046875	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	74% of cases	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
110	the mitochondrial gene	0.026921736583406887	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.5	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	3.0	0.04	0.6666666666666666	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	1.0	0.3333333333333333	0.0	1.0
24	Lipids;lipid;Lipid	0.7000545130899212	-0.9000000000000004	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.041682242990654206	1.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	4.0	0.04672897196261683	0.0	0.04	0.0	0.0	0.0	0.0	0.0
24	cardiovascular preventive polypill-based strategy	0.1677063103617086	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.04	0.04	6.0	0.058823529411764705	0.16666666666666666	1.0	0.0	-8.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
25	disorders;condition;disorder;Disorders;conditions;Disorder	0.029505801171214683	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-10.3	0.04	0.04	0.0	0.04	0.04	1.0	0.08545734657499363	0.6	5.0	0.0	-18.0	1.0	1.0	1.0	0.6	1.0	0.0	1.0	1.0	1.0	6.0	1.0	5.0	0.04	1.0	0.14285714285714285	1.0	0.0	0.0	1.0	0.0
114	GATC sites	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	proliferation;Proliferation	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
146	hepatocyte-specific genetic ablation	0.16960013180168657	-3.333333333333332	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.16666666666666666	1.0	-3.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.04615384615384615	0.04615384615384615	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04615384615384615	0.0	0.04	0.0	0.0	0.0	0.0	0.0
94	three;Three	0.12082106082285962	-5.1	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.800000000000001	0.0	0.0	0.0	0.04	0.04	0.0	0.046296296296296294	0.05062067562067562	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.054945054945054944	0.0	0.04	0.0	0.0	0.0	0.0	0.0
244	the PPP for malaria parasites	0.26905681404095005	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
256	3 (FGFR3(P250R)               )	0.6092180027722294	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
71	several components	0.08562527756069828	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	2.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
204	Chinese patients with achondroplasia	0.02066629928885651	0.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.25	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
168	synostosis;SYNOSTOSIS	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
236	spectra;Spectrum	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	recently not	0.10798483803488096	-6.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.25	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.05333333333333334	0.05333333333333334	2.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05333333333333334	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
85	miR-132 overexpression or PTBP2 knockdown	0.4157605462715009	0.0	0.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
67	Experimental Allergic Encephalomyelitis;Experimental autoimmune encephalomyelitis;experimental autoimmune encephalomyelitis;EAE;Experimental Autoimmune Encephalomyelitis;experimental allergic encephalomyelitis;autoimmune encephalomyelitis	0.9999999999999982	-1.3484848484848486	0.0	0.0	0.04	0.04	0.0	0.20346320346320346	0.0	0.0	0.0	0.0	-5.5	0.0	0.0	-9.12012987012987	0.04	0.04	0.0	0.04	0.04256869047074203	2.311688311688312	0.06504038041233746	0.0	77.0	0.0	-13.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	7.0	1.0	178.0	0.05128205128205128	0.0	0.08888888888888889	0.0	0.0	0.0	0.0	0.0
144	observations	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
71	Directly;directly	0.0963825651646273	-3.6000000000000014	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.04672897196261683	0.04672897196261683	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04672897196261683	0.0	0.04	0.0	0.0	0.0	0.0	0.0
144	1 Repeat (musS) motifs	0.34222259302452757	0.0	0.0	0.0	0.04	0.04	0.16666666666666666	0.16666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.04	0.04	6.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
221	for;For	0.0037109484831499007	-16.666666666666668	1.0	-17.5	0.13333333333333333	0.13333333333333333	1.0	1.0	1.0	-17.5	1.0	0.0	-16.666666666666668	0.0	0.0	-14.5	0.13333333333333333	0.09523809523809523	0.0	0.12	0.12	1.0	0.09523809523809523	1.0	1.0	0.0	-14.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.12	0.0	0.09523809523809523	1.0	0.0	0.0	0.0	0.0
102	Per2 promoter activity	0.4443682979630432	-4.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-4.0	1.0	1.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	3.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.047619047619047616	0.0	0.04	0.0	1.0	0.0	0.0	1.0
13	pump--probe experiments	0.25351262488919757	-4.666666666666666	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.04918032786885245	0.04918032786885245	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04918032786885245	0.0	0.04	0.0	0.0	0.0	0.0	0.0
106	Which genes	0.00890941454925386	-12.833333333333332	1.0	-10.666666666666666	0.06976744186046512	0.06976744186046512	1.0	1.0	1.0	-10.666666666666666	1.0	1.0	-12.833333333333332	1.0	1.0	-8.666666666666666	0.06976744186046512	0.06122448979591836	1.0	0.0821917808219178	0.0821917808219178	2.0	0.06122448979591836	1.0	2.0	1.0	-8.666666666666666	1.0	0.3333333333333333	1.0	1.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.0821917808219178	0.0	0.06122448979591836	1.0	1.0	0.5	0.0	1.0
52	CNS	0.7781755661025822	-9.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-9.0	0.0	0.0	0.0	0.04	0.04	0.0	0.0625	0.0625	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.0625	0.0	0.04	0.0	0.0	0.0	0.0	0.0
179	TOR signalling pathway;of the mammalian target of rapamycin (mTOR) signalling pathway;target of rapamycin signalling pathway	0.3810707504205999	-2.666666666666667	0.0	0.0	0.04	0.04	0.0	0.18181818181818182	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	-2.5	0.04	0.04	1.0	0.04	0.04542372881355933	7.0	0.045	0.4242424242424242	2.0	0.0	-5.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	14.0	0.05084745762711865	0.0	0.05	0.0	0.0	0.2121212121212121	0.0	0.0
239	some responsible genetic foci	0.07268312188736609	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04	0.04	4.0	0.04938271604938271	0.0	1.0	0.0	-4.75	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
4	MEN 1-associated disease	0.10846005907545943	-1.375	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.3333333333333333	1.0	-1.375	0.0	0.0	0.0	0.04	0.04	0.0	0.042328042328042326	0.042328042328042326	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.042328042328042326	0.0	0.04	0.0	0.0	0.0	0.0	0.0
176	the histone	0.1593698766917559	-2.125	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.5	1.0	-4.0	1.0	1.0	-5.2	0.04	0.047619047619047616	0.0	0.04	0.04393931421555731	2.0	0.05090311986863711	0.5	3.0	1.0	-7.6	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.047619047619047616	0.0	0.0574712643678161	0.0	1.0	0.0	0.0	1.0
242	Young Child;young child	0.11252629346355073	-3.7777777777777786	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.7777777777777786	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04712041884816754	0.04712041884816754	2.0	0.04819277108433735	0.0	2.0	0.0	-4.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04712041884816754	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
334	a critical early event in the chromatin response	0.041668101402144275	0.0	0.0	0.0	0.04	0.04	0.875	0.875	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.375	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
102	a transcription and translation feedback loop	0.0747829060298053	0.0	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
226	history;History	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
307	carboxy-terminal alpha-syn epitopes	0.5681483732487378	-2.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.043859649122807015	0.043859649122807015	7.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.043859649122807015	0.0	0.04	0.0	0.0	0.0	0.0	0.0
171	autosomal-dominant NCCM families	0.26905681404095005	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	the efficacy of flumazenil	0.31886508087042215	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-4.5	0.04	0.04878048780487805	0.0	0.04	0.04	4.0	0.04878048780487805	0.0	1.0	1.0	-4.5	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04	0.0	0.04878048780487805	0.0	1.0	0.0	0.0	1.0
206	extracellular levels	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	inhibition of BCR-ABL protein tyrosine kinase activity;inhibition of protein kinase activity	0.43484702359413585	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-5.307692307692308	0.04	0.05078125	1.0	0.04	0.04	9.0	0.05078125	0.4444444444444444	2.0	1.0	-5.307692307692308	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	18.0	0.04	0.0	0.05078125	0.0	1.0	0.1111111111111111	0.0	1.0
346	NELF and DSIF	0.41477933104515696	-3.1999999999999993	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-3.1999999999999993	1.0	1.0	-2.0	0.04	0.043478260869565216	0.0	0.04587155963302752	0.04587155963302752	3.0	0.043478260869565216	0.0	1.0	1.0	-2.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04587155963302752	0.0	0.043478260869565216	0.0	1.0	0.0	0.0	1.0
102	ubiquitination pathway	0.664894630570528	-3.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	0.0	0.04	0.04	0.0	0.046511627906976744	0.046511627906976744	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.046511627906976744	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	normal free thyroid hormone concentrations;Normal concentration	0.14942138320949097	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	BCR-ABL kinase	0.9648437374986814	-1.3111111111111122	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.6	-1.8888888888888893	0.6	0.0	-4.892307692307693	0.04	0.043478260869565216	1.0	0.04	0.04224626321545753	4.0	0.05004465027800966	0.5	5.0	0.6	-6.538461538461538	1.0	1.0	0.0	1.0	0.0	0.6	1.0	0.0	0.4666666666666666	1.0	1.0	20.0	0.04326923076923077	1.0	0.05416666666666667	0.0	1.0	0.25	0.2	1.0
165	history;History	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	patient treatment;patients during gabapentin treatment	0.021078754084976965	0.0	1.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.2	0.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	4.0	0.04918032786885245	0.25	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
132	relative binding affinity	0.33112350876741486	-9.8	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-9.8	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.06578947368421052	0.06578947368421052	3.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.06578947368421052	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
179	Link;linked	0.07238108731430415	-6.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	-9.6	0.04	0.06493506493506493	0.0	0.054545454545454536	0.054545454545454536	1.0	0.06493506493506493	0.0	1.0	0.0	-9.6	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.054545454545454536	0.0	0.06493506493506493	0.0	0.0	0.0	0.0	0.0
17	bilateral tubal occlusion secondary	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
26	duodenal;Duodenal	0.6039131868305536	-1.571428571428573	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.042682926829268296	0.042682926829268296	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.042682926829268296	0.0	0.04	0.0	0.0	0.0	0.0	0.0
100	effective anti-cancer drugs	0.1626511298884188	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-3.333333333333332	0.04	0.04615384615384615	0.0	0.04	0.04	3.0	0.04615384615384615	0.0	1.0	1.0	-3.333333333333332	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04615384615384615	0.0	1.0	0.0	0.0	1.0
215	Mitogen-activated protein kinase p38;Mitogen-Activated Protein Kinase p38	0.6690088687364605	0.0	0.0	0.0	0.04	0.04	0.14285714285714285	0.14285714285714285	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-3.3999999999999986	0.04	0.046296296296296294	0.0	0.04	0.04	7.0	0.046296296296296294	0.0	2.0	1.0	-3.3999999999999986	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	14.0	0.04	0.0	0.046296296296296294	0.0	1.0	0.0	0.0	1.0
222	/day;day	0.07493561883251082	-3.2222222222222214	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.2222222222222214	0.0	0.0	-5.800000000000001	0.04	0.052083333333333336	0.0	0.04591836734693877	0.04591836734693877	1.0	0.052083333333333336	0.0	1.0	0.0	-5.800000000000001	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04591836734693877	0.0	0.052083333333333336	0.0	0.0	0.0	0.0	0.0
247	50%;50	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
305	the majority of patients	0.019934346395877822	0.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	4.0	0.04918032786885245	0.25	1.0	0.0	-4.666666666666666	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
213	the LQT1 sub-type of LQTS	0.19746034348742605	0.0	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.125	1.0	0.0	0.0	0.0	-3.5	0.04	0.046511627906976744	0.0	0.04	0.04	5.0	0.046511627906976744	0.0	1.0	0.0	-3.5	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.046511627906976744	0.0	0.0	0.0	0.0	0.0
329	MMFF94 force field	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	auto-PBSCT or following treatment	0.11196840376497659	-5.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-3.8000000000000007	0.04	0.04716981132075472	0.0	0.05	0.05	4.0	0.04716981132075472	0.0	1.0	0.0	-3.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.05	0.0	0.04716981132075472	0.0	0.0	0.0	0.0	0.0
77	alters;Altered;change;Change	0.07467586938932552	-0.7222222222222227	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	-3.19047619047619	0.04	0.04375	0.0	0.04	0.04126520681265207	1.0	0.046017932489451484	0.0	3.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.043795620437956206	0.0	0.05	0.0	0.0	0.0	0.0	0.0
321	a dataset	0.26586926598687627	-2.6000000000000014	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.6000000000000014	0.0	0.0	0.0	0.04	0.04	0.0	0.044642857142857144	0.044642857142857144	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.044642857142857144	0.0	0.04	0.0	0.0	0.0	0.0	0.0
293	Gynaecological;gynecological	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
159	a reduced life expectancy	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
78	the 17	0.2824167356904098	-4.75	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.75	0.0	0.0	0.0	0.04	0.04	0.0	0.04938271604938271	0.04938271604938271	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04938271604938271	0.0	0.04	0.0	0.0	0.0	0.0	0.0
249	PRC2	0.7499266980896674	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.4375	0.04	0.06015037593984962	0.0	0.04	0.04	1.0	0.0603799575274063	0.0	4.0	0.0	-8.625	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.061068702290076333	0.0	0.0	0.0	0.0	0.0
313	PABPCs	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
66	Maternal;maternal	0.6959380922850743	-0.7777777777777773	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	-1.25	0.04	0.04	0.0	0.04	0.041372549019607845	1.0	0.04235294117647059	0.0	3.0	0.0	-3.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.044117647058823525	0.0	0.047058823529411764	0.0	0.0	0.0	0.0	0.0
274	carrier protein	0.0885685611970479	-1.4545454545454533	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.4545454545454533	0.0	0.0	-4.428571428571429	0.04	0.04861111111111112	0.0	0.04247104247104247	0.04247104247104247	2.0	0.04861111111111112	0.0	1.0	0.0	-4.428571428571429	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04247104247104247	0.0	0.04861111111111112	0.0	0.0	0.0	0.0	0.0
215	the initial stimuli	0.105744714509908	-3.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04597701149425287	0.04597701149425287	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04597701149425287	0.0	0.04	0.0	0.0	0.0	0.0	0.0
160	Aim;aimed	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
325	lead;???lead	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	made;Make	0.08300939667314712	-1.875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.875	0.0	0.0	-2.166666666666668	0.04	0.043795620437956206	0.0	0.043243243243243246	0.043243243243243246	1.0	0.043795620437956206	0.0	1.0	0.0	-2.166666666666668	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043243243243243246	0.0	0.043795620437956206	0.0	0.0	0.0	0.0	0.0
44	3;[3];<3	0.7883675257392322	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	4.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
146	age;AGE	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
277	the implementation	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
204	380(G380R	0.6171953679194666	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
66	the etiology	0.0412116784169971	-4.666666666666666	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.5	0.0	-4.666666666666666	0.0	0.0	-7.75	0.04	0.057971014492753624	0.0	0.04918032786885245	0.04918032786885245	2.0	0.057971014492753624	0.5	1.0	0.0	-7.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04918032786885245	0.0	0.057971014492753624	0.0	0.0	0.0	0.0	0.0
26	YEARS;YEAR;year;yr;years	0.3378223709031952	-3.8095238095238098	0.0	0.0	0.04	0.04	0.0	0.6666666666666666	0.0	0.0	0.0	0.0	-4.857142857142858	0.0	0.0	0.0	0.04	0.04	0.0	0.04375	0.04733550039401104	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	0.6666666666666666	0.0	1.0	0.0	1.0	0.0	0.0	5.0	1.0	3.0	0.04964539007092199	0.0	0.04	0.0	0.0	0.0	0.0	0.0
317	maintenance of normal adult stem cells;adult stem cell maintenance	0.06725626967277452	-2.8000000000000007	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.8000000000000007	0.0	0.0	0.0	0.04	0.04	0.0	0.04504504504504505	0.04504504504504505	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04504504504504505	0.0	0.04	0.0	0.0	0.0	0.0	0.0
327	epigenetic marks	0.20296469586287563	-3.25	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-8.4	0.04	0.06024096385542168	0.0	0.04597701149425287	0.04597701149425287	2.0	0.06024096385542168	0.0	1.0	0.0	-8.4	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04597701149425287	0.0	0.06024096385542168	0.0	0.0	0.0	0.0	0.0
204	used	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
307	the unaltered protein	0.04203301308494911	-2.3999999999999986	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.3333333333333333	1.0	-2.3999999999999986	1.0	1.0	-3.25	0.04	0.04597701149425287	1.0	0.04424778761061947	0.04424778761061947	3.0	0.04597701149425287	0.6666666666666666	1.0	1.0	-3.25	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	3.0	0.04424778761061947	0.0	0.04597701149425287	0.0	1.0	0.3333333333333333	0.0	1.0
145	diminished;Diminished;Decreased;decreased	0.07482086365367946	-0.809523809523809	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.428571428571427	0.0	0.0	-3.0	0.04	0.04	0.0	0.04	0.04143459915611814	1.0	0.04585365853658537	0.0	3.0	0.0	-4.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	3.0	0.04430379746835443	0.0	0.04878048780487805	0.0	0.0	0.0	0.0	0.0
228	new;NEW;Novel;novel	0.1664975425084762	-2.5666666666666664	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.6	0.0	0.0	-0.6666666666666666	0.04	0.04	0.0	0.04	0.045425883549453344	1.0	0.04126984126984127	0.0	6.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	6.0	0.05434782608695653	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
102	MELATONIN;melatonin	0.7769188464143443	-4.125	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047905909351692484	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	2.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
187	Short QT Syndrome (SQTS)	0.06224105453346128	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
144	myosin light chain-2;myosin light chain 2	0.5319516836830203	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
255	integral;Integral	0.5742561249408005	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.375	0.04	0.042328042328042326	0.0	0.04	0.04	1.0	0.042328042328042326	0.0	1.0	0.0	-1.375	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.042328042328042326	0.0	0.0	0.0	0.0	0.0
246	Loading dose;loading dose	0.16874251807703958	-4.25	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	-8.5	0.04	0.06060606060606061	0.0	0.04819277108433735	0.04819277108433735	2.0	0.06060606060606061	0.0	1.0	0.0	-8.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04819277108433735	0.0	0.06060606060606061	0.0	0.0	0.0	0.0	0.0
183	cloned;Cloning;cloning	0.5951013416514221	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
317	Kinetics;kinetics	0.5698910395796752	-2.1999999999999993	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.1999999999999993	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.043859649122807015	0.043859649122807015	1.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043859649122807015	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
41	the mating-type region	0.21252977397778025	-3.5	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-7.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04777777777777778	5.0	0.04	0.2	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.05555555555555555	0.0	0.04	0.0	0.0	0.0	0.0	0.0
204	Identified;identified	0.10245853400185427	-6.125	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-9.25	0.0	0.0	-3.5	0.04	0.04	0.0	0.045454545454545456	0.05447330447330447	1.0	0.04777777777777778	0.0	2.0	0.0	-7.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.06349206349206349	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
41	21–23)	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
334	organisms;Organisms	0.07619605405768606	-1.8888888888888893	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8888888888888893	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04326923076923077	0.04326923076923077	1.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04326923076923077	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
121	black persons	0.1764900500430126	-5.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.051724137931034475	0.051724137931034475	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.051724137931034475	0.0	0.04	0.0	0.0	0.0	0.0	0.0
246	elective stent implantation	0.6171953679194666	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
315	Adults, Young;young adults	0.20435920874540817	-6.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05263157894736842	0.05263157894736842	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.05263157894736842	0.0	0.04	0.0	0.0	0.0	0.0	0.0
213	nine;Nine	0.13116317601673694	-5.666666666666667	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	0.0	0.04	0.04	0.0	0.05084745762711865	0.05173951828724353	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.05263157894736842	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	Completely;completely	0.07099591202342687	-3.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	-7.25	0.04	0.056338028169014086	0.0	0.046296296296296294	0.046296296296296294	1.0	0.056338028169014086	0.0	1.0	0.0	-7.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046296296296296294	0.0	0.056338028169014086	0.0	0.0	0.0	0.0	0.0
14	an oligomer	0.6147740635287726	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.04	0.043165467625899276	0.0	0.04	0.04	2.0	0.043165467625899276	0.0	1.0	0.0	-1.8333333333333321	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.043165467625899276	0.0	0.0	0.0	0.0	0.0
50	each gene	0.10836003576119926	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	2.0	0.0	0.0	1.0	0.5	1.0	1.0	1.0	0.0	1.0	0.5	0.5	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
65	main;Main	0.0029385460196062786	-13.75	1.0	-18.0	0.14285714285714285	0.14285714285714285	1.0	1.0	1.0	-18.0	1.0	0.0	-13.75	0.0	0.0	-17.5	0.14285714285714285	0.13333333333333333	0.0	0.08888888888888889	0.08888888888888889	1.0	0.13333333333333333	1.0	1.0	0.0	-17.5	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.08888888888888889	0.0	0.13333333333333333	1.0	0.0	0.0	0.0	0.0
252	More;more	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
227	an association between iron deficiency	0.21922287393553483	-3.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	-3.0	1.0	1.0	-5.333333333333334	0.04	0.05084745762711865	1.0	0.045454545454545456	0.045454545454545456	5.0	0.05084745762711865	0.2	1.0	1.0	-5.333333333333334	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	5.0	0.045454545454545456	1.0	0.05084745762711865	0.0	1.0	0.2	1.0	1.0
107	In	0.2112150324485445	-0.9166666666666679	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-0.9166666666666679	0.0	0.0	-7.2857142857142865	0.04	0.056451612903225805	0.0	0.041522491349480974	0.041522491349480974	1.0	0.056451612903225805	0.0	1.0	0.0	-7.2857142857142865	1.0	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	0.041522491349480974	1.0	0.056451612903225805	0.0	0.0	0.0	1.0	0.0
251	the proper functions of Par protein complex	0.0823031601210742	-1.5555555555555571	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	1.0	-1.5555555555555571	0.0	0.0	-1.8888888888888893	0.04	0.04326923076923077	0.0	0.04265402843601896	0.04265402843601896	7.0	0.04326923076923077	0.2857142857142857	1.0	0.0	-1.8888888888888893	1.0	0.6666666666666666	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	7.0	0.04265402843601896	0.0	0.04326923076923077	0.0	0.0	0.0	0.0	0.0
247	Organized vaccination programs	0.10280257885569606	-5.166666666666666	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.2	1.0	-5.166666666666666	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.050420168067226885	0.050420168067226885	3.0	0.04938271604938271	0.3333333333333333	2.0	0.0	-4.75	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.050420168067226885	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
176	domains;Domain	0.0694099360521566	-3.875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.875	0.0	0.0	-8.2	0.04	0.05952380952380952	0.0	0.047337278106508875	0.047337278106508875	1.0	0.05952380952380952	0.0	1.0	0.0	-8.2	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047337278106508875	0.0	0.05952380952380952	0.0	0.0	0.0	0.0	0.0
80	a late onset	0.1488390187570526	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
241	the iliac bone	0.07183762434887417	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.3999999999999986	0.04	0.04424778761061947	0.0	0.04	0.04	3.0	0.04424778761061947	0.3333333333333333	1.0	0.0	-2.3999999999999986	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04424778761061947	0.0	0.0	0.0	0.0	0.0
80	negative;Negative	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	normal thyroid function;Normal thyroid function	0.1928597827393889	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
189	5;>5	0.6291675005041891	-4.333333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.048387096774193554	0.048387096774193554	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.048387096774193554	0.0	0.04	0.0	0.0	0.0	0.0	0.0
276	brain findings;brain MRI findings	0.1928597827393889	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
119	partner;Partner	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
160	Drugs;drugs	0.08595467246463842	-2.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	-1.8571428571428577	0.04	0.043209876543209874	0.0	0.044444444444444446	0.044444444444444446	1.0	0.043209876543209874	0.0	1.0	0.0	-1.8571428571428577	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.044444444444444446	0.0	0.043209876543209874	0.0	0.0	0.0	0.0	0.0
262	characterized;Characterized	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
71	the activation	0.12765092792387897	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.75	0.04	0.04938271604938271	0.0	0.04	0.04	2.0	0.04938271604938271	0.5	2.0	0.0	-4.75	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04938271604938271	0.0	0.0	0.0	0.0	0.0
90	greater BP/lipid control	0.26905681404095005	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
144	multiple independent transgenic mouse lines	0.18678376523677198	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	10.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
135	contaminants;Contaminant	0.08450736124817812	-1.9411764705882348	1.0	-8.454545454545455	0.04	0.04681318681318681	0.0	0.0	1.0	-2.8181818181818183	1.0	0.0	-4.647058823529411	0.0	0.0	-2.9166666666666665	0.06043956043956043	0.04419889502762431	0.0	0.04	0.04370275220628464	1.0	0.045326872526192545	1.0	3.0	0.0	-3.875	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.049132947976878616	0.0	0.047337278106508875	1.0	0.0	0.0	0.0	0.0
163	no significant effect;no effect;No effect	0.20580391090028155	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.5	0.04	0.04	0.0	0.04	0.04	2.5	0.045	0.0	4.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	10.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
199	[Adra2C-D5H4S43-Hdh];[Adra2C-D5H4S43-Hdh	0.8161472193133432	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.5	0.04	0.0	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	13.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
218	Instrument;instrument	0.14095469534932045	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	Imatinib mesylate (Glivec;imatinib mesylate (Glivec	0.25716071759295145	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	-2.2307692307692317	0.04	0.042622950819672135	0.0	0.04	0.04	4.0	0.04395955903352945	0.5	2.0	0.0	-2.9230769230769234	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.04	0.0	0.04529616724738676	0.0	0.0	0.0	0.0	0.0
225	their roles in endogenous regulation	0.057961055114664525	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
287	fallopian tube;FALLOPIAN TUBE	0.27926268070552995	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
161	syndactyly of hands and feet	0.0545353605669634	-3.75	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-3.75	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.047058823529411764	0.047058823529411764	5.0	0.04918032786885245	0.2	1.0	0.0	-4.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.047058823529411764	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
255	autosomal dominant mode	0.10863214124286318	-6.428571428571429	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-6.428571428571429	1.0	1.0	-5.25	0.04	0.05063291139240506	1.0	0.05384615384615385	0.05384615384615385	3.0	0.05063291139240506	0.3333333333333333	1.0	1.0	-5.25	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.05384615384615385	0.0	0.05063291139240506	0.0	1.0	0.3333333333333333	0.0	1.0
44	The presence of antisense RNA	0.07714423616525953	-10.5	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-10.5	0.0	0.0	-8.666666666666666	0.04	0.06122448979591836	0.0	0.06896551724137931	0.06896551724137931	5.0	0.06122448979591836	0.4	1.0	0.0	-8.666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.06896551724137931	0.0	0.06122448979591836	0.0	0.0	0.0	0.0	0.0
85	The cyclic AMP-responsive element binding- and NMDA-regulated microRNA miR-132	0.13369859184849003	0.0	1.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.14285714285714285	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	14.0	0.04	0.14285714285714285	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	14.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
258	tested	0.09524414484661932	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	1.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
264	similar;Similar	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
206	mice after an intrathecal (i.t.) administration	0.2437065367195448	0.0	0.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
40	the nodes	0.11763179700600951	-3.166666666666668	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.04580152671755725	0.04580152671755725	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04580152671755725	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	Analysis;analysis	0.13801711026548782	-2.0833333333333335	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-8.333333333333334	0.0	0.0	-1.5625	0.04	0.04	0.0	0.04	0.045000000000000005	1.0	0.043333333333333335	0.0	4.0	0.0	-6.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.06000000000000001	0.0	0.05333333333333334	0.0	0.0	0.0	0.0	0.0
67	a sample	0.08920834675818906	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04	0.04	2.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
89	Long Term;long-term	0.1187176919696614	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
89	In range;in a wide range	0.04133059847184054	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	the differential diagnosis	0.12511512763291846	-3.8000000000000007	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.8000000000000007	0.0	0.0	-7.75	0.04	0.057971014492753624	0.0	0.04716981132075472	0.04716981132075472	3.0	0.057971014492753624	0.0	1.0	0.0	-7.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04716981132075472	0.0	0.057971014492753624	0.0	0.0	0.0	0.0	0.0
161	acrocephalosyndactyly;APERT SYNDROME;Apert syndrome	0.8746213934217907	-3.8333333333333335	1.0	-11.666666666666666	0.04	0.04466666666666667	0.0	0.4	1.0	-1.5555555555555556	1.0	0.0	-13.75	0.0	0.0	-4.2	0.075	0.04	0.0	0.04	0.05051851851851852	1.8	0.05050367240787152	0.8	15.0	0.0	-12.666666666666668	1.0	0.0	0.0	0.8	0.0	0.0	1.0	0.0	0.0	3.0	1.0	27.0	0.08888888888888889	0.0	0.08108108108108109	1.0	0.0	0.0	0.0	0.0
199	autoimmune and cancer diseases	0.20159137434488644	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	base 1618 in exon 9	0.2239823304551331	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.16666666666666666	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
307	small;SMALL	0.09571079213856525	-3.3999999999999986	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.3999999999999986	0.0	0.0	0.0	0.04	0.04	0.0	0.046296296296296294	0.046296296296296294	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.046296296296296294	0.0	0.04	0.0	0.0	0.0	0.0	0.0
41	The MORF4-Related Gene on chromosome 15 (MRG15)	0.21305815400128145	0.0	0.0	0.0	0.04	0.04	0.36363636363636365	0.36363636363636365	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	11.0	0.04	0.09090909090909091	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	11.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
69	the adult neurogenesis	0.0793662226340656	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
92	10 nm diameter filaments in cells	0.1504878326996318	0.0	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.14285714285714285	1.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	6.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.16666666666666666	0.0	0.0
85	Alzheimer	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	a k-nearest neighbour algorithm to the whole	0.11867639862843804	0.0	0.0	0.0	0.04	0.04	0.5555555555555556	0.5555555555555556	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-3.333333333333332	0.04	0.04615384615384615	0.0	0.04	0.04	9.0	0.04615384615384615	0.2222222222222222	1.0	0.0	-3.333333333333332	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04	0.0	0.04615384615384615	0.0	0.0	0.0	0.0	0.0
99	AD-EDMD	0.23579541291950482	-4.25	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
133	c-Jun	0.7409201488454747	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	the incidence	0.41214310572029256	-8.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-11.333333333333334	0.0	0.0	-5.333333333333333	0.04	0.04	0.0	0.05263157894736842	0.06011592173338001	2.0	0.0529296066252588	0.0	3.0	0.0	-9.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.07317073170731708	0.0	0.06521739130434782	0.0	0.0	0.0	0.0	0.0
327	using;Using	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	Response;response	0.0938301236000151	-2.833333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.045112781954887216	0.045112781954887216	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045112781954887216	0.0	0.04	0.0	0.0	0.0	0.0	0.0
119	integrity	0.11184251287889924	-4.166666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.166666666666666	0.0	0.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.047999999999999994	0.047999999999999994	1.0	0.044642857142857144	0.0	1.0	0.0	-2.6000000000000014	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.047999999999999994	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
251	expression of mesenchymal markers	0.040321190107961875	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.2222222222222214	0.04	0.04205607476635514	0.0	0.04	0.04	4.0	0.04205607476635514	0.5	1.0	0.0	-1.2222222222222214	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04205607476635514	0.0	0.0	0.0	0.0	0.0
86	dronedarone;DRONEDARONE	0.6291675005041891	-4.333333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.0	0.0	0.0	0.04	0.04	0.0	0.048387096774193554	0.048387096774193554	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.048387096774193554	0.0	0.04	0.0	0.0	0.0	0.0	0.0
231	the mechanical properties	0.08600878234602069	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.2857142857142847	0.04	0.0440251572327044	0.0	0.04	0.04	3.0	0.0440251572327044	0.0	1.0	0.0	-2.2857142857142847	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.0440251572327044	0.0	0.0	0.0	0.0	0.0
69	CP110	0.7123617662367117	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	the first reports	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
159	subtypes	0.4243869373988075	-1.8	1.0	-11.666666666666666	0.04	0.047	0.0	0.0	1.0	-2.333333333333333	1.0	1.0	-5.0	1.0	1.0	-3.333333333333333	0.075	0.04	1.0	0.04	0.04352380952380953	1.0	0.04922068095838587	1.0	5.0	1.0	-12.0	1.0	1.0	0.0	1.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	5.0	0.05	1.0	0.07692307692307693	1.0	1.0	1.0	1.0	1.0
4	endocrine neoplasia	0.160709317948801	-2.4375	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.5	0.0	0.0	-1.9000000000000004	0.04	0.04	0.0	0.04419889502762431	0.04432166973603438	2.0	0.04358490566037736	1.0	2.0	0.0	-3.8000000000000007	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.044444444444444446	0.0	0.04716981132075472	1.0	0.0	0.0	0.0	0.0
259	individuals with healthy hearts	0.0884415052403157	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
99	recessive inheritance with mutations	0.3092508035780361	-4.5	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	0.0	0.04	0.04	0.0	0.04878048780487805	0.04878048780487805	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04878048780487805	0.0	0.04	0.0	0.0	0.0	0.0	0.0
334	from;From	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
56	pan;Pan	0.6066186994119565	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	0.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
222	10%;10	0.6221201843595147	-3.555555555555557	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.555555555555557	0.0	0.0	0.0	0.04	0.04	0.0	0.04663212435233161	0.04663212435233161	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04663212435233161	0.0	0.04	0.0	0.0	0.0	0.0	0.0
76	assessed;Assessed	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
245	results;Result	0.09297215030954452	-2.571428571428573	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.0445859872611465	0.0445859872611465	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0445859872611465	0.0	0.04	0.0	0.0	0.0	0.0	0.0
60	2003)	0.5950955347466511	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.04	0.04	2.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
276	patients;Patients;*^patient;patient	0.20216574887740799	-2.764705882352941	1.0	-15.166666666666668	0.04	0.04725822532402792	1.0	1.0	1.0	-1.7843137254901962	1.0	0.0	-14.125	0.0	0.0	-2.070588235294118	0.1016949152542373	0.04	0.0	0.04	0.04810242466837531	1.0	0.048003095975232196	1.0	17.0	0.0	-15.4	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	4.0	1.0	17.0	0.09195402298850575	0.0	0.10416666666666667	1.0	0.0	0.0	0.0	0.0
4	three;Three	0.00494164794371109	-5.875	1.0	-9.6	0.04	0.048311688311688306	1.0	1.0	1.0	-3.1999999999999997	1.0	0.0	-15.625	0.0	0.0	-3.9999999999999996	0.06493506493506493	0.04	0.0	0.04	0.0633816425120773	1.0	0.04909063535079796	1.0	3.0	0.0	-8.6	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.10666666666666667	0.0	0.06097560975609757	1.0	0.0	0.0	0.0	0.0
180	intron;Intron	0.6322779467993551	-6.055555555555556	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-9.0	0.0	0.0	-10.444444444444445	0.04	0.06666666666666667	0.0	0.04477611940298508	0.05377672448567972	1.0	0.06875901875901876	0.0	3.0	0.0	-11.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.0625	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0
117	enzyme;Enzyme	0.5605955648326031	-8.285714285714286	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-8.285714285714286	0.0	0.0	-9.75	0.04	0.06557377049180328	0.0	0.059829059829059825	0.059829059829059825	1.0	0.06557377049180328	0.0	1.0	0.0	-9.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.059829059829059825	0.0	0.06557377049180328	0.0	0.0	0.0	0.0	0.0
318	the ABL gene on chromosome 9	0.1283195979378923	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-1.3076923076923066	0.04	0.04220779220779221	0.0	0.04	0.04	6.0	0.04220779220779221	0.3333333333333333	1.0	1.0	-1.3076923076923066	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04220779220779221	0.0	1.0	0.0	0.0	1.0
265	NCCM	0.6921113048953613	-2.8000000000000007	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.044642857142857144	0.045048701298701296	1.0	0.048387096774193554	0.0	2.0	0.0	-4.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.045454545454545456	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
237	an inhibitory molecule	0.33117153913710956	-4.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.047619047619047616	0.047619047619047616	3.0	0.05	0.0	1.0	0.0	-5.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.047619047619047616	0.0	0.05	0.0	0.0	0.0	0.0	0.0
124	care for individualized treatment decision	0.05129066947010948	-6.333333333333334	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-8.333333333333334	0.04	0.06000000000000001	0.0	0.053571428571428575	0.053571428571428575	5.0	0.06000000000000001	0.2	1.0	0.0	-8.333333333333334	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.053571428571428575	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
137	duplex;Duplex	0.5273349720896606	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.6	0.04	0.051546391752577324	0.0	0.04	0.04	1.0	0.051546391752577324	0.0	1.0	0.0	-5.6	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.051546391752577324	0.0	0.0	0.0	0.0	0.0
163	end;End	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
48	nucleotide position	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
319	the compounds	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	80 patients	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
86	sarcoplasmic reticulum calcium adenosine triphosphatase;sarcoplasmic reticulum calcium-activated adenosinetriphosphatase	0.6104561342266209	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
127	cell lung cancer	0.10789782120691593	-3.833333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.833333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.047244094488188976	0.047244094488188976	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.047244094488188976	0.0	0.04	0.0	0.0	0.0	0.0	0.0
224	the purine analog	0.2908056726803701	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
24	Lipid lowering agents;lipid-lowering agents	0.36904857332920016	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.04	0.04	4.0	0.06666666666666667	0.0	3.0	0.0	-10.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	12.0	0.04	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
100	Double strand;double-stranded	0.2598421831356368	-3.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.045454545454545456	0.045454545454545456	3.0	0.045454545454545456	0.3333333333333333	2.0	0.0	-3.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.045454545454545456	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
122	the Affymetrix ADME gene chip	0.08644720917611623	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.0	0.04	0.05555555555555555	1.0	0.04	0.04	5.0	0.05555555555555555	0.2	1.0	0.0	-7.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.05555555555555555	0.0	0.0	0.2	0.0	0.0
345	stem-loop structure;stem loop structure	0.9981291116175479	-0.38124999999999987	1.0	0.0	0.04	0.04	0.75	0.765625	0.0	0.0	0.4979166666666667	0.0	-1.6999999999999993	0.0	0.0	-1.6375	0.04	0.04	0.0	0.04	0.04064995377390809	3.9375	0.043497468707645696	0.5104166666666666	16.0	0.0	-7.0	1.0	0.0	0.0625	1.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	63.0	0.04291845493562232	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
102	a heterodimer	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
24	large as those originally estimated	0.08279735195665178	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
264	SCH	0.9114774863600357	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	7.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
287	Reduplication;reduplication	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
15	keywords from users	0.13999263908502374	-1.3999999999999986	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-1.3999999999999986	0.0	0.0	-2.8000000000000007	0.04	0.04504504504504505	0.0	0.0423728813559322	0.0423728813559322	3.0	0.04504504504504505	0.0	1.0	0.0	-2.8000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.0423728813559322	0.0	0.04504504504504505	0.0	0.0	0.0	0.0	0.0
254	Decrease;decrease	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
86	TR cotransfection and treatment with the TRbeta1-selective agonist GC-1	0.21305815400128145	0.0	0.0	0.0	0.04	0.04	0.36363636363636365	0.36363636363636365	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	11.0	0.04	0.09090909090909091	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	11.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
195	genetic disorders;Genetic Disorders	0.10572182807333368	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.047619047619047616	0.047619047619047616	2.0	0.05263157894736842	0.0	2.0	0.0	-6.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.047619047619047616	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
237	different;Different	0.07948561966501638	-2.2857142857142847	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.2857142857142847	0.0	0.0	-3.571428571428573	0.04	0.04666666666666667	0.0	0.0440251572327044	0.0440251572327044	1.0	0.04666666666666667	0.0	1.0	0.0	-3.571428571428573	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0440251572327044	0.0	0.04666666666666667	0.0	0.0	0.0	0.0	0.0
110	nuclear (IV	0.30413320252407877	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.333333333333334	0.04	0.048387096774193554	0.0	0.04	0.04	3.0	0.048387096774193554	0.0	1.0	0.0	-4.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.048387096774193554	0.0	0.0	0.0	0.0	0.0
189	glucose regulation	0.289658730492229	-5.666666666666666	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.051724137931034475	0.051724137931034475	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.051724137931034475	0.0	0.04	0.0	0.0	0.0	0.0	0.0
318	the specific target	0.011314058902903967	-2.1111111111111107	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.3333333333333333	0.0	-2.1111111111111107	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.043689320388349516	0.043689320388349516	3.0	0.047619047619047616	0.6666666666666666	1.0	0.0	-4.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043689320388349516	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
229	Close;close	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
176	Gal repressor (GalR)	0.7082823492620991	-4.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.25	1.0	1.0	-7.0	0.04	0.05555555555555555	0.0	0.04819277108433735	0.04819277108433735	5.0	0.05555555555555555	0.0	1.0	1.0	-7.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.04819277108433735	0.0	0.05555555555555555	0.0	1.0	0.0	0.0	1.0
73	a novel feature of the TMBHMM method	0.03366913381858039	-1.2222222222222214	0.0	0.0	0.04	0.04	0.8571428571428571	0.8571428571428571	0.0	0.0	0.0	0.0	-1.2222222222222214	0.0	0.0	-2.666666666666668	0.04	0.04477611940298508	0.0	0.04205607476635514	0.04205607476635514	7.0	0.04477611940298508	0.2857142857142857	1.0	0.0	-2.666666666666668	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04205607476635514	0.0	0.04477611940298508	0.0	0.0	0.0	0.0	0.0
75	OL differentiation process	0.3260146601639773	-7.75	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-7.75	0.0	0.0	-8.75	0.04	0.06153846153846154	0.0	0.057971014492753624	0.057971014492753624	3.0	0.06153846153846154	0.0	1.0	0.0	-8.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.057971014492753624	0.0	0.06153846153846154	0.0	0.0	0.0	0.0	0.0
254	GWAS results	0.289658730492229	-5.666666666666666	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.051724137931034475	0.051724137931034475	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.051724137931034475	0.0	0.04	0.0	0.0	0.0	0.0	0.0
289	the last few years	0.052997877725278884	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
301	Classification;classification	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	the methylated domains through cooperative activity	0.04496151454271589	-1.6666666666666679	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-1.6666666666666679	0.0	0.0	-4.7142857142857135	0.04	0.04929577464788733	0.0	0.04285714285714286	0.04285714285714286	6.0	0.04929577464788733	0.16666666666666666	1.0	0.0	-4.7142857142857135	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04285714285714286	0.0	0.04929577464788733	0.0	0.0	0.0	0.0	0.0
137	endoluminal scaffold implantation	0.581619132542557	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.3000000000000007	0.04	0.04608294930875576	0.0	0.04	0.04	3.0	0.04608294930875576	0.0	1.0	0.0	-3.3000000000000007	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04608294930875576	0.0	0.0	0.0	0.0	0.0
214	the ratio	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	TBBPred	0.562845400200647	-1.875	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.875	0.0	0.0	-9.833333333333334	0.04	0.06593406593406594	0.0	0.043243243243243246	0.043243243243243246	1.0	0.06593406593406594	0.0	1.0	0.0	-9.833333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.043243243243243246	0.0	0.06593406593406594	0.0	0.0	0.0	0.0	0.0
90	The first of these studies	0.02443490465499735	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.04	0.04	5.0	0.06666666666666667	0.4	1.0	0.0	-10.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
129	Presence;presence	0.08135430915885998	-1.7777777777777786	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.7777777777777786	0.0	0.0	-2.571428571428573	0.04	0.0445859872611465	0.0	0.0430622009569378	0.0430622009569378	1.0	0.0445859872611465	0.0	1.0	0.0	-2.571428571428573	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.0430622009569378	0.0	0.0445859872611465	0.0	0.0	0.0	0.0	0.0
334	parallel;Parallel	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
312	kDa	0.6779585395550519	-3.166666666666668	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.04580152671755725	0.04580152671755725	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04580152671755725	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	minimizing therapy-related toxicity	0.16148496859110145	-3.5	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-3.5	0.0	0.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.046511627906976744	0.046511627906976744	5.0	0.044642857142857144	0.0	1.0	0.0	-2.6000000000000014	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.046511627906976744	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
201	Struck by projectile;struck by a projectile	0.08671490994812284	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
29	A. niger into an itaconic acid producer	0.10822444753400556	0.0	1.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.14285714285714285	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.2857142857142857	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
256	Mutations;mutation;mutations;Mutation	0.9656309899461203	-2.5714285714285716	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.0	0.0	-2.2857142857142856	0.04	0.04	0.0	0.04	0.0452193979657748	1.0	0.04494032824859893	0.0	14.0	0.0	-7.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	14.0	0.054545454545454536	0.0	0.05714285714285714	0.0	0.0	0.0	0.0	0.0
14	a given permutation on the arrangement	0.048090457414348524	-1.5	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-1.5	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.0425531914893617	0.0425531914893617	6.0	0.045454545454545456	0.16666666666666666	1.0	0.0	-3.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.0425531914893617	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
38	A certain level of CREB-binding protein;A-CREB protein	0.0394251036749164	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
124	normal-like, and ERBB2+	0.19068825328913477	-4.333333333333334	0.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.0	0.0	-4.333333333333334	0.0	0.0	-8.333333333333334	0.04	0.06000000000000001	0.0	0.048387096774193554	0.048387096774193554	7.0	0.06000000000000001	0.0	1.0	0.0	-8.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.048387096774193554	0.0	0.06000000000000001	0.0	0.0	0.0	0.0	0.0
257	thiol-dependent peroxidase	0.6693179288082355	-3.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	-3.0	1.0	1.0	-9.0	0.04	0.0625	0.0	0.045454545454545456	0.045454545454545456	4.0	0.0625	0.0	2.0	1.0	-9.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.045454545454545456	0.0	0.0625	0.0	1.0	0.0	0.0	1.0
226	visual problems	0.041831373405131954	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.5	0.0	0.0
198	nonsense mutation;Mutation, Nonsense;Nonsense;nonsense	0.5659193888313836	-5.05	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.199999999999999	0.0	0.0	-6.125	0.04	0.04878048780487805	0.5	0.04716981132075472	0.05029295941580165	1.5	0.05326655052264809	0.25	4.0	0.0	-7.5	1.0	0.0	0.0	0.5	0.0	0.0	1.0	0.0	0.0	4.0	1.0	6.0	0.05319148936170213	0.0	0.05714285714285714	0.0	0.0	0.25	0.0	0.0
226	fever-adenopathy	0.28241644002783295	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.666666666666666	0.04	0.054545454545454536	0.0	0.04	0.04	3.0	0.054545454545454536	0.0	1.0	0.0	-6.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.054545454545454536	0.0	0.0	0.0	0.0	0.0
285	highly likely	0.11256745824011959	-3.1999999999999993	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.1999999999999993	0.0	0.0	0.0	0.04	0.04	0.0	0.04587155963302752	0.04587155963302752	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04587155963302752	0.0	0.04	0.0	0.0	0.0	0.0	0.0
74	this specific type of neoplasm	0.04366222398827446	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.2	0.0	0.0
67	an animal model for MS	0.010374743667467014	0.0	1.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.4	0.0	0.0	0.0	0.0	-6.5	0.04	0.05405405405405406	1.0	0.04	0.04	5.0	0.05405405405405406	0.6	1.0	0.0	-6.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.05405405405405406	0.0	0.0	0.2	0.0	0.0
46	multiple;MULTIPLE	0.0652828110455638	-2.8499999999999996	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.699999999999999	0.0	0.0	-11.833333333333332	0.04	0.06976744186046512	0.0	0.04	0.045906735751295336	1.0	0.07655038759689922	0.0	2.0	0.0	-13.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.05181347150259067	0.0	0.08333333333333333	0.0	0.0	0.0	0.0	0.0
298	a more severe degree	0.0884415052403157	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
208	symptoms	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
4	the combined occurrence of parathyroid	0.10968617193066939	-3.875	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	1.0	-3.875	1.0	1.0	0.0	0.04	0.04	0.0	0.047337278106508875	0.047337278106508875	5.0	0.04	0.4	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.047337278106508875	0.0	0.04	0.0	1.0	0.0	0.0	1.0
229	Cleanse;refine	0.4891816291325318	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9.0	0.04	0.0625	0.0	0.04	0.04	1.0	0.0625	0.0	1.0	0.0	-9.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.0625	0.0	0.0	0.0	0.0	0.0
133	Mutations;mutations	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	Caf1p/Pop2p interaction	0.3947280245586662	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
261	trnD;TRND	0.7415049026490577	-2.428571428571427	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-2.428571428571427	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.04430379746835443	0.04430379746835443	1.0	0.058823529411764705	0.0	2.0	0.0	-8.0	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	2.0	0.04430379746835443	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
222	Assess;assess	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
80	15 bp-deletion	0.6000186669162998	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
160	longer;Long	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
129	genomic methylation patterns through DNA replication cycles	0.05916017236111682	0.0	1.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.1111111111111111	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.2857142857142857	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
226	alterations;Alteration	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
80	400	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
75	the absence	0.11668968578773643	-4.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04819277108433735	0.0	0.04	0.0	0.0	0.0	0.0	0.0
3	Dcm) enzyme activity	0.2345013238557958	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.571428571428571	0.04	0.048951048951048945	0.0	0.04	0.04	4.0	0.048951048951048945	0.25	1.0	0.0	-4.571428571428571	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.048951048951048945	0.0	0.0	0.0	0.0	0.0
344	Immunofluorescence;immunofluorescence	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
239	cardiac risk factors	0.23673926941830228	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
80	affect;Affect	0.0692172247533031	-3.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-7.800000000000001	0.04	0.05813953488372093	0.0	0.04615384615384615	0.04615384615384615	1.0	0.05813953488372093	0.0	1.0	0.0	-7.800000000000001	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04615384615384615	0.0	0.05813953488372093	0.0	0.0	0.0	0.0	0.0
95	a C-terminal nuclease domain	0.29956052836315394	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	10.29-24.45 pmol	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
95	Yeast Protein;yeast Pop2 protein	0.5245856043223371	-4.25	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-4.25	1.0	1.0	0.0	0.04	0.04	0.0	0.04819277108433735	0.04819277108433735	3.0	0.04	0.0	2.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.04819277108433735	0.0	0.04	0.0	1.0	0.0	0.0	1.0
342	actively transcribed genes	0.7408922453501746	-1.9333333333333336	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-2.0666666666666678	0.04	0.04	0.0	0.04	0.043499863499863504	3.0	0.043790609701824655	0.0	6.0	0.0	-3.6000000000000014	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	18.0	0.045454545454545456	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
178	nascent transcript	0.6353213422952859	-5.75	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.75	0.0	0.0	-4.833333333333334	0.04	0.04958677685950414	0.0	0.05194805194805195	0.05194805194805195	2.0	0.04958677685950414	0.0	1.0	0.0	-4.833333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.05194805194805195	0.0	0.04958677685950414	0.0	0.0	0.0	0.0	0.0
183	quantitative;Quantitative	0.6170544090123072	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
16	find;Find	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
204	3 gene mutation	0.05007604311808884	-3.25	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.5	0.0	-3.25	0.0	0.0	-7.5	0.04	0.05714285714285714	1.0	0.04597701149425287	0.04597701149425287	3.0	0.05714285714285714	0.6666666666666666	1.0	0.0	-7.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04597701149425287	0.0	0.05714285714285714	0.0	0.0	0.3333333333333333	0.0	0.0
205	obtained;Obtained	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
228	thieno[3,2-d]pyrimidines	0.5745128444850652	-6.6	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.6	0.0	0.0	0.0	0.04	0.04	0.0	0.05434782608695653	0.05434782608695653	9.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	9.0	0.05434782608695653	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	Naegleria (primary amoebic meningo-encephalitis)	0.488850960165391	0.0	0.0	0.0	0.04	0.04	0.125	0.125	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.0	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
58	world;World	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
189	Normal Range;normal range	0.169188290062278	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	3.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
178	critical;Critical	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
199	CENPA deposition	0.4164889550217535	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.25	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
206	striatal;Striatum	0.6261537547779711	-4.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.04	0.04	0.0	0.047619047619047616	0.047619047619047616	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047619047619047616	0.0	0.04	0.0	0.0	0.0	0.0	0.0
115	positional analysis	0.21385754139730112	-8.75	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-8.75	0.0	0.0	-11.666666666666666	0.04	0.075	0.0	0.06153846153846154	0.06153846153846154	2.0	0.075	0.0	1.0	0.0	-11.666666666666666	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.06153846153846154	0.0	0.075	0.0	0.0	0.0	0.0	0.0
328	autosomal dominant mode	0.2762338058814217	-1.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.6666666666666666	-3.0	0.6666666666666666	0.0	-4.75	0.04	0.04938271604938271	1.0	0.04	0.04181818181818182	3.0	0.04938271604938271	0.3333333333333333	3.0	0.6666666666666666	-4.75	1.0	0.5	0.0	1.0	0.0	0.6666666666666666	1.0	0.0	0.3333333333333333	1.0	1.0	9.0	0.045454545454545456	0.0	0.04938271604938271	0.0	1.0	0.3333333333333333	0.0	1.0
256	variety;Variety	0.10357417947446557	-5.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	0.0	0.04	0.04	0.0	0.051724137931034475	0.051724137931034475	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.051724137931034475	0.0	0.04	0.0	0.0	0.0	0.0	0.0
152	tube;TUBE	0.07195524223024728	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
228	Quinoline;quinoline	0.7723585199144279	-0.9500000000000002	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-3.8000000000000007	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04179245283018868	0.0	0.04	0.0	4.0	1.0	0.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	2.0	1.0	0.0	0.04716981132075472	0.0	0.04	0.0	1.0	0.0	0.0	1.0
329	*Number;number	0.053581639307085954	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-11.0	0.04	0.07142857142857142	0.0	0.04	0.04	1.0	0.07142857142857142	0.0	1.0	0.0	-11.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.07142857142857142	0.0	0.0	0.0	0.0	0.0
72	public users for review and submission	0.04939791392743804	-1.3000000000000007	0.0	0.0	0.04	0.04	0.8333333333333334	0.8333333333333334	0.0	0.0	0.0	0.0	-1.3000000000000007	0.0	0.0	-2.1999999999999993	0.04	0.043859649122807015	0.0	0.04219409282700422	0.04219409282700422	6.0	0.043859649122807015	0.16666666666666666	1.0	0.0	-2.1999999999999993	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04219409282700422	0.0	0.043859649122807015	0.0	0.0	0.0	0.0	0.0
69	contain	0.09382137550084416	-2.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	-5.666666666666666	0.04	0.051724137931034475	0.0	0.04477611940298508	0.04477611940298508	1.0	0.051724137931034475	0.0	1.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04477611940298508	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
117	globotriaosylceramide (Gb3) accumulation	0.5268707274962908	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-6.75	0.04	0.0547945205479452	0.0	0.043478260869565216	0.043478260869565216	5.0	0.0547945205479452	0.0	1.0	0.0	-6.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.043478260869565216	0.0	0.0547945205479452	0.0	0.0	0.0	0.0	0.0
310	tumor cell adhesion and production	0.08848691453375389	0.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
52	Able;able	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
72	text-mining modules	0.059377611407721534	-1.3000000000000007	1.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.3333333333333333	0.0	-1.3000000000000007	0.0	0.0	-2.6000000000000014	0.04	0.044642857142857144	0.0	0.04219409282700422	0.04219409282700422	4.0	0.044642857142857144	0.75	1.0	0.0	-2.6000000000000014	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04219409282700422	0.0	0.044642857142857144	0.0	0.0	0.0	0.0	0.0
318	patients with Philadelphia chromosome	0.09046252899762343	-1.5555555555555571	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-1.5555555555555571	0.0	0.0	-1.9230769230769234	0.04	0.043333333333333335	0.0	0.04265402843601896	0.04265402843601896	4.0	0.043333333333333335	0.5	1.0	0.0	-1.9230769230769234	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04265402843601896	0.0	0.043333333333333335	0.0	0.0	0.0	0.0	0.0
90	Kanyini-GAP)' trials	0.05688885653924138	-3.6000000000000014	1.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.6666666666666666	0.0	-3.6000000000000014	0.0	0.0	-19.5	0.04	0.18181818181818182	1.0	0.04672897196261683	0.04672897196261683	6.0	0.18181818181818182	0.16666666666666666	1.0	0.0	-19.5	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04672897196261683	0.0	0.18181818181818182	0.0	0.0	0.16666666666666666	0.0	0.0
198	30%;30	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
37	an;AN	0.5545819358302223	-5.333333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.333333333333334	0.0	0.0	-7.75	0.04	0.057971014492753624	0.0	0.05084745762711865	0.05084745762711865	1.0	0.057971014492753624	0.0	1.0	0.0	-7.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05084745762711865	0.0	0.057971014492753624	0.0	0.0	0.0	0.0	0.0
128	prokaryotic RNA interference	0.04717988807222648	0.0	1.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	1.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	1.0	0.0	0.0	0.0	0.0
344	functions;function	0.10890142469046696	-0.6875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.375	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04116402116402117	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.042328042328042326	0.0	0.04	0.0	0.0	0.0	0.0	0.0
127	CHRONIC;chronic	0.09059200192985256	-1.8333333333333321	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.043165467625899276	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043165467625899276	0.0	0.04	0.0	0.0	0.0	0.0	0.0
213	Study;study	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
29	a systematic process optimization	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
74	dryness of the mouth;Dryness, Mouth	0.0699384300835646	-1.8333333333333321	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	-1.8333333333333321	0.0	0.0	0.0	0.04	0.04	0.0	0.043165467625899276	0.043165467625899276	4.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	8.0	0.043165467625899276	0.0	0.04	0.0	0.0	0.0	0.0	0.0
73	a Hidden Markov Model;a hidden Markov model	0.25819924683527584	-1.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	1.0	-2.0	1.0	1.0	-2.416666666666666	0.04	0.043478260869565216	0.0	0.04	0.04173913043478261	4.0	0.044295521412226216	0.0	2.0	1.0	-2.833333333333332	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	8.0	0.043478260869565216	0.0	0.045112781954887216	0.0	1.0	0.0	0.0	1.0
155	Link;linked	0.06332505449114587	-5.166666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.166666666666666	0.0	0.0	-11.5	0.04	0.07407407407407407	0.0	0.050420168067226885	0.050420168067226885	1.0	0.07407407407407407	0.0	1.0	0.0	-11.5	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.050420168067226885	0.0	0.07407407407407407	0.0	0.0	0.0	0.0	0.0
290	assessment;Assessment	0.08511620032788242	-14.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-14.0	0.0	0.0	-12.0	0.04	0.07692307692307693	0.0	0.09090909090909091	0.09090909090909091	1.0	0.07692307692307693	0.0	1.0	0.0	-12.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.09090909090909091	0.0	0.07692307692307693	0.0	0.0	0.0	0.0	0.0
82	the HLA allele B*1502 as a marker	0.054536041289464085	0.0	0.0	0.0	0.04	0.04	0.5714285714285714	0.5714285714285714	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-3.6000000000000014	0.04	0.04672897196261683	0.0	0.04	0.04	7.0	0.04672897196261683	0.7142857142857143	1.0	0.0	-3.6000000000000014	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	7.0	0.04	0.0	0.04672897196261683	0.0	0.0	0.0	0.0	0.0
96	relapsed or refractory multiple myeloma	0.32410983397050513	-3.5	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	-3.5	1.0	1.0	-2.8000000000000007	0.04	0.04504504504504505	0.0	0.046511627906976744	0.046511627906976744	5.0	0.04504504504504505	0.0	1.0	1.0	-2.8000000000000007	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.046511627906976744	0.0	0.04504504504504505	0.0	1.0	0.0	0.0	1.0
124	Clinical ScenarioOncotype DX	0.20746220121390285	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
179	TSC1 or TSC2	0.3646046951820019	-6.333333333333334	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	1.0	-6.333333333333334	1.0	1.0	-9.4	0.04	0.06410256410256411	0.0	0.053571428571428575	0.053571428571428575	3.0	0.06410256410256411	0.0	1.0	1.0	-9.4	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.053571428571428575	0.0	0.06410256410256411	0.0	1.0	0.0	0.0	1.0
255	facial or shoulder girdle muscles	0.1421723709355855	-3.8571428571428577	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-3.8571428571428577	0.0	0.0	-6.25	0.04	0.05333333333333334	0.0	0.0472972972972973	0.0472972972972973	5.0	0.05333333333333334	0.0	1.0	0.0	-6.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.0472972972972973	0.0	0.05333333333333334	0.0	0.0	0.0	0.0	0.0
159	Pfeiffer hands and feet	0.06637442787073183	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.25	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
13	Record;recorded	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
334	ATM	0.7426660049357836	-1.1111111111111107	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.333333333333332	0.0	0.0	-1.4166666666666667	0.04	0.04	0.0	0.04	0.04205128205128205	1.0	0.04273092369477912	0.0	3.0	0.0	-4.25	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04615384615384615	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
48	Five of the seven duct lesions	0.0757949684166333	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.2857142857142847	0.04	0.046052631578947366	0.0	0.04	0.04	6.0	0.046052631578947366	0.16666666666666666	1.0	0.0	-3.2857142857142847	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.046052631578947366	0.0	0.0	0.0	0.0	0.0
4	FOLLICULAR ADENOMA;follicular thyroid adenoma	0.8876154938256459	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	3.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	9.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
320	text] value, quantitative estimation	0.29956052836315394	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
86	protein expression of alpha-MHC;MHC protein	0.22849696852052356	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
264	thyroid hormone substitution	0.4948473885772892	-4.5	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.04878048780487805	0.04878048780487805	3.0	0.045454545454545456	0.0	2.0	0.0	-3.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	6.0	0.04878048780487805	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
66	Echogenic Bowel;echogenic bowel;Echogenic bowel	0.9957274925614576	-2.356060606060606	1.0	-8.75	0.04	0.04097902097902098	0.0	0.0	1.0	-0.3977272727272727	1.0	0.0	-14.5	0.0	0.0	-2.352272727272727	0.06153846153846154	0.04	0.0	0.04	0.04589821134991843	2.0	0.045272606181697095	1.0	22.0	0.0	-10.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	3.0	1.0	44.0	0.09523809523809523	0.0	0.06666666666666667	1.0	0.0	0.0	0.0	0.0
130	one;ONE	0.07110288558633066	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.2857142857142865	0.04	0.04827586206896552	0.0	0.04	0.04	1.0	0.04827586206896552	0.0	1.0	0.0	-4.2857142857142865	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04827586206896552	0.0	0.0	0.0	0.0	0.0
172	thyroid hormone production	0.057286362387207905	0.0	1.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.25	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.6666666666666666	2.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
139	[19], [20]	0.40521863552491666	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04	0.04	7.0	0.05	0.14285714285714285	1.0	0.0	-5.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.05	0.0	0.0	0.0	0.0	0.0
14	that of transmembrane β-barrel proteins	0.02805863837170893	0.0	1.0	0.0	0.04	0.04	0.42857142857142855	0.42857142857142855	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	7.0	0.04	0.7142857142857143	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
79	23	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
224	Up to;up to	0.07947715734548454	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
245	pediatric;paediatric	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
38	CREB-binding protein gene	0.10699058841176723	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.2	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
97	Behavior;behavior	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
69	cilium;Cilium;cilia;Cilia	0.07466656474846133	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	1.0	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	4.0	1.0	2.0	0.04	0.0	0.04	1.0	0.0	0.0	0.0	0.0
192	restless leg syndrome and migraine	0.024649455342671548	0.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.6	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
330	Tofacitinib monotherapy at ≥3	0.5686077676215348	0.0	0.0	0.0	0.04	0.04	0.25	0.25	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	4.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
125	a colony of dogs	0.08760888685040237	-4.666666666666666	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.666666666666666	0.0	0.0	-4.25	0.04	0.04819277108433735	0.0	0.04918032786885245	0.04918032786885245	4.0	0.04819277108433735	0.0	1.0	0.0	-4.25	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04918032786885245	0.0	0.04819277108433735	0.0	0.0	0.0	0.0	0.0
198	the same allele	0.4184663729930198	-1.5333333333333325	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	-2.3999999999999986	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04270247891114216	3.0	0.04	0.0	3.0	1.0	0.0	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04424778761061947	0.0	0.04	0.0	1.0	0.0	0.0	1.0
329	structure-based pharmacophore	0.22088701812158124	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
254	pDC response	0.24670403976171063	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
26	liver;LIVER	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
96	as;AS	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
7	ANENCEPHALY;anencephaly	0.6686796180156888	-3.3333333333333335	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-6.083333333333333	0.04	0.0449438202247191	0.0	0.04	0.04666666666666667	1.0	0.05362861640340879	0.0	3.0	0.0	-7.75	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	3.0	0.05	0.0	0.057971014492753624	0.0	0.0	0.0	0.0	0.0
100	lines	0.10750721319952627	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
304	phase I/II trials;Phase I/II Trial	0.2548567281517205	-3.625	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-3.625	0.0	0.0	-3.2857142857142847	0.04	0.046052631578947366	0.0	0.04678362573099415	0.04678362573099415	5.0	0.046052631578947366	0.0	2.0	0.0	-3.2857142857142847	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	10.0	0.04678362573099415	0.0	0.046052631578947366	0.0	0.0	0.0	0.0	0.0
208	genetically susceptible;Genetic Susceptibility	0.5417912850402065	-3.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.25	0.0	0.0	-5.5	0.04	0.05128205128205128	0.0	0.04597701149425287	0.04597701149425287	2.0	0.05128205128205128	0.0	1.0	0.0	-5.5	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04597701149425287	0.0	0.05128205128205128	0.0	0.0	0.0	0.0	0.0
142	29 patients with pheochromocytoma)	0.24482457590685533	0.0	0.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-2.666666666666668	0.04	0.04477611940298508	0.0	0.04	0.04	5.0	0.04477611940298508	0.2	1.0	0.0	-2.666666666666668	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.04477611940298508	0.0	0.0	0.0	0.0	0.0
150	the lysosome-associated membrane protein type 2A;the lysosome-associated membrane protein type 2a	0.39616228388467495	-4.7142857142857135	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.5	-4.7142857142857135	0.0	0.0	-5.000000000000001	0.04	0.04580152671755725	0.0	0.04929577464788733	0.04929577464788733	8.0	0.050423699138595145	0.125	2.0	0.0	-6.833333333333334	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.0	0.16666666666666666	2.0	1.0	16.0	0.04929577464788733	0.0	0.05504587155963304	0.0	0.0	0.0	0.0	0.0
129	Agonist;agonist	0.5420224398639322	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.2857142857142865	0.04	0.04827586206896552	0.0	0.04	0.04	1.0	0.04827586206896552	0.0	1.0	0.0	-4.2857142857142865	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04827586206896552	0.0	0.0	0.0	0.0	0.0
291	prevention and treatment	0.10328782825765002	-2.571428571428573	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.0445859872611465	0.0445859872611465	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.0445859872611465	0.0	0.04	0.0	0.0	0.0	0.0	0.0
144	HB-EGF-induced COX-2	0.7611401241455492	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	6.0	0.04	0.0	1.0	0.0	0.0	1.0	0.6666666666666666	0.0	0.0	0.0	0.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
26	0.001)	0.6480714513906395	-1.571428571428573	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-1.571428571428573	0.0	0.0	0.0	0.04	0.04	0.0	0.042682926829268296	0.042682926829268296	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.042682926829268296	0.0	0.04	0.0	0.0	0.0	0.0	0.0
71	and;And	0.10235180207998074	-3.9000000000000004	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-5.0	0.04	0.05	0.0	0.04716981132075472	0.04739442946990117	1.0	0.05	0.0	2.0	0.0	-5.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.047619047619047616	0.0	0.05	0.0	0.0	0.0	0.0	0.0
136	51	0.6242324157995068	-6.333333333333334	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-6.333333333333334	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.053571428571428575	0.053571428571428575	1.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.053571428571428575	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
47	incorporation;Incorporation	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	processing of messenger RNA populations	0.15898064341854684	0.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
218	the mass scale	0.024946553448049788	0.0	1.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.04	0.04	1.0	0.04	0.04	3.0	0.04	0.3333333333333333	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.3333333333333333	0.0	0.0
8	Human;human	0.06703689305732215	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-10.0	0.04	0.06666666666666667	0.0	0.05	0.05	1.0	0.06666666666666667	0.0	1.0	0.0	-10.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05	0.0	0.06666666666666667	0.0	0.0	0.0	0.0	0.0
66	A disorder	0.19757264341197558	-2.666666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	1.0	-2.666666666666668	1.0	1.0	0.0	0.04	0.04	0.0	0.04477611940298508	0.04477611940298508	2.0	0.04	0.0	2.0	1.0	0.0	1.0	0.3333333333333333	1.0	0.0	1.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04477611940298508	0.0	0.04	0.0	1.0	0.0	0.0	1.0
80	MALIGNANT;malignant	0.5892832300888085	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
188	Potential;potential	0.07114135662103213	-3.166666666666668	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.166666666666668	0.0	0.0	-7.0	0.04	0.05555555555555555	0.0	0.04580152671755725	0.04580152671755725	1.0	0.05555555555555555	0.0	1.0	0.0	-7.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04580152671755725	0.0	0.05555555555555555	0.0	0.0	0.0	0.0	0.0
318	the first TKI	0.07052457854217124	-3.666666666666668	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-3.666666666666668	0.0	0.0	-6.0	0.04	0.05263157894736842	0.0	0.046875	0.046875	3.0	0.05263157894736842	0.3333333333333333	1.0	0.0	-6.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.046875	0.0	0.05263157894736842	0.0	0.0	0.0	0.0	0.0
90	Antihypertensive;antihypertensive	0.6561059373978616	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
226	95%CI 16.2-27.0), memory loss/lack	0.3222353111685164	0.0	0.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.125	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	8.0	0.04	0.0	0.04	0.0	1.0	0.0	0.0	1.0
277	kidney dysfunction;KIDNEY DYSFUNCTION	0.5313777172558067	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	3.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	6.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
225	YEARS;years	0.10984076224020731	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
146	Pathway;pathway	0.5679934648934067	-2.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-3.666666666666668	0.04	0.046875	0.0	0.043478260869565216	0.043478260869565216	1.0	0.046875	0.0	1.0	0.0	-3.666666666666668	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.043478260869565216	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
168	mild expression	0.14010502197254826	-4.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.047619047619047616	0.047619047619047616	2.0	0.04918032786885245	0.0	2.0	0.0	-4.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.047619047619047616	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
250	an independent predictor of mortality	0.09760147955041572	-2.0	0.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.0	0.0	-2.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.043478260869565216	0.043478260869565216	5.0	0.047619047619047616	0.2	1.0	0.0	-4.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.043478260869565216	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
41	like helicase domain	0.18174823907624738	0.0	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	1.0	0.0	0.0	0.0	-4.666666666666666	0.04	0.04918032786885245	0.0	0.04	0.04	3.0	0.04918032786885245	0.0	1.0	0.0	-4.666666666666666	1.0	0.3333333333333333	0.0	0.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	3.0	0.04	0.0	0.04918032786885245	0.0	0.0	0.0	0.0	0.0
3	the methyl donor byproduct AdoHcy	0.10242836992991579	0.0	1.0	0.0	0.04	0.04	0.4	0.4	0.0	0.0	0.25	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	5.0	0.04	0.6	1.0	1.0	0.0	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	1.0	1.0	5.0	0.04	0.0	0.04	0.0	1.0	0.2	0.0	1.0
26	analyses;Analysis	0.09021328365335247	-1.7142857142857153	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.7142857142857153	0.0	0.0	0.0	0.04	0.04	0.0	0.04294478527607362	0.04294478527607362	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04294478527607362	0.0	0.04	0.0	0.0	0.0	0.0	0.0
8	UNIMOD	0.6506498211190714	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
285	67%	0.6605710465498551	-3.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	0.0	0.04	0.04	0.0	0.045454545454545456	0.045454545454545456	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.045454545454545456	0.0	0.04	0.0	0.0	0.0	0.0	0.0
52	our previous report of 5'	0.12505793185429023	-10.0	0.0	0.0	0.04	0.04	0.8	0.8	0.0	0.0	0.0	0.0	-10.0	0.0	0.0	0.0	0.04	0.04	0.0	0.06666666666666667	0.06666666666666667	5.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	5.0	0.06666666666666667	0.0	0.04	0.0	0.0	0.0	0.0	0.0
46	multiple Notch pathway genes	0.0644783573298354	0.0	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.5	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.5	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
336	multiple;MULTIPLE	0.08958766532107301	-5.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.05	0.05	1.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.05	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
96	its boronic acid group	0.10972740606398296	0.0	0.0	0.0	0.04	0.04	0.75	0.75	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	4.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
122	C)	0.6340842748151425	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
30	stable, intramolecular, parallel G-quadruplex secondary structure under physiological conditions;stable condition	0.047415204199543426	0.0	1.0	0.0	0.04	0.04	0.38461538461538464	0.38461538461538464	0.0	0.0	0.14285714285714285	0.0	0.0	0.0	0.0	-3.1999999999999993	0.04	0.04587155963302752	0.0	0.04	0.04	13.0	0.04587155963302752	0.15384615384615385	1.0	0.0	-3.1999999999999993	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	13.0	0.04	0.0	0.04587155963302752	0.0	0.0	0.0	0.0	0.0
238	the design	0.10926132209370207	-2.333333333333332	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.333333333333332	0.0	0.0	0.0	0.04	0.04	0.0	0.044117647058823525	0.044117647058823525	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.044117647058823525	0.0	0.04	0.0	0.0	0.0	0.0	0.0
298	THYROID GLAND;thyroid gland	0.4247351894393581	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	2.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
160	proven antiosteoclast activity	0.14807813705636058	-2.166666666666668	0.0	0.0	0.04	0.04	0.6666666666666666	0.6666666666666666	0.0	0.0	0.0	0.0	-2.166666666666668	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.043795620437956206	0.043795620437956206	3.0	0.043478260869565216	0.0	1.0	0.0	-2.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.043795620437956206	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
276	always;Always	0.09192881091266093	-2.25	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-2.25	0.0	0.0	0.0	0.04	0.04	0.0	0.04395604395604396	0.04395604395604396	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04395604395604396	0.0	0.04	0.0	0.0	0.0	0.0	0.0
121	Clinical;clinical	0.6682729222079814	-3.722222222222222	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-6.0	0.0	0.0	-1.9722222222222223	0.04	0.04	0.0	0.04	0.0474714786268045	1.0	0.04391373639379898	0.0	12.0	0.0	-5.666666666666666	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	12.0	0.05263157894736842	0.0	0.051724137931034475	0.0	0.0	0.0	0.0	0.0
120	Prevention	0.138062657829642	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
279	a consequence of LKB1 haploinsufficiency	0.05298662294518741	0.0	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.25	1.0	0.0	0.0	0.0	-2.0	0.04	0.043478260869565216	0.0	0.04	0.04	5.0	0.043478260869565216	0.4	1.0	0.0	-2.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.04	0.0	0.043478260869565216	0.0	0.0	0.0	0.0	0.0
44	Derived;derived	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
288	mitochondrial inter-membrane space bridging (MIB) complex (Mitofilin	0.17979714347123418	0.0	1.0	0.0	0.04	0.04	0.2	0.2	0.0	0.0	0.14285714285714285	1.0	0.0	1.0	1.0	0.0	0.04	0.04	1.0	0.04	0.04	10.0	0.04	0.2	1.0	1.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	10.0	0.04	0.0	0.04	0.0	1.0	0.1	0.0	1.0
324	characterized;Characterized	0.09346436155514923	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	1.0	0.047619047619047616	0.0	2.0	0.0	-4.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
176	genomic DNA;Genomic DNA	0.27926268070552995	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	4.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
87	Levels;levels	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
97	muscular dystrophy;Dystrophy, Muscular	0.5884933816734491	-2.5	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-7.5	0.0	0.0	-1.2222222222222225	0.04	0.04	0.0	0.04	0.045714285714285714	2.0	0.04229166666666667	0.5	3.0	0.0	-3.666666666666668	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	2.0	1.0	6.0	0.05714285714285714	0.0	0.046875	0.0	0.0	0.0	0.0	0.0
320	a receptor	0.26637297321726805	-2.666666666666668	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	-2.666666666666668	0.0	0.0	0.0	0.04	0.04	0.0	0.04477611940298508	0.04477611940298508	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04477611940298508	0.0	0.04	0.0	0.0	0.0	0.0	0.0
44	a single copy	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
334	Increase;increase	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
280	patient;*^patient	0.10946385122960821	-10.75	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-10.75	0.0	0.0	-3.0	0.04	0.045454545454545456	0.0	0.07017543859649122	0.07017543859649122	1.0	0.045454545454545456	0.0	1.0	0.0	-3.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.07017543859649122	0.0	0.045454545454545456	0.0	0.0	0.0	0.0	0.0
72	biomedical domain	0.04879982928046636	-1.8000000000000007	1.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.3333333333333333	0.0	-1.8000000000000007	0.0	0.0	-2.8000000000000007	0.04	0.04504504504504505	0.0	0.04310344827586207	0.04310344827586207	2.0	0.04504504504504505	0.5	1.0	0.0	-2.8000000000000007	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04310344827586207	0.0	0.04504504504504505	0.0	0.0	0.0	0.0	0.0
176	Composition;composition	0.08897080828741459	-3.875	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-3.875	0.0	0.0	-2.1999999999999993	0.04	0.043859649122807015	0.0	0.047337278106508875	0.047337278106508875	1.0	0.043859649122807015	0.0	1.0	0.0	-2.1999999999999993	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.047337278106508875	0.0	0.043859649122807015	0.0	0.0	0.0	0.0	0.0
14	the network	0.038796028239976715	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.5	1.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
77	patient treatment;treatment of patients;treatment of Parkinson's disease patients	0.029298833145285766	-1.583333333333334	0.5	0.0	0.04	0.04	0.6666666666666666	0.8333333333333333	0.0	0.0	0.125	0.0	-3.166666666666668	0.0	0.0	-3.6428571428571432	0.04	0.04	0.0	0.04	0.042900763358778626	4.5	0.0482258064516129	0.6666666666666666	2.0	0.0	-7.2857142857142865	1.0	0.0	0.5	1.0	1.0	0.0	1.0	0.0	0.0	3.0	1.0	9.0	0.04580152671755725	0.0	0.056451612903225805	0.0	0.0	0.0	0.0	0.0
181	small;SMALL	0.08040843460801746	-1.7142857142857153	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-1.7142857142857153	0.0	0.0	-2.8000000000000007	0.04	0.04504504504504505	0.0	0.04294478527607362	0.04294478527607362	1.0	0.04504504504504505	0.0	1.0	0.0	-2.8000000000000007	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04294478527607362	0.0	0.04504504504504505	0.0	0.0	0.0	0.0	0.0
41	a high degree	0.09443079850955968	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	simple;Simple	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
93	intensity mild	0.10078084669438805	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	2.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
246	receptor;Receptor	0.6839327724019275	-4.25	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-4.25	0.0	0.0	-9.5	0.04	0.06451612903225806	0.0	0.04819277108433735	0.04819277108433735	1.0	0.06451612903225806	0.0	1.0	0.0	-9.5	1.0	0.5	0.0	0.0	0.0	0.0	1.0	0.5	0.5	2.0	1.0	1.0	0.04819277108433735	0.0	0.06451612903225806	0.0	0.0	0.0	0.0	0.0
128	the name of the analogous process;Process, The	0.005563155329277497	-11.416666666666666	1.0	-11.636363636363637	0.07482993197278912	0.07482993197278912	0.8333333333333334	0.8333333333333334	1.0	-11.636363636363637	1.0	0.0	-11.416666666666666	0.0	0.0	-10.909090909090908	0.07482993197278912	0.07096774193548387	0.0	0.07361963190184048	0.07361963190184048	6.0	0.07096774193548387	1.0	2.0	0.0	-10.909090909090908	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	12.0	0.07361963190184048	0.0	0.07096774193548387	1.0	0.0	0.0	0.0	0.0
26	disintegrative disorder	0.36107476275221134	-1.7142857142857153	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	1.0	-1.7142857142857153	1.0	1.0	0.0	0.04	0.04	0.0	0.04294478527607362	0.04294478527607362	2.0	0.04	0.0	1.0	1.0	0.0	1.0	0.5	0.0	0.0	0.0	1.0	1.0	0.5	0.5	1.0	1.0	2.0	0.04294478527607362	0.0	0.04	0.0	1.0	0.0	0.0	1.0
103	catalytic activity	0.26609910996598674	0.0	0.0	0.0	0.04	0.04	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.2857142857142865	0.04	0.056451612903225805	0.0	0.04	0.04	2.0	0.056451612903225805	0.0	2.0	0.0	-7.2857142857142865	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	4.0	0.04	0.0	0.056451612903225805	0.0	0.0	0.0	0.0	0.0
75	detecting;detect	0.09945790750549682	-4.5	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	-4.5	0.0	0.0	0.0	0.04	0.04	0.0	0.04878048780487805	0.04878048780487805	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04878048780487805	0.0	0.04	0.0	0.0	0.0	0.0	0.0
201	frightening	0.6680411133025101	-14.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-14.0	0.0	0.0	-10.333333333333334	0.04	0.06818181818181819	0.0	0.09090909090909091	0.09090909090909091	1.0	0.06818181818181819	0.0	1.0	0.0	-10.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.09090909090909091	0.0	0.06818181818181819	0.0	0.0	0.0	0.0	0.0
61	addition to ULK1 and ULK2, ATG13 and FIP200	0.17483598390772986	0.0	0.0	0.0	0.04	0.04	0.4444444444444444	0.4444444444444444	0.0	0.0	0.0	1.0	0.0	1.0	1.0	-8.25	0.04	0.05970149253731343	0.0	0.04	0.04	9.0	0.05970149253731343	0.0	1.0	1.0	-8.25	1.0	0.3333333333333333	0.0	0.0	0.0	1.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	9.0	0.04	0.0	0.05970149253731343	0.0	1.0	0.0	0.0	1.0
199	centromere protein A (Cenpa) null mice	0.26926488471876964	0.0	0.0	0.0	0.04	0.04	0.375	0.375	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	8.0	0.04	0.125	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	8.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
85	enriched	0.6918715471314438	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.2857142857142856	0.04	0.04	0.0	0.04	0.04	1.0	0.04447552447552447	0.0	2.0	0.0	-4.571428571428571	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04	0.0	0.048951048951048945	0.0	0.0	0.0	0.0	0.0
330	Tofacitinib (CP-690,550);Tofacitinib (CP-690,550	0.6438055408359781	-1.8888888888888893	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	1.0	-1.8888888888888893	1.0	1.0	-3.3125	0.04	0.04371584699453552	0.0	0.04326923076923077	0.04326923076923077	3.5	0.04624816739970679	0.41666666666666663	2.0	1.0	-4.5	1.0	0.6666666666666666	0.0	1.0	0.0	1.0	1.0	0.6666666666666666	0.6666666666666666	2.0	1.0	7.0	0.04326923076923077	0.0	0.04878048780487805	0.0	1.0	0.0	0.0	1.0
96	increased antitumor efficacy	0.3468221006691526	0.0	0.0	0.0	0.04	0.04	0.3333333333333333	0.3333333333333333	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	3.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	3.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
334	characterized;Characterized	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
45	5	0.6782771127416346	-1.8000000000000007	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-3.6000000000000014	0.0	0.0	-3.166666666666667	0.04	0.04	0.0	0.04	0.04336448598130842	1.0	0.04678571428571429	0.0	2.0	0.0	-6.333333333333334	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	2.0	0.04672897196261683	0.0	0.053571428571428575	0.0	0.0	0.0	0.0	0.0
206	20%;20	0.5988193933076963	-5.666666666666666	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	-5.666666666666666	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.051724137931034475	0.051724137931034475	1.0	0.047619047619047616	0.0	1.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.051724137931034475	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
332	prevents;PREVENT	0.0849159328016617	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.04	0.04	0.0	0.04	0.04	1.0	0.04	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	0.04	0.0	0.04	0.0	0.0	0.0	0.0	0.0
14	properties	0.09589125431898023	0.0	0.0	0.0	0.04	0.04	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.833333333333332	0.04	0.045112781954887216	0.0	0.04	0.04	1.0	0.045112781954887216	0.0	1.0	0.0	-2.833333333333332	1.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0	0.04	0.0	0.045112781954887216	0.0	0.0	0.0	0.0	0.0
4	other MEN1-associated tumors	0.06006846871692629	-1.625	1.0	0.0	0.04	0.04	0.6	0.6	0.0	0.0	0.5	1.0	-1.625	0.0	0.0	0.0	0.04	0.04	1.0	0.0427807486631016	0.0427807486631016	5.0	0.04	0.4	1.0	0.0	0.0	1.0	0.3333333333333333	0.0	1.0	0.0	0.0	1.0	0.3333333333333333	0.3333333333333333	1.0	1.0	5.0	0.0427807486631016	0.0	0.04	0.0	0.0	0.2	0.0	0.0
24	blinded Indian Polycap Study (TIPS)	0.2677359432279225	-3.0	0.0	0.0	0.04	0.04	0.2857142857142857	0.2857142857142857	0.0	0.0	0.0	0.0	-3.0	0.0	0.0	-8.0	0.04	0.058823529411764705	0.0	0.045454545454545456	0.045454545454545456	7.0	0.058823529411764705	0.0	1.0	0.0	-8.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	7.0	0.045454545454545456	0.0	0.058823529411764705	0.0	0.0	0.0	0.0	0.0
131	atypia;Atypia	0.6145093339004001	0.0	0.0	0.0	0.04	0.04	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.04	0.047619047619047616	0.0	0.04	0.04	1.0	0.047619047619047616	0.0	2.0	0.0	-4.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	2.0	0.04	0.0	0.047619047619047616	0.0	0.0	0.0	0.0	0.0
